NZ626126B2

NZ626126B2 - Ph20 polypeptide variants, formulations and uses thereof

Info

Publication number: NZ626126B2
Application number: NZ626126A
Authority: NZ
Inventors: Robert James Connor; H Michael Shepard; Ge Wei; Qiping Zhao
Original assignee: Halozyme Inc
Priority date: 2011-12-30
Filing date: 2012-12-28
Publication date: 2016-09-27

Abstract

Discloses a modified PH20 polypeptide, comprising an amino acid replacement in an unmodified PH20 polypeptide, wherein: the unmodified PH20 polypeptide consists of the sequence of amino acids set forth in SEQ ID NO: 3, 7 or 32-66, or a sequence of amino acids that is at least 95% identical to SEQ ID NO:3, 7 or 32-66; the modified PH20 polypeptide exhibits increased stability in the presence of a phenolic preservative(s) compared to the unmodified PH20 polypeptide not containing the amino acid replacement; the amino acid replacement is at a position corresponding to a position selected from among 10, 12, 20, 22, 26, 34, 36, 46, 50, 52, 58, 68, 70, 74, 82, 83, 84, 86, 97, 127, 131, 138, 142, 143, 144, 166, 169, 174, 193, 195, 196, 204, 205, 206, 213, 234, 237, 238, 240, 249, 261, 267, 277, 279, 291, 309, 310, 314, 315, 317, 318, 347, 367, 375, 376, 399, 401, 407, 416, 419, 421, 431, 433, 439, 440, 443 or 445 with reference to amino acid positions set forth in SEQ ID NO:3, wherein corresponding amino acid positions are identified by alignment of the PH20 polypeptide with the polypeptide having the sequence of amino acids set forth in SEQ ID NO:3, with the proviso that if the modified PH20 polypeptide includes only a single amino acid replacement, the replacement does not correspond to amino acid replacements V12A or E249Q with reference to amino acid positions set forth in SEQ ID NO:3; the amino acid replacement confers the increased stability; and increased stability is manifested as increased hyaluronidase activity in the presence of the phenolic preservative(s) compared to the hyaluronidase activity of the unmodified PH20 polypeptide not containing the amino acid replacement in the presence of the same phenolic preservative(s), and the activity is compared under the same conditions, wherein the sequences are as defined in the complete specification. Also discloses related compositions and uses in therapy. D NO:3, 7 or 32-66; the modified PH20 polypeptide exhibits increased stability in the presence of a phenolic preservative(s) compared to the unmodified PH20 polypeptide not containing the amino acid replacement; the amino acid replacement is at a position corresponding to a position selected from among 10, 12, 20, 22, 26, 34, 36, 46, 50, 52, 58, 68, 70, 74, 82, 83, 84, 86, 97, 127, 131, 138, 142, 143, 144, 166, 169, 174, 193, 195, 196, 204, 205, 206, 213, 234, 237, 238, 240, 249, 261, 267, 277, 279, 291, 309, 310, 314, 315, 317, 318, 347, 367, 375, 376, 399, 401, 407, 416, 419, 421, 431, 433, 439, 440, 443 or 445 with reference to amino acid positions set forth in SEQ ID NO:3, wherein corresponding amino acid positions are identified by alignment of the PH20 polypeptide with the polypeptide having the sequence of amino acids set forth in SEQ ID NO:3, with the proviso that if the modified PH20 polypeptide includes only a single amino acid replacement, the replacement does not correspond to amino acid replacements V12A or E249Q with reference to amino acid positions set forth in SEQ ID NO:3; the amino acid replacement confers the increased stability; and increased stability is manifested as increased hyaluronidase activity in the presence of the phenolic preservative(s) compared to the hyaluronidase activity of the unmodified PH20 polypeptide not containing the amino acid replacement in the presence of the same phenolic preservative(s), and the activity is compared under the same conditions, wherein the sequences are as defined in the complete specification. Also discloses related compositions and uses in therapy.

Description

EPH20".POLYPEPIITHJE NTS,FORMULATIONS AND'USESTHEREOF .

V RELATED APPLICATIONS ' ’ ' ' " Beneﬁt ofpriority is 'claimed to U.S."Provisional Application 'No. '61/63 1,3 13, ‘ﬁled 'Decemberf30,f2011, and to U.S.'Provisiona'l Application No. 61/796,208 ﬁled November ’1,- 2012, each entitled "PHZO Polypeptide "Variants, Formulations and Uses Thereof." ' Thisapplication isrelated to U.S. Application Serial No.‘13/684,’731,'ﬁled‘the same day herewith,.entitled "PHZO Polypeptide Variants, 'Formulationsrand Uses Thereof," which claims ty to'U.S. Provisional Application No. 61/631,313 and U.S. Provisional ation No. 61/796,208. '10 'Where permitted, the t matter ofeach of theabove-noted related applications is incorporated ‘by'reference in its entirety. 3INCORPORATION'BMREFERENCE' 0FSEQUENCE LISTINGiPROVlDED iEL‘ECTRONICALLY An electronic version of the Sequence Listing is 'ﬁled herewith, the contents of which 115 .are incorporated by:reference in'their entirety. The ronic ﬁle was created onDecember .28, 2012, is 3.48megabytes in size, and titled .3087seqPC1.‘txt.

IFIEL‘D‘OF THE INVENTION ‘ TModiﬁed EH20 hyaluronidasepolypeptides, ing'modiﬁedpolypepti'des that exhibit sed stability :and/or increasedactivity, .areiprOVided. Also provided are ‘20 compositions and ations and uses thereof.

BACKGROUND Hyaluronan (hyaluronic acid; HA) is apolypeptide that isfound in‘the extracellular ‘matrix ofmany .cells,-especially'in soft connective'tissues. HAalso. is ‘found predominantly in skin, cartilage, and in al ﬂuid in'mammals. onan also is themain constituent - 2'5 of'the vitreous of theeye. 'HA has arch in s physiological .processes, such as 'in water and plasma protein homeostasis (Laurent TC et a]. (1992) FASEBJ 6: 2397-2404). Certain diseases areassociated with expression and/or'production of hyaluronan. Hyaluronan- degrading enzymes, such as hyaluronidases, are s that degrade hyaluronan. .By 'catalyzing'I-I‘A degradation, hyaluronan-degrading s (e. g., hyaluronidases).can be used ‘to treat diseases or disorders associated with accumulation ofHA or other glycosaminoglycans. Also, since HA is a'major component ofthe interstitial r, hyaluronan-degrading enzymes (e.g., hyaluronidase) increase tissue permeability and thereforecan be used ‘to increase the dispersion and delivery of therapeutic agents. ‘Various hyaluronidases have been used therapeutically (e.g., HydaseTM, 'VitraseTM and WydaseTM), typically as dispersing and spreading agents in combination with other therapeutic .

RECTIFIED SHEET (RULE 91) lSA/EP WO 02144 PCT/US2012/072182 Many of these are ovine or bovine forms, which can be immunogenic for treatment of humans. Improved hyaluronan-degrading enzymes, such as hyaluronidases, and compositions thereof that can be used for ent are needed.

SUMMARY Provided are modiﬁed PHZO polypeptides that have an altered property or properties compared to the PHZO polypeptide that do not have the modiﬁcation(s). The modiﬁcations include amino acid replacement, deletion and/or insertions. Detailed structure/function of lly each amino acid in a PHZO polypeptide is provided , as well as the identiﬁcation of residues and loci that contribute to alteration of a property, such as stability in particular conditions, is provided. Hence, provided are modiﬁed PHZO polypeptides that contain one or more amino acid ements that result in a PHZO polypeptide that retains actiVity and/or ts increased or altered ity under a variety of conditions. Activity retained can be, for example, hyaluronidase actiVity that is as least about 40% or more of the PHZO polypeptide that does not include the replacement. Exemplary ations are amino acid replacements. For purposes , amino acid replacements are denoted by the single amino acid letter followed by the corresponding amino acid position in SEQ ID NO:3 in which the replacement occurs. Single amino acid abbreviations for amino acid residues are well known to a skilled artisan (see 6.g. Table l), and are used herein throughout the description and examples. For example, replacement with P at a position corresponding to position 204 in a PHZO polypeptide with reference to amino acid residue positions set forth in SEQ ID NO:3 means that the replacement encompasses F204P in a PHZO polypeptide set forth in SEQ ID N03, or the same replacement at the corresponding position in another PHZO polypeptide.

Provided are modiﬁed PHZO polypeptides that contain at least one amino acid replacement in a PHZO polypeptide, whereby the modiﬁed PHZO polypeptide exhibits increased stability compared to the PHZO polypeptide not containing the amino acid replacement. Increased stability can be manifested as increased resistance to one or more protein ions that are denaturing to proteins. The stability of modiﬁed and unmodiﬁed PHZO is compared under the same conditions. Exemplary protein denaturation (or denaturing, used interchangeably herein) conditions include, but are not limited to, elevated temperature greater than 30 0C or about 30 OC, agitation, low salt, including ially or substantially or no salt, and presence of ents that tend to re ns. Exemplary of such excipients are antiadherent(s), binder(s), coating(s), s) and diluent(s), ﬂavor(s), color(s), lubricant(s), glidant(s), preservative(s), detergent(s), sorbent(s) and combinations thereof WO 2013/102144 2012/072182 ,_ 3 - modiﬁed‘PHZO‘polypeptide can be one in which the unmodiﬁed ‘form thereofhasat least about 68% sequence identity‘to SEQ 111N013 and‘further contains modiﬁcations that - alter stability and/ocean be a PH20 polypeptide that includes asmany as about uptto 7100, .110, 1220, 130, 150 amino acid differences from PH20-but retains enzymatic activity, » particularly, at least about 140% of the activity of the unmodiﬁed PH20 polypeptide and ts increased stability, such as stability under ring conditions. Thus, included are modiﬁed 'PHZO polypeptides that have at least 68% or‘ about 68% amino :acid sequence - identity to the sequence of aminoacids set forth in SEQ ID NO:3. Included are'modiﬁed ’PHZO'polypeptides that have at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, '10 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity‘to the ’ sequence of amino acids set'forth in SEQ JD NO:3. Exemplary of.such'modiﬁed 'PH20 polypeptides 'are-polypeptidesthat contain aminoracid replacement(s) inza olypeptide that containsthe sequence of amino acid residues as set forth inany of SEQfID NOS: [3, ’7, £10, 122, .14, -66,‘69, '72, 857, 859, I861, 870 ora sequence of'amino acids that‘is at least '1‘5 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical‘to any of SEQ 'ID'NOS: E3, '7, 10,12, ,14, 24, .32-‘66,‘69, '72, ‘857, 1, or '870.

‘Forexamplenprovided herein is a'modiﬁed'PH20;pdlypeptide that-exhibits increased stability containing anamino acid replacement in 'aiPHZO,‘polypeptide'that.confersthe increased stability, wherein increased stability ismanifested as increased resistance 'to denaturation in thepresence of one or'moreprotein denaturation conditions, stability is increased compared tothe JPI-l20:polypeptide nottcontainingthe amino :acid replacement, and "the ﬁed PH201polypeptide consists of'the sequence ofamino .acids rsetzforth in SEQ ,ID 'NOS: '7 or issa C—‘terminal'truncated'fragment‘thereofthat is.a.solubleJPH20:polypeptide or has at least 85% sequence identity thereto. 'As above, the modified PH20'pOlypeptide that 225 exhibits increased stability exhibits increased stability'to a rationcondition"that is temperature r than or about ‘30 °C; agitation; low orrnoa salt; or ce ofan excipient or a denaturing agent, such asan antiadherent(s), binder(s),.coating(s), ﬁller(s) and diluent(s), ﬂavor(s), color(s), lubricant(s), t(s),_ preservative(s), detergent(s), t(s) or sweetener(s)'and a combination thereof, .and inparticular a preservative. In some examples ..30 ofsuch modiﬁed PH20 polypeptides that t increased stability, the denaturation condition is temperature greater than 30°C, and the modiﬁed PH20 polypeptide exhibits greater onidase activity at the temperature compared to the unmodiﬁed PH20 polypeptide not containing the amino acid r’eplacement(s) where the activities are compared under the same conditions. In other examples, the protein denaturation condition is the presence of low conCentrations of salt oflessthan 100 mM, and the modiﬁed PH20 RECTIFIED SHEET (RULE 91) lSA/EP WO 02144 PCT/US2012/072182 ._.-4.- ptide exhibits increased hyaluronidase activity in‘the presence of low concentrations of salt compared‘to :theunmodi‘ﬁed IPH20 polypeptide ‘notxcontaining ~- 'the.'amino acid replacement(s) Where the ties are ed underi'the'Same I I ,conditiOns'. I In any of the above examples of a modiﬁed PHZO polypeptide that exhibits increased stability, ity can be assessed based on a variety of parameters including hyaluronidase activity, solubility, aggregation and/or crystallization. Stability can be assessed in the. presence of a denaturing condition. When stability oftwo or more'polypeptides iscompared, stability isassessed under the same conditions. \In some instances, among'thePHZO polypeptides provided herein,’the modiﬁed PHZO'polypeptideexhibits-at least 120%, 130%, 135%, 140%,‘145%, 150%, 160%, 170%, 180%,200%,250%,.300%,.350%,»400%, 500%, ' 1500%, 2000%, .‘3000%,-4000%, .5000% or more of the hyaluronidase activity of‘the'PHZO polypeptide 'notcontaining the amino acid replacement(s). iIn:any of the above examples of a modiﬁed PH202polypeptide‘that exhibits increased 1155 stability, ring conditions include‘the ce ofexcipients that re’proteins.

Exemplary ofsuch conditions .isthetpresence of'a preservative, such:as:a phenolic preservative. ’Provided are modiﬁed PH20'polypeptides 'that- exhibit‘increased' stability inrthe :presence of ananti-microbialeffective amount of one or more phenolic preservatives. An icrobial .effectiveamount isthe'total amount of one or'more phenolicvpreservative agents, whichcan'be expressed‘asa percentage (%) ofmass concentration (w/v)‘that is or is between (or at least about or at about) 0.05% to 0.6%, 0.1%to 0.4%, to 0.3%, 0.15% to 0.325%, 0.159610 0.25%, 0.1% to 0.2%, 0.2%‘to 0.3% or 0.3%‘to 0.4%, ive.

Exemplary phenolic preservatives e, ‘but are not limited to,'phenol, metacresol (m- .cresol), benzylalcohol, and a‘paraben, suchas methylparaben 'propylparaben, 'm-cresol, .25 . phenol or m-cresol and phenol. Exemplary ofthe stability achieved byprovided'modiﬁed PH20 polypeptides are'those that exhibit at least 15% or about 15% of the hyaluronidase activity for at least 4‘hours in the presence of vative(s) compared to the d PH20 ‘pOlypeptide in absence ofpreservative. Activity is compared under the same conditions , except'for the ce of'preservative(s).'»For e, provided are modiﬁedPHZO polypeptides that :exhibit at least (or at‘least about) 16%, 17%, 18%, 19%, 20%, 25%, 30%, %, 40%, 45%, 50%, :‘55%,-60%, 65%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more of’ the onidase activity in the presence of a phenolic preservative(s) compared to absence of the same preservative(s). Thus, provided, among the modiﬁed PH20 polypeptides provided'herein, are PH20 polypeptides that, by virtue of amino acid replacement(s), are RECTIFIED SHEET (RULE 91) lSA/EP WO 2013/102144 2012/072182 hilic ed to PH20 polypeptides without such replacement. Included are modiﬁed PH20 polypeptides where the hyaluronidase activity is exhibited after at least 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks or more in the presence of the preservative(s) compared to the hyaluronidase activity of the modiﬁed PH20 polypeptide in the absence of preservative for the same time period and under the same conditions except for the presence of preservative(s).

In examples of a modiﬁed PH20 polypeptide that exhibits increased stability to a phenolic preservative, increased stability in a phenolic preservative can be exhibited under temperature conditions that include any temperature between, for e, 0 oC and 40 0C, such as between or about between 0 0C to 40 OC, 2 0C to 6 0C, 24 0C to 32 OC and 35 0C to 40 °C. Exemplary polypeptides exhibit increased stability at temperatures of between or about between 30 °C to 45 °C, 35 °C to 45 °C, 30 °C to 37 °C, 35 °C to 37 °C or 37 °C to 42 °C, each inclusive. The particular modiﬁed PH20 polypeptide and conditions depend upon the intended ation, conditions to which the formulation will be exposed and/or intended application. ular and exemplary modiﬁed PH20 polypeptides that exhibit increased stability, such as increased ity to a phenolic preservative, include those that contain a single amino acid modiﬁcation, such as a replacement, and combinations of modiﬁcations, such as at least or 2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14,15,16,17,18,19, 20, 30, 40, 50, 60, 70, 80, 90, 100 and more modiﬁcations. These include modiﬁed PH20 polypeptides that contain one or more amino acid replacements, where at least one replacement is at an amino acid position corresponding (i.e., by alignment) to a position selected from among 10, 12, 20, 22, 26, 34, 36, 46, 50, 52, 58, 68, 70, 74, 82, 83, 84, 86, 97, 127, 131, 138, 142, 143, 144, 166, 169, 174, 193, 195, 196, 204, 205, 206, 213, 219, 234, 237, 238, 240, 249, 261, 267, 277, 279, 291, 309, 310, 314, 315, 317, 318, 347, 367, 375, 376, 399, 401, 407, 416, 419, 421, 431, 433, 439, 440, 443 or 445 with reference to amino acid positions set forth in SEQ ID NO:3, wherein corresponding amino acid positions are identiﬁed by alignment of the PH20 polypeptide with the polypeptide set forth in SEQ ID NO:3. Exemplary of such modiﬁcations are at least one amino acid replacement selected from among replacement with: glycine (G) at a position corresponding to position 10; K at a on ponding to position 12; S at a position ponding to position 20; T at a position ponding to position 22; M at a position corresponding to position 26; W at a position corresponding to position 34; N at a position corresponding to position 36; L at a on corresponding to position 46; M at a position WO 2013/102144 PCT/US2012/072182 corresponding to position 50; T at a position corresponding to position 52; S at a position corresponding to position 52; C at a position corresponding to position 5 8; K at a position corresponding to position 58; R at a position corresponding to position 5 8; N at a on corresponding to position 58; Y at a position corresponding to position 5 8; P at a position corresponding to position 58; H at a position corresponding to position 5 8; P at a position corresponding to position 68; V at a position corresponding to position 70; E at a position corresponding to position 74; L at a position corresponding to position 82; N at a position corresponding to on 82; V at a position corresponding to position 83; Q at a position corresponding to position 83; S at a position corresponding to position 83; G at a position corresponding to position 83; N at a position corresponding to position 84; A at a position corresponding to position 86; K at a position corresponding to position 86; E at a position corresponding to position 97; L at a position corresponding to position 97; R at a position corresponding to position 127; R at a on corresponding to position 131; L at a position corresponding to position 138; K at a position corresponding to position 142; N at a position corresponding to position 142; P at a position corresponding to position 142; S at a position corresponding to position 142; T at a on corresponding to on 142; G at a position corresponding to position 143; K at a position corresponding to position 143; T at a position corresponding to position 144; Q at a position corresponding to position 166; T at a position corresponding to position 166; L at a position corresponding to position 169; G at a position corresponding to position 174; N at a position corresponding to position 174; Q at a position corresponding to position 193; T at a position ponding to position 195; N at a position corresponding to on 195 ; E at a position corresponding to on 196; R at a position corresponding to position 196; P at a on corresponding to position 204; A at a position corresponding to on 205; E at a position corresponding to position 205 ; I at a position corresponding to position 206; A at a position ponding to position 213; I at a on corresponding to position 219; M at a position corresponding to on 234; T at a on corresponding to position 237; H at a position corresponding to position 238; Q at a position corresponding to position 240; V at a on corresponding to position 249; A at a on corresponding to on 261; K at a position corresponding to position 261; T at a position corresponding to on 267; K at a on corresponding to position 277; H at a position corresponding to position 279; V at a position corresponding to position 279; V at a position corresponding to position 291; E at a position corresponding to position 309; Q at a position corresponding to on 310; Y at a position corresponding to position 314; Y at a position corresponding to position 315; N at a position corresponding to position 317; W at a position corresponding to position 317; D at a position corresponding to position 318; G at a position WO 2013/102144 PCT/US2012/072182 ._ '7 ._ _. correspondingvto position 3347; A at ion corresponding torposition .367; 1R.atzapositi0n. 53 75;‘R at a oncorrespondingtoposition i3 76; V ataposition , correspondingth position 1' , . corresponding'to position .399; ‘E at a position corresponding to position 401; A at 'a position .corresponding‘to position-407; 'L at a position corresponding to position 416;'K ata position sponding‘toposition 419; H at a position corresponding to positionl421;'E.at.a position corresponding to position «43 l; T at a position ponding to position‘433; V .at a position ponding "to position 433; C at a position ponding to position 439; ’P at aposition corresponding'to position-440; G at a position corresponding to position 4443; N at a position corresponding to position 445, with reference'to amino acid residue positions set forth in SEQ .10 ID N053. For example,'the modiﬁed PH20 ptide can contain at least one amino acid , replacement selected from among replacement with: T atta position .corresponding'to position .'52, K at :a position corresponding-to position 58, R at a position .corresponding'toposition .58, ‘P at a‘position corresponding to position 68, V at ion corresponding to position 83, P at aposition corresponding toposition 204, A at a‘position corresponding 'to position 261, Tat :a '1'5 oncorresponding to position .267, 'K at .aposition corresponding’to position 2'771and Hat .a position corresponding to position 421, with reference‘to aminoacidresiduepositions set 'forth in SEQ ID NO:’3. 'Anexemplary modiﬁed PH20 polypeptide is one'that includes P (or aconservative aminoacid'thereto) at a position corresponding‘to position 204 in :a ~PI-120 polypeptide with reference to :amino acid'residue-positions set forth in SEQ ID'NO:3.

’Thus,provided herein are'modiﬁed PH20 polypeptides that exhibit increased stability in'thetpresence of:aphenolic preservative containing an amino acid replacement inaéPHZO 'polypeptide'that confers the increased stability, n stabilitytis increased compared‘to ‘the unmodiﬁedpolypeptide‘without the amino acid replacement, and the unmodiﬁed -'PH20 polypeptide has the sequence of amino acids set 'forth'in SEQ ID NO: '7 or is a C-terminal truncated nt fthat is a soluble 'PH20 polypeptide or has at least 85% sequence identity thereto. .For example, the unmodiﬁed PH20 polypeptide .isa soluble PH20 ptide that has the sequence ofamino acidsset :forth in any of SEQ ID NOS: 3 or 32-66. In ular examples, the modiﬁed PH20 polypeptide has at least 85% ce identity‘to SEQ 'ID N053. In any of such examples of a 3O modiﬁed PH20 polypeptide, the polypeptide contains'v'l, .2, f3, ‘4, .5, 6, '7, 8, 9, 10, .11, ‘12, '13, '14, 15, '16, 1'7, 18, '19, 20, 21, 22,‘2‘3,.24,25, '26, 27, 28, 29, 30, 31, 32, 33, 34, ,36, 37, 38, 3'9, 40, 4'1, 42, 43, 44, 45, 46, .47, 48,49, .50, '5'1, .52, 53, 54, 55, :56, .57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73,74, 75_ or more amino acid replacements. In examples herein, the modiﬁed PH20 ptide is a human PH20.

RECTlFlED SHEET (RULE 91) lSA/EP WO 2013/102144 PCT/US2012/072182 ~8- The modiﬁed ".PH20polypeptide exhibits stability-in the presence ofphenolic » preservatives if it exhibits at least 15% of'the h'yaluronidase :activity in ‘the presence j -' Of rvative(s) ‘fOr at le’a’st'4 hours compared ‘tothe hyaluronidase activity in the, absence of the phenolic preservative(s), wherein "the activity is compared underthe same conditionsvexcept for the presence of the phenolic preservative(s). .In any of the i above examples, the modiﬁed PH20 polypeptide is stable in the presence of an ofan V V anti-microbial ive amount of one or more phenolic preservatives, such as a'total amount of one or more phenolic preservative agents as a'percentage (%) ofmass concentration (w/v) that "is from or from about 0.05%‘to 0.6%, 0.1%‘to 0.4%, 0.1%‘to 0.3%, 0.‘1:5%'to 0.325%, 0.1.5%'to 0.25%, 0.1% to 0.2%, 0.2%to 0.3% or o 0.4%, inclusive. The phenolic preservativecan be a'phenol, ’metacresol (m-cresol), benzyl alcohol or ajparaben, such as m-cresol, phenol, or m-cresoland . .The amino acid'replacement can be at amino acid e 204, :58, 10, 12,20, 22, .26, .34, '36,46,:'50,:52, 68,70, 74, 82, 83, 84,86, 97, 1,27, 1'31,138,142,143, L144, 166, 1169, ' ‘1-5 .174, L193, "195, 5,206, 213,219, .234, 237,723 8, 240, 249,261 , 267, 277, 279, 291, 309, 3310,3114,3'15,.317,.318,f347, $367,375, 376, .399, 401, 407,416, 419, 421, 431, 433, 439, 440,443 or-445 ference 'to amino acid ons set forth in SEQ 'ID ’NO:3, whereincorresponding aminoacid positions are identiﬁed by .alignment of the TPHZO-po'lypeptide with‘thejpolypeptide set forth in SEQ 'ID .NO:3. iForzexample, the aminoacid‘rep'lacement is G at ion corresponding to position ‘10; K .at;a position corresponding to position 212; 'S ataposition .corresponding'to;position 20; T at aposition corresponding'to position .22; M at 'a position corresponding‘to position .26; 'W at aposition corresponding 'to position '34; N at aposition corresponding to position '36; L at ion corresponding 'to position 46; M at a position corresponding 'to position ‘50; T at aposition ponding to position 52; ~S at 'a on corresponding to position ’52; C at aposition corresponding to position :58; 3K at a positioncorresponding'to position58; ‘R at a position corresponding to position 58; N at a position corresponding to position '58; Y at a position corresponding to position '58; ‘P at a on corresponding 'to position '58; H at aposition corresponding to position 58; .P at a position corresponding to-position 68; 'V at a position corresponding'to position 70; E at a on ponding to position 74; L at a position corresponding to position 82; N at a_position corresponding to position RECTIFIED SHEET (RULE 91) lSA/EP WO 2013/102144 PCT/US2012/072182 82; V at a position corresponding to position 83; Q at a position corresponding to position 83; S at a on ponding to position 83; G at a on corresponding to position 83; N at a on corresponding to on 84; A at a position corresponding to position 86; K at a position corresponding to position 86; E at a position corresponding to position 97; L at a position corresponding to position 97; R at a position ponding to position 127; R at a position corresponding to position 131; L at a position corresponding to position 138; K at a position corresponding to on 142; N at a position corresponding to position 142; P at a position corresponding to on 142; S at a position corresponding to position 142; T at a position corresponding to position 142; G at a position corresponding to position 143; K at a position corresponding to position 143; T at a on corresponding to position 144; Q at a position corresponding to position 166; T at a position corresponding to position 166; L at a position corresponding to position 169; G at a position corresponding to position 174; N at a position corresponding to position 174; Q at a position corresponding to position 193; T at a position ponding to position 195; N at a position corresponding to position 195; E at a position corresponding to position 196; R at a position corresponding to position 196; P at a position corresponding to position 204; A at a position corresponding to position 205; E at a position corresponding to position 205; I at a position corresponding to position 206; A at a position corresponding to position 213; I at a position corresponding to on 219; M at a position corresponding to position 234; T at a position corresponding to position 237; H at a position corresponding to position 238; Q at a position corresponding to position 240; V at a position corresponding to position 249; A at a on corresponding to position 261; K at a position corresponding to position 261; T at a position corresponding to position 267; K at a position corresponding to position 277; H at a position corresponding to position 279; V at a position corresponding to on 279; V at a position corresponding to position 291; E at a position corresponding to position 309; Q at a position ponding to position 310; Y at a position ponding to position 314; Y at a position corresponding to position 315; N at a position corresponding to position 317; W at a position corresponding to position 317; D at a position corresponding to position 318; G at a on corresponding to position 347; A at a WO 2013/102144 PCT/US2012/072182 -10" position corresponding to position 367; 'R at aposition corresponding toposition ,3 75; 'Ratapositio‘n corresponding to 'poSition’376; ‘V'at aposition corresponding to ' "positionf3 99; E at aposition corresponding‘toposition401;.Aata position 1- corresponding to on407; "L at a position ponding to position-41 6; Kata position corresponding to poSition 419; Hat aposition corresponding‘to position 421; "E at ioncorresp‘onding‘to positiOn-43'1; T at aposition ponding to position~433g 'V at a position corresponding toposition 433; C at a position corresponding‘to position-439; Pat aposition correspondingto position 440; G at a position corresponding to position 443; or'N at a position corresponding to on -.10 )44S,‘Mth:reference o acidr‘residue positions set‘forth in SEQ ID ZNO:3. ,In ular, the amino acid replacement is T at ion corresponding to position.52, L .K at a position corresponding :toposition '58,R at aposition corresponding to position :58,.'P at‘a position corresponding ‘to position 68, 'V at aposition corresponding'to position 83, Pat aposition ponding‘to position 204, A 'at aposition 1:5 correspondingrto position .26‘1,’T.at aposition corresponding to position 5267, ‘K at a position correspondingtoposition '277 or 'H at aposition corresponding to position 421 , with reference ~to amino .acid residue positions set :forth .in .SEQ 'ID 'NO:3 , .such2as replacement with P at aposition corresponding'to position '204-or.R.at:a:position ‘ corresponding'to position ‘58. 'The'modiﬁed‘PHZO polypeptide'that exhibits increased .20 stability 'to ic preservatives can be substantially puriﬁed orisolated. The modiﬁedIPHZOpolypeptide thatzexhibits increased stability to phenolicpreservatives can‘be'modiﬁed'by glycosylation, sialation, albumination, ‘farnysylation, carboxylation, hydroxylation and phosphorylation, and generally'is y'lated, whereby the polypeptide comprises at least an N-acetylglucosaminemoiety linked to ‘25 each of at least three asparagine (N) residues, such as at amino acidresidues corresponding'to amino acid residuesZOO, .333 and 358 of SEQ IID'NO:3. The modiﬁed .PH20'p01ypeptide that ts increased stability'to phenolic preservatives can be conjugated'to apo'lymer, such as‘PEG or dextran and/or can be .conjugatedto .a » moiety that is a ‘multimerization domain, a toxin, .a detectable 'label or a drug.

Among d PHZO polypeptides provided herein that exhibit increased stability I are those that exhibit increased hyaluronidase activity at the elevated temperature ed to the PH20 polypeptide not containing the amino acid replacement(s), such as at least 110%, V RECTIFIED SHEET (RULE 91) ISA/EP WO 02144 2012/072182 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 300%, 400%, 500% or more hyaluronidase activity for at least 4 hours compared to the PH20 polypeptide not containing the amino acid ement(s). Also among the polypeptides are those that exhibit actiVity, but also typically exhibit increased stability or other property at elevated temperatures, such as a modiﬁed PH20 polypeptide that ts at least 95%, 96%, 97%, 98%, 99%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 300%, 400%, 500% of the hyaluronidase ty for at least 4 hours at a ature of between or about between 32 0C to 37 OC compared to the hyaluronidase activity of the modiﬁed PH20 polypeptide at a temperature of between or about between 2 0C to 8 0C, where activity is compared under the same conditions except for the differences in temperature. The hyaluronidase actiVity can be exhibited after at least 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks or more at elevated temperatures of between or about between 32 0C to 37 OC compared to the hyaluronidase activity of the modiﬁed PH20 polypeptide at a temperature between or about between 2 0C to 8 0C, where actiVity is compared for the same time period and under the same ions except for the difference in temperature. ary of such modiﬁed polypeptides are those that contain at least one amino acid replacement at an amino acid position corresponding to a position selected from among 1, 11, 12, 14, 20, 26, 29, 34, 50, 58, 70, 82, 83, 84, 86, 87, 140, 142, 143,147,152,166,167,172,174,178,193,195, 206, 212, 213, 219, 233, 237, 240, 267, 277, 291, 292, 309, 313, 314, 317, 318, 347, 367, 368, 371, 374, 389, 392, 395, 396, 406, 419, 421, 439 and 443 with reference to amino acid positions set forth in SEQ ID NO:3, wherein corresponding amino acid positions are identiﬁed by alignment of the PH20 polypeptide with the ptide set forth in SEQ ID NO:3. Exemplary mutations include, for example, replacement with R at a position corresponding to position 1; S at a position corresponding to position 11; I at a position corresponding to position 12; V at a position corresponding to position 14; S at a position corresponding to position 20; M at a position corresponding to position 26; with R at a position corresponding to position 29; W at a position corresponding to position 34; M at a position corresponding to position 50; K at a position corresponding to on 58; Q at a position corresponding to position 5 8; Q at a on ponding to position 5 8; V at a position corresponding to position 70; L at a position ponding to position 82; Q at a position corresponding to position 83; R at a position corresponding to position 84; A at a position corresponding to position 86; S at a position corresponding to position 87; K at a position corresponding to position 140; S at a position corresponding to position 142; T at a position ponding to position 142; K at a position corresponding to WO 2013/102144 2012/072182 .42.- 2 position 143‘; 'S at apositiOn corresponding to position 3147; T at aposition corresponding :to -. position 152; T at aposition corresponding'top'osition 166;,D at ion.corresponding'to ' V position 167; A at aposition,corresponding'to position 172; G at a positioncorresponding to ~ 1 position 174; N at a position corresponding to position 174; R at a on corresponding to position 178}; Q at.a position corresponding to on 193; T at aposition corresponding to position 195; I at'a‘position corresponding toposition 206; S at a position corresponding to on (212; A at a position corresponding toposition 1213; I at aposition corresponding to position 219; G at aposition corresponding'to position 1233; T atta position corresponding to position123 7; A at a position corresponding toposition 240; Q at a position corresponding to position 240; .T at 'a position corresponding to position .267; E at aposition corresponding‘to position .277; ‘S at a'position corresponding toposition ‘291; H ataposition.corresponding‘to - position 292;’V at .a position corresponding .toposition .292; S at a position .corresponding'to position 309; H at a‘position corresponding to position ‘3 13; .S at aposition corresponding'to position '3 14;:I ata position corresponding to position 317; .T at a on corresponding to ‘15 position .317;‘W.at,a on corresponding'to position ,3 17; R at aposition corresponding to position 311 8; G at :aposition corresponding to position 347; A atra position corresponding to position .3 67; Rat aposition corresponding‘to position ‘3 68; S at 'aposition ponding'to position .371; P ition corresponding to position ‘3 74; A at 'a'position corresponding to on .3 89; 'V at aposition correspondingtopOsition 392; A at 'aiposition corresponding to .20 on .395; H at :a on ponding'to position ‘396; N at ‘a'position correspondingtto position 406; H at a'position corresponding toposition 419; K at'a position corresponding to position 419; 'R at aposition corresponding to position 421; S at a'position corresponding'to position 421; A at a on corresponding‘to position 439; C at'aposition .corresponding‘to position 439; and G at a position'corresponding to position 443, withreference to amino acid positions set‘forth in SEQ ID NO:3. In particular examples provided herein, any ofsuch modiﬁed PH20 polypeptides contain a single amino acid modiﬁcation, such as a replacement, and combinations of modiﬁcations, such as at least or.2, '3, 4, 5, '6, '7, 8, 9, 10, 11, 12,13, 14, , 16, 17, 18, 19,20, 30,40, 50, 60, 70, 80, 90, 100 and more ations. The modiﬁcation, such as replacement, can be in an unmodiﬁed PH20 polypeptide that has the 7 .30 sequence ofamino acids setforth in SEQ ID NO: 7 or is a C-tenninal truncated fragment thereof that is a soluble PH20 polypeptide, such aslis set forth in any of SEQ ID NOS: 3 or 32-66, or has at least 85% sequence identity thereto. .For example, any of such modiﬁed PH20 polypeptides has at least 85% ce identity to SEQ ID NO:3.

' Also ed are modiﬁed PH20 polypeptides that exhibit increased stability in low salt conditions, such as, for example, concentrations of NaCl of less than 100 mM, such as, RECTIFIED SHEET (RULE 91) lSA/EP WO 2013/102144 2012/072182 .- 1'3 .. .but not limited toconcentrations ofNaCl less than 90 mM, 80 mM, 70mM, 60 mM, .50 mM,: -.- . 540 mM,- f30‘m'M,Z25 mM,.ZO mM, 15 O mM,..5,-mM or less. Among the modiﬁed PH20 - polypeptidesare those thatexhibit sed hyaluronidase activity at lower concentrations-of 1 . salt compared to the PH20 polypeptide not .containing'thc amino acid 'replacement(s). Such .activity es, ‘for example, at least moretthan 100%, or at least 110%, 120%, 130%, 140%, 150%, 160%, .170%,.180%, 190%, 200%, 300%, 400%, 500% or more hyaluronidase activity compared'to the PH20 polypeptide not containing the aminoacid replacement(s).

Exemplary of such d PH20 polypeptides are those'that exhibit at least 60% of the hyaluronidase activity in lowconcentrations of salt, such as between or about between 10 mM NaCl and 100 mM NaCl, inclusive (or comparable concentrations of other salts or'mixtures of salts), compared to the hyaluronidase activity of the modiﬁed PH20‘polypeptide in 150 mM NaCl, where activities are compared under the same conditions except for the difference in salt concentration. Inparticular examples provided herein, any of such modiﬁed PH20 polypeptides contain a single amino acid modiﬁcation, such as a-replacement, and combinations ofmodiﬁcations, such as at least or‘2, 3,4, 5, 6,7, 8, 9, .10, i1 1, 1.2, 313, .14, 1.5, '16, 17, 18,19,120, 30,40,150, 60, '70, 80, 90, 100.and'more modiﬁcations. The-modification, such :as replacement, can be in.an unmodiﬁed'PHZO po'lypeptidethat'has the sequence of . amino acids set’forth lD'N02‘7 or is a C-terminal truncated fragment f'that is a soluble PHZO‘polypeptide, suchas is set‘forth in any of SEQ ID NOS: 3 or‘32-66, or'has at least‘85% sequence identity thereto. i-For example, any of such d PH20 polypeptides V has .at least 85% sequence identity "to SEQ ID N023.

Also provided are-modiﬁed'PI-IZOpolypeptides that n at least oneamino acid replacement in :a PH20 polypeptide, where the modiﬁed PH20 polypeptide exhibits increased hyaluronidase activity compared‘tothe PH20 ‘polypeptide'not containing the amino acid .25 replacement. When comparing activityamong ptides, activity is compared under the» same conditions. Among these are polypeptides, where the unmodiﬁed .PHZO exhibits at least 68%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 9.2%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity‘to the sequence of amino acids set forth in SEQ ID 'NO:3, or the resulting‘modified- PH20 ts such sequence identity to the . ce of amino acids set forth in SEQ ID N053. Exemplary of such modified'PHZO polypeptides are any that contain an amino acid ement(s) in the sequence of.amino, . acids set forth in any of SEQ ID NOS: 3,7, 10, 12, 14,24, 32-66, 69, or 72, or a sequence of amino acids that is at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to any of SEQ ID NOS: .3, '7, 10, 12, 14, 24, 32-66, 69, 3'5 or 72. The amino acid replacement(s) also can be made in the sequence of amino acids set RECTIFIED SHEET (RULE 91) lSA/EP WO 2013/102144 PCT/US2012/072182 forth in any of SEQ ID NOS: 857, 859, 861 or 870, or a sequence of amino acids that is at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to any of SEQ ID NOS: 857, 859, 861 or 870. In particular, provided are modiﬁed PH20 polypeptides that n an amino acid ement in the sequence of amino acids set forth in SEQ ID NOS: 3, 7, 32-66, 69 or 72. Among the d PH20 polypeptides are those that that exhibit at least 120%, 130%, 135%, 140%, 145%, 150%, 160%, 170%, 180%, 200%, 250%, 300%, 350%, 400%, 500%, 1500%, 2000%, 3000%, 4000%, 5000% or more of the hyaluronidase activity of the PH20 polypeptide not containing the amino acid replacement. Activity can be assessed at any temperature, in particular such activity is present When the hyaluronidase is exposed to a temperature that is at a temperature between or about between 2 0C to 8 0C. These modiﬁed PH20 polypeptides contain at least one amino acid replacement at an amino acid position corresponding to a position selected from among 1, 12, 15, 24, 26, 27, 29, 30, 31, 32, 33, 37, 39, 46, 48, 52, 58, 63, 67, 68, 69, 70, 71, 72, 73, 74, 75, 84, 86, 87, 92, 93, 94, 97,118,120,127,131,135,141,142,147,148,150, 151,152,155,156,163,164,165,166,169,170,174,198, 206, 209, 212, 213, 215, 219, 233, 234, 236, 238, 247, 257, 259, 260, 261, 263, 269, 271, 272, 276, 277, 278, 282, 291, 293, 305, 308, 309, 310, 313, 315, 317, 318, 320, 324, 325, 326, 328, 347, 353, 359, 371, 377, 380, 389, 392, 395, 399, 405, 407, 409, 410, 418, 419, 421, 425, 431, 433, 436, 437, 438, 439, 440, 441, 442, 443, 445, 446 and 447 With reference to amino acid positions set forth in SEQ ID NO:3, Wherein corresponding amino acid positions are identiﬁed by alignment of the PH20 polypeptide With the polypeptide set forth in SEQ ID NO:3. Exemplary modiﬁcations include at least one amino acid replacement selected from among ement With: histidine (H) at a position corresponding to position 1; Q at a position corresponding to on 1; E at a position ponding to position 12; T at a position corresponding to position 12; V at a position ponding to position 15; E at a position corresponding to position 24; H at a position corresponding to position 24; E at a position corresponding to position 26; K at a position corresponding to on 26; K at a position corresponding to position 27; R at a position corresponding to on 27; E at a position corresponding to position 29; I at a position corresponding to position 29; L at a position corresponding to on 29; M at a position corresponding to position 29; P at a position corresponding to position 29; S at a position corresponding to position 29; V at a position corresponding to position 29; G at a position corresponding to position 30; H at a position corresponding to position 30; K at a position corresponding to position 30; M at a position corresponding to on 30; R at a position corresponding to position 30; S at a position corresponding to position 30; A at a on corresponding to position 31; C at a on corresponding to position 31; H at a WO 2013/102144 PCT/US2012/072182 position corresponding to position 31; 1 at a position corresponding to position 31; K at a position corresponding to position 31; L at a position corresponding to position 31; P at a position ponding to position 31; R at a position corresponding to position 31; S at a position ponding to position 31; T at a position corresponding to position 31; V at a position corresponding to position 31; F at a position corresponding to position 32; G at a position corresponding to position 32; H at a position corresponding to position 32; W at a position corresponding to position 33; F at a position corresponding to on 37; N at a position corresponding to position 39; T at a position corresponding to position 39; R at a position corresponding to position 46; F at a position corresponding to position 48; H at a position corresponding to position 48; N at a position corresponding to position 48; Q at a position corresponding to position 52; K at a position ponding to position 58; Q at a position corresponding to position 5 8; W at a position corresponding to position 63; V at a position corresponding to position 67; H at a position corresponding to position 68; Q at a position corresponding to on 68; A at a position corresponding to position 69; C at a on corresponding to position 69; F at a position ponding to position 69; G at a position corresponding to position 69; I at a position corresponding to position 69; L at a position corresponding to position 69; M at a position corresponding to position 69; P at a position corresponding to position 69; R at a position ponding to position 69; W at a on corresponding to position 69; Y at a position corresponding to position 69; A at a position corresponding to position 70; C at a position corresponding to position 70; F at a position corresponding to position 70; G at a position ponding to position 70; H at a position ponding to position 70; K at a position corresponding to position 70; L at a position corresponding to position 70; N at a position corresponding to position 70; P at a position corresponding to position 70; R at a position corresponding to on 70; S at a on corresponding to position 70; T at a position corresponding to position 70; V at a on ponding to on 70; R at a position corresponding to position 71; S at a position corresponding to position 71; M at a position ponding to position 72; Q at a position ponding to position 72; H at a position corresponding to position 73; L at a position corresponding to position 73; W at a position corresponding to position 73; A at a position corresponding to position 74; C at a position corresponding to on 74; G at a position corresponding to position 74; N at a position corresponding to position 74; P at a position corresponding to position 74; R at a position corresponding to position 74; S at a position corresponding to position 74; V at a position corresponding to position 74; W at a position corresponding to position 74; F at a position corresponding to position 75; L at a position corresponding to position 75 ; R at a position corresponding to position 75; T at a WO 2013/102144 PCT/US2012/072182 position corresponding to position 75; G at a position corresponding to position 84; R at a position corresponding to position 84; A at a position corresponding to position 86; C at a position corresponding to position 87; T at a position corresponding to position 87; Y at a position ponding to position 87; C at a position corresponding to position 92; I at a position corresponding to position 93; L at a position ponding to position 93; R at a position corresponding to position 93; T at a position corresponding to position 93; R at a position corresponding to on 94; G at a position corresponding to on 97; Q at a position corresponding to position 118; F at a position corresponding to position 120; V at a position corresponding to position 120; Y at a position corresponding to position 120; H at a position corresponding to position 127; N at a position corresponding to position 127; G at a position corresponding to position 131; R at a position corresponding to position 131; V at a position corresponding to position 131; D at a position corresponding to position 135; G at a position ponding to position 135; R at a position corresponding to position 135, with H at a position corresponding to position 141; Y at a position corresponding to position 141; R at a position corresponding to position 142; R at a position corresponding to position 147; V at a position corresponding to position 147; K at a position corresponding to position 148; G at a position corresponding to on 150; K at a position corresponding to position 151; L at a position corresponding to position 151; M at a position corresponding to position 151; Q at a position corresponding to position 151; R at a position ponding to position 151; R at a on corresponding to position 152; G at a position corresponding to position 155; K at a position corresponding to position 155 ; D at a on corresponding to position 156; A at a position corresponding to position 163; E at a position corresponding to position 163; K at a position ponding to position 163; R at a position corresponding to position 163; M at a position corresponding to position 164; D at a position corresponding to position 165; N at a position corresponding to position 165 ; A at a on corresponding to position 166; F at a position corresponding to position 166; H at a on corresponding to position 166; L at a position corresponding to position 166; Q at a position corresponding to position 166; R at a position corresponding to position 166; T at a position ponding to position 166; Y at a position corresponding to position 166; L at a position ponding to position 169; R at a position ponding to position 170; K at a position corresponding to position 174; D at a position corresponding to on 198; K at a position corresponding to position 206; L at a position corresponding to position 206; N at a position ponding to position 212; M at a position corresponding to position 213; N at a position corresponding to position 213; M at a position corresponding to position 215; S at a on corresponding to on 219; K at a on corresponding to position 233; R at a position corresponding to position 233; M WO 2013/102144 PCT/US2012/072182 at a position corresponding to position 234; R at a position corresponding to on 236; E at a position corresponding to position 237; S at a position corresponding to position 238; 1 at a position corresponding to position 247; T at a position corresponding to position 257; P at a position ponding to position 259; Y at a position corresponding to position 260; K at a position corresponding to position 261; N at a position corresponding to position 261; K at a position corresponding to position 263; R at a position corresponding to position 263; A at a position corresponding to position 269; L at a position corresponding to position 271; M at a on corresponding to position 271; T at a position corresponding to position 272; D at a position corresponding to position 276; S at a position ponding to position 276; Y at a position corresponding to position 276; K at a position corresponding to position 277; R at a position corresponding to position 277; T at a position corresponding to position 277; H at a position corresponding to position 278; K at a position corresponding to position 278; N at a position corresponding to position 278; R at a position corresponding to position 278; S at a position corresponding to position 278; T at a position corresponding to position 278; Y at a position corresponding to position 278; M at a position corresponding to position 282; V at a position corresponding to position 291; A at a position corresponding to position 293; C at a position corresponding to position 293; F at a position corresponding to position 293; M at a position corresponding to position 293; P at a position corresponding to on 293; Q at a position corresponding to position 293; V at a on corresponding to position 293; E at a on corresponding to position 305; G at a position corresponding to position 308; N at a position corresponding to position 308; E at a position corresponding to position 309; L at a position corresponding to position 309; N at a on corresponding to position 309; Q at a on ponding to on 309; R at a position ponding to position 309; T at a position corresponding to position 309; A at a position corresponding to position 310; G at a position corresponding to position 310; K at a position corresponding to position 313; R at a position ponding to on 313; H at a position corresponding to position 315; I at a position corresponding to position 317; K at a position corresponding to position 317; R at a position corresponding to position 317; M at a position corresponding to position 318; H at a position corresponding to on 320; K at a position corresponding to position 320; R at a position corresponding to position 320; R at a position corresponding to position 324; A at a position corresponding to on 325; D at a position corresponding to position 325 ; E at a position ponding to on 325; G at a position corresponding to on 325 ; H at a position corresponding to position 325; K at a position ponding to position 325 ; M at a position corresponding to position 325; N at a position corresponding to position 325 ; Q at a position corresponding to position 325; S at a position corresponding to position 325 ; V at a WO 2013/102144 PCT/US2012/072182 position corresponding to position 326; I at a position corresponding to position 328; K at a position corresponding to position 328; L at a position corresponding to position 328; S at a position corresponding to position 328; Y at a position corresponding to position 328; G at a on ponding to position 347; S at a position corresponding to position 347; V at a position corresponding to position 353; With T at a position ponding to position 359; R at a position corresponding to position 371; P at a position corresponding to position 377; T at a position corresponding to position 377; W at a position corresponding to position 380; Y at a position corresponding to position 380; K at a position ponding to position 389; M at a position corresponding to position 392; R at a on corresponding to position 395; M at a position corresponding to position 399; T at a position corresponding to position 399; W at a position corresponding to position 399; G at a position corresponding to position 405; D at a position corresponding to position 407; Q at a on corresponding to position 407; A at a position corresponding to position 409; Q at a position corresponding to on 409; T at a position ponding to position 410; P at a position corresponding to position 418; F at a position corresponding to position 419; 1 at a position corresponding to position 419; K at a position corresponding to position 419; R at a position corresponding to position 419; S at a position corresponding to position 419; H at a position corresponding to position 421; K at a position corresponding to position 421; N at a position corresponding to position 421; Q at a position corresponding to position 421; R at a position corresponding to position 421; S at a position corresponding to position 421; K at a position corresponding to position 425; A at a on corresponding to on 431; H at a position corresponding to position 431; K at a position corresponding to position 431; Q at a position corresponding to position 431; R at a position corresponding to position 431; S at a position corresponding to position 431; V at a position corresponding to position 431; L at a position ponding to position 433; R at a on ponding to position 433; T at a position corresponding to position 433; V at a position corresponding to position 433; K at a position corresponding to position 436; I at a position corresponding to position 437; M at a position corresponding to position 437; T at a position corresponding to position 438; V at a position ponding to position 439; H at a position corresponding to on 440; R at a position corresponding to position 440; F at a position corresponding to position 441; R at a position corresponding to position 442; A at a position ponding to position 443; M at a position corresponding to position 443; M at a position ponding to position 445; P at a position corresponding to position 445 ; A at a on corresponding to position 446; D at a position corresponding to position 447; N at a on corresponding to position 447; and/or With Q at a position corresponding to position 447, With reference to amino acid positions set forth in SEQ ID NO:3.

WO 2013/102144 PCT/US2012/072182 ,_ 19.- Among the polypeptides that t sed hyaluronidase activityare'those‘that exhibit at .0-'fold_ of the onidaseactivity— of the PH20 polypeptide not containing 2 ' the amino eplacement. For example, among'these are d PH20 polypeptides that contain at least one 'amino acid replacement at an amino acid position corresponding'to a "position selected from among 24, 29, 31-, 48, 58, 69, 70, 75, 84, 97, '165, 166, 271,278, 31.7, ' _ 3'20, 325 and 326 with reference to positions set forth in SEQ ID NO:‘3, n corresponding amino acid positions are identiﬁed by alignment of the PH20 polypeptide with the ptide set forth in SEQ ID NO:3, such as d PH20 polypeptides that contain at least one amino acid replacement selected from among replacement with: .E at a position corresponding to position .24; E at a position corresponding‘to position .29;'V.at a position corresponding'to position 31; N at a position corresponding to ‘position'i48; K at aposition corresponding'to position 58; Q at a positioncorresponding'to position 58; A ataposition corresponding'toposition 69; F at a position ponding to position 69; G at a position 'corresponding'to position 69; P at a'position corresponding‘to position‘69; R ata position -'1‘5 corresponding toposition 69; A at a position corresponding to position 70; F .at a position corresponding toposition ‘70; G at a position corresponding to position '70; H at a‘position corresponding'to position ‘70; H at a position corresponding to position (70; Nata-position correspondingto position 70; osition corresponding to position '70; Tat a on corresponding to 'position'70; V at a on corresponding to position '70;"L;at:aposition correspondingsto position 75; T at'a‘position corresponding‘to position '75; G at 'a position corresponding‘to position 84; G at a position corresponding‘to position 97; 'D.at:a_.position corresponding'toposition 165; L at a'position corresponding'to position 166; .R at :a position corresponding to position 166; .T at a'position corresponding'to.position 166; .L ate-position corresponding'to position 271; H at a position corresponding to on 1278; R at:a:position .corresponding to position 278; 'K ata position corresponding‘to position 317; .K at a'position corresponding to position '320; E at a position corresponding to position 325, with G ata on corresponding to position 325; K at a position corresponding to position 325; N at a position corresponding to position 325; Q at a position corresponding to position .325; and V at-a position corresponding to position 326; with reference to amino acid positions set'forth in ‘ .

SEQ ID N023.

Among any of the polypeptides provided herein that exhibit increased‘hyaluronidase ' activity, any of such modiﬁed PH20 polypeptides contain a single amino acid ation, such as a replacement, and combinations of modiﬁcations, such as at least or 2, 3, 4, ‘5, 6, 7, 8, 9,10,", 12,13,14,15,l6,l7,18,19, 20, 30,40, 50, 60, 70, 80, 90, 100 and more ations. The modiﬁcation, such as replacement, can be in an unmodiﬁed PH20 RECTIFIED SHEET (RULE 91) lSA/EP WO 2013/102144 PCT/US2012/072182 .- 20.- "polypeptide that has the sequence of amino acids set forth in SEQID NO: '7- or is a C-terminal. » ' ‘ truncated fragment'thereofthat is a soluble PH20 polypeptide, such as is .set'forth in any of SEQ ID NOS: .3 or'f32-66, ‘or has at least 85% ce identity thereto. 'For example, any of such modiﬁed PH20'polypeptideshas at least quence identity toSEQ ID VNO:3.

Also provided are modiﬁed PHZO‘polypeptides that contain at least one amino acid replacement in the 'PH20 polypeptide whose sequence is set forth in SEQ ID NO:7,:a C- - terminally truncated nt f, a soluble fragment thereof, or in .a PHZO polypeptide that hasa sequence of amino acids "that is at least 91% identical to the sequence of amino acids set forth in'SEQ ID N017, where at least one amino replacement(s) is at an amino acid position corresponding to aposition‘ selected from among 1,2, 3,-4,‘5, 6, 8, -9, 10, 1'1, 12, 13, 14, 15,20, .22, 23,,24,.26,.27,28, .29, .30, (31,32, 33,34, 35, 36, 37, 38,..39,40,u41, 42, 43,44, , 47, 48,49, .50, .51, 52, .54, .58, .59, 60, 61, 63, 65, 66, 67, 68, 69, '70, "71,72, 73,74, 75, '77, 79, 81,82, 83, 84, 85, 86, 87, 89, 90, 91, 92, 93, 94, 96, 97, 98, 99, 102, 4, 105, . 106, 107, 108, 110, 114, 117,118, 119, 1.20, 122, 5, 127, .128, 130,’131,f1'32,-1’33,"1'34, L115 135, 136, I37, 138, 139, 140, 141, 142, 143, 144,145, 146, 147, 148, 149, 1.50, 151, 1:52, 153, 154, 155, 156,157, 158,159, 160, 161, 162, 163, 164,165, 166,167, 168, 169,170,11'71,'172, 173, 174,175,176, 177,178,179, 180, 181, 182, 183, 184, 186,192,193, 195, .196, 197, 198, .200,202,204,205,206,208,209,211,212,213, 214,215,216,217,218,.219, 220,221, .222, 224, 226, 230, 231, 232, 233,234, 235, 236, 237,23 8, 239, 240,242, 245, 247, 248, 251, .20 .253, 255,256, 257,258,259, .260, 261, 263, 264, 265,266,267, .269, 270, 271, 272, 273, .274, 275,276, 277, 278, 279, 280,282, 4, 285, .286, 287, 288, 289, 290,291 , 292, 293, 294, , 297,298,300,1301,.302,1304,Z305,.306, 307, 308, 309,310, 531 1,13 1.2,313,3114,131.5, 316,317, 318, .320, 321,323,324, 325, 326,327, 328,331,334,335,338, 339,342-343,347, 348,349, 351,353, 356,357, 358, 359, 360, 361, 367,368,369, 371, 373,374, 375,376,377, 378,379, .25 380, 381, 383, 385, 387, 388, 389, .391, 392, 393, 394, 6, ‘397, .398, 1, 403,404, 405, 406, 407, 409,410, 411,412,413, 414,415, 416, 417, 418, 419, 420,421, 422, 425, 426, 427, 428,-431,-432,433, 434, 43.5, 436, 43 7,438, 439, 440, 441, 442, 443,444,445, 446 and 447 with reference'to amino acid positions set ‘forth in SEQ ID NO:’3 or'7,‘Where corresponding amino acid positions are identiﬁed by alignment of the PH20 ptide with the polypeptide‘set forth in SEQ ID N03; and provided that if the modified PH20 ptide contains an amino acid replacement at a position corresponding to position 13, 47, 131, or .219 the replacement is not replacement with an e (A). Among these modiﬁed PH20 polypeptides are those that exhibit at least. 40% of the hyaiuronidase activity of the PH20 polypeptide not containing the amino acid replacement, where, as in all instances . herein activity is compared under the same conditions.

RECTIFIED SHEET (RULE 91) ISA/EP WO 2013/102144 PCT/US2012/072182 Included among these polypeptides are those that contain an amino acid replacement in the sequence of amino acids set forth in any of SEQ ID NOS: 3, 7, 32-66, 69 and 72, or in a sequence of amino acids that ts at least 91% sequence identity to any of SEQ ID NOS: 3, 7, 32-66, 69, or 72. In particular, the modiﬁed PH20 polypeptide contains amino acid ements in SEQ ID NO: 3, 7, 32-66, 69, or 72, Which are polypeptides that are a C- terminally truncated fragment of SEQ ID NO:7, or a PH20 polypeptide that has a sequence of amino acids that is at least 91% identical to the sequence of amino acids set forth in SEQ ID NO:7. In particular, among any of such modiﬁed PH20 ptides provided herein are any including those in Which the amino acid replacement is an amino acid replacement set forth in Table 3 below. For example, such modiﬁed PH20 polypeptides include those that have at least one amino acid replacement at an amino acid position corresponding to a position selected from among 1, 6, 8, 9, 10, 11, 12, 14, 15, 20, 22, 24, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 46, 47, 48, 49, 50, 52, 58, 59, 63, 67, 68, 69, 70, 71, 72, 73, 74, 75, 79, 82, 83, 84, 86, 87, 89, 90, 92, 93, 94, 97, 102, 104, 107, 114, 118, 120, 127, 128, 130, 131,132,135,138,139,140,141,142,143,144,146,147,148,149,150,151,152,155,156, 158,160,162,163,164,165,166,167,169,170,172,173,174,175,178,179,193,195,196, 198, 204, 205, 206, 209, 212, 213, 215, 219, 220, 221, 222, 232, 233, 234, 235, 236, 237, 238, 240, 247, 248, 249, 257, 258, 259, 260, 261, 263, 267, 269, 271, 272, 273, 274, 276, 277, 278, 279, 282, 283, 285, 287, 289, 291, 292, 293, 298, 305, 307, 308, 309, 310, 313, 314, 315, 317, 318, 320, 321, 324, 325, 326, 328, 335, 347, 349, 351, 353, 356, 359, 367, 368, 369, 371, 373, 374, 375, 376, 377, 380, 381, 383, 385, 389, 392, 393, 395, 396, 399, 401, 404, 405, 406, 407, 409, 410, 412, 416, 418, 419, 421, 425, 427, 428, 431, 433, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446 or 447 With reference to amino acid positions set forth in SEQ ID NO:3. Exemplary of such replacements are those that contain at least one amino acid replacement selected from among ement With: histidine (H) at a position ponding to on 1; A at a position corresponding to on 1; E at a position corresponding to position 1; G at a position corresponding to on 1; K at a position corresponding to position 1; Q at a position corresponding to on 1; R at a position corresponding to position 1; A at a position corresponding to position 6; M at a position corresponding to position 8; Q at a on corresponding to position 9; G at a position corresponding to position 10; H at a position corresponding to position 10; S at a position corresponding to position 11; E at a position corresponding to on 12; I at a position corresponding to position 12; K at a position corresponding to position 12; T at a position corresponding to position 12; V at a position corresponding to position 14; V at a position corresponding to position 15; M at a position corresponding to position 15 ; S at a position corresponding to WO 2013/102144 PCT/US2012/072182 position 20; T at a position corresponding to position 22; E at a position corresponding to position 24; H at a position corresponding to position 24; R at a position corresponding to position 24; A at a position corresponding to position 26; E at a position corresponding to position 26; K at a position corresponding to position 26; M at a on corresponding to position 26; Q at a on ponding to position 26; R at a position corresponding to on 26; D at a position corresponding to position 27; K at a position corresponding to position 27; R at a position corresponding to position 27; R at a position ponding to position 28; E at a position corresponding to position 29; 1 at a position corresponding to on 29; K at a position corresponding to position 29; L at a position corresponding to on 29; M at a position corresponding to position 29; P at a position corresponding to position 29; R at a position corresponding to position 29; S at a position corresponding to position 29; T at a position corresponding to on 29; V at a position corresponding to position 29; G at a on corresponding to position 30; H at a position corresponding to position 30; K at a position corresponding to position 30; L at a position corresponding to position 30; M at a position corresponding to position 30; R at a position corresponding to position 30; S at a position corresponding to position 30; A at a position corresponding to position 31; C at a position corresponding to position 31; G at a on corresponding to position 31; H at a position corresponding to position 31; 1 at a position corresponding to position 31; K at a on corresponding to on 31; L at a on corresponding to position 31; P at a position corresponding to position 31; R at a position corresponding to position 31; S at a position corresponding to position 31; T at a position corresponding to position 31; V at a position corresponding to position 31; W at a on corresponding to position 31; C at a position ponding to position 32; F at a position corresponding to position 32; G at a position corresponding to position 32; H at a on corresponding to position 32; W at a on ponding to position 33; G at a position corresponding to position 33; W at a position corresponding to position 34; Q at a position corresponding to position 35; V at a position corresponding to position 35; H at a position corresponding to position 36; N at a position corresponding to position 36; F at a position corresponding to position 37; M at a position corresponding to position 37; Y at a position corresponding to position 38; A at a position corresponding to position 39; L at a position corresponding to on 39; N at a position corresponding to position 39; T at a position corresponding to position 39; L at a position corresponding to position 40; T at a position corresponding to position 41; L at a position corresponding to position 46; R at a position corresponding to position 46; D at a position corresponding to position 47; F at a on corresponding to position 47; T at a position ponding to position 47; W at a position corresponding to WO 2013/102144 PCT/US2012/072182 position 47, With F at a position corresponding to position 48; H at a position corresponding to position 48; K at a position corresponding to position 48; N at a position corresponding to on 48; R at a position corresponding to position 49; D at a position corresponding to position 50; S at a position corresponding to position 50; M at a position ponding to position 50; N at a position corresponding to position 52; Q at a position corresponding to position 52; R at a position corresponding to position 52; S at a position corresponding to position 52; T at a position corresponding to position 52; C at a position corresponding to position 58; K at a on corresponding to position 5 8; L at a position ponding to position 5 8; P at a position corresponding to position 5 8; Q at a position ponding to position 5 8; R at a position corresponding to position 58; H at a position corresponding to position 5 8; N at a position ponding to position 5 8; Y at a position corresponding to on 5 8; N at a position corresponding to position 59; K at a position corresponding to position 63; L at a position corresponding to position 63; M at a on corresponding to position 63; R at a position corresponding to position 63; W at a position corresponding to position 63; V at a position corresponding to position 67; H at a position corresponding to position 68; P at a on corresponding to position 68; Q at a on corresponding to position 68; A at a position corresponding to position 69; C at a position corresponding to position 69; E at a position corresponding to position 69; F at a position corresponding to position 69; G at a position corresponding to position 69; I at a position corresponding to on 69; L at a position ponding to position 69; M at a position corresponding to on 69; P at a on corresponding to position 69; R at a position corresponding to position 69; T at a position corresponding to position 69; W at a position corresponding to position 69; Y at a position corresponding to position 69; A at a position ponding to position 70; C at a position corresponding to position 70; F at a position corresponding to position 70; G at a position corresponding to position 70; H at a position corresponding to position 70; K at a position corresponding to position 70; L at a position corresponding to position 70; N at a position corresponding to position 70; P at a position corresponding to position 70; R at a position corresponding to position 70; S at a position corresponding to on 70; T at a position corresponding to position 70; V at a position corresponding to position 70; Y at a position corresponding to position 70; G at a position corresponding to position 71; N at a position corresponding to position 71; R at a on corresponding to on 71; S at a position corresponding to position 71; K at a position corresponding to position 72; M at a position corresponding to on 72; Q at a position corresponding to position 72; A at a position corresponding to position 73; H at a on ponding to position 73; K at a position corresponding to position 73; L at a position corresponding to WO 2013/102144 PCT/US2012/072182 position 73; Q at a position corresponding to position 73; R at a on corresponding to position 73; T at a position corresponding to position 73; W at a position corresponding to position 73; A at a position corresponding to position 74; C at a position ponding to position 74; E at a position corresponding to position 74; F at a position corresponding to position 74; G at a position corresponding to position 74; H at a position corresponding to position 74; K at a position corresponding to position 74; L at a position corresponding to position 74; M at a position corresponding to position 74; N at a position corresponding to position 74; P at a position corresponding to position 74; R at a on corresponding to position 74; S at a position corresponding to position 74; V at a position corresponding to position 74; W at a position corresponding to position 74; F at a position corresponding to position 75; L at a position corresponding to position 75 ; M at position corresponding to position 75 ; R at a position ponding to position 75 ; T at a position corresponding to position 75 ; L at a position corresponding to position 79; L at a position ponding to position 82; N at a on corresponding to position 82; V at a position corresponding to position 83; Q at a position corresponding to position 83; S at a position corresponding to on 83; G at a position corresponding to position 83; E at a position corresponding to position 84; F at a position corresponding to position 84; G at a position corresponding to position 84; N at a position ponding to position 84; R at a position corresponding to position 84; A at a position corresponding to position 86; H at a position corresponding to position 86; K at a position corresponding to position 86; N at a position corresponding to position 86; S at a position corresponding to position 86; T at a position corresponding to position 86; W at a position corresponding to position 86; C at a position corresponding to position 87; G at a position corresponding to on 87; L at a position ponding to position 87; M at a on corresponding to position 87; R at a position ponding to position 87; S at a on corresponding to position 87; T at a position ponding to position 87; V at a position corresponding to position 87; Y at a position corresponding to position 87; C at a position corresponding to position 89; A at a position corresponding to position 90; E at a on corresponding to position 90; H at a on corresponding to on 90; K at a on corresponding to on 90; N at a position corresponding to position 90; R at a position corresponding to position 90; C at a position corresponding to position 92; L at a position corresponding to position 92; I at a position corresponding to position 93; L at a position corresponding to position 93; Q at a position corresponding to position 93; R at a position corresponding to position 93; S at a position corresponding to position 93; T at a position corresponding to position 93; D at a position ponding to position 94; Q at a position corresponding to position 94; R at a position corresponding to WO 2013/102144 PCT/US2012/072182 on 94; A at a position corresponding to position 97; C at an amino acid residue corresponding to position 97; D at a position corresponding to position 97; E at a position corresponding to position 97; G at a position corresponding to position 97; L at a position corresponding to on 97; S at a position corresponding to position 97; S at a position corresponding to position 102; T at a position ponding to position 102; R at a position corresponding to position 104; L at a position corresponding to position 107; A at a position corresponding to position 114; Q at a position corresponding to on 118; H at a position corresponding to position 120; F at a position corresponding to position 120; 1 at a position corresponding to position 120; S at a position corresponding to position 120; V at a position corresponding to position 120; Y at a position corresponding to position 120; E at a position corresponding to position 127; H at a position corresponding to on 127; N at a position ponding to position 127; Q at a position corresponding to position 127; R at a position corresponding to position 127; 1 at a position corresponding to position 128; R at a position ponding to position 130; G at a on corresponding to position 131; I at a position corresponding to position 131; M at a position ponding to position 131; Q at a position corresponding to position 131; R at a position corresponding to position 131; V at a on corresponding to position 131; N at a position corresponding to position 132; L at a position corresponding to position 132; D at a position corresponding to position 135; G at a position corresponding to position 135 ; R at a position corresponding to position 135, with L at a position corresponding to position 138; T at a position corresponding to position 139; K at a position corresponding to position 140; H at a position corresponding to position 141; R at a position corresponding to position 141; S at a position corresponding to position 141; W at a on corresponding to position 141; Y at a position corresponding to position 141; D at a on corresponding to position 142; G at a position corresponding to position 142; K at a position corresponding to on 142; N at a position corresponding to position 142; P at a position corresponding to position 142; Q at a position corresponding to position 142; R at a position corresponding to position 142; S at a position corresponding to position 142; T at a position corresponding to position 142; G at a position corresponding to position 143; K at a position corresponding to position 143; R at a position ponding to position 144; T at a position corresponding to position 144; P at a position ponding to position 146; R at a position corresponding to position 146; A at a position corresponding to on 147; F at a position corresponding to position 147; L at a position corresponding to position 147; R at a position corresponding to position 147; S at a position corresponding to position 147; V at a on corresponding to position 147; H at a position corresponding to position 148; K at a position corresponding to position 148; Q at a on corresponding to position 148; T at a WO 2013/102144 PCT/US2012/072182 position corresponding to position 149; V at a on corresponding to position 149; A at a position corresponding to position 150; D at a on corresponding to position 150; G at a position corresponding to position 150; N at a position corresponding to position 150; S at a position corresponding to position 150; W at a position corresponding to position 150; Y at a position corresponding to position 150; A at a position corresponding to position 151; H at a position corresponding to position 151; K at a position corresponding to position 151; L at a position corresponding to position 151; M at a position corresponding to position 151; Q at a position corresponding to position 151; R at a position corresponding to position 151; S at a position corresponding to position 151; T at a position corresponding to position 151; V at a position corresponding to position 151; W at a position corresponding to position 151; Y at a position corresponding to position 151; R at a position corresponding to position 152; T at a position corresponding to on 152; W at a on corresponding to position 152; D at a position corresponding to position 155; G at a position corresponding to position 155 ; K at a position corresponding to position 155; R at a position ponding to position 155 ; D at a position corresponding to position 156; Q at a position corresponding to position 158; S at a position corresponding to on 158; S at a position corresponding to position 160; E at a position corresponding to on 162; A at a position ponding to position 163; E at a position corresponding to position 163; K at a position corresponding to position 163; Q at a position corresponding to position 163; R at a on ponding to on 163; S at a position corresponding to position 163; M at a position corresponding to position 164; V at a position corresponding to position 164; D at a position corresponding to position 165; F at a position corresponding to position 165; N at a position ponding to position 165 ; S at a on corresponding to position 165; V at a position corresponding to position 165 ; A at a position corresponding to position 166; E at a position ponding to position 166; F at a position ponding to position 166; H at a position corresponding to position 166; L at a position corresponding to position 166; Q at a on ponding to position 166; R at a position corresponding to position 166; T at a position corresponding to position 166; W at a position corresponding to position 166; Y at a position corresponding to position 166; D at a position corresponding to position 167; L at a position corresponding to position 169; R at a position corresponding to position 170; A at a position corresponding to position 172; R at a position corresponding to position 173; G at a position corresponding to position 174; K at a position corresponding to position 174; N at a position corresponding to on 174; R at a position corresponding to position 174; T at a position corresponding to on 174; T at a on corresponding to position 175; K at a position corresponding to position 178; R at a position ponding to position 178; K at a position corresponding to position 179; Q at a WO 2013/102144 PCT/US2012/072182 position corresponding to position 193; T at a position corresponding to position 195; N at a position ponding to position 195; With E at a position corresponding to position 196; R at a position corresponding to position 196; With D at a position corresponding to position 198; P at a position corresponding to position 204; A at a position corresponding to position 205; E at a position corresponding to position 205; L at a position corresponding to position 205 ; T at a on corresponding to position 205; I at a position corresponding to position 206; K at a position corresponding to position 206; L at a position corresponding to position 206; R at a position corresponding to position 206; R at a position corresponding to position 209; N at a position corresponding to position 212; S at a position ponding to position 212; A at a on corresponding to position 213; M at a position corresponding to position 213; N at a position corresponding to position 213; H at a position ponding to position 215; M at a position corresponding to position 215 ; I at a position corresponding to position 219; K at a position corresponding to position 219; S at a position corresponding to position 219; H at a position corresponding to position 220; I at a position ponding to position 220; L at a position corresponding to position 220; V at a position corresponding to position 220; Q at a position corresponding to position 221; G at a position corresponding to position 222; F at a position corresponding to position 232; G at a position corresponding to position 233; K at a position corresponding to position 233; R at a position ponding to position 233; M at a position corresponding to position 234; A at a position corresponding to position 235; R at a position corresponding to position 236; C at a position corresponding to position 237; E at a position corresponding to position 237; H at a position corresponding to on 237; Q at a position corresponding to position 237; T at a on corresponding to position 237; E at a position ponding to position 23 8; H at a position corresponding to amino acid on 238; S at a position corresponding to position 238; A at a position corresponding to position 240; Q at a on corresponding to position 240; I at a on corresponding to position 247; A at a position corresponding to position 248; V at a on corresponding to on 249; G at a position ponding to position 257; T at a position ponding to position 257; R at a position corresponding to position 257; N at a position corresponding to position 258; S at a position ponding to position 258; P at a position corresponding to position 259; M at a position corresponding to position 260; Y at a position corresponding to position 260; A at a position corresponding to position 261; K at a position corresponding to position 261; N at a position corresponding to on 261; K at a position corresponding to position 263; R at a position corresponding to on 263; T at a position corresponding to position 267; A at a position corresponding to position 269; L at a position corresponding to position 271; M at a position corresponding to position 271; D at a position corresponding to WO 2013/102144 PCT/US2012/072182 position 272; T at a position corresponding to position 272; H at a position corresponding to position 273; Y at a position corresponding to position 273; F at a position corresponding to position 274; D at a position corresponding to position 276; H at a position corresponding to on 276; M at a position corresponding to position 276; R at a position corresponding to position 276; S at a position ponding to position 276; Y at a position corresponding to position 276; A at a position corresponding to position 277; E at a position corresponding to position 277; H at a position corresponding to position 277; K at a position corresponding to position 277; M at a position corresponding to position 277; N at a position corresponding to position 277; Q at a position corresponding to position 277; R at a position corresponding to position 277; S at a position corresponding to position 277; T at a position corresponding to position 277; E at a position corresponding to position 278; F at a position corresponding to on 278; G at a position corresponding to position 278; H at a position corresponding to on 278; K at a position corresponding to position 278; N at a position corresponding to position 278; R at a position corresponding to position 278; S at a on corresponding to position 278; T at a position corresponding to position 278; Y at a position corresponding to position 278; H at a position corresponding to position 279; M at a on corresponding to position 282; S at a position corresponding to position 283; H at a position corresponding to position 285; T at a position corresponding to on 287; S at a position corresponding to position 289; S at a position corresponding to position 291; V at a on corresponding to position 291; C at a position corresponding to position 292; F at a position corresponding to position 292; H at a position corresponding to position 292; K at a on corresponding to position 292; R at a position corresponding to position 292; V at a position corresponding to on 292; A at a position corresponding to on 293; C at a position corresponding to position 293; D at a position corresponding to position 293; F at a position corresponding to position 293; K at a position corresponding to position 293; M at a position corresponding to on 293; P at a on ponding to position 293; Q at a position corresponding to position 293; V at a position corresponding to position 293; Y at a position ponding to position 293; G at a position corresponding to position 298; E at a position corresponding to position 305; G at a position corresponding to position 307; D at a on corresponding to position 308; G at a position corresponding to on 308; K at a on corresponding to position 308; N at a position corresponding to position 308; R at a position corresponding to position 308; E at a position corresponding to position 309; G at a position corresponding to position 309; H at a position corresponding to position 309; L at a position corresponding to position 309; M at a position corresponding to position 309; N at a position ponding to position 309; Q at a on corresponding to on 309; R at a position corresponding to WO 2013/102144 PCT/US2012/072182 position 309; S at a position ponding to position 309; T at a position corresponding to position 309; V at a position corresponding to position 309; A at a position corresponding to position 310; G at a position corresponding to position 310; Q at a on corresponding to position 310; S at a position corresponding to position 310; A at a on corresponding to on 313; G at a position corresponding to position 313; H at a position corresponding to position 313; K at a position corresponding to position 313; P at a position corresponding to position 313; R at a position corresponding to position 313; T at a position corresponding to position 313; Y at a position corresponding to position 313; With S at a position corresponding to position 314; Y at a position corresponding to on 314; A at a position corresponding to position 315; H at a position corresponding to position 315; Y at a position corresponding to position 315; A at a position corresponding to position 317; I at a position ponding to position 317; K at a position corresponding to position 317; N at a position corresponding to position 317; Q at a position corresponding to position 317; R at a position corresponding to position 317; S at a position corresponding to position 317; T at a position corresponding to position 317; W at a position corresponding to position 317; D at a position corresponding to position 318; H at a position corresponding to position 318; K at a position corresponding to on 318; M at a position ponding to position 318; R at a position corresponding to position 318; H at a position ponding to position 320; K at a position corresponding to position 320; R at a position corresponding to position 320; R at a position corresponding to position 321; S at a on corresponding to position 321; N at a on corresponding to position 324; R at a on corresponding to position 324; A at a position corresponding to position 325; D at a position corresponding to on 325 ; E at a position corresponding to position 325 ; G at a position corresponding to position 325 ; H at a position corresponding to position 325 ; K at a position ponding to position 325 ; M at a position corresponding to position 325 ; N at a position corresponding to position 325 ; Q at a on corresponding to position 325 ; S at a position corresponding to on 325; V at a position corresponding to position 325 ; L at a position corresponding to position 326; V at a position corresponding to position 326; C at a on corresponding to position 328; G at a position corresponding to position 328; I at a position corresponding to position 328; K at a position ponding to position 328; L at a position corresponding to position 328; S at a position corresponding to position 328; Y at a position corresponding to position 328; S at a position corresponding to position 335; A at a position corresponding to position 347; G at a on corresponding to position 347; S at a position corresponding to position 347; M at a position corresponding to position 349; R at a on corresponding to position 349; S at a position corresponding to on 351; V at a position corresponding to position 353; with H at a WO 02144 PCT/US2012/072182 on corresponding to position 356; S at a position corresponding to position 356; E at a position corresponding to position 359; H at a position corresponding to on 359; T at a position corresponding to on 359; A at a position corresponding to position 367; G at a position corresponding to on 367; K at a position corresponding to position 367; S at a position corresponding to position 367; A at a position corresponding to position 368; E at a position ponding to on 368; K at a on ponding to position 368; L at a position corresponding to amino acid position 368; M at a position corresponding to amino acid position 368; R at a position corresponding to on 368; T at a position corresponding to amino acid position 368; H at a position corresponding to position 369; R at a position corresponding to on 369; F at a position corresponding to position 371; H at a position corresponding to on 371; K at a position ponding to position 371; L at a position corresponding to position 371; R at a position corresponding to position 371; S at a position corresponding to position 371; M at a position corresponding to position 373; H at a position corresponding to position 374; P at a position corresponding to position 374; A at a position corresponding to position 375; G at a position corresponding to position 375 ; K at a position corresponding to position 375 ; R at a on corresponding to position 375; D at a position corresponding to position 376; E at a position corresponding to position 376; Q at a position corresponding to position 376; R at a position corresponding to position 376; T at a position corresponding to position 376; V at a position corresponding to position 376; Y at a position corresponding to position 376; D at a position corresponding to position 377; E at a position corresponding to position 377; H at a position corresponding to position 377; K at a position corresponding to position 377; P at a position corresponding to position 377; R at a position corresponding to position 377; S at a position corresponding to position 377; T at a position corresponding to position 377; W at a position corresponding to position 380; Y at a position corresponding to position 380; S at a position corresponding to position 381; I at a position corresponding to position 383; K at a position corresponding to position 383; L at a position corresponding to position 383; S at a position corresponding to position 383; A at a position corresponding to position 385; Q at a position ponding to position 385 ; V at a position corresponding to position 385 ; A at a position corresponding to position 389; G at a position corresponding to on 389; L at a position corresponding to position 389; K at a position ponding to position 389; Q at a position corresponding to position 389; S at a position corresponding to position 389; A at a position corresponding to position 392; F at a position corresponding to position 392; M at a on corresponding to on 392; Q at a position corresponding to position 392; R at a position ponding to position 392; V at a position corresponding to position 392; F at a position corresponding to position 393; M at a position WO 2013/102144 PCT/US2012/072182 corresponding to position 393; A at a position corresponding to position 395; H at a position corresponding to position 395; R at a position corresponding to position 395; A at a position ponding to position 396; H at a position corresponding to position 396; Q at a on corresponding to position 396; S at a position corresponding to position 396; K at a position corresponding to position 399; M at a position corresponding to position 399; T at a position corresponding to position 399; V at a position ponding to position 399; W at a position corresponding to position 399; A at a on corresponding to position 401; E at a position corresponding to position 401; A at a position corresponding to position 404; G at a position corresponding to position 405; F at a position corresponding to position 406; N at a position corresponding to position 406; A at a position corresponding to position 407; D at a position corresponding to position 407; E at a position corresponding to position 407; F at a position corresponding to position 407; H at a position corresponding to on 407; Q at a position ponding to position 407; P at a position corresponding to position 407; A at a position corresponding to position 409; Q at a position corresponding to on 409; T at a position corresponding to position 410; Q at a position corresponding to position 412; R at a position corresponding to on 412; V at a position corresponding to position 412; L at a position corresponding to position 416; E at a position corresponding to position 418; L at a position corresponding to position 418; P at a position corresponding to position 418; R at a position corresponding to position 418; V at a position ponding to position 418; F at a position corresponding to position 419; H at a position corresponding to position 419; I at a position corresponding to position 419; K at a position corresponding to position 419; R at a position corresponding to position 419; S at a position corresponding to position 419; Y at a position corresponding to position 419; A at a on ponding to position 421; H at a position corresponding to position 421; K at a position corresponding to position 421; N at a position corresponding to position 421; Q at a position corresponding to position 421; R at a on corresponding to on 421; S at a position corresponding to position 421; G at a position corresponding to on 425; K at a position ponding to position 425 ; Q at a on corresponding to position 427; T at a position corresponding to position 427; L at a position corresponding to position 428; A at a position corresponding to position 431; G at a position corresponding to position 431; E at a position corresponding to position 431; H at a position corresponding to position 431; K at a on corresponding to position 431; L at a position corresponding to position 431; N at a position corresponding to position 431; Q at a position corresponding to position 431; R at a position corresponding to position 431; S at a position ponding to position 431; V at a position corresponding to position 431; A at a position corresponding to position 433; H at a position ponding to on 433; I at a position WO 2013/102144 PCT/US2012/072182 corresponding to position 433; K at a position corresponding to position 433; L at a position corresponding to position 433; R at a position corresponding to position 433; T at a position corresponding to position 433; V at a position ponding to position 433; W at a position corresponding to position 433; K at a position ponding to position 436; I at a position ponding to position 437; M at a on corresponding to position 437; A at a position corresponding to position 438; D at a position corresponding to position 438; E at a position corresponding to position 438; L at a position corresponding to position 438; N at a position corresponding to position 438; T at a position ponding to position 438; A at a position corresponding to position 439; C at a position corresponding to position 439; K at a position corresponding to position 439; P at a position corresponding to on 439; Q at a on corresponding to position 439; T at a position corresponding to on 439; V at a position ponding to position 439; D at a position corresponding to position 440; H at a position corresponding to on 440; M at a position corresponding to position 440; P at a position corresponding to position 440; R at a position corresponding to position 440; S at a position corresponding to position 440; A at a position corresponding to position 441; F at a position corresponding to position 441; C at a position corresponding to position 442; G at a position corresponding to position 442; R at a position corresponding to position 442; A at a position corresponding to on 443; E at a on corresponding to position 443; F at a position corresponding to position 443; G at a position corresponding to position 443; M at a position corresponding to position 443; N at a position corresponding to position 443; E at a position ponding to position 444; H at a position corresponding to on 444; V at a position corresponding to position 444; H at a position corresponding to position 445; M at a position corresponding to position 445 ; N at a position corresponding to on 445 ; P at a position ponding to position 445 ; Q at a position corresponding to position 445 ; S at a position corresponding to position 445 ; T at a position corresponding to on 445 ; V at a position corresponding to position 445 ; W at a position corresponding to position 445 ; A at a position ponding to position 446; M at a position corresponding to position 446; W at a position corresponding to position 446; D at a position corresponding to on 447; E at a position corresponding to position 447; G at a position corresponding to position 447; I at a position corresponding to position 447; N at a position corresponding to position 447; P at a position corresponding to position 447; Q at a position corresponding to position 447; T at a position corresponding to position 447, and/or replacement With V at a position corresponding to position 447, each With reference to amino acid positions set forth in SEQ ID NO:3. Among these modiﬁed PH20 polypeptides are those that exhibit at least 40% of the activity of the PH20 that does not contain the particular amino acid replacement. ty can vary between, WO 2013/102144 PCT/US2012/072182 for example, 40% to 5000%, 40% to 2000%, 40% to 1000%, 40% to 500%, 40% to 100%, 80% to 2000%, 80% to 600%, 80% to 200%, 80% to 300%, of the hyaluronidase activity of the PH20 polypeptide not containing the amino acid replacement. Such activity includes at least 50%, 60%, 70%, 80%, 90%, 100%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, 2000%, 3000% or more of the onidase activity of the PH20 polypeptide not containing the amino acid replacement, Where, as in all instances herein, the activities are compared under the same conditions.

In particular, provided are modified PH20 polypeptides that contain at least one amino acid ement in a PH20 ptide set forth in SEQ ID NO:7, a C-terminally truncated fragment thereof, or in a PH20 polypeptide that has a sequence of amino acids that is at least 91% identical to the sequence of amino acids set forth in SEQ ID NO:7 or a corresponding ted fragment, Where: the modified PH20 polypeptides exhibit less than % of the hyaluronidase activity of the PH20 polypeptide not containing the amino acid replacement, Where activities are compared under the same conditions; the amino acid replacement(s) is at an amino acid position corresponding to a position selected from among 2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14,15,16,17,18,19, 20, 21, 22, 23, 25, 27, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 94, 95, 96, 98, 99, 100, 2, 103, 104, 105, 106, 107, 108, 109, 110,111,112,113,114,115,116,117,118,119,121,122,123,124,125,126,127,128,129, 130,131,132,133,134,135,136,137,138,139,143,144,145,149,150,152,153,154,155, 156,157,158,159,161,163,164,165,166,167,168,169,170,171,172,173,174,175,176, 178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,197, 198,199, 200, 201, 202, 203, 204, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 278, 279, 280, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 331, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 408, 410, 411, WO 2013/102144 PCT/US2012/072182 412, 413, 414, 415, 416, 417, 419, 420, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 434, 437, 438, 439, 440, 441, 442, 443, 444, or 447 With reference to amino acid positions set forth in SEQ ID NO:3 or 7; corresponding amino acid positions are identiﬁed by alignment of the PH20 polypeptide With the polypeptide set forth in SEQ ID NO:3; and provided that: (i) if the d PH20 polypeptide contains an amino acid replacement at a position corresponding to on 200, 333, 358 or 393 the replacement is not replacement With an Alanine (A). (ii) if the modiﬁed PH20 polypeptide contains an amino acid replacement at a position corresponding to position 111 or 249 the replacement is not replacement With an asparagine (N); (iii) if the modiﬁed PH20 polypeptide contains an amino acid replacement at a position corresponding to on 113 the replacement is not replacement With a glutamine (Q); (iV) if the modiﬁed PH20 polypeptide contains an amino acid replacement at a position corresponding to position 176 the replacement is not replacement With a glycine (G); and (V) if the modiﬁed PH20 polypeptide contains an amino acid replacement at a position corresponding to position 252 the replacement is not replacement With a threonine (T).

Exemplary of such modiﬁed PH20 polypeptides are any that contain amino acid ement(s) in a PH20 polypeptide that has the sequence of amino acids set forth in any of SEQ ID NOS: 3, 7, 32-66, 69, or 72, or in a sequence of amino acids that exhibits at least 91% sequence identity to any of SEQ ID NOS: 3, 7, 32-66, 69, or 72. For example, the modiﬁed PH20 polypeptide contains amino acid replacement(s) in SEQ ID NOS: 3, 7, 32-66, 69, or 72, Which are ptides that are a inally ted fragment of SEQ ID NO:7, or a PH20 polypeptide that has a sequence of amino acids that is at least 91% identical to the sequence of amino acids set forth in SEQ ID NO:7. In examples of such modiﬁed PH20 polypeptides provided herein, the modiﬁed PH20 polypeptides can exhibit similar or the same actiVity as the PH20 t the modiﬁcation, or can exhibit increased actiVity or actiVity that is less than 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05% or less ofthe hyaluronidase actiVity ofthe PH20 ptide not containing the amino acid replacement. Exemplary of such modiﬁed PH20 polypeptides are any set forth in Table 5.

WO 2013/102144 2012/072182 ’ Among'any'and all of the modiﬁed, PH20polypeptides-provided herein and above, 7' the d PH20 polypeptide is one‘that’doe's not consist of the sequence of amino set f I.

I forth-in any of SEQ 'ID NOS: 3, 6-66, 69-72, 856-861, 869 or 870. 'In partiCular, amongiany ‘. , of the "modiﬁed PH20 polypeptides provided herein above or elsewhere herein are any that ' contain an amino acid replacement(s) in ajPI-IZO polypeptide having the ce of amino ' acids set'forth any of SEQ ID N013, 7, 69 or 72 provided that: (i) where the modiﬁed PH20 ptide includes only .a single amino acid replacement the replacement does not corresponds to amino acid replacements V12A,'N47A, D1 1 1N,.E113Q, N131A, , NZOOA, N219A, E249Q, 'R252T,'N333A or N358A, with reference‘to amino acid positions set forth in SEQ ID N023; (ii) where the modiﬁed PH20 polypeptide includes only two amino acid ements the replacements do-notCorrespond to amino acid replacements P1'3A/L464W, N47A/Nl'3 11A, N47A/N219A, N131A/N319A or N333A/N358A with reference to positions set forth in SEQ H) N03; and (iii) where the modiﬁed PH20 polypeptide es only three amino acid replacements the replacements do not correspond 1‘5 ‘to amino acid replacements 'N4'7A/N13 1A/N219A, with reference'to amino acid positions set forth in SEQ lD‘NOf3.

Any of the above'modiﬁed PHZO'polypeptides and any provided herein and described above and below canicontainil,.‘2,I3,-'4,:5,‘6, ‘7, 8, 9, 10,11, 12, 13,14, 15, 16,17, 18, 19,20, 2'1,;22,.23,24,25,26,27,128,29,30,3‘1, 32,33,34, 35, 36, 37,.38,39,-40,41,-42, 43, 44, 45, .20 746, 47,48,49, 50,51, :52, 4,.5'5, 56,57, '58, '59, 60, 61,62,63, 64,65,66, 67, 68, 69,70, 71,72, 73,74, 75,76, 77,78, 79, 80, ‘81, 82,83, 84, 85, 86, 87, 88,89, 90, or more of the amino acid replacements. The modiﬁed PHZO‘polypeptides can include .a signalsequence, ing the'native sequence or a heterologous sequence or amodiﬁed sequence, and also include a'mature PH20 polypeptidc'that lacks the signal sequence. .25 Among any of the modiﬁed PH20'polypeptides provided herein above or described below are modiﬁed PHZO polypeptides that contain or‘have'the sequence of amino acids set forth in any of SEQ ID'NOS: 73-855 or a sequence of amino acids that-exhibits at'least 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to a sequence ofamino acids set forth in any of SEQ ID NOS: 73-855 and that contains at least 3O one amino acid replacement, such as any described above or elsewhere herein, with reference - "to positions compared to the sequence of amino acids set forth in SEQ ID N013. In any of the ' examples of the modiﬁed PH20 polypeptides provided herein, the modiﬁed PH20 polypeptide does not have 'or contain the sequence of amino acids set forth in any of SEQ ID NOS; 8-3‘1, 69-72, 856—861, 869 or 870.

RECTIFIED SHEET (RULE 91) lSA/EP WO 02144 PCT/US2012/072182 The modiﬁed PH20 polypeptides provided herein can be substantially puriﬁed or isolated, can exhibit tic activity at neutral pH, can be secreted upon expression from cells and are soluble in the supernatant, and/or can include modiﬁed amino acids, such as a modiﬁcation selected from among glycosylation, sialation, albumination, farnysylation, carboxylation, hydroxylation, conjugation to a polymer, such as tion or conjugation to dextran, conjugation to another moiety, such as a erization domain, toxin, detectable label or drug, and phosphorylation. The modiﬁed PH20 polypeptide can be ylated, such as by containing at least an ylglucosamine moiety linked to each of at least three asparagine (N) residues, Where, for example, the three asparagine residues correspond to amino acid residues 200, 333 and 358 of SEQ ID NO:3. Multimerization domains include Fc domains.

Also provided are nucleic acid molecules that encode any of the modiﬁed PH20 ptides provided herein. Vectors, eukaryotic and prokaryotic, that contain the nucleic acid molecules are provided. The vectors e sion vectors and include mammalian vectors, ing viral vectors. Viral vectors e adenovirus vectors, retrovirus vectors, vaccinia Virus vectors, herpes simplex Virus and cytomegalovirus vectors, and other such Viral vectors. Of interest are oncolytic vectors that accumulate in or are targeted to tumors. Also provided are cells that contain the nucleic acid molecules and cells that n the vectors. The cells can be prokaryotic or eukaryotic, particularly mammalian cells, such as Chinese Hamster Ovary (CHO) cells.

Also provided herein is a modiﬁed PH20 polypeptide that is produced by any of the provided cells. Thus, provided herein are s of producing a modiﬁed PH20 polypeptide by culturing any of the cells provided herein under conditions Whereby an d modiﬁed PH20 polypeptide is produced and secreted by the cell, and recovering the expressed polypeptide. Also provided herein is a method of producing a modiﬁed PH20 polypeptide by introducing any of the c acids provided herein or any of the vectors provided herein into a cell capable of incorporating N—linked sugar moieties into the polypeptide, culturing the cell under conditions Whereby an encoded modiﬁed PH20 polypeptide is produced and ed by the cell, and recovering the sed polypeptide. In such examples, the nucleic acid is operably linked to a promoter. The cultured cell can be a eukaryotic cell, such as a mammalian cell, for example, a Chinese hamster ovary (CHO) cell.

Also provided are pharmaceutical compositions that contain any of the modiﬁed PH20 ptides provided herein or any of the nucleic acids or vectors provided herein.

The compositions can be formulated With other agents and/or With other components, such as preservatives. The compositions can be formulated so that the components, particularly the WO 2013/102144 2012/072182 PH20 and any other active agent, remain active or are stable under preselected conditions. In addition, as described herein, the PH20 polypeptides are modiﬁed so that they exhibit increased stability under various conditions. For example, provided are compositions in which the modiﬁed PH20 polypeptide is stable (i.e., s activity as described herein) at a temperature from or from about 2 0C to 8 OC, inclusive, for at least 1 month or is stable at a ature from or from about 30 0C to 42 OC, inclusive, for at least 3 days. Provided are compositions in which the modified PH20 polypeptide in the composition is stable at a temperature from or from about 2 0C to 8 OC, inclusive, for at least 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, at least 8 months, at least 9 months, at least 10 , at least 11 months, at least 12 , 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, months, 26 months, 27 months, 28 months, 29 months or 30 months. Also provided are compositions in which the modified PH20 polypeptide in the composition is stable at a temperature from or from about 30 0C to 42 OC, inclusive, for at least 3 days, at least 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, days, 35 days, 40 days, 45 days, 50 days, 60 days or more. The pharmaceutical compositions can contain a pharmaceutically acceptable excipient.

The conditions, formulations, components, and modified PH20 polypeptide are chosen to achieve a desired stability. The pharmaceutical compositions can be formulated for direct administration or can require dilution. They can be formulated for multiple or single dosage administration. Exemplary compositions include concentrations of modified PH20 between or about between 0.1 ug/mL to 100 ug/mL, 1 ug/mL to 50 ug/mL or 1 ug/mL to 20 ug/mL, or 10 U/mL to 5000 U/mL, 50 U/mL to 4000 U/mL, 100 U/mL to 2000 U/mL, 300 U/mL to 2000 U/mL, 600 U/mL to 2000 U/mL, or 100 U/mL to 1000 U/mL. ary salts include NaCl at a tration, for example, of less than or about or 200 mM, 180 mM, 150 mM, 140 mM, 130 mM, 120 mM, 110 mM, 100 mM, 90 mM, 80mM, 70mM, 60 mM, 50 mM, 40 mM, 30 mM, 25 mM, 20 mM, 15 mM, 10 mM, 5 mM or less, or between or about between 0.1mM to 200 mM, 0.1mM to 100 mM, 120 mM to 200 mM, 10 mM to 50 mM, 10 tho 90 mM, 80 tho 200 mM, 80 mM to 140 mM, 50 tho 100 mM, 80 tho 100 mM, 50 mM to 80 mM, 100 mM to 140 mM or 120 mM to 140 mM.

The pharmaceutical compositions can contain an anti-microbially effective amount of a preservative or mixture of preservatives, such as one, two, three, four or more of a ic preservative(s), a non-phenolic preservative(s) or a phenolic vative(s) and a non-phenolic preservative(s), such as, but not limited to, , m-cresol, methylparaben, WO 2013/102144 PCT/US2012/072182 benzyl alcohol, thimerosal, benzalkonium chloride, 4-chlorobutanol, chlorhexidine dihydrochloride, chlorhexidine digluconate, L-phenylalanine, EDTA, bronopol, mercuric acetate, glycerol, imidurea, chlorhexidine, sodium dehydroacetate, o-cresol, p-cresol, chlorocresol, ide, benzethonium chloride, ethyl paraben, propylparaben, butylparaben and any combinations thereof. Phenols include, for example, phenol, metacresol (m-cresol), benzyl alcohol, and parabens, such as paraben or propylparaben. Anti-microbial ive concentrations of one or more preservative agents (as a percentage (%) of mass concentration (w/v)) can be between 0.05% to 0.6%, 0.1% to 0.4%, 0.1% to 0.3%, 0.15% to , 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 0.3% to 0.4% inclusive. Examples thereof are ceutical compositions where the preservatives are phenol, m—cresol or phenol and m-cresol and the amount as a % of mass concentration (w/V) in the ation is between or about between 0.1% to 0.25% phenol and between or about between 0.05% to 0.2% m—cresol, is between or about between 0.10% to 0.2% phenol and between or about between 0.6% to 01.8% m—cresol, between or about n 0.1% to 0.15% phenol and 0.8% t 0.15% m-cresol, is between or about between 0.10% to 0.15% phenol and between or about between 0.06 to 0.09% ol or is between or about between 0.12% to 0.18% phenol and between or about between 0.14 to 0.22% m- cresol.

The pharmaceutical compositions can n a further therapeutically active agent.

The active agent can be formulated in the composition or provided as a combination with the PH20-containing composition, but in a separate composition for administration separately, sequentially, intermittently, simultaneously or together. Therapeutically active agents include, for example, an agent selected from among a chemotherapeutic agent, an analgesic agent, an anti-inﬂammatory agent, an antimicrobial agent, an amoebicidal agent, a trichomonacidal agent, an anti-parkinson agent, an anti-malarial agent, an anticonvulsant agent, an anti- depressant agent, and antiarthritics agent, an anti-fungal agent, an antihypertensive agent, an antipyretic agent, an anti-parasite agent, an antihistamine agent, an alpha-adrenergic agonist agent, an alpha blocker agent, an anesthetic agent, a bronchial dilator agent, a biocide agent, a bactericide agent, a iostat agent, a beta adrenergic blocker agent, a calcium channel blocker agent, a vascular drug agent, a contraceptive agent, a decongestant agent, a diuretic agent, a depressant agent, a diagnostic agent, a olyte agent, a hypnotic agent, a hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an ophthalmic agent, a parasympathomimetic agent, a psychic zer agent, a sedative agent, a sympathomimetic agent, a tranquilizer agent, an urinary agent, a vaginal agent, a de agent, a vitamin agent, a non-steroidal anti-inﬂammatory agent, an angiotensin WO 2013/102144 PCT/US2012/072182 -39_ a c acid, a drug, an organic . . converting enzyme inhibitoragent, a polypeptide, a protein, l'molecule and a sleep; inducer. Exemplary of such agents are antibodies,.-particularly ~_ -. monoclonal antibodies, an Immune Globulin preparation, a bisphosphonate, :a cytokine, a chemotherapeuticagent, a coagulation factor and an insulin. Insulins include, for e, . l'basal insulins and cting n, such asregular insulin, ularly recombinant human n, and insulin analogs, such as insulin lispro, insulin aspart or insulin glulisine. - Particular fast-acting insulins are those with an A chain having a sequence of amino acids set forth in SEQ ID NO:862 and a B chain having a sequence of amino acids set forth in SEQ ID - NO:863 or an insulin with an A chain with a sequence of amino acids set forth as amino acid residue'positions 88-108 of SEQ ID NO:864 and a B chain with :a ce of amino acids set ' . forth as amino acid-residue positions 25-54 of SEQ ID NO:864 or an insulin analog that is - selected from among an insulin having an ’A chain with a sequence of amino acidsset'forth in SEQJD NO:862 and .a B chain having a sequence of amino acids set forth in any of'SEQ S-867. .The amount of fast-acting insulin in the compositions can be empirically 1.5 determined, but’typically can be lO’U/mL‘to 1000 U/mL, ‘50 U/mL‘to .500 U/mL, 100 U/mL'to 1000 U/mL or.500 U/m'L to 1000 U/mL, inclusive.

'In particular examples,-provided herein is a ceutical ition.containingany of the modiﬁed PH20'polypeptides provided herein that exhibit increased stability to :a‘phenolic preservative and an insulin, such asa'fast-acting insulin. The vaHZO:pOlypeptides and .20 insulin can 'be provided in therapeutically effectiveamounts. .For example, provided herein is:a pharmaceutical composition that contains any of the modiﬁed ‘PH20 polypeptides provided herein that exhibits increased stability to a phenolic‘preservative .in an mount'that isfrom or from about /mL to 1000 U/rnL and a fast-acting insulin in an amount that is ‘from or from about 10 U/m'L to 1000 U/mL. For example, the fast-acting insulin can be an insulinanalog, .25 such as insulin lispro, insulin aspart or n .glulisine or other analog. Any of such _ pharmaceutical compositions can be formulated at a'pH that is from or:from about 7.0 to 7.6.

Any of such pharmaceutical compositions also can be ated to contain salt, such as'NaCl, at a concentration that is from or from about 0.1 'mM to .200 mM and/or an anti-microbial effective amount of at least one preservative where the composition generally contains at least .30 one ic preservative. The anti-microbial effective amount is a total amount of one or more. preservative agents as a percentage (%) of mass concentration (w/v) that is or is between 0.05% to 0.6%. The phenolic preservative(s) can be a phenol, metaoresol (m-cresol), benzyl alcohol, ora paraben. In any of the above examples of a pharmaceutical composition, the composition also can contain a surfactant, such as a polypropylene glycol, polyethylene glycol, 3‘5 glycerin, sorbitol, poloxamer or polysorbate, in an amount as a % of RECTIFlED SHEET (RULE 91)‘ lSA/EP WO 2013/102144 PCT/US2012/072182 mass tration (w/v) in the formulation that is at least or at least about 0.001%; a ing agent that is a non-metal binding agent or is a metal binding agent, such as Tris, histidine, phosphate or citrate, wherein the concentration of the buffering agent is between or between about 1 mM to 100 mM; glycerin in a concentration less than 60 mM; an antioxidant, such as cysteine, tryptophan or methionine, at a concentration between or from about between 2 mM to 50 mM, inclusive; and/or zinc at a tration of between or about between 0.001 to 0.1 mg per 100 units of insulin (mg/100U). Also provided herein are closed loop s, insulin pumps including continuous subcutaneous infusion insulin (CSII) pumps and n pens that contain any of the pharmaceutical compositions. The pharmaceutical compositions can be used in methods or uses for ng diabetes, such as type 1 diabetes mellitus, type 2 diabetes mellitus or gestational diabetes.

Other therapeutic agents in any of the pharmaceutical compositions provided herein include, but are not limited to Adalimumabs, dase Betas, Alefacepts, Ampicillins, Anakinras, Antipoliomyelitic Vaccines, Anti-Thymocytes, Azithromycins, Becaplermins, Caspofungins, Cefazolins, Cefepimes, Cefotetans, Ceftazidimes, Ceftriaxones, mabs, Cilastatins, Clavulanic Acids, Clindamycins, Darbepoetin Alfas, umabs, Diphtheria, Diphtheria xins, Diphtheria Toxoids, Efalizumabs, Epinephrines, Erythropoietin Alphas, Etanercepts, Filgrastims, Fluconazoles, Follicle-Stimulating Hormones, Follitropin Alphas, Follitropin Betas, Fosphenytoins, Gadodiamides, Gadopentetates, Gatiﬂoxacins, Glatiramers, GM-CSF's, Goserelins, Goserelin acetates, Granisetrons, Haemophilus Inﬂuenza B's, Haloperidols, Hepatitis vaccines, Hepatitis A Vaccines, Hepatitis B Vaccines, Ibritumomab Tiuxetans, Ibritumomabs, Tiuxetans, globulins, ilus za vaccines, Inﬂuenza Virus Vaccines, InﬂiXimabs, n lispro, 75% neutral protamine lispro (NPL)/25% n lispro, 50% neutral protamine Hagedorn (NPH)/ 50% regular insulin, 70% NPH/30% regular insulin; Regular insulin, NPH insulin, Ultra insulin, Ultralente insulin, and Insulin nes, Interferons, Interferon alpha, Interferon Betas, Interferon Gammas, Interferon 2a, Interferon alpha 2-b, Interferon Alphacon, Interferon alpha-n, Interferon Betas, Interferon Beta-l a's, Interferon Gammas, Interferon alpha-con, Iodixanols, Iohexols, Iopamidols, Ioversols, Ketorolacs, Laronidases, xacins, Lidocaines, Linezolids, Lorazepams, Measles Vaccines, Measles virus, Mumps viruses, Measles-Mumps-Rubella Virus Vaccines, Rubella es, Medroxyprogesterones, Meropenems, Methylprednisolones, Midazolams, Morphines, Octreotides, Omalizumabs, Ondansetrons, Palivizumabs, Pantoprazoles, Pegaspargases, Pegﬂlgrastims, Peg-Interferon Alpha-2a's, Peg- Interferon Alpha-2b's, Pegvisomants, Pertussis vaccines, Piperacillins, coccal Vaccines and coccal Conjugate Vaccines, Promethazines, Reteplases, Somatropins, WO 2013/102144 PCT/US2012/072182 Sulbactams, Sumatriptans, Tazobactams, Tenecteplases, Tetanus Puriﬁed Toxoids, illins, Tositumomabs, inolones, inolone Acetonides, Triamcinolone tonides, Vancomycins, Varicella Zoster immunoglobulins, Varicella vaccines, other vaccines, Alemtuzumabs, Alitretinoins, rinols, amines, Amifostines, Anastrozoles, Arsenics, Arsenic des, Asparaginases, Bacillus Calmette-Guerin (BCG) vaccines, BCG Live, Bexarotenes, Bleomycins, Busulfans, Busulfan intravenous, Busulfan orals, Calusterones, Capecitabines, Carboplatins, Carmustines, Carmustines With prosans, Celecoxibs, Chlorambucils, Cisplatins, Cladribines, Cyclophosphamides, Cytarabines, Cytarabine liposomals, Dacarbazines, Dactinomycins, Daunorubicin liposomals, Daunorubicins, ycins, Denileukin Diftitoxes, Dexrazoxanes, Docetaxels, Doxorubicins, Doxorubicin liposomals, Dromostanolone propionates, Elliott's B Solutions, Epirubicins, Epoetin alfas, Estramustines, Etoposides, Etoposide phosphates, Etoposide VP- l6s, tanes, Floxuridines, Fludarabines, Fluorouracils, 5-Fluorouracils, Fulvestrants, abines, Gemtuzumabs, Ozogamicins, Gemtuzumab ozogamicins, Hydroxyureas, Idarubicins, mides, Imatinib mesylates, Irinotecans, Letrozoles, Leucovorins, Levamisoles, Lomustines, CCNUs, Mechlorethamines, en mustards, Megestrols, Megestrol acetates, Melphalans, L-PAMs, Mercaptopurines, aptopurines, Mesnas, Methotrexates, Methoxsalens, Mitomycins, Mitomycin C’s, Mitotanes, Mitoxantrones, Nandrolones, Nandrolone Phenpropionates, momabs, Oprelvekins, latins, Paclitaxels, Pamidronates, Pegademases, Pentostatins, Pipobromans, Plicamycins, Mithramycins, Porﬁmers, Porﬁmer sodiums, Procarbazines, Quinacrines, Rasburicases, Rituximabs, Sargramostims, Streptozocins, Talcs, Tamoxifens, Temozolomides, Teniposides, Testolactones, Thioguanines, 6-Thioguanines, Triethylenethiophosphoramides (Thiotepas), Topotecans, Toremifenes, Trastuzumabs, Tretinoins, Uracil Mustards, Valrubicins, Vinblastines, Vincristines, Vinorelbines, Zoledronates, Acivicins, Aclarubicins, Acodazoles, nes, Adozelesins, eukins, Retinoic Acids, Alitretinoins, 9-Cis-Retinoic Acids, Alvocidibs, Ambazones, Ambomycins, Ametantrones, Aminoglutethimides, Amsacrines, AnaXirones, Ancitabines, Anthramycins, Apaziquones, Argimesnas, Asperlins, Atrimustines, Azacitidines, Azetepas, Azotomycins, Banoxantrones, Batabulins, Batimastats, BenaXibines, Bendamustines, Benzodepas, tamides, Bietaserpines, Biricodars, Bisantrenes, de Dimesylates, Bizelesins, Bortezomibs, Brequinars, imines, Budotitanes, Cactinomycins, Canertinibs, Caracemides, Carbetimers, Carboquones, Carmofurs, Carubicins, Carzelesins, Cedeﬁngols, Cemadotins, Chlorambucils, Cioteronels, Cirolemycins, Clanfenurs, Clofarabines, Crisnatols, Decitabines, Dexniguldipines, Dexormaplatins, Dezaguanines, Diaziquones, Dibrospidiums, Dienogests, ns, Disermolides, WO 2013/102144 PCT/US2012/072182 Dofequidars, Doxiﬂuridines, ifenes, Duazomycins, Ecomustines, Edatrexates, Edotecarins, Eﬂornithines, Elacridars, des, Elsamitrucins, Emitefurs, Enloplatins, Enpromates, Enzastaurins, Epipropidines, Eptaloprosts, Erbulozoles, Esorubicins, Etanidazoles, Etoglucids, nes, Exisulinds, Fadrozoles, Fazarabines, Fenretinides, Fluoxymesterones, Flurocitabines, Fosquidones, Fostriecins, Fotretamines, Galarubicins, Galocitabines, Geroquinols, Gimatecans, cils, Gloxazones, Glufosfamides, sines, Ilomastats, Imexons, Improsulfans, Indisulams, Inproquones, Interleukins, Interleukin-25, recombinant Interleukins, Intoplicines, Iobenguanes, atins, Irsogladines, ilones, Ketotrexates, L-Alanosines, Lanreotides, Lapatinibs, Ledoxantrones, Leuprolides, Leuprorelins, lcitols, Liarozoles, Lobaplatins, Lometrexols, Lonafarnibs, Losoxantrones, ecans, Mafosfamides, Mannosulfans, Marimastats, Masoprocols, Maytansines, Mechlorethamines, Melengestrols, Melphalans, Menogarils, Mepitiostanes, Metesinds, Metomidates, Metoprines, Meturedepas, Miboplatins, Miproxifenes, Misonidazoles, Mitindomides, Mitocarcins, Mitocromins, Mitoﬂaxones, Mitogillins, Mitoguazones, Mitomalcins, Mitonaﬁdes, Mitoquidones, ers, Mitozolomides, Mivobulins, Mizoribines, Mofarotenes, Mopidamols, Mubritinibs, Mycophenolic Acids, Nedaplatins, Neizarabines, Nemorubicins, Nitracrines, Nocodazoles, Nogalamycins, Nolatrexeds, Nortopixantrones, Ormaplatins, Ortataxels, Oteracils, ans, Oxophenarsines, Patupilones, Peldesines, Peliomycins, Pelitrexols, Pemetrexeds, Pentamustines, Peplomycins, Perfosfamides, sines, Picoplatins, Pinaﬁdes, Piposulfans, Pirfenidones, Piroxantrones, Pixantrones, PleVitrexeds, Plomestanes, Porﬁromycins, mustines, Propamidines, Prospidiums, Pumitepas, Puromycins, furins, Ranimustines, Riboprines, Ritrosulfans, Rogletimides, Roquinimexs, Rufocromomycins, Sabarubicins, Saﬁngols, Satraplatins, Sebriplatins, Semustines, Simtrazenes, Sizoﬁrans, Sobuzoxanes, Sorafenibs, sates, Sparfosic Acids, Sparsomycins, Spirogermaniums, Spiromustines, Spiroplatins, Squalamines, Streptonigrins, Streptovarycins, Sufosfamides, Sulofenurs, Tacedinalines, Talisomycins, Tallimustines, Tariquidars, Tauromustines, Tecogalans, Tegafurs, Teloxantrones, Temoporﬁns, Teroxirones, Thiamiprines, Tiamiprines, Tiazofurins, Tilomisoles, Tilorones, ars, Timonacics, zamines, Topixantrones, Trabectedins, Ecteinascidin 743, Trestolones, Triciribines, Trilostanes, Trimetrexates, Triplatin Tetranitrates, Triptorelins, famides, Tubulozoles, Ubenimexs, Uredepas, Valspodars, Vapreotides, orﬁns, stines, Vindesines, Vinepidines, Vinﬂunines, Vinformides, Vinglycinates, Vinleucinols, Vinleurosines, Vinrosidines, Vintriptols, idines, les, Xanthomycin A's, Guamecyclines, Zeniplatins, Zilascorbs [2-H], Zinostatins, Zorubicins, Zosuquidars, Acetazolamides, Acyclovirs, Adipiodones, WO 2013/102144 2012/072182 Alatroﬂoxacins, Alfentanils, Allergenic extracts, Alpha l-proteinase inhibitors, Alprostadils, Amikacins, Amino acids, aproic acids, Aminophyllines, Amitriptylines, Amobarbitals, Amrinones, Analgesics, Anti-poliomyelitic vaccines, Anti-rabic serums, Anti- tetanus immunoglobulins, tetanus vaccines, Antithrombin Ills, nom serums, Argatrobans, Arginines, Ascorbic acids, Atenolols, Atracuriums, Atropines, Aurothioglucoses, Azathioprines, Aztreonams, acins, Baclofens, Basiliximabs, Benzoic acids, Benztropines, Betamethasones, Biotins, Bivalirudins, Botulism antitoxins, Bretyliums, Bumetanides, Bupivacaines, Buprenorphines, Butorphanols, onins, riols, Calciums, Capreomycins, rosts, Carnitines, ndoles, Cefoperazones, CefotaXimes, Cefoxitins, Ceftizoximes, Cefuroximes, mphenicols, Chloroprocaines, Chloroquines, Chlorothiazides, Chlorpromazines, ChondroitinsulﬁJric acids, Choriogonadotropin alfas, Chromiums, Cidofovirs, Cimetidines, Ciproﬂoxacins, Cisatracuriums, Clonidines, Codeines, Colchicines, ins, ens, Corticorelin ovine triﬂutates, Corticotrophins, Cosyntropins, Cyanocobalamins, Cyclosporines, Cysteines, DacliXimabs, Dalfopristins, arins, Danaparoids, Dantrolenes, Deferoxamines, Desmopressins, Dexamethasones, Dexmedetomidines, Dexpanthenols, Dextrans, Iron dextrans, Diatrizoic acids, Diazepams, Diazoxides, Dicyclomines, Digibinds, Digoxins, Dihydroergotamines, Diltiazems, Diphenhydramines, Dipyridamoles, Dobutamines, Dopamines, Doxacuriums, ams, Doxercalciferols, Doxycyclines, Droperidols, Dyphyllines, Edetic acids, Edrophoniums, rilats, Ephedrines, Epoprostenols, Ergocalciferols, vines, Ertapenems, Erythromycins, Esmolols, Estradiols, Estrogenics, Ethacrynic acids, Ethanolamines, Ethanols, Ethiodized oils, Etidronic acids, Etomidates, Famotidines, Fenoldopams, Fentanyls, Flumazenils, Fluoresceins, Fluphenazines, Folic acids, Fomepizoles, Fomivirsens, Fondaparinuxs, Foscarnets, Fosphenytoins, Furosemides, Gadoteridols, Gadoversetamides, Ganciclovirs, Gentamicins, Glucagons, Glucoses, Glycines, Glycopyrrolates, Gonadorelins, Gonadotropin chorionics, Haemophilus B polysaccharides, Hemins, Herbals, Histamines, Hydralazines, Hydrocortisones, Hydromorphones, Hydroxocobalamins, Hydroxyzines, Hyoscyamines, Ibutilides, Imiglucerases, Indigo carmines, Indomethacins, Iodides, Iopromides, Iothalamic acids, onaglic acids, onilans, Isoniazids, Isoproterenols, Japanese encephalitis vaccines, Kanamycins, Ketamines, Labetalols, Lepirudins, pivacaines, Levothyroxines, Lincomycins, ronines, Luteinizing hormones, Lyme disease vaccines, odipirs, Manthtols, Meningococcal polysaccharide vaccines, Meperidines, Mepivacaines, Mesoridazines, Metaraminols, Methadones, arbamols, MethoheXitals, Methyldopates, Methylergonovines, Metoclopramides, Metoprolols, Metronidazoles, Minocyclines, Mivacuriums, Morrhuic acids, WO 2013/102144 PCT/US2012/072182 Moxiﬂoxacins, Muromonab-CD3 s, Mycophenolate mofetils, Nafcillins, Nalbuphines, Nalmefenes, Naloxones, Neostigmines, Niacinamides, Nicardipines, Nitroglycerins, Nitroprussides, Norepinephrines, Orphenadrines, Oxacillins, Oxymorphones, Oxytetracyclines, Oxytocins, Pancuroniums, Panthenols, Pantothenic acids, Papaverines, Peginterferon alpha 2As, llin Gs, Pentamidines, Pentazocines, arbitals, Perﬂutrens, Perphenazines, Phenobarbitals, Phentolamines, Phenylephrines, Phenytoins, Physostigmines, Phytonadiones, Polymyxin, oximes, Prilocaines, Procainamides, Procaines, Prochlorperazines, Progesterones, Propranolols, Pyridostigmine hydroxides, Pyridoxines, Quinidines, Quinupristins, Rabies immunoglobulins, Rabies vaccines, dines, Remifentanils, Riboﬂavins, Rifampins, Ropivacaines, ums, Scopolamines, Seleniums, Sermorelins, Sincalides, Somatrems, nomycins, Streptokinases, Streptomycins, Succinylcholines, Sufentanils, Sulfamethoxazoles, Tacrolimuses, Terbutalines, Teriparatides, terones, Tetanus antitoxins, Tetracaines, Tetradecyl sulfates, Theophyllines, Thiamines, Thiethylperazines, Thiopentals, Thyroid stimulating hormones, Tinzaparins, Tirof1bans, Tobramycins, lines, Tolbutamides, ides, amic acids, Treprostinils, Triﬂuoperazines, Trimethobenzamides, Trimethoprims, Tromethamines, Tuberculins, Typhoid vaccines, Urofollitropins, Urokinases, Valproic acids, Vasopressins, Vecuroniums, Verapamils, Voriconazoles, Warfarins, Yellow fever vaccines, Zidovudines, Zincs, idone hydrochlorides, Aclacinomycins, Actinomycins, Adriamycins, Azaserines, 6-Azauridines, ophilins, Chromomycins, Denopterins, 6 Diazo 5 Oxo-L-Norleucines, Enocitabines, Floxuridines, Olivomycins, Pirarubicins, Piritrexims, Pteropterins, Tegafurs, Tubercidins, Alteplases, Arcitumomabs, bevacizumabs, Botulinum Toxin Type A's, Botulinum Toxin Type B's, Capromab Pendetides, Daclizumabs, Dornase alphas, Drotrecogin alphas, Imciromab Pentetates, Iodine-131’s, an antibiotic agent; an angiogenesis inhibitor; anti-cataract and anti-diabetic retinopathy nces; carbonic anhydrase inhibitors; mydriatics; photodynamic therapy agents; glandin analogs; grth factor; eoplastics; anti-metabolites; anti-viral; amebicides and anti-protozoals; anti-tuberculosis and anti-leprotic; antitoxins and nins; antihemophilic factor, anti- inhibitor coagulant complex, antithrombin III, coagulations Factor V, coagulation Factor IX, plasma protein fraction, von Willebrand factor; antiplatelet agent a colony stimulating factor (CSF); an opoiesis stimulator; hemostatics and albumins; Immune Globulins; thrombin inhibitors; anticoagulants; a steroidal anti-inﬂammatory drug selected from among alclometasones, algestones, ethasones, betamethasones, budesonides, clobetasols, clobetasones, clocortolones, cloprednols, osterones, cortisones, cortivazols, corts, desonides, desoximetasones, dexamethasones, diﬂorasones, diﬂucortolones, diﬂuprednates, WO 2013/102144 PCT/US2012/072182 enoxolones, ﬂuazacorts, ﬂucloronides, asones, lides, olones, ﬂuocinonides, ﬁuocortins, ﬂuocortolones, ﬂuorometholones, ﬁuperolones, ﬁuprednidenes, ﬂuprednisolones, ﬁurandrenolides, ﬁuticasones, formocortals, halcinonides, halobetasols, halometasones, halopredones, hydrocortamates, hydrocortisones, loteprednol etabonate, mazipredones, medrysones, meprednisones, methylprednisolones, mometasone e, paramethasones, carbates, solones, prednisones, prednivals, prednylidenes, rimexolones, tixocortols and triamcinolones; Docosanols, prostaglandins, prostaglandin analogs, antiprostaglandins and glandin precursors; miotics, cholinergics and anti- esterase; and anti-allergenics.

The compositions and modiﬁed PH20 polypeptides can be used to treat any condition normally d by the PH20 polypeptide or the therapeutically active agent. These include, for example, conditions in Which hyaluronan plays a role or is associated With the etiology of the disease due to, for example, accumulation or overproduction of onan. Hence provided are methods, uses of the compositions and modiﬁed PH20 polypeptides for treating a hyaluronan-associated e or condition by administering any of the modiﬁed PH20 polypeptides or compositions provided herein. Hyaluronan-associated diseases and conditions include, for example, inﬂammatory e and tumors or cancers, ing a late-stage cancer, metastatic cancers and undifferentiated cancers, such as ovarian cancer, in situ carcinoma (ISC), squamous cell carcinoma (SCC), prostate cancer, pancreatic cancer, non-small cell lung cancer, breast cancer and colon cancer. The PH20 polypeptide can be modiﬁed to exhibit increased half-life for such treatments. For example, the PH20 polypeptide can be modiﬁed With a polymer such as a PEG moiety for such treatments.

Also provided are methods for increasing delivery of a therapeutic agent to a subject by: administering to a subject any of the modiﬁed PH20 polypeptides or compositions provided herein, and administering the therapeutic agent. The eutic agent can be administered in the same composition or separately, and can be administered before or after, aneously, or intermittently, With administration of the PH20 polypeptide(s).

Administration includes any route, including intravenous and subcutaneous administration, such as simultaneously With, intermittently With, or subsequent to stration of the therapeutic agent. The therapeutic agents include any of those set forth above, elsewhere herein and/or known to those of skill in the art.

Also provided are methods for treating an excess of glycosaminoglycans; for treating a tumor; for treating glycosaminoglycan accumulation in the brain; for treating a cardiovascular disorder; for treating an ophthalmic disorder; for treating ary disease; for increasing penetration of herapeutic agents into solid tumors; for treating cellulite; WO 2013/102144 PCT/US2012/072182 for treating a proliferative disorder; or for increasing bioavailability of drugs and other therapeutic agents by administering the modiﬁed PH20 polypeptides or compositions provided herein.

Also provided are pharmaceutical compositions for use in treating a onan- associated disease or disorder; for use in delivering a therapeutic agent to a subject; for treating an excess of glycosaminoglycans; for treating a tumor; for ng glycosaminoglycan accumulation in the brain; for treating a cardiovascular disorder; for treating an ophthalmic disorder; for treating pulmonary disease; for increasing penetration of chemotherapeutic agents into solid tumors; for ng cellulite; for ng a proliferative disorder; or for sing bioavailability of drugs and other therapeutic agents; and for any other use of compositions ning PH20 polypeptides.

Provided herein is a method for identifying or selecting a modiﬁed hyaluronan- degrading enzyme that exhibits stability under a ration condition that includes the steps of: a) testing the activity of a modiﬁed hyaluronan-degrading enzyme in a composition containing a denaturing agent and/or under a denaturing condition; b) testing the activity of the modiﬁed hyaluronan-degrading enzyme in the same composition and/or under the same ions as a) except absent the denaturing agent or condition; and c) selecting or identifying a d hyaluronan-degrading enzyme that exhibits activity in a) that is at least % of the activity in b). In such an example, the activity is hyaluronidase activity. In some examples of the methods, a modiﬁed hyaluronan-degrading enzyme is selected or ﬁed if the activity in a) is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more of the activity in b), for example, a modiﬁed hyaluronan-degrading enzyme is selected or identiﬁed if the activity in a) is at least 40% or more of the activity in b). The method also can include steps of: d) ing the activity of the modiﬁed onan-degrading enzyme in a) to the ty of the unmodiﬁed hyaluronan-degrading enzyme tested under the same conditions; and e) identifying or selecting a modiﬁed hyaluronan-degrading enzyme that exhibits at least 120%, 130%, 135%, 140%, 145%, 150%, 160%, 170%, 180%, 200%, 250%, 300%, 350%, 400%, 500%, 1500%, 2000%, 3000%, 4000%, 5000% or more of the hyaluronidase activity ed to the unmodiﬁed hyaluronan-degrading enzyme.

Also provide herein is a method for identifying or selecting a modiﬁed hyaluronan- degrading enzyme that exhibits stability, such as increased stability, under a denaturation condition, that includes the steps of: a) testing the activity of a modiﬁed hyaluronan- degrading enzyme in a composition containing a denaturing agent and/or under a denaturing condition; b) testing the activity of the corresponding unmodiﬁed hyaluronan-degrading WO 2013/102144 PCT/US2012/072182 enzyme in a composition containing the same denaturing agent and/or under the same denaturing condition as a), whereby the ty is tested under the same conditions as a); and c) selecting or fying a modiﬁed hyaluronan-degrading enzyme that exhibits greater activity than the unmodiﬁed hyaluronan-degrading enzyme, y identifying or selecting a modiﬁed hyaluronan-degrading enzyme that exhibits increased ity under a denaturation condition. In such an example, the activity can be a hyaluronidase activity. In examples of the method, a modiﬁed hyaluronan-degrading enzyme is selected or identiﬁed if the ty is at least 120%, 130%, 135%, 140%, 145%, 150%, 160%, 170%, 180%, 200%, 250%, 300%, 350%, 400%, 500%, 1500%, 2000%, 3000%, 4000%, 5000% or more ofthe activity compared to the unmodiﬁed hyaluronan-degrading enzyme. In such an example, the method also can include additional steps of: d) testing the activity of the selected or identiﬁed modiﬁed hyaluronan-degrading enzyme in a composition containing a ring agent and/or under a denaturing condition; e) testing the activity of the same selected or identiﬁed modiﬁed hyaluronan-degrading enzyme in the same composition and/or under the same conditions as d) except absent the denaturing agent or condition; and f) selecting or fying a modiﬁed hyaluronan-degrading enzyme that exhibits activity in d) that is at least % of the activity in e). In such an example, the activity is hyaluronidase activity. In some examples of the methods, a modiﬁed hyaluronan-degrading enzyme is selected or identiﬁed if the activity in d) is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more of the ty in e), for example, a modiﬁed hyaluronan-degrading enzyme is selected or identiﬁed if the activity in d) is at least 40% or more of the activity in e).

In any of the methods provided herein for identifying or ing a modiﬁed onan-degrading enzyme, the denaturing agent or condition is caused by temperature, agitation, no or low salt or the presence of an ent. For example, the denaturing agent or condition is caused by ed temperature that is from or from about 30 0C to 42 0C, such as greater than or greater than about 30 0C, 31 0C, 32 0C, 33 0C, 34 0C, 35 0C, 36 0C, 37 0C, 38 0C, 39 0C, 40 0C, 41 0C or 42 0C. In other es, the denaturing agent or condition is the absence of salt or low salt less than 100 mM, such as low salt less than 90 mM, 80mM, 70mM, 60 mM, 50 mM, 40 mM, 30 mM, 25 mM, 20 mM, 15 mM, 10 mM, 5 mM. In further examples, the denaturing agent or condition is a denaturing excipient selected from among an antiadherents, binders, coatings, ﬁllers and diluents, ﬂavors, colors, lubricants, glidants, preservatives, sorbents and sweeteners.

In particular examples of any of the methods provided herein for identifying or selecting a modiﬁed hyaluronan-degrading enzyme, the ring agent or condition is a WO 2013/102144 PCT/US2012/072182 preservative(s), for example, a phenolic preservative(s). The phenolic preservative(s) can be a phenol, metacresol (m—cresol), benzyl alcohol, or a paraben. For e, the denaturing agent or ion is a preservative(s) that is phenol and/or m—cresol. In such examples, the total amount of phenolic vative in the composition, as a percentage (%) of mass concentration (w/V), is from or from about 0.05% to 0.6%, 0.1% to 0.4%, 0.1% to 0.3%, 0.15% to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 0.3% to 0.4% inclusive.

In any of the s provided herein for identifying or selecting a modiﬁed hyaluronan-degrading enzyme, prior to testing the actiVity of a onan-degrading enzyme ition in a) and/or b), the hyaluronan-degrading enzyme is exposed to the denaturation condition or denaturing agent for a predetermined time. The predetermined time is a time period that is user selected depending on the particular hyaluronan-degrading enzyme that is being d or selected, the particular denaturation condition or denaturing agent, the amount or extent of the denaturation condition or denaturing agent, the application or use of the hyaluronan-degrading enzyme and other similar factors. For example, the predetermined time can be from or from about 1 minute to 1 month, 1 minute to 3 weeks, 1 minute to 2 weeks, 1 minute to 1 week, 1 minute to 24 hours, 1 minute to 12 hours, 30 minutes to 6 hours or 1 hour to 4 hours, such as at least or about at least 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, two days, three days, four days, ﬁve days, six days, 7 days, two weeks or one month.

In any of the methods provided herein for identifying or selecting a modiﬁed hyaluronan-degrading enzyme, the modiﬁed hyaluronan-degrading enzyme is one that contains an amino acid replacement, insertion or deletion of amino acids compared to an unmodiﬁed hyaluronan-degrading enzyme. For example, the modiﬁed hyaluronan-degrading enzyme contains an amino acid replacement, such as a single amino acid replacement or two, three, four, ﬁve, six, seven, eight, nine or more amino acid replacements compared to an unmodiﬁed form of the hyaluronan-degrading enzyme. In ular aspects of the method, a library or collection of modiﬁed hyaluronan-degrading s are screened in order to evolve or identify or select a modiﬁed hyaluronan-degrading enzyme that exhibits stability, such as increased ity, under a denaturation condition. Thus, in examples of the methods herein, a plurality of modiﬁed hyaluronan-degrading enzymes are tested in a) and/or b). In such examples, the plurality of d hyaluronan-degrading enzymes are modiﬁed ed to the corresponding unmodiﬁed hyaluronan-degrading enzyme to generate a collection of modiﬁed hyaluronan-degrading enzymes, y each modiﬁed protein in the collection is tested in each of a) and/or b). In the collection or library, each modiﬁed hyaluronan-degrading enzyme contains a single amino acid replacement compared to the WO 2013/102144 PCT/US2012/072182 unmodiﬁed form of the hyaluronan-degrading enzyme, such that the plurality of modiﬁed enzymes are such that the amino acid at each d position is ed by up to 1-19 other amino acids other than the original amino acid at the position, Whereby each modiﬁed hyaluronan-degrading enzyme contains a different amino acid replacement, and every amino acid along the length of the hyaluronan-degrading enzyme, or a selected portion thereof, is replaced.

In any of the methods provided herein, the modiﬁed hyaluronan-degrading enzyme is d compared to an unmodiﬁed hyaluronan-degrading enzyme by ion, deletion or replacement of an amino acid(s). The unmodiﬁed hyaluronan-degrading enzyme can be a chondroitinase or can be a hyaluronidase. In examples herein, the unmodiﬁed hyaluronidase is a PH2O hyaluronidase or truncated form thereof lacking a C-terminal glycosylphosphatidylinositol (GPI) anchor attachment site or a portion of the GPI anchor attachment site, Whereby the truncated form exhibits hyaluronidase activity. PH2O hyaluronidase can be a human, monkey, bovine, ovine, rat, fox, mouse or guinea pig PH20.

In particular examples, the PH2O hyaluronidase is a human PH2O or a C-terminal truncated form thereof. For example, the unmodiﬁed onan-degrading enzyme is one that has the sequence of amino acids set forth in any of SEQ ID NOS: 3, 7, 10, 12, 14, 24, 32-66, 69, 72, 857, 859, 861, 870 or a sequence of amino acids that is at least 80% sequence identity to any of SEQ ID NOS: 3, 7, 10, 12, 14, 24, 32-66, 69, 72, 857, 859, 861, 870, such as at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to any of SEQ ID NOS: 3, 7, 10, 12, 14, 24, 32-66, 69, 72, 857, 859, 861, or 870. In particular examples, the ﬁed hyaluronan-degrading enzyme is a PH2O hyaluronidase having the sequence of amino acids set forth in any of SEQ ID NOS: 3, 7, 32-66, 69 or 72, or a sequence of amino acids that exhibits at least 85% sequence identity to any of SEQ ID NOS: 3, 7, 32-66, 69 or 72, such as a sequence of amino acids that exhibits at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS: 3, 7, 32-66, 69 or 72.

In any of the methods provided herein for identifying or selecting a modiﬁed hyaluronan-degrading enzyme that exhibits stability, the method is performed in vitro. Also provided are any of the methods that are iterative, Whereby the steps of the method are ed a ity of times, Wherein in each repetition, r modiﬁed onandegrading enzymes of a selected modiﬁed hyaluronan-degrading enzyme are generated and tested, Whereby the modiﬁed hyaluronan-degrading enzyme is evolved to exhibit sed stability under a denaturation condition. Also ed herein is a modiﬁed hyaluronan- degrading enzyme identiﬁed by any of the methods provided herein.

WO 2013/102144 PCT/US2012/072182 BRIEF PTION OF THE FIGURES Figure 1 depicts the amino acid sequence of ength human PHZO (set forth in SEQ ID NO:7) and soluble C-terminal ted variants f. The C-terminal amino acid residue of exemplary C-terminal truncated variants of full-length PHZO are indicated by bold font. The complete amino acid sequences of exemplary C-terminal truncated variants of full- length PHZO also are provided in SEQ ID NOS: 3 and 32-66. The C-terminal amino acid residue of an ary soluble PH20, Whose complete sequence is set forth in SEQ ID NO:3, also is indicated by underline. Exemplary, miting, positions for amino acid replacements are indicated by highlighting. Corresponding positions can be identiﬁed by alignment of a sequence of interest With any of SEQ ID NOS: 3, 7 or 32-66, and in particular With SEQ ID NO:3.

Figure 2 depicts exemplary alignments of human soluble PHZO set forth in SEQ ID N03 with other PHZO polypeptides. A "*" means that the aligned residues are identical, a ":" means that aligned residues are not identical, but are similar and contain conservative amino acids es at the aligned position, and a "." means that the aligned residues are similar and n semi-conservative amino acid residues at the aligned position. Exemplary, non- limiting, corresponding positions for amino acid replacements are ted by highlighting.

For example, Figure 2A depicts the alignment of a human e PHZO set forth in SEQ ID N03 with chimpanzee PHZO set forth in SEQ ID NO:lO. Figure 2B depicts the alignment of a human soluble PHZO set forth in SEQ ID N03 with Rhesus monkey PHZO set forth in SEQ ID NO: 12. Figure 2C depicts the alignment of a human soluble PHZO set forth in SEQ ID N03 with lgus monkey PHZO set forth in SEQ ID NO: 14. Figure 2D depicts the alignment of human soluble PHZO set forth in SEQ ID N03 with bovine PHZO set forth in SEQ ID NO:l6. Figure 2E depicts the alignment of a human soluble PHZO set forth in SEQ ID N03 with mouse PHZO set forth in SEQ ID NO:20. Figure 2F depicts the alignment of a human soluble PHZO set forth in SEQ ID N03 with rat PHZO set forth in SEQ ID NO:22.

Figure 2G depicts the alignment of a human soluble PHZO set forth in SEQ ID N03 with rabbit PHZO set forth in SEQ ID NO:24. Figure 2H depicts the alignment of a human e PHZO set forth in SEQ ID N03 with guinea pig PHZO set forth in SEQ ID NO:29. Figure 21 depicts the alignment of a human soluble PHZO set forth in SEQ ID N03 with Fox PHZO set forth in SEQ ID N03 1. Figure 2J depicts the alignment of a human soluble PHZO set forth in SEQ ID N03 with Gibbon PHZO set forth in SEQ ID NO:857. Figure 2K depicts the alignment of a human soluble PHZO set forth in SEQ ID N03 with Marmoset PHZO set forth in SEQ ID NO:859. Figure 2L depicts the alignment of a human soluble PHZO set forth in SEQ ID N03 with Orangutan PHZO set forth in SEQ ID NO:861.

WO 2013/102144 PCT/US2012/072182 DETAILED DESCRIPTION Outline A. Deﬁnitions B PH20 Hyaluronidase 1. ure 2. Function 3. Soluble PH20 Polypeptides C. Modiﬁed PH20 Polypeptides 1. Active Mutants a. Increased Activity b. Increased Stability i. Phenophiles ii. Thermophiles iii. Absence of Salt 2. Inactive Mutants U) Additional Modiﬁcations a. Decreased Immunogenicity b. Conjugation to Polymers D. Methods for fying Modiﬁed Hyaluronan-Degrading Enzymes With Altered properties or Activities l. Hyaluronan-Degrading Enzymes and Libraries of Modiﬁed Hyaluronan-Degrading Enzymes 2. Screening or Testing for a Desired Activity or Property 3. Selection or Identiﬁcation 4. Iterative Methods E. Production of Modiﬁed Polypeptides and Encoding Nucleic Acid Molecules 1. Isolation or Preparation of Nucleic Acids Encoding PH20 Polypeptides 2. tion of Mutant or Modiﬁed Nucleic Acid and ng Polypeptides 3. Vectors and Cells 4. Expression a. Prokaryotic Cells b. Yeast Cells c. s and Insect Cells d. Mammalian expression e. Plants and plant cells . Puriﬁcation 6. ation of Polypeptides by PEGylation F. Pharmaceutical Compositions and Formulations, s and Administration 40 1. Formulations ds, injectables, ons and emulsions) a. Lyophilized b. Exemplary Formulations i. NaCl ii. pH and Buffer 45 iii. Preservatives iv. Stabilizers Compositions for Other Routes of Administration Dosages and Administration Exemplary PH20-Insulin Co-Formulations 50 zvéww ing, Articles of Manufacture and Kits ethods of Assessing Hyaluronidase Activity WO 2013/102144 PCT/US2012/072182 _ 52 _ l. Hyaluronidase Activity 2. Solubility 3. Purity, Crystallization or Aggregation 4. Pharmacodynamics/Pharmacokinetics H. Methods of Treatment and Combination Therapy 1. Methods of Delivering Therapeutic Agents ry of Insulin 2. Methods of Treating onan-Associated Disease and Conditions 3. Other Uses 4. Contraception I. Examples A. DEFINITIONS Unless deﬁned otherwise, all technical and scientiﬁc terms used herein have the same meaning as is ly understood by one of skill in the art to which the invention(s) belong. All patents, patent applications, published applications and publications, GenBank sequences, databases, websites and other published materials referred to hout the entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety. In the event that there are a plurality of deﬁnitions for terms herein, those in this section prevail.

Where reference is made to a URL or other such identiﬁer or address, it understood that such identiﬁers can change and particular information on the intemet can come and go, but equivalent information can be found by searching the intemet. nce thereto ces the availability and public dissemination of such information.

As used herein, a hyaluronan-degrading enzyme refers to an enzyme that catalyzes the cleavage of a hyaluronan polymer (also referred to as hyaluronic acid or HA) into smaller molecular weight fragments. Exemplary hyaluronan-degrading enzymes are onidases, and particular chondroitinases and lyases that have the ability to depolymerize hyaluronan.

Exemplary chondroitinases that are hyaluronan-degrading enzymes e, but are not limited to, chondroitin ABC lyase (also known as chondroitinase ABC), chondroitin AC lyase (also known as chondroitin sulfate lyase or chondroitin sulfate eliminase) and chondroitin C lyase. Chondroitin ABC lyase contains two enzymes, chondroitin-sulfate-ABC endolyase (EC 4.2.2.20) and oitin-sulfate-ABC se (EC 4.2.2.21). An exemplary chondroitin-sulfate-ABC endolyases and chondroitin-sulfate-ABC exolyases e, but are not limited to, those from Proteus vulgaris and Pedobacter heparinus (the Proteus vulgaris chondroitin-sulfate-ABC endolyase is set forth in SEQ ID ; Sato et al. (1994) Appl.

Microbiol. hnol. 41(1):39-46). Exemplary chondroitinase AC enzymes from bacteria include, but are not limited to, those from Pedobacter heparinus, set for thin SEQ ID NO: 923, Victivallis vadensis, set forth in SEQ ID NO:924, and Arthrobacter aurescens (Tkalec et al. (2000) Applied and Environmental iology 66(1):29-35; Ernst et al.

WO 02144 PCT/US2012/072182 (1995) Critical Reviews in Biochemistry and Molecular Biology 30(5):387-444). Exemplary chondroitinase C enzymes from bacteria include, but are not limited to, those from Streptococcus and Flavobacterium (Hibi et al. (1989) FEMS-Microbiol—Lett. 48(2): 121-4; Michelacci et al. (1976) J. Biol. Chem. 251 :1 154-8; Tsuda et al. (1999) Eur. J. m. 262:127-133).

As used herein, hyaluronidase refers to a class of enzymes that degrade hyaluronan.

Hyaluronidases include, but are not limited to, ial hyaluronidases (EC 4.2.2.1 or EC 4.2.99.1), hyaluronidases from leeches, other parasites and crustaceans (EC 3.2.1.36), and mammalian-type hyaluronidases (EC 3.2.1.35). Hyaluronidases include any of non-human origin including, but not limited to, murine, canine, , leporine, avian, bovine, ovine, porcine, equine, piscine, ranine, bacterial, and any from leeches, other parasites, and crustaceans. Exemplary human hyaluronidases include HYALl, HYAL2, HYAL3, HYAL4, and PH20. Also included amongst hyaluronidases are soluble hyaluronidases, including, ovine and bovine PH20, and soluble PH20. Exemplary hyaluronidases include any set forth in SEQ ID NOS: 6, 7-31, 69, 70, 71, 72, 856-861, 869-921, mature forms thereof (lacking the signal sequence), or c or species variants thereof. Hyaluronidases also include truncated forms thereof that exhibit onidase activity, including C-terminal truncated ts that are soluble.

As used herein, PH20 refers to a type of hyaluronidase that occurs in sperm and is neutral-active. PH-20 occurs on the sperm surface, and in the lysosome-derived acrosome, Where it is bound to the inner acrosomal membrane. PH20 includes those of any origin including, but not limited to, human, chimpanzee, Cynomolgus monkey, Rhesus monkey, , , ovine, guinea pig, rabbit and rat origin. Exemplary PH20 polypeptides, including precursor and mature forms, include those from human (SEQ ID NO:6 and 7), chimpanzee (SEQ ID NO:8, 9, 10, 869 and 870), Rhesus monkey (SEQ ID NO:11 and 12), Cynomolgus monkey (SEQ ID NO:13 and 14), cow (e.g., SEQ ID NOS:15-18); mouse (SEQ ID NO:19 and 20); rat (SEQ ID NO:21 and 22); rabbit (SEQ ID NO:23 and 24); sheep (SEQ ID NOS:25-27), guinea pig (SEQ ID NO:28 and 29); fox (SEQ ID NO: 30 and 31); Gibbon (SEQ ID NO:856 and 857), Marmoset (SEQ ID NO:858 and 859) and orangutan (SEQ ID NO:860 and 861) . Reference to PH20 includes precursor PH20 polypeptides and mature PH20 polypeptides (such as those in Which a signal sequence has been removed), ted forms thereof that have ty, and includes allelic variants and species variants, variants encoded by splice variants, and other ts, including polypeptides that have at least 40%, 45%, 50%, 55%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the precursor polypeptides set forth in SEQ ID NO:7, or the mature WO 2013/102144 PCT/US2012/072182 forms thereof. PH20 ptides also e those that contain chemical or posttranslational modiﬁcations and those that do not contain chemical or posttranslational modiﬁcations. Such modiﬁcations include, but are not limited to, PEGylation, albumination, glycosylation, lation, carboxylation, hydroxylation, phosphorylation, and other polypeptide modiﬁcations known in the art. Examples of commercially available bovine or ovine soluble hyaluronidases are Vitrase® hyaluronidase (ovine hyaluronidase) and Amphadase® hyaluronidase e hyaluronidase).

As used herein, a soluble PH20 refers to a polypeptide characterized by its solubility under physiological conditions. lly, a soluble PH20 lacks all or a portion of a glycophosphatidyl anchor (GPI) attachment sequence, or does not otherwise sufﬁciently anchor to the cell membrane. For example, a soluble PH20 can be a C-terminally truncated variant of a PH20 lacking a contiguous sequence of amino acids that corresponds to all or a portion of a glycophosphatidyl anchor (GPI) ment sequence. Hence, upon expression from a cell, a soluble PH20 is secreted into the . e PH20 proteins can be distinguished, for example, by its partitioning into the aqueous phase of a Triton X-l 14 solution warmed to 37 °C (Bordier et al., (1981) J. Biol. Chem, 256:1604-7). Membrane- anchored, such as lipid anchored hyaluronidases, will partition into the detergent rich phase, but will partition into the detergent-poor or aqueous phase following treatment with olipase-C. Included among soluble PH20 hyaluronidases are membrane anchored hyaluronidases in which one or more regions associated with anchoring of the hyaluronidase to the membrane has been removed or modiﬁed, where the soluble form retains hyaluronidase activity. Soluble hyaluronidases include recombinant e onidases and those contained in or puriﬁed from natural sources, such as, for example, testes extracts from sheep or cows. Exemplary of such soluble hyaluronidases are soluble human PH20 (SEQ ID NO: 3 or 32-66). Other soluble hyaluronidases include ovine (SEQ ID NO:25-27) and bovine (SEQ ID NO:l6 or 18) PH20.

As used herein, soluble human PH20 (sHuPHZO) includes human PH20 polypeptides that lack a contiguous ce of amino acids from the C-terminus of human PH20 that includes all or a portion of the glycosylphosphatidylinositol (GPI) anchor sequence (C- terminally truncated PH20 polypeptides) such that upon expression, the ptides are soluble under physiological conditions. For example, soluble human PH20 polypeptides are inally truncated polypeptides of human PH20 set forth as SEQ ID NO:6 in its precursor form or in SEQ ID NO:7 in its mature form lacking the signal sequence, or allelic variants thereof (e.g. set forth in any of SEQ ID NOS: 68-72). Solubility can be assessed by any suitable method that demonstrates lity under physiologic conditions. Exemplary of WO 2013/102144 PCT/US2012/072182 such methods is the Triton® X-l 14 assay, that assesses partitioning into the aqueous phase and that is described above. In addition, a soluble human PH20 polypeptide is, if produced in CHO cells, such as CHO-S cells, a polypeptide that is expressed and is ed into the cell culture medium. Soluble human PH20 polypeptides, however, are not limited to those ed in CHO cells, but can be produced in any cell or by any method, including recombinant expression and polypeptide synthesis. Reference to ion in CHO cells is deﬁnitional. Hence, if a polypeptide could be expressed and secreted in CHO cells and is soluble in the media, i.e., partitions into the aqueous phase When extracted With Triton® X- 114, it is a e PH20 polypeptide Whether or not it is so-produced. The precursor polypeptides for sHuPHZO polypeptides can include a signal sequence, such as a heterologous or non-heterologous (i.e., native) signal sequence. Exemplary of the precursors are those that include a signal sequence, such as the native 35 amino acid signal sequence at amino acid positions 1-35 (see, e.g., amino acids 1-35 of SEQ ID NO:6).

As used herein, "native" or "Wildtype" With reference to a PH20 polypeptide refers to a PH20 polypeptide encoded by a native or naturally occurring PH20 gene, including allelic variants, that is present in an organism, including a human and other animals, in .

Reference to Wild-type PH20 Without reference to a species is intended to encompass any species of a Wild-type PH20. Included among Wild-type PH20 ptides are the encoded precursor polypeptide, fragments f, and processed forms f, such as a mature form lacking the signal peptide as well as any pre- or post-translationally processed or modiﬁed forms f Also included among native PH20 polypeptides are those that are post- translationally modiﬁed, including, but not limited to, those that are modiﬁed by glycosylation, carboxylation and/or hydroxylation. The amino acid sequences of ary Wild-type human PH20 are set forth in SEQ ID NOS: 6 and 7 and those of allelic variants, including mature forms thereof, are set forth in SEQ ID NOS:68-72 .

Other animals produce native PH20, including, but not d to, native or Wildtype sequences set forth in any of SEQ ID NOS: 8-31, 856-861, 869 or 870.

As used herein, modiﬁcation is in reference to modiﬁcation of a sequence of amino acids of a polypeptide or a sequence of nucleotides in a nucleic acid molecule and es deletions, ions, and replacements of amino acids and nucleotides, respectively.

Modiﬁcations also can include post-translational modiﬁcations or other s to the molecule that can occur due to conjugation or linkage, ly or indirectly, to another moiety. Methods ofmodifying a polypeptide are e to those of skill in the art, such as by using recombinant DNA methodologies.

WO 2013/102144 2012/072182 As used herein, a "modiﬁed hyaluronan-degrading " refers to a hyaluronan- degrading enzyme that contains a modiﬁcation compared to a reference or unmodiﬁed hyaluronan-degrading enzyme. The modiﬁcation can be an amino acid replacement itution), insertion (addition) or deletion of one or more amino acid residues. The amino acid residue can be a l or non-natural amino acid. In some cases, the modiﬁcation can be a post-translational modiﬁcation. A modiﬁed hyaluronan-degrading enzyme can have up to 150 amino acid differences compared to a nce or unmodiﬁed onan-degrading enzyme, so long as the resulting modiﬁed hyaluronan-degrading enzyme exhibits hyaluronidase ty. Typically, a modiﬁed hyaluronan-degrading enzyme contains 1, 2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14,15,16,17,18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acid modiﬁcations.

As used herein, an unmodiﬁed hyaluronan-degrading enzyme refers to a starting polypeptide that is selected for modiﬁcation as provided herein. The starting polypeptide can be a naturally-occurring, Wild-type form of a polypeptide. In addition, the starting polypeptide can be altered or mutated, such that it differs from a native Wild type isoform but is nonetheless referred to herein as a starting unmodiﬁed polypeptide relative to the subsequently modiﬁed polypeptides produced herein. Thus, existing proteins known in the art that have been d to have a desired increase or decrease in a particular actiVity or property compared to an unmodiﬁed reference protein can be selected and used as the starting ﬁed polypeptide. For example, a n that has been modiﬁed from its native form by one or more single amino acid changes and ses either an increase or decrease in a desired ty, such as a change in an amino acid residue or residues to alter ylation, can be ed for modiﬁcation, and hence referred to herein as unmodiﬁed, for r modiﬁcation. An unmodiﬁed hyaluronan-degrading enzyme includes human and non-human hyaluronan-degrading enzymes, including hyaluronan-degrading enzymes from non-human mammals and bacteria. Exemplary unmodiﬁed hyaluronan-degrading enzyme are any set forth in SEQ ID NOS: 2, 3, 6, 7-66, 68-72, 856-861, 869-924 or mature, C-terminally truncated forms thereof that exhibit hyaluronidase actiVity, or a hyaluronan-degrading enzyme that exhibits at least 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOS: 2, 3, 6, 7-66, 68-72, 856-861, 869-924. It is understood that an unmodiﬁed hyaluronan-degrading enzyme generally is one that does not contain the modiﬁcation(s), such as amino acid replacement(s) of a modiﬁed hyaluronan-degrading enzyme.

WO 2013/102144 PCT/US2012/072182 As used herein, "modiﬁed PH20 polypeptide" or "variant PH20 polypeptide" refers to a PH20 polypeptide that ns at least one amino acid modiﬁcation, such as at least one amino acid replacement as described herein, in its sequence of amino acids compared to a reference unmodiﬁed PH20 polypeptide. A modiﬁed PH20 polypeptide can have up to 150 amino acid replacements, so long as the resulting d PH20 polypeptide exhibits onidase activity. Typically, a modiﬁed PH20 ptide contains 1, 2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14,15,16,17,18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acid replacements. It is understood that a modiﬁed PH20 polypeptide also can include any one or more other ations, in on to at least one amino acid replacement as described herein.

As used herein, an unmodiﬁed PH20 polypeptide refers to a starting PH20 polypeptide that is selected for modiﬁcation as provided herein. The starting polypeptide can be a naturally-occurring, Wild-type form of a polypeptide. In addition, the starting polypeptide can be altered or mutated, such that it differs from a native Wild type isoform but is nonetheless referred to herein as a starting unmodiﬁed polypeptide relative to the subsequently modiﬁed polypeptides produced herein. Thus, existing proteins known in the art that have been modiﬁed to have a desired increase or decrease in a particular activity or property compared to an unmodiﬁed reference protein can be selected and used as the starting unmodiﬁed polypeptide. For example, a n that has been modiﬁed from its native form by one or more single amino acid changes and possesses either an increase or decrease in a desired property, such as a change in an amino acid residue or residues to alter glycosylation, can be selected for modiﬁcation, and hence ed to herein as unmodiﬁed, for further modiﬁcation. Exemplary unmodiﬁed PH20 polypeptides is a human PH20 polypeptide or allelic or species variants thereof or other variants, ing mature and precursor polypeptides. For example, exemplary reference PH20 polypeptides is a mature full length PH20 polypeptide set forth in SEQ ID NOS: 7, 69 or 72, or in inally truncated forms thereof such as set forth in any of SEQ ID NOS: 3 and 32-66, or in a PH20 polypeptide that exhibits at least 68%, 69%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% ce ty to any of SEQ ID NOS: 3, 7, 32- 66, 69 or 72. A reference PH20 ptide also can include the corresponding precursor form such as set forth in any of SEQ ID NOS: 2, 6, 68, 70, 71 or other precursor forms, or in a PH20 polypeptide that exhibits at least 68%, 69%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOS: 2, 6, 68, 70, 71. It is understood that an unmodiﬁed hyaluronan-degrading WO 2013/102144 PCT/US2012/072182 enzyme generally is one that does not contain the ation(s), such as amino acid replacement(s) of a modiﬁed hyaluronan-degrading enzyme.

As used herein, an N-linked moiety refers to an asparagine (N) amino acid residue of a polypeptide that is e of being glycosylated by post-translational modiﬁcation of a polypeptide. ary N-linked moieties of human PH20 include amino acids N47, N131, N200, N219, N333, N358 and N365 of the sequence of amino acids set forth in SEQ ID NO: 3 or 7 (corresponding to amino acid residues N82, N166, N235, N254, N368, N393 and N490 of human PH20 set forth in SEQ ID NO: 6).

As used herein, an N-glycosylated polypeptide refers to a PH20 polypeptide containing oligosaccharide linkage of at least three N-linked amino acid residues, for example, N-linked moieties corresponding to amino acid residues N200, N333 and N358 of SEQ ID N03 or 7. An N-glycosylated polypeptide can include a polypeptide Where three, four, ﬁve and up to all of the ed moieties are linked to an oligosaccharide. The N- linked oligosaccharides can include oligomannose, x, hybrid or sulfated oligosaccharides, or other oligosaccharides and monosaccharides.

As used herein, an N-partially glycosylated polypeptide refers to a polypeptide that minimally contains an N-acetylglucosamine glycan linked to at least three ed moieties.

A partially glycosylated polypeptide can include various glycan forms, including ccharides, oligosaccharides, and branched sugar forms, including those formed by treatment of a polypeptide With EndoH, EndoFl, EndoF2 and/or .

As used herein, tions" refers to any parameter that can inﬂuence the actiVity or properties of a protein or agent. For purposes herein, conditions generally refer to the presence, including , of excipients, carriers or other components in a formulation other than the active agent (e. g., modiﬁed PH20 hyaluronidase); temperature; time (e.g., time of storage or exposure); storage vessel; properties of storage (e. g., agitation) and/or other conditions associated With exposure or use.

As used , "denaturation" or "denaturing" or grammatical variations thereof With reference to a n refers to a biochemical change in a protein so that a property or actiVity of the protein is diminished or eliminated. The biochemical change can be a change in the tertiary structure of the protein to unfold. The property or activity can be completely abolished or can be d by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more.

As used herein, property refers to a al or structural property, such as the three- dimensional structure, pI, half-life, conformation and other such physical characteristics. For WO 2013/102144 PCT/US2012/072182 example, a change in a property can be manifested as the solubility, ation or crystallization of a protein.

As used herein, activity refers to a functional actiVity or actiVities of a ptide or portion thereof ated with a full-length (complete) protein. Functional ties include, but are not limited to, biological actiVity, catalytic or enzymatic actiVity, antigenicity (ability to bind or compete with a polypeptide for binding to an anti-polypeptide antibody), immunogenicity, y to form multimers, and the ability to speciﬁcally bind to a receptor or ligand for the polypeptide.

As used herein, hyaluronidase actiVity refers to the ability to enzymatically catalyze the cleavage of onic acid. The United States Pharmacopeia (USP) XXII assay for hyaluronidase determines hyaluronidase actiVity indirectly by measuring the amount of higher molecular weight hyaluronic acid, or hyaluronan, (HA) substrate remaining after the enzyme is allowed to react with the HA for 30 min at 37 oC (USP XXII-NF XVII (1990) 644-645 United States Pharmacopeia tion, Inc, RockVille, MD). A Reference Standard solution can be used in an assay to ascertain the relative actiVity, in units, of any hyaluronidase. In vitro assays to determine the hyaluronidase actiVity of onidases, such as PH20, ing modiﬁed PH20 polypeptides, are known in the art and described herein. ary assays e the microturbidity assay described herein that measures cleavage of hyaluronic acid by hyaluronidase indirectly by detecting the insoluble precipitate formed when the uncleaved hyaluronic acid binds with serum albumin. Reference Standards can be used, for example, to generate a standard curve to determine the activity in Units of the hyaluronidase being tested.

As used herein, neutral active refers to the ability of a PH20 ptide to enzymatically catalyze the cleavage of hyaluronic acid at neutral pH, such as at a pH between or about between pH 6.0 to pH 7.8.

As used herein, "increased activity" with nce to a modiﬁed PH20 hyaluronidase means that, when tested under the same conditions, the modiﬁed PH20 hyaluronidase exhibits greater hyaluronidase actiVity compared to an unmodiﬁed PH20 hyaluronidase not containing the amino acid replacement(s). For example, a modiﬁed PH20 hyaluronidase exhibits at least or about at least 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, 300%, 400%, 500% 1000% or more ofthe activity ofthe , 600%, 700%, 800%, 900%, unmodiﬁed or reference PH20 hyaluronidase.

As used herein, ility" with reference to a protein refers to a protein that is nous in an aqueous solution, whereby protein molecules diffuse and do not sediment spontaneously. Hence a soluble protein solution is one in which there is an absence of a WO 2013/102144 2012/072182 Visible or discrete particle in a solution containing the protein, such that the particles cannot be easily ﬁltered. lly, a protein is soluble if there are no Visible or discrete particles in the solution. For e, a n is soluble if it contains no or few particles that can be removed by a filter With a pore size of 0.22 um.

As used herein, aggregation or llization With reference to a protein refers to the presence of Visible or discrete particles in a solution containing the n. Typically, the particles are greater than 10 um in size, such as greater than 15 um, 20 um, 25 um, 30 um, 40 um, 50 um or greater. Aggregation or crystallization can arise due to reduced solubility, increased denaturation of a protein or the formation of covalent bonds.

As used herein, "denaturing condition" or "denaturation condition" refers to any condition or agent that, When exposed to a protein, s or inﬂuences the degradation or denaturation of the protein, generally as a result of a loss or partial loss of the tertiary or ary structure of the protein. Denaturing conditions can result in effects such as loss or reduction in actiVity, loss or reduction of lity, aggregation and/or crystallization. The denaturing condition need not be one that is completely deadly to the protein, but nevertheless is one that leads to a reduction in the actiVity of the protein over time. Thus, a condition is denaturing if the activity of the n is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more in the ce of the condition than in its e. A denaturing condition can be due to an external stress or physical condition (e. g., agitation, temperature, time of e, absence of a stabilizer) or can be due to the presence of a denaturing agent. For example, the denaturing condition can be caused by heat, acid or a chemical denaturant. Exemplary ring conditions include, but are not limited to, the presence of a strong acid or base, a concentrated inorganic salt, an organic solvent (e. g., alcohol or chloroform), urea, high or low pH (extremes of pH), elevated temperature (e.g., heat), the presence of excipients that can be denaturing (e.g., phenolic preservatives or detergent), and low or substantially no stabilizing agent that otherwise is required for stability of the protein (e. g., NaCl).

As used , "denaturing agent" or "denaturant" refers to any substance, molecule or compound that causes denaturation. For example, a denaturing agent can include a strong acid or base, a concentrated inorganic salt, an organic solvent (e. g., alcohol or chloroform), a preservative, detergent or other excipient.

As used herein, "resistance to a denaturation condition" refers to any amount of decreased reduction or elimination of a property or actiVity of the protein associated With or caused by denaturation. For example, denaturation is associated With or causes sed crystallization or aggregation, reduced solubility or decreased ty. Hence, resistance to WO 2013/102144 PCT/US2012/072182 denaturation means that the protein exhibits decreased aggregation or crystallization, increased solubility or increased or greater activity (6. g., hyaluronidase activity) when exposed to a ring condition compared to a reference protein (6.g. unmodiﬁed enzyme).

The resistance to a denaturation ion need not be te or permanent, but can be ed because the ration of the d hyaluronan-degrading enzyme occurs more slowly than the unmodiﬁed enzyme in the denaturation condition such that an actiVity or property of the modiﬁed hyaluronan-degrading enzyme is achieved for longer. For example, a d hyaluronan-degrading enzyme, such as a d PH20 hyaluronidase, exhibits resistance to a ration condition if it exhibits, for example, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, ..., 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% more resistance to denaturation in the presence of a denaturation condition or denaturing agent than an unmodiﬁed polypeptide. In some instances, a modiﬁed polypeptide ts 105%, 110%, 120%, 130%, 140%, 150%, 200%, 300%, 400%, 500%, or more increased resistance to denaturation compared to an unmodiﬁed polypeptide.

As used herein, stability of a modiﬁed PH20 hyaluronidase means that it exhibits resistance to denaturation caused by a denaturation condition or denaturing agent. A modiﬁed PH20 polypeptide exhibits stability if it retains some activity in the ce of a denaturation condition or denaturing agent, such as at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the original or initial hyaluronidase activity prior to exposure to the denaturing condition(s). Generally, a modiﬁed PH20 hyaluronidase is stable if it retains at least 50% or more of the hyaluronidase activity under a denaturation condition compared to the absence of the denaturation condition. Assays to assess hyaluronidase ty are known to one of skill in the art and described herein. It is understood that the stability of the enzyme need not be permanent or long term, but is manifested for a duration of time in which actiVity is desired. For example, a modiﬁed PH20 hyaluronidase is stable if it exhibits an actiVity for at least 2 hours, 3 hours, 4 hours, 6 hours, 12 hours, 24 hours, one day, two days, three days, four days, ﬁve days, six days, one week, one month, six months or one year upon re, or during exposure, to one or more denaturing condition(s) or agent(s) (e.g., presence of a denaturing excipient such as a vative). For example, a modiﬁed PH20 hyaluronidase is stable if it exhibits an activity upon or during exposure to one or more denaturing condition(s) or agent(s) (e.g., presence of a denaturing excipient such as a preservative) for at least 1 month at temperatures from or from about 2 0C to 8 OC, inclusive or for at least 3 days at a temperature from or from about 30 0C to 42 OC, inclusive.

WO 2013/102144 PCT/US2012/072182 Hence, "stable" or lity," with reference to a formulation or a co-formulation ed herein, refers to one in which a modiﬁed hyaluronan-degrading enzyme, such as a modiﬁed PH20 hyaluronidase, therein is stable upon exposure to one or more denaturing condition(s) or agent(s) therein (e.g., presence of a denaturing excipient such as a preservative) for at least 1 month at temperatures from or from about 2 0C to 8 OC, inclusive or for at least 3 days at a temperature from or from about 30 0C to 42 OC, inclusive.

As used herein, "increased stability" with reference to a modiﬁed PH20 hyaluronidase means that, in the presence of the same denaturing or denaturation condition(s) (e.g., presence of a denaturing excipient such as a preservative), the modiﬁed PH20 hyaluronidase exhibits greater hyaluronidase ty ed to an unmodiﬁed PH20 hyaluronidase not containing the amino acid replacement(s). For example, a modiﬁed PH20 hyaluronidase exhibits increased stability if it exhibits at least or about at least 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, 300%, 400%, 500% , 600%, 700%, 800%, 900%, 1000% or more of the activity of the unmodiﬁed or reference PH20 hyaluronidase in the presence of a ring or denaturation condition(s) (e.g. , in the ce of a denaturing excipient such as a preservative).

As used herein, "elevated temperatures" refers to temperatures that are greater than room temperature or ambient temperature. Generally, an elevated temperature is a temperature that is at least, greater than, or about 30 °C, such as 30 °C to 42 °C, and generally 32 0C to 37 0C or 35 0C to 37 OC, inclusive.

As used herein, room temperature refers to a range generally from about or at to 18 °C to about or at 32 °C. Those of skill in the art appreciate that room temperature varies by location and ling ions. For example, room temperatures can be higher in warmer climates such as Italy or Texas.

As used herein, recitation that proteins are "compared under the same conditions" means that different proteins are treated identically or substantially identically such that any one or more conditions that can inﬂuence the actiVity or properties of a protein or agent are not varied or not substantially varied between the test . For example, when the hyaluronidase actiVity of a modiﬁed PH20 polypeptide is compared to an unmodiﬁed PH20 polypeptide any one or more conditions such as the amount or concentration of the ptide; presence, including amount, of excipients, rs or other ents in a formulation other than the active agent (e.g., modiﬁed PH20 hyaluronidase); temperature; time of storage; storage vessel; properties of storage (e.g., agitation) and/or other ions ated with exposure or use are identical or ntially identical between and among the compared polypeptides.

WO 2013/102144 PCT/US2012/072182 As used herein, "predetermined time" refers to a time that is established or decided in advance. For example, the predetermined time can be a time chosen in advance that is associated with the desired duration of activity of a hyaluronan-degrading enzyme depending on the d application or use of the protein. A ermined time can be hours, days, months or years. For example, a predetermined time can be at least about or about 2 hours, 3 hours, 4 hours, ﬁve hours, six hours, 12 hours, 24 hours, 2 days, three days, four days, ﬁve days, six days, one week, two weeks, three weeks, one month, six months, one year or more.

As used herein, "storage" means that a formulation is not immediately administered to a subject once prepared, but is kept for a period of time under particular conditions (e.g., particular temperature; time, and/or form (e. g., liquid or lyophilized form)) prior to use. For example, a liquid ation can be kept for days, weeks, months or years, prior to administration to a subject under varied temperatures such as refrigerated (0 °C to 10 °C, such ° to 8 OC), as 2 room temperature (e.g., temperature up to 32 °C, such as 18 °C to about or at 32 0C), or elevated temperature (e.g., 30 0C to 42 0C, such as 32 0C to 37 0C or 35 0C to 37 OC).

As used herein, an ient" refers to a compound in a formulation of an active agent that does not provide the ical effect of the active agent when administered in the absence of the active agent. Exemplary ents include, but are not limited to, salts, buffers, izers, tonicity modifiers, metals, polymers, surfactants, preservatives, amino acids and sugars.

As used , a stabilizing agent refers to compound added to the formulation to protect the modified PH2O polypeptide or other active agent from degradation, if necessary, such as due to denaturation conditions to which a formulation herein is exposed when handled, stored or used. Thus, included are agents that prevent proteins from degradation from other components in the compositions. Exemplary of such agents are amino acids, amino acid derivatives, amines, , polyols, salts and s, surfactants, inhibitors or substrates and other agents as described .

As used herein, an antimicrobial effectiveness test or preservative effectiveness test (PET) demonstrates the effectiveness of the preservative system in a t. A product is inoculated with a controlled quantity of ic organisms. The test then compares the level of microorganisms found on a control sample versus the test sample over a period of 28 days.

Generally, target markets have differing PET requirements. For example, the PET requirements of the United States Pharmacopoeia (USP) and the European Pharmacopoeia (EP) differ. Parameters for performing an antimicrobial effectiveness test, including in different markets, are known to one of skill in the art as described herein.

WO 2013/102144 PCT/US2012/072182 As used herein, an anti-microbially or icrobial effective amount of a preservative refers to an amount of the preservative that kills or inhibits the propagation of microbial organisms in a sample that may be introduced from storage or use. For example, for multiple-dose containers, an icrobially effective amount of a preservative inhibits the grth of microorganisms that may be introduced from repeatedly withdrawing individual doses. USP and EP (EPA and EPB) have anti-microbial ements that ine preservative effectiveness, and that vary in stringency. For example, an icrobial effective amount of a preservative is an amount such that at least a 1.0 loglo unit reduction in bacterial organisms occurs at 7 days following inoculation in an antimicrobial vative effectiveness test (APET). In a particular example, an anti-microbial effective amount of a preservative is an amount such that at least a 1.0 loglo unit reduction in bacterial organisms occurs at 7 days following inoculation, at least a 3.0 loglo unit reduction of bacterial organisms occurs at 14 days following inoculation, at least no further increase in bacterial organisms occurs after 28 days following inoculation, and at least no increase in fungal organisms occurs after 7 days following inoculation. In a further example, an icrobial effective amount of a preservative is an amount such that at least a 1.0 lOglo unit reduction of bacterial organisms occurs at 24 hours following inoculation, at least a 3.0 logro unit reduction of bacterial organisms occurs at 7 days following inoculation, no further increase in bacterial organisms occurs after 28 days following inoculation, at least a 1.0 logro unit reduction of fungal sms occurs at 14 days following ation, and at least no further increase in fungal organisms occurs after 28 days following inoculation. In an additional example, an anti-microbial effective amount of a preservative is an amount such that at least a 2.0 loglo unit reduction of bacterial organisms occurs at 6 hours following inoculation, at least a 3.0 loglo unit reduction of bacterial organisms occurs at 24 hours ing inoculation, no recovery of ial organisms occurs after 28 days ing inoculation of the composition with the microbial inoculum, at least a 2.0 loglo unit reduction of fungal organisms occurs at 7 days following inoculation, and at least no further increase in fungal organisms occurs after 28 days following ation.

As used herein, "preservative" refers to a naturally occurring or synthetically or recombinantly produced substance that, when added to a molecule or protein composition, prevents microbial growth, including bacterial or fungal growth, in the composition.

As used , a "phenolic preservative" refers to a preservative that contains one hydroxyl group attached to an aromatic carbon ring, such as a benzene ring. Exemplary ic preservatives, include but are not limited to, phenol, m—cresol, p-hydroxybenzoic WO 2013/102144 PCT/US2012/072182 acid, methylparaben, ethylparaben, and paraben. For example, cresols, including meta- cresol (m-cresol), has a methyl group substituted onto the benzene ring of a phenol molecule.

As used herein, a "phenophile" refers to a protein, such as a modiﬁed PH20 ptide, that exhibits stability in the presence of an icrobially effective amount of a preservative(s). The term "phenolphile" can be used interchangeably herein with "phenophile" and has the same meaning. For example, a modiﬁed PH20 polypeptide that is a phenophile or phenolphile typically exhibits sed stability compared to an unmodiﬁed PH20 hyaluronidase not containing the amino acid replacement(s) When tested under the same ring condition(s) ning a phenolic preservative(s). For example, a modiﬁed PH20 hyaluronidase exhibits at least or about at least 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, 300%, 400%, 500% , 600%, 700%, 800%, 900%, 1000% or more of the ty of the unmodiﬁed or reference PH20 onidase in the presence of a ic preservative(s).

As used herein, a "thermophile" refers to a protein, such as a modiﬁed PH20 polypeptide, that exhibits stability under elevated temperatures greater than or about 30 °C, such as 30 °C to 42 0C, and generally 32 0C to 37 0C or 35 0C to 37 °C. For example, a modiﬁed PH20 polypeptide that is a thermophile typically exhibits increased stability compared to an unmodiﬁed PH20 hyaluronidase not containing the amino acid replacement(s) When tested under the same elevated temperature denaturing condition(s). For example, a modiﬁed PH20 hyaluronidase exhibits at least or about at least 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, 300%, 400%, 500% , 600%, 700%, 800%, 900%, 1000% or more of the activity of the unmodiﬁed or reference PH20 hyaluronidase under elevated temperatures.

As used herein, the term "detergent" is used interchangeably with the term "surfactan " or "surface acting agen ." Surfactants are typically organic compounds that are amphiphilic, i.e., containing both hobic groups ("tails") and hydrophilic groups ("heads"), Which render surfactants soluble in both organic solvents and water. A surfactant can be classiﬁed by the ce of formally charged groups in its head. A non-ionic surfactant has no charge groups in its head, Whereas an ionic surfactant carries a net charge in its head. A zwitterionic surfactant ns a head With two oppositely charged groups.

Some examples of common surfactants include: c (based on e, sulfonate or carboxylate anions): perﬂuorooctanoate (PFOA or PFO), perﬂuorooctane sulfonate (PFOS), sodium dodecyl sulfate (SDS), ammonium lauryl sulfate, and other alkyl sulfate salts, sodium laureth e (also known as sodium lauryl ether sulfate, or SLES), alkyl benzene sulfonate; cationic (based on quaternary ammonium cations): cetyl trimethylammonium bromide WO 2013/102144 PCT/US2012/072182 (CTAB) a.k.a. hexadecyl trimethyl ammonium bromide, and other alkyltrimethylammonium salts, cetylpyridinium chloride (CPC), polyethoxylated tallow amine (POEA), benzalkonium chloride (BAC), benzethonium chloride (BZT); Zwitterionic (amphoteric): dodecyl betaine; cocamidopropyl betaine; coco ampho glycinate; nonionic: alkyl poly(ethylene oxide), alkylphenol poly(ethylene oxide), copolymers of poly(ethylene oxide) and poly(propylene oxide) (commercially known as Poloxamers or mines), alkyl polyglucosides, including octyl glucoside, decyl maltoside, fatty alcohols (e. g., cetyl alcohol and oleyl alcohol), cocamide MEA, cocamide DEA, polysorbates (Tween 20, Tween 80, etc), Triton detergents, and dodecyl ylamine oxide.

As used herein, a "buffer" refers to a substance, generally a solution, that can keep its pH constant, despite the on of strong acids or strong bases and external inﬂuences of temperature, pressure, volume or redox potential. A buffer prevents change in the concentration of another al substance, e.g., proton donor and acceptor systems that prevent marked changes in en ion concentration (pH). The pH values of all buffers are temperature and concentration dependent. The choice of buffer to maintain a pH value or range can be empirically determined by one of skill in the art based on the known buffering capacity of known buffers. Exemplary buffers e but are not limited to, bicarbonate , cacodylate buffer, ate buffer or Tris . For example, Tris buffer (tromethamine) is an amine based buffer that has a pKa of 8.06 and has an ive pH range between 7.9 and 9.2. For Tris buffers, pH increases about 0.03 unit per OC temperature decrease, and decreases 0.03 to 0.05 unit per ten-fold on.

As used herein, the residues of naturally occurring (x-amino acids are the residues of those 20 (x-amino acids found in nature which are incorporated into protein by the speciﬁc recognition of the charged tRNA molecule with its cognate mRNA codon in humans.

As used herein, nucleic acids include DNA, RNA and analogs thereof, including peptide nucleic acids (PNA) and mixtures thereof. Nucleic acids can be single or double- stranded. When referring to probes or primers, which are ally labeled, such as with a detectable label, such as a ﬂuorescent or radiolabel, single-stranded molecules are contemplated. Such molecules are typically of a length such that their target is statistically unique or of low copy number (typically less than 5, generally less than 3) for g or priming a library. Generally a probe or primer contains at least l4, 16 or 30 uous nucleotides of ce complementary to or identical to a gene of interest. Probes and primers can be 10, 20, 30, 50, 100 or more nucleic acids long.

As used herein, a e refers to a polypeptide that is from 2 to 40 amino acids in length.

WO 2013/102144 PCT/US2012/072182 As used herein, the amino acids which occur in the various sequences of amino acids provided herein are identiﬁed ing to their known, three-letter or one-letter abbreviations (Table l). The nucleotides which occur in the various nucleic acid fragments are designated with the standard -letter designations used routinely in the art.

As used herein, an "amino acid" is an organic compound ning an amino group and a carboxylic acid group. A polypeptide contains two or more amino acids. For purposes , amino acids e the twenty lly-occurring amino acids, non-natural amino acids and amino acid analogs (i.e., amino acids wherein the (x-carbon has a side chain).

As used herein, "amino acid residue" refers to an amino acid formed upon chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues described herein are presumed to be in the "L" isomeric form. Residues in the "D" isomeric form, which are so designated, can be substituted for any L-amino acid residue as long as the desired functional property is retained by the ptide. NH2 refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxyl terminus of a polypeptide. In keeping with standard polypeptide nomenclature described inJ. Biol. Chem, 243: 3557-3559 , and adopted 37 C.F.R. §§ 1.821-1 .822, iations for amino acid residues are shown in Table 1: Table 1 — Table of Correspondence SYMBOL 1-Letter 3-Letter AMINO ACID Y Tyr Tyrosine G Gly Glycine F Phe Phenylalanine M Met Methionine A Ala Alanine S Ser Serine I Ile Isoleucine L Leu Leucine T Thr Threonine V Val Valine P Pro Proline K Lys Lysine H His Histidine Q Gln Glutamine E Glu Glutamic Acid Z GlX Glu and/or Gln W Trp Tryptophan R Arg Arginine D Asp Aspartic Acid N Asn Asparagine B AsX Asn and/or Asp WO 2013/102144 PCT/US2012/072182 MM — 1-Letter 3-Letter AMINO ACID Unknown or Other It should be noted that all amino acid residue sequences represented herein by ae have a left to right ation in the conventional direction of amino-terminus to carboxyl-terminus. In addition, the phrase "amino acid e" is broadly deﬁned to include the amino acids listed in the Table of Correspondence (Table l) and modiﬁed and unusual amino acids, such as those referred to in 37 C.F.R. §§ l.821-l.822, and incorporated herein by nce. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further ce of one or more amino acid residues, to an amino-terminal group such as NH2 or to a carboxyl-terminal group such as COOH.

As used herein, "naturally occurring amino acids" refer to the 20 L-amino acids that occur in polypeptides.

As used herein, "non-natural amino acid" refers to an organic compound that has a structure similar to a natural amino acid but has been modified structurally to mimic the structure and reactivity of a natural amino acid. Non-naturally occurring amino acids thus include, for example, amino acids or analogs of amino acids other than the 20 naturally- occurring amino acids and include, but are not limited to, the D-stereoisomers of amino acids.

Exemplary non-natural amino acids are described herein and are known to those of skill in the art.

As used herein, an etic mixture is one in Which the molar ratios of amino acids has been adjusted based on their reported reaction rates (see, e.g., Ostresh et al., (1994) Biopolymers 34:1681).

As used herein, suitable conservative substitutions of amino acids are known to those of skill in this art and can be made generally t altering the biological activity of the resulting molecule. Those of skill in the art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological actiVity (see, e.g., Watson et al. Molecular Biology of the Gene, 4th Edition, 1987, The Benj amin/Cummings Pub. co., p.224). Such substitutions can be made in accordance With those set forth in TABLE 2 as follows: TABLE 2 Original e Exemplary conservative substitution Ala (A) Gly; Ser WO 2013/102144 PCT/US2012/072182 _ 69 _ Original residue Exemplary conservative substitution Ar_ R L s Asn (N) Gln; His Cys (C) Ser Gln (Q) Asn Glu E As.

Gl G Ala; Pro His (H) Asn; Gln Ile (1) Leu; Val Leu (L) Ile; Val L s K Ar_; Gln; Glu Met (M) Leu; Tyr; Ile Phe (F) Met; Leu; Tyr Ser (S) Thr Thr (T) Ser T o W T r Tyr (Y) Trp; Phe Val (V) Ile; Leu Other substitutions also are sible and can be ined empirically or in accord With known vative substitutions.

As used herein, a DNA construct is a single or double stranded, linear or circular DNA molecule that contains segments of DNA combined and juxtaposed in a manner not found in nature. DNA ucts exist as a result of human manipulation, and include clones and other copies of manipulated molecules.

As used , a DNA segment is a portion of a larger DNA molecule having speciﬁed attributes. For example, a DNA segment encoding a specified polypeptide is a portion of a longer DNA le, such as a plasmid or plasmid fragment, Which, When read from the 5’ to 3’ ion, encodes the sequence of amino acids of the specified polypeptide.

As used herein, the term polynucleotide means a single- or double-stranded polymer of deoxyribonucleotides or ribonucleotide bases read from the 5’ to the 3’ end.

Polynucleotides include RNA and DNA, and can be isolated from natural sources, synthesized in vitro, or prepared from a combination of natural and synthetic molecules. The length of a cleotide molecule is given herein in terms of nucleotides (abbreviated "nt") or base pairs viated "bp"). The term nucleotides is used for single- and double-stranded molecules Where the context permits. When the term is applied to double-stranded molecules it is used to denote overall length and Will be understood to be equivalent to the term base pairs. It Will be recognized by those skilled in the art that the two s of a double- stranded polynucleotide can differ slightly in length and that the ends thereof can be staggered; thus all nucleotides Within a double-stranded polynucleotide molecule cannot be paired. Such unpaired ends will, in general, not exceed 20 nucleotides in length.

WO 2013/102144 PCT/US2012/072182 As used , "at tiOn corresponding to" or tion‘that'nucleotides or amino . acid. ositions "corres ondto" nucleotides or amino acid" ositions in a disclosed se uence , . Cl a such asset forth in the Sequence listing,~refers to nucleotides oacidpositions identiﬁed ' : upon alignmentwith the disclosed ce to maximize identity using a standard alignment algorithm, such as the GAP algorithm. 'For purposes-herein, alignment of a‘PHZO sequence is "to the amino acid sequence Set forth many of SEQ ID NOS: '3, 7 or 32-66, and in ular . SEQ ID NO:3. Hence, reference herein that a position or amino acid replacement corresponds to positions with reference to SEQ ID .NO:3 alsomeansthat the position or aminoiacid replacement correspondsto positions with reference to any of SEQ ID NOS: ’7 or 32-66, since the sequences therein are identical to the corresponding residues as set forth in SEQ ID N023.

'By aligning the sequences, one skilledzin theart can identify ponding residues, for example, using conserved and identical cid residues as guides. .In general, to identify corresponding positions, the sequences of amino acids arealigned so that'the highest order - 'match is obtained (see, e.g.: Computational Molecular Biology, Lesk, A.M., ed., Oxford 1'5 University Press, New'York, 1988; Biocomputing: Informatics and Genome Projects, Smith, iD.W., ed., Academic Press, New 'York, 1993; Computer Analysis ofSequence Data, Part1, Griﬁ'm, AIM., and Grifﬁn, H;G., eds., Humana'Press, NewIJersey, 1994; Sequence Analysisin lar Biology, von , G., Academic'Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds.,‘M Stockton'Press,'New York, ’1991; Carrillo et al. (1988) SIAMJApplied Math 48:1073).,Figurei2 iﬁes exemplaryalignments and identiﬁcation of exemplary corresponding residues for'replacement.

As used herein,"‘.sequence identity" refers to the number of identical orssimilar amino acids or nucleotide bases in a.comparison between Nest and a‘reference polypeptide or polynucleotide. Sequence identity can be determined by sequence ent ofnucleic acid or protein sequences to identify regions of similarity or identity. For purposes herein, sequence identity is generally determined by alignment to identify identical residues. Alignment can be local or global, but 'for purposes herein alignment is generally a global alignment where the full-length ofeach sequence is compared. Matches, mismatches and gaps can be ﬁed n compared sequences. Gaps are null amino acids or nucleotides inserted between the residues ofaligned sequences so that identical or similar characters are aligned. Generally, there can be internal rminal gaps. Sequence identity can be determined by taking into accountgaps as the number of identical residues/ length of the shortest sequence x 100. When using gap penalties, sequence identity can be determined with no penalty for end gaps (e. g., al gaps are not penalized). Alternatively, sequence identity can be RECTlFlED SHEET (RULE 91) lSA/EP WO 2013/102144 PCT/US2012/072182 determined without taking into account gaps as the number of identical positions/length of the total aligned sequence X 100.

As used herein, a "global alignment" is an alignment that aligns two sequences from beginning to end, aligning each letter in each sequence only once. An ent is produced, regardless of whether or not there is similarity or identity between the sequences. For e, 50% sequence identity based on "global alignment" means that in an alignment of the full sequence of two compared sequences each of 100 nucleotides in length, 50% of the residues are the same. It is understood that global alignment also can be used in determining sequence identity even when the length of the aligned sequences is not the same. The differences in the terminal ends of the sequences will be taken into account in determining sequence identity, unless the "no y for end gaps" is selected. Generally, a global ent is used on sequences that share signiﬁcant similarity over most of their length.

Exemplary algorithms for ming global ent include the Needleman-Wunsch algorithm (Needleman et al. J. Mol. Biol. 48: 443 . Exemplary programs for performing global alignment are publicly available and include the Global Sequence Alignment Tool ble at the National Center for Biotechnology Information (NCBI) website (ncbi.nlm.nih.gov/), and the program available at deepc2.psi.iastate.edu/aat/align/align.html.

As used herein, a "local alignment" is an alignment that aligns two ce, but only aligns those portions of the sequences that share similarity or identity. Hence, a local alignment ines if gments of one sequence are present in another sequence. If there is no similarity, no alignment will be returned. Local alignment algorithms include BLAST or Smith-Waterman thm (Adv. Appl. Math. 2: 482 (1981)). For example, 50% ce ty based on "local alignment" means that in an alignment of the full sequence of two compared sequences of any length, a region of similarity or identity of 100 nucleotides in length has 50% of the residues that are the same in the region of similarity or identity.

For purposes herein, sequence identity can be determined by rd alignment algorithm programs used with default gap penalties established by each supplier. Default parameters for the GAP program can include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non identities) and the weighted comparison matrix of Gribskov et al. Nucl. Acids Res. 14: 6745 (1986), as described by Schwartz and Dayhoff, eds., Atlas ofProtein Sequence and ure, National Biomedical Research Foundation, pp. 353- 358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps. Whether any two nucleic acid molecules have nucleotide sequences or any two polypeptides have amino acid sequences that are at least WO 2013/102144 PCT/US2012/072182 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical," or other r variations reciting a percent identity, can be determined using known computer algorithms based on local or global alignment (see e.g., wikipedia.org/wiki/Sequence_alignment_software, providing links to dozens of known and publicly available alignment databases and programs). Generally, for purposes herein sequence identity is determined using computer algorithms based on global alignment, such as the man-Wunsch Global Sequence Alignment tool ble from NCBI/BLAST (blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&Page_TYPE=BlastHome); LAlign (William Pearson implementing the Huang and Miller algorithm (Adv. Appl. Math. (1991) 12:337-357)); and program from Xiaoqui Huang available at deepc2.psi.iastate.edu/aat/align/align.html. Generally, when comparing tide sequences herein, an alignment with penalty for end gaps is used. Local alignment also can be used when the sequences being compared are substantially the same length. ore, as used herein, the term "identity" represents a comparison or alignment between a test and a reference polypeptide or polynucleotide. In one non-limiting example, "at least 90% cal to" refers to percent identities from 90 to 100% relative to the nce polypeptide or polynucleotide. Identity at a level of 90% or more is indicative of the fact that, assuming for exempliﬁcation purposes a test and reference polypeptide or polynucleotide length of 100 amino acids or nucleotides are compared, no more than 10% (1.6., 10 out of 100) of amino acids or nucleotides in the test polypeptide or polynucleotide differs from that of the reference polypeptides. Similar comparisons can be made between a test and nce polynucleotides. Such differences can be represented as point mutations ly distributed over the entire length of an amino acid sequence or they can be red in one or more locations of varying length up to the maximum allowable, e.g., 10/100 amino acid difference (approximately 90% identity). Differences also can be due to deletions or tions of amino acid residues. Differences are deﬁned as nucleic acid or amino acid substitutions, insertions or deletions. Depending on the length of the compared sequences, at the level of homologies or identities above about 85-90%, the result can be independent of the program and gap parameters set; such high levels of identity can be assessed readily, often without relying on software.

As used herein, an allelic t or allelic variation references any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and can result in phenotypic polymorphism within populations.

Gene ons can be silent (no change in the d ptide) or can encode polypeptides haVing altered amino acid sequence. The term "allelic variant" also is used herein to denote a n encoded by an allelic variant of a gene. Typically the reference WO 2013/102144 PCT/US2012/072182 form of the gene encodes a wildtype form and/or predominant form of a polypeptide from a population or single reference member of a species. Typically, allelic variants, which include variants between and among species lly have at least 80%, 90% or greater amino acid identity with a wildtype and/or predominant form from the same species; the degree of identity depends upon the gene and whether comparison is interspecies or intraspecies.

Generally, intraspecies allelic variants have at least about 80%, 85%, 90% or 95% identity or greater with a wildtype and/or predominant form, including 96%, 97%, 98%, 99% or greater identity with a wildtype and/or predominant form of a polypeptide. Reference to an allelic variant herein generally refers to variations in proteins among members of the same species.

As used herein, "allele," which is used hangeably herein with "allelic variant" refers to alternative forms of a gene or portions thereof. Alleles occupy the same locus or position on homologous chromosomes. When a subject has two identical alleles of a gene, the subject is said to be homozygous for that gene or allele. When a subject has two different alleles of a gene, the subject is said to be heterozygous for the gene. Alleles of a speciﬁc gene can differ from each other in a single nucleotide or several nucleotides, and can include ations such as substitutions, deletions and insertions of nucleotides. An allele of a gene also can be a form of a gene containing a on.

As used herein, species variants refer to ts in polypeptides among different species, including different mammalian species, such as mouse and human. Exemplary of species variants provided herein are primate PH20, such as, but not limited to, human, chimpanzee, macaque, cynomolgus monkey, gibbon, orangutan, or marmoset. Generally, species variants have 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 98% sequence ty. Corresponding es n and among species ts can be ined by comparing and aligning sequences to maximize the number of matching nucleotides or residues, for example, such that identity between the sequences is equal to or r than 95%, equal to or r than 96%, equal to or greater than 97%, equal to or greater than 98% or equal to greater than 99%. The position of interest is then given the number assigned in the reference nucleic acid molecule. Alignment can be ed manually or by eye, particularly where sequence identity is greater than 80%.

As used herein, substantially pure means sufﬁciently homogeneous to appear free of readily detectable impurities, as determined by standard s of is, such as thin layer chromatography (TLC), gel electrophoresis and high performance liquid tography (HPLC), used by those of skill in the art to assess such purity, or sufﬁciently pure such that further puriﬁcation would not detectably alter the physical and al properties, such as enzymatic and biological activities, of the substance. Methods for WO 2013/102144 PCT/US2012/072182 puriﬁcation of the nds to produce substantially chemically pure compounds are known to those of skill in the art. A substantially chemically pure compound can, however, be a mixture of stereoisomers or isomers. In such instances, further puriﬁcation might increase the speciﬁc activity of the compound.

As used herein, isolated or puriﬁed polypeptide or n or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue from which the protein is d, or substantially free from chemical precursors or other chemicals when chemically synthesized. ations can be determined to be ntially free if they appear free of readily detectable impurities as determined by standard s of analysis, such as thin layer tography (TLC), gel electrophoresis and high performance liquid chromatography (HPLC), used by those of skill in the art to assess such purity, or sufﬁciently pure such that further puriﬁcation would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of the substance. Methods for puriﬁcation of the compounds to produce substantially chemically pure compounds are known to those of skill in the art. A substantially chemically pure compound, however, can be a mixture of stereoisomers. In such ces, further puriﬁcation might increase the speciﬁc activity of the compound.

Hence, reference to a substantially puriﬁed polypeptide, such as a substantially puriﬁed PH20 polypeptide refers to preparations of PH20 proteins that are substantially free of cellular material, includes preparations of proteins in which the protein is ted from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the term substantially free of cellular material es ations of enzyme proteins having less than about 30% (by dry weight) ofnon-enzyme proteins (also referred to herein as contaminating proteins), generally less than about 20% of non-enzyme proteins or 10% of non-enzyme proteins or less than about 5% enzyme proteins. When the enzyme protein is recombinantly produced, it also is substantially free of culture medium, i.e., e medium represents less than about or at 20%, 10% or 5% of the volume of the enzyme protein preparation.

As used herein, the term substantially free of chemical precursors or other chemicals includes preparations of enzyme proteins in which the n is separated from chemical precursors or other chemicals that are involved in the synthesis of the n. The term includes preparations of enzyme ns having less than about 30% (by dry weight), 20%, %, 5% or less of al precursors or non-enzyme chemicals or components.

As used herein, synthetic, with reference to, for example, a synthetic nucleic acid molecule or a synthetic gene or a synthetic peptide refers to a nucleic acid molecule or WO 2013/102144 PCT/US2012/072182 polypeptide molecule that is produced by recombinant methods and/or by chemical synthesis methods.

As used herein, production by recombinant means or using recombinant DNA methods means the use of the well known methods of molecular biology for expressing proteins encoded by cloned DNA.

As used herein, vector (or plasmid) refers to discrete elements that are used to introduce a heterologous nucleic acid into cells for either expression or replication thereof.

The vectors typically remain episomal, but can be designed to effect ation of a gene or portion thereof into a chromosome of the genome. Also contemplated are vectors that are artiﬁcial somes, such as yeast ial chromosomes and mammalian artiﬁcial chromosomes. Selection and use of such vehicles are well known to those of skill in the art.

As used herein, an sion vector includes s capable of expressing DNA that is operatively linked with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments. Such onal segments can include er and terminator ces, and optionally can include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or can contain elements of both.

Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA. riate expression s are well known to those of skill in the art and include those that are replicable in otic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.

As used herein, vector also includes "virus vectors" or "viral vectors." Viral vectors are engineered viruses that are operatively linked to ous genes to transfer (as vehicles or shuttles) the exogenous genes into cells. Viral vectors include, but are not limited to, adenoviral vectors, retroviral vectors and vaccinia virus vectors.

As used herein, "operably" or "operatively linked" when referring to DNA segments means that the segments are arranged so that they function in t for their intended purposes, 6. g. , ription initiates downstream of the promoter and upstream of any transcribed sequences. The promoter is usually the domain to which the transcriptional machinery binds to initiate transcription and proceeds through the coding segment to the terminator.

As used herein, a ate refers to a modiﬁed PH20 polypeptide linked directly or indirectly to one or more other polypeptides or chemical moieties. Such conjugates include WO 2013/102144 PCT/US2012/072182 _ '76 .- quion proteins, 'those‘produced by chemical conjugates and'thoseproduced by any other 7 "method Whereby atleast onemOdiﬁed PH20 polypeptide is- linked, directly. or indirectly to , ’ another polypeptide 0r chemical‘moiety solong as the conjugate retains hyaluronidase activity. EXemplai-y- of conjugates prOvided herein. inclUde PH20 polypeptides linked directly or indirectly to a multimerization domain (e.g. an'Fc ), a toxin, a label or a drug.

"As used herein, a fusion ‘protein’refer's to a polypeptide d by a nucleic acid -sequence containing a coding sequence from one nucleic acid molecule and the coding sequence from another nucleic acid le in which the coding sequences are in the same reading frame such that when the fusion construct istranscribed anslated in a host cell, ‘10 the protein isproduced containing the 'two proteins. The‘two molecules can be adjacent in the construct or separated bya linker polypeptide that contains, 1,2,3, or more, but‘typically ‘fewer than 10, 9, 8, ‘7, or 6 amino acids. The protein product d bya'fusion construct is referred 'to as a fusion polypeptide. Examples of fusion ptides include Fc’fusions.

As used herein, .a polymer that is conjugated to a modiﬁed PHZO'polypeptide refers to 135 any polymer that is covalently or otherwise stably linked, directly or via a linker,‘to such polypeptide. Suchpolymers, typically increase serum half-life, .and include, but are not limited'to, sialic moieties,'polyethylene glycol (PEG) moieties, dextran, .and suganand other i I ' es,.such asfor glycosylation.

As .used herein, the term assessing or determining is intended'to include tative and ative determination in'the sense of obtaining an absolute value for theactivity ofa product, and also of ing an index,‘ratio, percentage,'visual or other value indicative of the level of the ty. Assessment can be direct or indirect.

As used herein, 'a "composition" refers to any'mixture oftwo or more products or compounds. It can 'be a solution, a suspension, liquid, , a paste, aqueous,-non-aqueous, or bination thereof.

As used herein, a formulation-refers to .a composition containing at least one active pharmaceutical or therapeutic agent and one or more ents.

As used herein, a mulation refersto a composition containing two or more _‘ active or pharmaceutical or therapeutic agents and one or more ents. For example, a co-, ‘fOrmulation of a fast—acting insulin and a hyaluronan degrading enzyme ns a fast-acting insulin, a hyaluronan degradingenzyme, and one or more excipients.

As used herein, "a Combination" refers to any association between two or among more items or elements. Exemplary combinatiOns include, but are not limited to, two or more pharmaceutical compositions, a composition containing two or more active ingredients, such as two modiﬁed PHZO polypeptides; a-modiﬁed PHZO polypeptide and an anticancer: RECTIFIED SHEET (RULE 91) ISA/EP WO 2013/102144 PCT/US2012/072182 agent, such as a chemotherapeutic compound; a modiﬁed PHZO polypeptide and a therapeutic agent (e.g. an insulin); a modiﬁed PHZO polypeptide and a plurality eutic and/or imaging agents, or any association thereof. Such combinations can be packaged as kits.

As used herein, a kit is a packaged combination, optionally, including instructions for use of the combination and/or other reactions and components for such use.

As used herein, "disease or disorder" refers to a pathological condition in an organism resulting from cause or condition including, but not limited to, infections, acquired conditions, genetic conditions, and characterized by ﬁable symptoms.

As used herein, a hyaluronan-associated disease, disorder or condition refers to any disease or ion in which hyaluronan levels are elevated as cause, consequence or otherwise observed in the disease or condition. onan-associated diseases and conditions are associated with elevated hyaluronan expression in a tissue or cell, increased interstitial ﬂuid pressure, decreased vascular volume, and/or increased water content in a tissue. Hyaluronan-associated diseases, disorders or conditions can be treated by administration of a composition containing a onan degrading enzyme, such as a hyaluronidase, for e, a e hyaluronidase, either alone or in combination with or in addition to another ent and/or agent. Exemplary diseases and conditions, include, but are not limited to, hyaluronan-rich cancers, for example, tumors, including solid tumors such as late-stage cancers, metastatic cancers, undifferentiated s, ovarian cancer, in situ carcinoma (ISC), squamous cell carcinoma (SCC), prostate , pancreatic cancer, non- small cell lung cancer, breast cancer, colon cancer and other cancers. Exemplary hyaluronan-associated diseases and conditions also are diseases that are ated with elevated interstitial ﬂuid pressure, such as es associated with disc pressure, and edema, for example, edema caused by organ transplant, stroke, brain trauma or other .

Exemplary hyaluronan-associated diseases and conditions include diseases and conditions ated with elevated interstitial ﬂuid pressure, decreased ar , and/or increased water content in a tissue, including cancers, disc pressure and edema. In one example, treatment of the hyaluronan-associated condition, disease or disorder es amelioration, reduction, or other beneﬁcial effect on one or more of increased interstitial ﬂuid pressure (IFP), decreased vascular volume, and increased water t in a tissue.

As used herein, "treating" a subject with a disease or condition means that the subject’s symptoms are partially or totally alleviated, or remain static following treatment.

Hence treatment encompasses prophylaxis, therapy and/or cure. Prophylaxis refers to prevention of a potential disease and/or a prevention of worsening of symptoms or WO 2013/102144 PCT/US2012/072182 progression of a e. Treatment also encompasses any pharmaceutical use of a modiﬁed interferon and compositions provided herein.

As used herein, a pharmaceutically effective agent or therapeutic agent es any bioactive agent that can exhibit a therapeutic effect to treat a disease or disorder. Exemplary therapeutic agents are described herein. Therapeutic agents include, but are not d to, anesthetics, vasoconstrictors, dispersing agents, conventional therapeutic drugs, including small le drugs, including, but not limited to, bisphosphonates, and therapeutic proteins, including, but not limited to, insulin, IgG molecules, antibodies, cytokines and coagulation factors.

As used herein, "insulin" refers to a hormone, precursor or a synthetic or inant analog thereof that acts to increase glucose uptake and storage and/or decrease endogenous glucose production. Insulin and analogs f are well known to one of skill in the art, including in human and allelic and species ts thereof. n is translated as a precursor polypeptide designated preproinsulin (110 amino acid for human insulin), containing a signal peptide that directs the protein to the asmic reticulum (ER) wherein the signal sequence is cleaved, resulting in proinsulin. Proinsulin is processed further to release a C- or connecting chain peptide (a 31 amino acid n in human n). The resulting insulin contains an A-chain (21 amino acid in length in human n; set forth in SEQ ID NO:862) and a B-chain (30 amino acid in length in human insulin; set forth in SEQ ID NO:863) which are cross-linked by de bonds. A fully cross-linked human insulin contains three disulfide bridges: one between position 7 of the A-chain and position 7 of the B-chain, a second between position 20 of the A-chain and position 19 of the B-chain, and a third between positions 6 and 11 of the A-chain. Reference to an n includes monomeric and multimeric insulins, including hexameric insulins, as well as humanized insulins.

Exemplary insulin polypeptides are those of mammalian, including human, origin. Reference to insulin includes preproinsulin, proinsulin and insulin polypeptides in single-chain or two- chain forms, truncated forms thereof that have activity, and includes allelic variants and species variants of human insulin, variants encoded by splice variants, and other variants, such as n s. An exemplary n is human insulin having a sequence of amino acids of the A- and B- chains of human insulin are set forth in SEQ ID NOS: 862 and 863, respectively, and variants or analogs thereof that exhibit at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto to one or both of the A- chain or B-chain and that acts to se glucose uptake and storage and/or decrease endogenous glucose production. A further exemplary insulin is porcine insulin having a sequence of amino acids for the preproinsulin as set forth in SEQ ID NO:864, whereby the A WO 2013/102144 PCT/US2012/072182 chain ponds to amino acid residue positions 88-108 and the n correspond to amino acid, and variants or analogs thereof that exhibit at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% ce identity thereto to one or both of the A- chain or B-chain and that acts to increase glucose uptake and storage and/or decrease endogenous glucose production.

As used herein, "fast-acting insulin" refers to any insulin that exhibits peak insulin levels at or about not more than four hours ing aneous administration to a subject. Fast-acting ns include any insulin or any fast-acting insulin composition for acute administration to a diabetic subject in response to an actual, perceived, or anticipated hyperglycemic condition in the subject arising at the time of, or within about four hours ing, administration of the cting n (such as a prandial hyperglycemic condition ing or anticipated to result from, consumption of a meal), whereby the fast- acting insulin is able to prevent, control or ameliorate the acute hyperglycemic condition.

Fast-acting insulins include inant insulins and isolated insulins (also referred to as "regular" insulins) such as the insulin sold as human n, porcine insulins and bovine insulins, as well as rapid acting insulin analogs (also termed fast-acting insulin analogs herein) designed to be rapid acting by Virtue of amino acid changes. Exemplary regular insulin preparations include, but are not limited to, human regular insulins, such as those sold under the trademarks Humulin® R, n® R and Velosulin®, Insulin Human, USP and Insulin Human Injection, USP, as well as acid formulations of insulin, such as, for example, Toronto Insulin, Old Insulin, and Clear Insulin, and regular pig insulins, such as Iletin II® (porcine insulin). Regular insulins typically have an onset of action of between 30 minutes to an hour, and a peak insulin level of 2-5 hours post administration.

As used herein, rapid acting insulin analogs (also called fast-acting insulin analogs) are insulins that have a rapid onset of action. Rapid insulins typically are insulin analogs that have been engineered, such as by the introduction of one or more amino acid substitutions, to be more rapid acting than r insulins. Rapid acting insulin analogs typically have an onset of action of 10-30 minutes post injection, with peak insulin levels observed 30-90 minutes post ion. Exemplary rapid acting insulin analogs are analogs of human insulin containing one or more amino acid changes in the A-chain and/or B-chain of human insulin set forth in SEQ ID NO:862 or 863, respectively, and that t an onset of action 10-30 minutes post injection with peak insulin levels observed 30-90 minutes post injection.

Exemplary rapid acting insulin analogs include, but are not limited to, for example, insulin lispro (e.g., Humalog® insulin), insulin aspart (e.g., NovoLog® insulin), and insulin glulisine e.g A ., pidra® insulin the cting insulin composition sold as VLAj ect® and VIAtab® WO 2013/102144 PCT/US2012/072182 (see, e.g., US. Pat. No. 7,279,457). The amino acid sequence of exemplary rapid acting insulin analogs have an A chain with a sequence of amino acids set forth in SEQ ID NO:862 and a B chain having a sequence of amino acids set forth in any of SEQ ID NOS:865-867.

Also included are any other insulins that have an onset of action of 30 minutes or less and a peak level before 90 minutes, typically 30-90 minutes, post injection.

As used herein, a human insulin refers to an insulin that is synthetic or recombinantly produced based upon the human polypeptide, including allelic variants and analogs thereof.

As used herein, fast-acting human insulins or human fast-acting insulin compositions include any human insulin or composition of a human n that is fast-acting, but excludes non-human insulins, such as regular pig insulin.

As used herein, the terms -acting insulins," or "basal insulins" refer to insulins administered to maintain a basal insulin level as part of an overall treatment regimen for treating a chronic condition such diabetes. Typically, a basal-acting insulin is formulated to in an approximately steady state insulin level by the controlled release of insulin when administered periodically (e. g., once or twice daily). Basal-acting insulins include crystalline insulins (e.g., NPH and Lente®, protamine insulin, surfen insulin), basal insulin analogs (insulin glargine, HOE 901, NovoSol Basal) and other chemical formulations of insulin (e.g., gum arabic, lecithin or oil suspensions) that retard the absorption rate of regular insulin. As used , the basal-acting ns can include insulins that are typically understood as long-acting (typically reaching a vely low peak concentration, while having a maximum duration of action over about 20-30 hours) or intermediate-acting (typically causing peak insulin concentrations at about 4-12 hours after administration).

As used herein, treatment means any manner in which the ms of a condition, disorder or disease or other indication, are ameliorated or otherwise beneﬁcially altered.

As used herein, therapeutic effect means an effect resulting from treatment of a subject that alters, lly improves or ameliorates the symptoms of a disease or condition or that cures a disease or condition. A therapeutically effective amount refers to the amount of a composition, le or compound which results in a therapeutic effect following administration to a subject.

As used herein, the term "subject" refers to an animal, including a mammal, such as a human being.

As used herein, a t refers to a human t exhibiting ms of a e or disorder.

As used herein, amelioration of the ms of a particular disease or disorder by a treatment, such as by stration of a pharmaceutical composition or other therapeutic, WO 2013/102144 PCT/US2012/072182 refers to any lessening, whether permanent or temporary, lasting or transient, of the symptoms that can be attributed to or ated with administration of the composition or therapeutic.

As used herein, prevention or laxis refers to methods in which the risk of developing a disease or condition is reduced.

As used herein, a "therapeutically effective " or a "therapeutically ive dose" refers to the quantity of an agent, compound, material, or composition containing a nd that is at least sufﬁcient to produce a therapeutic effect. Hence, it is the quantity necessary for preventing, curing, ameliorating, arresting or partially arresting a symptom of a disease or disorder.

As used herein, unit dose form refers to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art.

As used herein, a single dosage formulation refers to a formulation containing a single dose of therapeutic agent for direct stration. Single dosage ations generally do not contain any preservatives.

As used herein, a multi-dose ation refers to a formulation that contains multiple doses of a therapeutic agent and that can be directly administered to provide several single doses of the therapeutic agent. The doses can be administered over the course of minutes, hours, weeks, days or months. Multidose formulations can allow dose adjustment, dose-pooling and/or plitting. Because multi-dose formulations are used over time, they generally contain one or more preservatives to prevent microbial growth.

As used herein, an "article of manufacture" is a product that is made and sold. As used throughout this application, the term is ed to encompass a therapeutic agent with a soluble PHZO, such as esPH20, or an esPH20 alone, contained in the same or te articles of packaging.

As used herein, ﬂuid refers to any composition that can ﬂow. Fluids thus encompass compositions that are in the form of semi-solids, pastes, ons, aqueous mixtures, gels, lotions, creams and other such compositions.

As used herein, a "control" or "standard" refers to a sample that is substantially identical to the test sample, except that it is not treated with a test parameter, or, if it is a plasma sample, it can be from a normal volunteer not affected with the condition of interest.

A control also can be an al control. For example, a control can be a sample, such as a Virus, that has a known property or actiVity.

As used herein, the singular forms "a," "an" and "the" include plural referents unless the context y dictates otherwise. Thus, for example, reference to "an" agent includes one 01‘ more agents.

WO 02144 PCT/US2012/072182 As used herein, the term "or" is used to mean "and/or" unless explicitly indicated to refer to atives only or the alternatives are mutually exclusive.

As used herein, ranges and amounts can be expressed as "about" a particular value or range. About also includes the exact amount. Hence "about 5 bases" means "about 5 bases" and also "5 bases." As used herein, "optional" or "optionally" means that the subsequently described event or circumstance does or does not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, an optionally substituted group means that the group is unsubstituted or is substituted.

As used herein, the abbreviations for any tive groups, amino acids and other compounds, are, unless ted otherwise, in accord with their common usage, ized abbreviations, or the lUPAC-IUB Commission on Biochemical Nomenclature (see, (1972) m. 11:1726).

For clarity of disclosure, and not by way of limitation, the detailed description is diVided into the subsections that follow.

B. PH20 Hyaluronidase Provided herein are modiﬁed PH20 polypeptides. PH20 (also known as sperm surface protein, sperm on molecule 1 or SPAMl) is a hyaluronidase that hydrolyzes hyaluronan (also called hyaluronic acid, hyaluronate or HA) found in connective tissues such as the extracellular matrix. Hyaluronan polymers are composed of repeating disaccharide units, D-glucuronic acid (Gch) and N—acetyl-D-glucosamine (GlcNAc), linked together Via alternating B-l—>4 and B-1 —>3 glycosidic bonds. Hyaluronan chains can reach about 25,000 disaccharide repeats or more in length, and polymers of hyaluronan can range in size from about 5,000 to 20,000,000 Da in vivo. Hyaluronan, also called hyaluronic acid or hyaluronate, is a non-sulfated glycosaminoglycan that is widely distributed throughout connective, epithelial, and neural s. Hyaluronan is an essential component of the extracellular matrix and a major constituent of the interstitial barrier. PH20 is an endo-B-N— acetyl-hexosaminidase that hydrolyzes the Bl—>4 glycosidic bond of hyaluronic acid into various oligosaccharide lengths such as tetrasaccharides and hexasaccharides. PH20 has both hydrolytic and lycosidase actiVities. In on to degrading onic acid, PH20 also can degrade chondroitin sulfates, such as C4-S and C6-S. PH20 can exhibit hyaluronidase ty at acidic pH and neutral pH. 1. Structure PH20 cDNA has been cloned from us mammalian species. Exemplary PH20 precursor polypeptides include, but are not limited to, human (SEQ ID NO:6), bovine (SEQ WO 2013/102144 PCT/US2012/072182 ID NOS:15 or 17), rabbit (SEQ ID , Cynomolgus monkey (SEQ ID NO:13), guinea pig (SEQ ID NO:28), rat (SEQ ID NO:21), mouse (SEQ ID NO:19), nzee (SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:869 ) Rhesus monkey (SEQ ID NO:11), Fox (SEQ ID , Gibbon (SEQ ID NO:856), Marmoset (SEQ ID NO:858) or orangutan (SEQ ID NO:860) PH20 polypeptides. The mRNA transcript is typically translated to generate a precursor protein containing a 35 amino acid signal sequence at the N-terminus. Following transport to the ER, the signal peptide is removed to yield a mature PH20 ptide.

Exemplary mature PH20 polypeptides include, but are not limited to, human (SEQ ID NO:7), bovine (SEQ ID NOS:16 or 18), rabbit (SEQ ID , Cynomolgus monkey (SEQ ID NO:14), guinea pig (SEQ ID NO:29), rat (SEQ ID NO:22), mouse (SEQ ID NO:20), chimpanzee (SEQ ID NO:10 or SEQ ID NO:870), Rhesus monkey (SEQ ID NO:12), Fox (SEQ ID NO:31), Gibbon (SEQ ID NO:857), Marmoset (SEQ ID NO:859) or orangutan (SEQ ID NO:861) PH20 polypeptides. For example, the human PH20 mRNA transcript is normally translated to generate a 509 amino acid sor protein (SEQ ID NO:6) containing a 35 amino acid signal sequence at the N-terminus (amino acid residue positions 1-35 of SEQ ID NO:6). Thus, following transport to the ER and removal of the signal peptide, a 474 amino acid mature polypeptide with an amino acid sequence set forth in SEQ ID NO:7 is produced. ces of PH20 from ovine are also known (see e.g., SEQ ID NOS: 25-27).

In particular, human PH20 has the sequence of amino acids set forth in SEQ ID NO:6. The mature human PH20 lacking a signal sequence is set forth in SEQ ID NO:7.

Allelic variants and other variants of PH20 are known. Other sequences of PH20 have been ed. For example, a PH20 variant is known as set forth in the precursor sequence set forth in SEQ ID NO:68 that contains an Ala at position 48 and a Trp at position 499, or the mature sequence thereof set forth in SEQ ID NO:69 containing the corresponding differences at positions 13 and 464, respectively, compared to the sequence set forth in SEQ ID NO:7 (see e.g., Gmachl et al. (1993) FEBS Lett., 336:545-548; GenBank ion No.

AAC60607). Further, a natural variant of PH20 has been identiﬁed containing a Glutamine (Gln; Q) at position 5 as compared to the precursor sequence of amino acids set forth in SEQ ID NO:6 (see e.g., SEQ ID NO:70, see also Varela et al. (2011) Nature, 469:539-542).

Another natural variant contains an e (Ala; A) at position 47 compared to the ce of amino acids set forth in SEQ ID NO:6 (as set forth in SEQ ID NO: 71) and corresponding to position 12 compared to the sequence of amino acids set forth in SEQ ID NO: 3 or 7 (as set forth in SEQ ID NO:72).

WO 2013/102144 PCT/US2012/072182 The sequence and structure of PH20 polypeptides is highly ved. Sequence identity between and among PH20 ns from various species is about 50% to 90%. The hydrophobic N—terminal signal sequence of 35 amino acids in length is generally conserved among PH20 hyaluronidase polypeptides. PH20 hyaluronidases contain a common core hyaluronidase domain region of about 340 amino acids in length that corresponds to amino acid residues 38-374 of the precursor human PH20 sequence set forth in SEQ ID NO:6. A mature PH20 polypeptide lacking the signal sequence and containing a contiguous sequence of amino acids having a C-terminal amino acid residue corresponding to amino acid residue 464 of SEQ ID NO:6 (e.g., amino acid residues corresponding to positions 36-464 of the amino acid sequence set forth in SEQ ID NO:6) is the minimal sequence ed for hyaluronidase activity (see e. g., US. Patent Application No. 10/795,095,which is issued as US. Patent No. 7,767,429; see also U.S. Publication No. US20100143457).

Within the common hyaluronidase domain region, at least 57 amino acids are conserved between and among species (see e.g., Arming et al. (1997) Eur. J. Biochem, 247:810-814; ten Have et al. (1998) . Fertil. Dev., -72; Chowpongpang et al. (2004) Biotechnology Letters, 26:1247-1252). For example, PH20 hyaluronidases contain 12 conserved cysteine residues corresponding to amino acid residue 25, 189, 203, 316, 341, 346, 352, 400, 402, 408, 423 and 429 of the sequence of amino acids of a mature PH20 lacking the signal sequence such as set forth in SEQ ID NO: 3 or 7 (corresponding to amino acid residues 60, 224, 238, 351, 376, 381, 387, 435, 437, 443, 458 or 464 of full-length human PH20 set forth in SEQ ID NO:6). ne residues corresponding to 25 and 316 and ne residues corresponding to 189 and 203 form disulﬁde bridges. The other cysteine residues also form disulﬁde s, are involved in posttranslational protein maturation and/or in activity modulation. For example, further four disulﬁde bonds are formed between the cysteine residues C376 and C387; between C381 and C435; between C437 and C443; and between C458 and C464 of the polypeptide exemplified in SEQ ID NO:6 (corresponding to positions C341 and C352; between C346 and C400; between C402 and C408; and between C423 and C429 of the mature polypeptide set forth in SEQ ID N03 or 7, respectively).

Amino acid residues corresponding to amino acid e D111, E113 and E249 of the sequence of amino acids set forth in SEQ ID NO: 3 or 7 are acidic residues part of the enzyme active site and are conserved between and among PH20 species. Amino acid residues R176, R246, R252 of the sequence of amino acids set forth in SEQ ID NO: 3 or 7 are also conserved between and among species and bute to substrate binding and/or hyaluronidase ty. Amino acid mutations D111N, E113Q, R176G, E249N and R252T WO 2013/102144 PCT/US2012/072182 result in enzymes that have no detectable enzymatic activity or residual enzymatic activity (see e.g., Arming et al. (1997) Eur. J. Biochem, 247:810-814).

The results herein conﬁrm the requirement of PH20 amino acid residues corresponding to positions 25, 111, 113, 176, 189, 203, 246, 249, 252, 316, 341, 346, 352, 400, 402, 408, 423 and 429 of the sequence of amino acids set forth in a mature PH20 lacking the signal sequence such as set forth in SEQ ID NO: 3 or 7 for hyaluronidase activity, since mutagenesis of these residues s in an enzyme that is not active (e. g., it is not expressed or is inactive When sed, see e. g., Tables 5 and 10). The exception is that amino acid replacement corresponding to R176K and C316D resulted in mutants that generated some residual hyaluronidase activity.

Glycosylation also is required for PH20 hyaluronidase activity based on the recognition motifNxS or NxT. There are six N-linked oligosaccharides at amino acid residues ponding to positions N47, N131, N200, N219, N333 and N35 8 of the ce of amino acids set forth in SEQ ID NO: 3 or 7 (corresponding to amino acid residues N82, N166, N235, N254, N368 and N393 ofhuman PH20 set forth in SEQ ID NO: 6). In particular, at least N-linked glycosylation sites corresponding to amino acid es N200, N333 and N358 are ed for secretion and/or activity of the enzyme (see e.g., U.S.

Publication No. US20100143457). For example, a PH20 polypeptide containing amino acid mutations N200A, N333A, N358A or N333A/N393A result in inactive ns. Single mutations of glycosylation sites N47A, N131A, N219A, N47A/N131A, N47A/N219A, N1 3 1A/N291A retain activity. The N-linked glycosylation site corresponding to amino acid residue N368 of human PH20 set forth in SEQ ID NO:6 is conserved between and among species (see e.g., ngpang et al. (2004) hnology Letters, 26:1247-1252). PH20 hyaluronidases also contains O-linked glycosylation sites. For example, human PH20 has one O-linked oligosaccharide at the amino acid residue corresponding to amino acid T440 of the sequence of amino acids set forth in SEQ ID N03 or 7 (corresponding to amino acid residue T475 in SEQ ID NO:6).

In addition to the tic sites, PH20 also contains a hyaluronan-binding site. This site is located in the Peptide 2 region, which corresponds to amino acid positions 205-235 of the precursor polypeptide set forth in SEQ ID NO:6 and positions 0 of the mature polypeptide set forth in SEQ ID N03 or 7. This region is highly conserved among hyaluronidases and is similar to the heparin binding motif Mutation of the arginine residue at on 176 (corresponding to the mature PH20 polypeptide set forth in SEQ ID N03 or 7) to a glycine results in a polypeptide With only about 1% of the hyaluronidase activity of the Wild type polypeptide (Arming et al., (1997) Eur. J. Biochem. 247:810-814).

WO 2013/102144 PCT/US2012/072182 PH20 polypeptides contain a glycosyl phosphatidylinositol (GPI) anchor attached to the C-terminus of the protein that anchors the protein to the extracellular leaﬂet of the plasma membrane of cells. At least human, monkey, mouse and guinea pig PH20 are strongly ed to the plasma membrane Via the GPI anchor, which can be released by treating with phosphatidylinositol-specific phospholipase C (Pl-PLC; see e. g., Lin et al. (1994) Journal of Cell Biology, 125:1157-1163; Lin et al. (1993) Proc. Natl. Acad. Sci., 90: 10075).

Other PH20 enzymes, such as bovine PH20, are loosely attached to the plasma membrane and are not anchored Via a phospholipase sensitive anchor. As sed below, soluble active forms that, when expressed, are not attached to the membrane but are secreted can be generated by removal of all of a portion of the GPI anchor attachment signal site (see also U.S. Patent No. 7,767,429; U.S. Publication No. 0143457) . These include, for example, soluble PH20 polypeptides set forth in any of SEQ ID NOS: 3 or 32-66, or precursor forms thereof containing a signal sequence.

GPl-anchored proteins, for example human PH20, are translated with a ble N- terminal signal e that directs the protein to the endoplasmic reticulum (ER). At the C- us of these proteins is another signal sequence that directs addition of a preformed GPI- anchor to the polypeptide within the lumen of the ER. Addition of the GPI anchor occurs following cleavage of the C-terminal portion at a speciﬁc amino acid position, called the 03- site (typically located approximately 20-30 amino acids from the C-terminus). Although there appears to be no consensus sequence to identify the location of the m-site, GPI anchored proteins contain a C-terminal chor attachment signal sequence or domain that typically contains a predominantly hydrophobic region of 8-20 amino acids, preceded by a hilic spacer region of 8-12 amino acids immediately downstream of the . This hydrophilic spacer region often is rich in charged amino acids and proline (White et al. (2000) J. Cell Sci. 113(Pt.4):721-727). There is generally a region of approximately 11 amino acids before the 03-1 position that is characterized by a low amount of predicted secondary structure, a region around the ge site (ca-site), from 03-1 to (9+2 that is characterized by the presence of small side chain residues, the spacer region between positions (9+3 and (0+9, and a hydrophobic tail from 03+10 to the C-terminal end (Pierleoni et al., (2008) BMC ormatics . gh there is no GPI-anchor attachment signal consensus ce, various in Silico methods and algorithms have been developed that can be used to identify such sequences in polypeptides (see, e. g., Udenfriend et al. (1995) Methods Enzymol. 250:571-5 82; Eisenhaber et al. (1999) J. Mol. Chem. 292: 741-758; Kronegg and Buloz, (1999), "Detection/prediction of GPI cleavage site (GPl-anchor) in a protein (DGPI)," WO 2013/102144 PCT/US2012/072182 129.194.185.165/dgpi/; Fankhauser et al. (2005) Bioinformatics 21 :1846-1852; Omaetxebarria et al. (2007) Proteomics 7: 1951-1960; Pierleoni et al. (2008) BMC Bioinformatics 9:392), including those that are y available on ormatic websites, such as the ExPASy mics tools site (expasy.ch/tools/). Thus, one of skill in the art can determine whether a PH20 polypeptide likely ns a GPl-anchor ment signal sequence, and, therefore, whether the PH20 polypeptide is a chored protein.

The covalent attachment of a GPl-anchor to the C-terminus of human PH20 and, therefore, the membrane-bound nature of PH20, has been confirmed using phosphatidylinositol-specific phospholipase C (Pl-PLC) hydrolysis studies (see e.g., Lin et al., (1994) J. Biol. Chem. 125:1157-1163). Phosphatidylinositol-specific phospholipase C (Pl-PLC) and D (Pl-PLD) hydrolyze the GPI anchor, releasing the PH20 polypeptide from the cell membrane. The prior art literature reports that a m-site cleavage site of human PH20 is identified n Ser-490 and Ala-491 and for monkey PH20 is identiﬁed n Ser491 and Thr492 (Lin et al. (1993) Proc. Natl. Acad. Sci, (1993) 90:10071-10075). Thus, the ture s that a GPl-anchor attachment signal sequence of human PH20 is located at amino acid positions 491-5 09 of the precursor ptide set forth in SEQ ID NO:6, and the m-site is amino acid position 490. Thus, in this modeling of human PH20, amino acids 491- 509 are d following transport to the ER and a GPI anchor is covalently attached to the serine residue at position 490. 2. Function PH20 is normally expressed in sperm from a single testis-specific gene. PH20 is a sperm-associated protein involved in fertilization. PH20 is normally localized on the sperm surface, and in the lysosome-derived acrosome, where it is bound to the inner acrosomal membrane. PH20 is multifunctional and exhibits hyaluronidase activity, hyaluronan (HA)— mediated cell-signaling activity, and acts as a sperm receptor for the zona pellucida surrounding the oocyte when present on acrosome d (AR) sperm. For example, PH20 is naturally involved in sperm-egg adhesion and aids penetration by sperm of the layer of cumulus cells by digesting hyaluronic acid. In addition to being a hyaluronidase, PH20 also appears to be a or for HA-induced cell signaling, and a receptor for the zona pellucida surrounding the oocyte. Due to the role of PH20 in fertilization, PH20 can be used as an antigen for immunocontraception.

PH20 is a neutral active hyaluronidase, although it can exhibit acid-active activity in some cases. The hyaluronidase activity of PH20 is exhibited by the plasma membrane- and inner acrosomal membrane-associated PH20. The plasma membrane PH20 exhibits hyaluronidase activity only at neutral pH, while the inner acrosomal membrane-associated WO 2013/102144 PCT/US2012/072182 PH20 exhibits acid-active enzyme activity. The structural basis for these differences is due to the presence of two catalytic sites in PH20. A ﬁrst catalytic site is designated the Peptide 1 region, corresponding to amino acid es 142-172 of SEQ ID NO:6, which is involved in enzyme activity of PH20 at neutral pH. A second catalytic site is designated the peptide 3 region, corresponding to amino acid residues 277-297 of SEQ ID NO:6, which is involved in enzyme activity at lower pH. A change in the structure of the inner acrosomal membrane- associated PH20 occurs after the me reaction, y PH20 is endoproteolytically cleaved but held together by disulﬁde bonds. The result of the endoproteolysis is that the e 3 region is activated and can thus effect neutral and acid-activity to PH20 (see e. g., Cherr et al. (2001) Matrix Biology, 20:515-525. Also, after the acrosome reaction, lower molecular weight forms are generated by e from the inner acrosomal membrane (e.g., a 53 kDa soluble form of PH20 is ted in monkey). The lower molecular weight ) also is acid active.

The hyaluronidase activity of PH20 accounts for the spreading activity observed in animal testes extracts that have been used clinically for decades to increase the dispersion and tion of drugs (see e.g., Bookbinder et al. (2006) J Controlled Release, 0-241).

For e, pharmaceutical preparations containing hyaluronidase were developed as fractionated extracts from bovine testes for therapeutic use as spreading agents and in other ations (Schwartzman (1951) J. Pediat, 39:491-502). Original bovine testicular extract preparations included, for example, extracts sold under the trademarks Wydase®, Hylase®, "Dessau," Neopermease®, Alidase® and Hyazyme®. It is now known that the spreading activity of testicular extract preparations are due to PH20 hyaluronidase activity. For example, in 2001 a sperm hyaluronidase in bull was identiﬁed as the onidase PH20 (Lalancette et al. (2001) Biol. Reprod., 65:628-36). By catalyzing the hydrolysis of hyaluronic acid, PH20 hyaluronidase lowers the viscosity of hyaluronic acid, thereby increasing tissue permeability. Hence, soluble forms of PH20 are used as a spreading or dispersing agent in conjunction with other agents, drug and proteins to enhance their dispersion and delivery, and to improve the pharmacokinetic and pharmacodynamic profile of the coadministered agent, drug or protein (see e. g., US. Patent No. 7,767,429; nder et al. (2006) J Controlled Release, 0-241). 3. Soluble PH20 Polypeptides PH20 can exist in membrane-bound or membrane-associated form, or can be secreted into the media when sed from cells, and thereby can exist in soluble form. Soluble PH20 can be detected and discriminated from insoluble, membrane-bound PH20 using methods well known in the art, including, but not limited to, those using a Triton® X-l l4 WO 2013/102144 PCT/US2012/072182 assay. In this assay, soluble PH20 hyaluronidases partition into the aqueous phase of a Triton® X-114 solution warmed to 37 °C (Bordier et al., (1981) J. Biol. Chem, 256:1604-7) While membrane-anchored PH20 onidases partition into the detergent rich phase. Thus, in addition to using algorithms to assess Whether a PH20 polypeptide is naturally GPI- anchored and hence membrane-bound, solubility experiments also can be performed.

Soluble PH20 s include hyaluronidases that contain a GPI-anchor attachment signal sequence, but that are loosely attached to the membrane such that they do not contain a phospholipase sensitive anchor. For example, soluble PH20 polypeptides include ovine or bovine PH20. Various forms of such soluble PH20 hyaluronidases have been prepared and approved for therapeutic use in subjects, including humans. For example, animal-derived hyaluronidase ations include Vitrase® (ISTA Pharmaceuticals), a d ovine ular hyaluronidase, and ase® (Amphastar Pharmaceuticals), a bovine testicular hyaluronidase. Soluble PH20 enzymes also include truncated forms of non-human or human membrane-associated PH20 hyaluronidases that lack one or more amino acid residues of a glycosylphosphatidylinositol (GPI) anchor ment signal ce and that retain hyaluronidase activity (see e.g., U.S. Patent No. 7,767,429; U.S. Publication No.

US20100143457). Thus, instead of having a GPI-anchor covalently attached to the C- terminus of the protein in the ER and being anchored to the extracellular leaﬂet of the plasma membrane, these polypeptides are secreted When expressed from cells and are soluble. In instances Where the soluble hyaluronan ing enzyme retains a portion of the GPI anchor attachment signal sequence, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acid residues in the GPI- anchor attachment signal sequence can be retained, provided the polypeptide is soluble (i.e., secreted When expressed from cells) and active.

Exemplary soluble onidases that are C-terminally truncated and lack all or a portion of the GPI anchor attachment signal sequence include, but are not limited to, PH20 polypeptides of primate origin, such as, for example, human and chimpanzee PH20 ptides. For example, soluble PH20 polypeptides can be made by C-terminal truncation ofa polypeptide set forth in SEQ ID NOS:7, 10, 12, 14, 69, 72, 857, 859, 861 or 870 or variants thereof that exhibit at least 80%, 85%, 90%, 95% or more sequence identity to any of SEQ ID NO: 7, 10, 12, 14, 69, 72, 857, 859, 861 or 870, wherein the ing ptide is active, soluble and lacks all or a portion of amino acid residues from the GPI-anchor attachment signal sequence.

Exemplary soluble PH20 polypeptides are inal truncated human PH20 polypeptides that are mature ng a signal sequence), soluble and exhibit neutral activity, and that contain a contiguous sequence of amino acids set forth in SEQ ID NO:6 or SEQ ID WO 2013/102144 PCT/US2012/072182 NO:7 that minimally has a C-terminal truncated amino acid residue at or after amino acid residue 464 of the ce of amino acids set forth in SEQ ID NO:6. For example, soluble PH20 polypeptides e C-terminal truncated polypeptides that minimally contain a contiguous sequence of amino acids 36-464 of SEQ ID NO:6, or includes a ce of amino acids that has at least 85%, for example at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% sequence identity to a contiguous sequence of amino acids that has a C-terminal amino acid residue after amino acid 464 of SEQ ID NO:6 and retains hyaluronidase activity. Exemplary inally truncated human PH2O polypeptides are mature polypeptides (lacking a signal sequence) that include a contiguous sequence of amino acids set forth in SEQ ID NO:6 With a C-terminal residue after 464 such as after amino acid position 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499 or 500 of the sequence of amino acids set forth in SEQ ID NO:6, or a variant thereof that exhibits at least 85% sequence ty, such as at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% sequence identity thereto and retains hyaluronidase activity. For example, exemplary C-terminal PH2O polypeptides have a sequence of amino acids 36 to 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499 or 500 of the sequence of amino acids set forth in SEQ ID NO:6, or a t thereof that exhibits at least 85% sequence identity, such as at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% sequence identity thereto and retains hyaluronidase activity. Soluble PH2O polypeptides e any that has the sequence of amino acids set forth in SEQ ID NOS: 3 or 32-66 or a sequence of amino acids that exhibits at least 85% sequence identity, such as at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% sequence identity to the sequence of amino acids set forth in any of SEQ ID NOS: 3 or 32-66.

In ular, a soluble human PH2O polypeptide is a polypeptide that is truncated after amino acid 482 of the sequence set forth in SEQ ID NO:6. Such a polypeptide can be generated from a nucleic acid molecule containing a signal ce and encoding amino acids 36-482, for example, as set forth in SEQ ID NO:1 (containing an IgG kappa signal ce) or SEQ ID NO:67 (containing the native signal sequence). Post translational processing removes the signal sequence, leaving a 447 amino acid soluble recombinant human PH2O (SEQ ID NO:3). A product produced upon expression of a vector set forth in SEQ ID NO:4 or 5, and ning a nucleic acid molecule set forth in SEQ ID NO:67, results in a secreted product, designated rHuPH20, in the e medium that exhibits heterogeneity WO 2013/102144 PCT/US2012/072182 at the C-terminus such that the product includes a mixture of species that can e any one or more of SEQ ID NOS: 3 and 44-48 in various abundance. Typically, rHuPH20 is ed in cells that facilitate correct N—glycosylation to retain activity, such as mammalian cells, for example CHO cells (e.g., DG44 CHO cells). Hylenex® (Halozyme) is a human recombinant hyaluronidase produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing c acid encoding a truncated human PH20 polypeptide (designated rHuPH20).

C. MODIFIED PH20 PTIDES Provided herein are d or variant PH20 polypeptides. The d PH20 polypeptides provided herein t altered ties or properties compared to a Wildtype, native or reference PH20 polypeptide. Included among the modiﬁed PH20 polypeptides provided herein are PH20 polypeptide that are active mutants, Whereby the polypeptides exhibit at least 40% of the hyaluronidase actiVity of the corresponding PH20 polypeptide not containing the amino acid modiﬁcation (e.g., amino acid replacement). In particular, provided herein are PH20 polypeptides that exhibit hyaluronidase actiVity and that exhibit increased stability ed to the PH20 not containing the amino acid modiﬁcation. Also provided are modiﬁed PH20 polypeptides that are inactive, and that can be used, for example, as antigens in contraception vaccines.

The modiﬁcations can be a single amino acid modiﬁcation, such as single amino acid ements (substitutions), insertions or deletions, or le amino acid modiﬁcations, such as multiple amino acid replacements, insertions or deletions. Exemplary modiﬁcations are amino acid replacements, including single or multiple amino acid replacements. The amino acid ement can be a conservative substitution, such as set forth in Table 2, or a non-conservative tution, such as any described herein. Modiﬁed PH20 polypeptides provided herein can contain at least or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, ll, l2, l3, 14, 15, l6, l7, l8, 19, 20, or more modiﬁed positions compared to the PH20 polypeptide not containing the modiﬁcation.

The modiﬁcations described herein can be in any PH20 polypeptide, including, including precursor, mature, or C-terminal truncated forms, so long as the modiﬁed form exhibits hyaluronidase actiVity. For example, the PH20 polypeptides contain modiﬁcations compared to a Wildtype, native or reference PH20 polypeptide set forth in any of SEQ ID NOS: 2, 3, 6-66, 68-72, 856-861, 869 or 870, or in a polypeptide that has a sequence of amino acids that is at least 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to any of SEQ ID NOS: 3, 6-66, 68- 72, 856-861, 869 or 870. For example, the modiﬁcations are made in a human PH20 WO 02144 PCT/US2012/072182 polypeptide having the ce of amino acids ing or set forth in SEQ ID NO:7, SEQ ID NO:69 or SEQ ID NO:72; a bovine PH20 polypeptide having a ce of amino acids including or set forth in SEQ ID NOS:16 or 18; a rabbit PH20 polypeptide having a sequence of amino acids including or set forth in SEQ ID NO:24; a Cynomolgus monkey PH20 polypeptide having a sequence of amino acids including or set forth in SEQ ID NO: 14; a guinea pig PH20 polypeptide haVing a sequence of amino acids including or set forth in SEQ ID NO:29; a rat PH20 polypeptide haVing a sequence of amino acids including or set forth in SEQ ID NO:22; a mouse PH20 polypeptide haVing a sequence of amino acids including or set forth in SEQ ID NO:20; a chimpanzee PH20 ptide haVing a sequence of amino acids including or set forth in SEQ ID NO:10 or 870; a Rhesus monkey PH20 ptide haVing a sequence of amino acids including or set forth in SEQ ID NO: 12; a Fox PH20 polypeptide haVing a sequence of amino acids including or set forth in SEQ ID NO:31; a Gibbon PH20 polypeptide haVing a sequence of amino acids including or set forth in SEQ ID NO:857; a Marmoset PH20 polypeptide haVing a sequence of amino acids including or set forth in SEQ ID NO: 859; an Orangutan PH20 polypeptide haVing a sequence of amino acids including or set forth in SEQ ID NO:861; or a sheep PH20 polypeptide having a sequence of amino acids including or set forth in any of SEQ ID NOS: 25-27; or in sequence variants or truncated variants that exhibit at least 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS: 7, 10, 12, 14, 16, 18, 20, 22, 24-27, 29, 31, 69, 72, 857, 859, 861 or 870.

In particular, provided herein are PH20 polypeptides that contain ations compared to a PH20 polypeptide set forth in SEQ ID NO: 3, 7, 32-66, 69 or 72, or a polypeptide that has a sequence of amino acids that is at least 68%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% cal to any of SEQ ID NOS: 3, 7, 32-66, 69 or 72. For example, the modiﬁcations provided herein also can be made in a PH20 polypeptide set forth as SEQ ID NO: 10, 12, 14, 24, 857, 859, 861 or 870.

In particular, provided herein are modiﬁed soluble PH20 polypeptides that are PH20 polypeptides containing a modiﬁcation provided herein, and that When expressed from cells are secreted into the media as a soluble n. For example, the modiﬁcations are made in a soluble PH20 polypeptide that is C-terminally ted Within or near the C-terminus portion containing the GPI-anchor signal sequence of a PH20 polypeptide that contains a GPI—anchor signal sequence. The C-terminal truncation can be a truncation or deletion of 8 contiguous amino acids at the C-terminus, 9, 10, 11, 12,13, 14, 15,16, 17, 18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 WO 02144 PCT/US2012/072182 or more amino acids at the C-terminus, so long as the ing C-terminally truncated polypeptide exhibits hyaluronidase activity and is secreted from cells (e. g., into the media) When expressed. In some examples, the modiﬁcations provided herein are made in a soluble PH20 polypeptide that is a C-terminally truncated polypeptide of SEQ ID NO:7, 10, 12, 14, 69, 72, 857, 859, 861 or 870 or a variant thereof that exhibits at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more ce identity to any of SEQ ID NOS: 7, 10, 12, 14, 69, 72, 857, 859, 861 or 870. In particular, the ations provided herein are made in a soluble or C-terminally truncated human PH20 polypeptide haVing the ce of amino acids set forth in SEQ ID NOS: 3 or 32-66 or a sequence of amino acids that exhibits at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% sequence identity to the sequence of amino acids set forth in any of SEQ ID NOS: 3 or 32-66. For example, modiﬁed PH20 ptides provided herein n amino acid replacements or substitutions, additions or deletions, truncations or combinations thereof With reference to the PH20 polypeptide set forth in SEQ ID NO:3.

Modiﬁcations also can be made in the corresponding precursor form containing a signal peptide of any of SEQ ID NOS: 3, 7, 10, 12, 14, 16, 18, 20, 22, 24-27, 29, 31, 32-66, 69, 72, 857, 859, 861 or 870. For example, modiﬁcations provided herein can be made in a precursor form set forth in any of SEQ ID NOS: 2, 6, 8, 9, 11, 13, 15, 17, 19, 21, 23, 28, 30, 856, 858, 860 or 869 or in a variant thereofthat exhibits at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS: 2, 6, 8, 9,11,13,15,17,19, 21, 23, 28, 30, 856, 858, 860 or 869.

In examples of modiﬁed PH20 polypeptides provided herein, the modiﬁed PH20 polypeptide does not contain the sequence of amino acids set forth in any of SEQ ID NOS: 3- 66, 68-72, 856-861, 869 or 870. Typically, the modiﬁed PH20 polypeptide is a human PH20 polypeptide, and does not contain the sequence of amino acids set forth in any of SEQ ID NOS: 8-31, 856-861, 869 or 870.

Generally, any modiﬁcation, such as amino acid replacement, on or substitution, can be made in a PH20 ptide, With the proviso that the modiﬁcation is not an amino acid replacement Where the only modiﬁcation is a single amino acid replacement that is V12A, N47A, D111N, E113Q, N131A, R176G, N200A, N219A, E249Q N333A or , R252T, N358A. Also, Where the modiﬁed PH20 polypeptide ns only two amino acid replacements, the amino acid replacements are not P13A/L464W, N47A/N131A, N47A/N219A, N131A/N219A or N333A/N358A. In a further example, Where the modiﬁed WO 2013/102144 PCT/US2012/072182 PH20 polypeptide ns only three amino acid replacements, the amino acid ements are not N47A/N 1 3 1A/N219A. Exemplary ations provided herein are described in detail below.

For purposes herein, reference to positions and amino acids for modiﬁcation herein, including amino acid replacement or replacements, are With reference to the PH20 polypeptide set forth in SEQ ID NO:3. It is Within the level of one of skill in the art to make any of the modiﬁcations provided herein in another PH20 ptide by identifying the corresponding amino acid residue in r PH20 polypeptide, such as any set forth in SEQ ID NOS: 6, 7, 8, 9,10,11,12,13,14,15,16,17,18,19, 20, 21, 22, 23, 24-27, 28, 29, 30, 31, 32-66, 68-72, 856, 857, 858, 859, 860, 861, 869 or 870 or a variant thereofthat exhibits at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS: 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24-27, 28, 29, 30, 31, 32-66, 68-72, 856, 857, 858, 859, 860, 861, 869 or 870. Corresponding positions in another PH20 polypeptide can be identiﬁed by alignment of the PH20 polypeptide With the reference to the PH20 polypeptide set forth in SEQ ID NO:3. For example, Figure 2 depicts alignment of exemplary PH20 polypeptides with SEQ ID N03, and identiﬁcation of exemplary corresponding positions. Also, since SEQ ID NOS: 3, 7, 32-66, 69 and 72 are all forms of a mature human PH20 With a different C-terminal amino acid residue, the numbering of amino acid residues in any of SEQ ID NOS: 7, 32-66, 69 and 72 is the same as SEQ ID N03, and hence the corresponding residues of each are identical to that set forth in SEQ ID NO:3 (see e.g., Figure 1). Further, SEQ ID NOS set forth in any of SEQ ID NOS: 2, 6, 70 or 71 are precursor forms thereof that differ by only the presence of a signal sequence. For purposes of modiﬁcation (e.g., amino acid ement), the corresponding amino acid e can be any amino acid residue, and need not be identical to the residue set forth in SEQ ID NO:3. Typically, the corresponding amino acid residue identiﬁed by alignment With residues in SEQ ID NO:3 is an amino acid residue that is identical to SEQ ID N03, or is a conservative or onservative amino acid residue o (see e.g., Figure 2). It is also understood that the exemplary replacements provided herein can be made at the corresponding residue in a PH20 polypeptide, so long as the replacement is different than exists in the unmodiﬁed form of the PH20 polypeptide. Based on this description and the ption elsewhere herein, it is Within the level of one of skill in the art to generate a modiﬁed PH20 polypeptide containing any one or more of the bed mutation, and test each for a property or activity as described herein.

Modiﬁcations in a PH20 polypeptide also can be made to a PH20 ptide that also contains other modiﬁcations, including modiﬁcations of the primary sequence and WO 2013/102144 PCT/US2012/072182 modiﬁcations not in the primary sequence of the polypeptide. For example, modiﬁcations described herein can be in a PH20 polypeptide that is a fusion polypeptide or chimeric polypeptide. The modiﬁed PH20 ptides ed herein also include polypeptides that are conjugated to a r, such as a PEG reagent.

Also provided herein are nucleic acid molecules that encode any of the modiﬁed PH20 polypeptides provided herein. In particular examples, the nucleic acid sequence can be codon optimized, for example, to increase expression levels of the encoded ce. The particular codon usage is dependent on the host organism in which the modiﬁed polypeptide is expressed. One of skill in the art is familiar with optimal codons for expression in mammalian or human cells, bacteria or yeast, including for example E. coli or romyces cerevisiae. For example, codon usage information is available from the Codon Usage Database available at kazusa.or.jp.codon (see Richmond (2000) Genome Biology, 1:reports241 for a description of the se). See also, Forsburg (1994) Yeast, 10:1045- 1047; Brown et al. (1991) Nucleic Acids Research, 19:4298; Sharp et al. (1988) Nucleic Acids Res., 12:8207-8211; Sharp et al. (1991) Yeast, 657-78). In some examples, the encoding nucleic acid molecules also can be modiﬁed to contain a heterologous signal sequence to alter (e.g., increased) expression and secretion of the polypeptide. Exemplary of a heterologous signal sequence is a nucleic acid encoding the IgG kappa signal ce (set forth in SEQ ID NO:868).

The modiﬁed polypeptides and encoding nucleic acid molecules provided herein can be ed by standard recombinant DNA techniques known to one of skill in the art. Any method known in the art to effect mutation of any one or more amino acids in a target protein can be employed. Methods include standard site-directed or random mutagenesis of encoding c acid molecules, or solid phase polypeptide synthesis methods. For example, nucleic acid molecules encoding a PH20 polypeptide can be subjected to mutagenesis, such as random mutagenesis of the encoding nucleic acid, error-prone PCR, site-directed mutagenesis, overlap PCR, gene shufﬂing, or other recombinant methods. The nucleic acid ng the polypeptides can then be introduced into a host cell to be sed logously. Hence, also provided herein are nucleic acid molecules encoding any of the d polypeptides provided herein. In some examples, the modiﬁed PH20 polypeptides are produced synthetically, such as using solid phase or solutions phase e sis.

In the subsections below, exemplary modiﬁed PH20 polypeptide exhibiting altered properties and activities, and encoding nucleic acid molecules, provided herein are described.

WO 2013/102144 PCT/US2012/072182 1. Active Mutants Provided herein are modiﬁed PH20 polypeptides that contain one or more amino acid ements in a PH20 polypeptide and that exhibit hyaluronidase activity. The modiﬁed PH20 polypeptides can t 40% to 5000% of the onidase activity of a Wildtype or reference PH20 polypeptide, such as the ptide set forth in SEQ ID NOS: 3 or 7. For example, d PH20 polypeptides provided herein exhibit at least 40% of the hyaluronidase activity, such as at least 50%, 60%, 70%, 80%, 90%, 100%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, 2000%, 3000% or more of the hyaluronidase activity of a Wildtype or reference PH20 polypeptide, such as the corresponding polypeptide not containing the amino acid modiﬁcation (e. g., amino acid replacement), for example, a polypeptide set forth in SEQ ID N03 or 7. For example, exemplary positions that can be modiﬁed, for example by amino acid replacement or substitution, include, but are not limited to, any of positions corresponding to position 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 20, 22, 23, 24, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 54, 58, 59, 60, 61, 63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 77, 79, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91, 92, 93, 94, 96, 97, 98, 99,102,103,104,105,106,107,108,110,114,117,118, 119,120,122,124,125,127,128,130,131,132,133,134,135,136,137,138,139,140,141, 142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160, 161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179, 180, 181, 182, 183, 184, 186, 192, 193, 195, 196, 197, 198, 200, 202, 204, 205, 206, 208, 209, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 224, 226, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 242, 245, 247, 248, 251, 253, 255, 256, 257, 258, 259, 260, 261, 263, 264, 265, 266, 267, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 297, 298, 300, 301, 302, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 320, 321, 323, 324, 325, 326, 327, 328, 331, 334, 335, 338, 339, 342, 343, 347, 348, 349, 351, 353, 356, 357, 358, 359, 360, 361, 367, 368, 369, 371, 373, 374, 375, 376, 377, 378, 379, 380, 381, 383, 385, 387, 388, 389, 391, 392, 393, 394, 395, 396, 397, 398, 399, 401, 403, 404, 405, 406, 407, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 425, 426, 427, 428, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446 or 447 with reference to amino acid positions set forth in SEQ ID NO:3. lly, the amino acid residue that is modiﬁed (e.g., replaced with another amino acid) at the position corresponding to any of the above positions in a PH20 polypeptide is an identical residue, a conservative residue or a semi-conservative amino acid residue to the amino acid residue set forth in SEQ ID NO:3.

WO 2013/102144 PCT/US2012/072182 To retain hyaluronidase activity, modiﬁcations typically are not made at those positions that are less tolerant to change or required for hyaluronidase actiVity. For example, generally modiﬁcations are not made at a position corresponding to on 7, 16, 17, 18, 19, 21,25,53,55,56,57,62,64,76,78,80,88,95,100,101,109,111,112,113,115,116,121, 123,126,129,185,187,188,189,190,191,194,199, 201, 203, 207, 210, 223, 225, 227, 228, 229,241,243,244,246,249,250,252,254,262,268,282,295,296,298,299,303,319,322, 0,332,333,336,337,340,341,344,345,346,350,352,354,355,362,363,364,365, 366,370,372,382,384,386,390,400,402,408,423,424,429,430,431,wdﬂ1reﬁuenceto amino acid positions set forth in SEQ ID NO:3. Also, in examples Where modiﬁcations are made at any ofpositions 2, 3, 4, 5, 6, 8, 9, 10, 11, 12,13,14, 15, 20, 22, 23, 27, 33, 34, 35, 36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,54,58,59,60,61,63,65,66, 67,68,69,70,71,72,73,74,75,77,79,81,82,83,84,85,86,87,89,90,91,92,94,96,98, 99,102,103,104,105,106,107,108,110,114,117,118,119,122,124,125,127,128,130, 131,132,133,134,135,136,137,138,139,143,144,145,149,150,152,153,154,155,156, 157,158,159,161,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177, 178,179,180,181,182,183,184,186,192,193,195,197,198,200,202,204,206,208,209, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 224, 226, 230, 231, 232, 233, 234,235,236,238,239,240,242,245,247,248,251,253,255,256,257,258,260,261,263, 264,265,266,267,269,270,271,272,273,274,275,276,278,279,280,282,283,284,285, 286,287,288,289,290,291,292,293,294,297,298,300,301,302,304,305,306,307,308, 310,311,312,313,314,315,316,317,318,320,321,323,324,325,326,327,331,334,335, 338,339,342,343,347,348,349,351,353,356,357,358,359,360,361,367,368,369,371, 373,374,375,376,377,378,379,380,381,383,385,387,388,389,391,392,393,394,395, 396,397,398,399,401,403,404,405,406,410,411,412,413,414,415,416,417,419,420, 422,425,426,427,428,431,432,434,437,438,439,440,441,442,443,444,or447xyﬁh reference to amino acid positions set forth in SEQ ID NO:3, the modiﬁcation(s) is/are not the corresponding amino acid ement(s) set forth in Table 5 or 10 herein, Which are amino acid replacements that result in an inactive ptide. For example, if the modiﬁcation is a modiﬁcation at a position ponding to position 2 With nce to SEQ ID NO:3, the modiﬁcation is not replacement to a histidine (H), lysine (K), phan (W) or tyrosine (Y).

Exemplary amino acid replacements at any of the above corresponding positions are set forth in Table 3. Reference to the corresponding amino acid on in Table 3 is With reference to positions set forth in SEQ ID NO:3. It is understood that the replacements can be made in the corresponding position in another PH20 polypeptide by alignment therewith With the sequence set forth in SEQ ID NO:3 (see e.g., Figure 1 and 2), Whereby the corresponding WO 2013/102144 PCT/US2012/072182 position is the aligned position. In particular es, the amino acid replacement(s) can be at the corresponding position in a PH20 polypeptide as set forth in any of SEQ ID NOS: 2, 3, 6-66, 68-72, 856-861, 869 or 870 or a variant thereofhaving at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, so long as the resulting modiﬁed PH20 polypeptide exhibits at least 40% of the hyaluronidase activity of the corresponding PH20 polypeptide not containing the amino acid ement. In particular, the replacement(s) can be in a corresponding position in a human PH20 polypeptide, for example, any set forth in any of SEQ ID NOS: 3, 7, 32-66, 69 or 72, or a variant thereof that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS: 3, 7, 32-66, 69 or 72. In one example, any one or more of the replacements are in SEQ ID NO:3, so long as the resulting modified PH20 polypeptide exhibits at least 40% of the hyaluronidase activity of the PH20 polypeptide set forth in SEQ ID NO:3.

TABLE 3: Active Mutants Corres- Replacement - Replacement Corres- Replacement ponding ponding g on Position Position 1 ACEFGHKNP 2 ACGILPQST 3 EHLY QRSTVW V 6 AHKLNQR 9 KLQRSV 12 RST AMV S 23 D 24 AEGHIKLMN 26 AEGHIKMPQ 27 ADEFHIKLP RTVY RSTVWY QRSTW 28 ADEFILMNP 29 AEGHIKLMP 30 AFGHKLMP RSTVW RSTVW QRSTVW TVWY QRSTVWY 34 W 35 FHLQTVY 36 ADGHKLNR T 39 ALNQRTY 40 LW 41 ACDEGHNTV 42 A W 44 E 45 IK 46 ACEFHLMNR 47 MQ 48 FGHIKMNQR STVY RSTWY SVY 49 IKRSV 50 ACDEHLMQR 51 ANRS SVY 52 NPQRST 54 AFNQSV 58 CGHIKLNPQ RSWY 60 K 61 FIMV TVW 67 FLRVY 68 EGHKLPQRS 69 ACEFGILMP T RTWY 70 ACFGHKLNP 71 ADGHLMNQ 72 ADEHKLMQ WO 2013/102144 PCT/US2012/072182 TABLE 3: Active Mutants — Replacement Corres- Replacement Corres- Replacement ponding ponding ponding Position Position Position R S T V Y U) RSY Nu.) A CDGHKLMQ 74 ACEFGHKLM 75 ACFHLMNQ R S T W NPRSVW RSTY NN E W NO LTV 00 ,_. "U 82 AEGHILMNQ RSTV 00 w FGHKLNQRS M DEFGHILMN 85 V ._] < PQRTWY 00 O‘\ ADEFGHIKL 87 ACEGHILMP 89 CKMPRW MNPRSTVW QRSTVY OO AEGHIKLNQ 91 AQR 92 CHLMTV RSTW OU.) DEFGHILMN 94 ACDEFHLMN 96 DLV PQRSTV QRST 97 ACDEFGILNP 98 ACDEHILMQ 99 ARS QRSWY R SVW 102 ACEGHKLMN QRSTW 103 N 104 ACGIKMRST 105 QRS TWV 106 107 FIL 108 110 V 114 AGHMS 117 118 V 119 FPQY 120 DFGHILNPR 122 M STVWY 124 HLR 125 AHRS 127 AEGHLMNQ RSTVW 1m ACGIKLQRS 130 IR 131 CEFGHILMQ W RSTVY 132 ACEFHIKLN B3 1 134 LTV QSTVY 135 ACDFGHKLN B6 ACDFHIMNQ 137 ACITACHIL QRSWY RSTW MNRSWY 139 ACDEFGHKL 140 ACDFGHIKL 141 ADEFGHLM MRSTV MRVWY QRSTVWY 142 CDEGHIKLM 143 CEGIKLNV IM RTW NPQRST 145 ACDEGHLMN M6 ACEGHIKNP 147 ACDFGILMP ~u 7:1 QRSTVY QRSVWY M8 CFGHIKLQRS 1w CGKLMQRST 150 ACDEFGILN TVWY PRSWY 151 ACGHKLMNQI! 152 ACFIMRTVW 153 ILS RSTVWY 154 IRTV 1% ACDFGHKLM 156 ACDGILMQR RSTVW STVW 157 W U8 AFGHLQS 159 MN QRSV m0 CFGHIKLMN 161 ACDERSV 162 ADEGHLMP QRSWVY QRSVWY 163 AEGKLQRST 164 LMVW 165 SV < 2 WY 166 LNQ 167 ADGHKMNP 168 H WO 2013/102144 PCT/US2012/072182 TABLE 3: Active Mutants Corres— Replacement Corres— ement Corres— Replacement ponding ponding g Position Position Position RTWY RSTY 169 LRV 170 AQNRV 171 IV 172 AC 173 QNR 174 AGHKMNQR STVWY 175 EHTVY 176 KL 177 V 178 GKMR 179 ACEGIKLMN 180 FGIKM 181 KMQ PRSTV 182 L 183 EL 184 W 186 Y 192 ST 193 FGQRSY 195 AGHILNQRS TWV 196 EGLNRSTWY 197 ADEFGHKLM 198 ADEHLNQRS QRSTW TWY 200 DT 202 M 204 PW 205 LRSTVWY 206 HIKLMQRST 208 ACKLMQRS TV 209 AEFGLNRST 211 LW 212 NST 213 AEGHKLMN QRVWY 214 Q 215 ADEGHKLM 217 M QRTVWY 218 FMV 219 KLM 220 ADHILMSTV RSTW 221 ACIMQTV 222 NRS 224 I V 226 W 230 I 231 T 232 S 233 AFGKLRY 234 LM 235 AEGHKT 236 AGHKRS 237 ACEFHLNQR 238 DEHKQRST STW 239 N 240 KAMPQRSV 242 F 245 H 247 ILM 248 AHWY 251 LMY 253 I 255 AGNQRS 256 AHLV 257 ACGIKLMNQ 258 GHNRS 259 EGIKLNPQR RTV STVWY 260 ADEGHLMQR 261 AFKMNQRTV 263 AHKMRTV SY W 264 AH 265 I 266 Y 267 MT 269 ACDS 270 MNST 271 FGLMSV 272 DMRST 273 HTY 274 AFS 275 LV 276 CDEGHILMR 277 ACDEGHKM SY NQRSTY 278 AEFGHIKNR 279 AHQRT 280 GQ STVY 282 DGMQ 283 EPRST 284 AEGHLMNQ STY 285 AFGHMNQY 286 RSW 287 INT 288 L" 2 289 KS 290 IM WO 2013/102144 PCT/US2012/072182 TABLE 3: Active Mutants Corres— Replacement Corres— Replacement Corres— Replacement ponding ponding ponding Position Position Position 293 ACDFGKLM VW PQSVY —— 300 R 303 DV 306 DES 309 MN QRSTVW 312 GKLNT 313 AEGHKLPRS 314 ADHINQRST 315 AEGHKLMR TVY Y TY 316 D 317 ADHIKMNQR 318 DFGHIKMNQ STW RST 320 EGHIKLMNR 321 ADHKRSTY 323 FIL SWVY 324 ADHMNRS 325 ADEGHKMN 326 CKLVY QSVW 327 M 328 ACGHIKLQR 331 CEV STVWY 338 Q 343 TV 349 AEKMNRT 356 ADHS 359 DEHKMTV —— 368 AEGHKLMR STVHRS 371 EFGHIKLMR 373 RSV 374 AHIMNPRST SV VWY 375 AGIKLMNRS 376 ADELMQRST 377 DEHKPRST T VY 380 Y 385 AGHNQRST TV V 387 S 388 FHIMRTVWY 389 AGHKLMPQ RSTY 391 C 392 AFGKLMQRS 393 ADFHKLMN TVWY RST 396 ADHLQRST 403 F TVW 404 APT 405 AFGKMPQRS 406 ACEFGINQS WY TVY 407 ADEFGHLMN 409 ADEGHIPQR 410 RS PQRVW STV TVY 411 AHNPRSTV 412 QPR 413 AEHKNQRS SVWY T 414 IKLM 415 GSWVY 416 FGHIKLNQR TVY 417 I 418 AEFGILMNP 419 EFGHIKLNR QRSVY SWY WO 2013/102144 PCT/US2012/072182 TABLE 3: Active s - Replacement Corres- Replacement Corres- Replacement ponding ponding ponding Position Position Position 420 IP 421 AEGHIKLMN 422 IT QRSTY 427 HIKQST 431 AEGHIKLNQ 432 EGHNSV RSVWY 433 ACDEGHIKL 434 FGIMV 435 ACEGHRSTV PRSTVW Y 436 CDEGHIKLM 437 ADGHIKLMQ 438 ACDEGLNPQ QRSTWY RSY RSTVW 439 ACFGHKLPQ 441 ADFGHKLN STVW PRSVY QSTVY 442 CGHKLPQRT 443 AEFGHLMNQ 444 DEFGHIKMN VWY RSTW RVWY 445 AGHLMNPQR 446 ACDEGHIKL 447 DEFGILMNP STVWY MQRTVW QRTVW In particular examples, provided herein is a modiﬁed PH20 polypeptide containing an amino acid replacement or ements at a on or positions corresponding to 1, 6, 8, 9, ,11,12,14,15, 20, 22, 24, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 46, 47, 48, 49, 50, 52, 58, 59, 63, 67, 68, 69, 70, 71, 72, 73, 74, 75, 79, 82, 83, 84, 86, 87, 89, 90, 92, 93, 94, 97,102,104,107,114,118,120,127,128,130,131,132,135,138,139,140,141, 142,143,144,146,147,148,149,150,151,152,155,156,158,160,162,163,164,165,166, 167, 169, 170, 172, 173, 174,175, 178, 179, 193, 195,196, 198, 204, 205, 206, 209, 212, 213, 215, 219, 220, 221, 222, 232, 233, 234, 235, 236, 237, 238, 240, 247, 248, 249, 257, 258, 259, 260, 261, 263, 267, 269, 271, 272, 273, 274, 276, 277, 278, 279, 282, 283, 285, 287, 289, 291, 292, 293, 298, 305, 307, 308, 309, 310, 313, 314, 315, 317, 318, 320, 321, 324, 325, 326, 328, 335, 347, 349, 351, 353, 356, 359, 367, 368, 369, 371, 373, 374, 375, 376, 377, 380, 381, 383, 385, 389, 392, 393, 395, 396, 399, 401, 404, 405, 406, 407, 409, 410, 412, 416, 418, 419, 421, 425, 427, 428, 431, 433, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446 or 447 With reference to amino acid ons set forth in SEQ ID NO:3. For example, the amino acid positions can be replacements at positions corresponding to replacement of Leucine (L) at position 1 (L1), P6, V8, 19, P10, N11, V12, F14, L15, A20, S22, F24, L26, G27, K28, F29, D30, E31, P32, L33, D34, M35, S36, L37, F38, S39, F40,141, 146, N47, A48, T49, G50, G52, V58, D59, Y63, 167, D68, S69, 170, T71, G72, V73, T74, V75, 179, K82, 183, S84, G86, D87, L89, D90, A92, K93, K94, T97, V102, N104, M107, E114, T118, A120, D127, V128, K130, N131, R132, E135, Q138, Q139, Q140, N141, V142, Q143, L144, L146, T147, E148, A149, T150, E151, K152, Q155, E156, E158, A160, K162, D163, F164, L165, V166, E167, 1169, K170, G172, K173, L174, L175, N178, H179, H193, K195, K196, G198, F204, N205, WO 2013/102144 PCT/US2012/072182 V206, K209, D212, D213, S215, N219, E220, S221, T222, T232, Q233, Q234, S235, P236, V237, A238, T240, V247, R248, E249, P257, D258, A259, K260, S261, L263, A267, T269, 1271, V272, F273, T274, Q276, V277, L278, K279, S282, Q283, E285, V287, T289, G291, E292, T293, A298, G305, L307, S308, 1309, M310, M313, K314, S315, L317, L318, D320, N321, E324, T325, 1326, N328, T335, Q347, Q349, V351, 1353, N356, S359, P367, D368, N369, A371, Q373, L374, E375, K376, G377, F380, T381, R383, K385, E389, E392, Q393, S395, E396, Y399, S401, S404, T405, L406, S407, K409, E410, A412, D416, D418, A419, D421, A425, G427, A428, D431, F433, P436, P437, M438, E439, T440, E441, E442, P443, Q444, 1445, F446 or Y447 With reference to amino acid positions set forth in SEQ ID NO:3.

Exemplary amino acid replacements in the modiﬁed PH20 polypeptides provided herein include, but are not limited, replacement With: histidine (H) at a position corresponding to on 1; A at a position ponding to position 1; E at a position ponding to position 1; G at a position corresponding to position 1; K at a position corresponding to on 1; Q at a position ponding to on 1; R at a position corresponding to position 1; A at a position ponding to position 6; M at a position corresponding to on 8; Q at a position corresponding to position 9; G at a position corresponding to position 10; H at a position corresponding to position 10; S at a position corresponding to position 11; E at a on corresponding to position 12; I at a position corresponding to position 12; K at a position corresponding to position 12; T at a position corresponding to position 12; V at a position corresponding to position 14; V at a position corresponding to position 15; M at a on corresponding to position 15 ; S at a position corresponding to position 20; T at a position corresponding to position 22; E at a position corresponding to position 24; H at a position corresponding to position 24; R at a position corresponding to position 24; A at a position corresponding to position 26; E at a on corresponding to position 26; K at a position ponding to position 26; M at a position corresponding to position 26; Q at a position corresponding to on 26; R at a position corresponding to position 26; D at a position corresponding to position 27; K at a on corresponding to position 27; R at a position corresponding to position 27; R at a position corresponding to position 28; E at a position corresponding to position 29; I at a position corresponding to position 29; K at a position corresponding to position 29; L at a position corresponding to position 29; M at a position corresponding to position 29; P at a position corresponding to position 29; R at a position corresponding to on 29; S at a position corresponding to position 29; T at a position corresponding to position 29; V at a position corresponding to position 29; G at a position corresponding to position 30; H at a position corresponding to position 30; K at a position corresponding to position 30; L at a position corresponding to WO 2013/102144 PCT/US2012/072182 —104— on 30; M at a position corresponding to position 30; R at a on corresponding to position 30; S at a position ponding to position 30; A at a position corresponding to position 31; C at a position corresponding to position 31; G at a position corresponding to position 31; H at a position corresponding to position 31; 1 at a on corresponding to position 31; K at a position corresponding to position 31; L at a position corresponding to position 31; P at a position corresponding to position 31; R at a position corresponding to on 31; S at a position corresponding to position 31; T at a position corresponding to position 31; V at a position corresponding to position 31; W at a position corresponding to position 31; C at a position corresponding to position 32; F at a on corresponding to position 32; G at a position corresponding to position 32; H at a position corresponding to position 32; W at a position corresponding to position 33; G at a position corresponding to position 33; W at a position corresponding to position 34; Q at a position corresponding to position 35; V at a position corresponding to position 35; H at a position corresponding to position 36; N at a position corresponding to position 36; F at a position corresponding to position 37; M at a position corresponding to on 37; Y at a position corresponding to on 38; A at a position corresponding to on 39; L at a on corresponding to position 39; N at a position corresponding to position 39; T at a position corresponding to position 39; L at a position corresponding to position 40; T at a position ponding to position 41; L at a position corresponding to position 46; R at a on corresponding to position 46; D at a position corresponding to position 47; F at a position corresponding to position 47; T at a position corresponding to position 47; W at a position corresponding to position 47, With F at a position ponding to position 48; H at a position corresponding to position 48; K at a position ponding to position 48; N at a position corresponding to position 48; R at a on corresponding to position 49; D at a position corresponding to position 50; S at a position ponding to position 50; M at a on corresponding to position 50; N at a position corresponding to position 52; Q at a position corresponding to position 52; R at a position corresponding to position 52; S at a position corresponding to on 52; T at a position corresponding to position 52; C at a position corresponding to position 58; K at a position corresponding to on 5 8; L at a position corresponding to position 5 8; P at a position corresponding to position 5 8; Q at a position corresponding to position 5 8; R at a position corresponding to position 58; H at a position corresponding to position 5 8; N at a position corresponding to position 5 8; Y at a position corresponding to position 5 8; N at a on corresponding to position 59; K at a position corresponding to position 63; L at a position corresponding to on 63; M at a position corresponding to position 63; R at a position corresponding to position 63; W at a position corresponding to WO 2013/102144 PCT/US2012/072182 position 63; V at a position corresponding to position 67; H at a on corresponding to position 68; P at a position corresponding to on 68; Q at a position corresponding to position 68; A at a position corresponding to position 69; C at a position ponding to position 69; E at a position corresponding to position 69; F at a position corresponding to on 69; G at a position corresponding to position 69; I at a position corresponding to position 69; L at a position corresponding to position 69; M at a position corresponding to on 69; P at a position corresponding to position 69; R at a position ponding to position 69; T at a position corresponding to on 69; W at a position ponding to position 69; Y at a position corresponding to position 69; A at a on corresponding to position 70; C at a position corresponding to position 70; F at a position corresponding to position 70; G at a position corresponding to position 70; H at a position corresponding to position 70; K at a position corresponding to position 70; L at a position corresponding to position 70; N at a position corresponding to position 70; P at a position corresponding to position 70; R at a position corresponding to position 70; S at a position corresponding to position 70; T at a position corresponding to position 70; V at a position ponding to position 70; Y at a position corresponding to position 70; G at a position corresponding to position 71; N at a position corresponding to position 71; R at a position corresponding to position 71; S at a position corresponding to position 71; K at a on corresponding to position 72; M at a position corresponding to position 72; Q at a position corresponding to position 72; A at a position corresponding to position 73; H at a position corresponding to position 73; K at a position corresponding to position 73; L at a position corresponding to position 73; Q at a position corresponding to position 73; R at a position ponding to position 73; T at a position corresponding to position 73; W at a position corresponding to position 73; A at a position ponding to position 74; C at a position corresponding to position 74; E at a position corresponding to position 74; F at a position corresponding to position 74; G at a position corresponding to on 74; H at a on corresponding to position 74; K at a position ponding to position 74; L at a on corresponding to position 74; M at a position corresponding to position 74; N at a position corresponding to position 74; P at a position corresponding to position 74; R at a position corresponding to position 74; S at a position corresponding to position 74; V at a position corresponding to position 74; W at a position corresponding to position 74; F at a position corresponding to position 75; L at a position ponding to position 75 ; M at position corresponding to position 75 ; R at a position corresponding to position 75 ; T at a position corresponding to position 75 ; L at a position corresponding to on 79; L at a position corresponding to position 82; N at a position corresponding to position 82; V at a on corresponding to WO 2013/102144 2012/072182 position 83; Q at a position corresponding to position 83; S at a position corresponding to on 83; G at a position corresponding to position 83; E at a position corresponding to position 84; F at a position corresponding to position 84; G at a position corresponding to position 84; N at a position corresponding to position 84; R at a position corresponding to position 84; A at a position corresponding to position 86; H at a position corresponding to position 86; K at a position corresponding to position 86; N at a on ponding to on 86; S at a position corresponding to position 86; T at a position corresponding to position 86; W at a position corresponding to position 86; C at a position corresponding to position 87; G at a position corresponding to position 87; L at a position corresponding to position 87; M at a position corresponding to position 87; R at a position corresponding to on 87; S at a position corresponding to position 87; T at a position corresponding to position 87; V at a on corresponding to position 87; Y at a position corresponding to on 87; C at a position corresponding to on 89; A at a position corresponding to position 90; E at a position corresponding to position 90; H at a position corresponding to position 90; K at a on corresponding to position 90; N at a position ponding to position 90; R at a position corresponding to position 90; C at a on corresponding to position 92; L at a position corresponding to position 92; 1 at a position corresponding to position 93; L at a position corresponding to position 93; Q at a position corresponding to position 93; R at a position ponding to position 93; S at a position corresponding to position 93; T at a position corresponding to position 93; D at a position corresponding to on 94; Q at a position corresponding to position 94; R at a position corresponding to position 94; A at a position corresponding to position 97; C at an amino acid e corresponding to position 97; D at a position corresponding to position 97; E at a position ponding to position 97; G at a position corresponding to position 97; L at a position corresponding to position 97; S at a position corresponding to position 97; S at a position corresponding to position 102; T at a position corresponding to position 102; R at a position corresponding to position 104; L at a position corresponding to position 107; A at a position corresponding to position 114; Q at a position corresponding to position 118; H at a position corresponding to position 120; F at a position corresponding to on 120; 1 at a position corresponding to position 120; S at a position corresponding to position 120; V at a position corresponding to position 120; Y at a position corresponding to position 120; E at a position corresponding to position 127; H at a position corresponding to on 127; N at a position ponding to position 127; Q at a position corresponding to position 127; R at a position corresponding to on 127; 1 at a position corresponding to position 128; R at a position corresponding to on 130; G at a position corresponding to position 131; I at a position WO 2013/102144 PCT/US2012/072182 corresponding to position 131; M at a position corresponding to position 131; Q at a position corresponding to position 131; R at a position corresponding to on 131; V at a position corresponding to position 131; N at a position corresponding to position 132; L at a position corresponding to position 132; D at a position corresponding to position 135; G at a position corresponding to position 135; R at a position corresponding to on 135, with L at a position corresponding to position 138; T at a position corresponding to position 139; K at a on corresponding to position 140; H at a position corresponding to position 141; R at a position corresponding to position 141; S at a position corresponding to position 141; W at a position corresponding to position 141; Y at a position corresponding to position 141; D at a position corresponding to position 142; G at a position corresponding to position 142; K at a on corresponding to position 142; N at a position corresponding to position 142; P at a position corresponding to position 142; Q at a position corresponding to position 142; R at a position corresponding to position 142; S at a position corresponding to position 142; T at a position corresponding to position 142; G at a position corresponding to on 143; K at a position corresponding to position 143; R at a position corresponding to position 144; T at a position corresponding to on 144; P at a position corresponding to on 146; R at a position corresponding to position 146; A at a position ponding to position 147; F at a position corresponding to position 147; L at a position corresponding to position 147; R at a on corresponding to position 147; S at a position corresponding to position 147; V at a position corresponding to position 147; H at a position corresponding to position 148; K at a position corresponding to position 148; Q at a position ponding to position 148; T at a position corresponding to position 149; V at a on corresponding to position 149; A at a position corresponding to position 150; D at a position corresponding to on 150; G at a position corresponding to position 150; N at a position ponding to position 150; S at a position corresponding to on 150; W at a position ponding to position 150; Y at a position corresponding to position 150; A at a position corresponding to position 151; H at a position corresponding to position 151; K at a position corresponding to position 151; L at a position corresponding to position 151; M at a position corresponding to position 151; Q at a position corresponding to position 151; R at a position corresponding to position 151; S at a position corresponding to on 151; T at a position corresponding to position 151; V at a on corresponding to on 151; W at a position corresponding to position 151; Y at a position corresponding to position 151; R at a position ponding to position 152; T at a position corresponding to on 152; W at a position ponding to position 152; D at a position corresponding to position 155; G at a position corresponding to position 155 ; K at a position corresponding to position 155; R at a position corresponding to position 155 ; D at a WO 2013/102144 PCT/US2012/072182 on corresponding to position 156; Q at a position corresponding to position 158; S at a position ponding to position 158; S at a position corresponding to position 160; E at a position corresponding to position 162; A at a position corresponding to position 163; E at a position corresponding to position 163; K at a position corresponding to on 163; Q at a position corresponding to position 163; R at a position corresponding to position 163; S at a on corresponding to position 163; M at a position corresponding to position 164; V at a position corresponding to position 164; D at a position corresponding to position 165; F at a position corresponding to position 165; N at a position corresponding to position 165 ; S at a position corresponding to on 165; V at a position corresponding to on 165 ; A at a position corresponding to position 166; E at a on corresponding to position 166; F at a position corresponding to position 166; H at a position corresponding to position 166; L at a position corresponding to position 166; Q at a position corresponding to position 166; R at a position corresponding to position 166; T at a position corresponding to position 166; W at a position corresponding to position 166; Y at a position corresponding to position 166; D at a position ponding to position 167; L at a position corresponding to position 169; R at a position ponding to position 170; A at a position corresponding to position 172; R at a position corresponding to position 173; G at a position corresponding to position 174; K at a on corresponding to on 174; N at a position corresponding to position 174; R at a position corresponding to position 174; T at a position corresponding to position 174; T at a position corresponding to position 175; K at a position ponding to position 178; R at a position corresponding to position 178; K at a position corresponding to position 179; Q at a position corresponding to position 193; T at a position corresponding to position 195; N at a position corresponding to position 195; With E at a position corresponding to position 196; R at a position corresponding to position 196; With D at a on corresponding to position 198; P at a position corresponding to position 204; A at a position corresponding to position 205; E at a position corresponding to position 205; L at a position corresponding to position 205 ; T at a position corresponding to position 205; I at a position corresponding to position 206; K at a position corresponding to position 206; L at a position corresponding to position 206; R at a position corresponding to position 206; R at a position corresponding to position 209; N at a position corresponding to position 212; S at a on corresponding to position 212; A at a position corresponding to position 213; M at a position corresponding to position 213; N at a position corresponding to position 213; H at a on corresponding to on 215; M at a on corresponding to position 215 ; A at a position corresponding to position 219; I at a position corresponding to on 219; K at a position corresponding to position 219; S at a position ponding to position 219; H at a position corresponding to position WO 2013/102144 PCT/US2012/072182 220; 1 at a position corresponding to position 220; L at a position corresponding to position 220; V at a position corresponding to position 220; Q at a position corresponding to position 221; G at a position corresponding to position 222; F at a position ponding to position 232; G at a position ponding to position 233; K at a position corresponding to position 233; R at a on corresponding to position 233; M at a position corresponding to position 234; A at a position corresponding to on 235; R at a position corresponding to position 236; C at a position corresponding to position 237; E at a position corresponding to position 237; H at a position corresponding to position 237; Q at a position corresponding to position 237; T at a position corresponding to position 237; E at a position corresponding to position 238; H at a position corresponding to amino acid position 238; S at a position corresponding to position 238; A at a position corresponding to position 240; Q at a position corresponding to position 240; 1 at a on corresponding to position 247; A at a position corresponding to position 248; V at a position ponding to position 249; G at a position corresponding to position 257; T at a position corresponding to position 257; R at a position corresponding to position 257; N at a position ponding to position 258; S at a position corresponding to position 25 8; P at a position corresponding to position 259; M at a position corresponding to position 260; Y at a position corresponding to position 260; A at a position corresponding to on 261; K at a position corresponding to position 261; N at a position corresponding to position 261; K at a position ponding to position 263; R at a position corresponding to position 263; T at a position corresponding to position 267; A at a position corresponding to on 269; L at a position corresponding to position 271; M at a position corresponding to position 271; D at a position corresponding to position 272; T at a position corresponding to position 272; H at a on corresponding to position 273; Y at a position corresponding to position 273; F at a position ponding to position 274; D at a position corresponding to position 276; H at a position corresponding to on 276; M at a position corresponding to position 276; R at a position corresponding to position 276; S at a position corresponding to position 276; Y at a position ponding to position 276; A at a position corresponding to position 277; E at a position corresponding to position 277; H at a position corresponding to position 277; K at a position corresponding to position 277; M at a position corresponding to position 277; N at a position corresponding to position 277; Q at a position corresponding to position 277; R at a position ponding to on 277; S at a position corresponding to position 277; T at a position ponding to position 277; E at a on corresponding to position 278; F at a position corresponding to position 278; G at a position corresponding to position 278; H at a position corresponding to position 278; K at a position ponding to position 278; N at a position corresponding to position 278; R at a position corresponding to WO 2013/102144 PCT/US2012/072182 position 278; S at a position corresponding to position 278; T at a position corresponding to position 278; Y at a position corresponding to position 278; H at a position corresponding to position 279; M at a position corresponding to position 282; S at a position corresponding to on 283; H at a on corresponding to position 285; T at a position ponding to position 287; S at a position corresponding to position 289; S at a position corresponding to position 291; V at a position ponding to position 291; C at a position corresponding to position 292; F at a position corresponding to position 292; H at a position corresponding to position 292; K at a position corresponding to position 292; R at a position corresponding to position 292; V at a position corresponding to position 292; A at a position corresponding to position 293; C at a position corresponding to position 293; D at a position corresponding to position 293; F at a position corresponding to position 293; K at a position corresponding to position 293; M at a position corresponding to position 293; P at a position corresponding to position 293; Q at a position ponding to position 293; V at a on corresponding to position 293; Y at a position corresponding to position 293; G at a position corresponding to position 298; E at a position corresponding to on 305; G at a position corresponding to position 307; D at a position ponding to position 308; G at a position corresponding to position 308; K at a position corresponding to on 308; N at a position corresponding to position 308; R at a position corresponding to on 308; E at a position corresponding to position 309; G at a position corresponding to position 309; H at a position corresponding to position 309; L at a position corresponding to position 309; M at a position corresponding to position 309; N at a position corresponding to position 309; Q at a position corresponding to position 309; R at a position corresponding to on 309; S at a on corresponding to position 309; T at a position corresponding to position 309; V at a position corresponding to on 309; A at a position corresponding to position 310; G at a position corresponding to position 310; Q at a position ponding to on 310; S at a position corresponding to position 310; A at a on corresponding to position 313; G at a position corresponding to position 313; H at a position corresponding to position 313; K at a position corresponding to position 313; P at a position corresponding to position 313; R at a position ponding to position 313; T at a position corresponding to position 313; Y at a position corresponding to on 313; With S at a on corresponding to position 314; Y at a position corresponding to position 314; A at a position ponding to position 315; H at a position corresponding to position 315; Y at a position corresponding to position 315 ; A at a position corresponding to position 317; I at a position corresponding to position 317; K at a on corresponding to position 317; N at a position corresponding to position 317; Q at a position corresponding to position 317; R at a position corresponding to position 317; S at a position WO 2013/102144 2012/072182 corresponding to position 317; T at a position corresponding to position 317; W at a position corresponding to position 317; D at a position corresponding to position 318; H at a position corresponding to position 318; K at a position corresponding to position 318; M at a on corresponding to position 318; R at a position corresponding to position 318; H at a position corresponding to position 320; K at a position corresponding to position 320; R at a position corresponding to position 320; R at a position corresponding to position 321; S at a position corresponding to position 321; N at a position corresponding to on 324; R at a on corresponding to position 324; A at a position ponding to position 325; D at a position corresponding to position 325 ; E at a position corresponding to position 325 ; G at a position corresponding to position 325 ; H at a on corresponding to position 325 ; K at a position corresponding to position 325 ; M at a position corresponding to position 325; N at a position corresponding to on 325 ; Q at a position corresponding to position 325 ; S at a position corresponding to position 325 ; V at a position corresponding to position 325 ; L at a on corresponding to position 326; V at a position corresponding to position 326; C at a position corresponding to on 328; G at a position corresponding to position 328; I at a position corresponding to position 328; K at a position corresponding to position 328; L at a on corresponding to position 328; S at a on corresponding to position 328; Y at a position corresponding to position 328; S at a position corresponding to on 335; A at a position corresponding to position 347; G at a position corresponding to position 347; S at a position corresponding to position 347; M at a position corresponding to position 349; R at a position corresponding to position 349; S at a position corresponding to position 351; V at a position ponding to position 353; With H at a position corresponding to position 356; S at a position corresponding to position 356; E at a on corresponding to position 359; H at a position corresponding to position 359; T at a position corresponding to position 359; A at a position corresponding to position 367; G at a on ponding to position 367; K at a position corresponding to position 367; S at a on corresponding to position 367; A at a position corresponding to position 368; E at a position corresponding to on 368; K at a position corresponding to position 368; L at a position corresponding to amino acid position 368; M at a position corresponding to amino acid position 368; R at a position corresponding to position 368; T at a position corresponding to amino acid position 368; H at a position corresponding to position 369; R at a position corresponding to position 369; F at a position corresponding to position 371; H at a position corresponding to position 371; K at a position ponding to position 371; L at a position corresponding to position 371; R at a on corresponding to position 371; S at a position corresponding to position 371; M at a position corresponding to position 373; H at a position corresponding to position 374; P at a position WO 2013/102144 PCT/US2012/072182 ponding to on 374; A at a position corresponding to position 375 ; G at a position corresponding to position 375 ; K at a position corresponding to position 375 ; R at a position corresponding to position 375; D at a position corresponding to on 376; E at a position corresponding to position 376; Q at a position corresponding to position 376; R at a position ponding to position 376; T at a position corresponding to position 376; V at a position corresponding to position 376; Y at a position corresponding to position 376; D at a position corresponding to on 377; E at a position corresponding to position 377; H at a position corresponding to position 377; K at a position ponding to position 377; P at a position corresponding to position 377; R at a position corresponding to position 377; S at a position corresponding to position 377; T at a on corresponding to position 377; W at a position corresponding to position 380; Y at a position corresponding to on 380; S at a position corresponding to position 381; I at a position ponding to position 383; K at a position corresponding to position 383; L at a position corresponding to position 383; S at a position corresponding to position 383; A at a position corresponding to position 385; Q at a position corresponding to on 385 ; V at a position corresponding to position 385 ; A at a position corresponding to position 389; G at a position corresponding to position 389; L at a position corresponding to position 389; K at a position corresponding to position 389; Q at a position corresponding to position 389; S at a position corresponding to position 389; A at a position corresponding to position 392; F at a position corresponding to position 392; M at a position corresponding to position 392; Q at a position corresponding to on 392; R at a position corresponding to position 392; V at a position corresponding to position 392; F at a position corresponding to position 393; M at a position corresponding to position 393; A at a position corresponding to position 395; H at a position ponding to position 395 ; R at a position corresponding to on 395 ; A at a on corresponding to position 396; H at a position corresponding to position 396; Q at a position corresponding to position 396; S at a position corresponding to position 396; K at a position corresponding to position 399; M at a position corresponding to position 399; T at a position corresponding to position 399; V at a position corresponding to position 399; W at a position corresponding to on 399; A at a position corresponding to position 401; E at a position ponding to on 401; A at a position ponding to position 404; G at a position corresponding to position 405; F at a position corresponding to position 406; N at a position corresponding to position 406; A at a position corresponding to position 407; D at a position corresponding to position 407; E at a position corresponding to on 407; F at a position corresponding to on 407; H at a on corresponding to position 407; Q at a position corresponding to position 407; P at a position corresponding to position 407; A at a position corresponding to position 409; Q at a position WO 2013/102144 PCT/US2012/072182 corresponding to position 409; T at a position corresponding to position 410; Q at a position corresponding to on 412; R at a position ponding to position 412; V at a on corresponding to position 412; L at a position corresponding to position 416; E at a on corresponding to position 418; L at a position corresponding to position 418; P at a position corresponding to on 418; R at a on corresponding to position 418; V at a position corresponding to position 418; F at a position corresponding to position 419; H at a position corresponding to position 419; 1 at a position corresponding to position 419; K at a position corresponding to on 419; R at a position corresponding to position 419; S at a on corresponding to position 419; Y at a position corresponding to position 419; A at a position corresponding to position 421; H at a on corresponding to position 421; K at a position corresponding to position 421; N at a position corresponding to position 421; Q at a on corresponding to position 421; R at a position corresponding to position 421; S at a position ponding to position 421; G at a position corresponding to position 425; K at a position corresponding to position 425 ; Q at a position corresponding to position 427; T at a position corresponding to position 427; L at a position corresponding to position 428; A at a position corresponding to position 431; G at a position corresponding to position 431; E at a position corresponding to position 431; H at a position corresponding to position 431; K at a position corresponding to position 431; L at a position corresponding to position 431; N at a position corresponding to position 431; Q at a position corresponding to position 431; R at a position corresponding to position 431; S at a position corresponding to position 431; V at a position corresponding to position 431; A at a on ponding to position 433; H at a position corresponding to position 433; I at a position corresponding to position 433; K at a position corresponding to position 433; L at a position ponding to position 433; R at a position corresponding to position 433; T at a position corresponding to position 433; V at a position corresponding to position 433; W at a position corresponding to position 433; K at a position corresponding to position 436; I at a on corresponding to position 437; M at a position corresponding to position 437; A at a position corresponding to position 438; D at a position corresponding to on 438; E at a position ponding to position 438; L at a position corresponding to on 438; N at a position ponding to position 438; T at a position corresponding to position 438; A at a position corresponding to position 439; C at a position corresponding to position 439; K at a position corresponding to position 439; P at a position corresponding to position 439; Q at a position corresponding to position 439; T at a position corresponding to position 439; V at a position corresponding to position 439; D at a position corresponding to position 440; H at a position corresponding to position 440; M at a position corresponding to position 440; P at a position corresponding to position 440; R at a position WO 2013/102144 PCT/US2012/072182 —114— corresponding to position 440; S at a position corresponding to position 440; A at a position corresponding to position 441; F at a position corresponding to position 441; C at a position corresponding to position 442; G at a position corresponding to position 442; R at a position corresponding to position 442; A at a position corresponding to position 443; E at a on corresponding to position 443; F at a position ponding to position 443; G at a position corresponding to position 443; M at a position corresponding to on 443; N at a position corresponding to position 443; E at a position corresponding to position 444; H at a position corresponding to position 444; V at a position corresponding to position 444; H at a position corresponding to position 445; M at a position corresponding to position 445; N at a position corresponding to position 445; P at a position corresponding to position 445; Q at a position corresponding to position 445 ; S at a position corresponding to position 445; T at a position corresponding to position 445 ; V at a position corresponding to position 445 ; W at a position corresponding to position 445 ; A at a position ponding to position 446; M at a position corresponding to position 446; W at a position corresponding to on 446; D at a position corresponding to position 447; E at a position corresponding to on 447; G at a position corresponding to position 447; I at a position corresponding to position 447; N at a position corresponding to position 447; P at a position corresponding to on 447; Q at a position corresponding to position 447; T at a position corresponding to on 447, and/or replacement With V at a position corresponding to position 447, each With reference to amino acid positions set forth in SEQ ID NO:3. ary of such modiﬁed PH20 polypeptides are any having the sequence of amino acids set forth in any of SEQ ID NOS: 74-855, or having a sequence of amino acids that exhibits at least 68%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more ce ty to any of SEQ ID NOS:74- 855 and contains the amino acid replacement and exhibits hyaluronidase activity.

Any of the above modiﬁed PH20 polypeptides ed herein can exhibit altered, such as ed or increased, properties or activities ed to the corresponding PH20 polypeptide not containing the amino acid modiﬁcation (e.g., amino acid replacement). For example, the d activities or properties can be an increased catalytic activity and/or an increased stability under denaturing conditions. a. Increased Activity Provided herein are modiﬁed or variant PH20 ptides that contain one or more amino acid replacements in a PH20 polypeptide and that exhibit increased hyaluronidase activity compared to the corresponding PH20 polypeptide not containing the amino acid replacement(s), for example, the PH20 polypeptide set forth in any of SEQ ID NOS: 2, 3, 6- WO 2013/102144 PCT/US2012/072182 -ll5- 66, 68-72, 856-861, 869 or 870 or a variant thereof having at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. In particular, the modiﬁed or variant PH20 polypeptides provided herein exhibit increased hyaluronidase activity compared to the corresponding PH20 polypeptide not containing the amino acid replacement, for example, the PH20 polypeptide set forth in any of SEQ ID NOS: 3, 7, 32-66, 69 or 72 and in particular the PH20 polypeptide set forth in SEQ ID N03.

The modiﬁed PH20 polypeptide can exhibit hyaluronidase activity that is at least or about at least or 120%, 130%, 135%, 140%, 145%, 150%, 160%, 170%, 180%, 200%, 250%, 300%, 350%, 400%, 500%, 1500%, 2000%, 3000%, 4000%, 5000% ofthe hyaluronidase activity of the corresponding PH20 polypeptide not containing the amino acid replacement(s), for example the PH20 polypeptide set forth in any of any of SEQ ID NOS: 2, 3, 6-66, 68-72, 856-861, 869 or 870 or a variant thereof, under the same conditions. For example, the hyaluronidase activity is increased at least or about at least ld, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, , 8-fold, 9-fold, d, 11-fold, 12-fold, 13-fold, 14-fold, 15- fold, 16-fold, d, 18-fold, d, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, ld, 200-fold, 300-fold, 400-fold or more.

In particular examples, the modiﬁed PH20 polypeptides contain an amino acid replacement at one or more amino acid positions identiﬁed as being ated With increased hyaluronidase ty. As described herein, such positions have been ﬁed using nesis and selection or ing methods to identify those positions that result in increased hyaluronidase activity. The PH20 polypeptide also can contain other modiﬁcations, such as other amino acid replacements, that alone are not associated With increased activity so long as the resulting modiﬁed PH20 polypeptide ts increased hyaluronidase ty compared to the PH20 not containing the amino acid ation(s), such as amino acid replacement(s). The modiﬁed PH20 polypeptide provided herein can contain 1, 2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14,15,16,17,18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, or more amino acid replacements. Additional modiﬁcations, such as insertions or deletions, also can be included. The amino acid replacement can be in a PH20 polypeptide as set forth in any of SEQ ID NOS: 2,3, 6-66, 68-72, 856-861, 869 or 870 or a variant thereof having at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity WO 2013/102144 PCT/US2012/072182 thereto. For example, the replacement(s) can be in a human PH20 polypeptide, for example, any set forth in any of SEQ ID NOS: 3, 7, 32-66, 69 or 72 or a variant thereof.

For example, the modiﬁed PH20 polypeptides provided herein contain an amino acid replacement (substitution) at one or more amino acid positions corresponding to ons 1, 12, 15, 24, 26, 27, 29, 30, 31, 32, 33, 37, 39, 46, 48, 52, 58, 63, 67, 68, 69, 70, 71, 72, 73, 74, 75, 84, 86, 87, 92, 93, 94, 97,118,120,127,131,135,141,142,147,148,150,151,152,155, 156,163,164,165,166,169,170,174,198, 206, 209, 212, 213, 215, 219, 233, 234, 236, 238, 247, 257, 259, 260, 261, 263, 269, 271, 272, 276, 277, 278, 282, 291, 293, 305, 308, 309, 310, 313, 315, 317, 318, 320, 324, 325, 326, 328, 347, 353, 359, 371, 377, 380, 389, 392, 395, 399, 405, 407, 409, 410, 418, 419, 421, 425, 431, 433, 436, 437, 438, 439, 440, 441, 442, 443, 445, 446 or 447 With reference to amino acid positions set forth in SEQ ID NO:3. For example, the amino acid positions can be replacements at positions corresponding to replacement of Leucine (L) at on 1 (L1), V12, L15, F24, L26, G27, F29, D30, E31, P32, L33, L37, S39, I46, A48, G52, V58, Y63, I67, D68, S69, I70, T71, G72, V73, T74, V75, S84, G86, D87, A92, K93, K94, T97, T118, A120, D127, N131, E135, N141, V142, T147, E148, T150, E151, K152, Q155, E156, D163, F164, L165, V166, 1169, K170, L174, G198, V206, K209, D212, D213, S215, N219, Q233, Q234, P236, A238, V247, P257, A259, K260, S261, L263, T269, 1271, V272, Q276, V277, L278, S282, G291, T293, G305, S308, I309, M310, M313, S315, L317, L318, D320, E324, T325, I326, N328, Q347, I353, S359, A371, G377, F380, E389, E392, S395, Y399, T405, S407, K409, E410, D418, A419, D421, A425, D431, F433, P436, P437, M438, E439, T440, E441, E442, P443, I445, F446 or Y447 With reference to amino acid positions set forth in SEQ ID NO:3. ary of such modiﬁed PH20 polypeptides are polypeptides that exhibit at least 1.5-fold or more the activity of the corresponding PH20 polypeptide not ning the amino acid replacement.

Exemplary of amino acid ements in the modified PH20 ptides provided herein include, but are not limited, replacement: With histidine (H) at a on corresponding to position 1; Q at a position corresponding to position 1; E at a on corresponding to position 12; T at a position corresponding to position 12; V at a position corresponding to position 15; E at a position corresponding to position 24; H at a position corresponding to position 24; E at a position corresponding to position 26; K at a position corresponding to position 26; K at a position corresponding to position 27; R at a position corresponding to position 27; E at a position corresponding to position 29; I at a position corresponding to position 29; L at a position corresponding to position 29; M at a position ponding to position 29; P at a position corresponding to position 29; S at a position corresponding to position 29; V at a position corresponding to position 29; G at a position corresponding to WO 02144 PCT/US2012/072182 position 30; H at a position corresponding to position 30; K at a position corresponding to position 30; M at a position corresponding to position 30; R at a position corresponding to position 30; S at a position corresponding to position 30; A at a position corresponding to position 31; C at a position ponding to position 31; H at a position corresponding to position 31; 1 at a position corresponding to position 31; K at a position corresponding to position 31; L at a position corresponding to position 31; P at a position corresponding to position 31; R at a position corresponding to position 31; S at a position corresponding to position 31; T at a position corresponding to position 31; V at a position corresponding to position 31; F at a position corresponding to position 32; G at a position corresponding to position 32; H at a position corresponding to position 32; W at a position corresponding to position 33; F at a position corresponding to position 37; N at a position corresponding to position 39; T at a position corresponding to position 39; R at a position corresponding to position 46; F at a position corresponding to position 48; H at a on corresponding to on 48; N at a position corresponding to position 48; Q at a position corresponding to position 52; K at a position corresponding to on 58; Q at a position corresponding to position 5 8; W at a position corresponding to position 63; V at a position corresponding to position 67; H at a position corresponding to position 68; Q at a position corresponding to position 68; A at a position corresponding to position 69; C at a position corresponding to position 69; F at a position corresponding to position 69; G at a position corresponding to position 69; 1 at a position corresponding to position 69; L at a on corresponding to on 69; M at a position corresponding to position 69; P at a position corresponding to on 69; R at a position corresponding to position 69; W at a position corresponding to position 69; Y at a position ponding to position 69; A at a position corresponding to position 70; C at a position corresponding to position 70; F at a position corresponding to position 70; G at a position corresponding to position 70; H at a position corresponding to position 70; K at a on corresponding to position 70; L at a position ponding to position 70; N at a on corresponding to position 70; P at a position corresponding to position 70; R at a position corresponding to on 70; S at a position corresponding to position 70; T at a on corresponding to position 70; V at a position corresponding to position 70; R at a position corresponding to position 71; S at a position corresponding to position 71; M at a position corresponding to position 72; Q at a position corresponding to on 72; H at a position corresponding to position 73; L at a position corresponding to position 73; W at a on corresponding to position 73; A at a position corresponding to on 74; C at a position corresponding to position 74; G at a on corresponding to position 74; N at a position corresponding to position 74; P at a on corresponding to WO 2013/102144 PCT/US2012/072182 position 74; R at a position corresponding to position 74; S at a position corresponding to position 74; V at a position corresponding to position 74; W at a position corresponding to on 74; F at a on corresponding to position 75; L at a position corresponding to position 75 ; R at a position corresponding to position 75 ; T at a position corresponding to position 75 ; G at a position corresponding to on 84; R at a position corresponding to position 84; A at a position corresponding to position 86; C at a position corresponding to position 87; T at a position corresponding to position 87; Y at a position corresponding to position 87; C at a position corresponding to position 92; 1 at a position corresponding to position 93; L at a position corresponding to position 93; R at a position corresponding to on 93; T at a position corresponding to position 93; R at a position corresponding to position 94; G at a position corresponding to position 97; Q at a position corresponding to position 118; F at a position corresponding to position 120; V at a position corresponding to position 120; Y at a position corresponding to position 120; H at a position corresponding to position 127; N at a position corresponding to on 127; G at a position corresponding to position 131; R at a position ponding to position 131; V at a position corresponding to on 131; D at a position corresponding to position 135; G at a on corresponding to position 135; R at a position corresponding to position 135, With H at a position corresponding to on 141; Y at a position corresponding to position 141; R at a position corresponding to position 142; R at a position corresponding to on 147; V at a position corresponding to position 147; K at a position corresponding to position 148; G at a position corresponding to position 150; K at a position corresponding to position 151; L at a position corresponding to position 151; M at a position corresponding to position 151; Q at a position ponding to position 151; R at a position corresponding to position 151; R at a position corresponding to position 152; G at a on corresponding to position 155; K at a position corresponding to position 155 ; D at a position corresponding to position 156; A at a position corresponding to position 163; E at a position ponding to position 163; K at a position corresponding to on 163; R at a position corresponding to position 163; M at a position corresponding to position 164; D at a position corresponding to position 165; N at a position corresponding to on 165 ; A at a position corresponding to on 166; F at a on corresponding to position 166; H at a position corresponding to position 166; L at a position ponding to position 166; Q at a position corresponding to position 166; R at a position corresponding to position 166; T at a position corresponding to on 166; Y at a position ponding to position 166; L at a position corresponding to position 169; R at a position corresponding to position 170; K at a position corresponding to position 174; D at a position corresponding to position 198; K at a position corresponding to on 206; L at a position WO 2013/102144 PCT/US2012/072182 corresponding to position 206; N at a position corresponding to on 212; M at a position corresponding to position 213; N at a position corresponding to position 213; M at a position corresponding to position 215; S at a position corresponding to position 219; K at a position corresponding to position 233; R at a position corresponding to position 233; M at a position corresponding to position 234; R at a position ponding to position 236; E at a position corresponding to position 237; S at a position corresponding to position 238; I at a position corresponding to position 247; T at a position corresponding to position 257; P at a position corresponding to position 259; Y at a position corresponding to position 260; K at a position corresponding to position 261; N at a position corresponding to position 261; K at a position corresponding to position 263; R at a position corresponding to position 263; A at a position corresponding to position 269; L at a position corresponding to position 271; M at a position corresponding to position 271; T at a position corresponding to position 272; D at a position corresponding to position 276; S at a position corresponding to position 276; Y at a position corresponding to position 276; K at a position corresponding to position 277; R at a position corresponding to on 277; T at a position corresponding to position 277; H at a position ponding to position 278; K at a position corresponding to position 278; N at a position ponding to position 278; R at a position corresponding to position 278; S at a on corresponding to position 278; T at a position ponding to position 278; Y at a position ponding to position 278; M at a position corresponding to position 282; V at a position corresponding to on 291; A at a position corresponding to position 293; C at a position corresponding to position 293; F at a position ponding to on 293; M at a position corresponding to on 293; P at a position corresponding to position 293; Q at a position corresponding to on 293; V at a position corresponding to position 293; E at a position corresponding to position 305; G at a position corresponding to position 308; N at a position corresponding to position 308; E at a position corresponding to on 309; L at a position corresponding to position 309; N at a position corresponding to position 309; Q at a position corresponding to position 309; R at a position corresponding to position 309; T at a position corresponding to position 309; A at a position corresponding to on 310; G at a on corresponding to position 310; K at a position corresponding to position 313; R at a position ponding to position 313; H at a position corresponding to position 315; I at a position corresponding to position 317; K at a position corresponding to position 317; R at a position corresponding to position 317; M at a position corresponding to position 318; H at a position corresponding to position 320; K at a on corresponding to position 320; R at a position corresponding to position 320; R at a position corresponding to position 324; A at a position corresponding to position 325; D at a position corresponding to position 325 ; E at a position WO 2013/102144 PCT/US2012/072182 corresponding to position 325 ; G at a position corresponding to position 325 ; H at a position corresponding to position 325 ; K at a position corresponding to position 325 ; M at a position corresponding to on 325; N at a position corresponding to position 325 ; Q at a position corresponding to position 325 ; S at a position ponding to position 325; V at a on corresponding to position 326; I at a position corresponding to position 328; K at a position corresponding to position 328; L at a position corresponding to position 328; S at a position corresponding to position 328; Y at a position ponding to position 328; G at a position corresponding to position 347; S at a on corresponding to position 347; V at a position corresponding to on 353; With T at a position corresponding to position 359; R at a position corresponding to position 371; P at a position corresponding to position 377; T at a on corresponding to position 377; W at a position corresponding to position 380; Y at a position corresponding to position 380; K at a position corresponding to position 389; M at a position ponding to position 392; R at a position corresponding to position 395; M at a position corresponding to position 399; T at a on corresponding to position 399; W at a position corresponding to position 399; G at a position corresponding to position 405; D at a on corresponding to position 407; Q at a position corresponding to position 407; A at a position corresponding to position 409; Q at a position corresponding to position 409; T at a position corresponding to position 410; P at a position corresponding to position 418; F at a position corresponding to position 419; I at a position corresponding to position 419; K at a position corresponding to position 419; R at a position corresponding to position 419; S at a position corresponding to position 419; H at a position corresponding to position 421; K at a position corresponding to on 421; N at a position corresponding to on 421; Q at a position corresponding to position 421; R at a position corresponding to position 421; S at a position corresponding to position 421; K at a position corresponding to position 425; A at a position corresponding to position 431; H at a position corresponding to on 431; K at a position corresponding to on 431; Q at a position ponding to position 431; R at a position corresponding to position 431; S at a position corresponding to position 431; V at a position ponding to position 431; L at a position corresponding to position 433; R at a position corresponding to position 433; T at a position corresponding to position 433; V at a position corresponding to on 433; K at a position corresponding to position 436; I at a position corresponding to position 437; M at a on corresponding to position 437; T at a position corresponding to position 438; V at a position corresponding to position 439; H at a position corresponding to position 440; R at a position corresponding to position 440; F at a on corresponding to position 441; R at a position ponding to position 442; A at a position corresponding to position 443; M at a position ponding to position 443; M at a WO 2013/102144 2012/072182 position corresponding to position 445; P at a position ponding to position 445; A at a position corresponding to position 446; D at a position corresponding to position 447; N at a position corresponding to on 447; and/or With Q at a position corresponding to position 447, each With reference to amino acid positions set forth in SEQ ID N03. The modiﬁed PH2O polypeptides can contain any one or more of the recited amino acid substitutions, in any ation, With or Without additional modiﬁcations, so long at the PH2O polypeptide exhibits hyaluronidase actiVity, such as increased hyaluronidase actiVity compared to the PH2O polypeptide not ning the ation(s) for example, at least 1.5-fold increased , hyaluronidase actiVity.

In some es, the modiﬁed PH2O polypeptides provided herein contain one or more amino acid ement(s) at a position(s) corresponding to position(s) 24, 29, 31, 48, 58, 69, 70, 75, 84, 97, 165, 166, 271, 278, 317, 320, 325, and/or 326 With reference to positions set forth in SEQ ID NO:3. For example, exemplary amino acid replacements include, but are not limited to, replacement With: E at a on corresponding to position 24; E at a position ponding to position 29; V at a position corresponding to position 31; N at a position corresponding to position 48; K at a position corresponding to position 58; Q at a position corresponding to position 5 8; A at a position corresponding to position 69; F at a position corresponding to position 69; G at a position corresponding to position 69; P at a position corresponding to position 69; R at a on corresponding to position 69; A at a position corresponding to position 70; F at a position ponding to position 70; G at a position corresponding to position 70; H at a position corresponding to position 70; H at a position corresponding to on 70; N at a position corresponding to position 70; R at a position corresponding to position 70; T at a position corresponding to position 70; V at a position corresponding to position 70; L at a position corresponding to position 75; T at a position ponding to position 75 ; G at a position corresponding to position 84; G at a position ponding to on 97; D at a position corresponding to position 165; L at a position corresponding to position 166; R at a position corresponding to position 166; T at a position corresponding to position 166; L at a position corresponding to position 271; H at a position corresponding to position 278; R at a position corresponding to position 278; K at a position corresponding to position 317; K at a position corresponding to position 320; E at a position corresponding to on 325, With G at a position corresponding to position 325; K at a position corresponding to position 325 ; N at a position corresponding to position 325 ; Q at a position corresponding to position 325 ; V at a position corresponding to position 326; each With reference to amino acid positions set forth in SEQ ID N03. The d PH2O polypeptides can contain any one or more of the recited amino acid substitutions, in any WO 02144 2012/072182 -l22- combination, With or Without additional modiﬁcations, so long at the PH20 polypeptide exhibits hyaluronidase activity, such as sed hyaluronidase activity compared PH20 polypeptide not containing the modiﬁcation(s), for example, at least 2.0-fold increased hyaluronidase actiVity.

Exemplary modiﬁed PH20 polypeptides that exhibit increased actiVity compared to the unmodiﬁed PH20 polypeptide (e.g., set forth in SEQ ID NO:3) are any haVing the sequence of amino acids set forth in any of SEQ ID NOS: 73, 78, 86, 89, 91, 95, 96, 99, 100, 105,106,108,109,111,112,113,115,117,118,119,120,123-126,128-136,139-141,149, 154,155,159,164,165,167,173,178,181,191-193,195-197,199-205, 207-221, 225, 226, 228, 229, 231, 233, 9, 242, 247-254, 256, 257, 267, 269, 270, 277, 283, 293, 295, 296, 298, 300, 303, 308, 316, 318, 321, 322, 324, 325, 330, 334, 335, 338-340, 344, 348, 355, 367, 369, 371, 377, 384-388, 394, 398, 399, 401, 406-408, 410, 412, 414, 416, 419, 421-426, 428, 430, 431, 435, 448, 455, 456, 459, 462, 463, 465, 469, 478-480, 482, 484, 490, 493, 497, 501, 503, 505, 506-508, 510-512, 514, 518, 522, 523, 527, 531, 533, 537-543, 545, 551, 558, 559, 561, 563-566, 569, 572, 574, 576, 579, 581-583, 585, 587, 588, 594, 596, 602, 605, 606, 609, 613, 618-620, 624-634, 637, 640-644, 647, 648, 652, 657, 675, 695, 698, 699, 700, 712, 717, 725, 731, 732, 734, 738, 742, 746, 748-750, 757, 760, 762-765, 768-773, 775, 779, 782, 783, 786-789, 794-797, 799-801, 807, 814, 816, 819, 822, 825, 826, 830, 836, 838, 844, 847, 851, 853 or having a sequence of amino acids that exhibits at least 68%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS: 73, 78, 86, 89, 91, 95, 96, 99, 100, 105, 106, 108, 109,111,112,113,115,117,118,119,120,123-126,128-136,139-141,149,154,155,159, 164,165,167,173,178,181,191-193,195-197,199-205, 207-221, 225, 226, 228, 229, 231, 233, 237-239, 242, 4, 256, 257, 267, 269, 270, 277, 283, 293, 295, 296, 298, 300, 303, 308, 316, 318, 321, 322, 324, 325, 330, 334, 335, 338-340, 344, 348, 355, 367, 369, 371, 377, 8, 394, 398, 399, 401, 406-408, 410, 412, 414, 416, 419, 421-426, 428, 430, 431, 435, 448, 455, 456, 459, 462, 463, 465, 469, 478-480, 482, 484, 490, 493, 497, 501, 503, 505, 506- 508, 510-512, 514, 518, 522, 523, 527, 531, 533, 537-543, 545, 551, 558, 559, 561, 563-566, 569, 572, 574, 576, 579, 581-583, 585, 587, 588, 594, 596, 602, 605, 606, 609, 613, 618-620, 624-634, 637, 640-644, 647, 648, 652, 657, 675, 695, 698, 699, 700, 712, 717, 725, 731, 732, 734, 738, 742, 746, 748-750, 757, 760, 762-765, 768-773, 775, 779, 782, 783, 9, 794- 797, 799-801, 807, 814, 816, 819, 822, 825, 826, 830, 836, 838, 844, 847, 851, 853 and ns the amino acid replacement and exhibits sed hyaluronidase actiVity compared to the corresponding unmodiﬁed polypeptide.

WO 2013/102144 PCT/US2012/072182 b. Increased ity ed herein are PH20 polypeptides that exhibit increased stability. In particular, the PH20 ptides exhibit increased stability in vivo and/or in vitro. For example, the PH20 polypeptides can exhibit increased stability under various storage conditions. The modiﬁed PH20 polypeptides provided herein that t increased stability display, among other parameters, increased resistance to denaturation conditions, including but not limited to, denaturation ions caused by temperature (e.g., elevated temperature such as heat), agitation, no or low salt, and/or ce of excipients. Exemplary excipients e, but are not limited to, antiadherents, binders, coatings, ﬁllers and diluents, , colors, lubricants, glidants, vatives, sorbents or sweeteners. For example, various excipients, such as preservatives, can act as protein denaturing agents. d PH20 polypeptides provided herein that exhibit increased protein stability exhibit d aggregation, reduced precipitation and/or increased activity When d to a denaturation condition compared to the corresponding PH20 not containing the amino acid replacement. For example, modiﬁed PH20 polypeptides provided herein exhibit at least or at least about or 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500% or more increased activity When exposed to a denaturation condition compared to the corresponding PH20 polypeptide not containing the amino acid replacement When exposed to the same denaturation condition.

The PH20 polypeptides provided herein that exhibit increased stability are modiﬁed or variant PH20 polypeptides that n an amino acid replacement (substitution), deletion or insertion or other modiﬁcation. Typically, the PH20 polypeptides provided herein that exhibit increased stability contain one or more amino acid replacements in a PH20 ptide compared to the corresponding PH20 polypeptide not containing the amino acid replacement(s), for example, the PH20 polypeptide set forth in any of SEQ ID NOS: 2, 3, 6- 66, 68-72, 856-861, 869 or 870 or a variant thereof having at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. In particular, the modiﬁed or variant PH20 polypeptides provided herein exhibit increased stability compared to the ponding PH20 polypeptide not containing the amino acid replacement, for example, the PH20 polypeptide set forth in any of SEQ ID NOS: 3, 7, 32-66, 69 or 72 and in particular the PH20 polypeptide set forth in SEQ ID NO:3.

In particular examples, the modiﬁed PH20 polypeptides contain an amino acid replacement at one or more amino acid ons identiﬁed as being associated With increased stability. As described herein, such positions can be identiﬁed using mutagenesis and WO 2013/102144 PCT/US2012/072182 —124— selection or screening methods to fy those positions that result in stability (e.g., increased activity) of the polypeptide compared to the ponding PH2O not containing the modiﬁcation upon re to one or more ration conditions. The PH2O polypeptide also can contain other modiﬁcations, such as other amino acid replacements, that alone are not associated With conferring stability, so long as the resulting modiﬁed PH2O polypeptide exhibits increased stability under one or more denaturation conditions compared to the PH2O not ning the amino acid modiﬁcation(s), such as amino acid replacement(s), and exhibits hyaluronidase actiVity. The modiﬁed PH2O polypeptide provided herein can contain 1, 2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14,15,16,17,18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, or more amino acid replacements. Additional modiﬁcations, such as insertions or deletions, also can be included. The amino acid replacement can be in a PH2O polypeptide as set forth in any of SEQ ID NOS: 2, 3, 6-66, 68- 72, 856-861, 869 or 870 or avariant thereofhaving at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. For example, the replacements can be in a human PH2O polypeptide, for example, any set forth in any of SEQ ID NOS: 3, 7, 32-66, 69 or 72 or a variant thereof.

Exemplary of modiﬁed PH2O polypeptides provided herein are PH2O polypeptides that t increased stability upon exposure to phenol compounds, high temperature (heat), and/or lack of NaCl. i. Phenophiles Provided herein are modiﬁed PH2O polypeptides that exhibit increased stability in the presence of phenolic compounds. Multidose formulations must contain crobial preservatives to protect them from microbial contamination. For parenteral drug ts, including insulin and other therapeutic agents, the most common preservatives are phenolic compounds, such as phenol, metacresol (m—cresol), benzyl alcohol, and parabens including paraben and propylparaben. The preservatives typically must be present at sufﬁcient concentrations to y regulatory rules. For example, tory requirements assert that the antimicrobial efﬁcacy of the formulation must satisfy the vative y test (PET) requirements of the target markets. Currently different regulatory agencies have different pharmacopeial criteria for antimicrobial effectiveness for pharmaceutical ts designed for multiple dosing. The PET requirements of the United States Pharmacopoeia (USP) and the European Pharmacopoeia (EP) differ considerably, imposing onal constraints in WO 2013/102144 PCT/US2012/072182 developing multidose formulations. Table 4 shows the criteria for inj ectable drugs to meet USP and EP criteria. lly, formulations that meet EP (EPA or EPB) anti-microbial requirements contain more preservative than those formulated only to meet USP anti- microbial requirements.

Table 4. USP and EP requirement for antimicrobial effectiveness testing United States Europe Reqmrement Time point .E.PB EPA (Minimum) (Preferred) 6 h 24 h Bacterial Log Reduction" 7 d 1.0 3 No recovery 3.0 No increase No recovery No increase No increase No recovery No increase Fungal Log ion" No increase 1 No increase No increase No increase No increase * LOgIO unit reduction from initial ed inoculum; No se: not more than 0.5 loglo unit increase than previously measured value.

Anti-microbial vatives can interact with ns resulting in aggregations and negative effects on stability. Thus, although a necessary component, preservatives pose a signiﬁcant problem in the development of stable, multidose formulations of proteins because they typically induce aggregation of the protein in aqueous solution. In particular, increasing or high amounts of preservatives can negatively impact the stability of a protein, including effects on physical stability (aggregation or precipitation) that can impact protein activity.

For example, to meet the EP preservative efficacy requirements, relatively high s of phenolic compounds, such as phenol or m-cresol, can be required, which can inﬂuence stability of the protein formulation. For example, preservatives such as phenol, m-cresol, and benzyl alcohol have been shown to induce ation of human grth hormone (Maa and Hsu (1996) Int. J. Pharm.140:155—168), recombinant eukin-1 or (Remmele (1998) Pharm. Res.15:200—208), human insulin-like growth factorl (Fransson (1997) Pharm. Res. 14:606—612), rthN—y (Lam (1997) Pharm. Res. 14:725—729) and cytochrome c (Singh et al. (2011) J. Pharm Sci., 100:1679-89). The ilizing effect that preservatives have on WO 2013/102144 PCT/US2012/072182 proteins in solution has been a limiting factor in the pment of multidose formulations, and to date, most protein eutics have been formulated for single use only.

PH20 hyaluronidase, such as rHuPH20, rapidly loses activity in the presence of preservatives, likely due to unfolding of the protein and subsequent aggregate formation. For example, as shown in the Examples herein, vatives reduce PH20 enzymatic activity, particularly at elevated temperatures (see also U.S. Provisional Appl. No.61/520,962; and U.S. Application Nos. 13/507,263 and 13/507,262). For example, following incubation with 0.4% m-cresol for 4 hours, PH20 (e.g., rHuPH20) retains only about 10% of its activity (see e.g., Example 5). When incubated in the presence of 0.1% phenol and 0.15% or 0.315% m- cresol for 6 days at 37 OC, PH20 (e.g., 0) s about 0% to 15% ty, depending on the presence of other excipients or amounts of other excipients in the formulation (see e.g., Examples 9 and 10). For example, the presence of a higher concentration of salt generally increases the stability of PH20. In particular, the melting temperature of PH20, such as rHuPH20, is d signiﬁcantly when phenolic preservatives, such as m—Cresol, are added to the formulation. For e, the unfolding temperature of rHuPH20 is reduced from 44 0C to 24 OC. The lower PH20 unfolding temperatures leads to increased PH20 aggregation, especially at ed temperatures, and reduced enzyme activity. The destabilizing effect is likely due to the hydrophobic nature of the phenolic preservatives. The hydrophobicity of the phenolic compounds can lead to interaction with rHuPH20 through nonspeciﬁc binding to the protein, ultimately bing the structural integrity of rHuPH20. This ates to a signiﬁcant loss ofrHuPH20 enzymatic activity in the presence of preservatives.

The modiﬁed PH20 polypeptides provided herein that exhibit sed stability in the presence of phenolic preservatives exhibit more than 15% enzymatic activity in the presence of at least one phenolic vative for at least 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks or more compared to the enzymatic activity of the modiﬁed PH20 polypeptide in the absence of preservative for the same time period and under the same conditions (except for the presence of preservative). In some examples, the modiﬁed PH20 polypeptides provided herein exhibit at least 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more enzymatic ty in the ce of a phenolic preservative compared to in the absence of preservative. For example, the phenolic preservative compound can be phenol, metacresol (m—cresol), benzyl alcohol, and/or parabens including paraben or propylparaben.

WO 2013/102144 PCT/US2012/072182 -l27- In particular examples, the increased stability in the presence of preservative is exhibited under temperature conditions of between or about between 0 0C to 40 0C, such as n or about between 2 0C to 6 0C, 24 0C to 32 0C or 35 0C to 40 OC, and generally at or about at 4 0C or 5 0C, 30 0C or 37 °C. It is understood that since high temperature also can have a destabilizing effect on PH20 activity (see below), the percentage of tic ty of a modiﬁed PH20 polypeptide provided herein in the presence of preservative is greater at lower temperatures than at higher temperatures.

Generally, the modiﬁed PH20 polypeptides provided herein exhibit increased stability, and the noted enzymatic activities, in the presence of an anti-microbial effective amount of preservative that kills or inhibits the propagation of microbial organisms in a sample of the composition. For example, the modiﬁed PH20 ptides provided herein exhibit increased stability in the presence of an anti-microbial ive amount of preservative that kills or inhibits the ation of microbial organisms such that at least a 1.0 loglO unit reduction in bacterial organisms occurs at 7 days following inoculation. In some examples, the modiﬁed PH20 polypeptides provided herein exhibit increased stability in the presence of an anti-microbial effective amount of preservative that kills or inhibits the propagation of microbial organisms such that, when tested in an antimicrobial preservative effectiveness test (APET), following inoculation of the composition with a microbial inoculum there is at least a 1.0 loglO unit reduction in ial organisms at 7 days following inoculation, at least a 3.0 loglO unit reduction of bacterial organisms at 14 days following inoculation, at least no r increase in bacterial organisms after 28 days following inoculation, and at least no se in fungal organisms after 7 days following inoculation. In other examples, the modiﬁed PH20 polypeptides provided herein t increased stability in the presence of an anti-microbial effective amount of preservative that kills or inhibits the propagation of microbial organisms such that, when tested in an antimicrobial preservative effectiveness test , following inoculation of the composition with a microbial inoculum there is at least a 1.0 log] 0 unit reduction of bacterial organisms at 24 hours following inoculation, at least a 3.0 loglO unit reduction of bacterial organisms at 7 days following inoculation, no r increase in bacterial organisms after 28 days following inoculation, at least a 1.0 loglO unit ion of fungal sms at 14 days ing inoculation, and at least no further increase in fungal organisms after 28 days following ation. In yet another example, the d PH20 polypeptides provided herein exhibit increased stability in the presence of an anti-microbial effective amount of the preservative that kills or inhibits the propagation of microbial organisms such that, when tested in an antimicrobial preservative effectiveness test (APET), following inoculation of the WO 2013/102144 PCT/US2012/072182 composition with a microbial inoculum there is at least a 2.0 log10 unit reduction of bacterial organisms at 6 hours following inoculation, at least a 3.0 log10 unit reduction of bacterial organisms at 24 hours following inoculation, no ry of bacterial sms after 28 days following inoculation of the composition with the ial um, at least a 2.0 log10 unit reduction of fungal organisms at 7 days following inoculation, and at least no further increase in fungal organisms after 28 days following inoculation.

For example, the modiﬁed PH20 polypeptides provided herein exhibit increased stability, and above recited enzymatic activity, in the presence of a total amount of one or more phenolic preservative agents as a percentage (%) of mass concentration (w/V) that is or is between 0.05% to 0.6%, 0.1% to 0.4%, 0.1% to 0.3%, 0.15% to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 0.3% to 0.4% inclusive.

Generally, modiﬁed PH20 polypeptides provided herein exhibit increased stability in the presence of m-cresol and/or phenol. For example, modiﬁed PH20 ptides provided herein exhibit increased stability in the presence of m—cresol in an amount as a % of mass concentration (w/V) in a formulation containing the modiﬁed PH20 polypeptide ofbetween or about between 0.05% to 0.6%, 0.1% to 0.4%, 0.1% to 0.3%, 0.15% to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 0.3% to 0.4%. In other examples, d PH20 polypeptides provided herein exhibit increased stability in the presence of phenol in an amount at a % of mass concentration (w/V) in a formulation containing the modiﬁed PH20 polypeptide ofbetween or about between 0.05% to 0.6%, 0.1% to 0.4%, 0.1% to 0.3%, 0.15% to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 0.3% to 0.4% m—cresol. In further examples, modiﬁed PH20 polypeptides provided herein exhibit sed stability in the presence of phenol and ol in an amount as a % of mass tration (w/V) in a formulation ning the d PH20 polypeptide of between or about between 0.05% to 0.25% phenol and between or about between 0.05% to 0.3% m-cresol, between or about between 0.10% to 0.2% phenol and between or about between 0.6% to 0.18% m-cresol, between or about between 0.1% to 0.15% phenol and 0.8% t 0.15% m—cresol, between or about between 0.10% to 0.15% phenol and between or about n 0.06% to 0.09% m- , or between or about between 0.12% to 0.18% phenol and between or about between 0.14% to 0.22% m—cresol. 1n es , modiﬁed PH20 polypeptides exhibit more than 15%, such as at least 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more enzymatic activity in the presence of at least about between or between 0.3% to 0.4%, inclusive, m-cresol and/or phenol for at least 4 hours at 37 oC compared to the enzymatic activity of the modiﬁed PH20 polypeptide in the absence of the WO 2013/102144 PCT/US2012/072182 -l29- preservative for the same time period and under the same conditions (except for the presence of preservative). For example, modiﬁed PH20 polypeptides exhibit more than 15%, such as at least 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more enzymatic activity in the presence of about or 0.4% m-cresol for at least 4 hours at 37°C compared to the enzymatic activity of the modiﬁed PH20 polypeptide in the absence of the preservative for the same time period and under the same conditions (except for the presence of preservative). Modiﬁed PH20 polypeptides provided herein also exhibit more than 15%, such as at least 16%, 17%, 18%, 19%, 20%, %, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more enzymatic activity in the presence of at least about between or between 0.2% to 0.4%, inclusive, m-cresol and/or phenol for at least 1 day, 2 days, 3 days, 4 days, 5 days or 6 days at 37 oC compared to the tic activity of the d PH20 polypeptide in the absence of preservative for the same time period and under the same conditions (except for the presence of preservative). For example, modiﬁed PH20 polypeptides provided herein exhibit more than 15%, such as at least 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more enzymatic activity in the presence of about or 0.10% phenol and about or 0.15% m-cresol for at least 1 day, 2 days, 3 days, 4 days, 5 days or 6 days at 37 OC compared to the enzymatic ty of the d PH20 polypeptide in the absence of preservative for the same time period and under the same conditions (except for the presence of preservative). In other examples, modiﬁed PH20 polypeptides provided herein exhibit more than 15%, such as at least 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more enzymatic activity in the presence of about or 0.315% m- cresol for at least 1 day, 2 days, 3 days, 4 days, 5 days or 6 days, generally for at least 6 days, at 37 oC compared to the enzymatic activity of the d PH20 polypeptide in the absence of preservative for the same time period and under the same conditions (except for the presence of vative).

For example, such modiﬁed PH20 polypeptides provided herein that exhibit increased stability to phenol compounds contain an amino acid replacement (substitution) at one or more amino acid positions corresponding to positions 10, 12, 20, 22, 26, 34, 36, 46, 50, 52, 58, 68, 70, 74, 82, 83, 84, 86, 97,127,131,138,142,143,144,166,169,174,193,195,196, 204, 205, 206, 213, 219, 234, 237, 238, 240, 249, 261, 267, 277, 279, 291, 309, 310, 314, 315, 317, 318, 347, 367, 375, 376, 399, 401, 407, 416, 419, 421, 431, 433, 439, 440, 443 or 445 With reference to amino acid positions set forth in SEQ ID NO:3. For example, the amino acid ons can be replacements at one or more ons corresponding to replacement of WO 02144 PCT/US2012/072182 (P) at on 10 (P10), V12, A20, S22, L26, D34, S36, I46, G50, G52, V58, D68, I70, T74, K82, 183, S84, Q86, T97, D127, N131, Q138, V142, Q143, L144, V166,1169, L174, H193, K195, K196, F204, N205, V206, D213, N219, Q234, V237, A238, T240, E249, S261, A267, V277K279, G291, 1309, M310, K314, S315, L317, Q347, P367, E375, K376, Y399, S401, S407, D416, A419, D421, D431, F433, E439, T440, P443 or 1445 With reference to amino acid positions set forth in SEQ ID NO:3.

Exemplary of amino acid replacements in the modiﬁed PH20 polypeptides provided herein e, but are not limited to, replacement With: glycine (G) at a position ponding to position 10; K at a position corresponding to position 12; S at a position corresponding to position 20; T at a position corresponding to position 22; M at a position corresponding to position 26; W at a position corresponding to position 34; N at a position corresponding to position 36; L at a position corresponding to position 46; M at a position corresponding to position 50; T at a position corresponding to position 52; S at a position corresponding to position 52; C at a on corresponding to on 58; K at a position corresponding to position 5 8; R at a position corresponding to position 5 8; N at a position corresponding to position 5 8; Y at a position corresponding to position 5 8; P at a position corresponding to position 5 8; H at a position corresponding to position 5 8; P at a position corresponding to position 68; V at a position ponding to on 70; E at a position corresponding to position 74; L at a position corresponding to position 82; N at a position corresponding to position 82; V at a position corresponding to position 83; Q at a position corresponding to position 83; S at a position corresponding to position 83; G at a position corresponding to on 83; N at a position corresponding to position 84; A at a position ponding to on 86; K at a position corresponding to position 86; E at a position corresponding to position 97; L at a position corresponding to position 97; R at a position corresponding to position 127; R at a position corresponding to position 131; L at a position corresponding to position 138; K at a position ponding to position 142; N at a position corresponding to position 142; P at a position corresponding to position 142; S at a position corresponding to position 142; T at a position corresponding to position 142; G at a position corresponding to on 143; K at a position corresponding to position 143; T at a position ponding to position 144; Q at a position corresponding to position 166; T at a position corresponding to position 166; L at a position corresponding to position 169; G at a position corresponding to position 174; N at a position corresponding to position 174; Q at a position corresponding to position 193; T at a position corresponding to position 195; N at a position corresponding to position 195 ; E at a on ponding to position 196; R at a position corresponding to on 196; P at a position corresponding to position 204; A at a position WO 2013/102144 PCT/US2012/072182 -l3l- ponding to on 205; E at a position corresponding to position 205; I at a position corresponding to position 206; A at a position corresponding to position 213; I at a position ponding to position 219; M at a position corresponding to position 234; T at a position corresponding to position 237; H at a position corresponding to position 238; Q at a on ponding to position 240; V at a position corresponding to position 249; A at a position corresponding to position 261; K at a position corresponding to position 261; T at a position corresponding to position 267; K at a position corresponding to position 277; H at a position ponding to position 279; V at a position corresponding to position 279; V at a position corresponding to position 291; E at a position corresponding to position 309; Q at a position corresponding to position 310; Y at a position corresponding to on 314; Y at a position corresponding to position 315; N at a position corresponding to position 317; W at a position corresponding to position 317; D at a position corresponding to position 318; G at a position corresponding to position 347; A at a position corresponding to position 367; R at a position ponding to position 375; R at a position corresponding to position 376; V at a position ponding to on 399; E at a position corresponding to position 401; A at a position corresponding to position 407; L at a position ponding to position 416; K at a position corresponding to position 419; H at a position corresponding to position 421; E at a position corresponding to position 431; T at a position corresponding to position 433; V at a position corresponding to position 433; C at a on corresponding to position 439; P at a position corresponding to position 440; G at a position corresponding to position 443; N at a position ponding to position 445 , each With reference to amino acid residue positions set forth in SEQ ID NO:3.

The amino acid replacement(s) can be in a PH20 polypeptide as set forth in any of SEQ ID NOS: 2, 3, 6-66, 68- 72, 1, 869 or 870 or avariant thereof haVing at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. For example, the replacement(s) can be in a human PH20 polypeptide, for example, any set forth in any of SEQ ID NOS: 3, 7, 32-66, 69 or 72 or a variant thereof Exemplary modified PH20 polypeptides that exhibit increased stability to phenol compounds compared to the ﬁed PH20 polypeptide (e.g., set forth in SEQ ID NO:3) are any haVing the sequence of amino acids set forth in any of SEQ ID NOS: 83, 88, 93, 94, 101,144,148,158,171,176,175,177,178,180,182,183,184,185,194, 221, 240, 259, 260, 261, 262, 263, 264, 268, 270, 272, 307, 309, 327, 334, 341, 351, 352, 353, 356, 357, 358, 359, 361, 424, 426, 430, 434, 436, 443, 444, 445, 446, 447, 449, 450, 451, 454, 461, 467, 480, 487, 489, 492, 495, 504, 505, 509, 527, 544, 576, 589, 600, 603, 607, 612, 614, 647, 658, 683, 687, WO 2013/102144 2012/072182 -l32- 733, 736, 741, 754, 763, 768, 781, 796, 797, 809, 818, 829 or 837 or having a sequence of amino acids that ts at least 68%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS: 83, 88, 93, 94,101,144,148,158,171,176,175,177,178,180,182,183,184,185, 194, 221, 240, 259, 260, 261, 262, 263, 264, 268, 270, 272, 307, 309, 327, 334, 341, 351, 352, 353, 356, 357, 358, 359, 361, 424, 426, 430, 434, 436, 443, 444, 445, 446, 447, 449, 450, 451, 454, 461, 467, 480, 487, 489, 492, 495, 504, 505, 509, 527, 544, 576, 589, 600, 603, 607, 612, 614, 647, 658, 683, 687, 733, 736, 741, 754, 763, 768, 781, 796, 797, 809, 818, 829 or 837 and contains the amino acid replacement, exhibits onidase activity and exhibits sed stability in the presence phenol compounds compared to the corresponding ﬁed polypeptide.

In particular, provided herein is a modiﬁed PH20 polypeptide that contains an amino acid replacement With P at a position corresponding to amino acid residue 204 With reference to SEQ ID NO:3. Typically, the modiﬁed PH20 polypeptide is a human polypeptide. For example, provided herein is a d PH20 polypeptide that contains an amino acid replacement F204P in a sequence of amino acids set forth in any of SEQ ID NOS: 3, 7, 69, 72 or 32-66, or a sequence of amino acids that exhibits at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS:3, 7, 69, 72 or 32-66 so long as the modiﬁed polypeptide contains the amino acid replacement corresponding to F204P. In other cases, the modiﬁed PH20 polypeptide is a non-human polypeptide. For example, provided herein is a modiﬁed PH20 polypeptide that contains an amino acid replacement F204P in a ce of amino acids set forth in SEQ ID NO:10, 12, 14, 857, 859, 861 or 870 or a sequence that exhibits at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS: 10, 12, 14, 857, 859, 861 or 870 so long as the modiﬁed polypeptide contains the amino acid replacement corresponding to F204P. In a further example, provided herein is a modiﬁed PH20 polypeptide that ns an amino acid replacement F205P in a sequence of amino acids set forth in SEQ ID NO:24 or Y204P in SEQ ID N03], or a sequence that exhibits at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:24 or 31. Exemplary of such a modiﬁed PH20 polypeptide is a polypeptide having the ce of amino acids set forth in SEQ ID NO:449, or having a sequence of amino acids that exhibits at least 68%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:449 and contains the amino acid replacement F204P, exhibits sed hyaluronidase activity and exhibits increased stability to phenol compounds compared to the WO 2013/102144 PCT/US2012/072182 corresponding unmodiﬁed polypeptide (e.g., SEQ ID NO:3). In any of the above examples, the modiﬁed PH20 polypeptide that contains an amino acid ement with P at a position corresponding to amino acid residue 204 with reference to SEQ ID NO:3 does not have the sequence of amino acids set forth in SEQ ID NO:15-22, 28 or 29.

In another example, provided herein is a modiﬁed PH20 polypeptide that contains an amino acid replacement at a on corresponding to amino acid residue 58 with reference to SEQ ID NO:3. Exemplary of amino acid replacements are replacement with lysine (K) or with arginine (R) at a position corresponding to amino acid residue 58 with reference to SEQ ID NO:3. Typically, the modiﬁed PH20 polypeptide is a human ptide. For example, provided herein is a modiﬁed PH20 polypeptide that contains an amino acid ement V58K or V58R in a sequence of amino acids set forth in any of SEQ ID NOS: 3, 7, 69, 72 or 32-66, or a ce of amino acids that exhibits at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS:3, 7, 69, 72 or 32-66. In other cases, the modiﬁed PH20 polypeptide is a non-human polypeptide. For example, provided herein is a modiﬁed PH20 polypeptide that contains an amino acid replacement V58K or V58R in a sequence of amino acids set forth in SEQ ID NO:10, 12, 14, 20, 22, 24, 29, 857, 859, 861 or 870 or a sequence that exhibits at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS: 10, 12, 14, 20, 22, 24, 29, 857, 859, 861 or 870. In a r example, provided herein is a d PH20 polypeptide that contains an amino acid replacement A58R in a sequence of amino acids set forth in SEQ ID NO:16 or 31, or a sequence that ts at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:16 or 31. Exemplary of such a modiﬁed PH20 polypeptide is a polypeptide having the sequence of amino acids set forth in SEQ ID NO:182, or having a sequence of amino acids that exhibits at least 68%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence ty to SEQ ID NO:182, which contains the amino acid replacement V58R and exhibits increased hyaluronidase activity and exhibits increased stability in the presence of phenol compounds compared to the corresponding unmodiﬁed polypeptide (e.g., SEQ ID NO:3). ii. philes At ed atures, PH20 hyaluronidases can lose activity.

Provided herein are modiﬁed PH20 polypeptides that exhibit increased stability at elevated temperatures of between or about between 30 0C to 45 OC, inclusive, such as between or about between 35 0C to 42 0C, in particular at or about 37 0C. For example, provided WO 2013/102144 PCT/US2012/072182 —134— herein are modiﬁed PH20 polypeptides that are stable at elevated temperatures greater than 32 0C such as 35 0C to 45 0C, 37 0C to 42 OC and in ular at or about 37 0C for at least 3 hours, 4 hours, 5 hours, 6 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, at least 5 days, at least 6 days or at least 7 days. Modiﬁed PH20 polypeptides that exhibit stability at elevated temperatures can be used in applications Where temperatures are elevated, can ﬂuctuate or can increase. This can occur, for example, in methods of administration utilizing pumps or other continuous infusion s.

In particular, modiﬁed PH20 polypeptides provided herein that t stability at elevated temperatures exhibit increased hyaluronidase activity at elevated temperature compared to the ponding PH20 polypeptide not containing the modiﬁcation, e.g., amino acid replacement. The PH20 polypeptides can exhibit increased onidase activity upon incubation at elevated temperatures greater than 32 0C such as 35 0C to 45 0C or 37 0C to 42 0C, in particular at or about 37 0C for at least 4 hours, 5 hours, 6 hours, 12 hours, 1 day, 2 days, 3 hours, 4 hours, 5 hours, 6 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, at least 5 days, at least 6 days or at least 7 days compared to the corresponding PH20 polypeptide not containing the modiﬁcation ted under the same conditions. For example, the hyaluronidase activity can be increased at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500% or more compared to the corresponding PH20 polypeptide not containing the modiﬁcation incubated under the same conditions. For example, the hyaluronidase activity can be increased at least 1.1-fold, 1.2-fold, 1.3-fold, 1.4- fold, ld, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold or more compared to the corresponding PH20 polypeptide not containing the modiﬁcation incubated under the same conditions.

In other es, modiﬁed PH20 polypeptides provided herein that t ity at elevated temperatures retain hyaluronidase activity at elevated temperatures compared to the ty of the modiﬁed PH20 polypeptide incubated at non-elevated temperatures under the same conditions (except for the differences in temperature). For e, modiﬁed PH20 polypeptides exhibit greater than or about 50%, such as greater than or at least 55%, 60%, 65%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% ofthe activity at elevated temperatures greater than 32 0C such as 35 0C to 45 0C or 37 0C to 42 0C, in particular at or about 37 oC compared to the activity of the PH20 at evated temperatures of between or about between 2 0C to 8 °C. In some examples, modiﬁed PH20 polypeptides provided herein that exhibit stability at elevated temperatures exhibit increased activity at elevated temperatures compared to the activity of the modiﬁed PH20 polypeptide incubated at non-elevated temperatures under the same conditions (except for the difference WO 2013/102144 2012/072182 -l35- in temperature). For example, modiﬁed PH20 polypeptides exhibit greater than or about 10% sed activity, such as r than or at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500% or more of activity at elevated temperatures greater than 32 0C such as 35 0C to 45 0C or 37 0C to 42 0C, in particular at or about 37 °C compared to the activity of the PH20 at non-elevated temperatures of between or about between 2 0C to 8 0C. For example, d PH20 polypeptides exhibit greater than or at least about 1.1-fold the hyaluronidase activity, such as greater than or at least 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, ld, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold or more of activity at elevated atures greater than 32 0C such as 35 0C to 45 0C or 37 0C to 42 0C, in particular at or about 37 oC compared to the activity of the PH20 at non-elevated temperatures of between or about between 2 0C to 8 °C.

For example, such modiﬁed PH20 ptides provided herein that exhibit increased stability at elevated temperatures contain an amino acid replacement (substitution) at one or more amino acid positions corresponding to positions 1, 11, 12, 14, 20, 26, 29, 34, 50, 58, 70, 82, 83, 84, 86, 87,140,142,143,147,152,166,167,172,174,178,193,195, 206, 212, 213, 219, 233, 237, 240, 267, 277, 291, 292, 309, 313, 314, 317, 318, 347, 367, 368, 371, 374, 389, 392, 395, 396, 406, 419, 421, 439 or 443 with reference to amino acid ons set forth in SEQ ID NO:3. For example, the amino acid positions can be replacements at one or more positions corresponding to replacement of (L) at position 1 (L1), N11, V12, F14, A20, L26, F29, D34, G50, V58,170, K82,183, S84, Q86, D87, Q140, V142, Q143, T147, K152, V166, E167, G172, L174, N178, H193, K195, V206, D212, D213, N219, Q233, V237, T240, A267, V277, G291, E292, 1309, M313, K314, L317, L318, Q347, P367,D368, A371, L374, E389, E392, S395, E396, L406, A419, D421, E439 or P443, with reference to amino acid positions set forth in SEQ ID N03 The resulting modiﬁed PH20 polypeptide exhibits increased stability at elevated temperatures greater than 32 0C such as 35 0C to 45 0C, 37 0C to 42 oC and in particular at or about 37 0C for at least 3 hours, 4 hours, 5 hours, 6 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, at least 5 days, at least 6 days, at least 7 days or more.

Exemplary amino acid replacements in the modiﬁed PH20 polypeptides provided herein e, but are not limited, replacement with: R at a position corresponding to position 1; S at a position corresponding to position 11; 1 at a on corresponding to position 12; V at a position corresponding to position 14; S at a position corresponding to position 20; M at a position corresponding to position 26; with R at a position corresponding to on 29; W at a position corresponding to position 34; M at a position corresponding to position 50; K at a position corresponding to position 58; Q at a position corresponding to position 5 8; Q at a position corresponding to on 5 8; V at a position corresponding to WO 2013/102144 PCT/US2012/072182 position 70; L at a position corresponding to position 82; Q at a position corresponding to position 83; R at a position corresponding to position 84; A at a on corresponding to position 86; S at a position ponding to position 87; K at a position ponding to position 140; S at a on corresponding to position 142; T at a position corresponding to position 142; K at a position corresponding to position 143; S at a position corresponding to position 147; T at a position corresponding to position 152; T at a position corresponding to position 166; D at a on corresponding to position 167; A at a position corresponding to position 172; G at a position corresponding to position 174; N at a position corresponding to position 174; R at a position corresponding to position 178; Q at a on ponding to position 193; T at a position corresponding to position 195; 1 at a position corresponding to on 206; S at a position corresponding to position 212; A at a position corresponding to position 213; 1 at a position corresponding to position 219; G at a position corresponding to position 233; T at a position corresponding to position 237; A at a position corresponding to on 240; Q at a position corresponding to position 240; T at a on corresponding to position 267; E at a position ponding to position 277; S at a position corresponding to position 291; H at a position corresponding to position 292; V at a position corresponding to position 292; S at a position corresponding to position 309; H at a position corresponding to position 313; S at a position corresponding to position 314; 1 at a position corresponding to position 317; T at a position ponding to position 317; W at a position corresponding to position 317; R at a position corresponding to position 318; G at a position corresponding to position 347; A at a position corresponding to position 367; R at a position corresponding to position 368; S at a on corresponding to position 371; P at a position corresponding to position 374; A at a position corresponding to position 389; V at a on corresponding to position 392; A at a position corresponding to position 395; H at a position corresponding to position 396; N at a position corresponding to position 406; H at a on corresponding to position 419; K at a position corresponding to position 419; R at a position corresponding to position 421; S at a position corresponding to on 421; A at a position corresponding to position 439; C at a position corresponding to position 439; or G at a position corresponding to on 443, each With reference to amino acid residue positions set forth in SEQ ID N03.

The amino acid replacement(s) can be in a PH20 polypeptide as set forth in any of SEQ ID NOS: 2, 3, 6-66, 68-72, 856-861, 869 or 870 or a variant thereof haVing at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto. For e, the replacement(s) WO 2013/102144 PCT/US2012/072182 -l37- can be in a human PH20 polypeptide, for e, any set forth in any of SEQ ID NOS: 3, 7, 32-66, 69 or 72 or a variant thereof. ary d PH20 polypeptides that exhibit sed stability to phenol compounds compared to the unmodiﬁed PH20 polypeptide (e.g., set forth in SEQ ID NO:3) are any having the sequence of amino acids set forth in any of SEQ ID NOS: 79, 85, 87, 90, 93,101,114,144,171,178,181, 221, 259, 262, 269, 270, 282, 343, 356, 357, 359, 368, 395, 426, 429, 432, 434, 436, 441, 443, 444, 454, 460, 461, 467, 477, 487, 491, 492, 509, 525, 550, 554, 557, 584, 593, 599, 605, 611, 612, 617, 647, 658, 667, 676, 679, 709, 720, 723, 727, 740, 761, 763, 772, 773, 808, 809, or 829 or having a sequence of amino acids that exhibits at least 68%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence ty to any of SEQ ID NOS: 79, 85, 87, 90, 93, 101, 114, 144, 171, 178, 181, 221, 259, 262, 269, 270, 282, 343, 356, 357, 359, 368, 395, 426, 429, 432, 434, 436, 441, 443, 444, 454, 460, 461, 467, 477, 487, 491, 492, 509, 525, 550, 554, 557, 584, 593, 599, 605, 611, 612, 617, 647, 658, 667, 676, 679, 709, 720, 723, 727, 740, 761, 763, 772, 773, 808, 809, or 829 and contains the amino acid replacement, exhibits hyaluronidase activity and exhibits increased stability to elevated temperatures compared to the corresponding unmodiﬁed polypeptide. iii. Absence of Salt PH20 denatures in the presence of low salt or no salt. Thus, PH20 requires a high salt concentration of between or about between 140 mM to 200 mM to maintain stability. Other therapeutic agents, for example insulin, exhibit decreased solubility and increased crystallization/aggregation in the presence of high salt. Thus, the high salt requirements of PH20 can affect the solubility and/or activity of co-formulated eutic agents, while the presence of low salt can decrease the activity of PH20. This can create ms for generating PH20 co-formulations.

Provided herein are modiﬁed PH20 ptides that exhibit increased stability in the presence of low concentrations of salt (e. g. NaCl) less than 100 mM, for example, less than 90 mM, 80mM, 70mM, 60 mM, 50 mM, 40 mM, 30 mM, 25 mM, 20 mM, 15 mM, 10 mM, 5 mM or less. Generally, the modiﬁed PH20 polypeptides provided herein exhibit stability in the presence of low concentrations of salt, for e, low concentrations ofNaCl of between or about between 10 mM NaCl and 100 mM NaCl, such as between or about between 15 mM to 80 mM NaCl. The modiﬁed PH20 polypeptides provided herein that exhibit stability at low concentrations of salt, such as low concentrations ofNaCl (i.e., less than 100 mM or less), exhibit increased hyaluronidase activity compared to the corresponding PH20 not containing the modiﬁcation(s) (e.g., amino acid ements). For example, WO 2013/102144 PCT/US2012/072182 modiﬁed PH20 polypeptides exhibit greater than or about 10% increased activity, such as greater than or at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500% or more of activity at low concentrations of salt, such as low trations of NaCl (i.e., less than 100 mM), compared to the actiVity of the corresponding PH20 not containing the amino acid modiﬁcation(s) (e.g., amino acid replacement(s) under the same conditions). For example, modiﬁed PH20 polypeptides exhibit greater than or at least about 1.1-fold the hyaluronidase activity, such as r than or at least 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold or more of actiVity at low concentrations ofNaCl less than 100 mM compared to the actiVity of the corresponding PH20 not containing the amino acid modiﬁcation(s) (e.g., amino acid replacement(s) under the same ions. 2. ve Mutants Provided herein are modiﬁed PH20 polypeptides that contain one or more amino acid replacements in a PH20 ptide and that are inactive, Whereby the ptides do not t hyaluronidase actiVity or exhibit low or diminished hyaluronidase activity. The modiﬁed PH20 polypeptides provided herein that are inactive generally exhibit less than 20%, such as less than 10%, of the hyaluronidase actiVity of a Wildtype or reference PH20 polypeptide, such as the polypeptide set forth in SEQ ID NO: 3 or 7. For example, modiﬁed PH20 polypeptides provided herein that are inactive t less than 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05% or less of the onidase activity of a Wildtype or reference PH20 polypeptide, such as the corresponding polypeptide not containing the amino acid modiﬁcation (e. g. , amino acid replacement), for example, a polypeptide set forth in SEQ ID N03 or 7.

For example, provided herein are PH20 polypeptides that are inactive and that are modiﬁed, for example by amino acid replacement or substitution, ed to a Wildtype or reference PH20 polypeptide. For example, a modiﬁed PH20 polypeptide provided herein that is inactive contains one or more amino acid replacements at position(s) corresponding to position 2, 3, 4, 5, 6, 7, 8, 9,10,11,12,13,14,15,16,17,18,19, 20, 21, 22, 23, 25, 27, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 94, 95, 96, 98, 99, 100, 101, 102, 103, 104, 105, 106,107, 9,110,111,112,113,114,115,116,117,118,119,121,122,123,124,125,126,127, 128,129,130,131,132,133,134,135,136,137,138,139,143,144,145,149,150,152,153, 154,155,156,157,158,159,161,163,164,165,166,167,168,169,170,171,172,173,174, 175,176,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194, WO 2013/102144 PCT/US2012/072182 195,197,198,199, 200, 201, 202, 203, 204, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 278, 279, 280, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 331, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 408, 410, 411, 412, 413, 414, 415, 416, 417, 419, 420, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 434, 437, 438, 439, 440, 441, 442, 443, 444, or 447 With reference to amino acid positions set forth in SEQ ID NO:3, so long as the resulting modiﬁed PH20 polypeptide is inactive and exhibits less than 20%, and generally less than 10%, of the hyaluronidase activity of the ponding PH20 polypeptide not containing the amino acid replacement. Typically, the amino acid residue that is modiﬁed (e.g., replaced) at the position corresponding to any of the above positions in a PH20 polypeptide is an identical residue, a conservative residue or a semi-conservative amino acid residue to the amino acid e set forth in SEQ ID NO:3.

Exemplary amino acid replacements at any of the above corresponding positions are set forth in Table 5. Reference to corresponding position in Table 5 is With reference to positions set forth in SEQ ID NO:3. It is understood that the replacements can be made in the corresponding on in another PH20 polypeptide by alignment therewith With the sequence set forth in SEQ ID NO:3 (see e.g., Figures 1 and 2), y the corresponding position is the d position. The amino acid replacement(s) can be at the corresponding position in a PH20 polypeptide as set forth in any of SEQ ID NOS: 2, 3, 6-66, 68-72, 856- 861, 869 or 870 or a variant thereof having at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 86%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, so long as the resulting modiﬁed PH20 polypeptide is inactive. For example, the replacement(s) can be in a corresponding position in a human PH20 polypeptide, for e, any set forth in any of SEQ ID NOS: 3, 7, 32-66, 69 or 72, or a variant thereof.

In particular, any one or more of the replacements are in SEQ ID NO:3, so long as the resulting modiﬁed PH20 ptide is inactive and exhibits less than 20%, and generally less than 10%, of the hyaluronidase activity of the PH20 polypeptide set forth in SEQ ID NO:3 WO 02144 PCT/US2012/072182 — 140 - TABLE 5: Inactive Mutants Corres— Replacement Corres— Replacement Corres- Replacement ponding g ponding Position on Position iHKWY 3 A G K P T V 4 DEFGLPWY U} DGILMNPQR 6 E F T V Y 7 CDFGHIKLQ TVWY RSTWY SW 9 C D E G N P 10 FILRAY ACFILPTWY 12 G H W 13 EGILMV AEGHKNPQW 15 EFGKNPQRS 16 ACDEFGHK h< MPRSTY p—l N |DEGHILNPQ m LMP 19 ACFGHILMP RSTVWY QSTVY QRSVWY NO DEFHKLNPR 21 ACDEGHILM 22 CEGKP TVY RSTVW NU.) AFLMNPRST 25 DEFGHIKLN 27 C PRSTVY U.) U.) CDHNVY M ILNSTV 35 ADGPRS U.) ON CFVWY W CEGNS 38 EGKLNQRT W U.) 0 CDFW m ADEGKNRST m Q V L"ﬁllN DEHIKLMPQ B AEFGIKLQR M ACFGHILNQ RSTV V RSTWY 4; L11 ADFGPW % PW M V H00 P @ CDGHP w V CFIMPTWY 52 CEFWY B ACDEGHLNP QRSTWY L11 4; DEGPRY 55 QRT % ACEGHIKLP VY RSTVW 57 ADFGIMPQR % A w AEILMPRTV < 2 WY w ADFGHILNP 61 AEFGHNPQR a LMP QSTVY TWY QRSTVY 63 CGP M ACDEFGHIK w ACDGHIKNR LPQRSTVW STVWY ON ON ACDEGIKLN m DEGPRTW w ACGILPVY PSTV Ox0 Z._] IINIIIIIIIEIIIII n P NN CFHIPVW B P B DGP NON A CFGIKLPQ W DELPQRTV m ADIMPTY RSTVW Co‘ A DFGHKNPS w ADEFGIKLM m ACEGHLNPS 2 < NRSTVY VWY 00N YEK M Y w ACDEFGHN QST 00 ON CP m P 88 ACEFGIKLM PRSTVY 00O ADEGQSTWY % CG 91 DEFGHILT ON EFHKPQRWY % GP 95 ACEFGHKL MPQSVWY 96 SVHPRSTW IINIIIIIIEIIIII 99 CEGINPVW 100 CEFGNPRST M1 ACFHIKLMN 102 P WY QRST VV()2013/102144 PCT/US2012/072182 —141— M3 AEFGHILQRT 1% FPW 1% CMN VWY 1% ACDFHLMNP 1W ACHKPQSVW 1% DEFKLMPQT SWY VY 1% CDELMRTW 1m FKLMPW 1M HIQ 1H CEGHLNPS 18 7:1 < 1H ILPTV ACDFGHIKL 1M ACDEGHILN 1H DGIKNQRSV MRSVY PQSVW W 1% CDEGPRWY 1w AKILNPR 1m ACEFGHKL MPWY 1% ACEFIKQRS IB ACDEHLMPQ 1% CDEFN RSTVY 1% ma w< 1% FHILNPY 1m K 1% 1" LPQ 1% CDGHLNST STVW WY Bl "U BZ P 1% DEFGHLMNP RTVW B4 ACDFGHKPQ P 1% 1% RSW 1W FGHNPRWY lull 1% 1% P 1% CHPRST IM- AEFIKPQSV 1% TW Y 1" IEEHIIIIIEIIIII 1w V lﬂ lﬂﬂﬂﬁﬂﬂ'l 1M DEGPSWY 1% "U 1-< 1M ACDEGHIKL V 1% DKPRY IEEIIIIIIWH'III 18 W 18 O "U m4 NPQ 1% CHPT R 1% U 1m V 1% ACDEFGKLP RSVWY m9 ADFGHKNPQ N0 CDEGMPWY 1% CDHMNRSW STY Y 1n TVW 1B DEGHILMPS 1M P Y VWY 1% CDGKPRS 1% ACEFGHIPQ 1W ACDFGHLM STVW QRSTVW 178 EILVW 1% ACEPRS 1% ACDEFHIKL RS m2 ACDEHNPQR m3 CDEGIKNPQ 1M ACDEFGHKL STVY RSV MPRSV 1% ADEFGIKPRS 1% ADGHIKLNP 1W AFGHILMNQ TVWY QRSVW RSTVWY 1% ACFGHLMNP 1W AEGHKLMNP 1% CEFGHKLNQ QRSTVW RSTVWY RSTVW 1% AEFGKLMPQ CFGKLMNPQ 1% 1% ADKLMPV RSTVWY RVWY 1% ACILPSTV ll 1% 1W C 1% < 2 1% EGHIKLPRS m0 AFGHKLMP W QRSWY N1 AFLMNPRST m2 AEFGHKNPQ m3 ADEGHLMN VW RVWY QRSTV m4 ACEGHIKQR 2% CDFGPY m7 AFGMPQRST ST VW 208 DGPW 209 (:P 2m ACDEGKMN PSTVWY WO 2013/102144 PCT/US2012/072182 211 CFGHIKMPR M2 MPV 213 PS STVW W M4 ACDEGHKNP 25 CP 216 DEGHIKLMN RSTY PQRTV M7 ACGHPQSTV 2m AIKLPSV 219 P W no GKNPRW 2M DEHKPR 222 PY M3 CDEGHKLPQ M4 ADEFGMPQR 225 ADEGHKPQ RSTVWY STWY RTVW M6 ACDEFGLNQ M7 AFGHIKLMP 228 AEFGHLMNP RSTVWY QRTVWY RSTW M9 EFGKLPQTV 2m AEGHKMNPR 231 ACDFGHIKL W STVWY PQRSV M2 CGHKLNPQV 233 DIPST‘ 234 ADEGHNPST Y VW IIEEIIIEEMEMHIII 2% CILNQTY 238 FGLPVWY M9 CFGHILPRST M0 EFGNWY 241 ACDEGIPRS VWY TVW M2 MPR 2% CDFGHLMPQ M4 ADGIVY STVW RSWY 2% ACFLPQRST M6 ACDEGHIKL 247 ACFHNPQRS V MPSTVW TWY M8 PT M9 AGHIKMQSY 250 CFGHKLMN PQRSTVW M1 DFGHKPSTW 2Q ADEFGHIKL 253 ADEGHLMN NPSTY QRSW 2M CDEGIKLPQ 255 CDLPVW 256 CDEG[ RTVWY I!257 258 LPVW 260 CP 261 M2 ADEGHIKQR 263 EFPQW STVWY 2M DEFGLMRTV 265 ADFGHKLM 266 QR WY NQRS STVW M7 DGHIKNRSW 268 ACFGHKLNP 269 EKLMNPQR QSTVW 272 HLNPW 2B ACDGILPQS 275 AFGIKLMQT VW VW 279 ACFGLWY M1 ADGHIKNPQ 282 FLVWY RSVW 284 CIP 286 ACDFHKMPT 287 ACDEGKLNP Y QRS M8 DEFGHIKPRT 289 ACEGHLPQR 290 DQY SY 2m ACDEFMNTW 292 ILT 293 EN Y M4 NPQ 296 CFGIKMQRS RSTW Y TVWY M7 CEHLNPQRS 299 ACDFGHLM TY WY PQT m0 ACDEFLMNP 301 EGHKMNPQR 302 CDEFGHLMP QSTVW SWY RSTY 303 ACDEFGKLM 304 ACDGIMNPQ 305 LPQRSTVY RWY STVY WO 2013/102144 PCT/US2012/072182 —143— IEMIIIEEEEEMMHII 308 CFLMVWY IIEEIIIIEEEEEIII 312 CEMVW IIHEIIIIIIEIIIII 315 CIV 3m EGIKLMPRST 318 CPW VWY B9 KMP 320 CPV 321 EMP QRSVWY B2 CDEGILNPRS 323 ACEGHKNRS 324 CFPVWY TVW TV 3B CREGHNW B7 AEFGHNQRS 329 CFGHIKLNQ TVWY RSTVWY B0 ACDEGILMN B1 ACDEFHKQR 332 ACDEFGHKL PRSVW STWY NPRSTY 3B GHIKPRSTW 334 ACDEGMNRS 335 FGHIKLPVW Y Y B6 AEFGKNPRS 338 CDEFGHIKL TVWY W PRTV B9 DEFGHLNPS 341 AEGHKLMN TVWY RSTVW QRSTVY B2 DEFHKLMPQ B4 FGHLMNPQ RTY RSTWY 3% ACEHKNQRT 346 ADFGIKLMP 347 CFIPTVW VY RSTVW 3M CHILPQRTV 349 DFGPVWY 350 ADEFHKLM WY NPRSTVY 3B RWY 352 ADEFGKMPQ 353 CFGHKLMQ RSTVWY RSW B4 CDEGHIKLM 355 NPQ 356 CGKLPRTV PQSVWY RSTVWY W ﬂﬂﬁlﬂﬂﬂﬂﬂl 359 AFGLPW 3w KLM 361 ACEGMNPQR 362 ACEGHKLM PQRV SVW NPRSTVW 3B ACDEFGHIP 364 ACDEFGKLM 365 ACDEGMNP QRSTVW PRSTVY QRSTWY B6 ACEFGKMPQ 368 CPW RTW 3w CEFIKLPQV 370 ADEGHKLNP 371 P W QRSVY B2 ADEFGHKLN 373 CPW 374 DE PRSTVW Ilﬁﬂllllﬂﬂﬁﬂﬂlll 377 CILV B8 DEFILMQTWI 380 CDEGQRS Y 3m GLPWY 382 EGHKLMNPQ 383 GP RSTWY 3M CFMQST 385 CLMPWY 386 ACFGHILMN QRSTVY B7 CEFGHILMN 3B CGPQ 389 FV VWY B0 ACEFGHLNP B1 PQR 392 CP RSTVWY STVWY 393 (:P B4 ADEGIKNPQ 395 CB[ RSTV B6 CFGIPY 397 ACEFGILMP 398 ACEGHILNP QTV RSTVWY 399 D P 400 ADEFGILMP 401 CFHKRWY WO 2013/102144 PCT/US2012/072182 — 144 — III-Illﬂﬁﬁﬂﬂll m2 ADEFLMPQR m3 ACEGHKLM m4 CDFGHLMN STVWY NPQRT RVWY «5 CIV 406 PR 408 AEFGIKLPR STVWY Ilﬂﬂllllﬂﬂﬂiﬂlll 412 EH IIHEIIEDEEEKEEH 415 CDEP 4n ADEFGHKMP 419 DP QR no ADFGHKLNR 02 CDGHLMNQ 423 LMP STWY RSY QRSTVW m4 ACEGHNQRS 425 ELPWY 426 CFMR WY 4% ACFLPVWY 428 NRS 429 ADKLNPSTV K: WY m0 ADELMNSTV m1 432 CFIKLMPY m4 HKPQRW m7 B8 Y m9 z7:1 4% M1 R 4m MNS l!!! 4m 3. Additional Modiﬁcations and Conjugates The modiﬁed PH20 polypeptides include those that contain chemical or posttranslational modiﬁcations. In some examples, modiﬁed PH20 polypeptides provided herein do not contain chemical or posttranslational modiﬁcations. Chemical and post- translational modiﬁcations include, but are not limited to, tion, sialation, albumination, glycosylation, famysylation, ylation, hydroxylation, orylation, and other polypeptide modiﬁcations known in the art.

Also, in addition to any one or more amino acid modiﬁcations, such as amino acid replacements, provided herein, modiﬁed PH20 polypeptides provided herein can be conjugated or fused to any moiety using any method known in the art, including chemical and inant methods, provided the resulting ptide s hyaluronidase activity. For example, in addition to any one or more amino acid modiﬁcations, such as amino acid replacements, provided herein, modiﬁed PH20 ptides provided herein also can contain other modiﬁcations that are or are not in the primary sequence of the polypeptide, including, but not limited to, modiﬁcation With a carbohydrate moiety, a polyethylene glycol (PEG) moiety, a sialic acid moiety, an F0 domain from immunoglobulin G, or any other domain or moiety. For example, such additional ations can be made to increase the stability or serum half-life of the protein.

In some instances, the domain or other moiety is a targeted agent, including any agent that targets the conjugate to one or more cell types by selectively binding to a cell surface receptor or other cell surface moiety. For e, the domain or other moiety is a targeted agent that targets the conjugate to tumor cells. In such examples, a modiﬁed PH20 WO 2013/102144 PCT/US2012/072182 —145— polypeptide, such as any provided herein, is linked directly or indirectly to a targeted agent.

Such targeting agents include, but are not d to, growth factors, cytokines, chemokines, antibodies, and hormones, or allelic variants, muteins, or fragments f so long as the targeting agent is internalized by a cell surface receptor. Exemplary, non-limiting, additional modiﬁcations are described below. a. Decreased immunogenicity The modiﬁed PH20 polypeptides provided herein can be made to have decreased immunogenicity. Decreased immunogenicity can be ed by sequence changes that elimiminate antigenic epitopes from the polypeptide or by altering post-translational modiﬁcations. One of skill in the art is familiar with methods of identiﬁying antigenic epitopes in a polypeptide (see e.g., Liang et al. (2009) BMC Bioinformatics, 10:302; Yang et al. (2009) Rev. Med. Virol., 19:77-96). In some examples, one or more amino acids can be modiﬁed in order to remove or alter an antigenic epitope.

In another example, altering the glycosylation of a protein also can effect immunogenecity. For example, altering the glycosylation of the peptide is contemplated, so long as the polypeptides minimally contain at least N-acetylglucosamine at amino acid es corresponding to amino acid residues set forth as N200, N333 and N358 of SEQ ID N03 or 7.

For example, the PH20 polypeptides can be modiﬁed such that they lack fucose, particularly sylation. In particular, the PH20 polypeptides provided herein are not bifucosylated. This can be ed by expressing and producing the PH20 polypeptide in host cells that do not effect bifucosylation. Fucose is a deoxyhexose that is present in a wide variety of sms, including mammals, s and plants. lated glycans are synthesized by l-transferases; see, e. g., Ma et al., Glycobiology, 16(12):158R-l 84R, (2006); Nakayama et al., J. Biol. Chem, 276:16100-16106 (2001); and Sturla et al., Glycobiology, 15(10):924-935 (2005). In humans, fucose ntly exists as a terminal modiﬁcation to glycan structures, and the presence of fucose (x1,6-linl acetylglucosamine has been shown to be important in rotein processing and recognition. In insects, N-glycan core ures t bifucosylation with 0t],6- and (11,3- linkages. Insect cell core fucosylation with 0t],3-linkages generates a carbohydrate epitope that is immunogenic in humans (see, e.g., US Publication No. 20070067855). For e, PH20 polypeptides provided herein can be generated in host cells that are incapable of bifucosylating the polypeptide. Thus, while insect cells or other cells that bifucosylate can be used for expression of the polypeptides, typically mammalian cells, such as CHO cells, are used.

WO 2013/102144 PCT/US2012/072182 In some examples, defucosylated, or fucose-deﬁcient PH20 ptides can be generated in insect cells with modiﬁed glycosylation pathways, through the use of baculovirus expression vectors containing eukaryotic oligosaccharide processing genes, thereby creating "mammalianized" insect cell expression s (see, e.g., US Patent No. 6,461,863). Alternatively, antigenicity can be eliminated by expression of PH20 polypeptides in insect cells g al,3-fucosylatransferase (FT3) (see, e.g., US Publication No. 20070067855). In other examples, defucosylated or fucose-deﬁcient PH20 polypeptides can be generated, for example, in cell lines that produce defucosylated proteins, including Lec13 CHO cells deﬁcient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533- 545 (1986); U.S. Pat. Pub. No. 2003/0157108; and WO 2004/056312), and knockout cell lines, such as alpha-1,6-ﬁJcosyltransferase gene, FUT8, ut CHO cells (Yamane- Ohnuki et al. h. Bioeng. 87: 614 (2004)). b. Conjugation to polymers In some examples, the modiﬁed PH20 polypeptides provided herein are conjugated to polymers. ary polymers that can be conjugated to the PH20 polypeptides, include natural and synthetic homopolymers, such as polyols (i.e., poly-OH), polyamines (i.e., poly- NH2) and polycarboxylic acids (i.e., poly-COOH), and further heteropolymers, i.e., polymers containing one or more different coupling groups, e.g., hydroxyl groups and amine groups.

Examples of suitable polymeric les include polymeric molecules selected from among polyalkylene oxides (PAO), such as polyalkylene glycols (PAG), including polyethylene glycols (PEG), methoxypolyethylene glycols (mPEG) and polypropylene glycols, PEG- glycidyl ethers (Epox-PEG), PEG-oxycarbonylimidazole EG), ed polyethylene glycols (PEGs), polyvinyl alcohol (PVA), rboxylates, polyvinylpyrrolidone, ,L- amino acids, polyethylene-co-maleic acid anhydride, polystyrene-co-maleic acid anhydride, ns including carboxymethyl-dextrans, heparin, homologous albumin, celluloses, including methylcellulose, carboxymethylcellulose, ethylcellulose, hydroxyethylcellulose, carboxyethylcellulose and hydroxypropylcellulose, ysates of chitosan, starches such as hydroxyethyl-starches and hydroxypropyl-starches, glycogen, agaroses and derivatives thereof, guar gum, pullulan, inulin, n gum, carrageenan, pectin, alginic acid hydrolysates and bio-polymers.

Typically, the polymers are polyalkylene oxides (PAO), such as polyethylene oxides, such as PEG, typically mPEG, which have few reactive groups capable of cross-linking.

Typically, the polymers are non-toxic polymeric molecules such as xy)polyethylene glycol (mPEG) which can be ntly conjugated to the PH20 polypeptides (e.g., to attachment groups on the protein surface) using a relatively simple chemistry.

WO 2013/102144 PCT/US2012/072182 —147— Suitable polymeric molecules for attachment to the PH20 polypeptides include, but are not limited to, hylene glycol (PEG) and PEG derivatives such as y— hylene glycols (mPEG), ycidyl ethers (Epox-PEG), PEG-oxycarbonylimidazole (CDl-PEG), branched PEGs, and polyethylene oxide (PEO) (see e.g., Roberts et al., Advanced Drug Delivery Review 2002, 54:459-476; Harris and Zalipsky (eds.) "Poly(ethylene glycol), Chemistry and Biological Applications" ACS Symposium Series 680, 1997; Mehvar et al., J.

Pharm. ceut. Sci, 3(1):125-136, 2000; Harris and Chess (2003) Nat Rev Drug Discov. 2(3):214-21; and Tsubery, J Biol. Chem 279(37):38118-24, 2004). The polymeric molecule can be of a molecular weight typically ranging from about 3 kDa to about 60 kDa. In some embodiments the polymeric molecule that is conjugated to a PH20 polypeptide ed herein has a molecular weight of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 or more than 60 kDa.

Various methods of modifying polypeptides by covalently attaching (conjugating) a PEG or PEG derivative (i. e., "PEGylation") are known in the art (see e.g., US. 104968; US. 5,672,662; US. 6,737,505; and US. 2004/0235734). Techniques for PEGylation include, but are not limited to, lized linkers and coupling chemistries (see e. g., s, Adv. Drug Deliv. Rev. 54:459-476, 2002), attachment of multiple PEG moieties to a single conjugation site (such as via use of branched PEGs; see e.g., Guiotto et al., Bioorg.

Med. Chem. Lett. 12:177-180, 2002), site-speciﬁc PEGylation and/or EGylation (see e. g., Chapman et al., Nature Biotech. 17:780-783, 1999), and site-directed enzymatic PEGylation (see e. g., Sato, Adv. Drug Deliv. Rev., 54:487-504, 2002) (see, also, for example, Lu and Felix (1994) Int. J. Peptide Protein Res. 43:127-138; Lu and Felix (1993) Peptide Res. 6:140-6, 1993; Felix et al. (1995) Int. J. Peptide Res. 46:253-64; Benhar et al. (1994) J. Biol.

Chem. 269:13398-404; nu et al. (1995) ol. 154:3088-95; see also, Caliceti et al. (2003) Adv. Drug Deliv. Rev. 55(10):1261-77 and Molineux (2003) Pharmacotherapy 23 (8 Pt 2):3S-8 S). s and techniques described in the art can produce proteins having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 PEG or PEG derivatives attached to a single protein molecule (see e.g., US. 2006/0104968).

Numerous reagents for PEGylation have been described in the art. Such reagents include, but are not limited to, N—hydroxysuccinimidyl (NHS) activated PEG, succinimidyl mPEG, mPEG2-N-hydroxysuccinimide, mPEG succinimidyl alpha-methylbutanoate, mPEG succinimidyl propionate, mPEG succinimidyl butanoate, mPEG carboxymethyl 3- hydroxybutanoic acid succinimidyl ester, homobifunctional PEG-succinimidyl propionate, homobifunctional PEG propionaldehyde, homobifunctional PEG butyraldehyde, PEG maleimide, PEG hydrazide, p-nitrophenyl-carbonate PEG, mPEG-benzotriazole carbonate, WO 2013/102144 PCT/US2012/072182 propionaldehyde PEG, mPEG butryaldehyde, ed mPEG2 butyraldehyde, mPEG acetyl, mPEG piperidone, mPEG methylketone, mPEG "linkerless" maleimide, mPEG Vinyl sulfone, mPEG thiol, mPEG orthopyridylthioester, mPEG orthopyridyl disulﬁde, Fmoc-PEG-NHS, Boc-PEG-NHS, Vinylsulfone PEG-NHS, acrylate PEG-NHS, ﬂuorescein PEG-NHS, and biotin PEG-NHS (see e.g., Monfardini et al., Bioconjugate Chem. 6:62-69, 1995; Veronese et al., J. Bioactive Compatible Polymers -207, 1997; US. 5,672,662; US. 5,932,462; US. 6,495,659; US. 6,737,505; US. 531; US. 4,179,337; US. 614; US. ,324,844; US. 090; US. 5,612,460; US. 5,643,575; US. 5,766,581; US. 569; US. 5,808,096; US. 5,900,461; US. 5,919,455; US. 5,985,263; US. 5,990,237; US. 6,113,906; US. 6,214,966; US. 6,258,351; US. 6,340,742; US. 6,413,507; US. 6,420,339; US. 6,437,025; US. 6,448,369; US. 6,461,802; US. 6,828,401; US. 6,858,736; US. 2001/0021763; US. 2001/0044526; US. 2001/0046481; US. 2002/0052430; US. 2002/0072573; US. 2002/0156047; US. 114647; US. 2003/0143596; US. 2003/0158333; US. 2003/0220447; US. 2004/0013637; US 2004/0235734;; US. 2005/0114037; US. 2005/0171328; US. 2005/0209416; EP 1064951; EP 0822199; WO 01076640; WO 0002017; WO 3; WO 9428024; WO 0187925; and WO 2005000360).

D. METHODS FOR IDENTIFYING MODIFIED HYALURONAN-DEGRADING ENZYMES WITH ALTERED PROPERTIES OR ACTIVITIES Provided herein are methods for identifying a modiﬁed or variant onan- degrading enzyme, such as a modiﬁed hyaluronidase or modiﬁed PH20 polypeptide, that exhibits an altered activity or property compared to an unmodiﬁed hyaluronan-degrading enzyme. In particular, the methods provided herein can be used to screen for one or more modiﬁed hyaluronan-degrading enzymes, such as one or more d onidase or PH20 polypeptide, that exhibits increased actiVity and/or increased stability in the presence of a denaturation agent or condition. For example, the methods can be used to identify a modiﬁed or variant hyaluronan-degrading enzyme, such as a modiﬁed or variant hyaluronidase or modiﬁed or variant PH20 ptide, that exhibits increased stability by virtue of increased resistance to denaturation conditions, including but not limited to, ration conditions caused by temperature (e.g., elevated temperature such as heat), agitation, no or low salt, presence of an excipient and/or a ring agent. Exemplary denaturing agents or excipients include, but are not limited to, antiadherents, binders, coatings, ﬁllers and diluents, ﬂavors, , lubricants, glidants, preservatives, sorbents or sweeteners. For example, various ents, such as preservatives, can act as protein denaturing agents. In the method, the actiVity also can be compared to an ﬁed hyaluronan-degrading enzyme under the same denaturation condition, and a modiﬁed WO 2013/102144 PCT/US2012/072182 —149— hyaluronan-degrading enzyme identiﬁed or selected that exhibits greater activity than the corresponding unmodiﬁed hyaluronan-degrading enzyme.

In the method, one or more modiﬁed hyaluronan-degrading enzymes are provided. In some examples, a library ofmodiﬁed molecules is ed. Methods of mutagenesis and generation of libraries or collections of t molecules is described herein and is known to one of skill in the art using standard recombinant DNA techniques. In one example, the enzymes that are tested can be pooled and screened, whereby the method permits selection of only those enzymes that exhibit a desired activity. In r example, the tested enzymes can be physically separated and screened individually, such as by formatting in arrays, such as addressable arrays.

In one aspect of the method, the modiﬁed hyaluronan-degrading enzymes are tested or screened for hyaluronidase activity in the presence and absence of one or more denaturation conditions or denaturing agent. After testing under both sets of ions, the activities are assessed in order to identify modiﬁed hyaluronan-degrading enzymes that exhibit activity in the presence of the denaturation condition. The desired level or amount of ty selected as a cut-off in the methods can be empirically determined by the user, and is dependent on factors such as the particular onan-degrading enzyme, the desired application or use of the hyaluronan-degrading enzyme, the particular ration condition or denaturing agent and other similar factors. Typically, a modiﬁed hyaluronan-degrading enzyme is identiﬁed that exhibits at least 5% or 10% of the activity in the presence of a denaturing agent or ion ed to in its absence, and generally at least 15%, 20%, %, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, for example at least 40% of the activity.

Additionally or alternatively, the activity of the modiﬁed hyaluronan-degrading enzyme in the presence of one or more denaturation conditions or denaturing agents is compared to the activity of the corresponding unmodiﬁed hyaluronan-degrading enzyme in the presence of the same denaturation agent(s) or ion(s). In such es, it is understood that the ty of the modiﬁed and ﬁed enzyme are tested under the same conditions (e.g., time, temperature, composition), except for the difference in the particular enzyme tested (unmodiﬁed versus modiﬁed). A modiﬁed hyaluronan-degrading enzyme is identiﬁed that exhibits greater activity, such as at least 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, 300%, 400%, 500% or more ofthe activity ofthe unmodiﬁed hyaluronan-degrading .

The method can be performed a plurality of times, Whereby the steps of the method are repeated 1, 2, 3, 4, or 5 times. The method provided herein also is iterative. In one WO 2013/102144 PCT/US2012/072182 example, after the method is performed, any identiﬁed modiﬁed hyaluronan-degrading enzyme can be modiﬁed or further modiﬁed to increase or optimize the activity.

A description of the steps of the method and components of the method are provided in the subsections that follow. 1. Hyaluronan-Degrading Enzymes and Libraries of Modiﬁed Hyaluronan- Degrading Enzymes In the methods herein, one or more modiﬁed onan-degrading enzymes, such as a hyaluronidase or a PH20 polypeptide, are tested for a desired activity or property, such as increased stability (e. g., increased resistance to a denaturation condition). The modiﬁed hyaluronan-degrading enzyme can be d compared to an unmodiﬁed hyaluronan- degrading enzyme, such as any hyaluronan-degrading enzyme known in the art. Hyaluronandegrading enzymes are a family of enzymes that degrade hyaluronic acid, which is an ial component of the extracellular matrix and a major tuent of the interstitial barrier. onan-degrading enzymes act to degrade hyaluronan by cleaving hyaluronan polymers, which are composed of repeating disaccharides units: uronic acid (Gch) and N—acetyl-D-glucosamine (GlcNAc), linked together via alternating B-l—>4 and B-l—>3 glycosidic bonds. By catalyzing the hydrolysis of hyaluronic acid, a major constituent of the interstitial barrier, hyaluronan-degrading enzymes lower the viscosity of hyaluronic acid, thereby increasing tissue bility. Accordingly, hyaluronan-degrading enzymes for the uses and methods provided herein include any enzyme having the ability to catalyze the cleavage of a onan disaccharide chain or polymer. In some es, the hyaluronan- ing enzyme cleaves the B-1—>4 glycosidic bond in the hyaluronan chain or polymer. In other examples, the hyaluronan-degrading enzyme catalyzes the cleavage of the B-l—>3 glycosidic bond in the hyaluronan chain or polymer.

Hyaluronan-degrading enzymes include enzymes that are membrane-bound or that are soluble forms that are secreted from cells. Thus, where hyaluronan-degrading enzymes e a glycosylphosphatidylinositol (GPI) anchor signal sequence and/or are otherwise ne-anchored or insoluble, such hyaluronan-degrading enzymes can be provided in e form by C-terminal truncation or deletion of all or a portion of the GPI anchor signal sequence to render the enzyme secreted and soluble. Thus, hyaluronan-degrading enzymes include C-terminally truncated variants, e.g., truncated to remove all or a portion of a GPI anchor signal sequence. es of such soluble hyaluronidases are soluble PH20 hyaluronides, such as any set forth in US. Patent No. 7,767,429; US. Publication Nos. US 2004/0268425 and US 2010/0143457.

WO 2013/102144 PCT/US2012/072182 -l5l- Exemplary hyaluronan-degrading enzymes are non-human animal or human hyaluronidases, bacterial hyaluronidases, hyaluronidases from leeches or chondroitinases that exhibit onan-degrading activity, including soluble or truncated forms thereof that are active. ary non-human animal hyaluronidases are any set forth in any of SEQ ID NOS: 8-31, 856-861, 869, 870, 6, or mature, C-terminally truncated variants that are e and active, or active forms thereof. Exemplary human hyaluronidases are any set forth in any of SEQ ID NOS: 2, 3, 6, 7, 32-66, 68-72 or 887-890, or mature, C-terminally truncated variants that are soluble and active, or active forms thereof, and in ular any of SEQ ID NOS: 3, 7, 32-66, 69 or 72. Exemplary bacterial hyaluronidases are any set forth in any of SEQ ID NOS: 891-919 or mature, C-terminally truncated variants that are soluble and active, or active forms thereof. Exemplary hyaluronidases from s are set forth in SEQ ID NO:920 or 921, or mature, C-terminally ted variants that are soluble and , or active forms thereof Exemplary chondroitinases that have hyaluronan-degrading enzyme actiVity are set forth in SEQ ID NO:922-924, or mature, C-terminally truncated variants that are soluble and active, or active forms thereof.

For example, one or more modiﬁed PH2O polypeptides are tested for a d actiVity or property, such as sed stability (e. g. , increased resistance to a denaturation condition). The modiﬁed PH2O polypeptide can be modiﬁed compared to an unmodiﬁed PH2O polypeptide, such as any known PH2O polypeptide native, wildtype or reference polypeptide. For example, the modiﬁed PH2O polypeptide is modiﬁed compared to a full- length, soluble or active form of a PH2O ptide, such as any set forth in any of SEQ ID NOS: 3, 7, 32-66, 69 or 72, or a polypeptide that exhibits at least 85%, such as at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS: 3, 7, 32-66, 69 or 72. In particular examples ofthe method herein, the starting or unmodiﬁed PH2O ptide has the sequence of amino acids set forth in SEQ ID NO:3.

Libraries or collections ofmodiﬁed hyaluronan-degrading s can be screened.

Hyaluronan-degrading enzymes can be modiﬁed by any process known to one of skill in the art that can alter the structure of a protein. Examples of modiﬁcations include replacement, addition, and on of one or more amino acids of the protein to form libraries or collections of modiﬁed hyaluronan-degrading enzymes. It is within the level of one of skill in the art to generate modiﬁed or variant proteins for use in the methods . Methods of mutagenesis are well known in the art and include, for example, site-directed mutagenesis such as for example QuikChange (Stratagene) or saturation mutagenesis. Mutagenesis methods include, but are not limited to, site-mediated mutagenesis, PCR mutagenesis, cassette WO 2013/102144 2012/072182 mutagenesis, site-directed mutagenesis, random point mutagenesis, mutagenesis using uracil containing templates, oligonucleotide-directed mutagenesis, phosphorothioate-modiﬁed DNA mutagenesis, mutagenesis using gapped duplex DNA, point mismatch repair, mutagenesis using repair-deficient host strains, restriction-selection and restriction-puriﬁcation, deletion mutagenesis, mutagenesis by total gene synthesis, double-strand break repair, and many others known to persons of skill. In the methods , mutagenesis can be effected across the full length of a protein or within a region of a protein. The mutations can be made rationally or randomly.

In some examples, the methods provided herein are performed such that the identity of each mutant protein is known a priori before the protein is . For example, the methods provided herein can be conducive to mutagenesis and screening or testing methods that are addressable. This can permit the ease of comparisons between the activities of tested proteins without the need for sequencing of identified proteins. For e, site-directed mutagenesis methods can be used to individually generate mutant proteins. Mutagenesis can be performed by the replacement of single amino acid residues at specific target positions one-by-one, such that each individual mutant generated is the single product of each single mutagenesis reaction. Mutant DNA les can be designed, generated by nesis and cloned individually, such as in addressable arrays, such that they are physically separated from each other and each one is the single t of an independent mutagenesis reaction.

The amino acids selected to replace the target positions on the particular protein being optimized can be either all of the remaining 19 amino acids, or a more restricted group containing only selected amino acids. In some methods provided herein, each amino acid that is replaced is independently replaced by 19 of the remaining amino acids or by less than 19 of the remaining amino acids, such as 10, ll, 12, l3, 14, 15, l6, 17 or 18 ofthe remaining amino acids. 2. Screening 0r Testing For A Desired Activity or Property The hyaluronidase ty or other ty of a composition containing a modiﬁed hyaluronan-degrading enzyme is screened or tested under conditions that expose the hyaluronan-degrading enzyme to a denaturation condition or a denaturing agent (presence of denaturation condition or denaturing . The denaturing condition or ring agent need not be a condition or agent that is completely deadly to the enzyme, but generally is any condition or agent that destabilizes enzyme activity over time. For example, the denaturation condition can be a condition caused by ature (6.g. ed temperature such as greater , than or about or 30 0C, for e, 30 0C to 42 0C such as or about 37 oC), agitation, no or WO 02144 PCT/US2012/072182 low salt (e.g., NaCl), and/or caused by the presence of a denaturing agent, such as the presence of excipients (e.g., presence of preservatives).

For purposes of selecting or identifying a modiﬁed hyaluronan-degrading enzyme that exhibits stability or increased stability under the denaturation condition, activity can be compared to activity of the modiﬁed hyaluronan-degrading enzyme in the absence of the denaturation condition and/or activity of the ponding unmodiﬁed hyaluronan-degrading enzyme in the presence of the denaturation condition. For example, the modiﬁed hyaluronan- degrading enzyme also can be screened or tested under the same conditions, except not including a denaturing condition or denaturing agent (absence of denaturation condition or denaturing . If desired, the activity of the corresponding unmodiﬁed hyaluronan- degrading enzyme (e.g., the hyaluronan-degrading enzyme not containing the amino acid replacement(s)) can also be tested under the same conditions that expose the hyaluronan- degrading enzyme to the same denaturation condition or a ring agent.

For example, each member of a library or collection ofmodiﬁed hyaluronan- degrading enzymes is ted under or exposed to one or more denaturation conditions.

The incubation or exposure can occur in vivo or in vitro. Typically, the assay is performed in vitro. The same modiﬁed enzyme also is exposed or incubated to a reference or control condition that does not contain the denaturation condition. The activities under both conditions are compared in order to identify modiﬁed hyaluronan-degrading enzymes that exhibit stability upon re to a denaturation condition or conditions. Further, in screening or identifying the activity of the enzyme under the two different sets of conditions, generally the only conditions that are varied in the assay relate to the presence or absence of one or more denaturation conditions. The other conditions of the assay, including but not limited to, time, temperature and/or other incubation conditions, can be the same for both sets of conditions.

For example, exposure can be achieved by incubation of a d onan- ing enzyme in an assay buffer or ition that has been modiﬁed or adjusted to contain a denaturing agent such as an excipient or low or no salt. ary denaturing agents or excipients include, but are not limited to, antiadherents, binders, coatings, ﬁllers and diluents, ﬂavors, colors, lubricants, glidants, preservatives, sorbents or sweeteners. The choice of buffer that is used can be empirically determined by one skilled in the art depending on the particular parameter or ters being d. Exemplary assay s are Good’s buffers (see e.g., Good et al. (1966) Biochemistry, 5:467-477). Examples of such buffers include, but are not d to ACES, ADA, BES, Bicine, BIS-TRIS, CAPS, HEPES, MES, MOPS, PIPES, TRIS or Trizma® buffers. Further the amount or concentration of the , WO 2013/102144 PCT/US2012/072182 —154— excipient or salt can be empirically determined by one of skill in the art ing on the choice of excipient or salt and the desired level or activity of the d hyaluronan- degrading enzyme.

In one example, the assay buffer or composition is modiﬁed by inclusion of an amount of a denaturing agent or denaturing excipient that is a preservative, for example, a ic preservative. The phenolic preservative can be phenol, metacresol sol), benzyl alcohol, and parabens including methylparaben and propylparaben. In particular, the phenolic vative is phenol and/or m-cresol. The total amount of one or more phenolic preservative agents as a tage (%) of mass concentration (w/v) can be between 0.05% to 0.6%, 0.1% to 0.4%, 0.1% to 0.3%, 0.15% to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 0.3% to 0.4% inclusive. In such an example, the activity of the modiﬁed hyaluronan-degrading enzyme is tested or assessed in the presence of such a total amount (e.g., between or about between 0.05% to 0.6%) of one or more preservatives, for example, one or more phenolic preservatives. In some examples, the modiﬁed hyaluronan-degrading enzyme also can be tested or assessed under a l or reference condition in which the assay buffer or composition is not modiﬁed to contain a preservative. In certain instances, as a control, the activity of modiﬁed hyaluronan-degrading enzymes also can be compared to the corresponding unmodiﬁed hyaluronan-degrading enzyme not containing the ation(s) under conditions that contain a preservative agent and/or under conditions that do not contain a preservative agent.

In another example, the assay buffer is modiﬁed by the presence of a denaturation condition that is low or no salt. As discussed elsewhere herein, onan-degrading enzymes, such as PH20, generally require salt (e.g., NaCl, Lys-Lys or MgClz) for activity.

Hence, the absence of salt or low salt is ring to the enzyme. In one example, the assay buffer is modiﬁed by inclusion of an amount of salt that is less than 100 mM, for example, less than 90 mM, 80 mM, 70 mM, 60 mM, 50 mM, 40 mM, 30 mM, 25 mM, 20 mM, 15 mM, mM, 5 mM or less. In such an example, the activity of the modiﬁed hyaluronan-degrading enzyme is tested in the absence of salt or in the presence of salt that is less than 100 mM. In some examples, the modiﬁed hyaluronan-degrading enzyme also can be tested or assessed under a control or nce condition in which the assay buffer contains a higher salt concentration, generally between or about between 140 mM to 200 mM. In certain instances, as a control, the activity of d hyaluronan-degrading enzymes also can be compared to the corresponding ﬁed hyaluronan-degrading enzyme not containing the modiﬁcation(s) under conditions that contain low or no salt, such as less than 100 mM and/or WO 2013/102144 PCT/US2012/072182 -l55- under conditions that n salt in an amount that is between or about between 140 mM to 200 mM.

Exposure of a hyaluronan-degrading enzyme to a denaturation condition also can be achieved by incubation of a modiﬁed hyaluronan-degrading enzyme under conditions that are known to be denaturing, such as under conditions of ed temperature such as a temperature greater than or about or 30 OC (e.g., 30 0C to 42 0C such as or about 37 °C) or agitation. For example, the actiVity of the modiﬁed hyaluronan-degrading enzyme is tested at elevated temperatures greater than or about or 30 °C to 42 °C. In some examples, the modiﬁed hyaluronan-degrading enzyme also can be tested or assessed under a control or reference condition where the temperatures is less than 30 °C, such as n or about between 0 °C to 25 °C, for example, 0 °C to 5 °C or 18 °C to 25 °C. In n instances, as a control, the activity of modiﬁed hyaluronan-degrading enzymes also can be compared to the corresponding unmodiﬁed hyaluronan-degrading enzyme not ning the modiﬁcation(s) under elevated temperatures greater than or about or 30 °C to 42 °C and/or temperatures is less than 30 °C, such as between or about n 0 °C to 25 °C, for example, 0 °C to 5 °C or 18 °C to 25 0C.

The modiﬁed hyaluronan-degrading enzyme can be d to one or more than one of the conditions. The exposure to one condition can occur simultaneously, subsequently, ittently or periodically to re to one or more other conditions.

In one example, in the method herein, the d hyaluronan-degrading enzyme is incubated or exposed to the denaturation ion or denaturing agent prior to performing an assay for hyaluronidase actiVity. For example, the modiﬁed hyaluronan-degrading enzyme is incubated in the presence of a denaturing agent or exposed to one or more denaturation conditions or control conditions, such as one or more of the denaturation ions or control conditions as described above. The incubation or exposure can be for any desired length of time, and can be empirically determined by one of skill in the art. For example, the modiﬁed hyaluronan-degrading enzyme can be incubated or exposed to one or more denaturation conditions, ring agents or control conditions for or about for] minute to 1 month, such as 1 minute to 3 weeks, 1 minute to 2 weeks, 1 minute to 1 week, 1 minute to 24 hours, 1 minute to 12 hours, such as 30 minutes to 6 hours or 1 hour to 4 hours, and generally at least or about at least 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours or 12 hours. After the time of incubation or exposure, the sample or composition containing the modiﬁed hyaluronan-degrading enzyme (or control unmodiﬁed enzyme) is assessed for hyaluronidase assay. In another example, the modiﬁed hyaluronan-degrading enzyme is exposed or incubated under one or more denaturation WO 2013/102144 PCT/US2012/072182 -l56- conditions and is simultaneously or concurrently ed for hyaluronidase activity. In any examples where a modiﬁed hyaluronan-degrading enzyme is assessed, it is understood that an unmodiﬁed hyaluronan-degrading enzyme not containing the modiﬁcations(s) also can be assessed under similar assay conditions for comparison.

Assays to assess hyaluronidase actiVity are well known in the art. es of such assays are described in Section G. In one example, hyaluronidase activity can be assessed in a microturbidity assay, wherein the amount of undegraded HA is ed by the addition of a reagent that precipitates HA (e. g., Cetylpyridinium chloride (CPC) or acidiﬁed serum) after the enzyme is allowed to react with HA. In r example, hyaluronidase ty can be assessed using a microtiter assay in which residual biotinylated hyaluronic acid is measured following incubation with hyaluronidase (see e.g., Frost and Stern (1997) Anal. Biochem. 251 :263-269, U.S. Pat. Publication No. 20050260186). The resulting activities under each of the tested ions is determined and compared. 3. Selection or Identiﬁcation In the method, after screening modiﬁed hyaluronan-degrading enzymes under one or more denaturation conditions, the hyaluronidase actiVities of the tested s are compared. The method is practiced in order to identify a modiﬁed onan-degrading enzyme that is more resistant to denaturation by a condition or a ring agent, whereby the actiVity of the enzyme is tive of the stability of the enzyme as a measure of its resistance to denaturation. It is understood that some reduction of enzyme actiVity, as a result of denaturation, can be tolerated in various ations, and thus the method can be practiced to select for a modiﬁed onan-degrading enzymes that exhibits a requisite actiVity upon exposure to a denaturation condition to permit its use or application (e.g. , therapeutic activity). For example, a modiﬁed enzyme can be selected that loses ty more slowly than the ponding unmodiﬁed or reference hyaluronan-degrading enzyme, but whose retained actiVity is ent for a particular application or purpose.

In examples of the methods herein, the actiVity of the modiﬁed hyaluronan degrading enzyme is assessed upon exposure to a ﬁrst denaturation ion and also assessed upon exposure to a second condition that is a control or non-denaturation condition, and the resulting hyaluronidase actiVities compared. For comparison, in some examples, the actiVity can be represented as a ratio of ty or a percentage of actiVity under a denaturation condition compared to under a control or non-denaturation condition. For example, where the parameter that differs between the ﬁrst and second condition is the presence of preservative (e.g., phenolic preservative), activity can be ented as a ratio of activity or percentage of activity observed in the presence of preservative (e.g., phenolic preservative) versus activity WO 2013/102144 PCT/US2012/072182 -l57- in the absence of preservative (e.g., phenolic preservative). In r example, Where the parameter that differs between the ﬁrst and second condition is temperature, activity can be represented as a ratio of activity or percentage of activity observed in the presence of elevated temperature (e.g., 30 °C to 42 OC) ed to ty in the presence of a lower ature such as 0 °C to 25 °C, for example 0 °C to 5 °C or 18 °C to 25 °C.

A modiﬁed hyaluronan-degrading enzyme is selected or identiﬁed that retains or exhibits any desired activity in the presence of the denaturation condition compared to in its absence. The particular cut-off of activity for selection of enzymes herein is dependent on the particular user and/or ce of the method and can be empirically determined depending on factors such as the particular denaturation condition or denaturing agent, the particular modiﬁed hyaluronan-degrading enzyme, the desired application of the identiﬁed or selected hyaluronan-degrading enzyme and other similar factors. Generally, a selected or identiﬁed modiﬁed hyaluronan-degrading enzyme exhibits ity if any detectable activity is measured or assessed upon exposure or incubation With a denaturation condition or denaturing agent. For example, a selected or identiﬁed modiﬁed hyaluronan-degrading enzyme exhibits stability, or resistance to a denaturation condition or denaturing agent, if it exhibits at least 5% or 10% of the activity of the same enzyme in the absence of the ration condition or denaturing agent, and generally if the modiﬁed hyaluronan- degrading enzyme exhibits an activity that is at least 15% of the initial hyaluronidase activity prior to incubation in the presence of the denaturation condition. For example, a modiﬁed hyaluronan-degrading enzyme is selected or identiﬁed that ts at least (or at least about) 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 110%, 120%, 130%, 140%, 150%, 200%, 300%, 400%, 500% or more of the initial hyaluronidase ty of the modiﬁed onan-degrading enzyme tested under a control or non-denaturation condition.

In other examples of the methods , the activity of the modiﬁed hyaluronan degrading enzyme is assessed upon exposure to a denaturation condition and the activity of the unmodiﬁed or reference hyaluronan-degrading enzyme also is assessed upon re to the same denaturation conditions. In such examples, the activities are compared When the enzymes are exposed to the same conditions. For comparison, the ty under a denaturation ion can be represented as a ratio of activity or a percentage of activity of a modiﬁed onan-degrading enzyme compared to an unmodiﬁed or reference hyaluronan- ing enzyme. In such examples, a modiﬁed hyaluronan-degrading enzyme is selected that exhibits greater activity under a ration condition than the unmodiﬁed or reference hyaluronan-degrading enzyme. Thus, the modiﬁed hyaluronan-degrading enzyme is one that WO 2013/102144 PCT/US2012/072182 -l58- is more resistant to the condition. For example, Where the denaturation condition is the presence of preservative (e.g., phenolic preservative), the activity observed in the presence of preservative (e.g., phenolic preservative) can be represented as a ratio of activity or percentage of activity of the modiﬁed hyaluronan-degrading enzyme compared to the unmodiﬁed or reference hyaluronan-degrading enzyme. In another example, Where the denaturation condition is high temperature, activity observed in the presence of elevated temperature (e.g., 30 °C to 42 0C) can be represented as a ratio of activity or percentage of activity of the modiﬁed hyaluronan-degrading enzyme ed to the unmodiﬁed or reference hyaluronan-degrading .

In such examples, a modiﬁed hyaluronan-degrading enzyme, such as a d PH20, is identiﬁed or selected that exhibits a ratio of ty that is greater than or at least 1.1, such that the enzyme exhibits greater activity than the unmodiﬁed or reference hyaluronan-degrading enzyme under the denaturation condition. For example, the ratio is at least or at least about 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0 or greater. A modiﬁed hyaluronan-degrading enzyme (e.g., a modiﬁed PH20) can be selected if its activity is at least 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, 300%, 400%, 500% or more of the activity of the ﬁed or reference hyaluronan-degrading enzyme when tested under the same conditions. Thus, d hyaluronan-degrading enzymes are identiﬁed that t greater or improved stability compared to the unmodiﬁed hyaluronan-degrading enzyme or a reference hyaluronandegrading enzyme as sted by increased resistance to a denaturation condition or denaturing agent. 4. Iterative Methods The method provided herein also is iterative. In one example, after the method is performed, any modiﬁed hyaluronan-degrading enzymes ﬁed as ting stability, such as increased ity, under a denaturation condition can be modiﬁed or r modiﬁed to increase or optimize the stability. A secondary library can be created by introducing additional modiﬁcations in a ﬁrst identiﬁed modiﬁed hyaluronan-degrading enzyme. For example, modiﬁcations that were identiﬁed as conferring stability, such as increasing ity, can be combined to te a combinatorial library. The secondary library can be tested using the assays and methods described herein.

In another example of an iterative aspect of the method, modiﬁed hyaluronan- degrading enzymes that are identiﬁed as not exhibiting stability such as increased stability (6.g. , such that they are not active or do not have increased activity under the a denaturation condition), can be further d and retested for stability under a denaturation condition.

WO 2013/102144 2012/072182 The r modiﬁcations can be targeted near particular regions (e. g. amino acid , particular residues) associated with activity and/or stability of the molecule. For example, residues that are associated with activity and/or stability of the molecule generally are critical residues that are involved in the structural g or other activities of the molecule. Hence, such residues are required for activity, generally under any condition. Critical residues can be ﬁed e, when mutated, a normal activity of the protein is ablated or reduced. For example, critical residues can be identiﬁed that, when mutated in a hyaluronan-degrading enzyme, exhibit reduced or ablated hyaluronidase activity under a normal or control assay condition.

A further library of modiﬁed proteins can be generated with amino acid mutations targeted at or near to the identiﬁed critical amino acid es, such as adjacent to the identiﬁed critical amino acid residues. In some examples, the mutations can be amino acid replacement to any other of up to 19 other amino acid residues. The secondary library can be tested using the assays and methods bed herein.

E. PRODUCTION OF MODIFIED PH20 POLYPEPTIDES AND ENCODING NUCLEIC ACID MOLECULES Polypeptides of a modiﬁed PH20 polypeptide set forth herein can be obtained by methods well known in the art for protein ation and recombinant protein expression.

Polypeptides also can be synthesized chemically. Modiﬁed or variant, including ted, forms can be engineered from a wildtype ptide using standard recombinant DNA s. For e, modiﬁed PH20 polypeptides can be engineered from a wildtype polypeptide, such as by site-directed mutagenesis. 1. Isolation 0r Preparation of Nucleic Acids Encoding PH20 Polypeptides Polypeptides can be cloned or isolated using any available methods known in the art for cloning and isolating nucleic acid molecules. Such methods include PCR ampliﬁcation of nucleic acids and screening of libraries, including nucleic acid hybridization ing, dy-based screening and ty-based screening.

For example, when the polypeptides are produced by recombinant means, any method known to those of skill in the art for identiﬁcation of nucleic acids that encode desired genes can be used. Any method available in the art can be used to obtain a full length or partial (i.e., encompassing the entire coding region) cDNA or genomic DNA clone encoding a PH20, such as from a cell or tissue source.

Methods for ampliﬁcation of nucleic acids can be used to isolate nucleic acid molecules encoding a desired polypeptide, including for example, polymerase chain reaction (PCR) methods. Examples of such s include use of a Perkin-Elmer Cetus thermal cycler and Taq rase (Gene Amp). A nucleic acid containing material can be used as a WO 2013/102144 2012/072182 -l60- starting material from which a d polypeptide-encoding nucleic acid molecule can be isolated. For example, DNA and mRNA preparations, cell ts, tissue extracts, ﬂuid samples (e.g., blood, serum, saliva), samples from healthy and/or ed subjects can be used in cation methods. The source can be from any eukaryotic species including, but not limited to, vertebrate, mammalian, human, porcine, bovine, feline, avian, equine, canine, and other primate sources. Nucleic acid libraries also can be used as a source of starting material. s can be designed to amplify a desired polypeptide. For example, primers can be designed based on expressed sequences from which a desired polypeptide is generated.

Primers can be designed based on back-translation of a polypeptide amino acid sequence. If desired, degenerate primers can be used for ampliﬁcation. Oligonucleotide primers that hybridize to sequences at the 3’ and 5’ termini of the desired sequence can be uses as primers to amplify by PCR sequences from a nucleic acid sample. Primers can be used to amplify the entire full-length PH20, or a truncated sequence thereof, such as a nucleic acid ng any of the soluble PH20 polypeptides provided herein. Nucleic acid molecules generated by ampliﬁcation can be sequenced and conﬁrmed to encode a desired polypeptide.

Additional nucleotide sequences can be joined to a ptide-encoding nucleic acid molecule, including linker sequences containing ction endonuclease sites for the purpose of cloning the synthetic gene into a vector, for example, a protein expression vector or a vector designed for the cation of the core protein coding DNA sequences.

Furthermore, additional nucleotide sequences specifying functional DNA elements can be operatively linked to a polypeptide-encoding nucleic acid molecule. es of such sequences include, but are not limited to, promoter sequences designed to facilitate intracellular protein expression, and secretion sequences, for example heterologous signal sequences, designed to facilitate protein ion. Such sequences are known to those of skill in the art. For example, exemplary heterologous signal ces include, but are not d to, human and mouse kappa lgG heterologous signal sequences set forth in SEQ ID NO: 868. Additional nucleotide residue sequences such as sequences of bases specifying protein binding regions also can be linked to enzyme-encoding c acid les. Such regions include, but are not limited to, ces of residues that facilitate or encode proteins that facilitate uptake of an enzyme into speciﬁc target cells, or otherwise alter pharmacokinetics of a product of a synthetic gene.

In addition, tags or other moieties can be added, for example, to aid in detection or afﬁnity puriﬁcation of the polypeptide. For example, additional nucleotide residue ces such as sequences of bases specifying an epitope tag or other detectable marker also can be WO 02144 PCT/US2012/072182 -l6l- linked to enzyme-encoding nucleic acid molecules. es of such sequences include nucleic acid sequences encoding a His tag or Flag Tag.

The identiﬁed and isolated c acids can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art can be used.

Possible vectors include, but are not limited to, ds or modiﬁed viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pCMV4, pBR322 or pUC plasmid tives or the Bluescript vector agene, La Jolla, CA). Other expression vectors include the H224 expression vector exempliﬁed herein (see e.g., SEQ ID NOS:4 and 5). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a g vector which has complementary cohesive termini. Insertion can be effected using TOPO cloning vectors (Invitrogen, Carlsbad, CA).

If the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules can be tically modiﬁed. atively, any site desired can be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers can contain speciﬁc chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative , the cleaved vector and protein gene can be modiﬁed by homopolymeric tailing.

Recombinant molecules can be introduced into host cells via, for example, transformation, transfection, infection, electroporation and sonoporation, so that many copies of the gene sequence are generated. In speciﬁc embodiments, ormation of host cells with recombinant DNA molecules that incorporate the ed protein gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene can be obtained in large quantities by growing transformants, isolating the recombinant DNA les from the transformants and, when necessary, retrieving the inserted gene from the isolated inant DNA.

In addition to recombinant production, modiﬁed PH20 polypeptides provided herein can be produced by direct peptide synthesis using solid-phase techniques (see e. g., Stewart et al. (1969) Solid-Phase Peptide Synthesis, WH Freeman Co., San Francisco; Merriﬁeld J (1963) JAm Chem Soc., 85:2149-2154). In vitro n synthesis can be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer, Foster City CA) in accordance with the instructions provided by the manufacturer. Various fragments of a polypeptide can be ally synthesized separately and combined using chemical methods.

WO 2013/102144 PCT/US2012/072182 -l62- 2. Generation of Mutant or Modiﬁed Nucleic Acid and Encoding Polypeptides The modiﬁcations provided herein can be made by standard recombinant DNA techniques such as are routine to one of skill in the art. Any method known in the art to effect on of any one or more amino acids in a target protein can be ed. s e standard irected mutagenesis (using e.g., a kit, such as QuikChange available from Stratagene) of encoding nucleic acid molecules, or by solid phase polypeptide synthesis methods. 3. s and Cells For recombinant expression of one or more of the desired proteins, such as any modiﬁed PH20 polypeptide described herein, the nucleic acid containing all or a portion of the nucleotide sequence encoding the protein can be inserted into an appropriate expression vector, Le. , a vector that contains the necessary elements for the transcription and translation of the inserted protein coding sequence. The ary transcriptional and translational signals also can be supplied by the native er for enzyme genes, and/or their g regions.

Also provided are vectors that n a nucleic acid encoding the enzyme. Cells containing the vectors also are provided. The cells include eukaryotic and prokaryotic cells, and the vectors are any suitable for use therein. Generally, the cell is a cell that is capable of effecting glyosylation of the encoded n. yotic and eukaryotic cells containing the vectors are provided. Such cells include bacterial cells, yeast cells, fungal cells, Archea, plant cells, insect cells and animal cells. The cells are used to produce a protein thereof by growing the above-described cells under conditions Whereby the encoded protein is expressed by the cell, and ring the expressed protein. For purposes herein, for example, the enzyme can be secreted into the medium.

A host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to s the expressed protein in the desired fashion. Such modiﬁcations of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing can impact the g and/or function of the polypeptide. Different host cells, such as, but not limited to, CH0 (DG44, DXBl l, CHO-Kl), HeLa, MCDK, 293 and W138 have speciﬁc cellular machinery and characteristic mechanisms for such post-translational activities and can be chosen to ensure the correct modiﬁcation and processing of the introduced protein.

Generally, the choice of cell is one that is capable of introducing N—linked glycosylation into the expressed ptide. Hence, eukaryotic cells containing the vectors are provided.

WO 2013/102144 PCT/US2012/072182 Exemplary eukaryotic cells are mammalian Chinese r Ovary (CHO) cells. For e, CHO cells deﬁcient in dihydrofolate reductase (e.g., DG44 cells) are used to e polypeptides provided herein. Note that bacterial expression of an PH20 polypepyideprovided herein will not result in a catalytically active ptide, but when combined with proper glycosylation ery, the PH20 can be artificially glycosylated.

Provided are vectors that contain a sequence of nucleotides that encodes the modiﬁed PH20 polypeptide, coupled to the native or heterologous signal sequence, as well as multiple copies thereof. The vectors can be selected for expression of the enzyme n in the cell or such that the enzyme protein is expressed as a secreted protein.

A variety of host-vector systems can be used to express the protein encoding ce. These include but are not limited to mammalian cell systems infected with Virus (e.g. , vaccinia Virus, adenovirus and other Viruses); insect cell systems infected with Virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage, DNA, d DNA, or cosmid DNA. The expression ts of vectors vary in their strengths and speciﬁcities. Depending on the host-vector system used, any one of a number of suitable transcription and translation elements can be used.

Any methods known to those of skill in the art for the insertion of DNA nts into a vector can be used to construct expression vectors containing a chimeric gene containing riate transcriptional/translational control signals and protein coding sequences. These methods can include in vitro recombinant DNA and synthetic techniques and in vivo recombinants (genetic recombination). Expression of nucleic acid sequences encoding protein, or domains, derivatives, fragments or gs thereof, can be regulated by a second nucleic acid sequence so that the genes or fragments thereof are expressed in a host transformed with the inant DNA molecule(s). For example, expression of the proteins can be controlled by any promoter/enhancer known in the art. In a specific embodiment, the promoter is not native to the genes for a desired n. Promoters which can be used include, but are not d to, the SV40 early promoter (Bemoist and Chambon, Nature 290:304-310 (1981)), the promoter contained in the 3’ long terminal repeat of Rous sarcoma Virus oto et al. Cell 22:787-797 (1980)), the herpes thymidine kinase promoter (Wagner et al., Proc. Natl. Acad. Sci. USA 78: 1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster et al., Nature 296:39-42 (1982)); prokaryotic expression vector promoters, such as the B-lactamase promoter (Jay et al. , (1981) Proc. Natl.

Acad. Sci. USA 78:5543) or the tac promoter (DeBoer et al., Proc. Natl. Acad. Sci. USA 80:21-25 (1983); see also Gilbert and Villa-Komaroff, "Useful Proteins from Recombinant WO 2013/102144 PCT/US2012/072182 Bacteria," Scientiﬁc American 242:74-94 (1980)); plant expression vector promoters, such as the nopaline synthetase promoter (Herrera-Estrella et al., Nature 303 13 (1984)) or the cauliﬂower mosaic virus 35S RNA promoter (Gardner et al. Nucleic Acids Res. 9:2871 , (1981)), and the er of the photosynthetic enzyme ribulose bisphosphate carboxylase (Herrera-Estrella et al., Nature 310:115-120 (1984)); promoter elements from yeast and other fungi such as the Gal4 promoter, the alcohol ogenase promoter, the phosphoglycerol kinase promoter, the alkaline phosphatase promoter, and the following animal transcriptional control regions that exhibit tissue speciﬁcity and have been used in enic animals: se I gene control region which is active in pancreatic acinar cells (Swift et al., Cell 38:639-646 (1984); Ornitz et al., Cold Spring Harbor Symp. Quant. Biol. 50:399-409 (1986); MacDonald, Hepatology 7:425-5 15 ); insulin gene control region which is active in pancreatic beta cells an et al., Nature 315:115-122 (1985)), immunoglobulin gene l region which is active in lymphoid cells (Grosschedl et al., Cell 38:647-65 8 (1984); Adams et al., Nature 318:533-538 (1985); Alexander et al., Mol. Cell Biol. 7:1436-1444 (1987)), mouse mammary tumor virus control region which is active in testicular, breast, id and mast cells (Leder et al., Cell 45 :485-495 (1986)), albumin gene control region which is active in liver (Pinkert et al., Genes and Devel. 1:268-276 (1987)), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., Mol. Cell. Biol. 5:1639-1648 (1985); Hammer et al., Science 235:53-5 8 1987)), alpha-l antitrypsin gene control region which is active in liver (Kelsey et al., Genes and Devel. 1:161-171 (1987)), beta globin gene control region which is active in myeloid cells m et al., Nature 315:338-340 (1985); s et al., Cell 46:89-94 (1986)), myelin basic protein gene l region which is active in oligodendrocyte cells of the brain (Readhead et al., Cell 48:703-712 (1987)), myosin light chain-2 gene control region which is active in skeletal muscle (Shani, Nature 314:283-286 (1985)), and gonadotrophic releasing hormone gene control region which is active in trophs of the hypothalamus (Mason et al., Science 72—1378 (1986)).

In a speciﬁc embodiment, a vector is used that contains a promoter operably linked to nucleic acids encoding a desired protein, or a domain, nt, derivative or homolog thereof, one or more origins of ation, and optionally, one or more selectable markers (e.g., an antibiotic resistance gene). Depending on the expression system, speciﬁc initiation signals also are required for efﬁcient translation of a PH20 sequence. These signals include the ATG initiation codon and adjacent sequences. In cases where the initiation codon and upstream sequences of PH20 or soluble forms thereof are inserted into the appropriate expression vector, no additional translational control signals are needed. In cases where only a coding sequence, or a portion thereof, is inserted, exogenous transcriptional control signals WO 2013/102144 PCT/US2012/072182 -l65- including the ATG initiation codon must be provided. Furthermore, the initiation codon must be in the correct reading frame to ensure transcription of the entire insert. Exogenous riptional elements and tion codons can be of various origins, both natural and tic. The efﬁciency of expression can be enhanced by the inclusion of ers appropriate to the cell system in use (Scharf et al. (1994) s Probl Cell Diﬂer 20: 125-62; Bittner et al. (1987) Methods in l, 153:516-544).

Exemplary plasmid vectors for transformation of E. coli cells include, for example, the pQE sion vectors (available from Qiagen, Valencia, CA; see also ture published by Qiagen describing the system). pQE vectors have a phage T5 er (recognized by E. coli RNA polymerase) and a double lac operator repression module to provide tightly regulated, high-level expression of recombinant proteins in E. coli, a synthetic ribosomal binding site (RBS 11) for efﬁcient translation, a 6xHis tag coding sequence, to and T1 transcriptional terminators, ColEl origin of replication, and a beta-lactamase gene for conferring ampicillin ance. The pQE vectors enable placement of a 6xHis tag at either the N— or C-terminus of the recombinant protein. Such plasmids include pQE 32, pQE 30, and pQE 31 which provide multiple cloning sites for all three reading frames and provide for the expression of N—terminally 6xHis-tagged proteins. Other exemplary plasmid vectors for transformation of E. coli cells, include, for example, the pET expression vectors (see, US. patent 496; available from Novagen, Madison, WI; see, also literature published by Novagen describing the system). Such plasmids include pET 11a, which ns the T7lac promoter, T7 terminator, the inducible E. coli lac or, and the lac repressor gene; pET 12a—c, which contains the T7 er, T7 terminator, and the E. coli ompT secretion signal; and pET 15b and pET19b (Novagen, Madison, WI), which contain a His-TagTM leader sequence for use in puriﬁcation with a His column and a thrombin cleavage site that s cleavage following puriﬁcation over the column, the T7-lac promoter region and the T7 terminator.

Typically, vectors can be plasmids, Viral vectors, or others known in the art, used for expression of the modiﬁed PH2O polypeptide in vivo or in vitro. For example, the modiﬁed PH2O polypeptide is expressed in mammalian cells, including, for example, Chinese r Ovary (CHO) cells. An exemplary vector for mammalian cell expression is the HZ24 expression . The HZ24 expression vector was derived from the pCl vector backbone (Promega). It contains DNA encoding the Beta-lactamase resistance gene (AmpR), an F1 origin of replication, a Cytomegalovirus immediate-early enhancer/promoter region (CMV), and an SV4O late polyadenylation signal (SV40). The expression vector also has an internal WO 2013/102144 PCT/US2012/072182 -l66- ribosome entry site (IRES) from the ECMV virus (Clontech) and the mouse dihydrofolate ase (DHFR) gene.

Viral vectors, such as adenovirus, retrovirus or vaccinia virus vectors, can be employed. In some examples, the vector is a ive or attenuated retroviral or other viral vector (see U. S. Patent No. 4,980,286). For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217: 581-599 (1993)). These retroviral vectors have been modiﬁed to delete retroviral sequences that are not ary for packaging of the viral genome and integration into host cell DNA.

In some examples, viruses armed with a nucleic acid encoding a modiﬁed PH20 polypeptide can facilitate their replication and spread within a target tissue for example. The target tissue can be a cancerous tissue whereby the virus is capable of selective replication within the tumor. The virus can also be a non-lytic virus wherein the virus selectively replicates under a tissue speciﬁc promoter. As the viruses replicate, the coexpression of the PH20 polypeptide with viral genes will facilitate the spread of the virus in vivo. 4. Expression Modiﬁed PH20 ptides can be produced by any method known to those of skill in the art ing in vivo and in vitro methods. Desired proteins can be expressed in any organism suitable to produce the required amounts and forms of the proteins, such as for example, those needed for administration and treatment. Expression hosts include prokaryotic and eukaryotic organisms such as E. coli, yeast, plants, insect cells, mammalian cells, including human cell lines and transgenic animals. Expression hosts can differ in their protein production levels as well as the types of post-translational modiﬁcations that are present on the expressed ns. The choice of expression host can be made based on these and other factors, such as regulatory and safety considerations, tion costs and the need and methods for puriﬁcation.

Many expression vectors are available and known to those of skill in the art and can be used for expression of ns. The choice of expression vector will be ced by the choice of host expression system. In general, expression vectors can include transcriptional promoters and optionally enhancers, translational s, and transcriptional and ational termination signals. Expression vectors that are used for stable transformation typically have a selectable marker which allows selection and maintenance of the transformed cells. In some cases, an origin of replication can be used to amplify the copy number of the vector.

Modiﬁed PH20 polypeptides also can be utilized or expressed as protein fusions. For example, an enzyme fusion can be generated to add additional functionality to an enzyme. es of enzyme fusion proteins include, but are not limited to, fusions of a signal WO 02144 PCT/US2012/072182 sequence, a tag such as for zation, e.g., a 6xHis or His6 tag or a myc tag, or a tag for puriﬁcation, for example, a GST fusion, and a sequence for ing protein secretion and/or membrane association.

For erm, ield production of recombinant proteins, stable expression is desired. For example, cell lines that stably express a modiﬁed PH20 polypeptide can be transformed using expression vectors that contain Viral s of replication or endogenous sion elements and a selectable marker gene. Following the introduction of the vector, cells can be allowed to grow for 1-2 days in an enriched medium before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows grth and recovery of cells that successfully express the introduced sequences. Resistant cells of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell types.

Any number of selection systems can be used to recover transformed cell lines.

These include, but are not limited to, the herpes simplex Virus thymidine kinase (Wigler, M et al. (1977) Cell, -32) and adenine phosphoribosyltransferase (Lowy, 1 et al. (1980) Cell, 22:817-23) genes, which can be employed in TK- or APRT- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection. For e, DHFR, which confers resistance to methotrexate (Wigler, M et al. (1980) Proc.

Natl. Acad. Sci, 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 re-Garapin, F et al. (1981) J. Mol. Biol., 150:1-14); and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, tively, can be used. Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of typtophan or hisD, which allows cells to utilize histinol in place of histidine (Hartman SC and RC Mulligan (1988) Proc. Natl. Acad. Sci, 85:8047-51). Visible s, such as but not limited to, anthocyanins, beta glucuronidase and its substrate, GUS, and luciferase and its substrate luciferin, also can be used to identify transformants and also to fy the amount of transient or stable protein expression attributable to a particular vector system (Rhodes CA et al. (1995) Methods Mol. Biol. 55:121-131).

The presence and expression of PH20 polypeptides can be monitored. For example, detection of a functional polypeptide can be ined by testing the conditioned media for hyaluronidase enzyme activity under appropriate conditions. Exemplary assays to assess the solubility and activity of expressed proteins are provided herein. a. Prokaryotic Cells Prokaryotes, especially E. coli, provide a system for producing large s of proteins. Transformation of E. coli is a simple and rapid technique well known to those of WO 2013/102144 PCT/US2012/072182 -l68- skill in the art. Expression s for E. coli can contain inducible promoters. Such promoters are useful for inducing high levels of protein expression and for expressing proteins that exhibit some toxicity to the host cells. Examples of inducible promoters include the lac promoter, the trp promoter, the hybrid tac er, the T7 and SP6 RNA promoters and the temperature regulated QtPL promoter.

Proteins, such as any provided herein, can be expressed in the cytoplasmic environment of E. coli. The cytoplasm is a reducing environment, and for some molecules, this can result in the formation of insoluble inclusion bodies. Reducing agents such as dithiothreotol and aptoethanol and denaturants, such as ine-HCl and urea can be used to resolubilize the proteins. An alternative approach effects protein expression in the periplasmic space of bacteria which es an oxidizing environment and chaperonin-like and disulﬁde isomerases, which can aid in the production of soluble protein. Typically, a leader sequence is fused to the protein to be expressed which directs the protein to the asm. The leader is then removed by signal ases inside the periplasm. Examples of periplasmic-targeting leader sequences include the pelB leader from the pectate lyase gene and the leader derived from the alkaline atase gene. In some cases, periplasmic expression allows leakage of the expressed protein into the culture medium. The secretion of proteins allows quick and simple puriﬁcation from the culture supernatant. Proteins that are not secreted can be obtained from the periplasm by c lysis. Similar to cytoplasmic expression, in some cases proteins can become insoluble and rants and reducing agents can be used to facilitate solubilization and refolding. ature of induction and grth also can inﬂuence expression levels and solubility, typically temperatures between 25 oC and 37 0C are used. Typically, bacteria produce aglycosylated ns. Thus, if proteins require glycosylation for function, glycosylation can be added in vitro after purification from host cells. b. Yeast Cells Yeasts such as Saccharomyces cerevisae, Schizosaccharomyces pombe, Yarrowia lipolytica, Kluyveromyces lactis and Pichia pastoris are well known yeast expression hosts that can be used for tion of proteins, such as any described herein. Yeast can be ormed with al replicating vectors or by stable chromosomal integration by homologous recombination. Typically, inducible promoters are used to regulate gene expression. Examples of such promoters include GAL], GAL7 and GALS and metallothionein promoters, such as CUPl, AOXl or other Pichia or other yeast promoters.

Expression vectors often include a selectable marker such as LEU2, TRPl, HIS3 and URA3 for selection and maintenance of the transformed DNA. Proteins expressed in yeast are often WO 2013/102144 PCT/US2012/072182 -l69- soluble. Co-expression With chaperonins such as Bip and protein disulﬁde isomerase can improve expression levels and solubility. Additionally, ns expressed in yeast can be directed for secretion using ion signal peptide s such as the yeast mating type alpha-factor secretion signal from romyces cerevisae and fusions With yeast cell surface proteins such as the Aga2p mating adhesion or or the Arxula adeninivorans glucoamylase. A se cleavage site such as for the Kex-2 protease, can be ered to remove the fused sequences from the expressed polypeptides as they exit the secretion pathway. Yeast also is capable of glycosylation at Asn-X-Ser/Thr motifs. c. Insects and Insect Cells Insect cells, particularly using baculovirus expression, are useful for expressing polypeptides such as PH20 polypeptides. Insect cells express high levels of protein and are capable of most of the post-translational modiﬁcations used by higher eukaryotes.

Baculoviruses have a restrictive host range Which improves the safety and reduces regulatory concerns of eukaryotic sion. Typical expression vectors use a promoter for high level expression such as the polyhedrin promoter of baculovirus. Commonly used baculovirus systems include a baculovirus, such as the Autographa califomica nuclear polyhedrosis Virus (AcNPV)or the bombyx mori nuclear polyhedrosis Virus (BmNPV), and an insect cell line, such as Sf9 derived from Spodoptera frugiperda, Pseudaletia unipuncta (A78) and Danaus plexippus (Dle). For high-level expression, the nucleotide sequence of the molecule to be expressed is fused immediately downstream of the polyhedrin initiation codon of the Virus.

Mammalian secretion signals are accurately processed in insect cells and can be used to secrete the expressed protein into the culture medium. In addition, the cell lines Pseudaletia unipuncta (A78) and Danaus plexippus (Dle) e proteins With glycosylation patterns r to mammalian cell systems. Exemplary insect cells are those that have been altered to reduce immunogenicity, ing those With lianized" baculovirus expression vectors and those lacking the enzyme FT3.

An alternative expression system in insect cells employs stably transformed cells.

Cell lines such as the der 2 ($2) and Kc cells (Drosophila melanogaster) and C7 cells (Aedes albopictus) can be used for expression. The Drosophila othionein er can be used to induce high levels of expression in the presence of heavy metal induction With cadmium or copper. Expression vectors are typically maintained by the use of selectable markers such as neomycin and hygromycin. d. Mammalian expression Mammalian expression systems can be used to express proteins including PH20 polypeptides. Expression constructs can be erred to mammalian cells by viral infection WO 2013/102144 PCT/US2012/072182 -l70- such as by adenovirus or by direct DNA er such as liposomes, calcium phosphate, DEAE-dextran and by physical means such as electroporation and microinj ection.

Expression vectors for mammalian cells typically include an mRNA cap site, a TATA box, a ational initiation sequence (Kozak consensus sequence) and enylation elements.

IRES ts also can be added to permit bicistronic expression With another gene, such as a selectable marker. Such vectors often include transcriptional promoter-enhancers for high- level sion, for example the SV40 promoter-enhancer, the human cytomegalovirus (CMV) promoter and the long terminal repeat of Rous sarcoma virus (RSV). These promoter-enhancers are active in many cell types. Tissue and cell-type promoters and enhancer regions also can be used for expression. Exemplary promoter/enhancer regions include, but are not limited to, those from genes such as elastase I, insulin, immunoglobulin, mouse mammary tumor virus, albumin, alpha fetoprotein, alpha 1 antitrypsin, beta globin, myelin basic protein, myosin light chain 2, and gonadotropic releasing hormone gene control.

Selectable markers can be used to select for and maintain cells With the expression construct.

Examples of able marker genes include, but are not d to, hygromycin B phosphotransferase, adenosine deaminase, xanthine-guanine phosphoribosyl transferase, aminoglycoside phosphotransferase, dihydrofolate reductase (DHFR) and thymidine kinase.

For example, sion can be performed in the presence of methotrexate to select for only those cells expressing the DHFR gene. Fusion With cell surface signaling les such as TCR-Z; and chRl-y can direct expression of the proteins in an active state on the cell surface.

Many cell lines are available for mammalian expression including mouse, rat human, monkey, chicken and r cells. Exemplary cell lines include but are not limited to CH0, Balb/3T3, HeLa, MT2, mouse NSO (nonsecreting) and other myeloma cell lines, hybridoma and heterohybridoma cell lines, cytes, fibroblasts, Sp2/O, COS, NIH3T3, HEK293, 293 S, 2B8, and HKB cells. Cell lines also are available adapted to serum-free media Which facilitates purification of secreted proteins from the cell culture media. Examples include CHO-S cells (lnvitrogen, ad, CA, cat # 11619-012) and the serum free EBNA-l cell line (Pham et al., (2003) Biotechnol. Bioeng. 84:332-42.) Cell lines also are available that are adapted to grow in special mediums zed for maximal expression. For example, DG44 CHO cells are adapted to grow in suspension culture in a ally deﬁned, animal product-free medium. 6. Plants Transgenic plant cells and plants can be used to express proteins such as any described . Expression constructs are typically transferred to plants using direct DNA transfer such as microproj ectile bombardment and diated transfer into protoplasts, WO 2013/102144 PCT/US2012/072182 -l7l- and with cterium—mediated ormation. Expression vectors can include promoter and enhancer sequences, riptional termination elements and translational control elements. Expression vectors and transformation techniques are usually divided between dicot hosts, such as Arabidopsis and tobacco, and t hosts, such as corn and rice.

Examples of plant promoters used for expression include the cauliﬂower mosaic virus promoter, the nopaline syntase promoter, the ribose bisphosphate carboxylase promoter and the ubiquitin and UBQ3 promoters. Selectable markers such as hygromycin, phosphomannose isomerase and neomycin phosphotransferase are often used to facilitate selection and maintenance of transformed cells. Transformed plant cells can be maintained in culture as cells, aggregates (callus tissue) or regenerated into whole plants. Transgenic plant cells also can include algae engineered to produce hyaluronidase ptides. Because plants have different glycosylation patterns than ian cells, this can inﬂuence the choice of protein produced in these hosts.

. Puriﬁcation Host cells transformed with a nucleic acid sequence encoding a modiﬁed PH20 polypeptide can be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein produced by a recombinant cell is generally secreted, but may be ned intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression s ning nucleic acid encoding PH20 can be ed with signal sequences that facilitate direct secretion of PH20 through prokaryotic or eukaryotic cell membranes.

Thus, methods for puriﬁcation of polypeptides from host cells will depend on the chosen host cells and expression systems. For secreted molecules, proteins are generally puriﬁed from the culture media after removing the cells. For intracellular expression, cells can be lysed and the proteins puriﬁed from the extract. When transgenic organisms such as transgenic plants and animals are used for expression, tissues or organs can be used as starting material to make a lysed cell t. onally, transgenic animal production can e the production of polypeptides in milk or eggs, which can be collected, and if necessary, the proteins can be extracted and further purified using standard methods in the art.

Proteins, such as modiﬁed PH20 polypeptides, can be d using standard protein puriﬁcation techniques known in the art including but not limited to, SDS-PAGE, size fractionation and size exclusion tography, ammonium sulfate precipitation and ionic exchange chromatography, such as anion ge tography. Afﬁnity puriﬁcation techniques also can be utilized to improve the efficiency and purity of the ations. For example, antibodies, receptors and other molecules that bind PH20 hyaluronidase enzymes WO 2013/102144 PCT/US2012/072182 -l72- can be used in afﬁnity puriﬁcation. For example, soluble PH20 can be puriﬁed from conditioned media.

Expression constructs also can be engineered to add an afﬁnity tag to a protein such as a myc epitope, GST fusion or His6 and afﬁnity puriﬁed with myc antibody, glutathione resin or Ni-resin, respectively. Such tags can be joined to the nucleotide sequence encoding a soluble PH20 as described elsewhere herein, which can facilitate puriﬁcation of soluble proteins. For example, a modiﬁed PH20 polypeptide can be expressed as a recombinant protein with one or more additional polypeptide domains added to facilitate protein puriﬁcation. Such ation tating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow puriﬁcation on immobilized metals, n A domains that allow puriﬁcation on immobilized immunoglobulin and the domain utilized in the FLAGS extension/afﬁnity ation system (Immunex Corp., Seattle . The inclusion of a cleavable linker sequence such as Factor XA or enterokinase (Invitrogen, San Diego, CA) n the ation domain and the expressed PH20 polypeptide is useful to facilitate puriﬁcation. One such expression vector provides for expression of a fusion n containing a PH20 polypeptide in and an enterokinase cleavage site. The histidine residues facilitate ation on IMIAC (immobilized metal ion afﬁnity tography), while the enterokinase cleavage site provides a means for purifying the polypeptide from the fusion protein.

Purity can be assessed by any method known in the art including gel electrophoresis, orthogonal HPLC methods, staining and spectrophotometric techniques. The expressed and puriﬁed protein can be analyzed using any assay or method known to one of skill in the art, for e, any described in Section G. These include assays based on the physical and/or functional properties of the protein, including, but not limited to, analysis by gel electrophoresis, immunoassay and assays of hyaluronidase activity.

Depending on the sion system and host cells used, the resulting polypeptide can be heterogeneous due to ases present in the culture medium upon production and puriﬁcation. For example, culture of soluble PH20 in CHO cells can result in a mixture of heterogeneous polypeptides. 6. Modiﬁcation of Polypeptides by PEGylation Polyethylene glycol (PEG) has been widely used in biomaterials, biotechnology and medicine primarily e PEG is a biocompatible, nontoxic, water-soluble r that is typically nonimmunogenic (Zhao and Harris, ACS Symposium Series 680: 45 8-72, 1997). In the area of drug delivery, PEG derivatives have been widely used in covalent attachment (i.e., "PEGylation") to proteins to reduce immunogenicity, proteolysis and kidney clearance and to WO 02144 PCT/US2012/072182 -l73- enhance lity (Zalipsky, Adv. Drug Del. Rev. 16:157-82, 1995). Similarly, PEG has been attached to low molecular weight, relatively hydrophobic drugs to enhance solubility, reduce toxicity and alter biodistribution. Typically, ted drugs are injected as solutions.

A closely related application is synthesis of crosslinked degradable PEG networks or formulations for use in drug delivery since much of the same chemistry used in design of degradable, soluble drug carriers can also be used in design of degradable gels (Sawhney et al., Macromolecules 26: 5 81-87, 1993). It also is known that intermacromolecular complexes can be formed by mixing solutions oftwo complementary polymers. Such complexes are generally stabilized by ostatic interactions (polyanion-polycation) and/or hydrogen bonds (polyacid-polybase) between the polymers involved, and/or by hydrophobic interactions between the polymers in an aqueous nding (Krupers et al., Eur. Polym J. 32:785-790, 1996). For example, mixing ons of polyacrylic acid (PAAc) and hylene oxide (PEO) under the proper conditions s in the formation of complexes based mostly on hydrogen bonding. Dissociation of these complexes at logic conditions has been used for delivery of free drugs (i.e., non-PEGylated). In addition, complexes of complementary polymers have been formed from both lymers and copolymers.

Numerous reagents for PEGylation have been described in the art. Such reagents include, but are not limited to, on of the polypeptide with N—hydroxysuccinimidyl (NHS) ted PEG, succinimidyl mPEG, mPEG2-N-hydroxysuccinimide, mPEG succinimidyl alpha-methylbutanoate, mPEG succinimidyl propionate, mPEG succinimidyl butanoate, mPEG carboxymethyl 3-hydroxybutanoic acid succinimidyl ester, homobifunctional PEG-succinimidyl propionate, homobifunctional PEG propionaldehyde, homobifunctional PEG butyraldehyde, PEG maleimide, PEG hydrazide, ophenyl- carbonate PEG, mPEG-benzotriazole carbonate, propionaldehyde PEG, mPEG butryaldehyde, branched mPEGz butyraldehyde, mPEG acetyl, mPEG piperidone, mPEG methylketone, mPEG "linkerless" maleimide, mPEG Vinyl sulfone, mPEG thiol, mPEG orthopyridylthioester, mPEG orthopyridyl disulﬁde, Fmoc-PEG-NHS, Boc-PEG-NHS, Vinylsulfone PEG-NHS, acrylate PEG-NHS, ﬂuorescein PEG-NHS, and biotin PEG-NHS (see e.g., Monfardini et al., Bioconjugate Chem. 6:62-69, 1995; Veronese et al., J. Bioactive Compatible rs -207, 1997; US. 5,672,662; US. 5,932,462; US. 659; US. 6,737,505; US. 4,002,531; US. 4,179,337; US. 5,122,614; US. 5,324, 844; US. ,446,090; US. 5,612,460; US. 5,643,575; US. 5,766,581; US. 5,795, 569; US. 5,808,096; US. 5,900,461; US. 5,919,455; US. 5,985,263; US. 5,990, 237; US. 6,113,906; US.

WO 2013/102144 2012/072182 —174— 6,214,966; U.S. 6,258,351; U.S. 742; U.S. 6,413,507; U.S. 6,420,339; U.S. 6,437,025; U.S. 6,448,369; U.S. 6,461,802; U.S. 6,828,401; U.S. 6,858,736; U.S. 2001/0021763; U.S. 2001/0044526; U.S. 2001/0046481; U.S. 2002/0052430; U.S. 2002/0072573; U.S. 2002/0156047; U.S. 2003/0114647; U.S. 2003/0143596; U.S. 158333; U.S. 2003/0220447; U.S. 2004/0013637; US 2004/0235734; W005000360; U.S. 2005/0114037; U.S. 2005/0171328; U.S. 2005/0209416; EP 1064951; EP 0822199; WO 01076640; WO 0002017; WO 0249673; WO 9428024; and WO 0187925).

In one example, the polyethylene glycol has a molecular weight ranging from about 3 kD to about 50 kD, and typically from about 5 kD to about 30 kD. nt attachment of the PEG to the drug (known as "PEGylation") can be accomplished by known chemical synthesis techniques. For example, the PEGylation of protein can be accomplished by reacting tivated PEG with the protein under suitable reaction conditions.

While numerous reactions have been described for PEGylation, those that are most generally able confer directionality, utilize mild reaction conditions, and do not necessitate extensive downstream processing to remove toxic sts or ducts. For instance, monomethoxy PEG (mPEG) has only one ve terminal hydroxyl, and thus its use limits some of the heterogeneity of the resulting PEG-protein product mixture. Activation of the hydroxyl group at the end of the polymer opposite to the terminal methoxy group is generally necessary to accomplish efﬁcient protein PEGylation, with the aim being to make the derivatised PEG more susceptible to nucleophilic attack. The attacking nucleophile is usually the n-amino group of a lysyl residue, but other amines also can react (e.g., the N—terminal alpha-amine or the ring amines of histidine) if local conditions are favorable. A more directed attachment is possible in proteins containing a single lysine or cysteine. The latter residue can be ed by PEG-maleimide for thiol-speciﬁc modiﬁcation.

Alternatively, PEG hydrazide can be d with a periodate oxidized hyaluronan-degrading enzyme and reduced in the presence ofNaCNBHg. More speciﬁcally, PEGylated CMP sugars can be reacted with a hyaluronan-degrading enzyme in the presence of appropriate glycosyl-transferases. One technique is the "PEGylation" technique where a number of polymeric molecules are coupled to the polypeptide in question. When using this technique, the immune system has difﬁculties in recognizing the epitopes on the polypeptide's surface responsible for the ion of antibodies, thereby reducing the immune response. For polypeptides introduced directly into the circulatory system of the human body to give a ular physiological effect (i.e., pharmaceuticals) the typical potential immune se is an IgG and/or IgM response, while polypeptides which are inhaled through the respiratory system (i.e., rial polypeptide) potentially can cause an IgE response (i.e., allergic WO 2013/102144 PCT/US2012/072182 -l75- response). One of the theories explaining the reduced immune response is that the polymeric molecule(s) (s) epitope(s) on the surface of the polypeptide responsible for the immune response leading to antibody formation. Another theory or at least a partial factor is that the heavier the conjugate is, the more reduced the resulting immune response is.

Typically, to make the PEGylated PH20 ptide provided herein, PEG moieties are conjugated, via covalent attachment, to the ptides. Techniques for PEGylation e, but are not limited to, specialized linkers and coupling chemistries (see e.g., Roberts, Adv. Drug Deliv. Rev. 54:459-476, 2002), attachment of multiple PEG moieties to a single conjugation site (such as via use of branched PEGs; see e. g., Guiotto et al., Bioorg. Med.

Chem. Lett. 12:177-180, 2002), site-speciﬁc PEGylation and/or mono-PEGylation (see e.g., Chapman et al., Nature Biotech. 17:780-783, 1999), and site-directed enzymatic PEGylation (see e.g., Sato, Adv. Drug Deliv. Rev., 54:487-504, 2002). Methods and techniques described in the art can produce ns having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 PEG or PEG derivatives attached to a single protein molecule (see e.g., U.S. 2006/0104968).

As an exemplary illustrative method for making a PEGylated PH20 polypeptide, PEG aldehydes, succinimides and carbonates have each been applied to conjugate PEG moieties, typically succinimidyl PEGs, to 0. For example, rHuPH20 has been conjugated with exemplary succinimidyl monoPEG (mPEG) ts including mPEG-Succinimidyl Propionates (mPEG-SPA), mPEG-Succinimidyl Butanoates (mPEG-SBA), and (for attaching "branched" PEGs) mPEG2-N-Hydroxylsuccinimide. These PEGylated succinimidyl esters contain different length carbon backbones n the PEG group and the activated cross- linker, and either a single or branched PEG group. These differences can be used, for example, to provide for different reaction cs and to potentially restrict sites available for PEG attachment to rHuPH20 during the conjugation process.

Succinimidyl PEGs (as above) containing either linear or branched PEGs can be conjugated to PH20. PEGs can used to generate PH20s reproducibly containing molecules having, on the average, between about three to six or three to six PEG les per hyaluronidase. Such PEGylated rHuPH20 compositions can be readily puriﬁed to yield compositions having speciﬁc activities of imately 25,000 or 30,000 Unit/mg protein hyaluronidase activity, and being substantially free of non-PEGylated PH20 (less than 5% non-PEGylated).

Using various PEG reagents, exemplary ns of a PEGylated PH20 polypeptide can be prepared, for e, using BA (30 kD), mPEG-SMB (30 kD), and branched ns based on NHS (40 kD) and mPEG2-NHS (60 kD). PEGylated ns of PH20 can be generated using NHS chemistries, as well as carbonates, and aldehydes, using WO 2013/102144 PCT/US2012/072182 -l76- each of the ing reagents: mPEG2-NHS-40K branched, mPEG-NHS-lOK branched, HS-20K branched, mPEG2-NHS-60K branched; mPEG-SBA-SK, mPEG-SBA-20K, mPEG-SBA-30K; mPEG-SMB-20K, mPEG-SMB-30K; mPEG-butyrldehyde; mPEG-SPA- 20K, mPEG-SPA-30K; and PEG-NHS-5K-biotin. PEGylated PH20 also can be prepared using PEG reagents available from Dowpharma, a diVision of Dow Chemical Corporation; including PH20 polypeptides PEGylated with Dowpharma's p-nitrophenyl-carbonate PEG (30 kDa) and with propionaldehyde PEG (30 kDa).

In one example, the tion includes conjugation of mPEG-SBA, for example, mPEG-SBA-30K (haVing a molecular weight of about 30 kDa) or r succinimidyl ester of a PEG ic acid derivative, to a PH20 polypeptide. Succinimidyl esters of PEG butanoic acid derivatives, such as mPEG-SBA-30K readily couple to amino groups of proteins. For example, covalent conjugation of m-PEG-SBA-30K and rHuPH20 (which is approximately 60 KDa in size) provides stable amide bonds between rHuPH20 and mPEG, as shown in Scheme 1, below.

Scheme 1 0 H3CO+CH2CH203-CH2CH2CH2CO—N|| + HzN—rHuPHZO n mPEG-SBA l 0 H300+CH20H20)’CH20H20H20—N—H H rHUPHZO I1 PEGylated rHuPH20 Typically, the mPEG-SBA-30K or other PEG is added to the PH20 polypeptide at a PEG:polypeptide molar ratio of 10:1 in a suitable , e.g., 130 mM NaCl /10 mM HEPES at pH 6.8 or 70 mM phosphate buffer, pH 7, followed by sterilization, e.g., e ion, and continued ation, for example, with stirring, overnight at 4 0C in a cold room. In one example, the conjugated PEG- PH20 is concentrated and buffer-exchanged.

Other methods of coupling imidyl esters ofPEG butanoic acid derivatives, such as mPEG-SBA-30K are known in the art (see e.g., U.S. 5,672,662; U.S. 6,737,505; and U.S. 2004/0235734). For example, a polypeptide, such as a PH20 polypeptide, can be coupled to an NHS activated PEG derivative by reaction in a borate buffer (0.1 M, pH 8.0) for one hour at 4 OC. The resulting PEGylated protein can be puriﬁed by ultraﬁltration. Another WO 2013/102144 2012/072182 -l77- method reacts polypeptide with mPEG-SBA in deionized water to which triethylamine is added to raise the pH to 7.2-9. The resulting mixture is stirred at room ature for several hours to complete the PEGylation.

Methods for PEGylation of PH20 polypeptides, ing, for example, - derived hyaluronidases and bacterial hyaluronan-degrading s, are known to one of skill in the art. See, for e, European Patent No. EP 2, which describes the PEGylation of bovine testes hyaluorindase and chondroitin ABC lyase. Also, U.S.

Publication No. 2006014968 describes PEGylation of a human hyaluronidase derived from human PH20. For example, the PEGylated hyaluronan-degrading enzyme generally contains at least 3 PEG moieties per molecule. In some es, the PH20 ptide ns three to six PEG molecules. In other examples, the enzyme can have a PEG to protein molar ratio between 5:1 and 9:1, for example, 7:1.

F. Pharmaceutical Compositions and Formulations, Dosages and Administration Pharmaceutical compositions of any of the modiﬁed PH20 polypeptides are provided herein for stration. Pharmaceutically acceptable itions are prepared in view of als for a regulatory agency or other agency prepared in accordance with generally recognized pharmacopeia for use in animals and in humans. Typically, the compounds are formulated into pharmaceutical compositions using techniques and procedures well known in the art (see e.g., Ansel Introduction to Pharmaceutical Dosage Forms, Fourth Edition, 1985, 1 26).

In particular, provided herein are pharmaceutical compositions that are stable as a liquid formulation for prolonged periods of time for at least 1 month at temperatures from or from about 2 0C to 8 OC, inclusive or for at least 3 days at a temperature from or from about 0C to 42 OC, inclusive. Pharmaceutical compositions, in particular liquid formulations, can be limited by the stability of the active agent, which can be tible to effects of storage conditions (time or length of storage, temperature and/or agitation) and/or formulation components contained in the composition. Hence, the stable pharmaceutical compositions generally contain a modified PH20 polypeptide as described in Section C.1.b that exhibits increased stability manifested as an increased resistance to one or more protein denaturation conditions. Such protein denaturation conditions can include, but are not limited to, elevated temperature greater than or equal to or about 30 OC, agitation, low or no salt, and presence of excipients. The increased stability is characterized by improved storage time, decreased ntation, and/or decreased aggregate formation, while still retaining the activity of the active agent(s), e.g., the PH20 hyaluronidase. Such formulations can be provided as "ready- to use" liquid formulations without further reconstitution and/or t any requirement for WO 02144 PCT/US2012/072182 -l78- further dilution. In some examples, the formulations also can be prepared in a lyophilized or concentrated form. ceutical compositions containing a modiﬁed PH20 polypeptide can be co- administered With another therapeutic agent. In such examples, the modiﬁed PH20 polypeptides can be formulated separately as a pharmaceutical composition and administered prior to, simultaneously with, intermittently with, or subsequent to a second composition containing an active therapeutic agent. In other examples, modiﬁed PH20 polypeptides can be co-formulated With pharmaceutical formulations of other eutic agents.

In particular, provided herein are co-formulations containing a modiﬁed PH20 polypeptide as described herein and a therapeutic agent that is a chemotherapeutic agent, an analgesic agent, an anti-inﬂammatory agent, an crobial agent, an cidal agent, a trichomonacidal agent, an arkinson agent, an anti-malarial agent, an anticonvulsant agent, an anti-depressant agent, and antiarthritics agent, an anti-fungal agent, an antihypertensive agent, an antipyretic agent, an anti-parasite agent, an antihistamine agent, an alpha-adrenergic agonist agent, an alpha r agent, an anesthetic agent, a ial dilator agent, a biocide agent, a bactericide agent, a iostat agent, a beta adrenergic blocker agent, a calcium channel blocker agent, a cardiovascular drug agent, a contraceptive agent, a decongestant agent, a diuretic agent, a sant agent, a stic agent, a electrolyte agent, a hypnotic agent, a hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an ophthalmic agent, a parasympathomimetic agent, a psychic energizer agent, a sedative agent, a sympathomimetic agent, a tranquilizer agent, an urinary agent, a vaginal agent, a Viricide agent, a Vitamin agent, a non-steroidal anti-inﬂammatory agent, an ensin converting enzyme tor agent, a polypeptide, a protein, a nucleic acid, a drug, an organic molecule or a sleep inducer. For example, d PH20 polypeptides provided herein can be co-formulated with an antibody such as a monoclonal antibody, an Immune Globulin, an antibiotic, a bisphosphonate, a cytokine, a chemotherapeutic agent, a coagulation factor or an insulin. Exemplary therapeutic agents that can be co-formulated With a modiﬁed PH20 polypeptide are described in described in Section H. In particular, provided herein are co-formulations containing a modiﬁed PH20 polypeptide and an insulin, such as a fast-acting insulin, for example, a regular insulin or a fast-acting (rapid-acting) insulin analog. The co-formulations provided herein include stable co-formulations, Whereby the active agents, i.e., the modiﬁed PH20 polypeptide and the therapeutic agent, exhibit increased stability and retain actiVity for ged periods as described herein.

WO 02144 PCT/US2012/072182 -l79- Formulations containing PH2O provided herein, including separate formulations thereof and co-formulations, are stable for prolonged s of time, ing at varied temperatures and under varied storage or use conditions such as agitation. For example, the formulations provided herein are stable and retain activity of active agent(s) (e. g., PH2O hyaluronidase) at "refrigerator" conditions, for example, at 2 °C to 8 °C, such as at or about 4 °C, for at least at least 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, 13 months, 14 months, 15 months, 16 , 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 25 months, 26 months, 27 months, 28 months, 29 months or 30 months or more. In another example, the formulations provided herein are stable and retain activity of active agent(s) (e. g., PH2O hyaluronidase) at room temperature for example at 18 °C to 32 °C, generally 20 °C to 32 °C, such as 28 °C to 32 °C, for at least 2 weeks to 1 year, for example, at least 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, at least 7 months, at least 8 months, at least 9 months, or at least 1 year or more. In a further example, the formulations provided herein are stable and retain actiVity of active agent(s) (e.g., PH2O hyaluronidase) at elevated temperatures of about or greater than 30 °C, lly from or from about 30 0C to 42 0C, such as 32 0C to 37 0C or 35 0C to 37 0C or about or 37 0C for at least 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 35 days, 40 days, 45 days, 50 days, 60 days or more.

Compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, and sustained release formulations. A ition can be ated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, e, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and other such agents. Topical formulations also are plated. The formulation should suit the mode of administration. 1. Formulations — s, injectables, ons The formulation lly is made to suit the route of administration. Parenteral administration, generally characterized by injection or infusion, either subcutaneously, intramuscularly, intravenously or intradermally is contemplated herein. Preparations for eral administration include e solutions ready for injection, sterile dry soluble products, such as lyophilized powders, ready to be combined with a solvent just prior to use, including hypodermic s, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions.

WO 2013/102144 PCT/US2012/072182 lnj ectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.

For example, the compositions ning a modiﬁed PHZO polypeptide, formulated separately or co-formulated with another therapeutic agent, can be provided as a pharmaceutical ation in liquid form as a solution, syrup or suspension. In liquid form, the pharmaceutical preparations can be provided as a concentrated preparation to be diluted to a therapeutically ive concentration before use. Generally, the preparations are ed in a dosage form that does not require dilution for use. In another e, ceutical preparations can be presented in lyophilized form for reconstitution with water or other suitable vehicle before use. lnj ectables are ed for local and systemic administration. For purposes herein, local stration is desired for direct administration to the affected interstitium. The solutions can be either aqueous or nonaqueous. If stered intravenously, suitable carriers include logical saline or phosphate buffered saline (PBS), and solutions ning thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.

The concentration of the pharmaceutically active compound is adjusted so that an ion or infusion provides an effective amount to produce the desired pharmacological effect. The exact dose depends on the age, weight and condition of the patient or animal as is known in the art. The unit-dose parenteral preparations can be packaged in, for example, an ampoule, a cartridge, a vial or a syringe with a needle. The volume of liquid solution or reconstituted powder preparation, containing the pharmaceutically active compound, is a function of the disease to be treated and the particular article of manufacture chosen for package. All preparations for parenteral administration must be sterile, as is known and practiced in the art. The percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the t.

Pharmaceutical compositions can include carriers or other excipients. For e, pharmaceutical compositions ed herein can contain any one or more of a diluents(s), adjuvant(s), antiadherent(s), binder(s), coating(s), filler(s), ﬂavor(s), color(s), lubricant(s), glidant(s), preservative(s), detergent(s), sorbent(s) or sweetener(s) and a combination thereof or vehicle with which a modiﬁed PHZO polypeptide is administered. For example, pharmaceutically acceptable carriers or excipients used in eral preparations include aqueous vehicles, nonaqueous vehicles, crobial agents, isotonic agents, s, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, WO 2013/102144 PCT/US2012/072182 sequestering or chelating agents and other pharmaceutically acceptable substances.

Formulations, including liquid preparations, can be prepared by conventional means With ceutically acceptable additives or excipients.

Examples of suitable ceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. . Such compositions Will contain a therapeutically effective amount of the compound, generally in purified form, together With a suitable amount of carrier so as to provide the form for proper stration to the patient. Such pharmaceutical carriers can be sterile liquids, such as water or oils, ing those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, n oil, mineral oil, and sesame oil. Water is a typical carrier When the ceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions also can be employed as liquid carriers, ularly for inj ectable solutions. es of aqueous vehicles include Sodium Chloride lnj ection, s Inj ection, Isotonic Dextrose Inj ection, Sterile Water Inj ection, Dextrose and Lactated Ringers lnj . Nonaqueous parenteral es include ﬁxed oils of ble origin, cottonseed oil, corn oil, sesame oil and peanut oil. Suspending and dispersing agents include, but are not limited to, sorbitol syrup, cellulose derivatives or hydrogenated edible fats, sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Emulsifying agents include, but are not limited to, lecithin or acacia. Detergents include, but are not limited to, rbate 8O (TWEEN 80). Non-aqueous vehicles include, but are not limited to, almond oil, oily esters, or fractionated vegetable oils. Anti-microbial agents or preservatives include, but are not limited to, methyl or propyl-p-hydroxybenzoates or sorbic acid, m-cresol, phenol. A diluent includes, but is not limited to, lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose. A lubricant includes, but is not limited to, magnesium stearate, calcium stearate or talc. A binder es, but is not limited to, starch, natural gums, such as gum acacia, gelatin, glucose, molasses, polyvinylpyrrolidine, celluloses and derivatives thereof, povidone, crospovidones and other such binders known to those of skill in the art.

Isotonic agents include, but are not limited to, sodium chloride and dextrose. Buffers include, but are not limited to, phosphate and citrate. idants e sodium bisulfate. Local anesthetics include procaine hydrochloride. A sequestering or chelating agent of metal ions includes EDTA. Other suitable pharmaceutical excipients include, but are not limited to, starch, glucose, lactose, dextrose, sucrose, gelatin, malt, rice, ﬂour, chalk, silica gel, sodium stearate, ol monostearate, talc, sodium de, dried skim milk, glycerol, propylene, glycol, saline, water, and ethanol. Pharmaceutical carriers also include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles and sodium hydroxide, WO 2013/102144 PCT/US2012/072182 hydrochloric acid, citric acid or lactic acid for pH adjustment. A composition, if desired, also can contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, or pH buffering agents, for example, acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, stabilizers, solubility enhancers, and other such agents such as for example, sodium acetate, sodium phosphate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins.

In particular, antimicrobial agents (e. g., preservatives) in bacteriostatic or fungistatic concentrations (e.g., an anti-microbial effective amount) can be added to parenteral preparations packaged in multiple-dose containers, which include phenols or s, mercurials, benzyl alcohol, butanol, methyl and propyl p-hydroxybenzoic acid , thimerosal, benzalkonium chloride and benzethonium chloride.

The volume of the formulations, including the separately formulated or co-formulated PHZO-containing formulations provided herein, can be any volume suitable for the container in which it is ed. In some examples, the formulations are provided in a Vial, e, pen, reservoir for a pump or a closed loop system, or any other suitable ner. For example, the formulations provided herein are between or about between 0.1 mL to 500 mL, such as 0.1mL to 100 mL, 1 mL to 100 mL, 0.1 mL to 50 mL, such as at least or about at least or about or 0.1mL, lmL, 2 mL, 3 mL, 4 mL, 5 mL, 10 mL, 15 mL, 20 mL, 30 mL, 40 mL, 50 mL or more. a. Lyophilized Powders Of st herein are lyophilized powders, which can be reconstituted for administration as solutions, emulsions and other mixtures. They may also be reconstituted and formulated as solids or gels.

The sterile, lyophilized powder is prepared by dissolving a nd of enzyme in a buffer solution. The buffer solution may contain an excipient which improves the stability or other pharmacological component of the powder or reconstituted solution, prepared from the powder. Subsequent sterile filtration of the solution ed by lyophilization under standard conditions known to those of skill in the art provides the desired formulation. A liquid formulation as described herein above can be prepared. The ing mixture is sterile ﬁltered or treated to remove particulates and to insure sterility, and apportioned into Vials for lyophilization. For example, the lyophilized powder can be prepared by dissolving an excipient, such as dextrose, sorbitol, se, corn syrup, l, in, glucose, sucrose or other le agent, in a suitable buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art. Then, a selected enzyme is added to the resulting mixture, and stirred until it dissolves.

WO 2013/102144 PCT/US2012/072182 Each Vial is made to contain a single dosage or multiple dosages of the compound.

The lyophilized powder can be stored under appropriate conditions, such as at about 4 0C to room temperature. titution of this lyophilized powder with an appropriate buffer solution provides a ation for use in eral stration. b. Exemplary Formulations Single dose ations of PH20 are known in the art. For example, Hylenex® recombinant (hyaluronidase human injection) contains, per mL, 8.5 mg NaCl (145 mM), 1.4 mg dibasic sodium phosphate (9.9 mM), 1.0 mg human albumin, 0.9 mg edetate disodium (2.4 mM), 0.3 mg CaClz (2.7 mM) and NaOH to adjust the pH to 7.4. Other formulations of human soluble hyaluronidase, such as the rHuPH20 formulations described in U.S. Pat. Pub.

No. US2011/0053247, include 130 mM NaCl, 10 mM Hepes, pH 7.0; or 10 mM histidine, 130 mM NaCl, pH 6.0. Any of the d PH20 polypeptides provided herein can be similarly formulated.

In addition to a therapeutically effective amount of a modified PH20 polypeptide and/or other therapeutic agent, exemplary ceutical compositions provided herein, including separately formulated- and co-formulated-PH20 containing formulations, can n a concentration ofNaCl and are prepared at a requisite pH to maintain the stability of the active s) (e. g., PH20 hyaluronidase and/or other co-formulated therapeutic agent).

For multi-dose formulations and other formulations stored for a prolonged time, the compositions generally also n one or more preservatives. Further stabilizing agents and other excipients also can be included. Exemplary components are described below. i. Salt (e.g. NaCl) In examples herein, the pharmaceutical compositions provided herein n a concentration of salt, such as sodium chloride (NaCl), to maintain the stability of the active agent(s) (e.g., PH20 onidase). Salt, such as NaCl, is generally required to retain PH20 stability and activity. Low salt concentrations of generally less than 120 mM can have deleterious effects on PH20 activity over time and depending on ature conditions.

Hence, the absence of salt (6. g. NaCl) or a low concentration of salt (e. g. NaCl) can result in instability of the protein. In some examples herein, however, d PH20 polypeptides that t increased stability in the absence of low or no salt, such as low or no NaCl (see e.g., Section C.1.b.iii), are not susceptible to denaturation. Also, the presence of salt (6.g.

NaCl) can have differing effects on other therapeutic agents. For example, the solubility of insulin and insulin analogs tends to increase with lower salt concentration (e.g. <140 mM) , and high salt concentrations can result in crystallization/aggregation of insulin, especially at lower temperatures (see e.g., U.S. Provisional Appl. No. 61/520,962; U.S. Application Serial WO 2013/102144 PCT/US2012/072182 Nos. 13/507,263 and 13/507,262; and International PCT Application No.

PCT/US2012/042816). Thus, pharmaceutical compositions provided herein are prepared in accordance with the ements of the active agent(s). It is within the level of one of skill in the art to assess the stability of the active agent(s) in the formulation and under various storage conditions (see e.g., Section G). In particular examples herein, the pharmaceutical compositions, including the tely formulated or mulated PH20-containing formulations provided herein, n NaCl at a concentration of between or about between mM to 200 mM, such as 10 mM to 50 mM, 50 mM to 200 mM, 50 mM to 120 mM, 50 mM to 100 mM, 50 mM to 90 mM, 120 mM to 160 mM, 130 mM to 150 mM, 80 mM to 140 mM, 80 mM to 120 mM, 80 mM to 100 mM, 80 mM to 160 mM, 100 mM to 140 mM, 120 mM to 120 mM or 140 mM to 180 mM. ii. pH and Buffer In examples herein, the pharmaceutical compositions provided herein are prepared at a pH to maintain the stability of the active agent(s) (e.g., PH20 hyaluronidase). For example, the pharmaceutical compositions provided herein are prepared at a pH of between or about between 6.5 to 7.8 such as between or about n 6.5 to 7.2, 7.0 to 7.8, 7.0 to 7.6 or 7.2 to 7.4. Reference to pH herein is based on ement of pH at room temperature. It is understood that the pH can change during storage over time, but typically will remain between or between about pH 6.5 to or to about 7.8. For example, the pH can vary by :: 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.3, 1.4, 1.5 or more. Exemplary co-formulations provided herein have a pH of or of about 7.0 :: 0.2, 7.1 :: 0.2, 7.2 :: 0.2, 7.3 :: 0.2, 7.4 :: 0.2, 7.5 :: 0.2 or 7.6 :: 0.2 when prepared. If necessary, pH can be adjusted using acidifying agents to lower the pH or alkalizing agents to increase the pH. Exemplary acidifying agents include, but are not limited to, acetic acid, citric acid, ic acid, hydrochloric acid, monobasic sodium phosphate solution, and phosphoric acid. Exemplary alkalizing agents include, but are not limited to, dibasic sodium phosphate solution, sodium ate, or sodium hydroxide.

The compositions are generally prepared using a buffering agent that maintains the pH range. Any buffer can be used in formulations ed herein so long as it does not adversely affect the ity of the active agent(s) (e. g., PH20 hyaluronidase), and supports the requisite pH range required. Examples of ularly suitable buffers include Tris, succinate, e, phosphate s, citrate, aconitate, malate and carbonate. Those of skill in the art, however, will recognize that formulations provided herein are not limited to a particular buffer, so long as the buffer provides an acceptable degree of pH stability, or "buffer capacity" in the range indicated. Generally, a buffer has an adequate buffer capacity WO 2013/102144 PCT/US2012/072182 within about 1 pH unit of its pK an er a]. In: The Theory and Practice of Industrial Pharmacy 3rd Edn. (Lachman, L., Lieberman, HA. and Kanig, J.L., Eds.), Lea and Febiger, Philadelphia, p. 45 8-460, 1986). Buffer suitability can be estimated based on published pK tabulations or can be determined empirically by methods well known in the art. The pH of the solution can be adjusted to the desired endpoint within the range as described above, for example, using any acceptable acid or base.

Buffers that can be included in the co-formulations provided herein include, but are not limited to, Tris thamine), histidine, phosphate s, such as dibasic sodium phosphate, and citrate buffers. Such buffering agents can be t in the co-formulations at concentrations between or about between 1 mM to 100 mM, such as 10 mM to 50 mM or 20 mM to 40 mM, such as at or about 30 mM. For example, such buffering agents can be present in the co-formulations in a concentration of or about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM,6mM,7mM, 8mM,9mM,lOmM,llmM,12mM,l3mM,l4mM,15mM,l6mM, 17 mM, 18 mM, 19 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, or more. iii. Preservative(s) In examples herein, dose formulations or formulations stored for prolonged periods contain an anti-microbially effective amount of preservative or mixture of preservatives in an amount to have a bacteriostatic or fungistatic effect. In particular es, the preservatives are t in a sufﬁcient concentration to provide the anti- microbial requirements of, for e, the United States Pharmacopoeia (USP) and the European Pharmacopoeia (EP), including the EP anti-microbial requirements (EPA) and the preferred EP anti-microbial requirements (EPB) (see Table 4). Since the presence of preservatives, and in particular phenolic preservatives, can have deleterious effects on the stability of PH20, such formulations typically contain a modified PH20 polypeptide that exhibits increased stability in the presence of preservatives, such as any described in Section C. l .b.i herein. Generally, the amount maintains the stability of the active agent(s) (e.g., PH20 hyaluronidase).

An anti-microbial effective amount of preservative is an amount that exhibits anti- ial activity by killing or inhibiting the propagation of microbial organisms in a sample of the ition as ed in an antimicrobial preservative effectiveness test (APET).

One of skill in the art is familiar with the antimicrobial preservative effectiveness test and standards to be meet under the USP and EPA or EPB in order to meet minimum requirements.

In general, the crobial preservative effectiveness test involves challenging a composition with prescribed inoculums of suitable rganisms, i.e., bacteria, yeast and WO 2013/102144 PCT/US2012/072182 fungi, storing the inoculated preparation at a prescribed temperature, withdrawing samples at speciﬁed intervals of time and counting the organisms in the sample (see, Sutton and Porter, (2002) PDA l ofPharmaceutical Science and Technology 56(4):300-311; The United States copeial Convention, Inc., (effective January 1, 2002), The United States Pharmacopeia 25"1 Revision, Rockville, MD, Chapter <51> Antimicrobial Effectiveness Testing; and European Pharmacopoeia, Chapter 5.1.3, Efﬁcacy of Antimicrobial Preservation). The microorganisms used in the challenge generally include three strains of bacteria, namely E. coli (ATCC No. 8739), Pseudomonas aeruginosa (ATCC No. 9027) and Staphylococcus aureus (ATCC No. 6538), yeast (Candida albicans ATCC No. 10231) and fungus (Aspergillus niger ATCC No. 16404), all of which are added such that the inoculated composition ns 105 or 106 colony forming units (cfu) of microorganism per mL of composition. The vative properties of the composition are deemed adequate if, under the conditions of the test, there is a signiﬁcant fall or no increase, as speciﬁed in Table 3 in the number of microorganisms in the inoculated ition after the times and at the atures prescribed. The criteria for evaluation are given in terms of the log ion in the number of viable microorganism as compared to the initial sample or the previous time point. miting es of preservatives that can be ed in the co-formulations provided herein include, but are not limited to, phenol, meta-cresol (m—cresol), methylparaben, benzyl alcohol, thimerosal, benzalkonium chloride, 4-chlorobutanol, chlorhexidine dihydrochloride, chlorhexidine onate, L-phenylalanine, EDTA, bronopol (2-bromonitropropane-1,3-diol), mercuric acetate, glycerol (glycerin), imidurea, exidine, sodium dehydroacetate, ortho-cresol (o-cresol), para-cresol (p-cresol), chlorocresol, cetrimide, benzethonium chloride, ethylparaben, propylparaben or butylparaben and any combination thereof For example, formulations provided herein can contain a single preservative. In other examples, the formulations contain at least two different preservatives or at least three different preservatives. For example, formulations provided herein can contain two preservatives such as L-phenylalanine and m-cresol, L-phenylalanine and methylparaben, L-phenylalanine and , m-cresol and methylparaben, phenol and methylparaben, m—cresol and phenol or other similar combinations. In one e, the preservative in the formulation contains at least one phenolic preservative. For example, the formulation contains phenol, m-cresol or phenol and m—cresol.

In the formulations provided herein, the total amount of the one or more preservative agents as a percentage (%) of mass concentration (w/v) in the formulation can be, for example, between from or between about from 0.1% to 0.4%, such as 0.1% to 0.3%, 0.15% to WO 2013/102144 2012/072182 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3%, or 0.3% to 0.4%. Generally, the formulations contain less than 0.4% (w/V) preservative. For example, the co-formulations provided herein contain at least or about at least 0.1% , 0.12%, 0.125%, 0.13%, 0.14%, 0.15%, 0.16% 0.17%, 0.175%, 0.18%, 0.19%, 0.2%, 0.25%, 0.3%, 0.325%, 0.35% but less than 0.4% total preservative.

In some es, the formulations provided herein contain between or between about 0.1% to 0.25% phenol and between or about between 0.05% to 0.2% m-cresol, such as n or about between 0.10% to 0.2% phenol and between or about between 0.06% to 0.18% ol, or between or about between 0.1% to 0.15% phenol and between or about n 0.08% to 0.15% m—cresol. For example, formulations provided herein contain or contain about 0.1% phenol and 0.075% m-cresol; 0.1% phenol and 0.15% m—cresol; 0.125% phenol and 0.075% m—cresol; 0.13% phenol and 0.075% m—cresol; 0.13% phenol and 0.08% m—cresol; 0.15% phenol and 0.175% m—cresol; or 0.17% phenol and 0.13% m-cresol. iv. izers In examples herein, the pharmaceutical itions provided herein optionally can contain one or more other stabilizing agent to maintain the stability of the active agent(s) (e.g., PH20 hyaluronidase). Included among the types of stabilizers that can be contained in the formulations provided herein are amino acids, amino acid derivatives, amines, sugars, polyols, salts and buffers, surfactants, and other agents. The formulations provided herein contain at least one izer. For example, the formulations provided herein contain at least one, two, three, four, ﬁve, six or more stabilizers. Hence, any one or more of an amino acids, amino acid derivatives, amines, sugars, polyols, salts and buffers, surfactants, and other agents can be included in the formulations herein. Generally, the formulations herein contain at least contain a surfactant and an appropriate buffer. Optionally, the formulations provided herein can contain other additional stabilizers. Other ents include, for example, one or more tonicity modiﬁers, one or more anti-oxidation agents, or other stabilizer.

Exemplary amino acid stabilizers, amino acid derivatives or amines include, but are not limited to, L-Arginine, Glutamine, Glycine, Lysine, Methionine, Proline, Lys-Lys, Gly- Gly, hylamine oxide (TMAO) or betaine. Exemplary sugars and polyols include, but are not d to, glycerol, ol, mannitol, ol, sucrose or trehalose. Exemplary salts and s include, but are not limited to, magnesium chloride, sodium sulfate, Tris such as Tris (100 mM), or sodium Benzoate. Exemplary surfactants include, but are not limited to, poloxamer 188 (e.g., ic® F68), polysorbate 80 (PS80), polysorbate 20 (PS20). Other stabilizers include, but are not limited to, hyaluronic acid (HA), human serum albumin (HSA), phenyl butyric acid, taurocholic acid, polyvinylpyrolidone (PVP) or zinc.

WO 2013/102144 PCT/US2012/072182 In particular examples herein, the formulations contain one or more ents, such as surfactants, to maintain the stability of the active agent(s) (e.g., PH20 hyaluronidase). For example, surfactants can inhibit aggregation of PH20 and minimize absorptive loss. The surfactants generally are nic surfactants. Surfactants that can be included in the formulations herein include, but are not d to, partial and fatty acid esters and ethers of polyhydric alcohols such as of glycerol, or sorbitol, poloxamers and polysorbates. For example, exemplary surfactants in the lations herein include any one or more of poloxamer 188 (PLURONICS® such as PLURONIC® F68), TETRONICS®, polysorbate 20, polysorbate 80, PEG 400, PEG 3000, Tween® (e.g., Tween® 20 or Tween® 80), Triton® X- 100, SPAN®, MYRJ®, BRIJ®, CREMOPHOR®, polypropylene glycols or polyethylene glycols. In some examples, the formulations herein contain poloxamer 188, polysorbate 20, polysorbate 80, generally poloxamer 188 (pluronic F68). The formulations provided herein generally contain at least one surfactant, such as 1, 2 or 3 tants.

In the formulations ed herein, the total amount of the one or more surfactants as a percentage (%) of mass concentration (w/V) in the formulation can be, for example, between from or between about from 0.005% to 1.0%, such as between from or between about from 0.01% to 0.5%, such as 0.01% to 0.1% or 0.01% to 0.02%. Generally, the formulations contain at least 0.01% surfactant and contain less than 1.0%, such as less than 0.5% or less than 0.1% surfactant. For example, the ations provided herein can contain at or about 0.001%, 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.035%, 0.04%, 0.045%, 0.05%, , 0.06%, , 0.07%, 0.08%, or 0.09% surfactant. In ular examples, the formulations provided herein contain or contain about 0.01% to or to about 0.05% surfactant.

Tonicity modiﬁers can be included in the formulation provided herein to produce a solution with the desired osmolality. The formulations ed herein have an osmolality of between or about between 245 mOsm/kg to 305 mOsm/kg. For example, the osmolality is or is about 245 mOsm/kg, 250 mOsm/kg, 255 mOsm/kg, 260 mOsm/kg, 265 mOsm/kg, 270 mOsm/kg, 275 mOsm/kg, 280 mOsm/kg, 285 mOsm/kg, 290 mOsm/kg, 295 mOsm/kg, 300 mOsm/kg or 305 mOsm/kg. In some examples, the formulations have an osmolality of or of about 275 mOsm/kg. Tonicity modif1ers e, but are not limited to, glycerin, NaCl, amino acids, cohols, trehalose, and other salts and/or sugars. The particular amount can be empirically ined in order to retain enzyme actiVity, and/or tonicity.

In other instances, glycerin (glycerol) is ed in the formulations. For example, formulations provided herein typically contain less than 60 mM glycerin, such as less than 55 mM, less than 50 mM, less than 45 mM, less than 40 mM, less than 35 mM, less than 30 mM, WO 2013/102144 2012/072182 less than 25 mM, less than 20 mM, less than 15 mM, 10 mM or less. The amount of glycerin typically depends on the amount ofNaCl present: the more NaCl present in the formulation, the less in is required to achieve the d osmolality or osmolarity. Thus, for example, in ations ning higher NaCl concentrations, little or no glycerin need be included in the formulation. In contrast, in formulations containing slightly lower NaCl concentrations, glycerin can be included. For example, formulations provided herein can contain glycerin at a concentration of 40 mM to 60 mM, such as less than 50 mM, such as 20 mM to 50 mM, for example at or about 50 mM.

The formulations provided herein also can contain antioxidants to reduce or prevent oxidation, in ular ion of the PH20 polypeptide. For example, oxidation can be effected by high concentrations of surfactant or hyaluronan oligomers. Exemplary antioxidants include, but are not limited to, cysteine, tryptophan and methionine. In particular examples, the anti-oxidant is methionine. The formulations provided herein can include an antioxidant at a concentration from between or from about between 5 mM to or to about 50 mM, such as 5 mM to 40 mM, 5 mM to 20 mM or 10 mM to 20 mM. For example, methionine can be provided in the formulations herein at a concentration from between or from about between 5 mM to or to about 50 mM, such as 5 mM to 40 mM, 5 mM to 20 mM or 10 mM to 20 mM. For e, an antioxidant, for example methionine, can be included at a tration that is or is about 5 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, 21 mM, 22 mM, 23 mM, 24 mM, 25 mM, 26 mM, 27 mM, 28 mM, 29 mM, 30 mM, 35 mM, 40 mM, 45 mM or 50 mM. In some examples, the ations contain 10 mM to 20 mM methionine, such as or about 10 mM or 20 mM nine.

The formulations provided herein also can contain an amino acid stabilizer, which contributes to the stability of the preparation. The stabilizer can be a non-polar or basic amino acid. Exemplary non-polar and basic amino acids include, but are not limited to, alanine, histidine, arginine, lysine, ornithine, isoleucine, valine, methionine, glycine and proline. For example, the amino acid stabilizer is glycine or proline, typically glycine. The stabilizer can be a single amino acid or it can be a combination of 2 or more such amino acids. The amino acid stabilizers can be natural amino acids, amino acid analogues, modiﬁed amino acids or amino acid equivalents. Generally, the amino acid is an L-amino acid. For example, when proline is used as the stabilizer, it is generally L-proline. It is also possible to use amino acid equivalents, for e, proline analogues. The concentration of amino acid stabilizer, for example glycine, included in the formulation ranges from 0.1 M to 1 M amino acid, typically 0.1 M to 0.75 M, lly 0.2 M to 0.5 M, for example, at least at or about 0.1 M, 0.15 M, WO 2013/102144 PCT/US2012/072182 -l90- 0.2 M, 0.25 M, 0.3 M, 0.35 M, 0.4 M, 0.45 M, 0.5 M, 0.6 M, 0.7 M, 0.75 M or more amino acid. The amino acid, for example glycine, can be used in a form of a pharmaceutically acceptable salt, such as hydrochloride, hydrobromide, sulfate, acetate, etc. The purity of the amino acid, for example glycine, should be at least 98%, at least 99%, or at least 99.5% or more.

In examples herein, if necessary, hyaluronidase inhibitors are included in a formulation to stabilize PH20, in particular to reduce the effects of otherwise destabilizing agents and conditions, such as, for example, low salt, high pH, the presence of preservatives and elevated temperatures, present in the formulation. Such a component generally is not ed for pharmaceutical compositions containing a modiﬁed PH20 ptide as provided herein that exhibits increased stability under such conditions. When provided, the hyaluronidase inhibitor is provided at least at its equilibrium concentration. One of skill in the art is familiar with various classes of hyaluronidase inhibitors (see e. g., Girish et al. (2009) Current Medicinal Chemistry, 16:2261-2288, and references cited therein). One of skill in the art knows or can determine by standard s in the art the equilibrium tration of a hyaluronidase inhibitor in a reaction or stable ition herein.

An exemplary onidase inhibitor for use in the compositions herein is hyaluronan (HA). Hyaluronic acid (HA, also known as hyaluronan and hyaluronate) is the natural substrate for PH20. HA is a non-sulfated glycosaminoglycan that is widely distributed throughout connective, epithelial, and neural tissues. It is a r of up to ,000 haride units, themselves composed of D-glucuronic acid and D-N- glucosamine. The molecular weight of HA ranges from about 5 kDa to 200,000 kDa.

Any size HA can be used in the compositions as a stabilizer. In some examples, the HA is a disaccharide, ed of D-glucuronic acid and D-N-acetylglucosamine. In other examples, the HA is an oligosaccharide, such as a tetrasaccharide, containing 2 repeating disaccharide units, or alternatively, the HA used in the co-formulations provided herein can contain multiple repeating disaccharide units, such as 3, 4, 5, 6, 7, 8, 9, 10, ll, l2, l3, 14, 15, l6, l7, l8, 19, 20, 25, 30 or more disaccharide units. In another example, the HA used in the formulations ed herein has a molecular weight that is from or from about 5 kDa to or to about 5,000 kDa; from or from about 5 kDa to or to about 1,000 kDa; from or from about 5 kDa to or to about 500 kDa; or from or from about 5 kDa to or to about 200 kDa. ary HA oligosaccharides for use in the formulations herein have a molecular weight of or of about 6.4 kDa, 74.0 kDa. or 234.4 kDa. The formulations can contain 1 mg/mL to 20 mg/mL HA, 8 mg/mL to 12 mg/mL, such as at least or about 1 mg/mL, 2 mg/mL, 3 mg/mL, 4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL, 8 mg/mL, 9 mg/mL, 10 mg/mL, 11 mg/mL, 12 mg/mL, l3 WO 02144 PCT/US2012/072182 -l9l- mg/mL, 14 mg/mL, 15 mg/mL, 16 mg/mL, 17 mg/mL, 18 mg/mL, 19 mg/mL or 20 mg/mL or more HA. In some examples, the molar ratio of HA to PH20 is or is about 100,000:1, 95,000:1, 90,000:1, 85,000:1, 80,000:1, 75,000:1, 70,000:1, 65,000:1, 60,000:1, 55,000:1, :1, 45,000:1, :1, 35,000:1, 30,000:1, 25,000:1, 20,000:1, :1, 10,000:1, 1,1,000:1, 900:1, 800:1, 700:1, 600:1, 500:1, 400:1, 300:1, 200:1, or 100:1 or less.

In some examples, a nicotinic compound is used as a stabilizing agent. Nicotinic compounds include, but are not limited to, nicotinamide, nicotinic acid, niacin, niacinamide, Vitamin B3 and/or salts f and/or any combination thereof. In particular applications, the stabilizing agent can include a nicotinic compound an amino acid or amino acids (see e.g., International ation No. W02010149772). For example, the amino acid can be arginine, glutamic acid and/or salts thereof or ations thereof. 2. itions for Other Routes of Administration Depending upon the condition treated other routes of administration, such as topical application, transdermal patches, oral and rectal administration are also contemplated herein.

For example, pharmaceutical dosage forms for rectal administration are rectal suppositories, capsules and tablets for systemic effect. Rectal suppositories include solid bodies for insertion into the rectum Which melt or soften at body temperature releasing one or more pharmacologically or therapeutically active ingredients. Pharmaceutically acceptable substances utilized in rectal suppositories are bases or vehicles and agents to raise the melting point. Examples of bases include cocoa butter (theobroma oil), in-gelatin, carbowax (polyoxyethylene glycol) and appropriate mixtures of mono-, di- and cerides of fatty acids. Combinations of the various bases may be used. Agents to raise the melting point of suppositories include spermaceti and wax. Rectal itories may be prepared either by the compressed method or by molding. The typical weight of a rectal suppository is about 2 to 3 gm. s and capsules for rectal administration are manufactured using the same pharmaceutically acceptable substance and by the same methods as for formulations for oral administration. Formulations suitable for rectal administration can be provided as unit dose suppositories. These can be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

For oral administration, pharmaceutical compositions can take the form of, for example, tablets or capsules ed by conventional means With pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinyl pyrrolidone or hydroxypropyl methylcellulose); ﬁllers (e. g., lactose, microcrystalline cellulose or m hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); WO 02144 2012/072182 -l92- disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e. g., sodium lauryl sulphate). The tablets can be coated by s well-known in the art. ations suitable for buccal (sublingual) administration include, for example, lozenges containing the active compound in a ﬂavored base, usually sucrose and acacia or anth; and pastilles containing the compound in an inert base such as gelatin and in or sucrose and acacia.

Topical mixtures are prepared as described for the local and systemic administration.

The resulting mixtures can be solutions, sions, emulsion or the like and are formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, es, dermal patches or any other formulations suitable for topical administration.

The compounds or pharmaceutically acceptable derivatives thereof may be formulated as aerosols for topical application, such as by inhalation (see, e.g., U. S. Patent Nos. 4,044,126, 4,414,209, and 4,364,923, Which describe aerosols for delivery ofa steroid useful for treatment of inﬂammatory diseases, particularly asthma). These formulations, for administration to the respiratory tract, can be in the form of an aerosol or on for a nebulizer, or as a microf1ne powder for insufﬂation, alone or in combination With an inert carrier such as lactose. In such a case, the particles of the formulation will typically have diameters of less than 50 microns, or less than 10 microns.

The compounds can be formulated for local or topical application, such as for topical ation to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or intraspinal application. Topical stration is contemplated for transdermal ry and also for administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the active compound alone or in combination With other pharmaceutically acceptable excipients also can be administered.

Formulations suitable for transdermal administration are provided. They can be provided in any suitable format, such as discrete patches adapted to remain in intimate t With the epidermis of the recipient for a prolonged period of time. Such s n the active compound in an optionally buffered aqueous solution of, for example, 0.1 to 0.2 M tration With respect to the active compound. Formulations suitable for transdermal administration also can be delivered by iontophoresis (see, e. g., Tyle, P, Pharmaceutical Research 3(6):318-326 (1986)) and typically take the form of an optionally buffered s solution of the active compound.

WO 2013/102144 2012/072182 Pharmaceutical compositions also can be administered by controlled release formulations and/or delivery devices (see e.g., in US. Patent Nos. 3,536,809; 123; 3,630,200; 3,845,770;; 3,916,899; 4,008,719;; 4,769,027; 5,059,595; 5,073,543; 5,120,548; ,591,767; 5,639,476; 5,674,533 and 5,733,566). 3. Dosages and Administration The modiﬁed PH20 ptides provided herein can be formulated as pharmaceutical compositions for single dosage or multiple dosage stration. The PH20 ptide is included in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side s on the patient treated. The therapeutically ive concentration can be determined empirically by testing the polypeptides in known in vitro and in vivo systems such as by using the assays provided herein or known in the art (see e. g., i et al. (1996) Anal. Biochem, 240: 60-67; Filocamo et al. (1997) J Virology, 71: 1417- 1427; Sudo et al. (1996) Antiviral Res. 32: 9-18; Bouffard et al. (1995) Virology, 209:52-59; Bianchi et al. (1996) Anal. Biochem, 237: 239-244; Hamatake et al. (1996) Intervirology 39:249-258; Steinkuhler et al. (1998) Biochem, 37:8899-8905; D’Souza et al. (1995) J Gen.

Virol., 76:1729-1736; Takeshita et al. (1997) Anal. Biochem, 247:242-246; see also e.g., Shimizu et al. (1994) J. Virol. 68:8406-8408; Mizutani et al. (1996) J. Virol. 70:7219-7223; Mizutani et al. (1996) Biochem. Biophys. Res. Commun, 227:822-826; Lu et al. (1996) Proc.

Natl. Acad. Sci (USA), 93:1412-1417; Hahm et al., (1996) Virology, 226:318-326; Ito et al. (1996) J. Gen. Virol., 77:1043-1054; ni et al. (1995) Biochem. Biophys. Res. Commun, 212:906-911; Cho et al. (1997) J. Virol. Meth. 65:201-207 and then extrapolated therefrom for dosages for humans.

The amount of a modified PH20 to be administered for the ent of a disease or condition can be determined by standard al techniques. In addition, in vitro assays and animal models can be employed to help identify optimal dosage ranges. The precise dosage, which can be determined empirically, can depend on the particular , the route of administration, the type of disease to be treated and the seriousness of the disease.

Hence, it is understood that the precise dosage and duration of treatment is a function of the disease being treated and can be determined empirically using known testing protocols or by olation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values also can vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, speciﬁc dosage regimens should be adjusted over time according to the dual need and the professional judgment of the person administering or ising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the WO 2013/102144 PCT/US2012/072182 —194— scope or use of compositions and combinations containing them. The compositions can be administered hourly, daily, weekly, monthly, yearly or once. Generally, dosage regimens are chosen to limit toxicity. It should be noted that the attending physician would know how to and when to terminate, interrupt or adjust therapy to lower dosage due to toxicity, or bone marrow, liver or kidney or other tissue dysfunctions. Conversely, the ing physician would also know how to and when to adjust treatment to higher levels if the clinical response is not te (precluding toxic side s).

Typically, a therapeutically effective dose of a modified PH20 enzyme is at or about Unit (U) to 500,000 Units, 100 Units to 100,000 Units, 500 Units to 50,000 Units, 1000 Units to 10,000 Units, 5000 Units to 7500 Units, 5000 Units to 50,000 Units, or 1,000 Units to 10,000 Units, generally 1,000 to 50,000 Units, in a stabilized solution or suspension or a lyophilized form. For example, a PH20 polypeptide, can be administered at a dose of at least or about at least or 10 U, 20 U, 30 U, 40 U, 50 U, 100 U, 150 U, 200 U, 250 U, 300 U, 350 U, 400 U, 450 U, 500 U, 600 U, 700 U, 800 U, 900 U, 1000 U, 2,000 U, 3,000 U, 4,000 Units, 5,000 U or more. The formulations can be provided in unit-dose forms such as, but not limited to, ampoules, syringes and individually packaged tablets or es.

The PH20 enzyme can be administered alone, or with other pharmacologically effective s) or therapeutic agent(s), in a total volume of 0.1 -100 mL, 1 -50 mL, 10- 50 mL, 10-30 mL, 1-20 mL, or 1-10 mL, typically 10-50 mL. Typically, volumes of injections or infusions of a PH20-containing ition are at least or at least about 0.01 mL, 0.05 mL, 0.2mL,0.3mL,0.4mL,0.5mL,1mL,2mL,3mL,4mL,5mL,6mL,7mL,8 mL, 9 mL, 10 mL, 20 mL, 30 mL, 40 mL, 50 mL or more. The formulations provided herein contain a modified PH20 polypeptide in an amount between or about n 30 Units/mL to 3000 U/mL, 300 U/mL to 2000 U/mL or 600 U/mL to 2000 U/mL or 600 U/mL to 1000 U/mL, such as at least or about at least 30 U/mL, 35 U/mL, 40 U/mL, 50 U/mL, 100 U/mL, 200 U/mL, 300 U/mL, 400 U/mL, 500 U/mL, 600 U/mL, 700 U/mL, 800 U/mL, 900 U/mL, 1000 U/mL, 2000 U/mL or 3000 U/mL. For example, the formulations provided herein contain a PH20 that is in an amount that is at least 100 U/mL to 1000 U/mL, for example at least or about at least or about or 600 U/mL.

The PH20 polypeptide can be provided as a solution in an amount that is at least or about or is 100 U/mL, 150 U/mL, 200 U/mL, 300 U/mL, 400 U/mL, 500 U/mL, 600 U/mL, 800 U/mL or 1000 U/mL, or can be provided in a more concentrated form, for example in an amount that is at least or about or is 2000 U/mL, 3000 Units/mL, 4000 U/mL, 5000 U/mL, 8000 U/mL, 10,000 U/mL or 20,000 U/mL for use ly or for dilution to the effective WO 2013/102144 2012/072182 -l95- concentration prior to use. The PH20 polypeptide compositions can be provided as a liquid or lyophilized formulation.

When the PH20 is co-formulated with a therapeutic agent, dosages can be provided as a ratio of the amount of a PH20 polypeptide to the amount of therapeutic agent stered.

For example, a PH20 polypeptide can be administered at 1 hyaluronidase U/therapeutic agent U (1:1) to 50:1 or more, for example, at or about 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1,10:1, 11:1, 12:1, 13:1,14:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1 or more.

The formulations provided herein, including mulations and/or stable formulations, can be prepared for single dose administration, multiple dose administration or continuous infusion administrations. Implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained (see e.g., U. S. Patent No. 3,710,795), is also contemplated herein.

For example, formulations of pharmaceutically therapeutically active nds and derivatives thereof are provided for administration to humans and s in unit dosage forms or multiple dosage forms. For example, nds can be formulated as tablets, capsules, pills, powders, es, sterile eral solutions or suspensions, oral solutions or suspensions, or oil—water emulsions containing le quantities of the compounds or pharmaceutically acceptable derivatives f. Each unit dose contains a predetermined quantity of therapeutically active compound(s) sufﬁcient to produce the desired eutic effect, in association with the required pharmaceutical carrier, vehicle or diluent. Examples of unit dose forms include ampoules and syringes and individually ed tablets or capsules. Unit dose forms can be administered in fractions or multiples thereof. A multiple dose form is a plurality of identical unit dosage forms packaged in a single container to be administered in segregated unit dose forms. Examples of le dose forms include vials, bottles of tablets or es or bottles of pints or gallons. Hence, multiple dose form is a multiple of unit doses that are not segregated in packaging. Generally, dosage forms or compositions containing active ingredient in the range of 0.005% to 100% with the balance made up from non-toxic carrier can be prepared.

Compositions provided herein typically are ated for administration by subcutaneous route, although other routes of administration are contemplated, such as any route known to those of skill in the art including intramuscular, intraperitoneal, intravenous, intradermal, intralesional, eritoneal injection, epidural, vaginal, rectal, local, otic, transdermal administration or any route of administration. Formulations suited for such routes are known to one of skill in the art. Administration can be local, topical or systemic depending upon the locus of treatment. Local administration to an area in need of treatment WO 2013/102144 PCT/US2012/072182 can be achieved by, for example, but not limited to, local infusion during surgery, l application, 6. g. , in conjunction with a wound dressing after surgery, by injection, by means of a er, by means of a suppository, or by means of an implant. Compositions also can be administered with other biologically active agents, either sequentially, intermittently or in the same composition.

The most suitable route in any given case depends on a variety of factors, such as the nature of the disease, the tolerance of the subject to a particular administration route, the severity of the disease, and the ular composition that is used. Typically, the compositions provided herein are administered parenterally. In some examples, modiﬁed PH20 polypeptide compositions are stered so that they reach the interstitiurn of skin or tissues, thereby degrading the interstitial space for subsequent delivery of a therapeutic agent.

Thus, in some examples, direct administration under the skin, such as by subcutaneous administration methods, is contemplated. Thus, in one e, local administration can be ed by injection, such as from a syringe or other article of manufacture containing an injection deVice such as a needle. In another example, local administration can be achieved by infusion, which can be tated by the use of a pump or other similar deVice. Other modes of administration also are contemplated. For example, modified PH20 polypeptides, included conjugated forms with increased half-life such as PEGylated forms thereof, can be administered intravenously. Pharmaceutical compositions can be formulated in dosage forms appropriate for each route of stration.

Administration methods can be employed to decrease the exposure of selected modiﬁed PH20 polypeptides to degradative processes, such as proteolytic degradation and immunological intervention Via antigenic and immunogenic responses. Examples of such methods include local administration at the site of treatment. PEGylation of eutics increases resistance to proteolysis, increases plasma half-life, and decreases nicity and immunogenicity. Examples of PEGylation methodologies are known in the art (see for example, Lu and Felix, Int. J. Peptide n Res., 43: 127-138, 1994; Lu and Felix, Peptide Res., 6: 140-6, 1993; Felix et al., Int. J. Peptide Res., 46 : 253-64, 1995; Benhar et al., J. Biol.

Chem., 269: 13398-404, 1994; Brumeanu et al., J1mmunol., 154: 3088-95, 1995; see also, Caliceti et al. (2003) Adv. Drug DeliV. Rev. 55(10):1261-77 and Molineux (2003) Pharmacotherapy 23 (8 Pt 2):3S-8S). PEGylation also can be used in the ry of nucleic acid les in Vivo. For e, PEGylation of adenovirus can increase stability and gene transfer (see, e.g., Cheng et al. (2003) Pharm. Res. 20(9): 1).

Various other delivery systems are known and can be used to administer selected PH20 polypeptides, such as but not limited to, encapsulation in liposomes, microparticles, WO 2013/102144 PCT/US2012/072182 -l97- microcapsules, recombinant cells capable of expressing the compound, receptor mediated endocytosis, and ry of c acid molecules encoding selected PH20 ptides such as retrovirus delivery systems.

Hence, in certain embodiments, liposomes and/or nanoparticles also can be employed with administration of soluble PH20 polypeptides. Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs)). MLVs generally have diameters of from 25 nm to 4 pm. Sonication ofMLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 angstroms containing an aqueous solution in the core.

Phospholipids can form a variety of structures other than mes when sed in water, ing on the molar ratio of lipid to water. At low ratios of lipid to water, liposomes form. Physical characteristics of liposomes depend on the pH, ionic strength and the ce of divalent cations. Liposomes can show low permeability to ionic and polar substances, but at elevated atures o a phase transition which markedly alters their permeability. The phase transition involves a change from a closely packed, ordered structure, known as the gel state, to a loosely packed, less-ordered ure, known as the ﬂuid state. This occurs at a characteristic phase-transition temperature and results in an increase in permeability to ions, sugars and drugs.

Liposomes interact with cells via different mechanisms: endocytosis by phagocytic cells of the loendothelial system such as macrophages and neutrophils; adsorption to the cell surface, either by nonspecif1c weak hydrophobic or electrostatic forces, or by c ctions with cell-surface components; fusion with the plasma cell ne by insertion of the lipid bilayer of the liposome into the plasma membrane, with simultaneous e of liposomal contents into the cytoplasm; and by transfer of liposomal lipids to cellular or subcellular membranes, or vice versa, without any association of the liposome contents.

Varying the liposome formulation can alter which mechanism is operative, although more than one can operate at the same time. Nanocapsules can generally entrap compounds in a stable and ucible way. To avoid side effects due to intracellular polymeric overloading, such ultraf1ne particles (sized around 0.1 um) should be designed using polymers able to be degraded in vivo. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use herein, and such particles can be easily made. 4. Exemplary PH20-Insulin Co-Formulation Provided herein are stable co-formulations of a fast acting insulin, such as a rapid acting (fast-acting) insulin analog, and a modified PH20 polypeptide. Any of the modified WO 2013/102144 PCT/US2012/072182 PH20 polypeptides provided herein can be included in a co-formulation With n, such as any of the mulations described in US. Application Serial Nos. 13/507,263 or 13/507,262 or in International PCT Application Serial No. PCT/US2012/042816.

In particular, the modiﬁed PH20 polypeptide is a modiﬁed PH20 polypeptide that exhibits increased stability under denaturation conditions, such as any set forth in Sections C. 1 .b. In particular, the PH20 polypeptide is a modiﬁed PH20 polypeptide that exhibits increased stability to one or more phenolic preservatives, such as any set forth in Section C. 1 .b.i. For e, the PH20 polypeptide is a modiﬁed PH20 ptide that contains an amino acid replacement With P at a position corresponding to position 204 With reference to amino acid positions set forth in SEQ ID NO:3, such as F204P With reference to any of SEQ ID NOS: 3, 7 or 32-66. In other examples, the PH20 ptide is a modiﬁed PH20 polypeptide that contains an amino acid ement With R at a position corresponding to on 58 With reference to amino acid positions set forth in SEQ ID NO:3, such as V58R With reference to any of SEQ ID NOS: 3, 7 or 32-66.

The fast acting insulin can be a regular insulin or a rapid acting (fast-acting) insulin analog. Insulin is a polypeptide that when processed is composed of 5 1 amino acids containing an A- and B- chain. Generally, insulin contains an n of about 21 amino acids and a B-chain of about 30 amino acids. The A- and B- chains are linked by disulﬁde s. Exemplary regular insulins include, for example, a human insulin (With an A chain having a sequence of amino acids set forth in SEQ ID NO:862 and a B chain having a sequence of amino acids set forth in SEQ ID NO:863) or a porcine insulin (with an A chain having a sequence of amino acids set forth as amino acid residue positions 88-108 of SEQ ID NO:864 and a B chain having a sequence of amino acids set forth as amino acid residue positions 25-54 of SEQ ID NO:864). ary fast-acting insulin analogs are insulin variants that contain one or more amino acid modiﬁcations compared to a human insulin set forth in SEQ ID NO: 862 and 863 (A and B chains). For example, exemplary insulin analogs are known to one of skill in the art, and include, but are not limited to, glulisine having an A- chain set forth in SEQ ID NO:862 and a B- chain that is a variant of SEQ ID NO:863 (B- chain; LysB3, GluB29), HMR-l 153 having an A-chain set forth in SEQ ID NO:862 and a B- chain that is a variant of SEQ ID NO:863 (B-chain; LysB3, IleB28), insulin aspart having an A-chain set forth in SEQ ID NO:862 and a B-chain that is a variant of SEQ ID NO:863 (B- chain; AspB28), and insulin lispro having an n set forth in SEQ ID NO:862 and a B- chain that is a variant of SEQ ID NO:863 in; , ProB29). In every instance above, the nomenclature of the analogs is based on a description of the amino acid substitution at c positions on the A or B chain of insulin, numbered from the N- WO 2013/102144 PCT/US2012/072182 terminus of the chain, in which the remainder of the sequence is that of natural human insulin.

Exemplary of such analog forms, are set forth in SEQ ID NOS:862 (A-chain) and having a B-chain set forth in any of SEQ ID NOS: 865-867.

The co-formulations are stable as a liquid formulation for prolonged periods of time for at least 1 month at temperatures from or from about 2 0C to 8 OC, inclusive, or for at least 3 days at a temperature from or from about 30 0C to 42 OC, inclusive. For example, the co- formulations are stable and retain ty of the PH20 hyaluronidase and n at "refrigerator" conditions, for example, at 2 °C to 8 °C, such as at or about 4 °C, for at least at least 2 , 3 months, 4 months, 5 months, 6 months, or 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, 13 , 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 , 24 months, 25 months, 26 months, 27 months, 28 months, 29 months or months or more. In another example, the formulations provided herein are stable and retain actiVity of the PH20 hyaluronidase and insulin at room temperature for example at 18 °C to 32 °C, generally 20 °C to 32 °C, such as 28 °C to 32 °C, for at least 2 weeks to 1 year, for example, at least 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, at least 7 months, at least 8 months, at least 9 months, or at least 1 year or more. In a further e, the formulations ed herein are stable and retain actiVity of the PH20 hyaluronidase and insulin at ed temperatures of about or greater than 30 °C, lly from or from about 30 0C to 42 0C, such as 32 0C to 37 0C or 35 0C to 37 0C or about or 37 0C for at least 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 35 days, 40 days, 45 days, 50 days, 60 days or more.

Assays to assess stability of active agents are well-known to one of skill in the art. n G provides exemplary assays to asses ity of PH20 hyaluronidase. The stability of insulin can be assessed using similar methods well-known to one of skill in the art. For example, insulin stability and solubility can be assessed by Visual assessment (e.g., including changes in color, clarity, presence of aggregates or clumping and material adhesion, or frosting), acid cation, optical microscopy, reversed phase high mance liquid chromatography (RP-HPLC), in vitro or in vivo bioassays and denaturing and non-denaturing size exclusion chromatography (SEC). In vitro or in vivo bioassays for insulin activity include, but are not limited to, a competitive binding assay using cells expressing insulin receptors (e. g., human placental cell membranes) and a radiolabeled insulin (see e.g., Weiss et al., (2001) J. Biol. Chem. 018-40024; Duttaroy et al., (2005) Diabetes 54:251-258); insulin-stimulated glucose uptake (Louveau et al., (2004) JEndocrin. 181 :271-280, Duttaroy WO 02144 PCT/US2012/072182 et al., (2005) Diabetes 54:251-258); assays to assess glucose tion in the presence of insulin (Wang et al., (2000) J. Biochem, 275: 14721, Duttaroy et al., (2005) Diabetes 54:25 1-25 8); and studies using diabetic and/or healthy animal models (Atkinson et al., (1999) Nature Med. 5:601-604; Nagoya-Shibata—Yasuda (NSY) mice, Zucker diabetic fatty (ZDF) rats and Gato-Katazaki (GK) rats (Cefalu (2006) ILAR Journal 47: 1 86-198).

Examples of such formulations contain 100 U/mL to 1000 U/mL of a modiﬁed PH20 polypeptide, and in ular at or about or at least 600 U/mL; 10 U/mL to 1000 U/mL of a cting insulin, and in particular at or at least or about 100 U/mL; NaCl at a tration of between or about between 80-140 mM; a pH ofbetween or about between 7.0 to 7.8; a buffering agent that maintains the pH range of between or about between 7.0 to 7.8; 0.1% to 0.4% preservative as a mass concentration (w/v). Optionally, a further stabilizing agent can be included. For example, the mulations provided herein contain 1 mM to 100 mM of a buffering agent. For example, the co-formulations provided herein contain 0.005% to 0.5% surfactant. Exemplary co-formulations provided herein also can contain less than 60 mM glycerin (glycerol) and 2 mM to or to about 50 mM of an antioxidant.

The following stable formulations are exemplary only and provide a platform from which minor ments can be made. It is understood that very small changes in the concentrations of the s excipients and other components (e. g., :: 15% of the stated concentrations), or small changes in pH, can be made while retaining some if not all of the insulin solubility and stability and PH20 stability. Further changes also can be made by adding or removing excipients. For example, the type of stabilizing surfactant can be changed.

For example, the exemplary co-formulations herein contain 100 U/mL to 1000 U/mL of a modified PH20 polypeptide, and in particular at least or about at least or about 600 U/mL of a modified PH20 polypeptide; 10 U/mL to 1000 U/mL of a fast-acting insulin, and in particular at least or about at least or about 100 U/mL of a cting insulin; from or from about 10 mM to or to about 50 mM Tris (e.g., from or from about 20 mM to 40 mM Tris, such as or as about 20 mM, 25 mM, 30 mM, 35 mM or 40 mM Tris); from or from about 80 mM to or to about 160 mM NaCl (e.g., at or about 80 mM, 90 mM, 100 mM, 110 mM 120 mM, 130 mM, 140 mM, 150 mM or 160 mM NaCl); from or from about 2 mM to or to about 50 mM methionine (e.g., at or about 5 mM, 10 mM, 20 mM, 30 mM, 40 mM or 50 mM methionine); from or from about 0 mM to or to about 50 mM glycerin (e.g., at or about 5 mM, mM, 20 mM, 30 mM, 40 mM or 50 mM in); from or from about 0.005% to or to about 0.5% poloxamer 188, such as 0.01% to 0.05% (e.g., at or about 0.01%, 0.02%, 0.03%, 0.04% or 0.05% poloxamer 188); from or from about 0.05% to or to about 0.25% phenol WO 2013/102144 PCT/US2012/072182 (e.g., at or about 0.1%, 0.12%, 0.125%, 0.13%, 0.14%, 0.15%, 0.16% or 0.17% phenol); and from or from about 0.05% to or to about 0.4% m—cresol (e.g., at or about 0.075%, 0.08%, 0.09%, 0.1%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16% or 0.17% m-cresol). The formulations are prepared With a pH from or from about 7.0 to or to about 7.6 (e.g., at or about pH 7.0, 7.1, 7.2, 7.3, 7.4, 7.5 or 7.6). In further es, zinc is included at a concentration of or about 0.017 mg/100 U, 0.018 mg/100 U, 0.02 mg/100 U, 0.022 mg/100 U or 0.024 mg/100 U insulin.

In particular examples, the fast acting insulin is insulin aspart, insulin lispro or insulin glulisine. Exemplary mulations ed herein that contain a modiﬁed PH20 polypeptide and insulin lispro are those that contain from or about 25 mM to or to about 35 mM Tris (e.g., at or about 30 mM Tris); from or from about 70 mM to or to about 100 mM NaCl (e.g., at or about 80 mM or 100 mM NaCl); from or from about 10 mM to or to about mM methionine (e.g., at or about 10 mM or 20 mM nine); from or from about 40 mM to or to about 60 mM glycerin (e.g., at or about 50 mM glycerin); from or from about 0.005% to or to about 0.05% poloxamer 188 (e.g., at or about 0.01% poloxamer 188); from or from about 0.017 mg zinc/100 U insulin to or to about 0.024 mg zinc/100 U insulin (e.g., 0.017 mg zinc/100 U insulin, 0.018 mg/100 U, 0.02 mg/100 U, 0.022 mg/100 U or 0.024 mg zinc/100 U insulin); from or from about 0.08% to or to about 0.17% phenol (e.g., 0.1%, 0.125% or 0.13% phenol); and from or from about 0.07% to or to about 0.17% m-cresol (e.g., 0.075%, 0.08%, 0.13% or 0.15% m—cresol). For example, the co-formulations can contain at or about 0.1% phenol and 0.015% m-cresol; at or about 0.125% phenol and 0.075% ol; at or about 0.13% phenol and 0.075% m—cresol; at or about 0.13% phenol and 0.08% m- cresol; or at or about 0.17% phenol and 0.13% m-cresol. Such formulations of insulin lispro and a modiﬁed PH20 polypeptide are prepared With a pH of or about 7.0 to or to about 7.5 (typically a pH of or about pH 7.2).

Exemplary co-formulations provided herein that contain a modiﬁed PH20 polypeptide and n aspart are those that n from or from about 25 mM to or to about mM Tris (e.g., at or about 30 mM Tris); from or from about 70 mM to or to about 120 mM NaCl (e.g., at or about 80 mM or 100 mM NaCl); from or from about 2 mM to or to about 30 mM methionine, such as 2 mM to 10 mM or 5 mM to 30 mM methionine (e.g., at or about 5 mM, 10 mM or 20 mM nine); from or from about 0.005% to or to about 0.05% poloxamer 188 (e.g., at or about 0.01% poloxamer 188); from or from about 0.08% to or to about 0.17% phenol (e.g., 0.1%, 0.125% or 0.13% phenol); and from or from about 0.07% to or to about 0.17% m-cresol (e.g., 0.075%, 0.08%, 0.13% or 0.15% m-cresol). For example, the co-formulations can contain at or about 0.1% Phenol and 0.015% m-cresol; at or about WO 2013/102144 PCT/US2012/072182 0.125% phenol and 0.075% m—cresol; at or about 0.13% phenol and 0.075% ol; at or about 0.13% phenol and 0.08% m—cresol; or at or about 0.17% phenol and 0.13% ol.

Such formulations of insulin aspart and a modiﬁed PH20 polypeptide are prepared With a pH of or about 7.0 to or to about 7.6 ally a pH of or about pH 7.4 or 7.3). r exemplary formulations provided herein that contain a modiﬁed PH20 ptide and insulin aspart are those that do not contain phenol. Such exemplary formulations n from or from about 25 mM to or to about 35 mM Tris (e.g., at or about mM Tris); from or from about 70 mM to or to about 120 mM NaCl (e.g., at or about 80 mM or 100 mM NaCl); from or from about 2 mM to or to about 30 mM methionine, such as 2 mM to 10 mM or 5 mM to 30 mM methionine (e.g., at or about 5 mM, 10 mM or 20 mM methionine); from or from about 0.005% to or to about 0.05% poloxamer 188 (e.g., at or about 0.01% poloxamer 188); and from or from about 0.07% to or to about 0.4% m-cresol, such as from or from about 0.2% to 0.4% m—cresol (e.g., 0.3%, 0.315%, 0.35%, 0.4% m- cresol). Such formulations of insulin aspart and a modiﬁed PH20 polypeptide are prepared with a pH of or about 7.0 to or to about 7.6 (typically a pH of or about pH 7.4 or 7.3).

Exemplary co-formulations provided herein that contain a modiﬁed PH20 polypeptide and insulin glulisine are those that contain from or from about 25 mM to or to about 35 mM Tris (e.g., at or about 30 mM Tris); from or from about 100 mM to or to about 150 mM NaCl (e.g., at or about 100 mM or 140 mM NaCl); from or from about 10 mM to or to about 30 mM methionine (e.g., at or about 10 mM or 20 mM methionine); from or from about 40 mM to or to about 60 mM glycerin (e.g., at or about 50 mM glycerin); from or from about 0.005% to or to about 0.05% poloxamer 188 (e.g., at or about 0.01% poloxamer 188); from or from about 0.08% to or to about 0.17% phenol (e.g., 0.1%, 0.125% or 0.13% phenol); and from or from about 0.07% to or to about 0.17% m-cresol (e.g., 0.075%, 0.08%, 0.13% or 0.15% m-cresol). For example, the co-formulations can contain at or about 0.1% phenol and 0.015% m—cresol; at or about 0.125% phenol and 0.075% m-cresol; at or about 0.13% phenol and 0.075% m—cresol; at or about 0.13% phenol and 0.08% m-cresol; or at or about 0.17% phenol and 0.13% ol. Such formulations of n glulisine and a modiﬁed PH20 polypeptide are prepared With a pH of or about 7.0 to or to about 7.6 (typically a pH of or about pH 7.4).

. Packaging, Articles of Manufacture and Kits Pharmaceutical nds of modiﬁed PH20 polypeptides, or nucleic acids encoding such polypeptides, or derivatives or variants thereof can be packaged as articles of manufacture ning packaging material, a pharmaceutical composition Which is effective for treating a disease or disorder, and a label that indicates that the pharmaceutical WO 2013/102144 PCT/US2012/072182 composition or therapeutic molecule is to be used for treating the disease or er.

Combinations of a selected modif1ed PH20 polypeptide, or a derivative or variant f and an therapeutic agent also can be packaged in an article of manufacture.

The es of manufacture provided herein contain packaging als. Packaging materials for use in ing pharmaceutical products are well known to those of skill in the art. See, for example, US. Patent Nos. 5,323,907, 5,052,558 and 5,033,252, each ofwhich is incorporated herein in its entirety. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material le for a selected formulation and intended mode of administration and treatment. The articles of manufacture can include a needle or other injection device so as to facilitate administration (e. g., sub-epidermal administration) for local injection purposes. A wide array of formulations of the compounds and compositions provided herein are contemplated including a modiﬁed PH20 polypeptide and a therapeutic agent, such as a fast-acting insulin, known to treat a particular disease or disorder. The choice of package depends on the PH20 and/or eutic agent, and whether such compositions will be packaged together or separately. In one example, the PH20 can be packaged as a mixture with the therapeutic agent. In another example, the components can be packaged as separate compositions ed PH20 polypeptides, therapeutic agents and/or articles of manufacture thereof also can be provided as kits. Kits can include a pharmaceutical ition described herein and an item for administration provided as an article of manufacture. For example a PH20 polypeptide can be supplied with a device for administration, such as a syringe, an inhaler, a dosage cup, a dropper, or an applicator. The compositions can be contained in the item for stration or can be provided separately to be added later. The kit can, optionally, include instructions for application including s, dosing regimens and instructions for modes of administration. Kits also can include a ceutical composition described herein and an item for diagnosis. For example, such kits can include an item for measuring the concentration, amount or activity of the selected protease in a subject.

G. Methods of Assessing PH20 Activity and ity Assays can be used to assess the stability and ty of the PH20 polypeptides provided herein. The assays can be used to assess the hyaluronidase activity of the PH20 ptide under particular conditions, temperature, and/or over time. Such assays can be used, for example, to ine the stability of the PH20 polypeptide under speciﬁc denaturation conditions, including, but not limited to, elevated temperatures greater than or about or 30 OC (e.g., 30 0C to 42 0C such as or about 37 oC), agitation, presence of excipients WO 2013/102144 PCT/US2012/072182 —204— (e.g., preservative), or low or no NaCl (salt). For example, stability under speciﬁc conditions can be red by assessing activity, solubility, and stability (e. g., formation of aggregates, etc.) in the absence of exposure to the denaturation condition and then at various time points thereafter in the presence of the condition. Hence, stability can be assessed over time.

Stability also can be assessed by comparing any one or more of activity, solubility or aggregation in the presence of one or more denaturation conditions compared to a native, wildtype or reference PH20 polypeptide. The assays also can be used make minor adjustments to the ations provided herein while ing the stability of both active agents. 1. Hyaluronidase Activity The activity of a modiﬁed PH20 ptide can be assessed using methods well known in the art. For example, the USP XXII assay for hyaluronidase determines activity indirectly by ing the amount of undegraded hyaluronic acid, or hyaluronan, (HA) substrate remaining after the enzyme is allowed to react with the HA for 30 min at 37 oC (USP XXII-NF XVII (1990) 644-645 United States Pharmacopeia Convention, Inc, lle, MD). A Hyaluronidase Reference Standard (USP) or National ary (NF) Standard Hyaluronidase solution can be used in an assay to ascertain the activity, in units, of any hyaluronidase. In one example, activity is measured using a microturbidity assay. This is based on the formation of an insoluble precipitate when hyaluronic acid binds with a reagent that precipitates it, such as acidiﬁed serum or cetylpyridinium chloride (CPC). The ty is measured by incubating hyaluronidase with sodium hyaluronate (hyaluronic acid) for a set period of time (e.g. , 10 minutes) and then precipitating the undigested sodium hyaluronate with the addition of acidiﬁed serum or CPC. The turbidity of the resulting sample is measured at 640 nm after an additional development period. The decrease in turbidity resulting from hyaluronidase activity on the sodium hyaluronate ate is a measure of onidase enzymatic activity.

In another example, hyaluronidase ty is measured using a iter assay in which residual biotinylated hyaluronic acid is measured following incubation with hyaluronidase (see e.g., Frost and Stern (1997) Anal. Biochem. 251 :263-269, US. Pat.

Publication No. 20050260186). The free carboxyl groups on the glucuronic acid residues of hyaluronic acid are biotinylated, and the biotinylated hyaluronic acid substrate is covalently coupled to a microtiter plate. Following incubation with onidase, the residual biotinylated hyaluronic acid substrate is detected using an avidin-peroxidase reaction, and compared to that obtained following reaction with hyaluronidase standards of known activity.

WO 02144 PCT/US2012/072182 Other assays to e onidase activity also are known in the art and can be used in the methods herein (see e.g., Delpech et al., (1995) Anal. Biochem. 229:35-41; Takahashi er al., (2003) Anal. Biochem. 322:257-263).

Many hyaluronidase assays have been based upon the measurement of the generation of new reducing N—acetylamino groups (Bonner and Cantey, Clin. Chim. Acta 13:746-752, 1966), or loss of viscosity (De Salegui et al., Arch. m. Biophys.121:548-554, 1967) or turbidity (Dorﬁnan and Ott, J. Biol. Chem. 172:367, 1948). With puriﬁed substrates all of these methods sufﬁce for determination of the presence or absence of endoglycosidase activity. ntially puriﬁed glycosaminoglycan substrates can also be used in a Gel Shift Assay. Glycosaminoglycans are mixed with recombinant PH20, such as a soluble PH20, to test for endoglycosidase activity that s in a shift in substrate mobility within the gel.

Examples of such substrates include, but are not limited to, chondroitin-4 and 6 sulfate, dermatan sulfate, heparan-sulfate, which can be obtained from Sigma Chemical. Human umbilical cord Hyaluronan can be obtained from ICN. For example, each test substrate can be diluted to at or about 0.1 mg/mL in a buffer range from pH 3.5 -7.5 . In such an exemplary assay, at or about 10 ul samples of puriﬁed soluble PH20 or conditioned media from PH20 expressing cells can be mixed with at or about 90 ul of test substrate in d buffer and incubated for 3 hours at 37 OC. Following incubation, samples are neutralized with sample buffer (Tris EDTA pH 8.0, Bromophenol Blue and glycerol) followed by electrophoresis.

Glycosaminoglycans can be detected using any method known in the art, for example, glycosaminoglycans can be detected by staining the gels using 0.5% Alcian Blue in 3% Glacial Acetic Acid overnight followed by destaining in 7% Glacial Acetic Acid. ation is determined by comparison of substrate mobility in the presence and absence of enzyme.

Hyaluronidase ty can also be detected by ate gel zymography (Guentenhoner et al. (1992) Matrix 12:388-396). In this assay, a sample is applied to an SDS-PAGE gel containing hyaluronic acid and the proteins in the sample separated by electrophoresis. The gel is then incubated in an enzyme assay buffer and subsequently stained to detect the onic acid in the gel. Hyaluronidase activity is visualized as a cleared zone in the substrate gel.

The ability of a PH20 polypeptide, including a modiﬁed PH20 polypeptide provided herein, to act as a ing or diffusing agent also can be assessed. For example, trypan blue dye can be injected subcutaneously with or without a PH20 polypeptide into the lateral skin on each side of nude mice. The dye area is then measured, such as with a microcaliper, to WO 2013/102144 2012/072182 determine the ability of the PH20 polypeptide to act as a spreading agent (US. Pat. Pub. No. 20060104968).

The onal ty of a PH20 polypeptide can be compared and/or normalized to a reference standard using any of these assays. This can be done to determine what a functionally equivalent amount of a PH20 polypeptide is. For example, the ability of a PH20 ptide to act as a spreading or diffusing agent can be assessed by injecting it into the l skin of mice with trypan blue, and the amount required to achieve the same amount of diffusion as, for e, 100 units of a Hyaluronidase Reference rd, can be determined. The amount of PH20 polypeptide required is, therefore, functionally equivalent to 100 hyaluronidase units. 2. Solubility The lity of a PH20 polypeptide can be determined by any method known to one of the skill in the art. One method for determining solubility is detergent partitioning. For example, a soluble PH20 polypeptide can be distinguished, for example, by its partitioning into the aqueous phase ofa Triton® X-114 solution at 37 °C (Bordier et al., (1981) J. Biol.

Chem, 256:1604-1607). Membrane-anchored polypeptides, such as lipid-anchored hyaluronidases, including GPI-anchored hyaluronidases, will ion into the detergent-rich phase, but will partition into the detergent-poor or aqueous phase following treatment with Phospholipase C. Phospholipase C is an enzyme that cleaves the phospho-glycerol bond found in GPI-anchored ns. Treatment with PLC will cause release of GPI-linked proteins from the outer cell membrane. 3. Purity, Crystallization 0r Aggregation The stability of a PH20 polypeptide ed herein also can be assessed using other methods and assays known in the art. In addition to assessing stability based on hyaluronidase activity, stability can be assessed by Visual inspection, percent recovery, protein purity and apparent melting temperature.

For example, protein purity can be measured by reversed phase high performance liquid chromatography (RP-HPLC). Protein purity, as determined by RP-HPLC, is the percent of the main PH20 n peak present, as compared to all of the protein species t. Thus, RP-HPLC, and similar methods known to one of skill in the art, can assess degradation of the enzyme. Protein purity can be assessed over time. Protein purity also can be assessed in the presence of one or more denaturation conditions and in varying amounts thereof. Percent recovery also can be determined as the relative percentage of the polypeptide under various ions (denaturation ions, time of storage, mode of storage such as vessel or container, or other similar parameters that can be altered) as compared to a reference WO 2013/102144 PCT/US2012/072182 sample. PHZO polypeptide stability also can be determined by measuring the oxidation of the hyaluronidase by RP-HPLC. Percent oxidation is a e of sum of the peak areas of the major (ox-l) and minor (ox-2) peaks.

In one e, the melting temperature of a PHZO polypeptide, such as a modiﬁed PHZO polypeptide, can be determined by measuring the hydrodynamic radius of particles by dynamic light scattering under various conditions (e. g., denaturation conditions or other storage conditions). An increase in particle size and a decrease in the melting temperature indicates denaturation and subsequent aggregation of the hyaluronidase.

Other methods known to one of skill in the art that can be used to determine the ity of the hyaluronidase in the co-formulations provided herein, include polyacrylamide gel electrophoresis , immunoblotting, nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, circular dichroism (CD) and dye-based ﬂuorescence assays. 4. Pharmacodynamics/Pharmacokinetics The effect of administration of a PHZO polypeptide, such as a modiﬁed PHZO polypeptide, alone or in combination with another therapeutic agent, on the pharmacokinetic and pharmacodynamic ties of any administered agent also can be assessed in vivo using animal models and/or human ts, such as in the setting of a clinical trial.

Pharmacokinetic or pharmacodynamic studies can be performed using animal models or can be performed during s with patients administered with a PHZO polypeptide or modiﬁed PHZO polypeptide.

Animal models include, but are not limited to, mice, rats, rabbits, dogs, guinea pigs and non-human e models, such as cynomolgus monkeys or rhesus macaques. In some instances, pharmacokinetic or pharmacodynamic studies are performed using healthy animals.

In other examples, the s are med using animal models of a disease for which therapy with hyaluronan is considered, such as animal models of any onan-associated disease or disorder, for example a tumor model.

The pharmacokinetic properties of a PHZO polypeptide, such as a d PHZO polypeptide, can be assessed by measuring such parameters as the maximum (peak) concentration (Cmax), the peak time (Le. when maximum concentration occurs; Tmax), the , minimum concentration (i.e., the minimum concentration n doses; le-n), the elimination half-life (T1/2) and area under the curve (i.e., the area under the curve generated by plotting time versus concentration; AUC), following administration. The absolute bioavailability of the hyaluronidase can be determined by ing the area under the curve of hyaluronidase following subcutaneous delivery (AUCsc) with the AUC of hyaluronidase following intravenous delivery (AUCiV). te ilability (F), can be calculated using WO 2013/102144 PCT/US2012/072182 the formula: F = ([AUC]SC >< dosesc) / ([AUCLV >< doseiv). A range of doses and different dosing frequency of dosing can be administered in the pharmacokinetic studies to assess the effect of increasing or decreasing concentrations enzyme, such as d PH20 polypeptide, in the dose.

H. Methods of Treatment and Combination Therapy Provided herein are methods and uses of any of the modiﬁed PH20 polypeptides provided herein that exhibit hyaluronidase activity based on its ability to degrade aminoglycan(s) such as hyaluronan. Due to such activity, the modiﬁed PH20 polypeptides can be used as a spreading factor to increase the delivery and/or bioavailability of subcutaneously stered therapeutic agents. Delivery of any therapeutic agent, including but not limited to, peptides, proteins, small molecule drugs, nucleic acids, or viruses can be facilitated or ed by co-administration With a modiﬁed PH20 polypeptide provided herein. For example, modiﬁed PH20 polypeptides can be used to increase the delivery of therapeutic agents such as antibodies (e.g., monoclonal antibodies), cytokines, Immune Globulin, an Insulin, or coagulation factors, to a desired locus, such as by increasing penetration of chemotherapeutic agents into solid tumors. The modiﬁed PH20 polypeptides also can be used to treat a hyaluronan-disease or disorder that is characterized by an excess or accumulation of hyaluronan. For example, modiﬁed PH20 polypeptides provided herein can be used to for treating a tumor; for treating glycosaminoglycan lation in the brain; for treating a cardiovascular disorder; for treating an ophthalmic disorder; for treating pulmonary disease; for treating ite; and/or for treating a proliferative disorder.

Other methods and uses of a modiﬁed PH20 ptide include any that are known to one of skill in the art. For example, various forms of PH20 onidases have been prepared and ed for therapeutic use in . For example, animal-derived onidase preparations include Vitrase® (ISTA Pharmaceuticals), a puriﬁed ovine testicular hyaluronidase, and Amphadase® (Amphastar Pharmaceuticals), a bovine ular hyaluronidase. Hylenex® (Halozyme Therapeutics) is a human recombinant hyaluronidase produced by genetically ered Chinese Hamster Ovary (CHO) cells containing nucleic acid encoding for soluble rHuPH20 (see e.g., US. Patent No. 7,767,429). Approved therapeutic uses for hyaluronidases include use as an adjuvant to se the absorption and dispersion of other therapeutic agents for hypodermoclysis (subcutaneous ﬂuid administration), and as an adjunct in subcutaneous phy for improving resorption of radiopaque agents. In addition to these indications, hyaluronidases can be used as a therapeutic or ic agent for the treatment of additional diseases and ions. For e, hyaluronidase is commonly used, for example, for peribulbar block in local WO 2013/102144 PCT/US2012/072182 anesthesia prior ophthalmic surgery. The presence of the enzyme prevents the need for additional blocks and reduces the time to the onset of akinesia (loss of eye movement).

Peribulbar and sub-Tenon's block are the most common applications of hyaluronidase for ophthalmic procedures. Hyaluronidase also can promote ia in cosmetic surgery, such as blepharoplasties and face lifts. It is tood that soluble PH20 onidases provided herein, including esPH20 hyaluronidases, can be used in any method of treatment or ation therapy for which a PH20 hyaluronidase is used (see e.g., U.S. Publication Nos.

US20040268425; US20050260186; US20060104968; and U.S. Appl. Serial Nos. 12/381,844, published as U.S. Publication No. US20100074885; 12/386,249, published as U.S.

Publication No. US20090311237; 12/387,225, published as U.S. Publication No. 0304665; and 12/386,222, published as U.S. Publication No. US201000323 8, each incorporated by reference in their entirety).

Exemplary, non-limiting, methods and uses are described in the following subsections. 1. Methods of Delivering Therapeutic Agents As noted above, onidase is a spreading or diffusing substance that modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue, and of certain specialized tissues, such as the umbilical cord and vitreous humor. When no spreading factor is present, materials injected subcutaneously, such as drugs, proteins, peptides and nucleic acid, spread very slowly. Co-inj ection with hyaluronidase, however, can cause rapid ing. The rate of diffusion is proportional to the amount of , and the extent of diffusion is proportional to the volume of solution. ed PH20 ptides provided herein can be used to promote or enhance the delivery agents and les to any of a variety of mammalian tissues in vivo. It can be used to facilitate the diffusion and, therefore, promote the ry, of small molecule pharmacologic agents as well as larger le pharmacologic , such as proteins, nucleic acids and ribonucleic acids, and macromolecular compositions than can contain a ation of components including, but not d to, nucleic acids, proteins, carbohydrates, lipids, lipid-based molecules and drugs (see e.g., U.S. Publication Nos.

US20040268425; US20050260186; and US20060104968). Modiﬁed PH20 polypeptides can be co-administered and/or co-formulated with a therapeutic agent to improve the bioavailability as well as pharmacokinetic (PK) and/or pharmacodynamic (PD) characteristics of co-formulated or co-administered agents. PK/PD parameters that can be improved by using soluble PH20, such as esPH20, include such measures as Cmax (the maximal WO 2013/102144 PCT/US2012/072182 concentration of agent achieved following absorption in, e.g., the bloodstream), Tmax (the time required to e maximal concentration), T1/2 (the time required for the concentration to fall by half), le-n (the l concentration of agent following metabolism and excretion), AUC (area under the curve of concentration versus time, a measure of the overall amount of ilability), concentrations in various tissues of interest (including, e.g., the rate of achieving desired concentrations, the overall levels, and the duration of maintaining desired levels), and Emax (the maximal effect ed).

The methods of ent provided herein e combination ies with a therapeutic agent for the treatment of a disease or disorder for which the therapeutic agent s. Any therapeutic agent that ameliorates and or otherwise lessens the severity of a disease or condition can be combined with a modiﬁed PH2O polypeptide provided herein in order to increase the bioavailability of such therapeutic agent. In particular, modiﬁed PH2O polypeptides provided herein can be used in each and all of the combinations described in applications see e.g., U.S. Publication Nos. US20040268425; US20050260186; US20060104968 and U.S. Appl. Serial Nos. 12/381,844, published as U.S. Publication No.

US20100074885; 12/386,249, published as U.S. ation No. US20090311237; 12/387,225, published as U.S. Publication No. US20090304665; and 12/386,222, hed as U.S. Publication No. US2010003238 in place of the disclosed hyaluronidase or hyaluronidase degrading enzyme.

Modiﬁed PH2O polypeptides can be administered prior to, subsequent to, intermittently with or simultaneously with the therapeutic agent preparation. Generally, the modiﬁed PH2O polypeptide is administered prior to or simultaneously with administration of the therapeutic agent preparation to permit the PH2O to degrade the hyaluronic acid in the interstitial space. The PH2O can be administered at a site different from the site of administration of the therapeutic molecule or the soluble PH2O can be administered at a site the same as the site of administration of the therapeutic molecule.

Examples of ceutical, therapeutic and cosmetic agents and les that can be administered with hyaluronidase include, but are not limited to, a chemotherapeutic or anticancer agent, an sic agent, an antibiotic agent, an anti-inﬂammatory agent, an antimicrobial agent, an amoebicidal agent, a trichomonacidal agent, an anti-parkinson agent, an anti-malarial agent, an anticonvulsant agent, an anti-depressant agent, an anti-arthritic agent, an anti-fungal agent, an antihypertensive agent, an antipyretic agent, an anti-parasitic agent, an antihistamine agent, an alpha-adrenergic agonist agent, an alpha r agent, an anesthetic agent, a ial dilator agent, a biocide agent, a bactericide agent, a bacteriostatic agent, a beta adrenergic blocker agent, a calcium channel r agent, a cardiovascular drug WO 2013/102144 PCT/US2012/072182 agent, a contraceptive agent, a cosmetic or esthetic agent, a decongestant agent, a diuretic agent, a depressant agent, a diagnostic agent, an electrolyte agent, a hypnotic agent, a hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an ophthalmic agent, a parasympathomimetic agent, a psychic energizer agent, a sedative agent, a sleep inducer, a sympathomimetic agent, a tranquilizer agent, a urinary agent, a vaginal agent, a viricide agent, a vitamin agent, a non-steroidal anti-inﬂammatory agent, or an angiotensin converting enzyme inhibitor agent, and any combination thereof. In ular, therapeutic agents include dies, including monoclonal dies, bisphosphonates, insulins, ation factors, cytokines and Immun Globulins.

For example, modiﬁed PH20 polypeptides provided herein can be used to increase the delivery of chemotherapeutic agents. Hyaluronidases have also been used to enhance the activity of chemotherapeutics and/or the accessibility of tumors to herapeutics (Schuller et al., 1991, Proc. Amer. Assoc. Cancer Res. 32:173, abstract no. 1034; Czejka et al., 1990, Pharmazie 45 :H.9; Baumgartner et al. (1988) Reg. Cancer Treat. 1:55-58; Zanker et al. (1986) Proc. Amer. Assoc. Cancer Res. 27:390). Combination chemotherapy With hyaluronidase is ive in the treatment of a y of cancers including urinary bladder cancer (Horn et al., 1985, J. Surg. Oncol. 28:304-307), squamous cell carcinoma (Kohno et al., 94, J. Cancer Res. Oncol. 3-297), breast cancer (Beckenlehner et al., 1992, J.

Cancer Res. Oncol. 118:591-596), and gastrointestinal cancer (Scheithauer et al., 1988, Anticancer Res. 8:391-396). In this example, the modiﬁed PH20 onidase enhances penetration of chemotherapeutic or other anti-cancer agents into solid tumors, thereby treating the disease.

Compositions containing soluble PH20 can be ed intratumorally With anti- cancer agents or enously for disseminated cancers or hard to reach . The anticancer agent can be a chemotherapeutic, an antibody, a peptide, or a gene therapy vector, virus or DNA. Additionally, hyaluronidase can be used to recruit tumor cells into the cycling pool for sensitization in previously chemorefractory tumors that have acquired multiple drug resistance (St Croix et al., (1998) Cancer Lett ber 131(1): 35-44).

Exemplary ancer agents that can be administered after, coincident With or before administration of a soluble PH20, such as an esPH20, include, but are not limited to Acivicins; Aclarubicins; Acodazoles; Acronines; Adozelesins; Aldesleukins; Alemtuzumabs; Alitretinoins -Retinoic Acids); Allopurinols; Altretamines; Alvocidibs; Ambazones; Ambomycins; Ametantrones; Amifostines; Aminoglutethimides; ines; Anastrozoles; Anaxirones; Ancitabines; Anthramycins; Apaziquones; Argimesnas; Arsenic Trioxides; Asparaginases; Asperlins; Atrimustines; Azacitidines; Azetepas; Azotomycins; WO 2013/102144 PCT/US2012/072182 Banoxantrones; lins; Batimastats; BCG Live; Benaxibines; ustines; Benzodepas; Bexarotenes; Bevacizumab; Bicalutamides; Bietaserpines; Biricodars; Bisantrenes; Bisantrenes; Bisnaﬁde Dimesylates; Bizelesins; Bleomycins; omibs; Brequinars; Bropirimines; Budotitanes; ans; Cactinomycins; Calusterones; Canertinibs; Capecitabines; Caracemides; Carbetimers; Carboplatins; Carboquones; Carmofurs; Carmustines with Polifeprosans; Carmustines; Carubicins; Carzelesins; Cedeﬁngols; Celecoxibs; Cemadotins; Chlorambucils; Cioteronels; Ciplactin; Cirolemycins; Cisplatins; Cladribines; Clanfenurs; Clofarabines; Crisnatols; Cyclophosphamides; Cytarabine liposomals; Cytarabines; Dacarbazines; Dactinomycins; Darbepoetin Alfas; Daunorubicin liposomals; Daunorubicins/Daunomycins; Daunorubicins; Decitabines; Denileukin Diftitoxes; Dexniguldipines; Dexonas; Dexrazoxanes; Dezaguanines; uones; Dibrospidiums; Dienogests; Dinalins; Disermolides; Docetaxels; Dofequidars; Doxiﬂuridines; Doxorubicin liposomals; Doxorubicin HCL; Doxorubicin HCL liposome injection; Doxorubicins; Droloxifenes; Dromostanolone Propionates; Duazomycins; tines; xates; Edotecarins; Eﬂornithines; Elacridars; Elinaﬁdes; Elliott's B Solutions; Elsamitrucins; Emitefurs; Enloplatins; Enpromates; Enzastaurins; Epipropidines; Epirubicins; Epoetin alfas; Eptaloprosts; Erbulozoles; Esorubicins; Estramustines; Etanidazoles; Etoglucids; ide phosphates; Etoposide ; Etoposides; Etoprines; tanes; Exisulinds; Fadrozoles; Fazarabines; Fenretinides; Filgrastims; Floxuridines; Fludarabines; Fluorouracils; 5- ﬂuorouracils; Fluoxymesterones; Flurocitabines; Fosquidones; Fostriecins; Fostriecins; Fotretamines; Fulvestrants; Galarubicins; Galocitabines; Gemcitabines; Gemtuzumabs/Ozogamicins; Geroquinols; Gimatecans; Gimeracils; Gloxazones; Glufosfamides; Goserelin acetates; Hydroxyureas; Ibritumomabs/Tiuxetans; Idarubicins; Ifosfamides; Ilmofosines; Ilomastats; ib mesylates; Imexons; Improsulfans; Indisulams; Inproquones; Interferon as; Interferon alfa-2bs; eron Alfas; Interferon Betas; Interferon Gammas; Interferons; Interleukin-2s and other Interleukins (including recombinant Interleukins); Intoplicines; Iobenguanes [131-1]; Iproplatins; Irinotecans; Irsogladines; Ixabepilones; Ketotrexates; L-Alanosines; Lanreotides; Lapatinibs; Ledoxantrones; Letrozoles; Leucovorins; Leuprolides; Leuprorelins (Leuprolides); Levamisoles; lcitols; oles; Lobaplatins; Lometrexols; Lomustines/CCNUs; Lomustines; Lonafarnibs; Losoxantrones; Lurtotecans; Mafosfamides; ulfans; Marimastats; Masoprocols; Maytansines; Mechlorethamines; Mechlorethamines/Nitrogen mustards; Megestrol acetates; Megestrols; Melengestrols; lans; Melphalan L-PAMs; Menogarils; ostanes; Mercaptopurines; 6-Mecaptopurine; Mesnas; Metesinds; Methotrexates; Methoxsalens; Metomidates; Metoprines; Meturedepas; Miboplatins; Miproxifenes; WO 02144 PCT/US2012/072182 Misonidazoles; omides; Mitocarcins; Mitocromins; xones; Mitogillins; Mitoguazones; Mitomalcins; Mitomycin Cs; Mitomycins; Mitonaﬁdes; Mitoquidones; Mitospers; Mitotanes; Mitoxantrones; Mitozolomides; Mivobulins; bines; Mofarotenes; Mopidamols; Mubritinibs; enolic Acids; Nandrolone Phenpropionates; Nedaplatins; bines; Nemorubicins; Nitracrines; Nocodazoles; Nofetumomabs; Nogalamycins; Nolatrexeds; Nortopixantrones; Octreotides; ekins; Ormaplatins; Ortataxels; ils; Oxaliplatins; OXisurans; Oxophenarsines; Paclitaxels; Pamidronates; Patupilones; Pegademases; Pegaspargases; Pegﬁlgrastims; Peldesines; ycins; Pelitrexols; Pemetrexeds; Pentamustines; tatins; Peplomycins; Perfosfamides; Perifosines; Picoplatins; Pinaﬁdes; Pipobromans; Piposulfans; Pirfenidones; Piroxantrones; Pixantrones; PleVitrexeds; Plicamycin Mithramycins; Plicamycins; Plomestanes; Plomestanes; Porﬁmer sodiums; Porﬁmers; Porﬁromycins; mustines; Procarbazines; Propamidines; Prospidiums; Pumitepas; Puromycins; Pyrazofurins; Quinacrines; Ranimustines; Rasburicases; Riboprines; Ritrosulfans; Rituximabs; Rogletimides; imexs; Rufocromomycins; Sabarubicins; Saﬁngols; Sargramostims; Satraplatins; Sebriplatins; Semustines; Simtrazenes; Sizoﬁrans; Sobuzoxanes; Sorafenibs; Sparfosates; Sparfosic Acids; Sparsomycins; Spirogermaniums; Spiromustines; Spiroplatins; Spiroplatins; Squalamines; Streptonigrins; Streptovarycins; Streptozocins; Sufosfamides; Sulofenurs; Sunitinib Malate; 6-TG; Tacedinalines; Talcs; Talisomycins; Tallimustines; Tamoxifens; Tariquidars; Tauromustines; Tecogalans; rs; Teloxantrones; Temoporﬁns; Temozolomides; Teniposides/VM-26s; Teniposides; Teroxirones; Testolactones; Thiamiprines; Thioguanines; pas; Tiamiprines; Tiazofurins; Tilomisoles; nes; Timcodars; Timonacics; Tirapazamines; Topixantrones; Topotecans; Toremifenes; Tositumomabs; Trabectedins (Ecteinascidin 743); Trastuzumabs; Trestolones; Tretinoins/ATRA; Triciribines; Trilostanes; Trimetrexates; Triplatin Tetranitrates; relins; Trofosfamides; Tubulozoles; Ubenimexs; Uracil Mustards; Uredepas; Valrubicins; Valspodars; Vapreotides; Verteporﬁns; Vinblastines; Vincristines; Vindesines; Vinepidines; Vinﬂunines; Vinformides; Vinglycinates; Vinleucinols; Vinleurosines; Vinorelbines; idines; Vintriptols; Vinzolidines; Vorozoles; Xanthomycin A's (Guamecyclines); Zeniplatins; Zilascorbs [2-H]; Zinostatins; Zoledronate; Zorubicins; and Zosuquidars, for example: Aldesleukins (e.g., PROLEUKIN®); Alemtuzumabs (e.g., CAMPATH®); Alitretinoins (e.g., PANRETIN®); Allopurinols (e.g., ZYLOPRIM®); Altretamines (e.g., HEXALEN®); Amifostines (e.g, ETHYOL®); Anastrozoles (e.g., ARIMIDEX®); Arsenic Trioxides (e.g., TRISENOX®); Asparaginases (e.g., ELSPAR®); BCG Live (e.g., TICE® WO 2013/102144 PCT/US2012/072182 —214— BCG); Bexarotenes (e.g., TIN®); Bevacizumab (AVASTIN®); Bleomycins (e.g., BLENOXANE®); Busulfan enous (e.g., BUSULFEX®); Busulfan orals (e.g., MYLERANTM); Calusterones (e.g., METHOSARB®); Capecitabines (e.g., XELODA®); Carboplatins (e.g., PARAPLATIN®); Carmustines (e.g., BCNU®, BiCNU®); tines With Polifeprosans (e.g., GLMDEL® ; Celecoxibs (e.g., CELEBREX®); Chlorambucils (e.g., LEUKERAN®); Cisplatins (e.g., PLATINOL®); Cladribines (e.g., LEUSTATIN®, 2-CdA®); Cyclophosphamides (e.g., CYTOXAN®, NEOSAR®); bines (e.g., CYTOSAR-U®); Cytarabine liposomals (e.g., DepoCyt®); Dacarbazines (e.g., omeu): omycins (e.g., COSMEGEN®); Darbepoetin Alfas (e.g., ARANESP®); Daunorubicin liposomals (e. g. DAUNOXOME®); Daunorubicins/Daunomycins (e.g., CERUBIDINE®); Denileukin Diftitoxes (e.g., ONTAK®); Dexrazoxanes (e.g., ZINECARD®); Docetaxels (e.g., TAXOTERE®); Doxorubicins (e.g., ADRIAMYCIN®, RUBEX®); Doxorubicin liposomals, including bicin HCL liposome injections (e.g., DOXIL®); Dromostanolone propionates (e.g., DROMOSTANOLONE® and MASTERONE® Injection); Elliott's B Solutions (e.g., Elliott's B Solution®); Epirubicins (e.g., ELLENCE®); Epoetin alfas (e.g., EPOGEN®); Estramustines (e. g., EMCYT®); Etoposide phosphates (e.g., ETOPOPHOS®); Etoposide VP- 16s (e.g., VEPESID®); Exemestanes (e.g., AROMASIN®); Filgrastims (e.g., NEUPOGEN®); Floxuridines (e.g., FUDR®); Fludarabines (e.g., FLUDARA®); uracils incl. 5-FUs (e.g., ADRUCIL®); Fulvestrants (e.g, FASLODEX®); abines (e.g., GEMZAR®); Gemtuzumabs/Ozogamicins (e.g., MYLOTARG®); Goserelin acetates (e.g., ZOLADEX®); yureas (e.g., HYDREA®); Ibritumomabs/Tiuxetans (e.g., ZEVALIN®); Idarubicins (e.g., IDAMYCIN®); Ifosfamides (e.g., IFEX®); Imatinib mesylates (e.g., GLEEVEC®); Interferon alfa—2as (e.g., ROFERON- A®); eron alfa—2bs (e.g., INTRON A®); Irinotecans (e.g., CAMPTOSAR®); Letrozoles (e.g., FEMARA®); Leucovorins (e.g., WELLCOVORIN®, LEUCOVORIN®); Levamisoles (e.g., ERGAMISOL®); Lomustines/CCNUs (e.g., CeeNU®); Mechlorethamines/Nitrogen mustards (e.g., MUSTARGEN®); Megestrol acetates (e.g., MEGACE®); Melphalans/L- PAMs (e.g., ALKERAN®); Mercaptopurine incl. 6-MPs (e.g., THOL®); Mesnas (e.g., MESNEX®); Methotrexates; Methoxsalens (e.g., UVADEX®); Mitomycin Cs (e.g., MUTAMYCIN®, MITOZYTREX®); Mitotanes (e.g., LYSODREN®); Mitoxantrones (e.g., NOVANTRONE®); Nandrolone Phenpropionates (e.g, DURABOLIN—50®); Nofetumomabs (e.g., VERLUMA®); Oprelvekins (e.g., NEUMEGA®); Oxaliplatins (e.g., ELOXATIN®); Paclitaxels (e.g., PAXENE®, ); Pamidronates (e.g., AREDIA®); Pegademases (e.g., ADAGEN®); Pegaspargases (e.g., ONCASPAR®); Pegﬁlgrastims (e.g., WO 2013/102144 PCT/US2012/072182 TA®); Pentostatins (e.g., NIPENT®); omans (e.g., VERCYTE®); Plicamycin/Mithramycins (e.g., MITHRACIN®); Porfimer sodiums (e.g., PHOTOFRIN®); Procarbazines (e. g., MATULANE®); Quinacrines (e.g., ATABRINE®); Rasburicases (e.g., ELITEK®); Rituximabs (e.g., RITUXAN®); Sargramostims (e.g., PROKINE®); Streptozocins (e.g., R®); Sunitinib Malates (e.g., SUTENT®); Talcs (e.g., SCLEROSOL®); Tamoxifens (e.g., NOLVADEX®); Temozolomides (e.g., TEMODAR®); Teniposides/VM-26s (e.g., ); Testolactones (e.g., TESLAC®); Thioguanines incl. 6-TG; Thiotepas (e.g., THIOPLEX®); Topotecans (e.g., HYCAMTIN®); Toremifenes (e.g., ON®); Tositumomabs (e.g., BEXXAR®); zumabs (e.g., TIN®); Tretinoins/ATRA (e.g., VESANOID®); Uracil Mustards; Valrubicins (e.g., VALSTAR®); Vinblastines (e. g., VELBAN®); Vincristines (e.g., ONCOVIN®); Vinorelbines (e.g., NAVELBINE®); and Zoledronates (e.g., ZOMETA®).

For example, exemplary antibiotic agents e, but are not d to, Aminoglycosides; Amphenicols; Ansamycins; Carbacephems; Carbapenems; Cephalosporins or Cephems; Cephamycins; Clavams; Cyclic lipopeptides; Diaminopyrimidines; Ketolides; Lincosamides; Macrolides; Monobactams; urans; Oxacephems; Oxazolidinones; Penems, thienamycins and miscellaneous beta-lactams; Penicillins; Polypeptides antibiotics; Quinolones; Sulfonamides; Sulfones; Tetracyclines; and other antibiotics (such as Clofoctols, Fusidic acids, Hexedines, amines, Nitrofurantoins Nitroxolines, Ritipenems, Taurolidines, Xibomols).

Also included among exemplary therapeutic agents are coagulation factors or other blood modiﬁers such as antihemophilic factors, anti-inhibitor ant complexes, antithrombin III, ation Factor V, coagulation Factor VIII, coagulation Factor IX, plasma protein fractions, von Willebrand factors; antiplatelet agents (including, for example, abciximabs, anagrelides, cilostazols, ogrel bisulfates, dipyridamoles, epoprostenols, eptifibatides, tirofibans; colony stimulating factors (CSFs) (including, for example, Granulocyte CSFs and ocyte Macrophage CSFs); erythropoiesis stimulators (including, for example, erythropoietins such as darbepoetin alfas) and epoetin alfas; hemostatics and albumins (including, for example, aprotinins, combinations of antihemophilic factors and plasma, Desmopressin Acetates, and albumins); immune globulins, as well as hepatitis B immune globulins; thrombin inhibitors (including for example direct thrombin inhibitors and lepirudin), and drotrecogin alfas; anticoagulants (including, for example, dalteparins, enoxaparins and other heparins, and ins).

Exemplary antibodies or other therapeutic agents e, but are not limited to, Cetuximab (IMC-C225; Erbitux®); Trastuzumab (Herceptin®); Rituximab (Rituxan®; WO 02144 PCT/US2012/072182 MabThera®); Bevacizumab (Avastin®); Alemtuzumab (Campath®; Campath-1H®; path®); Panitumumab (ABX-EGF; iX®); Ranibizumab (Lucentis®); Ibritumomab; Ibritumomab tiuxetan (Zevalin ®); momab; Iodine I 131 Tositumomab (BEXXAR®); Catumaxomab (Removab®); Gemtuzumab; Gemtuzumab ozogamicin arg®); Abatacept -Ig; Orencia®); Belatacept (L104EA29YIg; LEA29Y; LEA); Ipilimumab (MDX-010; MDX-101); Tremelimumab (ticilimumab; CP-675,206); PRS- 010 (see e.g., US20090042785); PRS-050 (US7585940; US20090305982); Aﬂibercept (VEGF Trap, AVE005; Holash et al., (2002) PNAS 99:11393-11398); VolociXimab (M200); F200 (Chimeric (human/murine) IgG4 Fab fragment of VolociXimab (M200)); MORAb-009 Mouse/human chimeric IgG1(US20050054048); Soluble fusion n:Anti-mesothelin FV linked to a truncated Pseudomonas exotoxin A (SS1P (CAT-5001); US20070189962); Cixutumumab (IMC-A12); Nimotuzumab (h-R3) (Spicer (2005) Curr Opin M0! Ther 7: 1 82- 191); Zalutumumab (HuMaX-EGFR; Lammerts van Bueren et al. (2008) PNAS 105:6109-14); Necitumumab IMC-11F8 (Li et al. (2008) Structure -227); Sym004 (Pedersen et al. 2010 Cancer Res 70:588-597); and 5.

In particular, therapeutic agents include, but are not limited to, immunoglobulins, Interferon beta, Interferon alpha-2as, Interferon alpha-1s, Interferon alpha-n3 s, Interferon beta-1, Interferon beta-las, Interferon gamma-lbs, Peg-interferon alpha-2 and Peginterferon alpha-2bs, insulin, a bisphosphate (e.g., Pamidronates or Zoledronates), Docetaxels, Doxorubicins, Doxorubicin mals and bevacizumabs.

Other ary therapeutic agents that can be combined by co-administration and/or co-formulation with a modiﬁed PH20 polypeptide provided herein, include, but are not limited to, umabs, Agalsidase Betas, Alefacepts, Ampicillins, Anakinras, Antipoliomyelitic Vaccines, Anti-Thymocytes, Azithromycins, Becaplermins, Caspofungins, Cefazolins, Cefepimes, Cefotetans, Ceftazidimes, Ceftriaxones, Cetuximabs, Cilastatins, anic Acids, Clindamycins, Darbepoetin Alfas, Daclizumabs, Diphtheria, Diphtheria antitoxins, Diphtheria Toxoids, Efalizumabs, Epinephrines, Erythropoietin , Etanercepts, Filgrastims, azoles, Follicle-Stimulating Hormones, ropin Alphas, Follitropin Betas, Fosphenytoins, Gadodiamides, Gadopentetates, Gatiﬂoxacins, Glatiramers, GM-CSF's, Goserelins, Goserelin acetates, Granisetrons, Haemophilus Inﬂuenza B's, Haloperidols, Hepatitis vaccines, Hepatitis A es, Hepatitis B Vaccines, Ibritumomab Tiuxetans, Ibritumomabs, ans, Immunoglobulins, Hemophilus inﬂuenza vaccines, Inﬂuenza Virus Vaccines, InﬂiXimabs, Insulins, n nes, Interferons, Interferon alphas, Interferon Betas, Interferon Gammas, Interferon alpha-2a's, Interferon alpha-2b's, Interferon alpha-1's, Interferon alpha-n3’s, Interferon Betas, Interferon Beta-1a's, Interferon WO 2013/102144 PCT/US2012/072182 , Interferon alpha-consensus, Iodixanols, Iohexols, Iopamidols, Ioversols, Ketorolacs, Laronidases, Levoﬂoxacins, Lidocaines, Linezolids, pams, Measles Vaccines, Measles virus, Mumps viruses, Measles-Mumps-Rubella Virus Vaccines, a vaccines, Medroxyprogesterones, Meropenems, Methylprednisolones, Midazolams, nes, Octreotides, Omalizumabs, Ondansetrons, Palivizumabs, Pantoprazoles, Pegaspargases, rastims, Peg-Interferon Alfa—2a's, Peg-Interferon Alfa-2b's, Pegvisomants, Pertussis vaccines, Piperacillins, Pneumococcal Vaccines and Pneumococcal Conjugate Vaccines, Promethazines, Reteplases, opins, Sulbactams, Sumatriptans, Tazobactams, Tenecteplases, Tetanus Puriﬁed Toxoids, illins, Tositumomabs, Triamcinolones, Triamcinolone Acetonides, Triamcinolone hexacetonides, Vancomycins, Varicella Zoster immunoglobulins, Varicella vaccines, other vaccines, Alemtuzumabs, Alitretinoins, Allopurinols, Altretamines, Amifostines, Anastrozoles, Arsenics, Arsenic Trioxides, Asparaginases, Bacillus Calmette-Guerin (BCG) vaccines, BCG Live, Bexarotenes, Bleomycins, Busulfans, Busulfan intravenous, Busulfan orals, Calusterones, Capecitabines, Carboplatins, Carmustines, Carmustines with Polifeprosans, Celecoxibs, Chlorambucils, Cisplatins, Cladribines, Cyclophosphamides, Cytarabines, bine liposomals, Dacarbazines, Dactinomycins, Daunorubicin liposomals, Daunorubicins, Daunomycins, ukin Diftitoxes, Dexrazoxanes, Docetaxels, Doxorubicins, Doxorubicin liposomals, Dromostanolone nates, Elliott's B Solutions, Epirubicins, Epoetin alfas, Estramustines, Etoposides, Etoposide phosphates, Etoposide VP-l6s, tanes, Floxuridines, abines, Fluorouracils, 5-Fluorouracils, Fulvestrants, Gemcitabines, Gemtuzumabs, Ozogamicins, Gemtuzumab ozogamicins, Hydroxyureas, Idarubicins, Ifosfamides, Imatinib mesylates, ecans, Letrozoles, Leucovorins, Levamisoles, Lomustines, CCNUs, rethamines, Nitrogen mustards, rols, rol acetates, Melphalans, L-PAMs, Mercaptopurines, 6-Mercaptopurines, Mesnas, Methotrexates, Methoxsalens, Mitomycins, Mitomycin C’s, Mitotanes, Mitoxantrones, Nandrolones, Nandrolone Phenpropionates, Nofetumomabs, ekins, Oxaliplatins, Paclitaxels, Pamidronates, Pegademases, Pentostatins, Pipobromans, Plicamycins, Mithramycins, Porﬁmers, Porﬁmer ns, Procarbazines, Quinacrines, Rasburicases, RituXimabs, Sargramostims, Streptozocins, Talcs, Tamoxifens, lomides, Teniposides, Testolactones, Thioguanines, 6-Thioguanines, Triethylenethiophosphoramides (Thiotepas), Topotecans, Toremifenes, Trastuzumabs, Tretinoins, Uracil Mustards, Valrubicins, Vinblastines, Vincristines, Vinorelbines, Zoledronates, Acivicins, bicins, Acodazoles, Acronines, Adozelesins, Aldesleukins, Retinoic Acids, Alitretinoins, 9-Cis-Retinoic Acids, Alvocidibs, Ambazones, cins, Ametantrones, Arninoglutethimides, Amsacrines, WO 2013/102144 PCT/US2012/072182 Anaxirones, Ancitabines, Anthramycins, Apaziquones, Argimesnas, Asperlins, Atrimustines, Azacitidines, Azetepas, Azotomycins, Banoxantrones, Batabulins, Batimastats, Benaxibines, Bendamustines, Benzodepas, Bicalutamides, Bietaserpines, Biricodars, renes, Bisnaﬁde Dimesylates, Bizelesins, Bortezomibs, Brequinars, Bropirimines, Budotitanes, Cactinomycins, Canertinibs, Caracemides, Carbetimers, Carboquones, Carmofurs, Carubicins, Carzelesins, Cedeﬁngols, Cemadotins, Chlorambucils, Cioteronels, Cirolemycins, Clanfenurs, Clofarabines, tols, Decitabines, Dexniguldipines, Dexormaplatins, Dezaguanines, Diaziquones, Dibrospidiums, Dienogests, ns, Disermolides, Dofequidars, Doxiﬂuridines, Droloxifenes, Duazomycins, Ecomustines, Edatrexates, Edotecarins, hines, Elacridars, Elinaﬁdes, Elsamitrucins, urs, Enloplatins, Enpromates, Enzastaurins, Epipropidines, Eptaloprosts, Erbulozoles, Esorubicins, azoles, Etoglucids, Etoprines, Exisulinds, oles, Fazarabines, Fenretinides, Fluoxymesterones, Flurocitabines, Fosquidones, Fostriecins, Fotretamines, Galarubicins, Galocitabines, Geroquinols, Gimatecans, Gimeracils, Gloxazones, Glufosfamides, Ilmofosines, Ilomastats, Imexons, Improsulfans, Indisulams, Inproquones, Interleukins, Interleukin-25, recombinant Interleukins, Intoplicines, Iobenguanes, Iproplatins, Irsogladines, Ixabepilones, exates, L-Alanosines, Lanreotides, Lapatinibs, ntrones, Leuprolides, relins, Lexacalcitols, Liarozoles, Lobaplatins, Lometrexols, Lonafarnibs, ntrones, Lurtotecans, amides, Mannosulfans, Marimastats, Masoprocols, VIaytansines, Mechlorethamines, Melengestrols, Melphalans, Menogarils, Mepitiostanes, Vietesinds, Metomidates, Metoprines, Meturedepas, Miboplatins, Miproxifenes, VIisonidazoles, Mitindomides, Mitocarcins, Mitocromins, Mitoﬂaxones, Mitogillins, VIitoguazones, Mitomalcins, Mitonaﬁdes, Mitoquidones, Mitospers, Mitozolomides, VIiVObulins, Mizoribines, Mofarotenes, mols, Mubritinibs, Mycophenolic Acids, \Iedaplatins, Neizarabines, Nemorubicins, Nitracrines, Nocodazoles, Nogalamycins, \Iolatrexeds, Nortopixantrones, Ormaplatins, xels, Oteracils, OXisurans, Oxophenarsines, Patupilones, Peldesines, Peliomycins, Pelitrexols, exeds, Pentamustines, Peplomycins, Perfosfamides, Perifosines, Picoplatins, Pinaﬁdes, Piposulfans, Pirfenidones, Piroxantrones, Pixantrones, PleVitrexeds, Plomestanes, Porﬁromycins, mustines, Propamidines, Prospidiums, Pumitepas, Puromycins, Pyrazofurins, Ranimustines, Riboprines, Ritrosulfans, imides, Roquinimexs, Rufocromomycins, bicins, Saﬁngols, Satraplatins, Sebriplatins, Semustines, zenes, Sizoﬁrans, Sobuzoxanes, Sorafenibs, Sparfosates, sic Acids, Sparsomycins, Spirogermaniums, Spiromustines, latins, Squalamines, Streptonigrins, Streptovarycins, Sufosfamides, Sulofenurs, nalines, Talisomycins, Tallimustines, Tariquidars, Tauromustines, WO 2013/102144 PCT/US2012/072182 -2l9- Tecogalans, Tegafurs, Teloxantrones, Temoporﬁns, Teroxirones, Thiamiprines, Tiamiprines, Tiazofurins, Tilomisoles, Tilorones, Timcodars, Timonacics, Tirapazamines, Topixantrones, tedins, Ecteinascidin 743, Trestolones, Triciribines, tanes, Trimetrexates, Triplatin Tetranitrates, relins, Trofosfamides, Tubulozoles, Ubenimexs, Uredepas, Valspodars, Vapreotides, Verteporﬁns, Vinblastines, Vindesines, Vinepidines, ines, Vinformides, Vinglycinates, cinols, Vinleurosines, Vinrosidines, Vintriptols, Vinzolidines, Vorozoles, Xanthomycin A's, Guamecyclines, Zeniplatins, Zilascorbs [2-H], Zinostatins, Zorubicins, Zosuquidars, olamides, Acyclovirs, Adipiodones, Alatroﬂoxacins, Alfentanils, enic extracts, Alpha l-proteinase inhibitors, Alprostadils, Amikacins, Amino acids, Aminocaproic acids, Aminophyllines, Amitriptylines, Amobarbitals, Amrinones, Analgesics, Anti-poliomyelitic es, Anti-rabic serums, Anti- tetanus immunoglobulins, tetanus vaccines, Antithrombin Ills, Antivenom serums, Argatrobans, Arginines, Ascorbic acids, Atenolols, Atracuriums, Atropines, Aurothioglucoses, Azathioprines, Aztreonams, Bacitracins, Baclofens, Basiliximabs, Benzoic acids, Benztropines, Betamethasones, Biotins, Bivalirudins, Botulism antitoxins, Bretyliums, Bumetanides, Bupivacaines, Buprenorphines, Butorphanols, onins, Calcitriols, Calciums, Capreomycins, Carboprosts, Carnitines, Cefamandoles, Cefoperazones, CefotaXimes, Cefoxitins, Ceftizoximes, Cefuroximes, Chloramphenicols, Chloroprocaines, Chloroquines, Chlorothiazides, Chlorpromazines, ChondroitinsulﬁJric acids, Choriogonadotropin alfas, Chromiums, Cidofovirs, Cimetidines, Ciproﬂoxacins, Cisatracuriums, Clonidines, Codeines, Colchicines, Colistins, Collagens, Corticorelin ovine triﬂutates, Corticotrophins, ropins, Cyanocobalamins, Cyclosporines, Cysteines, DacliXimabs, Dalfopristins, arins, Danaparoids, Dantrolenes, Deferoxamines, Desmopressins, Dexamethasones, Dexmedetomidines, DeXpanthenols, Dextrans, Iron dextrans, zoic acids, Diazepams, ides, Dicyclomines, Digibinds, Digoxins, Dihydroergotamines, Diltiazems, Diphenhydramines, Dipyridamoles, Dobutamines, Dopamines, Doxacuriums, Doxaprams, Doxercalciferols, Doxycyclines, Droperidols, lines, Edetic acids, oniums, Enalaprilats, Ephedrines, Epoprostenols, Ergocalciferols, Ergonovines, Ertapenems, Erythromycins, ls, Estradiols, Estrogenics, Ethacrynic acids, Ethanolamines, Ethanols, Ethiodized oils, Etidronic acids, Etomidates, Factor Vllls, Famotidines, Fenoldopams, Fentanyls, Flurnazenils, Fluoresceins, Fluphenazines, Folic acids, Fomepizoles, FomiVirsens, Fondaparinuxs, nets, Fosphenytoins, Furosemides, Gadoteridols, Gadoversetamides, Ganciclovirs, Gentamicins, Glucagons, es, Glycines, yrrolates, Gonadorelins, Gonadotropin nics, Haemophilus B polysaccharides, Hemins, Herbals, Histamines, Hydralazines, WO 2013/102144 PCT/US2012/072182 Hydrocortisones, Hydromorphones, ocobalamins, Hydroxyzines, Hyoscyamines, Ibutilides, Imiglucerases, Indigo es, Indomethacins, Iodides, Iopromides, Iothalamic acids, onaglic acids, onilans, Isoniazids, Isoproterenols, Japanese encephalitis vaccines, Kanamycins, Ketamines, Labetalols, Lepirudins, Levobupivacaines, Levothyroxines, Lincomycins, Liothyronines, izing hormones, Lyme disease vaccines, Mangafodipirs, Manthtols, ococcal polysaccharide vaccines, Meperidines, Mepivacaines, Mesoridazines, Metaraminols, Methadones, arbamols, Methohexitals, Methyldopates, Methylergonovines, Metoclopramides, Metoprolols, Metronidazoles, Minocyclines, Mivacuriums, Morrhuic acids, Moxiﬂoxacins, Muromonab-CD3 s, Mycophenolate mofetils, Nafcillins, Nalbuphines, Nalmefenes, Naloxones, gmines, Niacinamides, Nicardipines, Nitroglycerins, Nitroprussides, nephrines, Orphenadrines, Oxacillins, Oxymorphones, Oxytetracyclines, Oxytocins, Pancuroniums, Panthenols, Pantothenic acids, Papaverines, Peginterferon-alpha (e. g., interferon alpha 2a or 2b), Penicillin Gs, Pentamidines, Pentazocines, Pentobarbitals, Perﬂutrens, Perphenazines, Phenobarbitals, Phentolamines, Phenylephrines, Phenytoins, Physostigmines, Phytonadiones, Polymyxin bs, Pralidoximes, Prilocaines, Procainamides, Procaines, Prochlorperazines, Progesterones, Propranolols, Pyridostigmine hydroxides, Pyridoxines, Quinidines, Quinupristins, Rabies immunoglobulins, Rabies vaccines, Ranitidines, Remifentanils, vins, Rifampins, Ropivacaines, Samariums, Scopolamines, Seleniums, Sermorelins, Sincalides, Somatrems, Spectinomycins, Streptokinases, Streptomycins, Succinylcholines, anils, Sulfamethoxazoles, Tacrolimuses, Terbutalines, Teriparatides, Testosterones, Tetanus antitoxins, Tetracaines, ecyl sulfates, Theophyllines, Thiamines, Thiethylperazines, Thiopentals, Thyroid stimulating hormones, Tinzaparins, Tiroﬁbans, Tobramycins, Tolazolines, Tolbutamides, Torsemides, amic acids, Treprostinils, Triﬂuoperazines, hobenzamides, Trimethoprims, Tromethamines, Tuberculins, Typhoid vaccines, Urofollitropins, Urokinases, Valproic acids, Vasopressins, Vecuroniums, Verapamils, Voriconazoles, Warfarins, Yellow fever vaccines, Zidovudines, Zincs, Ziprasidone hydrochlorides, Aclacinomycins, Actinomycins, Adriamycins, Azaserines, 6-Azauridines, Carzinophilins, Chromomycins, erins, 6-DiazoOxo-L-Norleucines, Enocitabines, Floxuridines, Olivomycins, bicins, Piritrexims, Pteropterins, Tegafurs, Tubercidins, ases, Arcitumomabs, bevacizumabs, Botulinum Toxin Type A's, num Toxin Type B's, Capromab Pendetides, umabs, Dornase alfas, Drotrecogin alfas, Imciromab Pentetates, and Iodine-131’s.

Delivery of n Methods provided herein include methods of co-administering a modiﬁed PHZO polypeptide and an insulin to increase subcutaneous ry of the insulin, such as a fast- WO 2013/102144 PCT/US2012/072182 acting insulin (see e.g., US. Patent No. 7,767,429; US. Patent No. 7,846,431; US.

Publication No. US20090304665; and US. Application Serial Nos. 13/507,263; 13/507,262 and 13/507,261). Such methods include methods of direct administration, and pump and continuous infusion methods, including open and closed pump systems. For example, exemplary insulins that can be stered With a modiﬁed PH20 hyaluronidase provided herein are fast-acting insulins or n analogs. For example, a co-administered insulin includes a regular n, insulin aspart, insulin lispro, insulin glulisine or other similar analog variants. Exemplary insulins are insulins that contain an A chain set forth in SEQ ID NO:862 and a B chain set forth in SEQ ID NO:863 or variants that contain one or more amino acid modiﬁcations compared to a human insulin set forth in SEQ ID NO: 862 and 863 (A and B chains). For example, exemplary n analogs are known to one of skill in the art, and include, but are not limited to, those set forth in SEQ ID NOS:862 (A-chain) and haVing a B- chain set forth in any of SEQ ID NOS: 865-867.

The co-formulations can be administered subcutaneously to treat any condition that is amenable to treatment With insulin. Therapeutic uses include, but are not limited to, treatment for type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, and for glycemic control in ally ill patients. For example, the co-formulations of a fast acting insulin and hyaluronan degrading enzyme can be administered subcutaneously in te doses, such as Via a syringe or insulin pen, prior to a meal as prandial insulin therapy in subjects With diabetes to achieve glycemic control. The co-formulations also can be administered subcutaneously or intraperitoneally using an insulin pump or in the context of a closed loop system to continuously control blood glucose levels throughout the day and night and/or to control post-prandial glycemic excursions. It is Within the skill of a treating ian to fy such es or ions.

For any disease or condition, including all those exempliﬁed above, for Which a fast- acting insulin is indicated or has been used and for Which other agents and treatments are available, the co-formulations can be used in combination therewith. Depending on the disease or condition to be treated, exemplary ations include, but are not limited to, combinations With anti-diabetic drugs, including, but not limited to, sulfonylureas, biguanides, meglitinides, thiazolidinediones, glucosidase inhibitors, peptide analogs, ing glucagon-like peptide (GLP) analogs and, gastric inhibitory peptide (GIP) analogs and DPP-4 inhibitors. In another example, the co-formulations of a fast acting insulin and modiﬁed PH20 ptide described herein can be administered in ation with, prior to, intermittently With, or uent to, one or more other insulins, including fast-acting insulin, and basal-acting insulins.

WO 2013/102144 PCT/US2012/072182 2. Methods of Hyaluronan-Associated Diseases and Conditions (e.g., Tumors) In particular, PH20 hyaluronidase can be used to treat onan-associated diseases or conditions. Typically, hyaluronan-associated es and conditions are associated With elevated hyaluronan expression in a tissue, cell, or body ﬂuid (e.g., tumor tissue or tumor- associated tissue, blood, or interstitial space) compared to a control, e.g., another tissue, cell or body ﬂuid. The elevated onan expression can be elevated compared to a normal tissue, cell or body ﬂuid, for example, a tissue, cell or body ﬂuid that is ous to the sample being tested, but isolated from a different subject, such as a subject that is normal (1.6., does not have a disease or condition, or does not have the type of disease or condition that the subject being tested has), for e, a subject that does not have a hyaluronan-associated e or condition. The elevated hyaluronan expression can be elevated compared to an analogous tissue from another subject that has a similar disease or condition, but Whose disease is not as severe and/or is not hyaluronan-associated or expresses relatively less hyaluronan and thus is hyaluronan-associated to a lesser degree. For example, the subject being tested can be a subject With a hyaluronan-associated , Where the HA amounts in the tissue, cell or ﬂuid are relatively elevated compared to a subject having a less severe cancer, such as an early stage, entiated or other type of cancer. In another e, the cell, tissue or ﬂuid ns elevated levels of hyaluronan compared to a control sample, such as a ﬂuid, tissue, extract (e.g., cellular or nuclear extract), nucleic acid or peptide preparation, cell line, biopsy, standard or other sample, With a known amount or relative amount of HA, such as a sample, for example a tumor cell line, known to express vely low levels of HA, such as exemplary tumor cell lines described herein that express low levels of HA, for example, the HCT 116 cell line, the HT29 cell line, the NCI H460 cell line, the DUl45 cell line, the Capan-l cell line, and tumors from tumor models generated using such cell lines.

Hyaluronan- associated diseases and ions include those associated With high interstitial ﬂuid pressure, such as disc pressure, proliferative disorders, such as cancer and benign prostatic hyperplasia, and edema. Edema can result from or be sted in, for example, organ transplant, stroke or brain trauma. Proliferative disorders include, but are not limited to, cancer, smooth muscle cell proliferation, systemic sclerosis, cirrhosis of the liver, adult respiratory distress syndrome, idiopathic cardiomyopathy, lupus matosus, retinopathy, e. g. , diabetic retinopathy or other retinopathies, cardiac hyperplasia, reproductive system associated disorders, such as benign prostatic hyperplasia (BPH) and ovarian cysts, pulmonary ﬁbrosis, endometriosis, ﬁbromatosis, hamartomas, ngiomatosis, sarcoidosis, desmoid tumors. Cancers include solid and lymphatic/blood tumors and WO 2013/102144 PCT/US2012/072182 metastatic disease, and erentiated tumors. The tumors amenable to treatment typically exhibit cellular and/or stromal expression of a hyaluronan, compared to a non-cancerous tissue of the same tissue type or compared to a non-metastatic tumor of the same tumor-type.

Cancers include any one or more of ovarian cancer, in situ carcinoma (lSC), squamous cell carcinoma (SCC), prostate cancer, pancreatic cancer, other gastric cancers, non-small cell lung cancer, breast cancer, brain cancer and colon cancer.

Modifled PH20 polypeptides provided herein, such as PEGylated forms thereof, can be used to treat tumors. Thus, in addition to its ct anticancer effects, hyaluronidases also have direct anticarcinogenic effects. Hyaluronidase prevents grth of tumors transplanted into mice (De Maeyer et al., 1992, Int. J. Cancer 51 :657-660) and inhibits tumor formation upon re to carcinogens (Pawlowski et al., 1979, Int. J. Cancer 23:105-109; Haberman et al., 1981, Proceedings of the 17th Annual Meeting of the American Society of Clinical Oncology, Washington, DC, 22:105, abstract no. 415). PH20 onidase has been shown to treat various tumors (see e.g., U.S. Publication No. US2010/0003238 and U.S.

Application Serial No. 13/135,817, published as U.S. Publication No. US20120020951).

The hyaluronan-rich cancer can be a cancer in which the cancer cells produce HALOs, cancers that have elevated expression of hyaluronan (as determined by immunostaining, e.g., histological staining of sections from the tumor), cancers that have elevated HAS2 (Hyaluronan se 2), cancers that do not produce hyaluronidase (HYALl) in vitro. onan-rich s can be identiﬁed by any method for assessing hyaluronan sion, and other known methods for assaying protein/mRNA expression.

Several hyaluronan-rich cancers have been identiﬁed. In some cases, hyaluronan expression ates with poor prognosis, for example, decreased survival rate and/or recurrence-free survival rate, metastases, angiogenesis, cancer cell on into other tissues/areas, and other indicators of poor prognosis. Such ation has been ed, for example, in hyaluronan-rich tumors including ovarian , SCC, lSC, prostate cancer, lung cancer, including non-small-cell lung cancer (NSCLC), breast cancer, colon cancer and pancreatic cancer (see, for example, Anttila et al., Cancer Research, 60:150-155 (2000); Karvinen et al., British Journal ofDermatology, 148:86-94 (2003); Lipponen et al., Eur.

Journal ofCancer, 849-856 (2001); Pirinen et al., Int. J. Cancer: 95: 12-17 (2001); Auvinen et al., American Journal ofPathology, 156(2):529-536 (2000); Ropponen et al., Cancer Research, 58: 342-347 (1998)). Thus, onan-rich cancers can be treated by administration of a hyaluronidase, such as a soluble PH20, to treat one or more ms of the cancer. onan-rich tumors include, but are not limited to those of the prostate, breast, colon, ovarian, stomach, head and neck and other tumors and cancers.

WO 2013/102144 PCT/US2012/072182 —224— Other hyaluronan-associated diseases or conditions that are associated with excess glycosaminoglycans and that can be treated with a modiﬁed PH20 polypeptide provided herein include, but are not limited to, cardiovascular disease (e.g., following ischemia reperfusion; in osclerosis); Vitrectomy and ophthalmic disorders and conditions (e.g., in methods to y the Vitreous humor of the eye; reduce postoperative pressure; other ocular surgical procedures such as glaucoma, Vitreous and retina surgery and in corneal transplantation); in hypodermoclysis (i.e., infusion of ﬂuids and electrolytes into the hypodermis of the skin); cosmetic applications (e.g., in the treatment of cellulite, "pigskin" edema or e peel" edema); organ transplantation (e.g., associated with interstitial edemas in connection with ng of an organ); pulmonary disease. 3. Other uses In r examples of its therapeutic use, d PH20 polypeptides provided herein, can be used for such purposes as an antidote to local necrosis from paravenous injection of necrotic substances such as Vinca alkaloids (Few et al. (1987) Amer. J. .

Child Nurs. 12, 23-26), treatment of ganglion cysts (Paul et al. (1997) JHand Surg. 22 (2): 219-21) and treatment of tissue necrosis due to venous insufﬁciency (Elder et al. (1980) Lancet 648-649). d PH20 polypeptides also can be used to treat ganglion cysts (also known as a wrist cyst, Bible cyst, or dorsal tendon cyst), which are the most common soft tissue mass of the hand and are ﬂuid ﬁlled sacs that can be felt below the skin.

Modiﬁed PH20 polypeptides can be used in the treatment of spinal cord injury by ing oitin sulfate proteoglycans (CSPGs). Following spinal cord injury, glial scars containing CSPGs are produced by astrocytes. CSPGs play a crucial role in the inhibition of axon growth. In addition, the expression of CSPG has been shown to increase following injury of the central nervous system (CNS). Soluble PH20 also can be ed for the treatment of herniated disks in a process known as chemonucleolysis. Chondroitinase ABC, an enzyme cleaVing similar substrates as onidase, can induce the reduction of intradiscal pressure in the lumbar spine. There are three types of disk injuries. A protruded disk is one that is intact but bulging. In an extruded disk, the ﬁbrous wrapper has torn and the NP has oozed out, but is still connected to the disk. In a sequestered disk, a fragment of the NP has broken loose from the disk and is free in the spinal canal. Chemonucleolysis is typically ive on protruded and extruded disks, but not on sequestered disk injuries. 4. Contraception Modiﬁed PH20 polypeptides provided herein can be used as vaccines in contraceptive applications. PH20 is present in the male uctive tract, and is expressed in both the testis and epididymis and is present in sperm. PH20 plays a role in fertilization by WO 2013/102144 PCT/US2012/072182 facilitating entry of the sperm h the cumulus layer surrounding the unfertilized egg.

PH20 also is able to bind to onic acid (HA) on the zona pellucida during early phases of fertilization. This binding also initiates intracellular signaling that aids in the acrosome reaction. Immunization with PH20 has been show to be an effective contraceptive in male guinea pigs (Primakoff et al. (1988) Nature 335:543-546, Tung et al. (1997) Biol. Reprod. 56:1133-1141). It also has been shown to be an effective contraceptive in female guinea pigs due to the generation of anti-PH20 antibodies that prevent sperm and egg g. In examples herein, the modiﬁed PH20 polypeptides can be inactive enzymes, such as any described in Sections C2. The polypeptides can be stered ly or can be administered as a recombinant Virus to deliver the antigen. 1. EXAMPLES The following es are included for illustrative purposes only and are not intended to limit the scope of the invention.

EXAMPLE 1 GENERATION 0F RECOMBINANT HUMAN PH20 HYALURONIDASE (rHuPH20) A. Generation of a soluble rHuPHZO-expressing cell line A recombinant human PH20 hyaluronidase designated rHuPH20 was generated as described in hed U.S. Publication No. US201 10053247. Brieﬂy, the pCI-PH20-IRES- DHFR-SV40pa (HZ24) plasmid (set forth in SEQ ID NO:5) was used to transfect Chinese Hamster Ovary (CHO cells) (see e.g., US. Patent Nos. 7,767,429 and 7,781,607 and US.

Publication No. 2006-0104968). The HZ24 plasmid vector for sion of soluble rHuPH20 contains a pCI vector backbone ga), DNA encoding amino acids 1-482 of human PH20 hyaluronidase (SEQ ID NO:2), an internal ribosomal entry site (IRES) from the ECMV Virus (Clontech), and the mouse dihydrofolate reductase (DHFR) gene. The pCI vector backbone also includes DNA ng the Beta-lactamase resistance gene (AmpR), an f1 origin of ation, a Cytomegalovirus immediate-early enhancer/promoter region (CMV), a chimeric intron, and an SV40 late polyadenylation signal (SV40). The DNA encoding the soluble rHuPH20 construct contains an Nhel site and a Kozak consensus ce prior to the DNA encoding the methionine at amino acid position 1 of the native 35 amino acid signal sequence of human PH20, and a stop codon following the DNA encoding the tyrosine corresponding to amino acid position 482 of the human PH20 hyaluronidase set forth in SEQ ID NO:2, followed by a BamHI restriction site.

Non-transfected DG44 CHO cells growing in GIBCO Modified CD-CHO media for DHFR(-) cells, supplemented with 4 mM Glutamine and 18 mL/L Plurionic F68/L (Gibco), were seeded at 0.5 x 106 cells/mL in a shaker ﬂask in preparation for transfection. Cells were WO 2013/102144 PCT/US2012/072182 grown at 37 0C in 5% C02 in a humidiﬁed incubator, shaking at 120 rpm. Exponentially growing non-transfected DG44 CHO cells were tested for ity prior to transfection.

Sixty n Viable cells of the non-transfected DG44 CHO cell culture were pelleted and resuspended to a density of 2 ><107 cells in 0.7 mL of 2x transfection buffer (2x HeBS: 40 mM Hepes, pH 7.0, 274 mM NaCl, 10 mM KCl, 1.4 mM NaZHPO4, 12 mM dextrose). To each aliquot of resuspended cells, 0.09 mL (250 ug) of the linear HZ24 d rized by overnight digestion with Clal (New England Biolabs) was added, and the cell/DNA solutions were transferred into 0.4 cm gap BTX (Gentronics) electroporation cuvettes at room temperature. A negative control electroporation was med with no plasmid DNA mixed with the cells. The cell/plasmid mixes were electroporated with a capacitor discharge of 330 V and 960 uF or at 350 V and 960 uF.

The cells were removed from the es after electroporation and transferred into 5 mL of Modiﬁed CD-CHO media for DHFR(-) cells, supplemented with 4 mM Glutamine and 18 mL/L Plurionic F68/L (Gibco), and d to grow in a well of a 6-well tissue culture plate without selection for 2 days at 37 0C in 5% C02 in a humidiﬁed incubator.

Two days post-electroporation, 0.5 mL of tissue culture media was removed from each well and tested for the presence of hyaluronidase actiVity, using the microturbidity assay described in e 8. The results are set forth in Table 6.

Table 6: Initial Hyaluronidase Activity of HZ24 Transfected DG44 CHO cells at 40 hours 0st—transfecti0n ——Activit(Units/mL) Transfectionl 330V Transfection 2 350V Negative Control 0015 Cells from Transfection 2 (350V) were collected from the tissue culture well, counted and diluted to 1 ><104 to 2 ><104 Viable cells per mL. A 0.1 mL aliquot of the cell suspension was transferred to each well of ﬁve, 96 well round bottom tissue culture plates. One hundred microliters of CD-CHO media (GIBCO) containing 4 mM GlutaMAXTM-l supplement (GIBCOTM, InVitrogen Corporation) and without hypoxanthine and thymidine ments were added to the wells containing cells (ﬁnal volume 0.2 mL). Ten clones were identiﬁed from the 5 plates grown without methotrexate (Table 7).

Table 7. H aluronidase activi of identiﬁed clones Vell ID Relative H aluronidase WO 2013/102144 PCT/US2012/072182 Six HZ24 clones were expanded in culture and transferred into shaker ﬂasks as single cell suspensions. Clones 3D3, 3E5, 2G8, 2D9, 1E11, and 4D10 were plated into 96-well round bottom tissue e plates using a two-dimensional inﬁnite dilution strategy in which cells were d 1:2 down the plate, and 1:3 across the plate, starting at 5000 cells in the top left hand well. d clones were grown in a background of 500 non-transfected DG44 CHO cells per well, to provide necessary grth factors for the initial days in culture. Ten plates were made per subclone, with 5 plates containing 50 nM methotrexate and 5 plates without methotrexate.

Clone 3D3 ed 24 visual subclones (13 from the no methotrexate treatment, and 11 from the 50 nM methotrexate treatment). Signiﬁcant hyaluronidase activity was measured in the supematants from 8 of the 24 subclones (>50 Units/mL), and these 8 subclones were expanded into T-25 tissue culture ﬂasks. Clones isolated from the methotrexate treatment protocol were expanded in the presence of 50 nM methotrexate. Clone 3D35M was further expanded in 500 nM methotrexate giving rise to clones producing hyaluronidase activity in excess of 1,000 Units/mL in shaker ﬂasks (clone 3D35M; or Genl 3D35M). A master cell bank (MCB) of the 3D35M cells was then prepared.

B. Production Gen2 Cells Containing Soluble human PH20 (rHuPH20) The Genl 3D35M cell line described in Example 1.A was d to higher methotrexate levels to produce generation 2 (Gen2) clones. 3D35M cells were seeded from ished methotrexate-containing cultures into CD CHO medium containing 4 mM GlutaMAX-lTM and 1.0 uM methotrexate. The cells were adapted to a higher methotrexate level by g and passaging them 9 times over a period of 46 days in a 37 °C, 7% C02 humidiﬁed incubator. The ampliﬁed population of cells was cloned out by limiting dilution in 96-well tissue culture plates containing medium with 2.0 uM methotrexate. After approximately 4 weeks, clones were identiﬁed and clone 3E10B was selected for expansion. 3E10B cells were grown in CD CHO medium containing 4 mM GlutaMAX-l TM and 2.0 uM methotrexate for 20 passages. A master cell bank (MCB) of the 3E10B cell line was created and frozen and used for subsequent studies.

Ampliﬁcation of the cell line continued by culturing 3E10B cells in CD CHO medium ning 4 mM GlutaMAX-l TM and 4.0 uM rexate. After the 12Th passage, cells were frozen in vials as a research cell bank (RCB). One vial of the RCB was thawed WO 02144 PCT/US2012/072182 and cultured in medium containing 8.0 uM methotrexate. After 5 days, the rexate concentration in the medium was increased to 16.0 uM, then 20.0 uM 18 days later. Cells from the 8Th e in medium containing 20.0 uM methotrexate were cloned out by limiting dilution in 96-well tissue culture plates containing CD CHO medium containing 4 mM GlutaMAX-lTM and 20.0 uM rexate. Clones were identiﬁed 5-6 weeks later and clone 2B2 was selected for expansion in medium containing 20.0 uM methotrexate. After the 11Th passage, 2B2 cells were frozen in Vials as a research cell bank (RCB).

The resultant 2B2 cells are dihydrofolate reductase deﬁcient (dhfr-) DG44 CHO cells that express e recombinant human PH20 (rHuPH20). The soluble PH20 is present in 2B2 cells at a copy number of imately 206 copies/cell. Southern blot analysis of Spe 1- Xba I- and BamH I/Hind III-digested genomic 2B2 cell DNA using a rHuPH20-speciﬁc , probe revealed the ing restriction digest proﬁle: one major hybridizing band of ~7.7 kb and four minor hybridizing bands (~13.9, ~6.6, ~5.7 and N46 kb) with DNA digested with Spe I; one major hybridizing band of ~5.0 kb and two minor izing bands (~13.9 and ~65 kb) with DNA digested with Xba I; and one single hybridizing band of NI .4 kb observed using 2B2 DNA ed with BamH I/Hind 111.

C. Production of GenZ soluble rHuPH20 in 300 L Bioreactor Cell Culture A Vial of HZ24-2B2 was thawed and expanded from shaker ﬂasks through 36 L spinner ﬂasks in CD-CHO media (Invitrogen, Carlsbad, CA) supplemented with 20 uM methotrexate and GlutaMAX-lTM (Invitrogen). Brieﬂy, the Vial of cells was thawed in a 37 OC water bath, medium was added and the cells were centrifuged. The cells were re- suspended in a 125 mL shake ﬂask with 20 mL of fresh medium and placed in a 37 °C, 7% C02 incubaor. The cells were expanded up to 40 mL in the 125 mL shake ﬂask. When the cell density reached greater than 1.5 x 106 cells/mL, the culture was expanded into a 125 mL spinner ﬂask in a 100 mL culture volume. The ﬂask was incubated at 37 OC, 7% C02. When the cell density reached greater than 1.5 x 106 cells/mL, the culture was expanded into a 250 mL spinner ﬂask in 200 mL culture volume, and the ﬂask was incubated at 37 OC, 7% C02 When the cell density reached greater than 1.5 x 106 cells/mL, the culture was expanded into a 1 L spinner ﬂask in 800 mL e volume and incubated at 37 OC, 7% C02. When the cell y reached greater than 1.5 x 106 cells/mL the culture was expanded into a 6 L r ﬂask in 5000 mL culture volume and ted at 37 OC, 7% C02. When the cell density reached greater than 1.5 x 106 cells/mL the culture was expanded into a 36 L spinner ﬂask in 32 L culture volume and incubated at 37 OC, 7% C02.

A 400 L reactor was sterilized and 230 mL of CD-CHO media were added. Before use, the reactor was checked for contamination. Approximately 30 L cells were transferred WO 02144 PCT/US2012/072182 from the 36 L spinner ﬂasks to the 400 L bioreactor (Braun) at an inoculation density of 4.0 X 105 Viable cells per mL and a total volume of 260 L. Parameters were: temperature setpoint, 37 OC; Impeller Speed 40-55 RPM; Vessel re: 3 psi; Air Sparge 0.5- 1.5 ; Air Overlay: 3 L/min. The reactor was sampled daily for cell counts, pH veriﬁcation, media analysis, protein production and retention. Also, during the run nutrient feeds were added. At 120 hrs (day 5), 10.4L of Feed #1 Medium (4>< CD-CHO + 33 g/L e + 160 mL/L ax-1TM + 83 mL/L Yeastolate + 33 mg/L ulin) was added. At 168 hours (day 7), 10.8 L of Feed #2 (2>< CD-CHO + 33 g/L Glucose + 80 mL/L Glutamax-1TM + 167 mL/L Yeastolate + 0.92 g/L Sodium Butyrate) was added, and culture temperature was changed to 36.5 °C. At 216 hours (day 9), 10.8 L ofFeed #3 (IX CD-CHO + 50 g/L Glucose + 50 mL/L Glutamax-1TM + 250 mL/L Yeastolate + 1.80 g/L Sodium Butyrate) was added, and culture temperature was changed to 36 0C. At 264 hours (day 11), 10.8 L ofFeed #4 (IX CD-CHO + 33 g/L Glucose + 33 mL/L Glutamax-lTM + 250 mL/L Yeastolate + 0.92 g/L Sodium Butyrate) was added, and culture temperature was changed to 35.5 0C. The addition of the feed media was observed to dramatically enhance the production of soluble 0 in the ﬁnal stages of production. The reactor was harvested at 14 or 15 days or when the Viability of the cells dropped below 40%. The process ed in a ﬁnal productivity of 17,000 Units per mL with a maximal cell density of 12 million cells/mL. At harvest, the culture was sampled for mycoplasma, bioburden, endotoxin and Virus in vitro and in vivo, by Transmission Electron Microscopy (TEM) and enzyme actiVity.

The culture was pumped by a peristaltic pump through four Millistak ﬁltration system s pore) in parallel, each containing a layer of aceous earth graded to 4-8 um and a layer of diatomaceous earth graded to 1.4-1.1 um, followed by a cellulose membrane, then through a second single Millistak ﬁltration system (Millipore) containing a layer of diatomaceous earth graded to 0.4-0.1] um and a layer of diatomaceous earth graded to <0.1 um, followed by a cellulose membrane, and then through a 0.22 um ﬁnal ﬁlter into a sterile single use ﬂexible bag with a 350 L capacity. The harvested cell culture ﬂuid was supplemented with 10 mM EDTA and 10 mM Tris to a pH of 7.5. The culture was concentrated 10>< with a tangential ﬂow ﬁltration (TFF) apparatus using four Sartoslice TFF 30 kDa molecular weight cut-off (MWCO) polyether sulfone (PES) ﬁlter (Sartorious), followed by a 10>< buffer exchange with 10 mM Tris, 20 mM Na2S04, pH 7.5 into a 0.22 um ﬁnal ﬁlter into a 50 L sterile storage bag.

The concentrated, diaﬁltered harvest was inactivated for Virus. Prior to Viral vation, a solution of 10% Triton® X-100, 3% tri (n-butyl) phosphate (TNBP) was prepared. The concentrated, diaﬁltered harvest was exposed to 1% Triton® X-100, 0.3% WO 2013/102144 PCT/US2012/072182 TNBP for 1 hour in a 36 L glass reaction vessel immediately prior to puriﬁcation on the Q column.

D. Puriﬁcation of Gen2 soluble rHuPH20 A Q Sepharose (Pharmacia) ion exchange column (9 L resin, H: 29 cm, D: 20 cm) was prepared. Wash samples were collected for a determination ofpH, conductivity and endotoxin (LAL . The column was equilibrated with 5 column volumes of 10 mM Tris, mM , pH 7.5. Following viral inactivation, the concentrated, diaﬁltered harvest was loaded onto the Q column at a ﬂow rate of 100 cm/hr. The column was washed with 5 column volumes of 10 mM Tris, 20 mM , pH 7.5 and 10 mM Hepes, 50 mM NaCl, pH7.0. The protein was eluted with 10 mM Hepes, 400 mM NaCl, pH 7.0 into a 0.22 um ﬁnal ﬁlter into sterile bag. The eluate sample was tested for bioburden, protein concentration and hyaluronidase activity. A280 absorbance readings were taken at the beginning and end of the exchange.

Phenyl-Sepharose (Pharmacia) hydrophobic interaction tography was next performed. A Phenyl-Sepharose (PS) column (19-21 L resin, H=29 cm, D: 30 cm) was prepared. The wash was collected and sampled for pH, conductivity and endotoxin (LAL assay). The column was brated with 5 column volumes of 5 mM potassium phosphate, 0.5 M ammonium sulfate, 0.1 mM CaClz, pH 7.0. The protein eluate from the Q sepharose column was supplemented with 2M ammonium e, 1 M potassium phosphate and 1 M CaC12 stock solutions to yield ﬁnal concentrations of 5 mM, 0.5 M and 0.1 mM, respectively.

The protein was loaded onto the PS column at a ﬂow rate of 100 cm/hr and the column ﬂow thru collected. The column was washed with 5 mM potassium ate, 0.5 M ammonium sulfate and 0.1 mM CaC12 pH 7.0 at 100 cm/hr and the wash was added to the collected ﬂow thru. Combined with the column wash, the ﬂow through was passed through a 0.22 um ﬁnal ﬁlter into a sterile bag. The ﬂow through was sampled for bioburden, protein tration and enzyme activity.

An henyl boronate column (Prometics) was prepared. The wash was collected and sampled for pH, conductivity and endotoxin (LAL assay). The column was equilibrated with 5 column volumes of 5 mM potassium phosphate, 0.5 M ammonium sulfate. The PS ﬂow through containing puriﬁed protein was loaded onto the aminophenyl te column at a ﬂow rate of 100 cm/hr. The column was washed with 5 mM ium phosphate, 0.5 M ammonium sulfate, pH 7.0. The column was washed with 20 mM bicine, 0.5 M ammonium sulfate, pH 9.0. The column was washed with 20 mM bicine, 100 mM sodium chloride, pH 9.0. The protein was eluted with 50 mM Hepes, 100 mM NaCl, pH 6.9 and passed through a WO 2013/102144 PCT/US2012/072182 sterile ﬁlter into a sterile bag. The eluted sample was tested for bioburden, protein tration and enzyme activity.

The hydroxyapatite (HAP) column (Biorad) was prepared. The wash was collected and tested for pH, conductivity and endotoxin (LAL assay). The column was brated with 5 mM potassium phosphate, 100 mM NaCl, 0.1 mM CaClz, pH 7.0. The aminophenyl boronate puriﬁed protein was supplemented to ﬁnal concentrations of 5 mM potassium phosphate and 0.1 mM CaClz and loaded onto the HAP column at a ﬂow rate of 100 cm/hr.

The column was washed with 5 mM potassium phosphate, pH 7, 100 mM NaCl, 0.1 mM CaClg. The column was next washed with 10 mM ium phosphate, pH 7, 100 mM NaCl, 0.1 mM CaClg. The protein was eluted with 70 mM potassium phosphate, pH 7.0 and passed h a 0.22pm sterile ﬁlter into a sterile bag. The eluted sample was tested for bioburden, protein concentration and enzyme actiVity.

The HAP puriﬁed protein was then passed through a Virus removal ﬁlter. The ized Viosart ﬁlter (Sartorius) was ﬁrst prepared by washing with 2 L of 70 mM potassium phosphate, pH 7.0. Before use, the ﬁltered buffer was sampled for pH and conductivity. The HAP d protein was pumped Via a peristaltic pump through the 20 nM Virus removal ﬁlter. The ﬁltered protein in 70 mM potassium phosphate, pH 7.0 was passed through a 0.22 um ﬁnal ﬁlter into a sterile bag. The ﬁltered sample was tested for protein concentration, enzyme actiVity, oligosaccharide, monosaccharide and sialic acid proﬁling. The sample also was tested for process d impurities.

The protein in the ﬁltrate was then concentrated to 10 mg/mL using a 10 kDa molecular weight cut off (MWCO) Sartocon Slice tangential ﬂow ﬁltration (TFF) system (Sartorius). The ﬁlter was ﬁrst ed by g with 10 mM histidine, 130 mM NaCl, pH 6.0 and the permeate was sampled for pH and conductivity. Following concentration, the concentrated protein was d and tested for protein concentration and enzyme actiVity. A 6>< buffer exchange was performed on the concentrated protein into the ﬁnal buffer: 10 mM ine, 130 mM NaCl, pH 6.0. Following buffer exchange, the trated protein was passed though a 0.22 um ﬁlter into a 20 L sterile storage bag. The protein was sampled and tested for protein concentration, enzyme actiVity, free sulfydryl groups, oligosaccharide ng and osmolality. Lot number WRSZ was used as a standard in the assays described below, the results showed that the test description for appearance was clear and colorless; the pH was 7.4; the endotoxin level was <0.01 EU/mL; the osmolality was 308 mOsm/Kg; the density was 1.005 g/mL; the rHuPH20 content was 1.3 ppm; and the hyaluronidase actiVity was 145 USP U/mL.

WO 2013/102144 PCT/US2012/072182 The sterile ﬁltered bulk protein was then asceptically dispensed at 20 mL into 30 mL sterile Teﬂon Vials (Nalgene). The Vials were then ﬂash frozen and stored at -20 :: 5 OC.

EXAMPLE 2 GENERATION 0F PH20 MUTANT LIBRARY A. Cloning and Mutagenesis In this example, a human hyaluronidase PH20 library was created by cloning DNA encoding human PH20 into a plasmid followed by transfection and n sion.

The library was created by mutagenesis of a PH20 template that is a codon optimized version of PH20 with an Ig Kappa leader sequence. Speciﬁcally, for generating the library of variants, the HZZ4-PH20(OHO)-IRES-SEAP expression vector (set forth in SEQ ID NO:4) was used as a template, which contains the sequence of nucleotides encoding PH20 set forth in SEQ ID NO:1, which encodes a precursor PH20 set forth in SEQ ID N02 or a mature PH20 set forth in SEQ ID NO:3 lacking residues 1-22 corresponding to the IgK signal I5 sequence. The ne of the vector was derived from the al H224 vector containing the DHFR selection marker (see Example 1 and SEQ ID NO:5) with the addition of an IgK leader sequence and codon optimization. The expression vector also was modiﬁed to contain the gene for secreted alkaline phosphatase (SEAP). Hence, in addition to sequence ng PH20, the HZZ4-PH20(OHO)-IRES-SEAP expression vector also contains an internal ribosome entry site (EMCV IRES) that is linked to the coding sequence for the gene for secreted alkaline phosphatase (SEAP), and a single CMV promoter that drives expression of PH20 and SEAP in the construct. It also contains a gene for ampilcillin resistance. With reference to the sequence of tides set forth in SEQ ID NO:4, the sequence of nucleotides encoding PH20 corresponds to nucleotides 105 8-2464 (including the IgK leader sequence), the ce of nucleotides ng SEAP corresponds to nucleotides 2970- 4529, and the ampicillin resistance gene corresponds to nucleotides 5778-6635.

The ﬁrst library was made to generate encoded t proteins wherein each of residues 23-469 of SEQ ID NO:2 (corresponding to residues 1-447 of SEQ ID N03 or residues 36-482 of SEQ ID NO:6) was changed to one of about 15 amino acid es, such that each member contained a single amino change. The resulting library contained 6753 t members, each containing a single amino acid mutation compared to residues 23-469 of SEQ ID NO:2 (corresponding to residues 1-447 of SEQ ID N03 or residues 36-482 of SEQ ID NO:6). Glycerol stocks of the resulting y were prepared and stored at -80 OC.

The amino acid replacements (mut) in each member are listed in Table 8 below, and correspond to amino acid replacements with reference to the sequence of amino acids of WO 2013/102144 PCT/US2012/072182 PH20 set forth in SEQ ID N03 (and SEQ ID NOS: 7 or 32-66, Which are the mature sequence of PH20 or other C-terminally ted fragments thereof). The corresponding mutated codons (cod) of each PH20 variant in the library are also listed in Table 8, and correspond to nucleotide e changes in the corresponding encoding nucleotide for PH20 set forth as 105 8-2464 of SEQ ID NO:4. Each member was expressed and screened for hyaluoridase activity as described below.

TABLE 8: PH20 Variants mut cod B: cod mut cod mut cod B: Ic0 mut cod L001A GCG Y066S AGT R132N AAT G198T ACT V265G GGT I331K AAG L001C TGT Y066T ACG R132P CCT G198V GTT V265H CAT I331L CTG L001D GAT Y066V GTG R132Q CAG G198W TGG V2651 ATT I331Q CAG L001E GAG 1067C C1||._]C)~1~]TGT R1328 AG G198Y TAT V265K IIAAC) I331R OG L001F TTT 1067D GAT R132T AC Y199A GCG V265L CTG 13318 AG L001G GGT 1067E GAG R132V Y199C TGT V265M ATG I331T ACT L001H CAT 1067F TTT R132Y .4A.4 Y199E GAG V265N AAT I331W TGG L001K iC) 1067G GGG S 1 33A GCT Y199G GGG V265P CCT I331Y TAT L001N AAT 1067H CAT Sl33D GA.4 Y199H CAT V265Q CAG I332A GC.4 L001P CCG 1067L TTG Sl33E GAG Y199I ATT V265R AGG I332C ._]G L001Q CAG 1067N AAT Sl33F TTT Y199K AAG V2658 TCT I332D GA1—]'-l L001R CGG 1067P CCG Sl33G GGG Y199L CTT V265W ._]C)C) I332E GAG L001S TCT 1067Q CAG Sl33H OA Y199N AAT V265Y TAT I332F .4.4.4 L001T ACG IO67R F266A GCG I332G GG L001V GTG 1067T F266C TGT I332H CA L001W TGG IO67V GTT $133M ATG Y199R AGG F266D GAT I332K AAG \002A GCT 1067W TGG Sl33N AAT Y199S TCG F266G GGG I332L CTG \002C TGT IO67Y IllTAT Sl33P OC._] Yl99T ACG F266H CAT I332N AAT \OOZF TTT D068A GCT Sl33R GC) Yl99W TGG F266L CTT I332P CCT \002G GGG D068C TGT S l 33T AC._] \200A GCT F266M CCG I332R AGG \002H CAT D068E GAG S 1 33V Q._] *1 \200D GAT F266P ATG I332S AGT \0021 ATT D068G GGG S l 33W TGG \200F CAG F266Q CAG I332T ACT \002K AAG D068H CAC Il34A GCT \200G GGT F266R CGG I332Y TAT \002L TTG D0681 ATT Il34C .4G.4 \200H CAT F266S TCG \333A GCT \002P CCG D068K AAG Il34D GAT \200K AAG F266T ACG \333E GAG \002Q CAG D068L TTG Il34F TTT \200L CTG F266V GTG \333G GGT \002S AGT D068P CCT Il34G GGG \200M ATG F266W TGG \333H CAT \002T ACG D068Q CAG Il34H CAT \200P CCT F266Y TAT \333I ATT \002V GTT D068R CGG Il34K AAG \200Q CAG A267D GAT \333K G \002W TGG D068S TCG Il34L TTG \200R >C)G A267E GAG \333L CTG \002Y TAT D068T ACT Il34P CCT \200S TCT A267G GGT \333M ATG F003A GCT D068V GTG Il34Q CAG \200T ACT A267H CAT \333P CCT F003E GAG D068Y TAT Il34R CGT \200V C)._]C) A2671 ATT \333R CGG WO 2013/102144 PCT/U82012/072182 —234— TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod F003G GGG 8069A GCT 11348 TCG N200W 67K AAG N333S AGT F003H CAT 8069C TGT 1134T ACT N200Y 1—11—1>C)HC) 67L CTT N333T ACT F0031 ATT SO69E GAG 1134V T G201A GC Ox \1E ATG N333V C)TT F003K AAG SO69F TTT 1134W 3C)C)C) G201E QC)C) ii3‘]2 il._]C)C)N333W F003L TTG SO69G GGG E135A GCT G201F .4.4.4 PS3‘]"U CCG N333Y TAT F003M ATG 80691 ATT E135C TGT G201H CAT F003N AAT 8069L CTT E135D GAT G201K AAG A2678 TCT V334C TGT F003P CCT 8069M ATG E135F TTT G201L CTT GTG V334D GAT F0038 TCG 8069P CCT E135H CAT G201N AAT A267W TGG V334G GGG F003T ACT 8069R CGT E135K E G201P CCT Y268A GCT V334H CAT F003V GTG 8069T ACG E135L TTC) G201Q CAG Y268C TGT V334L TTC) F003Y TAT 8069V GTT E135N E G201R CGT Y268F TTT V334M T R004A GCG 806O2 ._]C)C) E135P CT G2018 TCG Y268G GGG V334N R004D GAT 8069Y TAT E135Q OAC) G201T ACG Y268H CAT V334P CCT R004E GAG 1070A GCT E135R OC)C) G201V GTG Y268K iG V334Q CAG R004F TTT 1070C TGT E1358 ] G201W TGG Y268L CTT V334R AGG R004G GGG IO70F TTT E135W ._] C) 8202A GCG Y268N E V3348 TCT R0041 ATT IO70G GGG E135Y ._]A’€ 8202B GAG Y268P CCT V334T ACT R004L TTG IO70H CAT L136A GCT 8202F TTT Y268Q CAG V334Y TAT R004M ATG 1070K iG L136C TGT 8202G GGT Y268R CGT T335A GCT R004N AAT IO70L TTG L136D GAT 8202H CAT Y2688 TCG T335C TGT R004F CCT IO70N iT L136F TTT 8202K AAG Y268T ACT T335F TTT R0048 TCT IO70P CCG L136G GGT 8202M ATG Y268V GTG T335G GGT R004T ACG IO70Q CAG L136H CAT 8202N AAT Y268W TGG T335H CAT R004V GTG IO70R CGT L136T ATT 8202P CCT T269A GCT T3351 ATT R004W TGG 10708 TCT L136M ATG 8202Q CAG T269C TGT T335K AAG R004Y TAT IO70T ACT L136N AAT 8202R CGT T269D GAT T335L TTG A005D GAT IO70V GTT L136P CCT 8202T ACG T269E GAG T335N AAT A005G GGG IO70Y TAT L136Q CAG 8202V GTT T269G GGT T335P CCT A005H CAT T071A GCT L136R CGT 8202W TGG T269K AAG T335Q CAG A0051 ATT T071C TGT L1368 TCG 8202Y TAT T269L CTG T3358 TCT A005L CTT T071D GAT L136T ACT C203A GCG T269M ATG T335V C)TC) A005M ATG T071E GAG L136W TGG C203D GAT T269N AAT T335W TGG A005N AAT T071G GGG V137A GCT C203E GAG T269P CCG T335Y TAT A005P CCG T071H CAT V137C TGT C203G GGG T269Q CAG L336A C)CT A005Q CAG T071L TTG V137E C)AC) C203H CAT T269R AGG L336E C)AC) A005R AGG T071M ATG V137F TTT C203L CTT T2698 TCG L336F TTT A0058 TCG T071N AAT V137G GGG C203M ATG T269V GTG L336G C)C)C) A005T ACG T071P CCT V137H CAT C203N AAT T269YITAT L336H CA WO 02144 PCT/U82012/072182 TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod A005V GTG T071Q CAG V1371 ATT C203P CCG R270A GCT L336K AAG AOOSW TGG T071R CGG V137L TTG C203Q CAG R270C TGT L336M ATG A005Y TAT T0718 TCG V137N AAT C203R AG \10D GAT L336N AAT P006A GCG T071V GTG V137P CCT C203 S > ii\10m GAG L336P CCT P006D GAT T071Y TAT V137Q CAG C203T > \1 o’11 TTT L336R AGG P006E GAG G072A GCT V137R CGT C203V GTG 5570G GGG L3368 TCT P006F TTT G072C TGT V1378 TCT C203w TGG P006G GGG G072D GAT V137T ACT F204A GCG P006H CAT G072E GAG V137W TGG F204C TGT P006K AAG G072F TTT V137Y TAT F204E GAG R270N AAT L336Y TAT P006L CTT G072H CAT Q138A GCT F204G GGG R270P CCT A337C TGT P006N AAT G0721 ATT Q138C TGT F204H CAT R270Q CAG A337P TTT P006Q CAG G072K AAG Q13 8E GAG F2041 ATT TCG A337G GGG P006R AGG G072L TTG Q13 8F TTT F204K AAG ACT A337H CAT P0068 AGT G072M ATG Q13 8G GGG F204L CTT 70V GTG A3371 ATT P006T ACG G072P CCT Q138H CAT F204M ATG E5555~"33>Hm0Y TAT A337K E P006V GTG G072Q CAG Q1381 ATT F204P CCT GCT A337L TTG P006W TGG G072R CGG Q13 8L TTG F204Q CAG 1271D GAT A337M >TC) P006Y TAT G0728 TCT Q138M ATG F204R AGG 1271B GAG A337N P007A GCT G072T ACT Q13 8N AAT F2048 AGT 1271F TTT A337P 0CT P007C TGT G072V GTG Q13 8R CGT F204T ACT 1271G GGG A337R 0 P007D GAT G072W TGG Q13 88 AGT F204V GTG 1271H CAT A3378 TCT P007F TTT G072Y TAT Q13 8V GTT F204W TGG 1271K AAG A337T ACT P007G GGT V073A GCG Q138W TGG \205A GCG 1271L CTT A337V GTT P007H CAT V073C TGT Q13 8Y TAT \205D GAT 1271M ATG A337W TGG P0071 ATT V073D GAT Q139A GCT \205E GAG 1271P CCT A33 8C TGT P007K AAG V073F TTT Q139C TGT \205F TTT 1271R AGG A33 8D GAT P007L TTG V073G GGG Q139D GAT \205G GGG 12718 AGT A33 8B C)AC) P007M ATG V073H CAT Q139E GAG \205K AAG 1271T ACT A33 8F TTT P007Q CAG V073K AAG Q139F TTT \205L CTG 1271V GTT A33 8G GGG P007R CGG V073L CTT Q139G GGG \205M ATG 1271W TGG A33 8H CAT P0078 AGT V073M ATG Q139H CAT \205P CCT V272A GCT A33 81 ATT P007T ACT V073P CCG Q139K AAG \205R AGG V272C TGT A33 8K AAG P007V GTG V073Q CAG Q139L CTG \2058 TCG V272D GAT A33 8L CTT P007W TGG V073R TGG Q139M >TC) /205T ACG V272E GAG A33 8P CCT P007Y TAT V0738 TCG Q139P OCT /205V GTG V272G GGG A338Q CAG V008A GCT V073T ACG Q139R CC)._] /205W TGG V272H CAT A33 8R CGT V008D GAT V07 WU.) 0C)C) Q1398 ._]C._] /205Y TAT V272K AAG A33 88 TCG V008E GAG T074A GCT Q139T ACT V206C TGT V272L TTG A33 8T ACT V008G GGT T074C TGT Q139V C)TC) V206D GAT V272M ATG A33 8V GTG WO 2013/102144 PCT/U82012/072182 TABLE 8: PH20 ts mut cod mut cod mut cod mut cod mut cod mut cod V008H CAT T074E GAG Q140A GCT V206F TTT V272N AAT K339D GAT V0081 ATT T074F TTT Q140C TGT V206G GGG V272P CCT K339E GAG V008L TTG T074G GGT Q140D GAT V206H CAT V272R AGG K339F TTT V008M ATG T074H CAT Q140F TTT V2061 ATT V2728 IIC)C)TCG K339G V008N AAT T074K AAG Q140G C) V206K AAG V272T ACT K339H CAT V008P CCT T074L TTG Q140H CA V206L CTT V272W TGG K339L CTG V008Q CAG T074M ATG Q1401 ATT V206M ATG F273A GCT K339M ATG V008R CGG T074N AAT Q140K V206P CCG F273C TGT K339N AAT V0088 TCT T074P CCG Q140L TTG V206Q CAG F273D GAT K339F CCT V008T ACT T074R CGG Q140M ATG V206R CGG F273G GGG K339R CGG V008W TGG T0748 TCG Q140R CGG V2068 TCT F273H CAT K3398 AGT 1009A GCT T074V GTG Q1408 AGT V206T ACG F2731 ATT K339T ACT 1009C TGT T074W TGG Q140V C)TC) V206Y TAT F273L CTG K339V C)TT 1009D GAT V075A GCG Q140W TGG E207A GCT F273P CCT K339W ._]C) 1009B GAG V075C TGT Q140Y TAT E207F TTT F273Q CAG K339Y .4A.4 1009G GGG V075D GAT \ 141A GCT E207G GGG F273R CGG V1340A GCT 1009N AAT V075L CTT \141G GGT E207L TTG F273W TGG V1340F TTT 1009P CCT V075M ATG \141H CAT E207M ATG F273Y IC)C)TAT V1340G 1009Q CAG V075N AAT \141L TTG E207P CCG T274A GCG V1340H CAT 1009R CGG V075P CCG \ 141M ATG E207Q CAG T274C TGT V1340K AAG 10098 AGT V075Q CAG \141P CCT E207R AGG T274E GAG V1340L CTG 1009T ACG V075R CGT \141Q CAG E2078 TCT T274F ATG V1340P CCT 1009V GTT V0758 TCT \ 141R CGT E207T ACG T274G GGG V1340R CGG P010D GAT V075T ACT \ 1418 TCT E207V GTT T274H CAT V13408 TCG P010E GAG V07L112 ._]C)C) / 141T 3>CT E207W TGG T274L CTG V1340T ACT P010F TTT V075Y TAT / 141V C)TT I208A GCT T274N AAT V1340V GTG P010G GGT \076A GCT \ 141W ._]C)C) I208C TGT T274P CCT V1340W TGG P010H CAT \076C TGT \141Y .4A.4 I208D GAT T274Q CAG C341A GCT P0101 ATT \076D GAT V142C .4C).4 I208E GAG T274R CGT C341E GAG P010L CTT /076FITTT V142D AT I208G GGG T2748 AGT C341G C)GC) P010M ATG //076G GGG V142E GAG I208K AAG T274V GTT C341H CAT P010N AAT 0761 ATT V142G GGG I208L TTG T274W TGG C341K AAG P010Q CAG 076K AAG V142H CAT I208M ATG T274Y TAT C341L TTG P010R CGG / ||076L CTG V1421 TT I208P CCG D275A GCT C341M ATG P0108 TCG //076P CCT V142K AAG I208Q CAG D275C TGT C341N AAT P010T ACT 076Q CAG V142L TTG I208R CGT D275E GAG C341Q CAG P010W TGG \076R CGT V142M ATG 12088 AGT D275F TTT C341R AGG WO 2013/102144 PCT/US2012/072182 TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod P010Y TAT N0768 AGT V142N AAT 1208T ACG D275G GGG C3418 TCT \011A GCG N076T ACT V142P CCT 1208V GTG D2751 ATT C341T ACT \011C TGT N076V GTT V142Q OAC) 1208W TGG D275K AAC) C341V GTT \011D GAT N076W ) V142R OC)C) K209A GCG D275L CTT C341W TGG \011E GAG G077D GAT V1428 >C)._] K209C TGT D275M ATG C341Y TAT \011F TTT G077E GAG V142T ACT K209D GAT D275Q CAG 8342A GCT \011G GGG G077F D275R CGT 8342D GAT \011K AAG G077L D275V GTG 8342G GGG \011L CTG G077M ATG Q143H CAT K209N AAT D275W TGG 8342H CAT \011P CCG G077N AAT Q1431 ATT K209P CCG Q276C TGT 83421 TT \0118 TCG G077P CCG Q143K AAG K209R CGG Q276D GAT 8342K \011T ACG G077Q CAG Q143L TTG K2098 AGT Q276E GAG 8342L TTC) \011W TGG G077R CGT Q143M ATG K209T ACT Q276F TTT 8342M >TC) \011Y TAT G0778 TCG Q143N AAT K209V GTT Q276G GGG S342P CCT V012A GCT G077T ACG Q143P CCT K209W TGG Q276H CAT 8342Q CAG V012D GAT G077VII I!GTGQ143R CG K209Y TAT Q2761 ATT 8342R CG V012E GAG G077Y TAT Q143 S TCG R210A GCG Q276L CTT 8342T ACT V012G GGG G078A GCG Q143T ACT R210C TGT Q276M ATG 8342Y TAT V012H CAT G078C TGT Q143V C)TC) R210D GAT Q276P CCT Q343C TGT V0121 ATT G078D GAT Q143Y TAT R210E GAG Q276R CGT Q343D GAT V012K AAG G078H CAT L144A GCT R210G GGT Q2768 AGT Q343E C)AC) V012L CTT G0781 ATT L144E GAG R210K AAG Q276V GTT Q343F TTT V012M ATG G078K AAG L144F TTT R210L CTG Q276W TGG Q343G GGG V012N AAT G078L TTG L144G C)GC) R210M ATG Q276Y TAT Q3431 TT V012P CCG G078M ATG L1441 ATT R210N AAT V277A GCT Q343L CTT V012R AGG G078P CCG L144K AAG R210P CCT V277C TGT Q343M ATG V0128 TCG G078Q CAG L144N AAT R2108 TCG V277D GAT Q343P CCT V012T ACT G078R AGG L144P CCT R210T ACT V277E GAG Q343R AGG V012W TGG G0788 TCG L144Q CAG R210V GTG V277G GGG Q343 S AGT P013A GCT G078T ACT L144R CGT R210W TGG V277H CAT Q343T ACT P013E GAG G078V GTG L1448 TCT R210Y TAT V277K AAG Q343V C)TC) P013F TTT G078Y TAT L144T ACT N211A GCG V277L TTG Q343W ._] C) P013G GGG 1079A GCT L144V GTT N211C TGT V277M ATG Q343Y TAT P013H CAT 1079D GAT L144W TGG N211F TTT V277N AAT V344E GAG P0131 ATT 1079F TTT L144Y TAT N211G GGG V277Q CAG V344F TTT P013L CTT 1079G GGG 8145A GCT N211H CAT V277R AGG V344G C)C) P013M ATG 1079H CAT 8145C TGT N2111 ATT V2778 TCT V344H CA._] P013Q CAG 1079K AAG 8145D GAT N211K AAG V277T ACT V3441 ATT WO 2013/102144 PCT/U82012/072182 TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod P013R CGT 1079L TTG 8145E C)AC) IN211L CTG V277Y TAT V344L CT P013 S TCG 1079N AAT 8145F TTT N211M ATG L278A GCT V344M ATG P013T ACT 1079P CCG 8145G 8h1C) N211P CCT L278E GAG V344N AAT P013V GTG 1079R CGT 8145H CA N211R CGG L278F TTT V344P CCT P013W TGG 10798 AGT 8145L TTG N2118 AGT L278G GGG V344Q CAG P013Y TAT 1079T ACT 8145M ATG N211T ACT L278H CAT V344R CGT F014A GCG 1079V GTT 8145N AAT N211V GTT L2781 ATT V3448 TCG F014D GAT 107"2° TGG 8145P CCT N211W TGG L278K E V344T ACT F014E GAG 1079Y TAT 8145R CGT D212A GCT L278M TTT V344W TGG F014G GGT P080A GCG 8145T ACT D212E GAG L278N AAT V344Y TAT F014H CAT P080D GAT 8145V GTT D212G GGG L278P CCG L345A GCT F0141 ATT P080E GAG 8145W TGG D212H CAT L278R CGT L345C F014K AAG P080F TTT L146A GCT D2121 ATT L2788 TCT L345D AT F014M ATG P080G GGG L146C TGT D212K AAG L278T ACT L345E A F014N AAT P0801 ATT L146E GAG D212L CTG L278V GTT L345G ’€ F014P CCT P080K AAG L146G GGG D212M ATG L278Y TAT L345H CA F014Q CAG P080L CTT L146H CAT D212N AAT K279A GCG L345K F014R CGG P080M|ATGL1461 TT D212P CCT K279C TGT L345N F014T ACT P080N AAT L146K AAG D212Q CAG K279D GAT L345P CT F014V GTG P080R AGG L146N AAT D2128 TCG K279F TTT L345Q OAC) F014W TGG P0808 TCT L146P CCT D212T ACT K279G GGG L345R CGT L015A GCG P080T ACG L146Q CAG D212V GTG K279H CAT L345T ACT L015E GAG P080V GTG L146R CG D212W TGG K279L CTG L345V GTT L015F TTT P080YIITAT L1468 TCG D213A GCT K279P CCT L345W TGG L015G GGG Q081A GCT L146T ACT D213E GAG K279Q CAG L345Y TAT L015K AAG Q081C TGT L146V GTT D213G GGG K279R AGG C346A GCT L015M ATG Q081E GAG L146Y TAT D213H CAT K2798 TCT C346D GAT L015N AAT Q081F TTT T147A GCT D213K AAG K279T ACG C346F TTT L015P CCG Q081G GGG T147C TGT D213L CTG K279V GTG C346G GGG L015Q CAG Q081H CAT T147D GAT D213M ATG K279W TGG C3461 ATT L015R CGG Q081L CTG T147F TTT D213N AAT K279Y TAT C346K AAG L0158 TCG Q081M ATG T147G GGT D213P CCT F280D GAT C346L CTT L015T ACT Q081N|AATT1471 TT D213Q CAG F280E GAG C346M ATG L015V GTT Q081P CCG T147L CTT D213R CGT F280G GGG C346P CCT L015W TGG Q081R AGG T147M ATG D213 8 TCG F280H CAT C346Q CAG L015Y TAT Q0818 TCT T147P OCT D213V GTG F2801 ATT C346R CGG W016A GCG Q081V GTT T147Q OAC) D213W TGG F280L TTG C3468 TCT W016C TGT Q08 .4C)C) T147R C .4 D213Y TAT F280M ATG C346T ACT W016D GAT Q081Y TAT T1478 >C)._] L214A GCG F280N AAT C346V GTG W016E GAG K082A GCT T147V GTT L214C TGT F280P CCT C346W TGG WO 2013/102144 PCT/US2012/072182 TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod W016F TTT K082E GAG T147W TGG L214D GAT F280QICAG Q347A CT W016G GGT K082G GGT T147Y TAT L214E GAG F280R CGT Q347C .4C).4 W016H CAT K082H CAT E148C TGT L214G GGG F280S TCG Q347E C)AC) W016K AAG K0821 ATT E148F TTT L214H CAT F280T ACT Q347F TTT W016L CTT K082L CTT E148G GGG L214K AAG F280V GTG Q347G C)C)T W016M ATG K082M ATG E148H CAT L214N AAT F280W ._]C)C) Q3471 ATT W016P CCT K082N AAT E1481 ATT L214P CCG L281A GCG Q347L TTG W016R CGT K082P CCT E148K AAG L214Q CAG L281D GAT Q347M ATG W016S TCG K082QIICAG E148L CT L214R CGG L281F TTT Q347P CCT W016T ACT K082R CGT E148P CCT L214S TCG L281G GGT Q347R AGG W016Y TAT K082S AGT E148Q CAG L214T ACG L281H CAT Q347S TCT A017D GAT K082T ACT E148R 1—10 C)C) L214V GTG L2811 ATT Q347T ACT A017E GAG K082V GTG E148S C.4 L214Y TAT L281K Q347V T A017G GGG K082W ._]C)C) E148T C)£1>CT S215A GCT L281Z iiQ347W .4C)C) A017H CAT K082Y TAT E148V TC) S215C TGT L281P CCG Q347Y TAT A0171 ATT 1083E GAG E148W ._]C)C) S215D GAT L281Q CAG E348C TGT A017L CTT 1083F TTT E148Y ] S215E GAG L281R CGG E348D GAT A017N AAT 1083G GGT A149C ._] 1—1 S215G GGG L281S AGT E348G GGT A017P CCG 1083H CAT A149E AQ S215H CAT L281V GTT E348H CAT A017Q CAG 1083K iG A149F TTT S215K AAG L281W ._]C)C) E3481 ATT A017R AGG 1083L CTG A149G GGT S215L TTG L281Y TAT E348L TTG A017S TCG 1083N iT A149K AAG S215M ATG S282A GCG E348M ATG A017T ACG 1083P CCT A149L TTG S215P CCG S282C TGT E348P CCT A017V GTG 1083Q CAA A149M ATG S215Q CAG S282D GAT E348Q CAG A017W TGG 1083R CGT A149P CCT S215R CGG S282E GAG E348R CGG A017Y TAT 1083 S TCG A149Q CAG S215T ACT S282F TTT E348S TCT W018C TGT 1083T ACT A149R CGG S215V GTG S282G GGT E348T ACT W018D GAT 1083V GTT A149S TCT S215W TGG S282L CTT E348V GTT W018F TTT 1083Y TAT A149T ACT W216D GAT S282M ATG E348W TGG W018G GGG S084D GAT A149V GTT W216E GAG S282P CCT E348Y TAT W018H CAT S084E GAG A149W TGG W216G GGT S282Q CAG Q349A GCT W0181 ATT S084F TTT A149Y TAT W216H CAT S282R CGT Q349D GAT W018L CTG S084G GGT T150A GCT W2161 ATT S282T ACT Q349E C)AC) W018M ATG S084H CAT T150C TGT W216K AAG S282V GTT Q349F TTT W018P CCG S0841 ATT T150D GAT W216L CTG S282W .4C)C) Q349G GGT W018Q CAG S084L CTT T150E GAG W216M ATG S282Y TAT Q349H CA.4 W018R CGG S084M ATG T150F TTT W216N AAT Q283A GCG Q349K W018S AGT S084N IIC)C) AAT T150G W216P CCT Q283C TGT Q349L CT W018T ACG S084P CCT T1501 ATT W216Q CAG Q283D GAT Q349M ATG W018V GTG S084Q CAG T150L TTG W216R CGG Q283E GAG Q349N AAT WO 2013/102144 2012/072182 —240— TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod W018Y TAT 8084R CGG T150N AAT W216T ACG Q283F TTT Q349P CCT \019A GCG 8084T ACT T150P CCT W216V GTG Q283G GGG Q349R CGT \019C TGT 8084W ._]C) T150R AGG W216Y TAT Q283H CAT Q3498 TCG \019F TTT 8084YII TAT T1508 TCT L217A GCG Q283L CTT Q349T ACT \019G GGG L085A GCT T150V GTG L217C TGT Q283N AAT Q349V GTG \019H CAT L085C TGT T150W TGG L217E GAG Q283P CCG Q349W TGG \0191 ATT L085D GAT T150Y TAT L217G GGT Q283R CGT Q349Y TAT \019L CTG L085E GAG E151A GCT L217H CAT Q2838 TCT G350A GCT \019M ATG L085F TTT E151C TGT L217I ATT Q283T ACT G350D GAT \019P CCG L085G GGG E151G GGT L217M ATG Q283W TGG G350E GAG \019Q CAG L085H CAT E151H CAT L217P CCG Q283Y TAT G350F TTT \019R CGT L085K II:%E151K AAG L217Q CAG D284A GCT G350H CAT \0198 TCG L085N E151L TTG L217R AGG D284C TGT G350K AAG \019V GTT L085P CCT E151M ATG L2178 TCT D284E GAG G350L CT \019W TGG L085Q CAG E151N AAT L217T ACG D284G GGT G350M ATG \019Y TAT L085R CGT E151Q CAG L217V GTG D284H CAT G350N AAT A020D GAT L0858 TCG E151R AGG L217W TGG D2841 ATT G350P CCT A020E GAG L085T ACT E1518 TCG L217Y TAT D284L TTG G350R CGT A020F TTT L085V GTT E151T ACT W218A GCT D284M ATG G3508 TCT A020G GGG Q086A GCT E151V GTT W218D GAT D284N AAT G350T ACT A020H CAT Q086C TGT E151W TGG W218F TTT D284P CCG G350V GTG A020K AAG Q086D GAT E151Y TAT W218G GGT D284Q CAG G350Y TAT A020L CTG Q086E GAG K152A GCT W218H CAT D2848 TCT V351A GCT A020N AAT Q086F TTT K152C TGT W21 81 ATT D284T ACG V351C TGT A020P CCG Q086G GGT K152F TTT W218K AAG D284V GTT V351D GAT A020Q CAG Q086H CAT K152G GGT W218L CTT D284Y TAT V351E C)AC) A020R CGT Q0861 ATT K1521 ATT W218M ATG E285A GCG V351F TTT A0208 TCT Q086K AAG K152L TTG W218P CCT E285F TTT V351G GGT A020T ACT Q086L CTG K152M ATG W218Q CAG E285G GGG V351H CAT A020V GTT Q086M ATG K152N AAT W218R CGG E285H CAT V3511 ATT A020Y TAT Q086N AAT K152P CCT W2188 TCG E285K AAG V351L TTG P021A GCG Q086P CCT K152R AGG W218T ACT E285M ATG V351N AAT P021C TGT Q086R CGG K1528 TCT W218V GTG E285N AAT V351Q CAG P021D GAT Q0868 TCT K152T >CT N219A GCG E285P CCT V351R AGG P021E GAG Q086T ACT K152V GTG N219C TGT E285Q CAG V3518 TCT P021G GGG Q086V GTG K152W 1—11—] C)C) N219D GAT E285R CGT V351W TGG P021H CAT Q086W TGG K152Y A._] N219E GAG E2858 AGT V351Y TAT P0211 ATT D087A GCT A153C ._] 1-] N219G GGG E285T ACG C352A GCT P021K AAG D087C TGT A153E AQ N219H CAT E285V GTG C352D GAT P021L CTT D087E GAG A153F TTT N219I ATT E285W TGG C352E GAG WO 2013/102144 PCT/US2012/072182 —241— TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod P021M ATG D087G GGG A153G GGT N219K AAG E285Y TAT C352F TTT P021R CGT D087H CAT A153H CAT N219L CTT L286A GCG C352G GGG P0218 TCT D0871 ATT A1531 TT N219M ATG L286C TGT C352K AAG P021T ACG D087L|| CTG A153K AAG N219P CCT L286D GAT C352M ATG P021V GTT D087M ATG A153L CTG N219R CGT L286E GAG C352P CCT P021W TGG D087P CCT A153M ATG N2198 TCG L286F TTT C352Q CAG 8022A GCT D087Q CAG A153P CCT N219T ACT L286G GGT C352R CGT 8022C TGT D087R AGG A153Q CAG N219W TGG L286H CAT C3528 AGT 8022D GAT D0878 TCG A153R CGT E220A GCG L286K AAG C352T ACT 8022E GAG D087T ACT A153 S AGT E220D GAT L286M ATG C352V GTG 8022G GGG D087V GTT A153T ACT E220G GGG L286P CCT C352W TGG 8022H CAT D087Y TAT A153V T E220H CAT L286R AGG C352Y TAT 8022K AAG H088A GCT A153W C)C) E2201 ATT L2868 AGT I353A GCT 8022L CTG H088C TGT K154A C)CT E220K AAG L286T ACG I353C TGT 8022M ATG H088E GAG K154C .4C).4 E220L TTG L286W .4C)C) I353E GAG 8022N AAT H088FITTT K154D AT E220M ATG L286Y TAT I353F TTT 8022P CCG H088G GGG K154E GAG E220N AAT V287A GCT I353G GGG 8022R CGG H0881 ATT K154G C)C)T E220P CCG V287C TGT I353H CAT 8022T ACT H088K AAC) K154H CA._] E220R CGG V287D GAT I353K AAG 8022V GTG H088L TTG K1541 >TT E2208 TCT V287E GAG I353L CTT 8022Y TAT H088M ATG K154L CTG E220T ACG V287F TTT I353M ATG E023A GCT H088P CCT K154P CCT E220V GTG V287G GGG I353Q CAG E023D GAT H088RlCGT K154R CG E220W TGG V2871 ATT I353R CGT E023F TTT H0888 AGT K1548 AGT 8221A GCG V287 gG 1353 8 TCG E023G GGG H088T ACT K154T ACT 8221C TGT V287L CTT I353T ACT E023H CAT H088V GTT K154V GTG 8221D GAT V287N E I353V GTG E023L CTT H088Y TAT K154W TGG 8221E GAG V287P CCT I353W TGG E023M ATG L089A GCT K154Y TAT 8221G GGG V287Q CAG R354C TGT E023N AAT L089C TGT Q155A GCT 8221H CAT V287R CGG R354D GAT E023P CCT L089D GAT Q155C TGT 82211 ATT V2878ITCT R354E A E023Q CAG L089E GAG Q155D GAT 8221K AAG V287T ACT R354G GGT E023R CGG L089G GGG Q155F TTT 8221L TTG Y288D GAC R354H CAT E023 8 TCT L089K AAG Q155G C)GC) 8221M ATG Y288E I!GAG R3541 TT E023T ACG L089M ATG Q155H CAT 8221P CCG Y288F TTT R354K AAG E023V GTG L089N AAT Q155K AAG 8221Q CAG Y288G GGG R354L CTT E023W TGG L089P CCT Q155L CTT 8221R CGG Y288H CAT R354M ATG F024A GCG L089Q CAG Q155M >TC) 8221T ACT Y288I ATT R354P CCT F024C TGT L089R AGG Q155P 0CT 8221V GTG Y288K ilAA R354Q CAG F024E GAG L0898 TCG Q155R OC)C) T222A GCG Y288L CTG R3548 TCT F024G GGG L089T ACT Q1558 >C)._] T222D GAT Y288P CCT R354V GTG WO 2013/102144 PCT/US2012/072182 —242— TABLE 8: PH20 ts mut cod mut cod mut cod mut cod mut cod mut cod F024H CAT L089W TGG Q155T ACT T222E GAG Y288Q CAG R354W TGG F0241 ATT L089Y TAT Q155V GTT T222F TTT Y288R CGT R354Y TAT F024K AAG D090A GCT Q155W TGG T222G GGG Y2888 TCT K355D GAT F024L TTG D090C TGT Q155Y TAT T2221 ATT Y288T ACT K355F TTT F024M ATG D090E GAG E156A GCT T222K AAA Y288V GTG K355G GGG F024N AAT D090G GGG E156C TGT T222L TTG Y288W TGG K355H CAT F024P CCT D090H CAT E156D GAT T222N AAT T289A GCT K355L CTG F024R CGT D0901|ATT E156G GGT T222P CCG T289C TGT K355M ATG F024T ACG D090K E E1561 ATT T222R CGG T289E GAG K355N AAT F024V GTT D090L CTT E156K AAG T2228 AGT T289G GGT K355P CCT F024Y TAT D090N E E156L CTG T222V GTT T289H CAT K355Q CAG C025D GAT D090P CCT E156M ATG T222W TGG T289K AAG K355R CGT C025E GAG D090Q CAG E156P CCT T222Y TAT T289L CTT K3558 TCT C025F TTT D090R AGG E156Q CAG A223C TGT T289M ATG K355T ACT C025G GGG D0908 AGT E156R CGG A223D GAT T289N AAT K355V GTG C025H CAT D090T ACT E1568 TCT A223E GAG T289P CCT K355W TGG C0251 ATT D090W TGG E156T ACT A223G GGG T289Q CAG K355Y TAT C025K AAG K091A GCT E156V GTT A223H CAT T289R AGG \356A GCT C025L TTG K091D GAT E156W TGG A223K AAG T2898 TCG \356C TGT C025N AAT K091E GAG F157A GCT A223L CTG T289V GTG \356D GAT C025P CCT K091F TTT F157C TGT A223P CCT T289Y TAT \356F TTT C025R CGT K091G GGG F157D GAT A223Q CAG F290A GCT \356G GGG C0258 TCT K091H CAT F157E C)AC) A223R AGG F290C TGT \356H CAT C025T ACT K0911 ATT F157G GGT A223 8 TCT F290D GAT \356K AAG C025V GTG K091L TTG F157H CAT A223T ACG F290G GGG \356L CTG C025Y TAT K091N AAT F1571 ATT A223V GTG F290H CAT \356P CCT L026A GCT K091Q CAG F157K AAG A223W TGG F2901 ATT \356Q CAG L026E GAG K091R CGT F157L TTG A223Y TAT F290K AAG \356R CG L026G GGT K0918 TCT F 1 57M ATG L224A GCT F290L I!TTG \3568 AGT L026H CAT K091T ACT F157P CCT L224D GAT F290M ATG \356T ACT L0261 ATT K091Y TAT F157Q CAG L224E GAG F290Q CAG \356V C)TC) L026K AAG A092C TGT F157R CGG L224F TTT F290R AGG \356W ._]C)C) L026M ATG A092E GAG F1578 TCG L224G GGG F2908ITCG W357A CT L026P CCG A092F TTT F157T ACT L2241 ATT F290T ACT W357C .4C).4 L026Q CAG A092G GGT F157V GTG L224M ATG F290V GTT W357D GAT L026R CGG A092H CAT F157W TGG L224P CCG F290Y TAT W357E C)AC) L0268 TCT A092K AAG E158A GCT L224Q CAG G291A GCT W357F TTT L026T ACT A092L CTG E158C TGT L224R AGG G291C TGT W357G C)C)C) L026V GTT A092M ATG E158D GAT L2248 AGT G291D GAT W357K E L026W TGG A092P CCT E158F TTT L224T ACT G291E GAG W357L TTG WO 2013/102144 2012/072182 —243— TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod L026Y TAT A092Q CAG E158G GGG L224V GTT G291F TTT W357M ATG G027A GCT A092R CGT E158H CAT L224W TGG G291H CAT W357P CCT G027C TGT A092T ACT E158K AAG L224Y TAT G291L CTG W357Q CAG G027D GAT A092V GTT E158L CT Y225A GCG G291M ATG W357R CGT G027E GAG A092W ._]C)C) E158N Y225D GAT G291N AAT W357S AGT G027F TTT A092Y TAT E158P OCT Y225E GAG G291P CCT W357T ACT G027H CAT K093D GAT E158Q CAG Y225G GGT G291Q CAG W357V GTG G027I ATT K093EIIGAGE158R OC) Y225H CAT G291R CGG \358C TGT G027K AAG K093F TTT E158S TCC) Y225K AAG G291$ ||TCT \358D GAT G027L CTG K093G GGT E158V GTG Y225L CTG G291T ACT \358E GAG G027P CCT K093H CAT E158Y TAT Y225P CCG G291V GTG \358G GGG G027Q CAG K0931 ATT K159A GCT Y225Q CAG G291W ._]C)Q \358H CAT G027R CGG K093L CTG K159D C)AT Y225R AGG G291Y TAT /3581 :>TT G027S TCG K093M ATG K159E C)AC) Y225S TCT E292A GCT /358K G027T ACT K093N AAT K159F TTT Y225T ACG E292C TGT 358L GECT G027W TGG K093P CCT K159G GGT Y225V GTG E292P TTT // 358P 0CT K028A GCG K093Q CAG K159H CAT Y225W TGG E292G GGT \358Q CAG K028D GAT K093R CGG K159L CTT P226A GCG E292H CAT \358R CGT K028E GAG K093 S AGT K159M ATG P226C TGT E2921 ATT \358S TCT K028F TTT K093T ACT K159N AAT P226D GAT E292K AAG \358T ACT K028G GGG K093V GTT K159Q CAG P226E GAG E292L TTG \358V C)TC) K0281 ATT K094A GCT K159R CGG P226F TTT E292N E \358W ._]C)C) K028L TTG K094C TGT K159S TCT P226G GGT E292P CCT S359A CT K028M ATG K094DallGAT K159V GTG P226L CTT E292Q I!CAG S3 59C .4 .4 K028N AAT K094E GAG K159W .4C) P226N AAT E292R CGG S359D GAT K028P CCT K094F TTT K159Y .4A.4 P226Q CAG E292T ACT S3 59E GAG K028R CGG K094G GGG A160C .4C).4 P226R AGG E292V GTT S3 59F TTT K0288 AGT K094H IIC)C)CAT A160F TTT P226S TCT E292WI._]C)C) S359G C)C) K028T ACT K094L TTG A160G P226T ACG T293A GCT S359H CAT K028V GTT K094M ATG A160H CAT P226V GTT T293C TGT S359K AAG K028W TGG K094N AAT A1601 ATT P226W TGG T293D GAT S3 59L TTG F029A GCT K094P CCT A160K AAG P226Y TAT T293E GAG S359M ATG F029C TGT K094QlCAGA160L CT S227A GCT T293F TTT S3 59P CCT F029E GAG K094R AGG A160M ATG S227F TTT T293G GGT S359R CGG F029G GGG K094S TCT A160N AAT S227G GGG T293K AAG S3 59T ACT F029H CAT K094T ACT A160Q CAG S227H CAT T293L CTT S359V GTT F0291 ATT D095A GCT A160R AGG S2271 ATT T293M ATG S359W ._] C) F029K AAG D095C TGT A1608 AGT S227K AAG T293N I!AAT S360A CT F029L CTT D095E GAG A160V GTG S227L TTG T293P CCT S3 60C .4C).4 F029M ATG D095F TTT A160W TGG S227M ATG T293Q CAG S3 60E C)AC) WO 2013/102144 2012/072182 —244— TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod F029P CCG D095G GGG A160Y TAT 8227P CCT T2938 TCT 8360F TTT F029R CGG D095H CAT G161A GCT 8227Q CAG T293V GTG 8360G C) F0298 TCG D095K AAG G161C TGT 8227R CGG T293Y TAT S3601 >TT F029T ACG D095L TTG G161D GAT 8227T ACG V294A GCT 8360K F029V GTG D095M ATG G161E GAG 8227V GTG V294C TGT 8360L CT F029W TGG D095P CCT G161H CAT 8227W TGG V294E GAG 8360M ATG D030A GCG D095Q CAG G1611 ATT 8227Y TAT V294G GGG 8360N AAT D030E GAG D0958 TCT G161K AAG 1228A GCG V294H CAT 8360P CCT D030F TTT D095V GTG G161L CTT 1228B GAG V294K AAG 8360Q CAG D030G GGG D095W ._]C)C) G161M ATG 1228F TTT V294L TTG 8360R AGG D030H CAT D095Y TAT G161Q CAG 1228G GGG V294M ATG 8360T ACT D030K AAG 1096A GCT G161R CGT 1228H CAT V294N AAT 8360V GTT D030L TTG 1096C TGT G1618 AGT 1228K AAG V294P CCT D361A GCT D030M ATG 1096D GAT G161T ACT 1228L TTG V294Q CAG D361C TGT D030P CCT 1096E GAG G161V GTG 1228M ATG V294R AGG D361E GAG D030Q CAG 1096F TTT G161W TGG 1228N AAT V2948 AGT D361G GGG D030R CGG 1096G GGG K162A GCT 1228P CCG V294T ACT D361H CAT D0308 TCG 1096H CAT K162D C)AT 1228Q CAG V294W ._]C)C) D361L TTC) D030T ACT 1096L TTG K162E C)AC) 1228R CG._] 0 L110 TGT D361M >TC) D030V GTT 1096N AAT K162F TTT 12288 TCT 05D GAT D361N E D030W TGG 1096P CCT K162G GGG 1228T ACT BPS00 mm mm C)>C) D361P CCT E031A GCG 1096R CGT K162H CAT 1228W TGG TTT D361Q CAG E031G GGG 1096T ACT K162M ATG Y229F TTT E031H CAT 1096V GTG K162P CCT Y229G GGT A2951 ATT D361V GTT E0311 ATT 1096W TGG K162Q CAG Y229H CAT A295L CTG D361W TGG E031K AAG T097A GCT K162R CGG Y2291 ATT A295N AAT D361Y TAT E031L CTG T097C IC)EITGTK1628 TCG Y229K CT Y362A GCT E031N AAC T097D GAT K162V GTG Y229L TTG A295Q CAG Y362C TGT E031P CCG T097E GAG K162W TGG Y229N AAT A2958 AGT Y362E GAG E031R CGG T097F TTT K162Y TAT Y229P CCT A295T ACT Y362G GGG E0318 TCT T097G GGG D163A GCT Y229Q CAG 95V GTT Y362H CAT E031T ACG T0971 ATT D163C TGT Y229R CG 5Y!TAT Y362K E031V GTG T097L CTT D163E GAG Y2298 TCG L296A GCT Y362L CTT E031W TGG T097N AAT D163F TTT Y229T ACT L296C TGT Y362M >TC) E031Y TAT T097P CCT D163G GGG Y229V GTG L296F TTT Y362N 2 P032A GCG T097Q CAG D163H CAC Y229W TGG L296G GGT Y362P OCT P032C TGT T097R CGG D163K AAG L230A GCG L296I ATT Y362R OC) P032F TTT T0978 TCG D163L CTT L230E GAG L296K AAG Y3628 > P032G GGG T097W ._]C)C) D163P CCT L230G GGG L296M ATG Y362T ACT WO 2013/102144 PCT/U82012/072182 —245— TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod P032H CAT T097Y TAT D163Q CAG L230H CAT L296P CCT Y362V GTG P032K AAG F098A GCT D163R AGG L2301 ATT L296Q CAG Y362W TGG P032L CTG F098C TGT D1638 TCG L230K AAG L296R CGT L363A GCT P032M ATG F098D GAT D163T ACT L230M ATG L296S TCG L363C TGT P032N AAT F098E GAG D163V GTG L230N AAT L296T ACT L363D GAT P032Q CAG F098G GGG D163W TGG L230P CCT L296V GTT L363E GAG P032R CGG F098H CAT F164A GCT 123011 CGT L296W ._]C)C) L363F TTT P0328 TCG F0981 ATT F164C TGT L23OS AGT L296Y TAT L363G C)C) P032T ACT F098L TTG F164D GAT L230T ACT G297A GCT L363H CA’—]C) P032V GTG F098M ATG F164E GAG L230V GTT G297C TGT L3631 >TT P032W TGG F098P CCT F164G GGG L230W TGG G297E GAG L363P CCT P032Y TAT F098Q CAG F164H CAT L230Y AT G297H CAT L363Q CAG L033C TGT F098R CGT F164L TTG \231A GCT G2971 ATT L363R CG L033D GAT F098s TCG F164M ATG \231C TGT G297L I!CTT L363S TCG L033G GGG F098V GTT F164N AAT \231D GAT G297N AAT L363T ACT L033H CAT F098w TGG F164P CCT \231F TTT G297P CCT L363V GTG L0331 ATT Y099A GCT F164Q CAG \231G GGG G297Q CAG L363W TGG L033M ATG Y099C TGT F164R OC) /231H CAT G297R CGG H364A GCT L033N AAT Y099E GAG F164s E>—]C) /2311 ATT G297s AGT H364C TGT L033P CCG Y099F TTT F164V C)TT /231K AAG G297T ACT H364D GAT L033Q CAG Y099G GGT F164W ) \231L CTT G297V GTG H364E GAG L033R AGG Y099I ATT L165A GCT \231P CCT G297w TGG H364F TTT L033S TCG Y099LlTTG L165C .4 .4 \231Q CAG G297Y TAT H364G C)GC) L033T ACT Y099N AAT L165D GAT \231R CGT \o 00O TGT H364K AAG L033V GTT Y099P CCT L165F TTT \231s TCT 98E GAG H364L CTG L033W TGG Y099Q CAG L165G GGG \231T ACG 98G GGG H364M ATG L033Y TAT Y099R AGG L165H CAT \231V GT 981 ATT H364P CCT D034A GCT Y099S TCG L165N AAT T232A GCG TTG H364R CGC) D034E GAG Y099T ACT L165P CCT T232C TG 98M ATG H364s TCT D034G GGT Y099V GTT L165Q CAG T232F TTT 98N AAT H364T ACT D034H CAT Y099W TGG L165R CGG T232G GGG 98P CCT H364V GTG D0341 ATT V1100C TGT L1658 TCG T232H CAT 98Q CAG H364Y TAT AAG W D034L CTT VIIOOF TTT L165V GTG T232L CTT A2988 TCG L365C TGT D034N AAT VIIOOG GGT L165W TGG T232M ATG A298T ACT L365D GAT D034P CCT VIIOOK AAG L165Y TAT T232N AAT 8V GTG L365E D034Q CAG VIIOOLICTG V166A GCT T232P CC 98W TGG L365G D034R CGT VIIOON AAT V166C TGT T232Q CAG 8Y TAT L3 651 >C)C)C)C)C)ATT D0348 AGT VIIOOP CCT V166D GAT T232R AGG 8299A GCT L365M ATG D034T ACG VIIOOQ CAG V166E GAG T2328 AGT 8299C TGT L365N AAT WO 02144 PCT/US2012/072182 TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod D034V GTT M100R CGG V166F TTT T232V GTG 8299D GAT L365P CCT D034W TGG M1008 TCT V166G GGT T232Y TAT 8299B GAG L365Q CAG V1035A GCG M100T ACT V166H CAT Q233A GCG 8299F TTT L365R CG V1035D GAT M100V GTT V166L CTT Q233C TGT 8299G I! GGG L3658 AGT V103 5F TTT M100W TGG V166N AAT Q233D GAT 8299H CAT L365T ACT V1035G GGG M100Y TAT V166P CCT Q233F TTT 82991 ATT L365V GTG V1035H CAT P101A GCT V166Q CAG Q233G GGG 8299L CTT L365W TGG V103 5I ATT P101C TGT V166R CG Q2331 ATT 8299M ATG L365Y TAT V103 5L TTG P101FllTTT V166T ACT Q233K AAG 8299P CCT \366A GCT V1035N AAT P101G GGG V166W TGG Q233L CTG 8299Q CAG \366C TGT V103 5P CCG P101H CAT V166Y TAT Q233P CCG 8299R AGG \366E GAG V1035Q CAG P1011 ATT E167A GCT Q233R AGG 8299T ACT /366F TTT V1035R CGT P101K AAG E167D GAT Q233 S TCG 8299Y TAT /366G C)C)C) \/10358 TCT P101L CTT E167F TTT Q233T ACG G300A GCT 366K E V103 5T ACT P101M ATG E167G GGT Q233V GTG G300C TGT /366L TTC) V1035V GTT P101N AAT E167H CAT Q233W TGG G300D GAT \366M ATG V1035Y TAT P101Q CAG E167K E Q233Y ._]AT G300E GAG \366P CCT 8036A GCG P101R AGG E167L TT Q234A GCT G300F TTT \366Q CAG 8036C TGT P101 S TCT E167M >EmT Q234C TGT G300L CTT \366R AGG 8036D GAT P101T ACT E167N Q234D GAT G300M ATG \3668 TCT 803 6F TTT P101YITAT E167P CT Q234E GAG G300N AAT \366T ACT 8036G GGT V102A GCT E167R >C)C) Q234G GGT G300P CCT \366V GTT 8036H CAT V102ClTGT E1678 TC Q234H CAT G300Q CAG \366W TGG 8036K AAG V102E GAG E167T ACT Q234L CTT G300R AGG P367A GCT 803 6L TTG V102G GGT E167V GTT Q234M ATG G3008 TCG P367C TGT 8036N AAT V102H CAT E167Y TAT Q234N AAT G300T ACT P367E GAG 803 6P CCG V102K AAG T168A GCT Q234P CCG G300V GTT P3 67F TTT 8036R CGG V102L TTG T168C TGT Q234R CGG G300Wi._]C) P367G GGT 803 6T ACG V102M ATG T168D GAT Q2348 AGT I301A GCT P367H CAT 8036V GTT V102N AAT T168E GAG Q234T ACT I301E GAG P3671 ATT 8036W TGG V102P CCT T168F TTT Q234V GTG I301G GGG P367K AAG 8036Y TAT V102Q CAG T168G GGG Q234W TGG I301H CAT P367L CTG L037A GCG V102R AGG T168H CAT 8235A GCG I301K AAG P367M ATG L037C TGT V1028 TCT T168K AAG 8235E GAG I301L CTG P367Q CAG L037E GAG V102T ACT T168L CTG 823 5F TTT I301M ATG P367R CGT L03 7F TTT V102W TGG T168P CCT 8235G GGG I301N AAT P3678 TCG L037G GGG D103A GCT T168R CG 8235H CAT I301P CCT P367V GTT L037I ATT D103E GAG T1688 TCT 8235K AAG I301Q CAG P367W TGG L037K AAG D103F TTT T168V GTG 8235L CTT I301R CGG D368A GCT L037M ATG D103G GGG T168W TGG 8235M ATG 13018 AGT D368C TGT WO 2013/102144 2012/072182 —247— TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod L037N AAT D103H CAT T168Y TAT S23 5P CCT I301V GTT D368E GAG L037P CCT D1031 ATT 1169A GCT S235Q CAG I301W TGG D368G GGT L037R AGG D103L CTT 1169D GAT S235R CGG I301Y TAT D368H CAT L037S TCT D103N AAT 1169F TTT S235T ACG V302C TGT D368K AAG L037T ACG D103Q CAG 1169G GGG S235V GTG V302D GAT D368L CTT L037V GTG D103R AGG 1169H CAT S235W TGG V302E GAG D368M ATG L037W TGG D103 S TCG 1169K AAG S23SY TAT V302F TTT D368P CCT F03 8A GCG D103T ACT 1169L TTG P236A GCT V302G GGT D368R CGT F03 8C TGT D103V GTT 1169N AAT P236C TGT V302H CAT D368S AGT F03 8E GAG D103W ._]C) 1169P CCT P236E GAG V3021 ATT D368T ACT F03 8G GGG D103Y TAT 1169Q CAG P236G GGG V302L TTG D368V TT F03 8K AAG \ 104A GCT 1169R CGG P236H CAT V302MQI ATG D368W ._] C) F03 8L CTT \ 104C TGT 1169s TCG P2361 ATT V302P CCT D368Y .4A.4 F03 8M ATG \104F TTT 1169T ACT P236K AAG V302R AGG \369A CT F03 8N AAT \ 104G GGG 1169V GTT P236L CTG V302S TCG \369C .4 .4 F03 8P CCT \104H CAT 1169Y TAT P236N AAT V302T ACT \369E GAG F03 8Q CAG \ 1041 ATT K170A GCT P236Q CAG V302W ._]C)C) \369F TTT F03 8R AGG \ 104K AAC) K170C TGT P236R CGT V302Y TAT /369H CA._] F03 8S TCT \104L CTG K170D GAT P236S AGT I303A GCT 3691 >TT F03 8T ACT \ 104M ATG K170E GAG P236T ACT I303C TGT // 369K E F038W TGG \104P CCT K170G GGG P236W TGG I303D GAT \369L CTT F03 8Y TAT \ 104R AGG K1701 ATT P236Y TAT I303E GAG \369P CCT SO39A GCG \104S TCT K170L TTG V237A GCG I303F TTT \369Q CAG SO39C TGT \ 104T ACT K170M ATG V237C TGT I303G GGT \369R CGG SO39D GAT \ 104V GTT K170N AAT V237E GAG I303K AAG \369S TCG SO39F TTT \ 104W TGG K170P CCT V237F TTT I303L TTG \369T ACT SO39G GGT L105A GCT K170Q CAG V237G GGT I303M ATG \369V GTG SO39L TTG L105C TGT K170R CGT V237H CAT I303P CCT \369W TGG SO39M ATG L105D GAT K170V GTT V237L TTG I303R CGT F370A GCT SO39N AAT L105E GAG K170W TGG V237N AAT 1303 S AGT F370D GAT SO39P CCG L105G GGT K170Y TAT V237P CCT I303V GTG F370E GAG SO39Q CAG L105H CAT L171A GCT V237Q CAG Hw 3W TGG F370G GGG SO39R CGT L1051 ATT L171C TGT V237R CGG I303Y TAT F370H CA._] SO39T ACT L105M ATG L171D GAT V237S TCG II0W304A GCT F3701 >TT SO39V GTT L105N AAT L171G GGG V237T ACG W304C TGT F370K E SO39W TGG L105P CCT L171H CAT V237W TGG 304D GAT F370L CT SO39Y TAT L105Q|CAGL1711 TT V237Y TAT 304G GGT F370N F040A GCG L105R CGG L171M ATG A23 8D GAT 3041 ATT F3 70P 0CT F040D GAT L105$ TCT L171N AAT A23 8E GAG 2304L CTG F370Q OAC) F040E GAG L105T ACT L171P CCT A23 8F TTT W304M ATG F370R >C)C) WO 2013/102144 PCT/US2012/072182 TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod F040G GGT L105V GTT L171Q CAG A23 8G GGT W304N AAT F3708 TCT F0401 ATT L105W .4C)C) L171R CGT A23 8H CAT W304P CCT F370V GTG F040K AAG G106A GCT L171 S >C).4 A23 8K C) iim04Q CAG F370Y TAT F040L CTG G106CI! TGT L171V T A23 8L CTT 304R CGG A371C TGT F040N AAT G106D GAT L171W F]C)C) A23 8P CCG W3048 AGT A371E GAG F040Q CAG G106E GAG L171Y TAT A23 8Q CAG W304T ACT A371F TTT F040R CGG G106F TTT G172A GCT A23 8R AGG 304V GTG A371G C)8 F0408 TCT G106HIICAT G172C TGT A23 88 AGT 2304Y TAT A371H CAa F040T ACT G1061 ATT G172D GAT A23 8T ACG G305C TGT A3711 >TT F040V GTT G106L CTG G172E GAG A23 8V GTG G305D GAT A371K E F040W TGG G106M ATG G1721 ATT A238W TGG G305E GAG A371L CTT F040Y TAT G106N AAT G172L CTT A23 8Y TAT G305F TTT A371M ATG 1041A GCG G106P CCT G172M ATG A239C TGT G305H CAT A371P CCT 1041C TGT G1068 AGT G172P CCT A239F TTT G305K iG A371R CGT 1041D GAT G106V GTG G172Q CAG A239G GGT G305L CTT A371 S TCG 1041E GAG G106W TGG G172R CGT A239H CAT G305z iT A371T ACT 1041F TTT G106Y TAT G1728 .4C.4 A2391 ATT G305P CCT A371V GTG 1041G GGG \/1107A GCT G172T CT A239K AAG G305Q CAG A371W TGG 1041H CAT C |Q|||TGT G172V C)TT T240K AAG G305R CGT 1372A GCT 1041N AAT \/1107D GAT G172W 1—11—] A239L TTG G3058 TCG 13 72D GAT 1041P CCG \/1107F TTT G172Y AHC) A239N AAT G305T ACT 13 72B GAG 1041Q CAG \/1107G GGG K1 73D GAT A239P CCT G305V GTG 13 72F TTT 1041R AGG \/1107H CAT K173E C)AC) A239R AGG G305Y TAT 13 72G GGT 10418 TCT \/11071 ATT K173G GGG A2398 TCT T306A GCT 1372H CAT 1041T ACG \/1107K AAG K173H CAT A239T ACT T306C TGT 1372K AAG 1041V GTT \/1107L CTT K1731 ATT A239V GTT T306D GAT 13 72L CTG 1041W TGG \/1107P CCT K1 73L CTT A239W TGG T306E GAG 13 72N AAT G042A GCT \/1107Q CAG K1 73M ATG A239Y TAT T306F TTT 13 72P CCT G042C TGT \/1107R CGT K1 73N AAT T240A GCG T306G GGT 13 72R CGG G042D GAT V11078 TCT K1 73P CCT T240E GAG T306H CAT 13728 TCT G042E GAG \/1107V GTT K1 73Q CAG T240F TTT T3061 ATT 13 72T ACT G042H CAT V1107W TGG K1 73R CGG T240G GGG T306L CTG 13 72V GTG G0421 ATT A108D GAT K173 8 TCG T240L CTT T306P CCT 1372W TGG G042K AAG A108E GAG K1 73V GTG T240M ATG T306R AGG Q3 73A GCT G042L CTG A108F TTT K1 73W TGG T240N AAT T3068 AGT Q3 73C TGT G042M ATG A108G GGT K173Y TAT T240P CCT T306V GTG Q3 73E GAG G042P CCT A108H CAT L174A C)CT T240Q CAG T306W TGG Q3 73F TTT G042Q CAG A108K AAG L174C ._] 1—1 T240R CGT T306Y TAT Q3 73G GGT G042R CGG A108L TTG L174G C)Q T2408 AGT L307C TGT Q3 73H CAT G0428 TCT A108M ATG L174H CAT T240V GTG L307E GAG Q3 73K AAG WO 2013/102144 PCT/US2012/072182 —249— TABLE 8: PH20 ts mut cod mut cod mut cod mut cod mut cod mut cod G042T ACT A108N AAT L174K AAG T240W TGG L307FITTT Q373L CT G042V GTT A108P CCT L174M ATG T240Y TAT L307G GGG Q373M ATG SO43A GCG A108Q CAG L174N AAT L241A GCG L307I ATT Q373N AAT SO43D GAT A108R CGG L174P CCT L241C TGT L307K AAG Q373P CCT SO43E GAG A1088 TCT L174Q CAG L241D GAT L307N AAT Q373R CGT SO43F TTT A108T ACT L174R CGT L241E GAG L307P CCT Q373 S TCT SO43G GGT A108V GTG L174S TCG L241F TTT L307Q CAG Q373T ACT SO43H CAT A108Y TAT L174T ACT L241G GGG L307R AGG Q373V GTT SO43T ATT V109A GCT L174V TT L2411 ATT L307S AGT Q373W TGG SO43K AAG V109C TGT L174W ._]C)C) L241K AAG L307T ACT L374A GCT SO43L CTT V109D GAT L174Y TAT L241P CCT L307V GTG L374D GAT SO43N AAT V109E GAG L175C .4QC).4 L241Q CAG L307W TGG L374E GAG SO43P CCT V109F TTT L175D AT L241R CGG L307Y TAT L374G GGT SO43Q CAG V109G GGG L175E C)AC) L241 S TCT S308C TGT L374H CAT SO43R CGG V109H CAT L175F TTT L241T ACG S308D GAT L3 741 ATT SO43T ACT V109L TTG L175G GGG L241V GTT S308F TTT L374M ATG SO43V GTG V109M ATG L175H CAT L241W TGG S308G GGT L374N AAT P044A GCT V109P CCT L175K AAG Y242A GCG S308H CAT L374P CCT P044C TGT V109Q CAG L175N AAT Y242C TGT S308K AAG L374R AGG P044E GAG V109R AGG L175P CCT Y242D GAT S308L CTG L3748 AGT P044F TTT V109T ACT L175R CGT Y242F TTT S308M ATG L374T ACT P044G GGG V109W TGG L175$ TCT Y242G GGT S308N AAT L374V GTG P044H CAT V109Y TAT L175T ACT Y242I ATT S308P CCT L374W TGG P0441 ATT 1110A GCT L175V GTG Y242K AAG S308R CGG L374Y TAT P044L CTT 1110C TGT L175W TGG Y242L CTT S308T ACT E375A GCT P044N AAT 1110D GAT L175Y TAT Y242M ATG S308V GTT E375C TGT P044Q CAG 1110F TTT R176A GCT Y242P CCG S308W TGG E375F TTT P044R CGT 1110G GGG R176C TGT Y242R CGG S308Y TAT E375G GGT P044S TCT 1110H CAT R176E GAG Y242S TCT I309D GAT E3751 ATT P044T ACT 1110K AAG R176F TTT Y242T ACG I309E GAG E375K AAG P044W TGG 1110L CTG R176G GGG Y242V GTT I309G GGT E375L CTT P044Y ACG 1110M ATG R176H CAT Y242W TGG I309H CAT E375M ATG R045A GCG 1110N AAT R176I ATT V243A GCG I309K AAG E375N AAT R045D GAT 1110P CCT R176K AAG V243C TGT I309L CTG E375P CCT R045F TTT 1110R CGT R176L CTT V243D GAT I309M ATG E375R CGT R045G GGG 11108 AGT R176P CCT V243F TTT I309N AAT E3758 TCT R045H CAT 1110V GTT R176Q CAG V243G GGG I309Q CAG E375T ACT R0451 ATT 1110W TGG R176S AGT V243H CAT I309R CGT E375V GTT R045K AAG D111C TGT R176T ACT V243L CTT I309S AGT E375Y TAT R045M ATG D111E GAG R176V GTG V243M ATG I309T ACT K376A GCT WO 2013/102144 PCT/US2012/072182 TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod R045P CCT D111G GGT R1 76W TGG V243P CCT I309V GTG K3 76D GAT R045Q CAG D111H CAT P177A GCT V243Q CAG I309W TGG K376E GAG R0458 TCG D1111 ATT P177C TGT V243R AGG I309Y TAT K3 76G C) C) R045T ACG D111K AA P177D GAT V243 S AGT V1310AI!GCT K3761 >TT R045V GTG D111L TTG P177F TTT V243T ACG V1310C TGT K3 76L TTG R045W TGG D111M ATG P177G GGG V243W TGG V1310E GAG K3 76M ATG R045Y TAT D111P ACT P177H CAT V243Y TAT V1310F TTT K3 76P CCT 1046A GCG D111Q CAG P177L CTT R244A GCG V1310G GGG K376Q CAG 1046C TGT D111R CGG P177M ATG R244D GAT V1310K AAG K3 76R CGT 1046E GAG D1118 AGT P177Q CAG R244G GGG V1310L CTG K3768 AGT 1046F TTT D111T ACT P177R CGG R244H CAT V1310N AAT K3 76T ACT 1046H CAT D111V GTT P1778 TCT R2441 ATT V1310P CCT K3 76V GTG 1046L CTT D111WIITGG P177T ACT R244K AA V1310Q CAG K3 76W TGG 1046M ATG D111Y TAT P177V GTT R244M ATG V1310R CGG K3 76Y TAT 1046N AAT W112C TGT P177W TGG R244N AAT V13108 AGT G3 77C TGT 1046P CCT W112D GAT P177Y TAT R244P CCT V1310V GTG G3 77D GAT 1046R CGT W112E GAG \ 178A GCT R244Q CAG V1310W TGG G377E GAG 10468 TCT W112F TTT / 178D C)AT R2448 TCT V1310Y TAT G3 77F TTT 1046T ACT W112G GGG / 178E C)AC) R244T ACG R311A GCT G3 77H CA 1046V GTT W112H CAT \ 178G C)C)C) R244V GTG R311C TGT G3 771 >TT 1046W TGG W1121 ATT \ 1781 ATT R244W TGG R311E GAG G3 77K 1046Y TAT W112L CTT \ 178K AAG R244Y TAT R311F TTT G3 77L CTT \047A GCT W112N AAT \178L TTG \245A GCG R311G GGT G377M ATG \047D GAT W112P CCT \178M ATG \245C TGT R311H CAT G377P CCT \047F TTT W112Q CAG \178P CCT \245F TTT R3111 ATT G377R AGG \047G GGG W112R CGT \ 178R CGG \245G GGG R311K AAG G3778 TCG \047H CAT W1128 TCT \1788 AGT \245H CAT R311L TTG G377T >CT \0471 ATT W112V GTT \178T ACT \2451 ATT R311P CCT G377V C)TC) \047K AAG W112Y TAT \178V GTG \245K AAG R311Q CAG G377Y TAT \047L CTT E113A GCT \178W TGG \245L CTG R3118 TCT G378D GAT \047M ATG E113C TGT \178Y TAT \245P CCG R311T ACT G378E GAG \047P CCT E113D GAT H179A GCT \245Q CAG R311V GTG G378F TTT \047Q CAG E113F TTT H179C TGT \245R CGG TGG G378I TT \047R CGG E113G GGG H179E GAG \2458 TCG 8312A GCT G378K E \0478 TCT E113H CAT H179G GGG \245T ACG 8312CITGT G378L CT \047T ACG E113L CTT H1791 ATT \245V GTG 8312E GAG G378M ATG \047V GTG E113P CCT H179K AAG \245W TGG 8312F TTT G378N AAT \047W TGG E113QllCAG H179L CT R246A GCG 8312G GGG G378Q CAG \047Y TAT E113R CGT H179M ATG R246C TGT 8312H CAT G378R AGG A048C TGT E113 8 TCT H179N AAT R246D GAT 8312K AAG G3788 TCT WO 2013/102144 PCT/US2012/072182 TABLE 8: PH20 ts mut cod mut cod mut cod mut cod mut cod mut cod A048E GAG E113T ACT H179P CCT R246E GAG S312L CTG G378T ACT A048F TTT E113V GTT H179R AGG R246G GGG S312M ATG G378V GTG A048G GGT E113W T H179S AGT R246H CAT S312N AAT G378W TGG A048H CAT E113Y IIC) CAT H179T ACT R2461 ATT S312P CCT G378Y TAT A0481 ATT E114A GCT H179V GTG R246K AAG S312Q CAG K379A GCT A048K AAG E114C TGT H179W TGG R246L TTG S312R CGG K379C TGT A048L CTG E114D GAT L180A GCT R246M ATG S312T ACT K379E GAG A048M ATG E114G GGG L180C .4C).4 R246P CCT S312V GTT K379F TTT A048N AAT E114H CAT L180E C)AC) R246S AGT S312W TC)C) K379G C)C)C) A048P CCT E1141 ATT L180F TTT R246T ACG V1313A GCT K379H CAT A048Q CAG E114L CTG L180G GGT R246V GTT V1313C TGT K3 791 ATT A048R CGG E114M ATG L180H CAT R246W TGG V1313D GAT K379L CTT A048S TCT E114P CCT L1801 TT V247A GCG V1313E GAG K379M ATG A048V GTT E114R CGG L180K V247C TGT V1313F TTT K379N AAT A048W TGG E114S TCT L180M >T2:; V247F TTT V1313G GGG K379R CGT A048Y TAT E114T ACT L180N V247H CAT V1313H CAT K379S TCT T049A GCG E114V GTG L180P CCT V2471 ATT V1313K AAG K379T ACT T049C TGT E114W||TC)C) L180R C)C) V247L CTG V1313L CTT K379V GTT T049D GAT E114Y TAT L180S TCC) V247M ATG V1313P CCT K379W TGG T049F TTT W115A GCT L180T ACT V247N AAT V1313R CGT F3 80A GCT T049G GGG W115C TGT L180W TGG V247P CCT V1313 S TCG F3 80C TGT T049H CAT W115D GAT W181A GCT V247Q CAG V1313T ACT F3 80D GAT T0491 ATT W115F TTT W181C TGT V247R CGT V1313V GTT F3 80E A T049K AAG W115G GGT W181D GAT V247S TCT V1313Y TAT F3 80G C)C)C)C)C) T049L TTG W115H CAT W181E GAG V247T ACT K314A GCT F3 801 ATT T049N AAT W1 151 ATT W181F TTT V247W TGG K314C TGT F3 80L CTT T049P CCG W115K AAG W181H CAT V247Y TAT K314D GAT F3 80P CCT T049R AGG W115L|CTT W1811 TT R248A GCT K314H CAT F3 80Q CAG T049S TCG W115M ATG W181K AAG R248C TGT K3141 ATT F3 80R CGG T049V GTT W115P CCT W181L CTG R248D GAT K314L TTG F3 80S AGT T049W TGG W115R CGG W181M ATG R248E GAG K314N AAT F3 80T ACT G050A GCG W115S AGT W181N AAT R248G GGG K314P CCT F3 80V GTG G050C TGT W115V GTG W181Q CAG R248H CAT K314Q CAG F3 80W TGG G050D GAT W115Y TAT W181R CGT R2481 ATT K314R CGG F3 80Y TAT G050E GAG R116A GCT W181S TCT R248L CTT K314S TCG T381A AGC G050F TTT R116C TGT W181V C)C)TC) R248M ATG K314T ACT T381E GAG G050H CAT R116D GAT G182A CT R248P CCG K314V GTT T3 81F TTT G050L CTT R116E GAG G182C .4C).4 R248S TCG K314W ._]C) T381G GGT G050M ATG R116G GGG G182D GAT R248T ACG K314Y TAT T3 81H CAT G050P CCT R116H CAT G182E GAG R248V GTG S315A GCT T3 81K AAG WO 2013/102144 PCT/US2012/072182 TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod G050Q CAG R1161 ATT G182H CAT R248W TGG S315C TGT T381L TTG G050R CGG R116L CTG G182L CTT R248Y TAT S315E GAG T3 81N AAT G050S AGT R116N AAT G182M ATG E249A GCT S315G GGT T3 81P CCT G050V GTT R116P CCT G182N AAT E249G GGG S315H CAT T3 81Q CAG G050W TGG R116Q CAG G182P CCT E249H CAT S3151 ATT T3 81R CGT G050Y TAT R116S TCT G182Q CAG E2491 ATT S315K AAG T3 81S AGT Q051A GCG R116T ACT G182R CGT E249K AAG S315L CTG T3 81V GTG Q051C TGT R116V GTG G182S AGT E249L CTG S315M ATG T381W TGG Q051D GAT R1162 TGG G182T ACT E249M ATG S315P CCT T3 81Y TAT Q051F TTT P117D GAT G182V GTT E249P CCT S315R CGG V3 82E GAG Q051H CAT P117E GAG G182Y TAT E249Q CAG S315T ACT V3 82G GGG Q0511 ATT P117F TTT Y183A GCT E249R CGG S315V GTT V3 82H CAT Q051K AAG P117G GGT Y183C TGT E249S TCT S315W TGG V3821 TT Q051M ATG P117H CAT Y183D GAT E249T ACT S315Y I!TAT V3 82K AAG Q051N AAT P1171 ATT Y183E GAG E249V GTG C316A GCT V3 82L TTG Q051P CCT P117 Y183G GGG E249W TGG C316D GAT V382M ATG Q051R CGG P117 Y1 831 ATT E249Y TAT C316E GAG V3 82N AAT Q051S TCT P117Q CAG Y183K AAG A250C TGT C316G GGG V3 82P CCT Q051T ACG P117R AGG Y183L TTG A250F TTT C3161 ATT V3 82Q CAG Q051W TGG P1 17S TCG Y183N AAT A250G GGT C316K AAG V3 82R CGG Q051Y TAT P117T ACT Y183P CCT A250H CAT C316L CTG V3 82S TCG G052A GCT P117V GTT Y183Q CAG A250K AAG C316M ATG V3 82T ACT G052C TGT P117W .4GC) Y183R CC)._] A250L CTG C316P CCT V382W TGG G052E GAG P117Y TAT Y183 S .4C.4 A250M ATG C316R AGG V3 82Y TAT G052F TTT T118C TGT Y183V C)TT A250N AAT C316S TCT R3 83A GCT G052H CAT T118D GAT Y183W ._]C)C) A250P CCT C316T ACT R3 83E GAG G052K AAG T118E GAG Y184A GCT A250Q CAG C316V GTT R3 83F TTT G052L CTT T118GlGGGY184C .4 .4 A250R AGG C316W TC)C) R3 83G C)C)C) G052N AAT T118H CAT Y184D GAT A250S TCT C316Y TAT R3 83H CA._] G052P CCT T118K AAG Y184E GAG A250T ACG L317A GCT R3 831 ATT G052Q CAG T118L CTG Y184F TTT A250V GTG L317C TGT R3 83K AAG G052R CGG T118M ATG Y184G GGT A250W TGG L317D GAT R3 83L CTG G052S AGT T118N AAT Y184H CAT I251C TGT L317G GGG R3 83M ATG G052T ACT T118P CCT Y184K AAG I251D GAT L317H CAT R3 83N AAT G052W TGG T118Q CAG Y184L CTT I251F TTT L3 171 ATT R3 83P CCT G052Y TAT T118R CGT Y184M ATG I251G GGG L317K AAG R3 83S TCG V053A GCG T118V GTT Y184P OCT I251H CAT L317M ATG R3 83T CT V053C TGT T118W TC)C) Y184R C)C) I251K AAG L317N AAT R383V ) V053D GAT T118Y TAT Y184S TCC) I251L CTT L317P CCT R383W ._]C)C) V053E GAG W119A GCT Y184V GTG I251M ATG L317QICAG G3 84A CT WO 2013/102144 PCT/US2012/072182 TABLE 8: PH20 ts mut cod mut cod mut cod mut cod mut cod mut cod V053G GGG W119D GAT Y184W TGG I251P CCG L317R AGG G3 84C .4C1C).4 V053H CAT W119E GAG L185A GCT I251Q CAG L3 17S TCG G3 84D AT V053L CTG W119F TTT L185D C)AT 12518 AGT L317T ACT G3 84E C)AC) V053N AAT W119G GGT L185E C)AC) I251T ACT L317W TC)C) G3 84F TTT V053P CCG W1 191 ATT L185F TTT I251V GTG L318C TGT G3 84H CA*1 V053Q CAG W119K AAG L185G GGG I251W TGG L318D GAT G3 841 ATT V053R CGG W119L CTG L1 851 ATT I251Y TAT L318F TTT G3 84K V053S AGT W119N AAT L185K AAG R252A GCT L318G GGG G3 84L CTT V053T ACT W119P CCT L185N AAT R252D GAT L318H CAT G384M ATG V053W TGG W119Q CAG L185P CCT R252E GAG L3 181 ATT G3 84P CCT V053Y TAT W119R CGG L185R CGG R252F TTT L318K AAG G3 84Q CAG T054A GCG W119S TCT L185S TCG R252G GGT L318M ATG G3 84R AGG T054D GAT W119V GTT L185T >CT R252H CAT L318N AAT G3 848 TCG T054E GAG W119Y TAT L185V C)TC) R2521 ATT L318P CCT G3 84T CT T054F TTT A120C TGT L185W ._]C)C) R252K AAG L318Q CAG K3 85A CT T054G GGG A120D GAT L185Y TAT R252L CTG L318R CGG K3 85C .4 .4 T054H CAT A120F TTT F186A C)CT R252N AAT L318S AGT K3 85G 8h1C) T0541 ATT A120G GGG F186D AT R252P CCT L318T ACT K3 85H CA T054M ATG A120H CAT F186G GGT R252S TCG L318W TC)C) K3 85L CTT T054N AAT A1201 ATT F186H CAT R252T ACT L319C TGT K385M >TC) T054P CCG A120L CTT F1861 ATT R252V GTG L319E GAG K3 85N T054Q CAG A120N AAT F186K AAG R252Y TAT L319F TTT K3 85P CC T054R CGT A120PIICCT F186L CTT V253A GCG L319G GGG K3 85Q OAC)C) T054S AGT A120R CGT F186N AAT V253D GAT L319H CAT K3 85R CGT T054V GTT A1208 TCT F186P CT V253E GAG L3 191 ATT K3 85S TCT T054Y TAT A120T ACT F186Q CAG V253G GGG L319K AAG K3 85T ACG 1055A GCT A120V GTG F186R >C)C) V253H CAT L319M ATG K3 85V GTT 1055C TGT A12O2 .4C)C) F186S .4C.4 V2531 ATT L319P CCT K385W TGG 1055D GAT A120Y TAT F186V C)TT V253L CTG L319Q CAG K3 85Y TAT 1055F TTT R121A GCT F186W ._]C)C) V253M ATG L319R AGG P3 86A GCG 1055G GGG R121C TGT F186Y .4A.4 V253N AAT L319S TCG P3 86C TGT 1055H CAT R121D GAT P187A GCT V253P CCT L319V GTT P3 86F TTT 1055L CTG R121E GAG P187F TTT V253Q CAG L319W TC)C) P3 86G C)C) 1055N AAT R121F HIC)C) TTT P187G V253R CGG L319Y TAT P3 86H CA’—]C) 1055P CCT R121G GGT P187H CAT V253S TCG D320C TGT P3861 >TT 1055Q CAG R121H CAT P1871 ATT V253T ACG D320E GAG P3 86L CTT 1055R CGT R121K AAG P187L CTT V253W TGG D320F TTT P3 86M ATG 1055s TCG R121L CTG P187M ATG S254C TGT D320G GGG P3 86N AAT 1055T ACT R121M ATG P187N AAT S254D GAT D320H CAT P3 86Q CAG 1055V GTT R121P CCT P187Q CAG S254E GAG D3201 ATT P3 86R CGT WO 02144 PCT/US2012/072182 —254— TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod 1055Y TAT R1218 TCG P187R AGG 8254G GGG D320K AAG P3868 >C)'—] F056A GCG R121T ACT P1878 TCG 82541 ATT D320L TTG P3 86T ACC) F056C TGT R121V GTT P187T >CT 8254K AAG D320M ATG P3 86V C)TT F056E GAG R121W ._]C)C) P187V TT 8254L TTG D320N AAT P3 86Y .4A.4 F056G GGG R121Y TAT P187W ._]C)C) 8254N AAT D320P CCT T3 87C .4C).4 F056H CAT \ 122A GCT P187Y TAT 8254P CCT D320R AGG T3 87E GAG F0561 ATT / 122C TGT D188A C)CT 8254Q CAG D3208 AGT T3 87F TTT F056K AAG \122E GAG D188C .4 .4 8254R CGG D320V GTG T3 87G C) F056L TTG / 122F TTT D188F TTT 8254T ACT D320W ._]C)C) T3 87H CA F056N AAT / 1221 ATT D188G GGG 8254V GTG D320Y TAT T3 871 >TT F056P CCG 122K AAG D188H CAT 8254W TGG \321A GCT T387K F056R CGT / 122L CTG D188L CTT 8254Y TAT \321D GAT T3 87L CTG F0568 TCT \122M ATG D188M ATG K255A GCG \321E GAG T387M >T F056T ACT / 122P CCT D188N AAT K255C TGT 321G GGT T3 87N F056V GTT \122Q CAG D188P CCT K255D GAT /321H CAT T3 87Q OAC) F056W TGG \122R CGG D188Q CAG K255G GGT 3211 ATT T3878 TCG Y057A GCT 1228 TCT D188R AGG K255H CAT /321K AAG T3 87V GTT Y057D GAT 122T ACT D1888 AGT K255L TTG /321L CTG T387W TGG Y057E GAG 122V GTT D188T ACT K255N AAT \321M ATG T387Y .4A.4 Y057F TTT \ 122W ._]C)C) D188V GTG K255P CCG /321P CCT L3 88A GCG Y057G GGG W123A GCT D188W TGG K255Q CAG \321R CGG L388C .4C).4 Y057I ATT W123C TGT C189A GCT K255R CGG / II3218 TCT L388F TTT Y057L TTG i123D GAT C189E C)AC) K2558 TCG \321T ACT L388G C)C) Y057M ATG 2123E GAG C189G GGT K255T ACT \321V GTG L388H CAT Y057P CCG GGG C189H CAT K255V GTT \321Y Y057R CGG Y322D GAT L388P CCT Y057T ACG CCT C189N ACT I256C TGT Y322F Y057V GTG W123Q CAG C189P CCT I256D GAT Y322G GGT L3888 TCG Y057W TGG W123R AGG C189R AGG I256E GAG Y322H CAT L388T ACG V058A GCT AGT C1898 TCG I256G GGG Y322I ATT L388V GTT V058C TGT 123T ACT C189T >CT 1256H CAT Y322L CTG L3 88W TGG V058D GAT 123V GTT C189V C)TC) 1256L CTT Y322N AAT L3 88Y TAT V058G GGT W123Y TAT C189W .4C)C) 1256M ATG Y322P CCT E3 89A GCT V058H CAT N4;> C)O.4 C189Y TAT 1256N AAT Y322R CGT E3 89F TTT V0581 ATT N4;O TGT Y190C TGT 1256P CCG Y3228 TCT E3 89G GGT V058K AAG K124D GAT Y190E GAG 1256Q CAG Y322T ACT E3 89H CAT V058L CTT K124E GAG Y190F TTT 1256R AGG Y322V GTG E3 891 ATT V058N AAT K124F TTT Y190G C)GC) 1256T ACG Y322W TGG E389K AAG WO 2013/102144 PCT/US2012/072182 TABLE 8: PH20 Variants mut cod BE cod mut cod mut cod BE cod mut cod V058P CCT K124G GGG Y190H CAT I256V GTT \/1323A GCT E3 89L CTG V058Q CAG K124H CAT Y190K AAG I256W TGG \/1323C TGT E3 89M ATG V058R CGG K1241 ATT Y190L CTT P257A GCG \/1323E GAG E3 89P CCT V058S TCG K124L CTT Y190N AAT P257C TGT V1323F TTT E3 89Q CAG V058W TGG K124N AAT Y190P CCT P257D GAT \/1323G GGG E3 89R CGG V058Y TAT K124P CCT Y190Q CAG P257G GGG V1323H CAT E3 89S TCG D059A GCT K124R CGG Y190R CGT P2571 ATT V1323I ATT E3 89T ACT D059E GAG K124S TCT Y190S TCT P257K AAC) \/1323K AAG E3 89V GTT D059G GGG K124T ACT Y190T ACT P257L CTT L TTG E3 89Y TAT D059H CAT K124V GTG Y190V GTG P257M ATG V1323N AAT D390A GCG D0591 ATT K124W TGG Y190W TGG P257N AAT V1323P CCT D390C TGT D059L CTT P125A GCT \ 191A GCT P257Q CAG \/1323R CGG D390E GAG D059M ATG P125C TGT / 191E C)AC) P257R CGT V1323 S D390F TTT AGT D059N AAT P125D GAT / 191F TTT P257S TCG \/1323T IIC)C) ACT D390G D059P CCT P125G GGG \ 191G E8C) P257T ACG V1323V GTT D390H CAT D059Q CAG P125H CAT \ 191K P257V GTG E324A GCT D390L CTT D059R CGT P1251 ATT \191L TTG P257W TGG E324C TGT D390N 2 D059T ACG P125L CTT \ 191M >TC) D258A GCG E324D GAT D390P CC D059V GTG P125N AAT \191P CT D258E GAG E324F TTT D390R 8C)C) D059W TGG P125Q CAG \191Q OAC) D258G GGG E324G GGG D390S >C)._] D059Y TAT P125R CGT \ 191R 8C)C) D258H CAT E324H CAT D390T ACT R060A GCG P125S TCG \ 191 S TC D2581 ATT E324L TTG D390V T R060D GAT P125T ACT \ 191T CT D258L CTT E324M ATG D390W ._]C)C)C)C) R060F TTT P125V GTG \ 191V C)TT D258N AAT E324N AAT D390Y .4A.4 R060G GGT P125W .4C)C) \ 191W .4C)C) D258P CCG E324P CCT L391A GCT R060H CAT P125Y TAT \191Y TAT D258Q CAG E324R CGG L391C 3a R0601 ATT K126A GCT H192C TGT D258R CGT E324S AGT L391D GAT R060K AAG K126D GAT H192F TTT D258S AGT E324V GTG L391G C)Q R060L CTT K126E GAG H192G GGT D258T ACG E324W ._]C)C) L391H CA R060N AAT K126F TTT H192K AAG D258V GTG E324Y TAT L391K R060P CCG K126G GGT H192L CTT D258W TGG T325A GCT L391N 2 R060Q CAG K126H CAT H192M ATG D258Y TAT T325C TGT L391P CT R060S TCG K1261 ATT H192N AAT A259E GAG T325D GAT L391Q 00AC) R060T ACG K126L CTG H192P CCT A259G GGG T325E GAG L391R OC)C) R060V GTT K126M ATG H192Q CAG A2591 ATT T325G GGT L391 S TCT R060Y TAT K126N AAT H192R CGT A259K AAG T325H CAT L391T ACT L061A GCT K126P CCT H192S TCG A259L TTG T3251 ATT L391V GTG L061E GAG K126Q CAG H192T ACT A259M ATG T325K AAG L391W TGG L061F TTT K126R AGG H192V GTT A259N AAT T325M ATG L391Y TAT L061G GGG K126S TCT H192W TGG A259P CCT T325N AAT E392A GCT WO 2013/102144 2012/072182 TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod L061H CAT K126T ACT H192Y TAT A259Q CAG L0611 ATT K126V GTG H193A GCT A259R CGT CGG E392F TTT L061M ATG K126W L061N AAT K126Y L061P CCT D127A GCT H193F TTT A259V GTG T325W TGG E392L CTG L061Q CAG D127E GAG H193G GGG A259W TGG GCT E392M ATG L061R AGG D127F TTT H193K AAG A259Y TAT L061T ACT D127G L061V GTT D127H CAT H193M ATG K260C TGT L061W TGG D127K AAG H193F CCG K260D GAT GGG E3928 AGT L061Y TAT D127L CTG H193Q CAG K260E GAG CAT E392T ACT G062A GCG D127M ATG H193R AGG K260G GGG AAG E392V GTT G062C TGT D127N G062D GAT D127Q AAT E392Y TAT G062F TTT D127R CGT H193V GTG K260M ATG CCT Q393A GCG G062I ATT D127S AGT H193Y TAT K260P CCG CGG Q393C TGT G062K AAG D127T ACT Y194A GCT K260Q CAG G062L CTT D127V G062M ATG D12E G062P CCT V128A GCT Y194F TTT K260V GTT G062Q CAG V128C GCT Q3931 ATT G062R CGT V128E GAG Y194I ATT K260Y TAT GAT Q393K AAG G062S AGT V128F G062T ACT V128G G062V GTG V128H CAT Y194P CCT S261F TTT G062Y TAT V1281 ATT Y194Q CAG S261G GGG CAT Q393P CCG Y063A GCG V128K AAG Y194R AGG S2611 ATT ATG Q393R CGT Y063C TGT V128L Y063G GGT V128P CCT Y194T ACG S261L CTT Y063H CAT V128Q CAG Y194V GTG S261M ATG CGG F394A GCG Y063I ATT V128R AGG Y194W TGG S261N AAT AGT F394D GAT Y063K AAG V1288 ACT F394E GAG Y063L CTG V128W Y063M ATG V128Y L327W TGG F3941 ATT Y063N AAT Y129A GCT K195G GGT S261T ACT Y063P CCT Y129C GCT F394L CTG Y063R AGG Y129D Y063 S TCT Y129E Y063T ACG Y129G GGG K195N AAT P262D GAT Y063V GTG Y129H CAT K195Q CAG P262E GAG CAT F394R CGT WO 2013/102144 PCT/U82012/072182 TABLE 8: PH20 ts mut cod mut cod mut cod mut cod mut cod mut cod Y063W TGG Y129L TTG K195R CGT P262F TTT 3281 ATT F3948 TCG Y064A GCT Y129M ATG K1958 TCT P262G GGG \328K AAG F394T ACT Y064C TGT Y129P CCT K195T >CT P262H CAT // 328L CTT F394V GTT Y064D GAT Y129Q CAG K195V T P2621 3>TT 328Q CAG F394W TGG Y064E GAG Y129R CGG K195W ~1C)QC)C) P262K AAG \328R AGG S395A GCG Y064F TTT Y129S AGT K195Y TAT P262Q CAG 3288 AGT S395C TGT Y064G GGT Y129T ACT K196A GCT P262R CGT // 328T ACT S395D GAT Y064H CAT Y129V GTT K196C ~1C)’€ P2628 TCT \328V GTG S395E A Y0641 ATT Y129W ._]C)C) K196D C)C)AT P262T ACT /32 002 ._]C)C) S395G C)C)C) Y064K AAG K130C TGT K196E AC) P262V GTG /328Y TAT S395H EQC)CA._] Y064L CTT K130D GAT K196G GGG P262W TGG P329C TGT 8395K Y064P CCT K130E GAG K1961 ATT P262Y TAT P329F TTT 8395L CTT Y064Q CAG K130G P329G GGT 8395M ATG Y064R CGG K130H CAT K196N AAT L263E GAG P329H CAT 8395P CCT Y0648 AGT K1301 ATT K196P CCG L263F TTT P3291 ATT 8395R CGG Y064T ACT K130L P329K AAG 8395T ACG Y064V GTT K130N AAT K1968 TCG L263H CAT P329L CTG 8395V GTT Y064W TGG K130Q CAG K196T >CT L263K AAG P329N g 8395W TGG P065A GCT K130R AGG K196V C)TC) L263M ATG P329Q CAG 8395Y TAT P065C TGT K1308 TCT K196W ._]C)C) L263N AAT P329R CGT E396A GCG P065D GAT K130T ACT K196Y TAT L263P CCG P3298 AGT E396C TGT P065F TTT K130V GTG P197A GCT L263Q CAG P329T ACT E396D GAT P065G GGG K130W .4C)C) P197C .4C).4 L263R CGG P329V GTT E396F TTT P065H CAT K130Y TAT P197D AT L263 S AGT P329W ._]C)C) E396G GGG P0651 ATT / 131C TGT P197E C)C)AC) L263T ACT P329Y TAT E396H CAT P065K AAG \131E GAG P197F TTT L263V GTT Y330A GCT E3961 ATT P065N AAT / 131F TTT P197G GGT L263W TGG Y330C TGT E396L CTT P065R CGG \131G GGG P197H CAT P264A GCG Y330D IIGAT E396P CC P0658 TCG \131H CAT P197K AAG P264D GAT Y330E GAG E396Q CAG P065T ACG \1311 ATT P197L TTG P264E GAG Y330F TTT E396R AGG P065V GTT \131L CTT P197M ATG P264F TTT Y330G GGT E3968 TCT P065W TGG \131M ATG P197Q CAG P264G GGT Y3301 ATT E396T ACT P065Y TAT \131P CCT P197R CGT P264H CAT Y330L CTG E396V C)TC) Y066A GCG \131Q CAG P1978 AGT P264L CTT Y330M ATG E396Y TAT Y066C TGT \131R CGG P197T ACT P264M ATG Y330N AAT K397A GCT Y066D GAT \ 1318 AGT P197W TGG P264N AAT Y330P CCT K397C .4C).4 Y066E GAG \131T ACT G198A GCT P264R CGG Y330R AGG K397E C)AC) Y066G GGT \131V GTG G198C TGT P2648 AGT Y3308 AGT K397F TTT Y066H CAT 131Y TAT G198D GAT P264T ACT Y330V GTT K397G GGT Y066I ATT R132A GCT G198E GAG P264V GTT I331V GTG K3971 ATT WO 02144 PCT/US2012/072182 TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod Y066K AAG R132C TGT G198H CAT P264W TGG Y330W TGG K397L TTG Y066L CTG R132E GAG G198L CTG P264Y TAT 1331A GCT K397M ATG Y066N AAT R132F TTT G198N AAT V265A GCG 1331C TGT K397N AAT Y066P CCT R132H CAT G198P CCG V265C TGT 1331D II GAT K397P CC Y066R CGG R1321 ATT G198Q CAG V265D GAT 1331E GAG K397Q CAG K397T ACT R132K AAG G198R AGG V265E GAG 1331F TTT K397R AGG K397V GTT R132L TTG G1988 TCT V265F TTT 1331H CAT K3978 TCG F398A GCT L406P CCT K415G GGT C423T ACT A432L TTG E441D GAT F398C TGT L406Q CAG K415L CT C423V GTG A432M ATG E441F TTT F398E GAG L406R CGG K415M ATG C423W TGG A432N AAT E441G GGG F398G GGT L4068 AGT K415P CCG 1424A GCT A432P CCT E441H CAT F398H CAT L406T ACG K415Q CAG 1424C TGT A432R AGG E441K AAG F3981 ATT L406V GTT K415R CG 1424E GAG A4328 TCT E441L CTT F398L CTT L406Y TAT K4158 TCT 1424G GGG A432V GTG E441N F398N AAT 8407A GCG K415T ACT 1424H CAT A432Y TAT E441Q 0AC) F398P CCT 8407D GAT K415V GTG 1424K AAG F433A GCT E441R F398R AGG 8407E GAG K415W TGG 1424L CTT F433C TGT E4418 >02% F3988 TCT 8407F TTT K415Y TAT 1424N AAT F433D GAT E441T CT F398T ACT 8407G GGT D416C TGT 1424Q CAG F433E GAG E441V C)3>TC) F398V GTT 8407H CAT D416F TTT 1424R CGG F433G GGG E441Y TAT F398W TGG 8407L CTG D416G GGT 14248 TCG F433H CAT E442C TGT F398Y TAT 8407M ATG D416H CAT 1424T ACT F4331 ATT E442G GGG Y399A GCG 8407N|AATD4161 TT 1424V GTT F433K AAG E442H CAT Y399C TGT 8407P CCT D416K AAG 1424W TGG F433L TTG E442K AAG Y399D GAT 8407Q CAG D416L CTT 1424Y TAT F433P CCT E442L CTT Y399E GAG 8407R CGG D416N AAT A425C TGT F433R CGG E442M ATG Y399G GGG 8407T ACG D416Q CAG A425D GAT F433 8 AGT E442N AAT Y399K AAG 8407VlGTGD416R CG A425E GAG F433T ACT E442P CCT Y399M ATG 8407W .4C)C) D4168 TCT A425G GGT F433V GTG E442Q CAG Y399N AAT C408A GCG D416T ACG A4251 ATT F433W .4C)C) E442R CGG Y399P CCT C408E GAG D416V GTG A425K AAG L434F TTT E4428 AGT Y399Q CAG C408F TTT D416W TGG A425L TTG L434G GGT E442T ACT Y399R CGG C408G GGG D416Y TAT A425M ATG L434H CAT E442V C)TC) Y3998 TCG C4081 ATT T417A GCT A425N AAT L4341 ATT E442W TGG Y399T ACG C408 iG T417D GAT A425P CCT L434K AAG E442Y TAT Y399V GTT C408L CTT T417E GAG A425R AGG L434M ATG P443A GCT Y399W TGG C4082 iT T417F TTT A4258 AGT L434N AAT P443D AT C400A GCG C408P CCT T417G C)GC) A425V GTG L434P CCT P443E C)AC) C400D GAT C408R CGT T417H CAT A425W TGG L434Q CAG P443F TTT C400E GAG C4088|TCG T4171 TT A425Y TAT L434R CGG P443G C)C)C) WO 2013/102144 PCT/U82012/072182 TABLE 8: PH20 ts mut cod mut cod mut cod mut cod mut cod mut cod C400F TTT C408T ACT T417K AAG D426A GCT L434S AGT P443H CAT C400G GGG C408V GTT T417L TTG D426C TGT L434T ACT P4431 ATT C4001 ATT C408W ._]C) T417M ATG D426E GAG L434V GTT P443L CTT C400L CTG C408YIiTAT T417P CCT D426F TTT L434W ._]C)C) P443M >TC) C400M ATG K409A GCG T417Q CAG D426G GGG L434Y TAT P443N E C400P CCG K409C TGT T417R CGT D4261 ATT K435A GCT P443Q CAG C400Q CAG K409D GAT T4178 TCG D426K AAG K435C C400T ACG K409H CAT D418C TGT D426N AAT K435G GGT P443W TGG C400V GTG K4091 ATT D418E GAG D426P CCT K435H CAT Q444C TGT C400Y TAT K409L CTG D418F TTT D426Q CAG K43 51 ATT Q444D GAT 8401A GCT K409P CCG D418G GGT D426R CGT K435L CTG Q444E C)AC) 8401C TGT K409Q|| CAG D4181 TT D4268 TCG K435P CCT Q444F TTT 8401D GAT K409R AGG D418L TTG D426Y TAT K435R AGG Q444G C) C) 8401E GAG K4098 TCG D418M >TC) G427A GCT K4358 TCT Q444H CAam 8401F TTT K409T ACG D418N E G427C TGT K435T ACT Q4441 ATT 8401G GGG K409V GTG D418P CT G427F TTT K435V GTT Q444K E 8401H CAT K409W ._]C)C) D418Q OA G427H CAT K435W ._]C)C) Q444L CT 8401K AAG A412Y TAT D418R OC)C)C) G427I ATT K435Y TAT Q444M >TC) 8401L CTT E410D GAT D4188 TCG G427K AAG P436C TGT Q444N E 8401N AAT E410G GGG D418V GTG G427L CTG P436D GAT Q444R OC)C) 8401Q CAG E4101 ATT D418Y TAT G427P CCT P436EIGAG Q444V TT 8401R CGT E410K AAG A419D GAT G427Q CAG P436G GGG Q444W ._]C)C) 8401T ACT E410L CTT A419E GAG G427R CGT P436H CAT Q444Y TAT 8401W TGG E410M ATG A419F TTT G4278 AGT P4361 ATT I445A GCT 8401Y TAT E410N AAT A419G GGG G427T ACT P436K AAG I445C TGT C402A GCT E410P||CCG A419H CAT G427V GTG P436L CTG I445D GAT C402D GAT E410Q CAG A4191 TT G427W TGG P436M ATG I445G GGG C402E GAG E410R CGT A419K E G427Y TAT P436Q CAG I445H CAT C402F TTT E4108 TCG A419L CTT V428A GCT P436R CGG I445K AAG C402G GGG E410T ACG A419N AAT V428C TGT P4368 TCT I445L CTT C402L TTG E410V GTG A419P CCT V428D GAT P436T ACT I445M ATG C402M ATG E410W .4C)C) A419R CGG V428E GAG P436W .4C)C) I445N AAT C402P CCT E410Y TAT A4198 TCT V428F TTT P436Y TAT I445P CCT C402Q CAG K41 1A GCT A419T ACT V428G GGT P437A GCT I445Q CAG C402R CGG K411D GAT A419W TGG V428H CAT P437D GAT I445R AGG C4028 TCT K41 1E GAG A419Y TAT V428L CTT P43 7F TTT 14458 AGT C402T ACG K41 1F TTT V420A GCT V428M ATG P437G GGT I445T ACT C402V GTT K41 1G GGG V420D GAT V428N AAT P437H CAT I445V GTG WO 2013/102144 PCT/US2012/072182 TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod C402W TGG K411H CAT V420F TTT V428P CCT P4371 ATT I445W TGG C402Y TAT K41 11 ATT V420G GGT V428R CGG P437K AAG I445Y TAT Y403A GCT K411L||CTG V420H CAT V428S TCG P437L CTG F446A GCT Y403C TGT K411N AAT V4201 TT V428T ACT P437M ATG F446C TGT Y403E GAG K41 1P CCT V420K AAG V428Y TAT P437Q CAG F446D GAT Y403F TTT K411R AGG V420L CTT C429A GCT P437R CGT F446E GAG Y403G GGT K411S TCG V420N AAT C429D GAT P437S TCT F446G C) C) Y403H CAT K41 1T ACT V420P CCT C429G GGT P437T ACT F446H CA Y403K AAG K411V||| GTT V420R AGG C4291 ATT P437W ._]C)C) F4461 >TT Y403L TTG K411W TGG V420S TCT C429K AAG P437Y TAT F446K E Y403M ATG A412D GAT V420T ACT C429L TTG V143 8A GCT F446L TTG Y403N AAT A412E GAG V420W TGG C429M ATG V143 8C TGT F446M ATG Y403P CCG A412G GGG V420Y TAT C429N AAT V143 8DIIGAT F446Q CAG Y403Q CAG A412H CAT D421A GCT C429P CCT V143 8E GAG F446R CG Y403R CGG A4121 ATT D421E GAG C429R CGG V143 8G GGG F446T ACT Y403 S TCT A412L CTG D421G GGT C429S TCG V143 8L TTG F446V GTT Y403T ACG A412N AAT D421H CAT C429T ACT V143 8N AAT F446W ._]C1C)C) S404A GCT A412P||CCT D4211 TT C429V GTT V143 8P CCT Y447D AT S404C TGT A412Q CAG D421K AAG C429W TGG V143 8Q CAG Y447E C)AC) S404D GAT A412R CGG D421L TTG C429Y TAT V143 8R AGG Y447F TTT S404F TTT A412S AGT D421M ATG I430A GCT V143 8S TCG Y447G GGT S404G GGT A412V GTT D421N AAT I430D GAT V143 8T ACT Y447I ATT S404H CAT A41N2I._]C) D421Q CAG I430E GAG V143 8V GTG Y447K AAG S404L CTT D413A GCG D421R CGG I430G GGG V143 8W TGG Y447L CTT S404M ATG D413E GAG D421 S TCG I430H CAT V143 8Y TAT Y447M ATG S404N AAT D413F TTT D421T ACT I430K AAG E439A GCT Y447N AAT S404P CCT D413G GGT D421W TGG I430L TTG E439C TGT Y447P CCT S404R AGG lCAT D421Y TAT I430M ATG E439F TTT Y447Q CAG S404T ACG D4131 ATT V422A GCT I430N AAT E439G GGG Y447R AGG S404V GTG D413 V422C TGT I430P CCT E439H CAT Y447T ACT S404W TGG D413L CTG V422D GAT I430R AGG E439K Y447V GTT S404Y TAT D4132 E V422E GAG I430S TCT E439L CTT Y447W ._]C)C) T405A GCG D413P CCG V422G C)GC) iI430T ACT E439N T405C TGT D413Q CAG V422H CAT I430V GTT E439P CCT T405F TTT D413R CGT V4221 ATT I430W TGG E439Q CAG T405G GGG D413 S TCG V422L CT D431A GCT E439R CGG T4051 ATT D413T ACT V422M >TC)C) D431E GAG E439S TCG T405K AAG D413W ._]C)C) V422N g D431G GGT E439T ACT T405L TTG V414A GCG V422P CCT D431H CAT E439V |||GTT T405M ATG V414D GAT V422Q CAG D4311 ATT E439W ._]C)Q WO 2013/102144 PCT/US2012/072182 TABLE 8: PH20 Variants mut cod mut cod mut cod mut cod mut cod mut cod T405P CCG V414E GAG V422R CGT D431K AAG T440A GCT T405Q CAG V414F TTT V4228 TCG D431L CTT T440D GAT T405R CGT V414G GGT V422T ACT D431N AAT T440E GAG T4058 TCT V414H CAT V422W TGG D431P CCT T440F TTT T405V GTG V4141 ATT V422Y TAT D431Q CAG T440G GGG T405W TGG V414K AAG C423A GCT D431R CGT T440H CAT T405Y TAT V414L TTG C423D GAT D4318 TCT T4401 ATT L406A GCT V414M ATG C423E GAG D431V GTT T440L CTT L406C TGT V414Q CAG C423F TTT D431W TGG T440M ATG L406D GAT V414R AGG C423G GGG D431Y TAT T440P CCT L406E GAG V414S TCG C423H CAT A432C TGT T440Q CAG L406F TTT V414T ACT C423L CTG A432E GAG T440R AGG L406G GGT V414Y TAT C423M ATG A432F TTT T44OS AGT L4061 ATT K415A GCG C423P CCT A432G GGG T440V GTG L406N AAT K415C TGT C423Q CAG A432H CAT T440Y TAT K415D GAT C423R AGG A4321 ATT E441A GCT K415E GAG C423S TCG A432K AAG E441C TGT 2. Expression For expression of each mutant, HZZ4-PH20-IRES-SEAP d DNA containing cDNA encoding one of the variant PH20 or encoding wildtype PH20 was transfected into monolayer CHO-S cells (lnvitrogen, Cat. No. 11619-012) using Lipofectamine 2000 (1nvitrogen, Cat. No. 11668-027) according to the protocol suggested by the manufacturer.

CHO-S cells were seeded the night before transfection and grown in DMEM with 10% FBS to be 80% conﬂuent the next day. Then, the medium of the CHO-S cells was replaced with Opti-MEM. A mixture of d DNA and lipofectamine was made (0.2 ug DNA and 0.5 uL Lipofetamine). The Lipofectamine/DNA mixture was added to CHO-S cells and incubated overnight. The next day, the cells were supplemented with CD-CHO serum free medium (1nvitrogen, Cat. No. 10743-029). Supernatant from transfected cells was collected at s time points after transfection, and generally 96 hours after transfection. The atant, containing the t PH20 protein or wildtype PH20 having a sequence of amino acids set forth in SEQ ID NO:3, was stored at -20 OC. Activities of the supernatants were screened as described in the following examples.

WO 2013/102144 PCT/US2012/072182 EXAMPLE 3 SCREENING OF LIBRARY WITH A HYALURONIDASE ACTIVITY ASSAY TO IDENTIFY TY MUTANTS In this example, supematants of sed PH20 variants ted in Example 2 were screened using a hyaluronidase activity assay to assess ty of each . In on, activity of the secreted alkaline phosphatase (SEAP) was also measured to allow for normalizing PH20 activity of the expressed mutants to the PH20 wildtype. Active and inactive mutants were identiﬁed. 1. Generation of Biotinylated HA (bHA) Substrate A 1.2-MDa HA (Lifecore) was biotinylated for use as a substrate in the hyaluronidase activity assay. First, 1.2 grams (g) of 1.2 MDa HA was ed at 4 0C in 600 mL ddH20 for a week at a concentration of 2 mg/mL with stirring. Next, 645.71 mg Biotin Hydrazide was dissolved in 100 mL DMSO to a concentration of 25 mM (6.458 mg/mL, 247.8 mg in 38.37 mL DMSO). The biotin solution was warmed brieﬂy at 37 0C until the on was clear. Also, 368.61 mg Sulfo-NHS in 20 mL ddH20 was dissolved to make a 100K solution (18.4 mg/mL Sulfo-NHS). A 30 mM (1000X) water-soluble carbodiimide EDC solution was made by dissolving 17.63 mg EDC in 3 mL ddH20 at a concentration of .7513 mg/mL right before the reaction was started.

To four (4) 1000-mL sterile capped bottles, the following components were added at room temperature (RT) and in the following order with stirring: 1) 200 mL of 2 mg/mL HA solution; 2) 80 mL of 0.5M MES, pH 5.0 with gentle mixing; and 3) 91.6 mL of ddH20 with gentle mixing. Next, 24 mL of 25 mM Biotin-Hydrazide and 4 mL of 100X NHS solution were added sequentially, immediately followed by the addition of 500 uL EDC.

After the addition of each component, the on was mixed by inverting three times and stirring. After the addition of the last component, the solution was mixed by stirring overnight at 4 OC. Then, Guanidine hydrochloride was added to a ﬁnal concentration of 4 M by adding 38.2 g per 100 mL and was allowed to dissolve completely before adjusing the solution volume to 600 mL with ddH20.

For dialysis, 200 mL from each batch of the conjugated HA guanidine hydrochloride solution was transferred into dialysis membranes. Over the course of three days, the solution was dialyzed against ddH20 with a change in ddH20 at least six times. The resulting volume of about 840 mL was adjusted to a ﬁnal volume of 1000 mL with ddH20. The ﬁnal tration of the biotinylated hyaluronan (bHA) was 0.4 mg/mL.

WO 2013/102144 PCT/US2012/072182 2. Hyaluronidase Activity Assay The enzyme assay was a modiﬁcation of the method described by Frost et al. (1997) (A iter-Based Assay for Hyaluronidase Activity Not Requiring Specialized Reagents.

Analytical Biochemistry (1997) 251 :263-269) that es a measure of PH20 hyaluronidase ty.

First, biotinylated HA (bHA) substrate was bound to plastic microtiter plates to generate assay plates. Brieﬂy, 100 pl ofb-HA at 1 mg/mL in 0.5 M carbonate buffer (pH 9.6) was dispensed into each well of a high bind microplate olon 4 HBX extra high binding; Thermo Scientiﬁc). The plate was covered with a plate sealer and stored between 2- 8 0C for 24-48 hours.

Then, the assay plate was washed with 1 X phosphate buffered saline (PBS) wash buffer containing 0.05% (v/v) Tween 20 (PBST). PBST was generated from 1X PBS (generated from Catalog No. P5368, Sigma (10 mM Phosphate Buffer, 2.7 mM Potassium Chloride, 137 mM Sodium Chloride, pH 7.4) by g the contents of one packet of PBS into a 1-L graduated cylinder with 800 mL deionized water, dissolved by stirring or shaking and adding sufﬁcient quantity of water to 1 L) by adding 500 pl Tween 20 (Catalog No. 6505; EMD Bioscience) to 900 mL of 1 X PBS and adding sufﬁcient ty of water to 1 L.

Washing was done using the BioTek ELx405 Select CW plate washer (BioTek) by washing ﬁve (5) times with 300 pl PBST wash buffer per well for each wash. At the end of each wash, the plate was tapped on a paper towel to remove excess liquid from each well. Prior to incubation with s, 200 pl ng Buffer (1.0% w/v Bovine Serum Albumin (BSA) in PBS) was added to each well and the assay plate was incubated at 37 0C for approximately 1 hour prior. The Blocking buffer was ted by adding 2.5 g of BSA (Catalog No. 001- 000-162; Jackson Immuno Research) to 200 mL 1 X PBS, stirring, adding a sufﬁcient quantity of 1 X PBS to 250 mL and ﬁltering through an 0.2 uM PES ﬁlter unit.

Transfected variant or wildtype PH20 supematants generated as described in Example 1 were diluted in duplicate 1:25 in assay diluent buffer (pH 7.4 HEPES buffer; 10 mM HEPES, 50 mM NaCl, 1 mM CaClg, 1 mg/mL BSA, pH 7.4, 0.05% Tween-20) in uncoated 4XHB high bound microplates. For the rd curve, 1:3 serial dilutions of rHuPH20 (generated as described in Example 1 with a speciﬁc activity of 145 U/mL) were made in assay diluent buffer in duplicate starting from 3 U/mL for standards as s: 3 U/mL, 1 U/mL, 1/3 U/mL, 1/9 U/mL, 1/27 U/mL, 1/81 U/mL, and 1/243 U/mL. One hundred microliters (100 pl) of each standard and sample were transferred to the assay plates and incubated for approximately 1.5 hours at 37 OC.

WO 02144 PCT/US2012/072182 After the incubation, the plate was washed with PBST using the BioTek ELx405 Select CW plate washer by g ﬁve (5) times with 300 pl PBST wash buffer per well for each wash. At the end of each wash, the plate was tapped on a paper towel to remove excess liquid from each well. Then, 100 pl of 1 :5000 diluted Streptavidin-HRP (SA-HRP) was added to each well of the plate and incubated at ambient temperature for approximately 1 hour. For the dilution, a 1 mg/mL stock of Streptavidin-HRP conjugate (Catalog No. 21126; Thermo Scientiﬁc) was diluted 1:5000 into dilution buffer (1 mg/mL BSA, 0.025% Tween20, 137 mM NaCl, 20 mM Tris pH 7.5). After the incubation, the plate was washed with PBST using the BioTek ELx405 Select CW plate washer by washing ﬁve (5) times with 300 pl PBST wash buffer per well for each wash. At the end of each wash, the plate was tapped on a paper towel to remove excess liquid from each well. Then, 100 pl of TMB solution (Catalog No. 03, KPL; ambient temperature and protected from light) was added to each well for approximately ﬁve (5) minutes at room temperature or until an optimal color development was yielded. To stop the reaction, 100 pl 1.0 N Sulfuric Acid or TMB Stop solution (Catalog No. 5006) were added to each well and the plates tapped to mix. Optical density was measured at 450 nm within 30 minutes of adding the stop on. Since more PH20 in a standard or sample would lead to less bHA available to bind , the optical density (450 nm) value was inversely proportional to the concentration of hyaluronidase activity in each specimen. 3. SEAP Activity Activity of secreted alkaline atase (SEAP) in the cell culture supernatant also was measured using a colorimetric assay of placental alkaline phosphatase using pNPP as a phosphatase substrate (Anaspec SensoLyte pNPP SEAP kit; Catalog No. 72144, Anaspec) ing to the manufacturer’s instructions. The absorbance signal was measured at optical density (OD) of 405 nm.

The criteria for the high throughput (HTP) screening were that the transfected supernatant resulted in a SEAP signal of 2 0.1 and the signal for the rHuPH20 wildtype l produced a signal of Z 1 U/mL. Also, the criteria for each screen were that the standard curves had a signal to noise ratio (S/N) for the 0 U/mL standard versus the 3 u/mL standard at OD405 of Z 5, had less than three (3) standards with a ient of variation (CV) Z 10%, and at least four (4) of the standards were in the linear range.

EXAMPLE 4 SELECTED PH20 VARIANTS WITH ALTERED HYALURONIDASE ACTIVITY Each generated variant was screened for nidase activity as described in Example 3. The SEAP expression was used to ize PH20 activity of each variant to the WO 2013/102144 PCT/US2012/072182 PH20 wildtype. Mutants were identiﬁed that exhibited d hyaluronidase activity compared to wildtype. 1. Active Mutants Active mutants were selected whereby at least one duplicate sample exhibited greater than 40% of wildtype activity when ized to SEAP actiVity. The identiﬁed active mutants are set forth in Table 9. The Table sets forth the amino acid ement compared to the sequence of amino acids of PH20 set forth in SEQ ID N03. The amino acid sequence of exemplary mutants also is set forth by reference to a SEQ ID NO. The Table also sets forth the average hyaluronidase actiVity of tested duplicates normalized by SEAP values compared to average of wildtype PH20 actiVities in each plate, which were also normalized by their own SEAP values. For example, a value of 0.40 indicates that the variant exhibits 40% of the hyaluronidase actiVity of wildtype PH20, a value of 1 indicates that the variant ts a similar hyaluronidase actiVity of wildtype and a value of 3.00 indicates that the variant exhibits 300% of the hyaluronidase actiVity of wildtype PH20 or 3-fold increased activity compared to wildtype.

The results in Table 9 show that over 600 tested mutants exhibit ty that is increased compared to wildtype. For example, about 536 mutants exhibit 120% or r than 120% of the hyaluronidase actiVity of wildtype PH20 and about 75 of the mutants exhibit 300% or r than 300% of the hyaluronidase actiVity of wildtype PH20. In particular, the results in Table 9 show that that onidase actiVity ed to wildtype of mutant S69A is about 22-fold; mutant S69R is about 14-fold; mutant I70A is about 27-fold; mutant I70K is about 14-fold; mutant I70R is about 14-fold; and mutant 1271L is about 10-fold.

TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ AvgNorm ID Act. ID Act. ID Act.

N0 N0 N0 LOOlA 74 0.95 Q14OG T293F 561 1.94 mm QMOH T2936 L001E 75 0.55 Q1401 T293K 562 1.35 mm QMOK s43 0-93 m 76 062 QMOL T293Q Q14ov msv W m 79 0-72 WO 2013/102144 PCT/US2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ m mutant SEQ AvgNorm mutant SEQ $6 Act. Act. ID NO -L001S 074 N141D 1.09 A298G 568 _L001T N141E 0.67 A2981 -L001V 1.00 N141F 0.81 G300R L00 S 0.88 N141G 1.15 I301A -Q//002A 0.61 N141H 344 2.03 I301V -002C 0.4 N0021 0.37 V287N _291C 0.27 G297A 0.57 V302W 002G 0.44 / 141L 0.61 V3021 _//002L 0.46 N141M 0.48 I303V -002P 0.54 / 141Q 1.16 W304G 002Q 0.84 \ 141R 345 1.40 W304I -/002s 0.78 \ 141s 346 0.72 G305D 002T 1.05 141T 3311311 569 002V 0.65 141V -FOO3E 0.42 N141W 347 0.83 _FOO3H 0.68 141Y 348 1.55 T306S -FOO3L 0.59 V142C -FOO3Y 0.50 V142D 349 0.71 _ROO4A 0.73 142E 131173 -R0041 0.54 V142G 350 0.98 L307s _R004S 142H -ROO4T V1421 13m _R004V 1.09 V142K 351 1.40 L307W -AOOSH 0.44 V142L -POO6A 80 0.78 V142M 3311311 571 _POO6H 0.58 V142N 352 0.98 S308G 572 -POO6K 0.80 V142P _POO6L 0.76 V142Q 354 1.04 S308K 573 -POO6N 0.40 V142R 3311313 574 -POO6Q 0.89 V142s _POO6R 0.56 V142T 357 1.19 S308R 575 -POO7M 0.57 Q143E _V0081 1.17 Q143G -VOO8L 0.53 Q1431 0.44 I309E 576 _VOO8M 8 1 0.47 143K 359 1.30 I309G 577 -VOO8P 0.33 1009Q -1009K 43L 1311311 578 _1009L 1.08 Q143N -IOO9R 0.53 Q143V 131131 579 WO 02144 PCT/U82012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ ID Act. ID Act. ID N0 N0 NO 10098 L144T 580 1009V L144W 581 P010D 8145A 582 P010Em 145C 583 P010G 8145D 584 P010H 8145E 585 P010N 8145G 586 P010Q 8145H P010R 8145L M3104 587 P0108 8145M 588 P01 0W 8145N 589 N011D 8145P N011G s145R 590 N011HmL146A N011K L146C N0118 G305N mom 570 M310F M310Y 0.38 R311G V012A L146E 0.50 R311H V012E L146G 0.62 R311K V0121 L146H 0.78 R311Q V012K L1461 0.82 R311s V012L L146K 0.84 R311T V012N L146N 0.57 8312G V012R L146P 362 0.93 s312N V0128 L146Q 0.84 8312T V012T L146R 363 1.47 591 P013H L1468 0.71 P0138 L146T 0.74 592 P013TmL146V 0.84 SSSS0909930.) 5555 EQD'JCV 593 P013Y L146Y 0.80 594 F014D 8312K 0.38 F0141 T147A 364 1.20 F014M T147C 0.47 595 F014V 90 0.46 T147D 596 L015A T147F 365 L015M 92 0.45 T147G 597 L015V 91 2.20 T1471 A0208 93 0.50 T147L 3661- 598 WO 2013/102144 2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ $6 Act. $6 Act. ID 0 -SO22H 0.57 T147M 0.79 K314A _SO22M 0.49 T147P 1.09 K314D -SO22T 0.48 T147Q 1.29 K314H _SO22Y 0.45 T147R -E023D 0.97 T147S -F024A T147V _F024E 95 3.99 T147W -F024G 0.75 T147Y 599 _F024H O\ 2.07 E148C"- -F0241 0.70 E148F 0.42 K314Y 600 _F024K E148G S3154 601 -F024L 0.62 E148H -F024M 0.85 E1481 _F024N E148K 371 1.63 S315H 602 -F024R 97 1.22 E148L _F024T 1.18 E148Q 372 1.44 -F024V 1.15 E148R 0-97 -F024Y E148S ms _L026A 9 1.30 E148T 0-82 -L026E 99 3.22 E148V S315Y 603 _L026G 0.81 E148W 0-43 -L026H 0.97 E148Y 0.95 L317A 604 _L0261 0.51 149C 1.15 —L317D -L026K 100 1.88 >D>149G 0.52 L317H -L026M 101 1.43 149K m 605 _L026P 0.55 149L 0.88 L317K 606 -L026Q 102 1.44 A149M _L026R 103 1.43 A149Q 1.15 L317N 607 -L026S 0.78 149R mm 608 -L026T 0.87 149s mm 609 _L026V 0.52 A149T 373 1.24 L317S 610 2 0.53 A149V m 611 _L026Y 0.52 T150A 375 1.21 L317W 612 -G027A 0.79 T150C 0.70 L318D 614 _G027D 104 1.22 T150D -G027E 1.18 T150E -G027F 0.61 T150F mm 615 _G027H 1.11 T150G -G0271 0.41 T1501 MK 616 WO 2013/102144 PCT/US2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ AvgNorm $6 Act. ID Act. ID Act.

N0 NO G027K 105 2.71 T150L mm G027L 0.76 T150N 378 0.91 G027P 0.46 T150P G027Q 1.12 T150R mm G027R 106 1.88 T1508 379 0.92 L318s G027S—0.94 T150W 380 1.25 L318T G027T—0.61 T150Y 381 1.36 D320E G027W—0.76 E151A 382 1.27 D320G A 0.78 E151C D320H 618 1.75 -—K028D 0.62 E151G D3201 _—K028E 0.54 E151H 383 1.34 D320K 619 6.42 -—K028F 0.75 E151K 384 2.05 D320M -—K0281 0.55 E151L 385 1.03 D320N _—K028L 0.51 E151M 386 1.26 D320R 620 3.19 -—K028M 0.67 E15m mos _—K028N 0.58 E151Q 387 2.01 D320W -—K028P 0.40 Dm Dszov R 107 0.71 E151R 388 1.61 D320Y _—K028S 0.46 E1518 389 1.28 -—K028T 0.68 E151T 390 1.21 _—K028V 0.76 E151V 391 1.38 -—K02 0.51 E151W 392 1.31 _—E.F029A E151Y 393 -—F029E 108 4.03 K152A -—F029G 1.05 K152C _—F029H 0.82 K152F -—F0291 109 1.53 K1521 _—F029K 110 1.34 K152M -—F029L 111 2.36 K152R 3 94 -—F029M 112 2.08 K152T 3 95 1.20 _—F029P 113 3.79 K152V 0.82 -—F029R 114 1.24 K152Y 0.67 _—F029S 115 2.21 A1531 0.93 -—F029T 116 0.85 A153L 0.51 mm V 117 1.65 K154R mm F029W—0.48 K154T D030A—1.12 K154V D030F—0.84 Q155A T325D 626 1.78 D030G—118 2.02 Q155C T325E 627 4.03 WO 2013/102144 PCT/US2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ AvgNorm ID Act. ID Act. ID Act.

N0 N0 N0 -005055 05550 55250 _005055 1 20 . 05555 552555 -D030L 2 . ii155G 398 1.61 T325K _005054 22 . )—I 5555 552554 -DO3OP Q155K 399 1.57 T325N -00500 05555 55250 _DO3OR 23 . Q155M 0.97 T325s -D030s 24 . Q155R 400 1.27 T325V _550505 i5555 -0050v 05555 3 DO 555v 55255 555 5.50 -EO31A 1 25 205. U} I326V 637 6.29 -50550 5 26 255. 55554 55255 _EO31G 7 . E156D 405 505 -E031H 12 E156G 045 _E0311 2 E1561 0.55 -EO31K E156L 0-45 -E031L 1 E156M 052 _EO31P E156Q 0.54 -EO31R E156R 0.43 \328K _E031s E156s 0.62 \328L -EO31T E156T _EO31V E156V 045 -5505E 5555500 0.49 \328S -E031Y F157W 055 _PO32A E158A 0.55 -PO32C E158F 0.51 \328Y _PO32F E158H 0-54 -55250 55255 055 -55550 555555 0-54 _50520 40 . 555555 0-44 -PO32H E158Q .b02 1.25 T335s _505255 555555 405 005 -50525 555554 054 _505254 555500 0-52 -005255 5 045 -00520 5555555 024 _505255 555505 052 -00525 5555554 WO 2013/102144 PCT/US2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ ID Act Act. ID N0 NO -16221 1616211 0.73 Q347G 647 _1622v 161626 0.92 Q347M P03 3 161621 0.88 Q347R _16222 161626 0.67 Q347S 648 -L033G 143 0 57 K159V 0.41 E348D -162211E 1666 0.61 E348G _L033P 0 87 >160F 0.79 E348s -16226 >160G 0.75 Q349A _162211 616611 0.47 Q349E -16226 61661 0.43 Q349K _16221 616616 0.91 Q349M 649 -L03%’ 142 158 >160L 0.67 U)49N -126246 U) LII6 0.37 M035V 11 616611 0.77 Q349R 650 -D034H 160N 0.56 Q349T _D034K 160O 0.65 V351A -126246 16611 V2616 661 -1262411 >1666 1262 4 161w 12m 662 -116261 16616 _1162611m 1616"- -M035L 161C N356H 653 _M035T 161D 0.86 N356S 654 -116262 16112 -66266 16111 _SO36D SO36N 148 0.38 L037W -SO36G G161s 0.77 W357S _SO36H 7 G161V 0.42 W357T -SO36K K162A 0.50 N358C -SO36L K162D 0.77 N358G _SO36R K162E 405 0.51 N358T -Q347L V351C 0.35 V3511 _V351Q W357K 0.36 N358L -SO36T K162G 0.56 S359D _L037F K162H S359E 655 -L037I K162L 0.54 S359H 656 -162116 1616211 _162111 161621 -L037P K162Q 0.58 S359T 657 WO 2013/102144 PCT/US2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ AvgNorm $6 Act. $6 Act. ID Act.

NO LO37R 0.51 K162R 0.52 S359V L037V 0.57 K162S 0.47 S360T FO38Y 15 1 1.29 K162V 0.52 P3676 SO39A 152 1.06 K162W 1.01 P3676: SO39L 153 0.80 K162Y 0.72 P3676 SO39N 154 2.32 D163A 406 1.52 P3676 SO39Q 1.10 D163E SO39R 0.56 D163G 1.15 33673 SO39T 155 1.57 D163K 408 1.90 D3636 SO39Y 0.56 D163L 1.18 D3633 FO4OL 156 0.92 D163Q 409 1.40 D368G F043 1.11 61633 436 136-" 1041A 0.67 D163S D3636 1041C 0.53 D163T D3636 10411) 0.78 D163V 0.76 336366 IO41E 0.51 F164L D3633 IO41G 0.76 F164M 1041H 0.77 F164V 413 1.23 D3633 1041N 0.40 SO43N 10411 157 1.47 F164W IO41V 0.73 L165A 0.48 6 104E L165D 414 5.79 333633 GO42A 0.64 L165F 415 1.23 N369S SO43T 0.43 L165N 416 2.19 A371E PO44E 0.59 L165R A371F 671 0.52 R0451 0.45 L165S 417 1.31 A371H 672 1.20 RO45K 0.53 L165V 418 1.22 A3711 1046A 1.04 L165W 1.14 63716 1046C 0.37 A371G IO46E 0.43 L165Ym63736 IO46F 0.73 V166A 1046H 0.82 166C 63713 IO46L 158 1.08 V166E 420 1.28 63733 1046M 1.00 V166F 1046N 166G IO46R 159 2.29 V66 1046s 0.64 V66 IO46T 0.55 V1666 IO46V 1.01 v366R WO 2013/102144 PCT/US2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ m mutant SEQ m Act. ID Act. ID Act.

N0 N0 IO46Y 070 V0000 007000 /O47A 0.40 700007 0470 000 002 700000 000470 000 002 000700 II/0470 002 00070 ———m 047H 1.16 L374H O47K 0.67 E167H 0.89 2047M 0.77 E167K 0.91 I047Q E167M 0.87 /O47R 0.84 E167N 0.83 L374P II0478 0.85 E167P 0.58 O47T 162 1.49 E167R 1.02 2of]g 163 0.63 E1678 1.17 _—O47Y 0.45 E167T 0.59 -—AO48F 164 2.51 E167Y 0.55 -m _—AO48G 0.83 T168H E375A -—A048H 165 1.99 1169L 430 2.08 E375G -—A0481 0.64 1169R 0.54 E375K _—A040K 000 0.20 00007 -—0004000 070 K070N _—0004000 007 425 K070K -—AO48Q 1.05 K17OV E375R ——m0004000 00700 -—000400 106 00700 -—E.000407 007200 _—A048Y 0.81 G172C 1.03 K376D -—T0491 0.42 K173N K376E _—0040K 0-05 K070K -—TO49R 168 1.41 L174A K376Q -—T0498 0.92 L174G 434 0.40 K376R _—00407 045 0074K -—GOSOA 0.93 L174M K376T _—G050C 0.41 L174N 436 1.36 K376V -—G050D 169 1.37 L174Q K376Y _—G050E 0.78 L174R 437 1.50 G377D -—G050H 0.74 L174S 0.85 G377E -—G050L 0.43 L174T 438 1.12 G377H _—G050M 171 0.47 L174V G377K -—G050Q 0.86 L174W G377P WO 02144 PCT/US2012/072182 —274— TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ ID Act. ID Act. ID N0 N0 N0 G050R L174Y G377R 696 G0508 L175E G377S 697 99999 999111 G050Y L175H G377T 698 Q051N L175T 439 1.43 G378K Q0518 L175V 0.94 G378N G052N L175Y C)378R G052P R176K 0.67 K379G G052Q N178G 0.85 K379H G052R N178K 440 0.85 K379R G0528 N178M 0.88 K3798 E3751 K376L 0.37 K379T F38OV F38OT 0.39 M035Q 145 99921 1911919 199411 1111911 19941 111199 T054N H179E F38OW 699 19949 111199 199 19949 111191 m- T054VmH179K 442 1.39 T381K V058C H179L 0.73 T381N V058G H179M 0.63 T381Q V058H H179N T381R V0581 H179P 044 T3818 701 V058K H179R T381V V058L H1798 0.51 R383A V058N H179T 0.43 R383E V058P H179V 0.42 R383H 99999 11991 192 999919 11999 199 99999 1199K 194 9998W 119911 9-64 V058Y W181M 0.88 199999 19611 9-9 1999919 9-99 199 RO6OK QE 500 182L -R383T L0611 Y183L 0.70 -R383V L061M F186Y 0.59 K385A 706 LO61V H1928 0.49 K385G WO 2013/102144 PCT/US2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ m mutant SEQ AvgNorm mutant SEQ ID Act. $6 Act. ID N0 NO Y063A H192T 0.50 K385H Y063H H193G 0.68 K385N Y0631 H193Q 443 0.82 K385Q 707 Y063K H193S 0.42 K385R Y063L H193Y 0.58 K3858 Y063M K195A 0.51 K385T Y063NmK195G 0.45 K385V 708 Y063R K195H 0.45 T387S Y063S K1951 0.50 L388F Y063T K195L 0.45 L388H Y063V K195N 445 0.74 L388I OO\% K195Q 0.71 L388M PO65R K195R 0.85 L388R YO66H K1958 0.42 L388T YO66R K195T 444 0.58 L388V IO67F K195W 0.49 L388W 1067L K196E 446 0.43 L388Y IO67R D068G 0.37 E392W IO67V K196G 709 IO67Y K196L 710 DO68E K196R D068H K196S 712 DO68K K196T 711 DO68L K196W DO68P P197A DO68Q P197D 713 DO68R P197E D068s P197F 714 DO68T P197G 0.75 E389T SO69A P197H 0.62 E389Y SO69C P197K L391C SO69E P197L 715 SO69F P197M 716 SO69G 200 6.06 P197Q E392G S0691 201 3.12 P197R 0.5 8 E392K SO69L 3.44 P197S 0.70 E392L $06914 2.67 P197T 717 SO69P 8.14 G198A E3929 718 SO69R 14.06 G198D 448 1.99 719 WO 02144 PCT/US2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ AvgNorm ID Act. E Act. ID Act.

N0 £3 N0 SO69T G198E 0.49 SO69VV G198H 0.84 $06934 QC)198L 0.48 1070A 1981J 0.80 1070C 210 2.57 G198Q 0.55 IO7OF 198R 0.58 1070(} 212 6.22 198s 0.76 107044 213 9.09 G198T 0.41 10703: G198Y 0.81 1070L 215 3.05 N200D 0.46 107044 $20204 IO7OP F204P IO7OR 218 13.95 \205A 1070s /205D 1070T \205E 1070\/ /205F 107034 \205(3 TO71A 2053: T071D Z20504 T071(} \205P T07111 205R ———m T071L 205s T07lhd /205T T0711J /205\/ TO71Q 14205vv T071R 225 2.17 V206H T071s V/206I G072A V206K G072D 206L s39"é m<395T G072E WM G072H V206R G072K 227 1.39 <206S G072L G072Y 607204 228 311 V206T G072Q 229 2.33 I208A G072R I208C 0.48 G072s I208K 0.91 VO73A 230 1.38 I208L 0.84 WO 2013/102144 PCT/US2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ ID Act. ID Act. ID N0 NO NO -VO73C 1208M 0.88 Y399S _VO73D 1208Q 732 -V073G 1208R 733 _V073H 231 1.54 1208s 734 -V073K 232 1.42 1208T 1 .01 S401A 735 -VO73L 233 1.59 1208V 736 _V073M ﬂ09A -VO73Q 234 0.96 K209E _V073R 235 0.72 K209G S4041 737 -VO73S K209N F398L -S401Q S404T -VO73T 236 1.34 K209R _V07% 237 1.91 K209S 738 -TO74A 238 2.28 K209T _TO74C 239 2.18 D212N -TO74E 240 1.38 D212S -10741? 1.43 D212T _TO74G 2.75 D213A 461 0.85 T405R -TO74H 1.40 D213E 0.79 T405S _TO74K 1.29 D213G 0.81 T405W -10741 1.43 D213H 0.75 T405Y _TO74M 0.52 D213K 0.82 L406A -TO74N 2.12 D213L 0.56 L406C -107413 2.45 D213M 462 1.56 L406E 2 2.22 D213N 463 1.53 739 -1074s 1.80 D213Q _T074V 2.27 D213R -107E 252 2.13 D213V 740 -VO75A D213W 0.49 L406Q _V075C D213Y 0.49 L406S -V075F 253 2.00 L214Q 0.57 L406T _V075H S215A 0.74 L406V -V075L 254 5.22 S215D 0.62 L406Y _V075M 255 1.16 S215E 741 -V075N U)215G 0.88 S407D 742 -V075Q S215H 464 0.91 S407E 743 _V075R 256 3.02 s2151<"—744 -VO75S S215Lm- WO 2013/102144 2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ ID Act. ID Act. ID N0 N0 NO VO75T S215M 465 1.77 S407H 745 V075Y S215Q 0.79 S407M G077H G077K 0.32 K411H 1079L S215R 0.71 S407N 10791 S215T 747 IO79V S215V"—746 Q081PmU) [\D b—K LIIW KO82A W216Y K082E L217M KO82G me K4091 748 K082H N219A 466 1.29 K409D K0821 N219C 0.43 K409E K082L 259 0.87 N219D 0.75 K409G K082M N219E 0.95 K409H K082N N219H 0.97 K4091 K082Q N2191 467 0.60 K409P KO82R N219K 468 1.45 K409Q 749 K082s N219L 0.72 K409R K0821 N219M 1.02 K409S KO82Y 1083H 0.4 1083K KO82V N219R 1.10 K409T IO83F N219s 469 2.48 K409V 1083G 264 1.05 N219T 0.82 A412Y 1083L N219W 0.48 E410D 1083N E220A 0.75 E410K 1083Q 262 1.07 E220H 470 1.40 E410M IO83R E2201 471 1.34 E410N 1083s E220L 472 1.45 E410P 10831 E220s 0.62 E410Q 1083V E2201 0.91 E410R SO84D E220V 473 1.35 E410S s084E S221A m \] U} 0 S084F s221c SO84G 267 8.68 s221M SO84H 22 Q._1 474 1.37 K411A s0841 U)2211 Km S084L S221V $08411 T222D SO84N 268 0.89 T222F ms WO 2013/102144 PCT/US2012/072182 TABLE 9: ACTIVE S mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ ID Act. Act. ID N0 $6 O SO84P T222G 475 0.49 K411T SO84Q T222K 0.75 K411V SO84R 269 1.89 T222L 0.64 A412D SO84T T222N 0.80 A412G U)0 004w T222R 0.75 A4121 -SO84Y E220D 0.39 E220M _s2211 T2221 0.4 P226W -LO85V T222S 0.63 A412L _Q086A 270 2.70 T222V 0.79 A412N -Q086D L2241 0.61 A412P _Q086E L23 01 44m 752 -Q086F N231T ms -Q086G T232F 476 0.73 A412V 753 _Q086H 271 1.70 T232S -Q0861 Q2334 D4142 _Q086K 272 0.97 Q233F MK -Q086L Q233G 477 0.46 D413N -Q086M Q233K 478 1.69 D413R _Q086N 273 1.28 i[\D "—33L -Q086P Q233R 479 1.50 V4141 _Q086R QM WM -Q086s 274 0.85 Q234Mi80 1.65 K415G _Q086T 275 0.58 S235A 481 0.47 K415S -Q086V S235E 1.00 K415W Q08O\ 276 1.21 235G 0.95 D416F _DO87A U)235H 0.44 D416G -DO87C 277 1.77 s2351< 0.53 D416H _DO87E S235T D4161 -DO87G 278 1.00 P236A 1.07 D416K -D087H P236G 1.09 D416L 754 _D0871 P236H 0.46 D416N -D0871 279 0.55 P236K 0.71 D416Q _D087M 280 0.58 P236R 482 3.09 D416R -DO87P Q234L 0.40 V237C 483 _DO87Q P236S -DO87R 281 1.28 V237A"— -DO87S 282 0.99 V237E _DO87T 283 1.70 V237F -A412H A412Q WO 2013/102144 2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ ID Act. $6 Act. ID N0 O -D413H A413Q 0.38 D413S _V414K <414L 0.36 K415Y -K415V D418G 0.45 _D087V 284 0.66 V237H 485 0.75 D418A -DO87Y 285 2.72 <237L 1.12 D418E 755 -L089C 286 1.46 237N _LO89R L089W -LO89K 237Q _LO89M 237R -DO9OA 287 1.48 <237s 1.03 D418L 756 _DO9OE 288 1.15 237T -D090G <8\]2 -D090H 289 1.24 238D 0.75 D418P 757 _D0901 >>>>><<<<>238E -D09OK 290 1.36 238H 489 0.60 D418R 758 _D090L 238Km— -D090N 291 1.18 238Q 2v 759 -D090Q 238R _DO9OR 292 1.49 A2388 -D090s >238T 760 _DO9OT T240K -D093 T240A 761 _KO91A 224022 762 -KO91Q T2402 763 -KO91R 22409 _AO92C 293 1.97 T240R -A092H A222N _A092L 294 1.29 T2408 764 -AO92M 22m 765 -AO92T 2222 _AO92V N245H 766 -KO93D V2471 _KO93E V2472 -KO93F V2422 0.52 D421A 767 _K093G E422 -KO93H R248w -K0931 295 3.25 E4‘32 768 R248H 12512 -K093L 296 1.53 I251L 769 WO 2013/102144 PCT/US2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ m mutant SEQ AvgNorm mutant SEQ ID Act. Act. ID N0 N0 K093M 1251M 0.43 D421L KO93N V2531 ll?)e0.76 D421M KO93Q 297 0.84 ﬁ55A D421N 770 KO93R 298 1.52 ﬁ D421Q 771 K0938 299 1.25 531%oz 0.91 D421R 772 KO93T 300 3.93 K255R D421s 773 KO93V KO93P 0.38 KO94C KO94A K2558 0.43 D421T KO94D 301 0.93 1256A 0.42 D421Y K094E 1256H 0.51 V4221 K094F 1256L 0.64 V422T K094H 1256V A425G 774 8894 8287A K094M P257G 496 0.51 A425K 775 K094Nm P2571 1.07 A425M KO94Q 302 1.22 P257K 0.92 A425N KO94R 303 3.94 P257L A425R K0948 P257M A4258 K094T P257N D426E 1096DmP257Q 0.61 D426G 1096L P257R 498 1.38 D426N 1096V P257T 497 2.04 D426P T097A 304 1.25 P257V 0.88 D426Q T097C 305 0.53 D258H 0.84 D426Y T097D 306 1.31 D258N 499 1.44 G427K T097E 307 1.19 D258R 0.45 G427S TO97F D258s 500 1.44 V428L \1 00 82578 D2588 D426K D426s G427T 777 G427H G427I G427Q 776 T097G 308 4.84 A259E 0.85 V428M T0971 A259G 0.68 V428P TO97L 309 1.22 A2591 0.46 V428T TO97N >>>259K 0.76 D431A 779 88978 2598 781 88978 2898 788 88978 A2898 82 T0978 310 1.21 A259Q 888788 .6ng 788 WO 2013/102144 PCT/US2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ $6 Act. ID Act. ID N0 N0 TO97Y 074 784 FO98A 259T 785 FO98C 0.58 8 259V D431Q 786 7099 0.47 >8E 787 FO98E 0.44 788 709877 1.06 789 60Am- F0981 0.52 §§>259Y 60D 0.41 D431W F098L 0.58 K260E 0.58 D431Y F098M 0.87 ﬂ60H 0.87 A432E F098Q 0.65 K260L A432G P436C 0.39 E249V A432H F098R 0.72 K260M 502 0.85 A432N F098S 0.56 S3c 0.58 A4328 F098V 0.46 K260R 0.83 A432V FO98W 0.81 K2608m-790 YO99A 0.33 ﬂ60G YO99R 0.53 K26OY YO99S 0.43 SZ61A V102A 0.83 s261F 7702c sme V102E 261M 791 V102G 0.67 s261N 792 V102H 0.88 s261Q 793 V102K 1.03 U)261R 794 V102L 0.71 s261T"- V102M 0.77 s261V 795 V102N 1.02 s261w V102Q 1.03 L263A 796 V102R 0.94 L263K 507 2.73 F433V 797 V102s L») p—A 1 1.41 L263M 798 V102T 312 1.26 L263R L434F V102 0.76 L263T D103N 0.39 N1041 N704 mm mm 0.41 7264A mom 0.48 72647 mi- N104K 0.88 V2651 N104M 0.61 F266Y N104R 313 1.25 A267M WO 02144 PCT/U82012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ Act. ID Act. ID N0 N0 N1048 1.03 A267T 509 1.34 K435G N104T 0.71 T269A 510 1.63 K435H L105A 0.54 T269C 0.75 K435R L105G 0.51 T269D 0.76 K4358 L1051 0.94 T2698 1.01 K435T L105P 0.84 R270M 0.46 K435V L105Q E5‘z 0.52 K435Y L105R 0.65 R2708 P436D L1058 0.61 I271F 0.72 P436E L105T 0.51 I271G 1.29 P436G L10E 0.34 L105C 0.33 L105H L105V I271L 511 10.62 P436H G106V 0.43 V272E 0.39 V272M M107F 0.91 I271M 512 3.24 P4361 M1071 0.67 12713 733 M107L 1.32 12717 A108G 0.47 72723 1110V 0.51 72723 E114A 1.44 72723"- E114G 0.73 72727 E114H 0.75 727313 E114M 0.44 72737 E1148 72733 P117D 0.56 72744 T118H 0.47 72747 T118K 0.33 72743 T118L 703 2733 T118M 0.53 Q276D 518 1.69 P4371 800 T118N 037 32733 T118Q 3-37 327313 T118V 0.79 Q2761 0.51 P437M 801 W119F 033 32733 W1 1913 033 we W119Y 1.08 Q276M A120D 0.76 Q276R A120F 318 2.62 Q276s A120G 1.03 Q276Y M438A 802 A120H U) ._1 \] 1.11 V277A A1201 319 1.33 V277C M438D 803 WO 2013/102144 2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm SEQ $6 Act. $6 A120L 1.25 277D A120N 0.81 V277E 525 A120P 0.42 <277G A120R 0.82 V277H A120s 320 1.21 V277K A120T 0.62 V277M A120V 321 1.53 V277N A120W 0.59 V277Q A120Y U) 1.95 V277R N122M 0.56 V277S K124L 0.34 K124H K124R 0.62 V277T 533 1.94 P125H 0.43 V277Y E4394 P125R 0.63 L278A we P125s 0.54 L278E 534 1.03 D127A 0.89 L278F 535 1.26 E439G D127E U) U) 1.31 L278G 536 1.33 E439H D127G 0.97 L278H 537 4.50 E439K 810 1.20 D127H L» 4; 2.33 L2781 D127L 0.84 L278K 538 1.75 E439P 811 1.16 D127M 0.4 D275v Q2766 D127N U) [\D LII 1.69 L278N 539 1.74 E439Q 812 1.32 D127Q U) MN0 1.21 L278R 540 5.87 E4398 D127R U) \l 0.51 L278s 541 1.67 E439T 813 1.15 D127S 0.77 L278T 542 1.66 E439V 814 1.57 D127T 1.11 L278v E439w D127V 0.56 L278Y 543 1.51 T44OA E[\D \1g 0.44 K279H 544 0.44 T440D 815 1.03 V128A 0.53 K279Q V128C 0.68 1.10 V128G 0.49 0.86 V1281 1.25 0.47 mm V128K 1.16 0.43 V128L 0.95 0.41 V128Q 0.55 s282G T44OM 817 1.08 V128R 0.74 545 2.64 T440P 818 0.88 V128S 0.53 s282Q T440R 819 1.77 V12°2° 0.50 Q283E T44OS 820 1.17 K1301 0.50 Q2831) mov WO 2013/102144 PCT/US2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ ID Act. ID Act. ID N0 N0 NO -K13OR i.[\D 83R 459 C Q283s 546 1.73 E441A 821 -131E Q2831 _N131F D284A 822 -131G 330 2.47 D284E 1.21 E441G -//131H D284G E441H _N1311 331 1.40 D284H 0.51 E441K -Z/131L D284L 0.50 E441L _131M 332 0.99 D284M 0.56 E441N 131Q 333 1.24 D284N 0.40 E441Q _///131R 334 2.81 D284Q 0.95 E441 8 -1318 D284S E4411 -1311 E285F 0.47 E441V 131V 335 2.08 E285G 0.52 E441Y 131Y E285H 547 1.30 E442C 823 _R132A E285M 0.43 E442G 824 -R132C E285N 0.40 E442H -R132E E285Q 0.59 E442K _R132FmE285Y E442P -R132HmL286S 0.46 E442Q K279A D284T 0.39 D284Y -E285A L286R 0.53 L286W _R1321 V2871 0.51 E442R 825 -R132K V287T -R132L 337 0.76 Y288L _R132N 336 1.28 Y288W -R132Q T289K 44444 826 _R132S T289S 549 0.48 P443E 827 -R132T F2901 P4444 828 -R132V F290M 44434 829 _R132Y 429m -S1331 G291R _1134L G291S 550 0.41 P443M 830 -11341 C)291V 551 1.63 P443N 831 _1134V m[\D0 [\D>"— -E135A E292C -E135C E292F _E135D 338 2.68 E292G -E135F E292H WO 2013/102144 PCT/US2012/072182 TABLE 9: ACTIVE MUTANTS mutant SEQ AvgNorm mutant SEQ ID Act. ID Act. ID N0 NO NO E442L E442W 0.38 Q444M E135G 339 2.79 E292K 555 1.27 E135H E292NmQ444E 832 E135K E292P E135L E292R E135N E292V Q444H 833 E135Q E292W E135R 340 2.08 T293A ms T293C Ewsw T293D _mm V137C mm 834 -mm V137S -we 137L _mm 143C 4R _mm K152W 396 0.37 I445H 835 -mm A153S -mm K1541 0.38 I445M 836 _mm E156C mm 837 -mm E158G 0.37 144513 838 _mm K159G 0.38 I445Q 839 -ms A160W _m G161V 0.42 I445S 840 -m2 D163W 841 -WA D163F msv 842 _m L165C 0.27 I445W 843 -W V166N _@381mE167F 0.31 F446A 844 -Q138C K170A F446c -QwsH K170Q _Q1381 K173O -Q138L 341 0.59 L174H _MM R176L -lesN P177V _Q138R L1801 -Q138S WK m Q13 00 Y183E 845 _Q138Y Y184W we -Q139A H193R WO 2013/102144 PCT/US2012/072182 TABLE 9: ACTIVE MUTANTS SEQ AvgNorm mutant SEQ AvgNorm mutant SEQ AvgNorm ID Act. ID Act. ID Act.

NO N0 NO H193F K195V K196N mm K196Y mm P197W mm G198W N200T mm F204W m NM wow———m wow K209F K209L 1L mm N211W W218M ——mW2;< mm 2. Inactive Mutants The other mutants that exhibited less than 20% hyaluronidase activity of wildtype PH20, in at least one of the duplicates, were rescreened to conﬁrm that the dead mutants are inactive. To conﬁrm the inactive mutants, the hyaluronidase activity assay described in Example 3 was modiﬁed to incorporate an overnight 37 oC substrate-sample tion step prior to measurement of tic activity. The modiﬁed assay is intended to detect PH20 activities below 0.2 U/mL.

The preparation of the bHA coated plates and blocking of the plates prior to addition of the transfected variant supernatants or wildtype PH20 was the same as described in Example 3. The assay was d as follows. First, transfected variant supernatants or wildypte PH20 not containing a mutation generated as described in Example 2 were diluted in duplicate 1:25 in assay diluent. For the standard curve, 1:3 serial dilutions of rHuPH20 (generated as bed in e 1) were made in assay diluent in duplicate starting from 0.1 U/mL down to 0.00014 U/mL. A blank well also was included. Then, 100 pl ofthe diluted s or standard were added to pre-designated wells of the bHA-coated and blocked plate and d to incubate at 37 OC overnight. After the incubation, the plates WO 2013/102144 2012/072182 were washed and binding to bHA detected as described above in Example 3. Optical y was measured at 450 nm within 30 minutes of adding the stop solution.

The identiﬁed reconﬁrmed inactive mutants are set forth in Table 10. The Table sets forth the amino acid replacement compared to the sequence of amino acids of PH20 set forth in SEQ ID NO:3.

TABLE 10: Inactive Mutants N002H R060V R121W C189P P2361 V287N L336W G377V N002K R060Y R121Y C189R P236L V287P L336Y G378D N002W L061A \ 122A C1898 P236N V287Q A337C G378E N002Y L061E \ 122C C189T P236Q V287R A337F G378F F003A L061F \122E C189V P236T V2878 A337G G378I F003G L061G \122F C189W P236Y Y288D A3371 G378L F003K L061H N122I C189Y A23 8F Y288E A337K G378M F003P L061N \ 122K Y190C A23 8G Y288F A337L G378Q F003T L061P \122Q Y190E A23 8L Y288G A337M G378T F003V L061Q \ 122R Y190F A23 8P Y288H A337R G378W R004D L061R \ 1228 Y190G A23 8V Y288I A337T G378Y R004E L061T \ 122T Y190H A238W Y288K A337W K379A R004F L061W \ 122V Y190K A23 8Y Y288P A338C K379C R004G L061Y W123A Y190L A239C Y288R A338D K379E R004L G062A W123C Y190N A239F Y288T A338E K379F R004P G062C W123D Y190Q A239G T289A A338F K3 791 R004W G062D W123E Y190R A239H T289C A338G K379L R004Y G062F W123H Y1908 A2391 T289E A338H K379M A005D G062I W123L Y190T A239L T289G A3381 K379W A005G G062K W123M Y190V A239P T289H A338K F3 80C A0051 G062L W123P Y190W 9R T289L A338L F380D A005L G062M 2123Q \191A A2398 T289P A338P F380E A005M G062P W123R \191E A239T T289Q A338R F3 80G A005N G062Q W123S \191F A239V T289R A338T F3 80Q A005P G062R W123T \ 191G A239W T2898 A338V F3 80R A005Q G0628 W123V \ 191K A239Y T289Y K339D F3808 A005R G062T W123Y \191L T240E F290D K339E T381G A005T G062V K124C N191M T240F F290Q K339F T381L A005V G062Y K124D \191P T240G F290Y K339G T381P A005W Y063C K124E \191Q T240N G291A K339H T381W A005Y Y063G K124F \ 191R T240W G291C K339L T381Y P006E Y063P K124N \ 1918 T240Y G291D K339N V3 82E P006F Y064A P125C \ 191T L241A G291E K339P V3 82G P006T Y064C P125D \ 191V L241C G291F K3398 V3 82H P006V Y064D P125G N191W L241D G291M K339T V3 82K WO 02144 PCT/US2012/072182 TABLE 10: Inactive Mutants V382L V382M V382N V382P V382Q V382R V3828 V382T V382W V382Y R383G R383P G384C G384F G384M G384Q G384S G384T K385C K385L K385M K385P K385W K385Y P386A P386C P386F P386G P386H P3861 P386L P386M P386N P386Q P386R P3868 P386T P386V P386Y T387C T387E WO 2013/102144 2012/072182 TABLE 10: Inactive Mutants m wow me WO 2013/102144 PCT/US2012/072182 TABLE 10: ve Mutants mw Q3930 Q39» we WO 02144 PCT/US2012/072182 TABLE 10: Inactive Mutants me my woe WW WO 2013/102144 2012/072182 TABLE 10: Inactive Mutants S401Y C402A C402D C402E C402F C402L C402M C402P C402Q C402R C4028 C402T C402V C402W C402Y Y403A Y403C Y403E Y403G Y403H Y403K Y403L Y403M Y403N Y403P Y403Q Y403R Y403T S404C S404D S404F S404G S404H S404L S404M S404N S404R S404V s404w S404Y T405C WO 2013/102144 PCT/US2012/072182 — 294 — TABLE 10: ve Mutants 04w Emw WO 2013/102144 PCT/US2012/072182 TABLE 10: ve Mutants we wow we WO 2013/102144 2012/072182 TABLE 10: Inactive Mutants C423A C423D C423E C423F C423G C423H C423L C423M C423P C423Q C423R C4238 C423T C423V c423w I424A 1424C I424E I424G I424H I424N I424Q I424R 1424s I424W I424Y A425E A425L A425P Aw A425Y D426C D426F D426R G427A G427C G427F G427L G427P WO 02144 PCT/US2012/072182 TABLE 10: Inactive Mutants G427V Gm G427Y V428A V428C V428D V428E V428G V428H V428N V428R V4288 V428Y C429A C429D C429K C429L C429N C429P C4298 C429T C429V c429w C429Y I430A I430D I430E I430L I430M I430N I43OS I430T I430V D431P A432C A432F A4321 A432L A432P WO 2013/102144 PCT/US2012/072182 TABLE 10: Inactive Mutants «m woe EXAMPLE 5 ASSAY FOR HYALURONIDASE ACTIVITY UNDER TEMPERATURE AND PHENOPHILIC CONDITIONS Supematants from PHZO activity variants set forth in Table 9, as identiﬁed in Example 4, were tested for stability uner thermophilic and/or phenophilic conditions. The assay to measure hyaluronidase activity under temperature and phenophile conditions using biotinylated-HA (bHA) as substrate for measuring hyaluronidase activity was modiﬁed from the original assay described in Example 3 in that it incorporated a 4-hour 37 oC tion of samples with or without m-cresol prior to measurement of enzymatic activity. The assay was used to identify PHZO mutants with thermophilic properties ity greater at 37 oC ion than at 4 0C) and/or with phenolphilic properties (greater activity in the presence of m—cresol than wildtype PHZO). 1. Primary Screen Prior to incubating s with bHA, variant PHZO samples were diluted into designated wells of an uncoated 4XHB plate for pre-incubation at 37 0C for 4 hours under the following conditions: 1) pre-incubation at 37 0C with 0.4% ol; and 2) pre-incubation at 37 OC without 0.4% ol. For the preincubation at 37 0C with 0.4% m-cresol, a 1% m- WO 2013/102144 PCT/US2012/072182 cresol intermediate stock was prepared from 50% (v/v) m—cresol stock on. Brieﬂy, in a 2 mL Wheaton glass vial a 50% stock of m—cresol (Fluka, Catalog No. 65996; Spectrum, Catalog No. C2773) was made in methanol based on the density (D=1.034 g/L). The vial was sealed and stored at -20°C with protection from light in small aliquotes. Then, the 1% intermediate stock was generated by dilution in HEPES assay buffer (10 mM HEPES, 50 mM NaCl, 1 mM CaClg, 1 mg/mL BSA, pH 7.4, 0.05% Tween-20) daily immediately prior to use in a fume hood with vortexing.

Then, duplicates of transfected variant supernatant samples set forth in Table 9, generated as bed above in Example 2, were each separately ted to a 1:25 dilution of 1% m-cresol in HEPES assay buffer/ transfected supernatant to obtain 0.4% ﬁnal traion of m-cresol. For the preincubation at 37 °C without 0.4% m—cresol, transfected variant supernatant samples were subjected to a 1:25 dilution in HEPES assay buffer/transfected supernatant. In on, for each condition, an internal killing control was also tested by spiking in 3 U/mL of rHuPH20 in pH 7.4 HEPES buffer (generated as described in Example 1) that was diluted the same as described above for the transfected samples. The plates were sealed with plate s and incubated at 37 0C for 4 hours.

The preparation of the bHA coated plates and blocking of the plates prior to addition of the transfected variant tants or wildtype PH20 was the same as described in Example 3. The assay was further d as follows. First, samples were diluted in duplicate 1:10 in HEPES assay buffer in 4XHB plates. For each variant, the samples that were tested were 1) non-preincubated ected variant supernatant (no incubation; 4 OC ); 2) preincubated transfected variant supematants preincubated at 37 0C for 4 hours with 0.4% m—cresol (Cresol); or 3) preincubated transfected variant supernatant preincubated at 37 0C for 4 hours without 0.4% m—cresol (no cresol; 37 0C). In addition, the spiked-in samples also were tested. A standard curve using 0 was made as described in Example 3 without m—cresol. One hundred microliters (100 pl) of each standard and sample were transferred to pre-designated wells of the bHA-coated and blocked plate and incubated for approximately 1.5 hours at 37 OC. Thus, each sample of each t was tested in quadruplicate due to the preincubation of duplicate samples of each transfected variant supernatants in the pre- incubation step and the further duplicate of each sample in the bHA assay.

After the tion, the plates were washed and binding to bHA detected as described above in e 3. Optical density was ed at 450 nm within 30 minutes of adding the stop solution.

The U/mL activity was calculated from the standard curve and compared. The results were depicted as the percent (%) activity ing under each of the following parameters: WO 2013/102144 PCT/US2012/072182 ratio of activity at 1) 37 OC preincubation without m—cresol/4 OC; 2) 37 0C after preincubation with m-cresol/4 °C; and 3) 37 0C after preincubation with m-cresol/after preincubation at 37 oC without m-cresol. Initial phenophile hits for reconﬁrmation were identiﬁed as those that in a ate assay ted a percentage of remaining activity under condition 3) of Z 20% of the original activity at 37 OC.

Initial Hits were rescreened using a 6-well plate rescreen assay. For the rescreen, plasmid DNA corresponding to the potential Hit was transformed into E. coli bacteria and plasmid DNA prepared and purified using MaXiPrep according to the manufacturers instructions. The DNA sequence was conﬁrmed.

The plasmid DNA was transfected into monolayer CHO-S cells (Invitrogen, Cat. No. 11619-012) grown on 6-well plates at a density of about 50-80% conﬂuency using Lipofectamine 2000 (Invitrogen, Cat. No. 11668-027) according to the protocol suggested by the manufacturer. Transfections were performed in duplicate. The cells were incubated at 37 0C in a C02 incubator for 96 hours post-transfection before collecting the supernatant for the assay. As controls, cells also were transfected with the HZ24-PH20(OHO)-IRES—SEAP expression vector (SEQ ID NO:4) that contains a codon-optimized wildtype PH20 sequence (OHO). Mock cells also were included as controls.

Ninety-Six (96) hours post-transfections, supernatant was collected from each sample, including the OHO and mock controls, and assayed for hyaluronidase activity under s ions as described above: 1) non-preincubated ected variant supernatant (no tion; 4 oC ); 2) preincubated transfected variant supematants preincubated at 37 0C for 4 hours with 0.4% m—cresol l; 37 0C); or 3) preincubated transfected variant atant preincubated at 37 0C for 4 hours without 0.4% ol (no cresol; 37 OC).

Hyaluronidase activity was determined as described above using the bHA assay.

The results were assessed as described above. Absolute hyaluronidase activity (U/mL) was generated from the rd curve. In addition, percent activity was determined as a ratio of activity at 37 °C/4 0C, 37 OC plus m—cresol/4 OC, and 37 OC plus m—cresol/37 °C. The s are set forth in Tables 11 and 12 below.

TABLE 11: te H aluronidase Activi No incubation 37 °C n0 cresol 37 °C with m-cresol (37 Mutant (4 °C) (37 °C) °C lus m-cresol) L001A 2.993 2.511 3.529 3.214 0.287 0.295 WO 2013/102144 PCT/US2012/072182 TABLE 11: Absolute H aluronidase Activi N0 incubation 37 °C n0 cresol 37 °C with ol (37 Mutant (4 0C) (37 °C) °C lus m-cresol) b—tU.) . #N 00 H00 4.088 3.495 0.404 0.435 . 1.856 1.678 0.000 0.008 0 U.) 00 ._1 0.469 0.476 0.031 0.030 P010G 0.564 0.820 0.688 0.123 0.114 O . 4; 00 U} 0.624 0.548 0.000 0.000 0 0O\[\J 1.313 1.263 0.094 0.064 V012E 11.019 5.519 5.312 5.528 0.753 0.934 U.) 00 .b .b 3.610 6.566 0.106 0.090 V012K 1.963 2.479 2.243 0.330 0.321 O . ._1 0 LI} 0.222 0.242 0.003 0.000 ._1 O \l U.) 1.026 0.901 0.017 0.017 AOZOS 2.205 2.822 2.620 0.413 0.397 U.) . \l 00 00 3.375 3.273 0.684 0.748 ._1 [\D [\D O\ 2.027 1.704 0.224 0.178 0.845 1.043 0.925 0.112 0.095 ._1 LI} ._1 ._1 1.848 1.839 0.140 0.140 F029S 3.615 3.566 3.521 0.250 0.283 ._1 . \l ._1 [\J 1.839 2.065 0.220 0.212 O 4; ._1 0 0.476 0.534 0.006 0.040 L033G 0.566 0.700 0.686 0.627 0.001 0.026 D034W 0.340 0.499 0.471 0.076 0.069 M035V 0.887 000 . . \]O\U.) U}U.)[\) NOH 0.721 0.652 0.116 0.023 . 1.178 1.135 0.117 0.026 O 0 U.) U.) 0.893 0.859 0.171 0.260 L037M 0.404 0.455 0.353 0.049 0.032 U.) 0J;. ._1 3.515 4.148 0.277 0.361 [\D 0 U} 0 4.011 3.342 0.513 0.557 N047D 2.359 2.573 2.639 0.032 0.021 A0 "‘4; ca \IU} H. 0.423 0.456 0.000 0.017 . 14.252 23.873 0.797 0.902 13.334 9.685 12.102 0.563 0.649 U.) ._1 4; oo 3.084 3.020 0.242 0.264 G050M 2.333 2.780 3.244 0.250 0.393 0 . 00 O0 6.939 13.978 1.109 1.083 ._1 [\J [\J .b 1.795 1.433 0.381 0.463 (30528 1.999 2.120 1.963 0.498 0.566 ._1 U.) ._1 [\J 1.321 1.301 0.212 0.210 28.000 61.016 61.016 23.586 23.586 J; . O\ 00 00 5.542 4.822 3.134 3.149 ._1 ._1 \l U} 1.550 1.525 0.200 0.175 V058Y 0.770 1.071 1.088 0.388 0.454 U}l\)t—‘ 000‘ \l-bw A005 L»). 18.458 45.092 1.567 2.166 . 2.799 5.121 0.592 0.884 . 7.590 9.222 0.826 1.205 O [\D ._1 U} 0.213 0.180 0.001 0.184 S069T 1.927 2.179 2.671 2.671 0.289 0.240 WO 2013/102144 PCT/US2012/072182 TABLE 11: Absolute H aluronidase Activi N0 tion 37 °C n0 cresol 37 °C with m-cresol (37 (4 °C) (37 °C) °C lus m-cresol) Np—A JkUl U30 \IU.) 1.306 1.589 0.010 0.032 3.099 3.335 0.433 0.363 U) .5 .5 )—k 5.880 5.827 0.383 0.477 VO73R 0.803 0.720 0.804 0.018 0.059 u.) 00 u.) .5 3.868 3.871 0.666 0.626 O \l .5 .5 0.656 0.771 0.079 0.083 NW 1.905 2.565 2.995 0.281 0.204 p—A LI] 0 L») 2.525 2.648 0.309 0.265 mm 0.820 0.806 1.066 0.060 0.023 p—A N 00 O 1.365 1.460 0.101 0.080 p—A O 00 \1 1.233 1.321 0.003 0.028 mm 1.311 1.563 3.302 0.325 0.354 u.) .5 ._. ._. 3.396 3.244 0.792 0.861 N O\ U.) U.) 5.194 3.615 1.552 1.017 1.946 2.665 3.674 0.720 0.510 ._. O U) .5 0.880 1.005 0.235 0.268 10836 2.443 2.418 1.866 0.545 0.601 )—k .5 oo .5 1.834 1.683 0.115 0.115 ._1 [\D ._1 [\D 0.982 1.103 0.025 0.000 SO84N 1.888 3.268 2.476 0.597 0.547 )—A[\)»—A 01—14; ON\] OO\] 0 10.230 30.016 1.117 1.494 2.845 3.310 0.405 0.322 1.218 1.296 0.087 0.065 O p—A p—A O 0.126 0.072 0.032 0.023 Q0868 2.082 2.539 2.149 0.173 0.241 [\J U) .5 [\J 2.832 4.562 0.290 0.406 N p—A \] O\ 2.252 1.971 0.034 0.122 D087L 2.277 2.195 2.311 0.324 0.299 p—Ap—AN mom OWN #OUI LI) 2.510 2.038 0.191 0.335 6.983 14.399 0.569 0.928 1.553 1.187 0.142 0.189 p—A N N00 7.666 19.836 1.093 1.234 D090N 2.775 3.123 2.737 0.379 0.290 [\D O0 LI] 2.267 1.971 0.132 0.131 [\J 00 O\ [\J 3.094 2.842 0.362 0.465 K094D 2.088 2.071 2.132 0.135 0.211 )—k U) .5 5) 1.764 1.676 0.158 0.166 T0970 0.618 0.545 0.505 0.044 0.087 O L!) O\ L!) 0.643 0.664 0.055 0.073 )—k .5 )—k 0 1.394 1.623 0.217 0.262 T097L 1.198 1.065 1.241 0.246 0.300 [\D U.) U) 0 2.876 2.790 0.279 0.238 2.551 2.028 2.883 0.168 0.199 0.339 0.149 0.199 0.105 0.068 3.313 3.546 3.401 0.389 0.504 .678 27.143 15.899 0.505 0.447 WO 2013/102144 2012/072182 TABLE 11: Absolute H aluronidase Activi N0 incubation 37 °C n0 cresol 37 °C with m-cresol (37 Mutant (4 0C) (37 °C) °C lus m-cresol) F—‘OO . OO\] \].[> 000 7.724 8.392 1.645 1.626 . 2.280 1.962 0.233 0.214 U) [\D U) LI} 3.259 2.966 0.337 0.430 Q138L 1.660 1.611 1.521 0.410 0.347 4; O O\ U}. 4.996 4.464 0.546 0.559 p—A L») NO 1.334 1.527 0.058 0.035 N141S 2.201 2.708 2.900 2.966 0.135 0.164 p—A LI] O\ 00 1.927 1.643 0.100 0.105 V142D 2.186 2.914 3.193 0.128 0.067 )—k . \l0 O} 1.597 1.621 0.211 0.219 [\J U.) 00 ._1 3.867 3.681 0.571 0.575 V142N 0.567 0.672 0.589 0.103 0.087 \l N. p—A L») 7.722 7.021 1.074 1.081 O\ 0OO 7.618 6.897 0.678 0.678 2.595 2.941 2.689 0.364 0.330 [\J 0 00 00 4.763 3.497 0.416 0.591 V142T 3.260 4.313 4.031 0.495 0.472 4; 0O U.). 5.632 4.846 0.782 0.780 U.) 0\ \l ._1 7.285 5.008 1.043 1.039 L144R 3.810 4.581 5.191 5.107 0.556 0.520 L144T 1.496 1—101—1 . 1—‘\]O\ #0000 ONH 1.941 1.831 0.285 0.219 L146P 0.818 . 0.954 0.904 0.011 0.031 . 1.399 1.497 0.055 0.039 O U} 00 U} 0.622 0.684 0.039 0.046 T150S 1.400 1.875 1.988 0.120 0.121 [\D . [\D O\ 0 2.965 2.860 0.359 0.337 U) [\D 00 0 4.446 4.007 0.218 0.251 E151S 4.591 5.987 6.262 0.371 0.294 H.593 #No N-PO Ago 00. 3.134 3.309 0.000 0.000 . 4.459 4.232 0.326 0.314 . 11.352 13.524 0.131 0.121 p—A L») \l \1 1.796 1.883 0.100 0.067 K152W 1.795 2.549 2.406 0.063 0.069 OO . p—AU) 00 U}\] 0.451 0.407 0.000 0.000 . 0.114 0.080 0.004 0.024 .250 5.075 5.075 0.600 0.725 [\D U} 0 \l 2.937 2.958 0.392 0.324 V166T 1.315 1.821 1.800 0.231 0.235 O 0. )—k O 1.109 1.480 0.111 0.056 )—k \l0 O} 2.540 2.196 0.335 0.341 K17OR 2.054 2.536 1.995 0.209 0.201 01—‘0 . OU}U} OOLhOO \]>—A>—A 0.692 0.777 0.052 0.056 . 1.766 2.083 0.173 0.156 . 0.210 0.230 0.026 0.031 [\D [\D \l O\ 2.494 2.872 0.331 0.543 0.566 0.689 0.820 0.090 0.050 WO 2013/102144 PCT/US2012/072182 —304_ TABLE 11: Absolute H aluronidase Activi N0 imon 37 °C n0 cresol 37 °C with m-cresol (37 (37 °C) °C lus m-cresol) ~45 Wm oo\1 NLII o. 4.891 4.513 0.258 0.362 . 16.287 20.033 0.665 0.790 p—A L») 0 \] 2.264 1.888 0.346 0.346 K195T 0.806 1.548 1.911 0.348 0.292 )—k . .5 L» \l 1.649 1.385 0.369 0.353 O O\ O\O 0.663 1.017 0.244 0.239 K196R 2.285 2.383 2.174 0.315 0.384 .5 U} U} 0 2.925 3.750 2.475 4.725 N205A 0.837 0.717 0.854 0.153 0.160 [\J OO.5. 1.627 1.870 0.314 0.346 )—k 0 [\D0 1.165 0.000 0.123 0.088 N205T 0.367 0.428 0.406 0.043 0.053 0 . LI] 0 00 0.600 0.565 0.079 0.088 ) .5 U} L» 2.445 1.951 0.291 0.077 4.549 6.271 6.016 0.167 0.322 p—A LI] 0N 2.442 2.222 0.204 0.152 D213A 0.283 0.432 0.438 0.116 0.060 [\D O 00 O. 2.650 2.046 0.181 0.142 U) 0 U} O\ 2.670 2.414 0.268 0.139 S215M 2.175 2.618 1.630 0.110 0.146 LIIUJO . NOON GNU] N000 0.860 0.728 0.076 0.082 - 4.993 4.349 0.371 0.257 . 5.399 5.549 0.033 0.044 )—k 5) .5 5) 0.716 0.781 0.089 0.153 Q233G 0.095 0.115 0.121 0.000 0.000 O\ O U.). ._1 5.764 4.871 1.286 0.988 0 LI] 0 [\J 0.714 0.607 0.079 0.073 V237C 0.708 0.860 0.824 0.000 0.000 t—‘OO . (XDD—KLI) 001—1 000 0.370 0.459 0.046 0.034 . 0.254 0.247 0.054 0.053 . 1.945 2.559 0.159 0.171 O U) 0 U) 0.345 0.743 0.090 0.062 T240A 0.900 1.564 1.302 0.143 0.118 0 . LI] p—A O 0.542 0.617 0.080 0.085 ) .500 2.575 3.115 0.027 0.075 3.894 4.284 4.325 0.655 0.712 .5 .5 U}N 4.985 5.022 0.039 0.034 K260M 0.960 0.839 0.935 0.072 0.068 L») . p—A p—A \] 1.872 2.686 1.264 1.451 U} .5 [\J ._. 9.860 6.297 1.583 1.437 S261N 40.257 20.219 14.303 2.115 1.917 000 .. LII-[>0 0W0 01001 0.102 0.106 0.036 0.041 0.417 0.519 0.025 0.031 . 0.668 0.519 0.052 0.050 p—A 00 \l \] 2.027 1.997 0.181 0.201 0.768 0.762 0.806 0.043 0.000 WO 2013/102144 PCT/US2012/072182 TABLE 11: Absolute H aluronidase Activi N0 incubation 37 °C n0 cresol 37 °C with m-cresol (37 (4 0C) (37 °C) °C lus ol) 1—‘0 . N\] ._1._1 N\] 7.383 14.593 0.807 1.281 . 1.497 1.681 0.149 0.147 ._1 O\ .5 U.) 1.692 2.129 0.118 0.110 V277E 2.340 4.289 4.577 0.161 0.239 LI] . U.) 0 [\J 7.181 7.300 0.227 0.512 00 00 O\ 33.627 33.627 4.442 4.045 V277M 1.279 1.622 1.754 1.818 0.264 0.270 .5 U.) 0 O\ 12.865 11.772 0.938 0.796 V277Q 5.461 6.547 6.343 0.373 0.493 ._1 [\D O L») 00. 17.581 20.641 2.737 2.023 ._1 O .5 .5 .5 9.509 15.135 0.727 0.716 V277T 7.804 8.497 11.184 0.679 0.871 [\J . \l0 LI] 3.330 2.800 0.170 0.202 \1 .5 U} 0 9.173 7.760 0.596 0.612 1.087 1.234 1.339 0.185 0.269 O O\ O\ \l 0.843 0.832 0.139 0.100 T289S 1.019 0.819 1.001 0.008 0.007 O . U) [\D [\D 0.419 0.385 0.051 0.016 U.) \lO \] 4.131 5.599 0.821 0.706 E292C 1.344 1.599 1.711 1.617 0.138 0.144 E292F 6.106 8.422 0.520 6.216 0.363 E292H 2.620 NW4; . . u—AUJO \lt—‘O OOO\\] 4.458 3.830 0.389 0.451 . 3.155 2.829 0.398 0.339 ._1 ._1 [\D ._1 1.453 1.494 0.193 0.177 T293A 3.110 2.546 1.789 0.086 0.076 O . [\J \l .b 0.342 0.236 0.030 0.022 O O\ O\ ._1 0.726 0.605 0.000 0.000 s308D 0.325 0.337 0.344 0.014 0.010 N-PO . 00-h" HON CON 0.826 0.716 0.011 0.000 . 6.808 6.128 0.386 0.362 . 3.921 3.663 0.637 0.528 U} .5 5)0 6.824 6.194 0.503 0.400 1309L 0.403 0.501 0.431 0.048 0.047 LAN . 3.467 3.383 0.278 0.239 . t—t-lk \oq Ho.) 5.444 5.054 0.380 0.327 28.759 18.217 158.604 0.748 1.367 [\D U} 00 2.989 3.735 0.228 0.207 I309V 1.292 1.929 1.787 0.029 0.062 O\ . U) 0 \l 7.568 7.084 0.866 0.915 U) ._1 \l 0 3.912 3.380 1.088 0.955 M313G 0.325 0.348 0.355 0.034 0.036 [vb—1L1} \ONN ow—tq #5305N. 10.243 10.395 0.380 0.404 . 15.085 12.984 0.129 0.072 . 4.198 3.919 0.209 0.177 ._1 O 00 O\ U) 7.288 3.568 0.337 0.296 4.474 4.705 4.467 0.331 0.313 WO 2013/102144 PCT/US2012/072182 TABLE 11: Absolute H aluronidase Activi N0 incubation 37 °C n0 cresol 37 °C with m-cresol (37 Mutant (4 0C) (37 °C) °C lus m-cresol) Ap—A . JkN L110 ON 1.276 1.300 0.096 0.089 . 4.042 5.879 0.391 0.533 0 ._1 U.) ._1 0.226 0.182 0.013 0.020 S315A 1.082 1.345 1.484 0.222 0.148 U.) NA [\J. 3.648 3.414 0.440 0.371 O O\ [\J O\ 0.477 0.362 0.146 0.143 L317A 3.254 2.845 4.019 3.776 0.280 0.317 ._1 LI] [\JA 2.021 1.687 0.257 0.180 L317K 9.382 11.668 12.591 0.402 0.445 U.) 0 O\ O\. 3.703 3.717 0.445 0.540 ._1 U} ._1 00 \l 20.585 15.106 0.796 0.857 29.267 10.535 25.114 1.637 1.613 ._1 O \l U.). 1.953 1.656 0.136 0.018 ._1 ._1 [\D 00 1.326 1.665 0.158 0.171 1.970 1.847 1.930 0.322 0.322 O 00 O O\ 1.072 1.005 0.046 0.074 L318R 3.464 4.583 4.187 0.258 0.260 4; . 4;O0 5.059 4.946 0.482 0.426 O \l ._1 O 0.700 0.772 0.058 0.035 E324N 4.309 2.530 4.508 3.321 0.348 0.303 T325E 1.071 #OH . LIILIIN #0" Ul-bo 1.337 1.352 0.193 0.143 N328G 0.379 . 0.747 0.553 0.031 0.040 . 4.758 4.543 0.490 0.477 O \l 00 \l 0.977 0.986 0.113 0.062 Q347A 11.961 8.432 11.508 0.918 1.266 ._1 . ._1 [\D O 3.021 2.319 0.253 0.209 ._1 O\ [\D 0 1.486 1.760 0.178 0.217 Q349R 0.572 0.663 0.598 0.078 0.079 01—11—1 . 4;on U.) 1—‘-PU.) 1.804 1.647 0.000 0.000 . 3.090 2.697 0.323 0.321 . 0.445 0.588 0.038 0.023 O [\D U} U.) 0.136 0.318 0.000 0.008 S359E 2.635 3.547 3.560 0.382 0.333 0 . U.) \l ._1 0.445 0.374 0.000 0.000 O \l 00 [\J 1.074 0.996 0.139 0.131 0.530 0.686 0.650 0.000 0.000 O \l O\ \l 0.890 0.513 0.045 0.052 P367S 3.478 2.946 3.073 0.424 0.505 [\J . U.) N ._1 2.143 1.895 0.031 0.040 A 0AA 5.772 4.842 0.530 0.555 D368L 0.566 0.607 0.619 0.000 0.006 u—ALhu—A . CNO ®\]0\ WOU} 1.031 1.104 0.028 0.028 . 7.418 6.226 0.754 0.735 . 2.512 2.525 0.072 0.085 [\D \l ._1 0 2.503 2.022 0.160 0.125 .207 4.974 3.980 0.308 0.222 WO 2013/102144 PCT/US2012/072182 TABLE 11: Absolute H idase Activi N0 incubation 37 °C n0 cresol 37 °C with m-cresol (37 Mutant (4 0C) (37 °C) °C lus m-cresol) #00 00} U}U}. 0000 \l 77.531 77.531 1.403 1.316 . 3.900 3.879 0.000 0.334 U.) U} .5 O\ 3.963 4.055 0.509 0.505 A371L 40.668 76.587 43.516 1.159 0.964 L» . .5 .5 U} 3.472 2.075 0.000 0.025 [\D LI} 00 LI} LI} ‘1:5: E:5: 2.851 3.634 A371R 6.592 7.733 7.987 7.576 0.000 0.196 U) U} 0 U} 4.916 4.611 0.412 0.781 L374P 7.129 11.522 8.771 0.665 0.646 0 . U} 0 \] 0.557 0.683 0.000 0.014 p—A N00 2.025 1.806 0.209 0.265 E375R 1.132 1.529 1.318 0.201 0.260 O . L») p—A N 0.518 0.515 0.064 0.026 ._. O0.5 1.572 1.674 0.213 0.174 0.940 0.910 0.846 0.116 0.102 ._1 U.) LI} ._1 1.704 2.690 0.539 0.279 K376T 1.001 1.026 1.135 0.153 0.064 O . 00 O\ ._1 1.036 1.021 0.033 0.026 O \l \l \] 1.353 0.747 0.125 0.097 G377D 1.159 1.332 1.285 1.763 0.202 0.186 G377E 0.877 1.144 0.092 1.189 0.088 G377H 3.037 #WO . . H-PO OWN HNO 4.460 3.598 0.372 0.364 . 6.405 4.911 0.283 0.245 p—A N LI] \1 1.312 1.191 0.077 0.085 G377S 0.452 0.492 0.457 0.034 0.036 N . L») p—A L») 2.474 2.522 0.424 0.461 [\J \l 0 00 \] 25.734 29.353 2.566 2.716 T381S 3.161 3.886 3.558 0.521 0.367 ONO . O\U}® 0.5L» 0000 10.340 6.820 0.655 0.513 . 3.228 3.044 0.339 0.321 . 0.604 0.754 0.028 0.000 [\D O 00 0 2.403 2.609 0.217 0.196 K385V 1.750 1.387 1.410 0.071 0.042 ._. O 0.5.5. 21.081 24.610 0.449 0.449 O [\D O U) 0.188 0.284 0.004 0.000 E389L 1.814 2.142 2.598 2.403 0.370 0.303 L» .5 L» 5) 3.459 3.423 0.411 0.437 E389S 2.640 3.059 2.456 0.000 0.007 p—A . L») \l O 2.021 2.133 0.147 0.136 )—k .5O \] 1.821 2.023 0.071 0.079 E392Q 4.653 6.583 4.364 0.693 0.729 NNU} . HOW OOUJO 000 5.900 6.548 0.218 0.193 . 4.747 4.544 0.367 0.291 . 2.455 2.222 0.260 0.226 ._1 00 [\J O\ 1.749 1.588 0.028 0.049 6.127 8.788 6.906 1.141 0.856 WO 2013/102144 PCT/US2012/072182 TABLE 11: Absolute H aluronidase Activi N0 incubation 37 °C n0 cresol 37 °C with m-cresol (37 Mutant (4 0C) (37 °C) °C lus m-cresol) 1—‘N . 1—‘N 000 451—1 2.574 2.564 0.323 0.268 . 1.497 1.524 0.126 0.149 O U} U) [\D 0.751 0.684 0.069 0.022 E396Q 1.625 1.611 1.559 0.162 0.160 LI} . \1O0 5.274 6.380 0.146 0.129 U) [\D U} O 3.313 3.989 0.000 0.002 Y399V 2.738 2.697 3.028 3.129 0.484 0.557 )—k 00 00 U.) 1.715 1.946 0.236 0.233 S401A 3.171 3.216 3.148 0.447 0.410 ._1 . O\O ._1 2.110 2.060 0.344 0.309 p—A O\ L») LI] 1.924 1.724 0.000 0.019 L406F 0.490 0.867 0.716 0.000 0.000 0 . \l0 LI} 0.943 1.044 0.060 0.070 [\J 0.50 3.432 3.255 0.389 0.548 .790 5.038 5.682 0.569 0.575 [\J \lO 00 3.812 3.301 0.261 0.366 A412Q 2.918 2.925 2.902 0.279 0.247 LI] . p—A L») N 6.390 6.347 0.570 0.596 U.) .5 U} ._. 3.789 3.511 0.189 0.189 D416L 0.610 0.817 0.737 1.043 0.130 0.160 D418R 4.541 .5 . 00 J; \1 5.347 5.438 0.406 0.583 A419H 10.409 20.311 25.109 38.221 2.214 2.293 H O .N \o oo 24.536 9 2.556 3.173 LI} 0\ ._1 \l 6.094 16.940 0.761 0.764 D421H 48.012 160.106 32.481 16.300 28.113 U} . [\D [\D U} 6.864 5.346 0.523 0.725 00 O\ U.) LI} 10.039 8.645 1.502 1.422 D421Q 5.581 7.858 8.016 0.842 0.994 OOU}U} . 9.211 7.537 0.815 0.737 . 7.899 8.898 0.869 0.762 . OOUJ-P NU}O\ \lU}U) 7.796 10.676 0.827 1.189 )—k [\D LI} [\D 1.342 1.230 0.031 0.106 G427T 1.380 1.664 1.643 0.080 0.065 NN . N\] No 00 2.930 3.029 0.053 0.030 . 1.972 2.112 0.519 0.438 3.185 4.017 3.028 0.294 0.301 p—A O\ 0 LI] L») 19.563 11.575 2.272 2.339 D431L 1.215 1.564 1.448 0.164 0.170 )—k [\D O O\ L»). 16.358 15.131 1.601 1.399 0 00 [\D 00 14.157 10.760 1.533 1.153 D431s 10.220 11.338 9.075 0.853 0.829 NN-P . 0W0 #0" U)\]U) 5.943 4.649 0.581 0.595 . 2.574 2.108 0.347 0.356 . 2.990 2.299 0.338 0.382 )—k .5 .50 U} 16.240 49.615 1.806 1.790 6.719 10.572 8.960 1.113 0.857 WO 02144 PCT/US2012/072182 TABLE 11: Absolute H aluronidase Activi No incubation 37 °C no cresol 37 °C with m-cresol (37 (4 °C) (37 °C) °C lus m-cresol) .941 9.716 8.019 1.327 1.542 7.762 150.315 8.696 2.415 1.505 0.795 0.784 0.903 0.082 0.068 P4371 0.996 1.130 1.066 0.027 0.019 1.518 2.125 2.060 0.214 0.210 2.522 3.002 2.857 0.305 0.074 M438E 4.992 5.386 5.680 0.431 0.518 .268 6.663 11.324 0.670 0.739 M438N 5.531 8.050 5.568 0.649 0.662 2.411 2.308 2.500 0.309 0.304 4.432 4.883 4.235 0.568 0.596 E439A 0.998 1.694 1.470 0.080 0.109 0.256 0.286 0.286 0.042 0.045 0.588 0.580 0.616 0.077 0.065 3.736 3.394 3.267 0.529 0.490 0.848 1.087 1.080 0.116 0.115 E439T 1.889 2.179 2.323 0.313 0.263 4.443 4.931 3.533 0.568 0.651 1.982 3.297 2.595 0.147 0.196 mm 3.305 2.878 2.873 0.254 0.367 3.987 3.277 0.540 0.566 2.533 2.895 0.283 0.284 1.813 1.560 0.204 0.178 3.193 3.347 0.327 0.367 mm 0.710 0.856 0.928 0.044 0.063 2.370 2.683 2.321 0.301 0.286 2.921 9.751 4.614 0.835 0.756 Q444E 3.861 6.800 6.213 0.581 0.594 .pgmw o-wao Nwom gooqo 5.746 4.710 0.486 0.513 2.847 2.583 0.384 0.284 4.480 4.489 0.773 0.691 3.592 3.515 0.499 0.455 I445W 2.694 2.683 2.695 0.314 0.296 2.464 2.363 2.685 0.391 0.345 1.352 1.358 1.401 0.187 0.162 Y447P 1.383 1.379 1.490 0.190 0.183 2.919 2.173 2.773 2.105 0.145 0.178 3.984 4.463 4.215 4.823 0.189 0.253 |2.725 3.325 0.1 0.125 250] 2.883 2.370 3.158 0.452 0.522 positive 2.989 10.835 3.914 control ggég 0.485 0.219 .356 2.609 3.643 0.542 0.402 (0H0) .279 5.422 2.815 4.026 0.618 0.401 4.775 4.385 2.845 3.327 0.718 0.540 3.617 4.264 3.322 3.427 0.633 0.479 .881 4.511 5.518 4.359 0.743 0.848 WO 2013/102144 PCT/US2012/072182 TABLE 11: Absolute H idase Activi N0 incubation 37 °C n0 cresol 37 °C with m-cresol (37 (4 °C) (37 °C) °C lus m-cresol) n/a (not available; e.g., beyond detection limit) TABLE 12: Percent (%) Activi dunlicatez % activity % ty % activity % activity % activity % activity at 37 °C + m- 37 °C + m- at 37 °C + m- 37 °C + m- 37 °C/4 °C cresol/37 cresol/4 °C 37 °C/4 °C cresol/37 cresol/4 °C °C °C LOOlA 117.908 8.13 9.179 11.75 LOOlE 107.231 13.14 10.727 13.43 LOOlG 171.264 9.23 4.586 5.32 L001Q 119.435 10.13 11.121 9.87 L001R 117.366 6.96 5.623 9.02 POO6A 137.875 9.88 12.446 13.56 v008M 134.884 0.00 E_—0.477 0.57 1009Q 104.922 6.61 6.303 7.87 P010G 109.772 15.00 16.570 20.21 POIOH 131.924 0.00 E_—0.000 0.00 mm 152.320 7.16 5.067 6.65 V012E 48.208 14.18 16.896 16.92 v0121 128.745 2.94 1.371 2.34 V012K 146.600 13.31 14.311 16.35 F014V 154.167 1.35 0.000 0.00 L015M 113.747 1.66 1.887 1.58 A0208 9 14.64 15.153 18.00 80221 111.203 20.27 22.854 19.75 L026M 5 11.05 10.446 14.52 K028R 110.487 10.74 10.270 11.24 F029R 154.644 7.58 7.613 9.27 F0298 118.119 7.01 8.037 7.83 F029T 126.740 11.96 10.266 12.38 PO32C 128.649 1.26 7.491 9.55 LO33G 1 0.15 4.147 3.71 DO34W 146.765 15.23 14.650 21.50 M035v 81.285 16.09 3.528 3.60 SO36H 106.222 9.93 2.291 3.46 SO36N 112.045 19.15 30.268 27.87 L037M 79.268 10.77 9.065 7.92 FO4OL 135.036 7.88 8.703 9.16 WO 2013/102144 PCT/US2012/072182 TABLE 12: Percent (%) Activi du licate 1 dulicateZ % activity % activity % activity % activity % activity % activity at 37 °C + m- 37 °C + m- at 37 °C + m- 37 °C + m- 37 °C/4 °C cresol/37 cres01/4 °C 37 °C/4 °C cresol/37 cresol/4 °C °C °C 1046L 132.507 12.79 16.667 18.82 N047D 115.797 1.24 0.796 0.89 N047W 104.703 0.00 m_—3.728 4.10 A048N 114.954 5.59 3.778 1.96 T049R 4 5.81 5363 4.87 G050D 93.824 7.85 8.742 8.39 G050M 157.686 8.99 12.115 16.85 G052N 96.148 15.98 7.748 11.04 G052T 116.407 21.23 32.310 37.83 G052S 98.513 23.49 28.833 28.31 V058C 92.507 16.05 16.141 16.01 V058K 217.914 38.66 38655 84.24 V058R 96.905 56.55 65305 67.17 V058N 129.167 12.90 11.475 14.89 V058Y 102.981 36.23 41.728 58.96 V058Q 154.383 8.49 4.804 14.10 83.304 21.15 29.98 V058P V058H 200.264 10.88 13067 23.75 D068P 99.070 0.47 102222 85.58 S069T 138.609 10.82 8985 11.01 107013 3 0.77 2014 2.01 1070v 170.462 13.97 10885 14.90 V073Q 121.337 6.51 8.186 8.77 V073R 137.931 2.50 7338 7.35 T074E 1 17.22 16172 16.33 T074M 115.290 12.04 10-765 11.16 T074N 91.870 10.96 6811 10.71 T074P 108.323 12.24 10-008 16.64 T074R 80.681 7.44 2158 2.80 T074V 115.093 7.40 5.479 6.25 V075M 134.460 0.24 2.120 2.58 K082L 114.758 20.79 10-721 27.00 K082N 106.059 23.32 26541 25.24 1083V 140.151 29.88 28133 38.63 1083Q 112.163 27.02 13881 26.21 1083s 104.637 26.70 26667 25.43 1083G 106.239 22.54 32-208 24.60 S084E 124.762 6.27 6833 7.75 S084F 83.291 2.55 0.000 0.00 S084N 2 18.27 22-092 28.97 S084R 119.873 10.92 4977 10.11 Q086A 136.516 14.24 9-728 15.19 Q086H 102.612 7.14 5-015 6.50 WO 2013/102144 PCT/US2012/072182 TABLE 12: Percent (%) Activi du licate 1 dulicateZ % activity % activity % activity % activity % activity % activity at 37 °C + m- 37 °C + m- at 37 °C + m- 37 °C + m- 37 °C/4 °C cresol/37 cres01/4 °C 37 °C/4 °C cresol/37 cresol/4 °C °C °C Q086K 99.213 25.40 31.944 20.91 Q086S 100.435 6.81 11.215 11.58 Q086T 93.837 10.24 8.900 15.97 D087G 81.742 1.51 6.190 5.61 D087L 106.039 14.76 12938 13.13 D087M 110.964 7.61 16438 14.41 D087S 1 8.15 6.445 9.01 D087V 114.107 9.14 15.922 13.86 D090E 92.910 14.26 6.221 10.03 D090N 111.060 12.14 10.596 10.45 K093Q 91.008 5.82 6.646 6.34 K093R 103.617 11.70 16.362 16.25 K094D 86.544 6.52 9.897 10.11 K094R 125.373 8.96 9.905 10.77 T097C 165.152 8.07 17.228 14.08 T097D 4 8.55 10.994 12.92 T097E 127.190 15.57 16.143 18.58 T097L 118.465 23.10 24.174 25.04 N104R 114.673 9.70 8530 10.10 A120H 94.107 8.28 6.903 7.80 D127R 56.439 70.47 34.171 20.06 V1281 113.654 10.97 14.819 15.21 N131M 177.000 1.86 2.811 2.16 N131R 94.253 21.30 19376 18.59 N131V 137.681 10.22 10.907 11.44 R132L 98.578 10.34 14.498 13.29 Q138L 107.831 25.45 22.814 20.90 Q140K 176.600 10.93 12.522 13.75 N141R 103.411 4.35 2292 2.65 N141S 8 4.66 5.529 6.06 N141W 130.644 5.19 6.391 6.70 V142D 114.185 4.39 2.098 3.06 V142G 117.686 13.21 13.510 12.19 V142K 109.485 14.77 15.621 24.15 V142N 155.556 15.33 14.771 15.34 V142P 166.998 13.91 15.397 14.99 V142Q 149.666 8.90 9.830 9.83 V142R 149.441 12.38 12.272 12.72 v142s 170.778 8.73 16.900 19.78 V142T 223.936 11.48 11.709 14.48 Q143G 143.600 13.88 16.096 15.91 Q143K 200.468 14.32 20747 28.30 L144R 136.247 10.71 10182 11.35 L144T 129.746 14.68 11961 13.03 WO 2013/102144 PCT/U82012/072182 TABLE 12: Percent (%) Activi du licate 1 teZ % activity % activity % activity % activity % ty % activity at 37 °C + m- 37 °C + m- at 37 °C + m- 37 °C + m- 37 °C/4 °C cresol/37 cresol/4 °C 37 °C/4 °C cresol/37 cresol/4 °C °C °C L146P 116.626 1.15 3429 3.96 T1478 142.175 3.93 2.605 3.39 T150N 140.724 6.27 6.725 7.86 T1508 107.327 6.40 6.087 8.64 E151A 103.310 12.11 11783 14.85 E151L 5 4.90 6.264 7.63 E1518 115.423 6.20 4.695 6.40 E151T 128.337 0.00 m_—0.000 0.00 E151V 111.531 7.31 7.420 7.39 E151W 158.415 1.15 0.895 0.85 K152T 149.169 5.57 3.558 4.87 K152W 122.313 2.47 2.868 3.84 E1588 133.038 0.00 m_—0.000 0.00 K162E 67.857 3.51 30.000 12.31 L165F 106.283 11.82 14.286 13.81 V166Q 155.975 13.35 10.953 12.92 V166T 183.384 12.69 13.056 17.87 E167D 136.745 10.01 3.784 6.15 1169L 140.177 13.19 15528 18.99 K170R 160.710 8.24 10075 9.79 G172A 167.554 7.51 7.207 9.64 K173R 106.771 9.80 7.489 10.06 L174G 114.130 12.38 13478 35.63 L174N 154.332 13.27 18907 23.86 L174T 124.819 13.06 6.098 8.83 N178K 166.871 5.27 8.021 8.27 N178R 199.596 4.08 3.943 5.72 H193Q 213.585 15.28 18326 25.31 K195T 126.161 22.48 15280 36.23 K195N 130.253 22.38 25.487 24.57 K196E 90.574 36.80 23.500 36.21 K196R 106.100 13.22 17.663 16.81 F204P 83.571 84.62 0 103.85 N205A 139.223 21.34 18.735 19.12 N205E 160.930 19.30 18.503 17.27 N205L 107.472 10.56 #DIV/O! 8.55 N205T 145.085 10.05 13.054 14.44 V2061 4 13.17 15.575 17.32 K209R 119.794 11.90 3.947 3.14 D212N 112.626 2.66 5.352 7.08 D2128 122.899 8.35 6.841 10.12 D213A 183.830 26.85 13.699 21.20 D213M 159.255 6.83 6940 6.83 8215H 109.069 10.04 5.758 4.55 WO 2013/102144 PCT/US2012/072182 —314— TABLE 12: Percent (%) Activi du licate 1 du licate 2 % activity % activity % activity % ty % activity % activity at 37 °C + m- 37 °C + m- at 37 °C + m- 37 °C + m- 37 °C/4 °C cresol/37 cres01/4 °C 37 °C/4 °C cresol/37 cresol/4 °C °C °C S215M 174.883 4.20 8957 6.71 N219I 254.438 8.84 11-264 32.80 E220V 131.985 7.43 5909 6.71 T222G 153.033 0.61 0793 0.84 T232F 132.839 12.43 195% 12.32 Q233G 280.488 0.00 IM_— 0000 0.00 Q234M 95.605 22.31 20-283 16.38 S235A 129.818 11.06 120% 14.54 v237c 138.042 0.00 IM_— 0000 0.00 V237H 122.112 12.43 7407 10.76 V237T 167.105 21.26 21-457 27.04 A238E 94.878 8.17 6682 9.50 A238H 59.585 26.09 8-345 17.08 T240A 141.283 9.14 9063 13.11 T240Q 162.763 14.76 13-776 16.67 R248A 7 1.05 2408 3.00 E249V 142.752 15.29 16-462 18.28 P257G 125.220 0.78 0677 0.76 K260M 116.690 8.58 7273 7.08 S261A 57.547 67.52 54-021 46.55 S261K 161.931 16.05 22-820 26.51 S261N 142.901 10.46 13-403 4.76 A267T 196.154 35.29 38-679 43.16 F273H 122.647 6.00 5973 7.11 F273Y 119.713 7.78 9634 9.90 Q276H 74.908 8.93 W—10-065 10.71 Q276M 98.323 5.64 0000 0.00 Q276R 121.431 10.93 8-778 13.18 Q276S 110.643 9.95 8-745 12.13 V277A 140.765 6.97 5167 6.70 V277E 175.779 3.75 m_—5222 10.21 V277H 129.434 3.16 7014 9.66 V277K 1 13.21 12-029 44.96 V277M 137.138 15.05 14-851 16.65 V277N 89.645 7.29 6762 18.49 V277Q 119.930 5.70 7-772 9.03 V277R 96.071 15.57 9-801 16.81 v277s 66.260 7.65 4-731 6.86 V277T 101.010 7.99 7-788 11.16 L278E 75.408 5.11 7-214 7.23 L278G 122.274 6.50 7887 8.21 K279H 138.964 14.99 20-090 24.75 V287T 145.345 16.49 12-019 14.99 T289S 104.598 0.98 0699 0.69 WO 2013/102144 PCT/US2012/072182 TABLE 12: Percent (%) Activi du licate 1 dulicateZ % activity % activity % activity % activity % ty % activity at 37 °C + m- 37 °C + m- at 37 °C + m- 37 °C + m- 37 °C/4 °C cresol/37 cresol/4 °C 37 °C/4 °C cresol/37 cresol/4 °C °C °C G291 S 184.581 12.17 4156 4.97 G291V 112.807 19.87 12.609 19.05 E292C 127.307 8.07 8.905 9.01 E292F 137.930 6.17 5.840 7.73 E292H 170.153 8.73 11775 13.60 E292R 112.278 12.61 11.983 15.56 E292V 163.075 13.28 11.847 15.79 T293A 128.197 3.38 4.248 2.44 A298G 2 8.77 9.322 8.03 L307G 117.857 0.00 m-—0.000 0.00 S308D 127.652 4.15 2.907 3.08 S308K 126.882 1.33 0.000 0.00 S308N 170.413 5.67 m-—5.907 8.22 I309E 7 16.25 14.414 18.73 I309G 102.601 7.37 6.458 7.37 I309L 153.681 9.58 10.905 11.66 I309M 123.425 8.02 m—7.065 9.66 I309N 111.901 6.98 6.470 6.30 I309S 169.951 4.11 0862 4.75 I309T 97.936 7.63 5.542 8.25 I309V 113.138 1.50 3.470 4.80 M310G 167.656 11.44 12916 14.30 M310Q 107.237 27.81 28-254 30.04 M313G 138.095 9.77 10141 11.08 M313H 271.914 3.71 3.886 7.66 M313K 118.882 0.86 0.555 0.59 M313P 103.654 4.98 4.516 6.00 M313R 157.272 4.62 8296 2.72 M313T 4 7.04 7007 7.00 M313Y 120.038 7.52 6.846 7.05 K314S 141.924 9.67 9.066 11.98 K314Y 243.011 5.75 10.989 15.27 S315A 91.372 16.51 9.973 13.68 S315H 151.244 12.06 10.867 11.44 S315Y 170.968 30.61 39.503 22.84 L317A 123.510 6.97 8.395 11.14 L317I 7 12.72 10.670 11.81 L317K 96.199 3.45 3.534 4.74 L317N 127.382 12.02 14.528 17.61 L317R 238.501 3.87 5.673 5.64 L317S 90.929 15.54 6.423 5.51 L317T 145.964 6.96 1.087 1.68 L317W 163.704 11.92 10270 15.16 L318D 105.543 17.43 16684 16.35 WO 2013/102144 PCT/US2012/072182 TABLE 12: Percent (%) Activi du licate 1 dulicateZ % activity % activity % activity % activity % activity % ty at 37 °C + m- 37 °C + m- at 37 °C + m- 37 °C + m- 37 °C/4 °C cresol/37 cres01/4 °C 37 °C/4 °C cresol/37 cresol/4 °C °C °C L318H 99.907 4.29 7363 9.18 L318R 160.469 5.63 6.210 7.51 N321R 164.842 9.53 8.613 9.66 N321S 102.489 8.29 4534 4.93 E324N 104.618 7.72 9124 11.98 T325E 124.837 14.44 10.577 11.26 N328G 197.098 4.15 7.233 7.94 N328Y 180.981 10.30 10.500 10.50 T335S 107.956 11.57 6.288 7.88 Q347A 101.395 10.89 11.001 10.58 Q347G 222.459 8.37 9.013 18.66 Q349M 99.531 11.98 12.330 13.32 Q349R 7 11.76 13.211 13.81 v351s 130.819 0.00 m_—0.000 0.00 1353v 132.334 10.45 11.902 16.43 N356H 100.000 8.54 3.912 5.10 N356S 51.908 0.00 m_—2.516 3.16 S359E 135.589 10.77 9.354 12.64 S359H 110.422 0.00 m_—0000 0.00 P367A 167.030 12.94 13.153 16.75 P367G 115.683 0.00 m_—0.000 0.00 P367K 125.884 5.06 10.136 6.78 P367S 74.263 14.39 16.433 14.52 D368A 121.623 1.45 2111 1.72 D368E 166.628 9.18 11.462 11.23 D368L 108.977 0.00 m_—0.969 1.06 D368M 119.744 2.72 2.536 2.63 D368R 164.735 10.16 11.805 13.95 D368T 107.122 2.87 3366 4.26 N369R 161.693 6.39 6.182 4.60 A371F 180.217 6.19 5.578 4.26 A371H 5 1.81 1.697 1.52 A371H 3 0.00 m_—8.610 8.23 A371K 136.514 12.84 12.454 14.24 A371L 695.108 1.51 2.215 2.37 A371L 104.327 0.00 m_—1.2os 0.73 A371R #VALUE! ! ! 14.06 A371R 121.162 0.00 m_—2.587 2.53 A371S 147.672 8.38 16.938 22.28 L374P 392.038 5.77 7.365 9.06 E375A 88.836 0.00 m_—2.050 2.76 E375G 126.880 10.32 14673 20.40 E375R 163.180 13.15 19727 22.97 K376D 113.100 12.36 5.049 8.33 WO 2013/102144 PCT/US2012/072182 TABLE 12: Percent (%) Activi du licate 1 teZ % activity % activity % activity % activity % activity % activity at 37 °C + m- 37 °C + m- at 37 °C + m- 37 °C + m- 37 °C/4 °C cresol/37 cres01/4 °C 37 °C/4 °C cresol/37 cresol/4 °C °C °C K376E 100.000 13.55 10.394 15.90 K376Q 125.172 12.75 12.057 10.85 K376R 81.687 31.63 10.372 20.65 K376T 121.133 14.91 5.639 6.39 K376V 124.221 3.19 2547 3.02 K376Y 102.812 9.24 12.985 12.48 G377D 1 15.72 10.550 13.96 G377E 130.445 8.04 7.401 9.50 G377H 146.855 8.34 10.117 10.61 G377K 185.922 4.42 4.989 5.97 G377R 119.708 5.87 7.137 6.76 G377S 108.609 6.91 7.877 7.96 G377T 112.557 17.14 18.279 19.93 F380W 147.077 9.97 9.253 9.70 T381S 135.827 13.41 10.315 11.61 R3831 527.820 6.33 7.522 7.40 R383S 132.894 10.50 10.545 12.60 K385A 126.096 4.64 0.000 0.00 K385Q 137.629 9.03 7512 9.38 K385V 1 5.12 2.979 2.40 E389A 306.767 2.13 1.824 4.10 E389G 113.253 2.13 0.000 0.00 E389L 143.219 14.24 12609 14.15 E389Q 135.807 11.88 12-767 12.73 E389S 165.620 0.00 m_—0.285 0.27 E392A 112.465 7.27 6.376 9.93 E392F 115.619 3.90 3.905 5.61 E392Q 112.993 10.53 16.705 15.67 E392R 129.528 3.69 2947 3.64 E392V 124.365 7.73 6.404 9.91 Q393F 139.966 10.59 10.171 10.34 Q393M 6 1.60 3.086 2.68 S395A 208.246 12.98 12.395 13.97 S395H 159.975 12.55 10.452 11.85 E396A 131.894 8.42 9.777 12.58 E396H 210.364 9.19 3.216 4.14 E396Q 122.977 10.06 10.263 9.85 E396S 156.267 2.77 2.022 2.26 Y399T 130.536 0.00 m-—0.050 0.06 Y399V 2 15.98 17.801 20.65 Y399W 122.500 13.76 11.973 12.37 S401A 122.003 13.90 13024 12.93 S401E 125.223 16.30 15-000 19.30 S404A 9 0.00 m_—1.102 1.16 WO 2013/102144 PCT/US2012/072182 TABLE 12: Percent (%) Activi du licate 1 dulicateZ % ty % activity % activity % activity % ty % activity at 37 °C + m- 37 °C + m- at 37 °C + m- 37 °C + m- 37 °C/4 °C /37 cresol/4 °C 37 °C/4 °C cresol/37 cresol/4 °C °C °C L406F 122.805 0.00 m_—0.000 0.00 L406N 152.836 6.36 6.705 8.81 S407A 141.351 11.33 16.836 18.58 S407D 241.053 11.29 10120 9.93 S407P 143.308 6.85 11088 13.52 A412Q 146.177 9.54 8.511 8.46 A412R 140.070 8.92 9.390 11.61 A412V 146.804 4.99 5.383 5.48 D416L 120.820 17.64 15.340 19.58 D418R 117.749 7.59 10.721 12.03 A419H 241.224 8.82 5.999 11.29 A419K 191.165 10.42 1.523 30.81 D421A 102.111 12.49 4.510 13.60 D421H 333.471 10.18 86.552 58.55 D421K 0 7.62 13.562 13.88 D421N 6 14.96 16.449 16.47 D421Q 104.370 10.72 12.400 17.81 D421R 138.783 8.85 9.778 13.49 D421 s 142.171 11.00 8564 14.23 A425G 74.810 10.61 11.137 13.47 G427Q 133.135 2.31 8.618 8.47 G427T 125.113 4.81 3.956 4.71 V428L 137.044 1.81 0.990 1.08 D431E 70.178 26.32 20739 19.73 D431H 186.490 7.32 9.941 9.45 D431K 240.835 11.61 20.207 13.80 D431L 129.149 10.49 11.740 13.99 D431N 138.404 9.79 9246 11.60 D431Q 232.960 10.83 10716 11.73 D431S 78.069 7.52 9.135 8.11 F433A 147.286 9.78 12.798 12.73 F433H 140.196 13.48 16.888 14.85 F4331 108.569 11.30 16.616 14.45 F433K 91.159 11.12 3.608 12.35 F433R 128.958 10.53 9.565 12.75 F433T 161.799 13.66 19.229 25.96 F433V 1412.071 1.61 17.307 19.39 F433W 149.049 10.46 7.530 8.55 P4371 148.880 2.39 1.782 1.91 M438A 106.463 10.07 10.194 13.83 M438D 105.370 10.16 2.590 2.93 M438E 115.061 8.00 9.120 10.38 M438L 65.794 10.06 6526 14.03 M438N 130.428 8.06 11.889 11.97 WO 2013/102144 PCT/US2012/072182 TABLE 12: Percent (%) Activi du licate 1 dulicateZ % activity % activity % activity % ty % activity % activity at 37 °C + m- 37 °C + m- at 37 °C+m- 37 °C + m- 37 °C/4 °C cresol/37 cres01/4 °C 37 °C/4 °C cresol/37 cresol/4 °C °C °C M438T 104.058 13.39 12.160 12.61 E439A 137.279 11.63 14.073 13.45 E439A 154.140 4.72 7.415 10.92 E439C 193.243 14.69 15734 17.58 E439K 124.464 13.28 10552 11.05 E439P 0 15.59 14.998 13.12 E439Q 101.589 10.67 10.648 13.56 E439T 110.891 14.36 11.322 13.92 T440D 118.877 11.52 18.426 14.65 T440H 142.296 4.46 7.553 9.89 T440M 84.722 8.83 12.774 11.10 T440P 111.931 13.54 17.272 15.75 T440S 100.436 11.17 9.810 12.87 E441F 129.315 11.25 11.410 12.65 E442G 111.216 10.24 10.965 10.99 P443E 94.377 5.14 6-789 8.87 P443F 146.612 11.22 12.322 12.07 P443G 239.171 8.56 16.385 25.88 Q444E 81.997 8.54 9561 15.38 Q444H 1 8.46 10.892 13.03 Q444V 129.822 13.49 10.995 13.48 1445M 85.090 17.25 15.393 15.57 1445N 106.430 13.89 12945 11.31 I445W 117.213 11.70 10983 10.99 Y447E 99.579 16.55 12.849 14.00 Y447G 143.704 13.77 11.563 11.98 Y447P 139.152 13.78 12.282 13.23 94.998 5.23 8.456 8.19 105.798 4.48 5.246 5.67 100.000 3.33 3.759 4.59 94.762 19.07 16.529 18.11 142.024 4.48 5.595 7.33 45.115 20.77 11.035 7.51 53.324 21.95 9.960 7.40 positive 59.581 25.24 16.231 12.31 l 91.844 19.05 13.977 11.23 (OHO) 93.828 13.47 19.454 18.80 57.773 17.04 17.573 14.68 100.000 18.56 16.239 24.07 74.325 18.29 9.286 5.68 98.132 8.48 10.006 8.77 93.817 9.62 9.745 9.96 96.922 8.56 9.064 7.98 96.648 9.91 9.938 8.63 WO 2013/102144 PCT/US2012/072182 n/a (not available; e.g., beyond detection limit) 2. Summary of Results for F204P For mutant F204P, the results above of tested supernatant from transient transfection of CHO-S cells ted in the presence of ol in a bHA enzymatic activity assay showed that the F204P mutant protein was highly resistant to 0.4% m-cresol treatment. The results showed that the activity that remained after 4 hours incubation with 0.4% m-cresol at 37°C was approximately equal to the activity ed when the enzyme was incubated at either 4 0C or at 37 0C in the e of m-cresol. The ve control (WT PH20 — OHO) showed a reduction in activity of 75% and 83% on the day of the assay (as assayed from two different OHO transfections). This demonstrated that the F204P phenophile was able to retain 60% to 90% or greater of its activity above the residual activity of the wildtype PH20 control enzyme.

In order to confirm the ity of F204P upon m-cresol treatment or exposure to sed temperature, a second transfection of F204P was performed in duplicate using CHO-S cells, and clariﬁed supernatant was again tested for its stability at 4 0C, at 37 0C for 4 hours with 0.4% m-cresol and at 37 0C for 4 hours without 0.4% m-cresol. The results confirmed that the F204P mutant enzyme retained a high amount of hyaluronidase activity after the 4 hour incubation in m-cresol at 37 OC. The results were similar to the results seen in the ﬁrst screening of the mutant, with F204P retaining anywhere from 57% to greater than 90% of its activity above the residual activity of the wildtype PH20 control enzyme after the 4 hour incubation.

A summary of the enzyme activity of F204P compared to the pe control is set forth in Table 13.

Table 13: Summar of En me Activi Remaining Activity Remaining Activity after 4h incubation after 4h incubation Transfection (37 °C + m-cre/ 37 (37 °C + m-cre/ # °C) Net % se 4°C) Net % Increase ---in Activity Over WT in Activity Over F204P (0H0) WT (37 °C) F204P (0H0) WT (4 °C) 73.6% 16.4% 57.2% 86.0% 25.3% 60.7% 122.3% 25.2% 97.1% 109.7% 16.6% 93.1% WO 2013/102144 2012/072182 EXAMPLE 6 LARGE SCALE EXPRESSION AND PURIFICATION OF PH20 HIT VARIANT 1. Expression and Puriﬁcation HZZ4-PH20-IRES-SEAP plasmid DNA ning cDNA encoding one of the variant PH20 was transfected into monolayer CHO-S cells as generally described in Example 2. CHO-S cells were cultured in shaker ﬂasks using CD-CHO media supplemented with GlutaMAX (8 mM). On the day of transfection, 15 ﬂasks were prepared of approximately 300 mL volume containing the CHO-S cells at an approximate density of 1.0 x 106 cells/mL.

Each 300 mL ﬂask was transfected using 375 ug of plasmid DNA encoding the F204P mutant combined with 375 uL of yle MAX ection reagent. The transfected plasmid DNA had a sequence of tides set forth in SEQ ID NO:4 containing a codon change of TTC to CCT at tide ons 1733-1735, thereby encoding the F204P mutant. The transfected cells were then allowed to remain in culture for 96 hours, whereupon the cells and media were harvested and pooled. The cells were ed by centrifugation (4000 x g, 20’), and the supernatant retained for puriﬁcation of the F204P protein (approximately 4.5 liters).

The crude supernatant was concentrated 10x using a 30 kDa Tangential ﬂow ﬁlter (TFF) system (Millipore Pellicon XL, Bimax 30, 200 mL void volume; 50 cm2 ﬁlter surface area) until the volume was approximately 450 mL. The permeate was saved for assay to detect ﬂow through of the F204P protein. A free-ﬂow buffer exchange for the retentate was then performed using 4 liters of buffer (10 mM NaPO4; 25 mM NaCl, pH 7.2). The volume of the retentate was reduced again to imately 200 mL, and then the remaining permeate in the system was purged (void volume ~200 mL) and the system was ﬂushed using approximately 50 mL of buffer to yield a ﬁnal concentrated product of approximately 450 mL.

An anti-rHuPH20 afﬁnity column was prepared by coupling antigen afﬁnity puriﬁed Rabbit anti-rHuPH20 IgG to CNBr—activated Sepharose 4 Fast Flow (GEHealth catalog No. 1701). Brieﬂy, 0.7 g of pre-activated Sepharose 4 powder was suspended in 1 mM HCl in a 10 mL glass column for 30 minutes to allow the powder to swell. The solution was drained from the column and washed with 15 gel volumes (about 30 mL) of cold 1 mM HCl by gravity. The column was washed with 5 gel volumens of ng buffer (0.1M NaHC03, 0.5M NaCl at pH 8.3). Next, 5 mg of Rabbit anti-rHuPH20 IgG at > 1.0 mg/mL in coupling buffer was added to the column at a protein/gel ratio of 2-3 mg/mL gel. The column was rotated head to head at 4 OC ght. The ﬂow-through was collected for coupling efﬁciency determination. The gel was washed with 2 gel volumes of coupling buffer, and then washed and resuspended in 1 M ethanolaminine pH 9.5 for 2 hours at room temperature WO 02144 2012/072182 to block unused activated sites. The gel was washed 6 times with 5 gel volumes per wash alternating coupling buffer and 0.1 NaAc, 0.5M NaCl, pH 4.5. The gel was then washed with gel s of TBS (20 mM Tris-HCl, 0.15 M NaCl, pH 7.5). The coupling efﬁciency was determined (l-post-coupling protein concentration/pre-coupling protein concentration x 100%). The antibody coupled gel was stored in TBS with 0.02% NaN3 at 4 OC.

The concentrated supernatant product was subsequently loaded onto a anti-rHuPH20 afﬁnity column at an approximate rate of 5 mL/min. The n was performed according to standard procedure using a GETM AKTA FPLC puriﬁcation system (GE care, Product No. 0-26), whereby the protein was eluted via a low pH glycine wash (0.1 M glycine- HCl, pH 2.5) in 1 mL fractions. Each fraction was immediately neutralized by the addition of 100 ML of 1M Tris, pH 7.5.

The eluted protein was assayed by resolving n bands on a 4-20% SDS-PAGE gradient Tris-glycine gel. e®Plus2 Pre-stained MW standards (Life Teechnologies; Catalog No. ) were used as molecular weight standards, and 50 ng rHuPH20 (as described in Example 1) was used as a positive control. The polyacrylamide gel was stained with Instant Blue to show total n from each fraction. To conﬁrm the bands on the gel are PH20, the gel was tranferred to a PVDF membrane (Invitrogen), which was subjected to Western Blot using a Rabbit anti-PH20 primary antibody generated by immunizing rabbits with rHuPH20 and an HRP—Goat anti-rabbit secondary antibody (Calbiochem, Cat. No.

DC03L).

Then, the ﬂow-through from the initial loading of the afﬁnity column was re-loaded onto the column twice due to the low capacity of the afﬁnity column. All fractions containing the n were then combined resulting in a total volume that was approximately 13 mL.

This product was then dialyzed overnight versus four liters of buffer (10 mM NaPO4, 140 mM NaCl, pH 7.2) using a Slide-A-Lyzer Dialysis Cassette G2 (20,000 MWCO) with a 15 mL capacity. The buffer was then changed and the product dialyzed against a second fresh four liters of the same buffer. The F204P protein was then concentrated using an Amicon Ultra Centrifugation column (Millipore; 10,000 MWCO) to a ﬁnal volume of approximately 450 uL (10 minutes at 4000 xg). 2. Characterization of Protein The purﬁed protein was characterized for its n concentration, activity, and purity.

To determine the protein concentration of the puriﬁed protein, a quantiﬁcation ELISA was performed as bed in Example 7. Also, hyaluronidase activity was determined as described in Example 3. The protein concentration after centrifugation was WO 02144 PCT/US2012/072182 estimated to be approximately 400 ug/mL. The puriﬁed protein also was resolved on a 4- % SDS-PAGE nt Tris-glycine gel, which was then stained with Instant Blue. The staining results demonstrated that the protein was essentially a single molecular weight protein of approximately 63 kDa, similar to the rHuPH2O control. No appreciable degradative products were detected by this method. Approximate yields of the protein at various timepoints and activity during the puriﬁcation are described in Table 14.

TABLE 14: Characterization of Puriﬁcation Ste n s —_Activit Assa Quant ELISA Assa — Total Protein Total Speciﬁc Volume Activity Puriﬁcation Step ty Conc. Protein Activity (mL) (U/mL) (U) ( -/mL) (-) (U/ -) Supernatant 4500 2.66 11 700 0 046 207 Conc. after TFF & 178 Buffer ge Pooled Fractions -7 after AC, O.45 11’741 96 Dialysis & Conc. — A280 The purity of the d protein was determined by Reverse Phase HPLC (RP- HPLC). The elution time from the reverse phase column was essentially identical as that observed with the recombinant human hyaluronidase (HUB), and es a basis for crude tion of the purity of the sample at approximately 80-90%.

EXAMPLE 7 QUANTIFICATION USING ELISA The ﬁcation of PH2O or variants were performed using an ELISA that captures the protein using a monoclonal anti-rHuPH2O e antibody. Speciﬁcally, one day prior to ming the ELISA, 96-well 4HBX plates were coated with capture antibody (Protein G puriﬁed rabbit polyclonal anti-PH2O antibody generated by immunizing rabbits with rHuPH20; 1 mg/mL stock) at l ug/mL in 100 mM phosphate (pH 7.2) in a total volume of 100 uL per well. The plates were stored at 4 oC overnight. On the next day, the plates were washed 5x with leBS at 300 uL/well with a plate washer. After each wash, the plated were patted dry on paper towels. Then, the plates were blocked with 200 uL PBS containing Tween 20 (leBST) per well at room temperature for 1 hour.

The standards and samples were added to the plate. For generation of the standard, a 1 mg/mL stock of rHuPH2O (Example 1) was freshly d to 50 ug/mL in HEPES pH 7.4 assay buffer as an intermediate stock. Then, for the standards, the 50 ug/mL stock was diluted in duplicates into 360 uL of 0.5xPBST at 300 ng/mL for the ﬁrst standard (ﬁrst row).

WO 2013/102144 PCT/US2012/072182 —324— For the other standard rows, 240 uL 0.5XPBST were added to each well, and 1:3 serial dilutions made. For the transfected atant samples, 360 uL per well was added in duplicate into the ﬁrst row, and each were also serially diluted as described above into 0.5x PBST. For puriﬁed samples, 100 uL was added per well. The plates were incubated for 2 hours at room temperature. After incubation, the plates were washed 5X with 1XPBST at 300 l using a plate washer. After each wash, the plates were patted dry on paper towels.

An HRP-conjugated anti-PH20 antibody was prepared for detection using an HRP conjugation kit (Pierce, Thermo-Fisher; Catlog No. 31489). 1 mg of a Protein G d rabbit polyclonal antibody generated by immunizing rabbits with rHuPH20 was d in 1 mL PBS and 1 mL of 2 X carbonate kit buffer. Next, 100 uL of peroxidase were added to 1 mL of the above antibody solution and incubated at room temperature for 1 hour. Then, 10 uL NaBH4 stock was added in a fume hood, and the sample incubated at room temperature for 20 minutes. To quench the reaction, 20 uL of ethanolamine was added and incubated at room temperature for 15 minutes. To this, 1/25 volume 5% human serum albumin (0.1 mL syringe) was added to give a 2 mg/mL albumin stock reaction. The pH was adjusted to about 7.9 by addition of 250 uL of 1 M Tris pH 7.4. The concentration of the stock was 400 ug/mL. The stock solution was further diluted 1/10 in PBS Tween20 (0.05%) containing 0.5% human serum albumin and preservatives, and then was sterile ﬁltered. The stock was stored at 4 0C or was frozen at -20 OC.

Antibodies were detecting using the HRP-conjugated anti-PH20 antibody that was diluted 1000X into 0.5x PBST. 100 uL of the diluted antibody was added to all wells of the plate and the plate incubated for a further 2 hours at room temperature. After incubation, the plates were washed 5X with 1XPBST at 300 uL/well using a plate washer. After each wash, the plates were patted dry on paper towels. Then, 100 "L of TMB substrate were added to each well and the reaction was stopped after 5-10 minutes by adding 100 uL of stop solution per well. The plate was read at OD450.

EXAMPLE 8 DETERMINATION OF ENZYMATIC ACTIVITY OF PH20 Enzymatic activity of PH20 in samples such as cell cultures, puriﬁcation ons and d ons was determined using a turbidimetric assay, which is based on the ion of an ble precipitate when hyaluronic acid binds with cetylpyridinium chloride (CPC). The activity is measured by incubating PH20 with hyaluronan for a set period of time (30 minutes) and then precipitating the undigested hyaluronan with the addition of WO 02144 PCT/US2012/072182 CDC. The turbidity of the resulting sample is measured at 640 nm. The decrease in turbidity ing from enzyme activity on the hyaluronan ate is a e of the PH20 enzymatic actiVity. The method is run using a ation curve generated with dilutions of a PH20 assay working reference rd (rHuPH20 standard generated as described in Example 1), and sample actiVity measurements are made relative to this ation curve.

Dilutions of the sample and standards were prepared in Enzyme Diluent Solution (70 mM NaCl, 0.1% human serum albumin [HSA], 0.67 g/L gelatin hydrolysate in 25 mM PIPES buffer, pH 5.5). The samples were diluted to an appropriate concentration. Hyaluronic acid (HA, average MW of 20 — 50 kDa) from Lifecore Biomedical (Chaska, MN) also was prepared at 1 mg/mL in substrate solution that contains 25 mM PIPES, 70 mM NaCl at pH .5. Equal amounts of the above two solutions were mixed to prepare a 1 mL reaction mixture and incubated at 37 0C for 30 min. The reaction was stopped by on of 4 mL of Cetylpyridinium de Solution (CPC, 5.0 mg/mL). After brief vortexing, the turbidity of the sample mixture was read at 640 nm and the actiVity was determined by ﬁtting against a standard curve. Speciﬁc activity (Units/mg) was ated by dividing the enzyme ty (U/mL) by the protein concentration (mg/mL).

EXAMPLE 9 STABILITY OF F204P-PH20 VARIANT IN VATIVE To conﬁrm the screening results, an amount estimated to be about 450 U/mL of the puriﬁed F204P protein as described in Example 6 was formulated in 10 mM sodium phosphate, pH 6.5, 120 mM NaCl, 10 mM methionine, 0.01% Pluronic F-68, 0.1% phenol and 0.15% m—cresol. A test article that also contained an amount estimated to be about 450 U/mL wild type rHuPH20 (generated as described in Example 1) in the same formulation was also prepared to serve as a control. Each formulation solution was aliquotted in 0.5 mL and ﬁlled into 2 mL USP Type I borosilicate glass with a chlorobutyl rubber stopper and an aluminum seal. The Vials were incubated at 5 0C, 30 0C or 37 °C. Samples were withdrawn from the incubator at various times and enzymatic activity was measured as described in Example 8.

The results of the enzymatic actiVity measurements are shown in Table 15. As can be seen, the rHuPH20 wild type control showed a rapid decrease in actiVity when incubated at 37 0C in the presence of phenolic preservatives. In contrast, the F204P mutant showed no signiﬁcant loss in actiVity throughout the study. The results also show that actiVity of PH20 is ed after incubation for up to 4 weeks at 5 oC and 30 oC compared to the ty of the rHuPH20 wildtype control not containing the mutation. These results conﬁrm that F204P WO 2013/102144 PCT/US2012/072182 tolerates EPB level of preservative (0.1% phenol and 0.15% m—cresol) and is stable at 37 0C for at least up to 6 days at at 5 oC and 30 0C for greater than one month.

TABLE 15: Stability of rHuPH20 wildtype and F204P mutant incubated at with u reservative PH20 relative PH20 relative PH20 ve activity ID activit (%) at 5 °C activi (%) at 30 °C (%) at 37 °C mm" F204P 100 91.8 84.1 100 96.6 105 91.1 95.9 wild econtr01100 81.9 66.7 61.7 60.5 48.6 29.6 15.2 EXAMPLE 10 STABILITY OF F204P-PH20 VARIANT IN INSULIN ULATION The PH20 variant F204P was tested for its stability in a coformulation containing an insulin analog (insulin aspart or insulin lispro).

In the tested coformulations, the insulin lispro was a commercial product (Insulin Lispro: Eli Lilly Humalog® (insulin Lispro) 100 U/mL, Lot AS72364).

In the tested coformulations, the insulin aspart analog was a reprocessed aspart prepared by pooling 12 vials (10 mL each) of a commercial product (Insulin Aspart: Novo Nordisk, NovoRapid® (insulin Aspart), Lot XS60195), which was then concentrated using an Amicon el-10 K column concentrator until the ﬁnal tration was about 5 times the original concentration. The insulin analog was precipitated by addition of 1 M sodium acetate, pH 5.3 and 30 mM zinc chloride (Zl’lClg, EMD, Cat No. -1) at 1/10 ofthe protein solution volume. The solution was placed on ice for 30 minutes followed by fugation at 5600 rpm for 20 minutes in an Avanti J-E Centrifuge with JS-5.3 swinging bucket rotor (Beckman Coulter). The supernatant was decanted and the pellet was resuspended and washed with 20 mM sodium acetate, 2 mM zinc chloride, pH 5.5 solution.

The resuspended on was centrifuged as described above. The washing step was repeated a total of 5 times. A ﬁnal wash was performed with 20 mM sodium acetate, pH 5 .5 to remove all traces of zinc chloride. The resulting protein paste was ved with water containing 20 mM HCl. After complete dissolution, 250 mM Tris, pH 10.7 was added to a ﬁnal Tris concentration of 20 mM. The pH of the resulting solution was adjusted such that the insulin analog was formulated as bed below and the protein concentration was adjusted to about 15-20 mg/mL. An insulin analog ed in this way typically had a yield of about 90%, with a residual preservative tration at less than 100 times the starting material.

WO 2013/102144 PCT/US2012/072182 Brieﬂy, three (3) ations were generated each containing 600 Units (U) of PH20-F204P or wildtype rHuPH20 ated as described in Example 1) for a total of 6 formulations as set forth in Table 16: TABLE 16: Summar of Insulin Formulations Tonic1ty Buffer Anti-OX Metal Surfactant Preservatives API modiﬁer Tris/H Methioni Glyceri PH20 Analog NaCl Zn Cl ne n (mg/mL) 0. 315% 3.5 0.315% 3.5 0.010% 0.150% 3.5 0.010% 0.150% 3.5 0.010% 0.315% 3.5 0.010% 0.315% 3.5 Each formulation solution was dispensed in 0.5 mL aliquots into 2 mL USP Type I borosilicate glass vials with a chlorobutyl rubber stopper and an um seal. The vials were incubated at 5 0C, 30 OC and 37 °C. Samples were withdrawn from the incubator at scheduled time points for enzymatic actiVity measurements as described in Example 8.

The results of the enzymatic actiVity ements for samples incubated at 37 0C, 30 OC and 5 0C are shown in Tables 17-19, tively. At 37 0C, the enzymatic activity of samples containing wildtype rHuPH20 (F2, F4 and F6) were almost totally lost within two days of incubation. In contrast, after 6 days incubation at 37 OC, formulation F3 and F5, which contains PH20-F204P, lost only about 10% and 30%, respectively. The PH20-F204P formulated in commercial g (F1) lost most of its ty within 2 days at 37 oC most likely due to the lack ofNaCl in the formulation.

A similar trend for enzymatic activities of es incubated at 30 0C was noted between the PH20-F204P and rHuPH20. For formulations that contain an EPA preservative level, the differences between wild type and F204P were dramatic (Table 17; F1 and F5 vs.

F2 and F6). When the preservative concentration was reduced to an EPB level (F3 and F4), the F204P still outperformed wildtype rHuPH20, although there was slighly higher rHuPH20 stability compared to EPA conditions. In both EPA and EPB vative levels, PH20- F204P was able to in its actiVity up to 14 days at 30 oC when 100 mM ofNaCl was included in the formulation.

WO 2013/102144 PCT/US2012/072182 Table 17. Enzymatic activity of rHuPH20 wild type and F204P mutant incubated at 37 oC PH20 activity U/mL, (% of remaining activity) {1% Initial Activit F1.Humalog -- 583 (100%) 61 (10%) 15 (3%))0 10 (2%))0 F204P alog -- wt 439 (100%) 4 (1%) - - F3.Aspart -- 625 (100%))0 613 (98%))0 496 0 570 (91 A1)0 532 (85 A1)0 F2041> F4.Aspart + wt 566 (100%) 58 (10%) 24 (4%) 4 (1%) — "3%? " 657 (100%) 484 (74%) 462 (70%) 478 (73%) 360 (55%) F6.Aspart+ wt 596 (100%) —1 (0%) — — — Table 18. Enzymatic ty of rHuPH20 wild type and F204P mutant incubated at 30°C 11)"‘ Initial Activit "—— alog -- F204P 583 (100%) 345 (59%) 250 (43%) 111 (19%) F2.Humalog -- wt 439 (100%) 1 (0%) 16 (4%) —1 F3.Aspart -- F204P 625 (100%) 601(96%) 650(104%) 579 (93%) F4.Aspart -- wt 566 (100%) 428 (76%) 390 (69%) 277 (49%) F5.Aspart -- F204P 657 (100%) 632 (96%) 655 (100%) 561 (85%) F6.Aspart+ wt 596 (100%) 145 (24%) 65 (11%) 9 (1.5%) TABLE 19: En matic Activit at 5 oC PH20 t U/mL at 5 oC EXAMPLE 11 STABILITY OF V58R-PH20 IN INSULIN COFORMULATION A. Stability of V58R—PH20 The PH20 variant V58R was expressed in CHO-S cells as bed in Example 2 or Example 6. The transfected plasmid DNA had a sequence of nucleotides set forth in SEQ ID NO:4 containing a codon change of GTG to CGG at nucleotide ons 1295-1297, thereby encoding the V58R mutant. The V58R mutant was tested for its stability in a coformulation containing insulin aspart ( insulin aspart analog prepared as described in Example 10) and under EPA or EPB preservative levels. Brieﬂy, four (4) formulations were generated each WO 2013/102144 PCT/US2012/072182 containing 600 Units (U) of PH20-V58R or wildtype 0 (generated as described in Example 1) as set forth in Table 20. Formulations F1 and F2 represent the EPB preservative levels while formulations F3 and F4 represent the EPA preservative levels.

TABLE 20: Summar of Insulin Formulations API Glyceri PH20 Analog Z" n (U/mL) (mg/mL) 0.010% 0.100% 0.150% 3.5 0.010% 0.100% 0.150% 3.5 0.010% 0.315% 3.5 0.010% 0.315% 3.5 Each formulation on was dispensed in 0.5 mL aliquots into 2 mL USP Type 1 borosilicate glass vials with a chlorobutyl rubber stopper and an aluminum seal. The vials were incubated at 30 OC and 37 °C. Samples were withdrawn from the incubator at led time points for enzymatic activity measurements as described in e 8.

The results of the enzymatic actiVity measurements for samples incubated at 37 0C and 30 0C are shown in Table 21 and Table 22. At 37 0C, the enzymatic actiVity of samples ning wildtype rHuPH20 (F2 and F4) were almost totally lost within two days of incubation. In st, after 6 days tion at 37 OC, ations F1 (EPB) and F3 (EPA), containing V58R-PH20, lost only about 25% and 40% activity, respectively. At 0C, the enzymatic actiVity of samples containing wildtype rHuPH20 also was dramatically reduced in the presence of EPA or EPB preservatives levels within one month of incubation, although there was a slighlty less dramatic loss in actiVity in the presence of EPB preservative levels. In constrast, for V58R-PH20, there was no loss of enzymatic actiVity for either tested formulation up to 1 month.

Table 21. En matic activi of rHuPH20 wild t e and V58R mutant incubated at 37 °C Formulation PH20 activi U/mL Initial Activi —-E-m- F1.Aspart + V58R 1350 1099 1094 1006 F2.As. art + rHuPH20 wt———— F3.As . art + V58R 1189 F4.As. art+ rHuPH20 wt——"— WO 02144 PCT/US2012/072182 Table 22. Enzymatic activity of rHuPH20 wild type and V58R mutant incubated at °C PH20 activit U/mL Initial Activi F1.Asart+V58R 1350 1368 1208 F2.As . art + 0 wt F3.Aspart + V58R 1189 1228 1171 F4.Aspart+ rHuPH20 wt Comparison of Stability of F204P and V58R The PH20 variant V58R-PH20 was compared to F204P for its stability in a ulation containing insulin aspart (insulin aspart analog prepared as described in Example 10) and under EPA or EPB preservative levels. Brieﬂy, eight (8) formulations were generated as set forth in Table 23. Formulations F1-F4 represent the EPB preservative levels while formulations F5-F8 represent the EPA preservative levels. Formulations F3 and F4 and formulations F7 and F8 were identical and represent the wildtype l formulations ations used for the EPB or EPA studies, respectively.

TABLE 23: Summar of Insulin Formulations ID Buffer Metal Surfacta Preservatives nt 1er NaP Tris/ NaCl Methio Glyce Zn F68 Phen m- PH20 Analog 04 nine rin 01 Cresol U/mL mg/mL F1.Aspart 7.3 100 5 mM 0.010% 0.10 0.150 600 U.) LI} -- V5 8R mM 0% % F2 Aspart 7.3 100 5 mM 0.010% 0.10 0.150 600 U.) U} -- F204P mM 0% F3.Aspart 7.3 BL»go 100 5 mM 0.010% U.) U} mM rHuPH20 wt(1) F4.Aspart 7.3 30 100 5 mM 0.010% U.) LI} + B mM rHuPH20 wt(2) F5.Aspart 7.3 BUJBUJ 100 5 mM 0.010% 0.315 600 U.) U} -- V5 8R mM % F6 Aspart 7.3 100 5 mM 0.010% 0.315 600 U.) U} -- F204P mM % F7.Aspart 7.3 BL»go 100 5 mM 0.010% 0.315 600 U.) U} mM % rHuPH20 wt(1) art 7.3 30 100 5 mM 0.010% U.) U} + mM mM rHuPH20 wt(2) WO 2013/102144 PCT/US2012/072182 Each formulation solution was dispensed in 0.5 mL aliquots into 2 mL USP Type I borosilicate glass Vials with a chlorobutyl rubber stopper and an aluminum seal. The Vials were ted at 30 OC and 37 °C. Samples were withdrawn from the incubator at led time points for enzymatic activity measures as described in Example 8.

The results show that the percentage hyaluronidase activity in the tested formulations after preincubation at 37 °C was ly r for both PH20 mutants when formulated in EPB and not EPA preservative levels. While the t of actiVity remaining was greater than 80% for both tested mutants after 6 days incubation in formulations containing EPB vative , it was less in the presence of EPA preservative levels. For example, the actiVity remaining at 6 days in EPA preservative levels was slightly less than 80% after 6 days for F204P-PH20, while it was only about 40% for V58R-PH20. Hence, the results also show that at 37 °C, V58R-PH20 is somewhat less stable than the F204P-PH20, in particular in a formulation with EPA preservative levels. Aftter incubation at 30 °C for at least a week, the F204P-PH20 and H20 were stable and exhibited almost 100% initial actiVity in the presence of both EPA and EPB vative levels. In contrast, 0 exhibited only about 40% of its initial actiVity after 4 weeks at 30 °C in the presence of EPB preservative levels, while it exhibited no detectable actiVity after 4 weeks at 30 °C in the presence of EPA preservative levels.

E 12 EXPRESSION OF F204P-PH20 USING A LENTIVIRUS EXPRESSION VECTOR A lentiVirus expression vector, pLV-EFl a-PH20(F204P)-IRES-GFP-Bsd was generated containing a codon-optimized mutant hyaluronidase cDNA encoding F204P-PH20.

The sequence of pLV-EFla-PH20(F204P)-IRES-GFP-Bsd is set forth in SEQ ID .

The pLV-EFla-PH20(F204P)-IRES-GFP-Bsd vector contains an ampicillin resistance gene (AmpR) located at nucleotides 471, an EFla promoter at residues 1933 to 2327, an IRES at residues 4786-5370, a GFP-Bsd at residues 5394-6527 and nucleotides encoding F204P-PH20 at residues 3369-4781.

LentiVirus was produced as described in Bandaranayake et al. ((2011) Nucleic Acids Research, 39:e143). Brieﬂy, 293T cells (ATCC) were plated at 6 x 106 cells onto 10 cm tissue culture plates. After 24 hours, 6 ug of psPAX2 (SEQ ID NO:926; Addgene plasmid No. 12260), 3 ug of PMD2.G (SEQ ID NO:927; e plasmid #12259) and 9 ug lentiViral vector plasmid pLV-EFla-PH20(F204P)-IRES-GFP-Bsd were mixed in 1.5 mL Opti-MEM (Life Technologies). 45 uL of Lipofectamine 2000 (LF2000; Life Technologies) were diluted into 1.5 mL Opti-MEM (Life Technologies). The DNA and LF2000 were mixed gently, and WO 2013/102144 PCT/US2012/072182 incubated at room temperature for 20 minutes to allow the DNA and lipid to form complexes.

In the meantime, the overnight culture medium was ed with 5.0 mL DMEM + 10% FBS without antibiotics. A volume of 3.0 mL ning the DNA-LF2000 complexes were added to the 293T cells. The medium containing the DNA-LF2000 complexes was replaced with 10 mL complete medium at 12-16 hours post-transfection. The supernatant was collected at 48 hours post-transfection and the medium was transferred to a polypropylene e tube. The virus-containing medium was spun at 1300 rpm for 5 minutes to pellet any 293T cells that were carried over during collection. The supernatant was carefully transferred to a e polypropylene storage tube.

CHO-S cells (Invitrogen) were grown in CHO-S media (Invitrogen) with shaking at 120 rpm at 37 °C and 5% C02 in vented 125-mL shake ﬂasks (Nalgene). For transduction, CHO-S cells were added to wells of a six-well plate at 2 X 106 cells per well in 2 ml of CHO-S media containing 4 ug/mL hexadimethrine bromide at a ﬁnal concentration of 4 ug/mL (Polybrene; SIGMA). Virus was added to each well at a multiplicity of infection (MOI) of 10 and the cells were ted with shaking (120 rpm) at 37 °C and 5% C02 for 6 hours.

The cells were then harvested and pelleted by low speed centrifugation (500 x g, 5 min). The transduction medium was removed and replaced with 10 mL of fresh CHO-S medium (Invitrogen) supplemented with GlutaMax (50 mL/liter) and erred to a T-25 ﬂask.

Three days post infection, blasticidin (Invitrogen) was added to the growth medium at a concentration of 1 ug/mL. The medium was changed regularly at 3-4 day intervals, and the cells were transferred to a T75 ﬂask for ion. Two weeks after the initial ion, the cells were ed to shaker ﬂasks and maintained in culture using medium containing 1 ug/mL blasticidin. F204P-PH20 n secreted into the CHO-S medium was collected and puriﬁed by affinity chromatography using an anti-rHuPH20 afﬁnity column as described in Example 6. The n was prepared in standard API buffer (10 mM Histidine, 130 mM NaCl, pH 6.5).

EXAMPLE 13 ANALYSIS OF SECONDARY STRUCTURE AND MELTING TEMPERATURE The secondary structure and melting temperature of the PH20 variant F204P was tested and compared to wild-type rHuPH20 (generated as described in Example 1) to further assess stability of the variant. The secondary structure was tested by circular dichroism. A Jasco J150$ equipped with PTC-424S was employed for the CD spectral measurement and the CD spectra were ted by Spectra Manager (Version 1.5, Jasco). Procedures for instrumental set up and data tion are described in Table 24.

WO 2013/102144 PCT/US2012/072182 Table 24: CD S n ectrosco 0 n eration Conditions ters Conditions Nitrogen ﬂow rate 25 ft /h Samole temoerature 30-75 °C Sample concentration Approx. 0.1 mg/mL Cell pathlength 1 mm Wavelength 220 nm Data pitch 1 °C Dela time 60 seconds Temperature slope 1 °C/min Sensitivity standard Response 4 s Band width 1 nm 1. Sample Preparation and Measurement Two hundred (200) uL of a 0.1 mg.mL protein sample diluted in Mcllvaine’s buffer (Mcllvaine (1921) JBC 49:183) adjusted to pH 6.5 were prepared. A series of samples of the F204P variant were also generated that varied in pH by ment using Mcllvaine’s buffer to a pH range from 5.0 to 7.5 as set forth in Table 25. In addition, samples also were generated by adjusting the NaCl concentration to 17.5 mM to 140 mM as set forth in Table 26. Samples were d using a 0.2 um syringe filter prior to measurement. Similar s were generated for rHuPH20. Then, 200 uL samples were transferred to a rectangular cuvetted having a 1 mm width and seated on Jasco J-810 spectropolarimeter. CD spectra of the samples were collected under the conditions described in Table 20. The melting temperature (Tm) was calculated using Spectra Manager (V 1.5, Jasco) from the CD spectral ity measured at the temperature range from 30 °C to 75 °C. The es were cleaned by rge® cleaner (C577-12, Fisher scientific) between individual sample loading and after the run.

Table 25: Sam u le H and concentration Target pH Actual pH F204P (uL) Buffer (uL) F204P concentration "—— Table 26: Sodium Concentration in Sam n les at H 6.5 Target NaCl NaCl, 2.8 M F204P (uL) Buffer at pH F204P concentration (uL) 6.5 (11L) concentration mM m_/mL WO 2013/102144 PCT/US2012/072182 V 32. Results The results showthat the secondary structure'of F204P is similar to rHuPH20. As a function of temperature, circular dichroism showed that a change in the absorption was ed with increasing temperatures. As a on of pH, the Tm distribution was closely comparable for both F204P and O and the highest'Tm for each was obtained between pH .5 :5 and pH .60 The results, however, showed that Tm of the '-F204P variant was approximately 9 °C higher at all tested ranges than wildtype rHuPHZO. This result indicated that the F204P mutant is more stable t thermm stress conditions. As a function of salt, "the s showthat the F204P and wildtype rHuPH20 both exhibited an increasingT.m with higher salt concentration, showing that'both have a proportional inclination toward .salt concentration.

Example '14 Assessment ofEnzymatic Activity 'In :an iIntradermal Trypan ‘Blue Dispersion Assay 1:5 Spreading activity of ZO variant 'F_204P was assessed usingra dye dispersion in vivo assay. Brieﬂy, puriﬁed 'PH20 t 'F204P (prepared as described in Example 1'2).and wild-typetrHu'PHZO (prepared as described in Example 1) were both formulated in API buffer (10 mM Histidine, 130 l,‘pH 6.5) at a concentration of 10,000 U/mL. The :stocks were'further d to three target concentrations of 1000, 100 and 10 U/mL by serial 1:.10 .20 dilutions in API'buffer. Purified ns (either rHuPHZO or F204P-‘PH20) were diluted 1 :1 with 0.4% Trypan Blue (0.4% liquid solution; Catalog No. 15250,’Invitrogen)‘to give 'asﬁnal concentration of.5, :50 and 500 U/mL protein, each containing 0.2% trypan blue. A vehicle control (API buffer).also was prepared. Forty-two (42) female NCr nu/nu homozygous mice were used in the study with six mice used per group as set forth in Table27. ——-._—TABLE 727: Summa ofTreatment Grou s for D e Dis ersion‘Stud ’Mice Blue nits/mL Blue Volume mL I"___-— H.

H"___— HE"___—' "___— nn_—_— ___—H RECTIFIED SHEET (RULE 91) lSA/EP WO 2013/102144 PCT/US2012/072182 Forty (40) uL of samples were administered by a single intradermal injection. The area of dye dispersion was measured at 2.5, 5, 10, 15 and 20 minutes post-injection and was recorded by photographic imaging by photograph of the injection site with a Nikon D90 digital camera with 60 mm prime micro-lens. A laser distance meter (Leica D3) was used to accurately position the camera at a pre-determined distance from the Trypan Blue dye area on the animal. The area of the dye was determined using Image-Pro Analyzer 7.0 Cybemetics, Inc). The calculated areas were expressed as mmZ.

The results are set forth in Table 28. The results showed that the sion actiVity of the PHZO variant F204P was substantially identical to the dispersion actiVity of rHuPHZO.

The ability to increase the area of dye dispersion was ependent, with both proteins having greatest activity at 500 U/mL. The s also showed that the area of dye dispersion increased with time post-intradermal injection. The areas of dye sion of rHuPHZO and F204P-PH20 were signiﬁcantly greater than the areas of dye dispersion for the controls ) at all time points when formulated at all concentrations (5, 50 and 500 U/mL) with the exception of rHuPHZO at the lowest concentration (5 U/mL). When compared to each other, rHuPHZO and F204P-PH20 showed similar dispersion effects, gh there was a signiﬁcant difference in dispersion between the two groups at 5 U/mL and 500 U/mL but not at 50 U/mL. In sum, the results show that both rHuPHZO and F204P-PH20 ed a statistically signiﬁcant increase in the area of dye dispersion compared to the vehicle control.

TABLE 28: Tr an Blue Dis 1 ersion Area (mm2) 2.5 min 5 min 10 min 15 min 20 min 48.77 2.14 356133;?" 53.50 1.59 $531333 57.17 3.28 55‘ 31%? 54.11 1.01 (75502933) 64.44 2.17 WO 2013/102144 PCT/US2012/072182 Example 15 Assessment of tic Activity By Dermal Barrier Reconstitution Activity of F204P-PH20 was assessed and compared to rHuPH20 to measure the amount of time required for the dermal barrier to reconstitute itself after intradermal onidase administration. Dermal reconstitution was evaluated by comparing the duration of the hyaluronidase spreading activity as assessed by monitoring the area of diffusion of 0.4% Trypan Blue over time. The proteins used in the study were puriﬁed PH20 variant F204P red as described in Example 12) and wild-type rHuPH20 (prepared as described in Example 1) that were both formulated in API buffer (10 mM Histidine, 130 mM NaCl, pH 6.5). Vehicle (API buffer) was used as a l. Male NCr nu/nu homozygous mice were used in the study with three animals per time point for a total of n mice used per group as set forth in Table 29.

TABLE 29: Summa of Treatment Grou n s for Dermal r Reconstitution Stud Mice (h) (Units/mL) Volume (mL) --—-—48 48 48 All mice received two intradermal doses of vehicle control or rHuPH20 or F204P- PH20 at 100 U/mL in 0.04 mL at study time 0. The same control or test article was injected on the opposing l sides of each animal (right, R; left, L). lnj ection sites were marked with a permanent marker. Trypan Blue Stain (0.4% liquid solution; 15250, lnvitrogen) was administered at a volume of 0.04 mL by intradermal injection at the same injection site at 0.5, l, 4, 24 and 48 hours post-injection of test article or l. At 5 and 20 minutes post- injection of the Trypan Blue Stain, the area of the dye at the injection site was measured by digital imaging of the region as described in Example 14.

The results are set forth in Table 30. The results show that when the area of dye dispersion was measured at s time points after administration of the test article or l, there was a statistically significant increase in the area of dye dispersion at 30 min and 1 hour post-inj ection ofrHuPH20 or F204P-PH20. By 4 hours post-administration of the enzymes, however, there was not a statistically significant increase in the area of dye dispersion compared to control. In addition, no statistically signiﬁcant differences in the area of dye dispersion was ed between the rHuPH20 and F204P-PH20 treatment groups.

WO 2013/102144 2012/072182 ore, the duration of the spreading activity of rHuPH20 and F204P were similar and show that rHuPH20 and F204P-PH20 have comparable in vivo mance.

TABLE 30: Dermal Reconstitution time min Vehicle rHuPH20 F204P-PH20 Point post- in' ection 49.96 :: 2.05 80.84 :: 8.03 80.76 :I 4.46 __64.42 :: 2.49 94.55 :: 7.09 95.75 :: 5.18 58.01:: 3.21 82.56 :: 6.40 77.11 :: 3.18 __65.19:: 6.21 96.19:: 6.39 91.45 :21.73 52.10:: 3.47 67.19:: 2.39 67.33 :: 3.93 __57.69:: 3.92 81.15:: 4.45 82.21 :I 4.14 49.87 :: 3.25 59.01 :: 2.15 54.91 :: 3.54 :: 3.47 67.65 :: 2.27 62.91 :: 3.30 53.64 :: 2.99 53.53 :: 4.88 55.64 :: 7.19 __61.57 :: 4.02 66.33 :: 4.12 63.11 :I 5.97 Example 16 In Vivo Pharmacokinetics of F204P-PH20 Compared to rHuPH20 The pharmacokinetics (PK) of rHuPH20 and F204P-PH20 were compared following intravenous tail-vein administration by measuring the plasma hyaluronidase levels over time after administration. The proteins used in the study were purified PH20 variant F204P (prepared as described in Example 12; batch concentration 1.02 mg/mL) and wild-type rHuPH20 (prepared as described in Example 1; batch concentration 0.95 mg/mL) formulated in API buffer (10 mM ine, 130 mM NaCl, pH 6.5). The proteins were prepared at a concentration of 0.087 mg/mL in API buffer for a dose volume of about 5 mL. An animal that was not stered with protein was used a control (pre-dose control). Forty two (42) male CD-1 mice (N 20-30 grams) were used in the study with six s per treatment group as set forth in Table 31.

TABLE 31: Pharmacokinetics of Single Intravenous Dose of rHuPH20 0r F204P-PH20 number of Test Article Euthanasia animals (N0.) 1 6 (Nos. 1-6) no treatment N/A 2 6 (Nos. 7-12) rHuPH20 0.433 3 6 (Nos. 13-18) rHuPH20 0 433 4 6 (Nos. 19 24) rHuPH20 O 433 6 (Nos. 25-30) F204P-PH20 0.433 WO 2013/102144 PCT/US2012/072182 l 6 6 (Nos. 21-36) F204P-PH20 0.433 I 5 ‘ 5 :l: 1 min ‘ L 7 6 (Nos. 37—42) F204P—PH20 0.433 5 10 a: 2 min Mice were intravenously administered 0.433 mg/kg rHuPHZO or F204P-PH20 by tail vein injection. Blood samples were obtained from animals 1 minute, 5 minutes and 10 minutes post—administration. Blood samples were obtained by terminal bleed (cardiac puncture) and collected into blood collection tubes containing the anti-coagulant EDTA for the preparation of plasma. Blood samples were centrifuged at 500 g for 10 minutes and the plasma removed and frozen at -80° C until assessment of hyaluronidase activity using the microturbidity assay described in Example 8.

The results are set forth in Table 32. The results show that hyaluronidase activity is not detected in plasma prior to treatment with the onidase. Within 1 minute post- treatment with either rHuPH20 or F204P—PH20 hyaluronidase, there is a ably high amount of hyaluronidase ty t in the plasma, which is similar between both treatment groups. Over time, the hyaluronidase activity rapidly decreases for both treatment groups, although there is ably hyaluronidase activity t in the plasma 10 minutes post-administration. At the 5 minute and 10 minute post-administration time points, ty in the plasma in animals treated with F204P-PH20 is greater than in animals treated with rHuPHZO. This shows that F204P—PH20 exhibits somewhat greater activity for a prolonged time period, and therefore exhibits r ife in vivo than rHuPHZO.

Table 32: rHuPH20 and F204P—PH20 Activity (U/mL) in Mouse Plasma KZEDTA Time Point (min 18.3 7.70 8.85 .5 BQL — Below Quantiﬁable Limit < 0.625 U/mL with minimum required dilution a - Hemolyzed WO 02144 PCT/US2012/072182 Since modiﬁcations Will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

Claims

1. A modified PH20 polypeptide, comprising an amino acid ement in an unmodified PH20 polypeptide, wherein: the unmodified PH20 polypeptide consists of the sequence of amino acids set forth in SEQ ID NO: 3, 7 or 32-66, or a sequence of amino acids that is at least 95% identical to SEQ ID NO:3, 7 or 32-66; the modified PH20 polypeptide exhibits increased stability in the presence of a phenolic preservative(s) compared to the unmodified PH20 polypeptide not containing the amino acid ement; the amino acid ement is at a position corresponding to a position selected from among 10, 12, 20, 22, 26, 34, 36, 46, 50, 52, 58, 68, 70, 74, 82, 83, 84, 86, 97, 127, 131, 138, 142, 143, 144, 166, 169, 174, 193, 195, 196, 204, 205, 206, 213, 234, 237, 238, 240, 249, 261, 267, 277, 279, 291, 309, 310, 314, 315, 317, 318, 347, 367, 375, 376, 399, 401, 407, 416, 419, 421, 431, 433, 439, 440, 443 or 445 with reference to amino acid positions set forth in SEQ ID NO:3, n corresponding amino acid positions are fied by alignment of the PH20 polypeptide with the polypeptide having the sequence of amino acids set forth in SEQ ID NO:3, with the proviso that if the modified PH20 polypeptide includes only a single amino acid replacement, the replacement does not pond to amino acid replacements V12A or E249Q with reference to amino acid positions set forth in SEQ ID NO:3; the amino acid replacement confers the increased stability; and increased stability is manifested as increased onidase activity in the presence of the phenolic preservative(s) ed to the hyaluronidase activity of the unmodified PH20 polypeptide not containing the amino acid replacement in the presence of the same phenolic preservative(s), and the activity is compared under the same conditions.

2. The modified PH20 polypeptide of claim 1, wherein the modified PH20 polypeptide exhibits at least 95% amino acid sequence identity to the sequence of amino acids set forth in SEQ ID NO:3.

3. The modified PH20 polypeptide of claim 1 or claim 2, wherein the amino acid replacement(s) is in an unmodified PH20 polypeptide that consists of the sequence of amino acids set forth in any of SEQ ID NOS: 3, 7 or 32-66. 341

4. The modified PH20 polypeptide of claim 3, wherein the amino acid replacement is in an fied PH20 polypeptide that consists of the ce of amino acids set forth in SEQ ID NO: 3.

5. The modified PH20 polypeptide of any of claims 1-4, wherein the PH20 ptide is stable for at least 4 hours in the presence of the preservative(s).

6. The modified PH20 polypeptide of any of claims 1-5, wherein the modified PH20 polypeptide is stable in the presence of an anti-microbial effective amount of one or more phenolic preservatives.

7. The modified PH20 polypeptide of claim 6, wherein the anti-microbial effective amount is a total amount of one or more phenolic preservative agents as a percentage (%) of mass concentration (w/v) that is from or from about 0.05% to 0.6%, 0.1% to 0.4%, 0.1% to 0.3%, 0.15% to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 0.3% to 0.4%, inclusive.

8. The modified PH20 polypeptide of any of claims 1-7, wherein the phenolic preservative is selected from among one or more of phenol, metacresol (m-cresol), benzyl l and a paraben.

9. The modified PH20 polypeptide of claim 8, wherein the preservative is a paraben that is methylparaben or propylparaben.

10. The ed PH20 ptide of any of claims 1-7, wherein the preservative is a phenolic preservative that is m-cresol, phenol, or a ation of m-cresol and phenol.

11. The modified PH20 polypeptide of any of claims 1-10, wherein: the modified PH20 polypeptide exhibits at least 15% of the hyaluronidase activity in the presence of a preservative(s) for at least 4 hours compared to the hyaluronidase activity in the e of the preservative(s), wherein the activity is compared under the same conditions except for the ce of preservative(s).

12. The modified PH20 polypeptide of any of claims 1-11, comprising at least one amino acid ement selected from among replacement with: G at a position corresponding to position 10; K at a position corresponding to position 12; S at a position corresponding to position 20; T at a position corresponding to position 22; M at a position corresponding to position 26; W at a position corresponding to on 34; N at a position corresponding to position 36; L at a position corresponding to position 46; M at 342 a position corresponding to position 50; T at a position corresponding to on 52; S at a position corresponding to position 52; C at a position corresponding to position 58; K at a position corresponding to on 58; R at a position corresponding to position 58; N at a on corresponding to position 58; Y at a position corresponding to position 58; P at a position corresponding to position 58; H at a on ponding to position 58; P at a position corresponding to position 68; V at a position corresponding to position 70; E at a position corresponding to position 74; L at a position corresponding to position 82; N at a position ponding to position 82; V at a position corresponding to position 83; Q at a position corresponding to position 83; S at a position ponding to position 83; G at a position corresponding to position 83; N at a position corresponding to position 84; A at a position corresponding to position 86; K at a position ponding to position 86; E at a position corresponding to on 97; L at a position ponding to position 97; R at a position corresponding to position 127; R at a on corresponding to position 131; L at a position corresponding to position 138; K at a position corresponding to position 142; N at a position ponding to position 142; P at a position ponding to position 142; S at a position corresponding to position 142; T at a position corresponding to position 142; G at a position corresponding to position 143; K at a position corresponding to position 143; T at a position corresponding to position 144; Q at a position corresponding to position 166; T at a position corresponding to position 166; L at a position corresponding to position 169; G at a position corresponding to position 174; N at a position corresponding to position 174; Q at a position corresponding to position 193; T at a position corresponding to position 195; N at a position ponding to position 195; E at a position corresponding to position 196; R at a position corresponding to position 196; P at a on corresponding to position 204; A at a position corresponding to position 205; E at a position corresponding to position 205; I at a on corresponding to position 206; A at a on corresponding to position 213; I at a position corresponding to position 219; M at a position corresponding to on 234; T at a position corresponding to position 237; H at a position corresponding to position 238; Q at a position corresponding to position 240; V at a position corresponding to position 249; A at a position corresponding to position 261; K at a position corresponding to position 261; T at a position corresponding to position 267; K at a position corresponding to position 277; H at a position corresponding to position 279; V at a position corresponding to position 279; V at a position corresponding to on 291; E at a on corresponding to position 309; Q at a position corresponding to position 310; Y at a position corresponding to position 314; Y at a position corresponding to position 315; N at a position corresponding to position 317; W at a 343 on corresponding to position 317; D at a on corresponding to position 318; G at a position corresponding to position 347; A at a position corresponding to position 367; R at a on corresponding to position 375; R at a position ponding to position 376; V at a position corresponding to position 399; E at a position corresponding to position 401; A at a position corresponding to position 407; L at a position corresponding to position 416; K at a position corresponding to position 419; H at a position corresponding to position 421; E at a position corresponding to position 431; T at a position corresponding to position 433; V at a position corresponding to position 433; C at a position corresponding to position 439; P at a position ponding to position 440; G at a on corresponding to on 443; and N at a position corresponding to position 445, with reference to amino acid residue positions set forth in SEQ ID NO:3.

13. The modified PH20 ptide of any of claims 1-12, comprising at least one amino acid replacement selected from among replacement with: T at a position corresponding to position 52, K at a position corresponding to position 58, R at a position corresponding to position 58, V at a position corresponding to on 83, P at a position corresponding to position 204, M at a position ponding to position 234, A at a position corresponding to position 261, Q at a position corresponding to position 310; and H at a position corresponding to position 421, with reference to amino acid residue positions set forth in SEQ ID NO:3.

14. The modified PH20 ptide of any of claims 1-13, comprising ement with P at a position corresponding to position 204 in a PH20 polypeptide with reference to amino acid residue positions set forth in SEQ ID NO:3.

15. The modified PH20 polypeptide of any of claims 1-13, comprising replacement with R at a position corresponding to position 58 in a PH20 polypeptide with reference to amino acid positions set forth in any of SEQ ID NOS: 3, 7 and 32-66.

16. A modified polypeptide of claim 12, comprising replacement with P at a position corresponding to position 204 in a PH20 polypeptide, wherein the amino acid replacement(s) is in an unmodified PH20 ptide that consists of the sequence of amino acids set forth in any of SEQ ID NOS: 3, 32-66, 69 and 72, or a sequence of amino acids that has at least 95% sequence identity to any of SEQ ID NOS:3, 7, 69, 72 or 32-66 so long as the modified polypeptide contains the amino acid replacement corresponding to F204P. 344

17. The modified polypeptide of claim 1 or claim 16, comprising replacement with P at a position corresponding to position 204 in a PH20 polypeptide and up to 5 additional amino acid replacements, wherein the amino acid replacement(s) is/are in an unmodified PH20 polypeptide that consists of the sequence of amino acids set forth in any of SEQ ID NOS: 3, 7 and 32-66.

18. A modified PH20 polypeptide of any of claims 1- 17, comprising a sequence of amino acids set forth in any of SEQ ID NOS: 83, 88, 93, 94, 101, 144, 148, 158, 171, 175- 178, 180, 182-185, 194, 221, 240, 4, 268, 270, 272, 307, 309, 327, 334, 341, 351-353, 356-359, 361, 424, 426, 430, 434, 436, 443-447, 449-451, 454, 461, 467, 480, 487, 489, 492, 495, 504, 505, 509, 527, 544, 551, 576, 589, 600, 603, 607, 612, 614, 647, 658, 683, 687, 733, 736, 741, 754, 763, 768, 781, 796, 797, 809, 818, 829 and 837 or a sequence of amino acids that exhibits at least 96% ce identity to a ce of amino acids set forth in any of SEQ ID NOS: 83, 88, 93, 94, 101, 144, 148, 158, 171, 175-178, 180, 182-185, 194, 221, 240, 259-264, 268, 270, 272, 307, 309, 327, 334, 341, 351-353, 9, 361, 424, 426, 430, 434, 436, 443-447, 449-451, 454, 461, 467, 480, 487, 489, 492, 495, 504, 505, 509, 527, 544, 551, 576, 589, 600, 603, 607, 612, 614, 647, 658, 683, 687, 733, 736, 741, 754, 763, 768, 781, 796, 797, 809, 818, 829 and 837 and that contains the amino acid replacement.

19. The modified PH20 polypeptide of any of claims 1-18 that exhibits catalytic activity at l pH.

20. The modified PH20 polypeptide of any of claims 1-19, wherein the modified PH20 ptide is secreted upon expression from cells and is soluble in the atant.

21. The modified PH20 polypeptide of any of claims 1-20 that is substantially purified or ed.

22. The modified PH20 polypeptide of any of claims 1-21 that is modified by modification selected from among glycosylation, sialation, albumination, farnysylation, carboxylation, hydroxylation and phosphorylation.

23. The modified PH20 polypeptide of claim 22, wherein the ed PH20 polypeptide is glycosylated, whereby the polypeptide comprises at least an N- acetylglucosamine moiety linked to each of at least three asparagine (N) residues.

24. The modified PH20 polypeptide of claim 23, wherein the three asparagine residues correspond to amino acid residues 200, 333 and 358 of SEQ ID NO:3. 345

25. The ed PH20 ptide of any of claims 1-24 that is modified by conjugation to a r.

26. The ed PH20 polypeptide of claim 25, wherein the polymer is dextran or PEG.

27. The modified PH20 polypeptide of any of claims 1-26, wherein the modified PH20 polypeptide is conjugated to a moiety selected from among a multimerization domain, toxin, detectable label or drug.

28. The modified PH20 polypeptide of claim 27, wherein the modified PH20 polypeptide is conjugated to an Fc domain.

29. The modified PH20 polypeptide of any of claims 16, 17 and 19-28, comprising replacement with P at a on corresponding to position 204 in a PH20 polypeptide, n the amino acid replacement(s) is in an unmodified PH20 polypeptide that consists of the sequence of amino acids set forth in SEQ ID NO. 41.

30. The modified PH20 polypeptide of any of claims 16, 17 and 19-28 that has only the replacement with P at a position corresponding to position 204 in a PH20 polypeptide.

31. The modified PH20 polypeptide of any of claims 1-30, comprising up to 10 amino acid modifications selected from among amino acid ements, insertions and deletions.

32. A nucleic acid molecule, encoding a modified PH20 ptide of any of claims 1-20.

33. A vector, comprising the nucleic acid molecule of claim 32.

34. The vector of claim 33 that is a eukaryotic or a prokaryotic vector.

35. The vector of claim 33 or claim 34 that is a mammalian vector or a viral vector.

36. The vector of claim 35 that is a viral vector, wherein the viral vector is an adenovirus vector, a retrovirus vector or a vaccinia virus vector.

37. An isolated cell, comprising the vector of any of claims 33-36.

38. The cell of claim 37 that is a mammalian cell. 346

39. The cell of claim 38, wherein the ian cell is a Chinese Hamster Ovary (CHO) cell.

40. A modified PH20 polypeptide that is produced by the cell of any of claims 37- 39.

41. A method of producing a modified PH20 polypeptide, comprising: introducing the nucleic acid of claim 32 or the vector of any of claims 33-36 into a cell capable of incorporating N-linked sugar moieties into the polypeptide; culturing the cell under conditions whereby an encoded ed PH20 polypeptide is produced and secreted by the cell; and recovering the expressed polypeptide.

42. The method of claim 41, wherein the nucleic acid is operably linked to a promoter.

43. The method of claim 41 or claim 42, n the cell is a eukaryotic cell.

44. The method of any of claims 41-43, wherein the cell is a mammalian cell.

45. The method of any of claims 41-44, wherein the cell is a Chinese hamster ovary (CHO) cell.

46. A pharmaceutical composition, comprising a modified PH20 polypeptide of any of claims 1-31.

47. The pharmaceutical composition of claim 46, wherein the modified PH20 ptide in the composition is stable at a temperature from or from about 2 C to 8 C, ive, for at least 1 month or is stable at a temperature from or from about 30 C to 42 C, inclusive, for at least 3 days.

48. The pharmaceutical composition of claim 46 or claim 47, wherein the pharmaceutical composition comprises a pharmaceutically able excipient.

49. The pharmaceutical composition of any of claims 46-48 that is for single dose administration or is for multiple dose administration.

50. The ceutical composition of any of claims 46-49, wherein the concentration of modified PH20 polypeptide is from or from about 0.1 µg/mL to 100 µg/mL, 1 µg/mL to 50 µg/mL or 1 µg/mL to 20 µg/mL. 347

51. The pharmaceutical composition of any of claims 46-50, wherein the amount of a modified PH20 polypeptide is n or about between 10 U/mL to 5000 U/mL, 50 U/mL to 4000 U/mL, 100 U/mL to 2000 U/mL, 300 U/mL to 2000 U/mL, 600 U/mL to 2000 U/mL, or 100 U/mL to 1000 U/mL.

52. The pharmaceutical composition of any of claims 46-51, wherein the volume of the composition is from or from about 0.5 mL to 50 mL, 1 mL to 10 mL, or 1 mL to 5 mL.

53. The pharmaceutical composition of any of claims 46-52, comprising NaCl at a concentration less than or about or 200 mM, 180 mM, 150 mM, 140 mM, 130 mM, 120 mM, 110 mM, 100 mM, 90 mM, 80 mM, 70 mM, 60 mM, 50 mM, 40 mM, 30 mM, 25 mM, 20 mM, 15 mM, 10 mM, 5 mM or less.

54. The pharmaceutical ition of any of claims 46-53, comprising NaCl at a concentration from or from about 0.1 mM to 200 mM, 0.1 mM to 100 mM, 120 mM to 200 mM, 10 mM to 50 mM, 10 mM to 90 mM, 80 mM to 200 mM, 80 mM to 140 mM, 50 mM to 100 mM, 80 mM to 100 mM, 50 mM to 80 mM, 100 mM to 140 mM or 120 mM to 140 mM.

55. The pharmaceutical composition of any of claims 46-54, comprising an antimicrobially effective amount of a preservative or mixture of preservatives.

56. The ceutical composition of claim 55, wherein the preservative(s) is a phenolic preservative(s), a enolic preservative(s) or a phenolic vative(s) and a non-phenolic preservative(s).

57. The pharmaceutical composition of claim 55 or claim 56, wherein the preservative(s) is(are) selected from among , m-cresol, methylparaben, benzyl alcohol, thimerosal, benzalkonium chloride, 4-chlorobutanol, chlorhexidine dihydrochloride, chlorhexidine digluconate, L-phenylalanine, EDTA, bronopol, phenylmercuric acetate, glycerol, imidurea, chlorhexidine, sodium dehydroacetate, o-cresol, p-cresol, chlorocresol, ide, benzethonium chloride, ethyl paraben, propylparaben, butylparaben and any combinations thereof.

58. The pharmaceutical composition of any of claims 55-57, wherein the composition contains a single preservative.

59. The pharmaceutical composition of any of claims 55-57, n the composition contains a e of preservatives that contains 2, 3 or 4 different preservatives. 348

60. The pharmaceutical composition of any of claims 46-59, comprising at least one phenolic preservative.

61. The pharmaceutical composition of any of claims 60, wherein the preservative(s) is(are) selected from among , metacresol (m-cresol), benzyl alcohol, and a paraben.

62. The pharmaceutical composition of claim 61, wherein the vative is a n that is methylparaben or propylparaben.

63. The pharmaceutical composition of any of claims 55-62, wherein the antimicrobial effective amount is a total amount of one or more preservative agents as a percentage (%) of mass concentration (w/v) that is or is between 0.05% to 0.6%, 0.1% and 0.4%, 0.1% to 0.3%, 0.15% to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 0.3% to 0.4% ive.

64. The pharmaceutical composition of any of claims 46-63, comprising a therapeutically active agent.

65. The pharmaceutical ition of claim 64, wherein the therapeutic agent is formulated with the composition or in a separate composition.

66. The pharmaceutical composition of claim 64 or claim 65, wherein the therapeutic agent is a ptide, a protein, a nucleic acid, a drug, a small molecule or an organic molecule.

67. The pharmaceutical composition of any of claims 64-66, wherein the therapeutically active agent is selected from among a chemotherapeutic agent, an analgesic agent, an anti-inflammatory agent, an antimicrobial agent, an amoebicidal agent, a trichomonacidal agent, an anti-parkinson agent, an anti-malarial agent, an anticonvulsant agent, an anti-depressant agent, and antiarthritics agent, an anti-fungal agent, an antihypertensive agent, an retic agent, an anti-parasite agent, an antihistamine agent, an alpha-adrenergic agonist agent, an alpha blocker agent, an anesthetic agent, a bronchial dilator agent, a biocide agent, a icide agent, a bacteriostat agent, a beta adrenergic r agent, a calcium channel blocker agent, a cardiovascular drug agent, a contraceptive agent, a decongestant agent, a ic agent, a depressant agent, a diagnostic agent, a electrolyte agent, a hypnotic agent, a hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an ophthalmic agent, a parasympathomimetic agent, a psychic energizer agent, a sedative agent, a sympathomimetic agent, a tranquilizer 349 agent, a urinary agent, a vaginal agent, a viricide agent, a n agent, a non-steroidal antiinflammatory agent, an angiotensin converting enzyme inhibitor agent, or a sleep inducer.

68. The pharmaceutical composition of any of claims 64-67, wherein the therapeutic agent is selected from among an antibody, an Immune Globulin, a bisphosphonate, a cytokine, a chemotherapeutic agent, a coagulation factor and an insulin.

69. The pharmaceutical ition of claim 68, wherein the therapeutic agent is an insulin that is a fast-acting insulin.

70. The pharmaceutical composition of claim 69, wherein the fast-acting insulin is regular insulin or is an insulin analog.

71. The pharmaceutical composition of claim 69 or claim 70, wherein the fastacting insulin is a regular insulin that is a human n or a pig insulin.

72. The pharmaceutical composition of any of claims 69-71, n: the fast-acting insulin comprises an A chain having the sequence of amino acids set forth in SEQ ID NO:862 and a B chain having the sequence of amino acids set forth in SEQ ID NO:863; or the fast-acting insulin ses an A chain with the sequence of amino acids set forth as amino acid residue positions 88-108 of SEQ ID NO:864 and a B chain with the sequence of amino acids set forth as amino acid residue positions 25-54 of SEQ ID NO:864.

73. The pharmaceutical composition of claim 69 or claim 70, wherein the fastacting insulin is an insulin analog ed from among insulin lispro, insulin aspart or n glulisine.

74. The pharmaceutical composition of claim 73, wherein the insulin analog is selected from among an insulin having an A chain with the ce of amino acids set forth in SEQ ID NO:862 and a B chain having the sequence of amino acids set forth in any of SEQ NOS:865-867.

75. The pharmaceutical composition of any of claims 70-74, wherein the amount of fast-acting insulin is from or from about 10 U/mL to 1000 U/mL, 50 U/mL to 500 U/mL, 100 U/mL to 1000 U/mL or 500 U/mL to 1000 U/mL, inclusive.

76. The ceutical composition of any of claims 64-67, wherein the therapeutic agent is selected from among Adalimumabs, Agalsidase Betas, Alefacepts, Ampicillins, Anakinras, Antipoliomyelitic Vaccines, Anti-Thymocytes, Azithromycins, 350 ermins, ungins, Cefazolins, Cefepimes, tans, idimes, Ceftriaxones, Cetuximabs, Cilastatins, Clavulanic Acids, Clindamycins, oetin Alfas, Daclizumabs, Diphtheria, Diphtheria antitoxins, Diphtheria Toxoids, Efalizumabs, Epinephrines, Erythropoietin Alphas, Etanercepts, Filgrastims, Fluconazoles, Follicle-Stimulating Hormones, Follitropin Alphas, Follitropin Betas, Fosphenytoins, Gadodiamides, Gadopentetates, Gatifloxacins, Glatiramers, GM-CSF's, Goserelins, Goserelin acetates, Granisetrons, Haemophilus Influenza B's, Haloperidols, Hepatitis es, Hepatitis A Vaccines, Hepatitis B Vaccines, Ibritumomab Tiuxetans, Ibritumomabs, Tiuxetans, Immunoglobulins, Hemophilus influenza vaccines, Influenza Virus Vaccines, Infliximabs, Insulin lispro, 75% neutral protamine lispro (NPL)/25% insulin lispro, 50% neutral protamine Hagedorn (NPH)/ 50% regular n, 70% NPH/30% regular n; Regular insulin, NPH insulin, Ultra insulin, Ultralente insulin, and Insulin Glargines, erons, Interferon alpha, Interferon Betas, Interferon Gammas, Interferon alpha-2a, Interferon alpha 2-b, Interferon Alphacon, Interferon alpha-n, Interferon Betas, Interferon Beta-1a's, Interferon Gammas, Interferon con, Iodixanols, Iohexols, Iopamidols, Ioversols, Ketorolacs, Laronidases, Levofloxacins, Lidocaines, Linezolids, Lorazepams, s es, Measles virus, Mumps viruses, Measles-Mumps-Rubella Virus Vaccines, Rubella vaccines, Medroxyprogesterones, Meropenems, Methylprednisolones, Midazolams, Morphines, Octreotides, umabs, Ondansetrons, Palivizumabs, Pantoprazoles, Pegaspargases, Pegfilgrastims, Peg-Interferon Alpha-2a's, terferon Alpha-2b's, Pegvisomants, sis vaccines, Piperacillins, coccal Vaccines and Pneumococcal Conjugate Vaccines, Promethazines, Reteplases, Somatropins, tams, Sumatriptans, Tazobactams, Tenecteplases, Tetanus Purified Toxoids, Ticarcillins, Tositumomabs, Triamcinolones, Triamcinolone ides, Triamcinolone hexacetonides, Vancomycins, Varicella Zoster immunoglobulins, Varicella vaccines, other vaccines, Alemtuzumabs, Alitretinoins, Allopurinols, Altretamines, Amifostines, Anastrozoles, Arsenics, Arsenic Trioxides, Asparaginases, Bacillus Calmette-Guerin (BCG) vaccines, BCG Live, Bexarotenes, Bleomycins, Busulfans, Busulfan intravenous, Busulfan orals, Calusterones, Capecitabines, Carboplatins, Carmustines, Carmustines with prosans, Celecoxibs, Chlorambucils, Cisplatins, Cladribines, Cyclophosphamides, Cytarabines, Cytarabine liposomals, Dacarbazines, Dactinomycins, Daunorubicin liposomals, Daunorubicins, Daunomycins, Denileukin Diftitoxes, Dexrazoxanes, Docetaxels, Doxorubicins, Doxorubicin liposomals, Dromostanolone propionates, Elliott's B Solutions, Epirubicins, Epoetin alfas, Estramustines, ides, Etoposide phosphates, Etoposide VP-16s, Exemestanes, Floxuridines, 351 Fludarabines, Fluorouracils, 5-Fluorouracils, Fulvestrants, Gemcitabines, Gemtuzumabs, Ozogamicins, Gemtuzumab ozogamicins, Hydroxyureas, Idarubicins, Ifosfamides, Imatinib mesylates, Irinotecans, Letrozoles, orins, Levamisoles, Lomustines, CCNUs, Mechlorethamines, Nitrogen mustards, Megestrols, Megestrol acetates, Melphalans, LPAMs , Mercaptopurines, 6-Mercaptopurines, Mesnas, Methotrexates, Methoxsalens, Mitomycins, Mitomycin C’s, Mitotanes, Mitoxantrones, lones, Nandrolone opionates, Nofetumomabs, Oprelvekins, Oxaliplatins, Paclitaxels, Pamidronates, Pegademases, Pentostatins, Pipobromans, Plicamycins, Mithramycins, ers, Porfimer sodiums, bazines, Quinacrines, Rasburicases, Rituximabs, Sargramostims, Streptozocins, Talcs, Tamoxifens, Temozolomides, Teniposides, Testolactones, Thioguanines, 6-Thioguanines, Triethylenethiophosphoramides epas), Topotecans, Toremifenes, Trastuzumabs, oins, Uracil Mustards, Valrubicins, Vinblastines, Vincristines, Vinorelbines, Zoledronates, Acivicins, Aclarubicins, Acodazoles, Acronines, Adozelesins, Aldesleukins, Retinoic Acids, Alitretinoins, 9-Cis-Retinoic Acids, Alvocidibs, nes, cins, Ametantrones, Aminoglutethimides, Amsacrines, ones, bines, Anthramycins, Apaziquones, Argimesnas, Asperlins, Atrimustines, Azacitidines, Azetepas, Azotomycins, Banoxantrones, Batabulins, stats, Benaxibines, Bendamustines, Benzodepas, Bicalutamides, Bietaserpines, Biricodars, Bisantrenes, ide Dimesylates, Bizelesins, Bortezomibs, Brequinars, Bropirimines, Budotitanes, Cactinomycins, Canertinibs, Caracemides, Carbetimers, uones, Carmofurs, Carubicins, Carzelesins, Cedefingols, Cemadotins, Chlorambucils, Cioteronels, Cirolemycins, Clanfenurs, Clofarabines, Crisnatols, Decitabines, Dexniguldipines, Dexormaplatins, anines, Diaziquones, Dibrospidiums, Dienogests, Dinalins, Disermolides, Dofequidars, Doxifluridines, ifenes, Duazomycins, Ecomustines, Edatrexates, Edotecarins, Eflomithines, Elacridars, Elinafides, Elsamitrucins, Emitefurs, Enloplatins, Enpromates, Enzastaurins, Epipropidines, Eptaloprosts, Erbulozoles, Esorubicins, Etanidazoles, Etoglucids, Etoprines, Exisulinds, Fadrozoles, Fazarabines, Fenretinides, Fluoxymesterones, Flurocitabines, Fosquidones, Fostriecins, Fotretamines, Galarubicins, Galocitabines, Geroquinols, Gimatecans, Gimeracils, Gloxazones, famides, sines, Ilomastats, Imexons, Improsulfans, Indisulams, Inproquones, Interleukins, Interleukin-2s, inant Interleukins, Intoplicines, Iobenguanes, Iproplatins, Irsogladines, Ixabepilones, Ketotrexates, L-Alanosines, Lanreotides, Lapatinibs, Ledoxantrones, Leuprolides, Leuprorelins, Lexacalcitols, Liarozoles, Lobaplatins, Lometrexols, Lonafarnibs, Losoxantrones, Lurtotecans, Mafosfamides, Mannosulfans, 352 Marimastats, Masoprocols, Maytansines, Mechlorethamines, Melengestrols, Melphalans, Menogarils, Mepitiostanes, Metesinds, Metomidates, Metoprines, Meturedepas, Miboplatins, Miproxifenes, Misonidazoles, Mitindomides, Mitocarcins, Mitocromins, Mitoflaxones, Mitogillins, Mitoguazones, Mitomalcins, fides, Mitoquidones, Mitospers, Mitozolomides, Mivobulins, Mizoribines, Mofarotenes, Mopidamols, inibs, Mycophenolic Acids, Nedaplatins, abines, Nemorubicins, Nitracrines, zoles, Nogalamycins, Nolatrexeds, Nortopixantrones, Ormaplatins, Ortataxels, Oteracils, Oxisurans, narsines, Patupilones, Peldesines, Peliomycins, Pelitrexols, Pemetrexeds, Pentamustines, Peplomycins, Perfosfamides, Perifosines, Picoplatins, Pinafides, Piposulfans, idones, Piroxantrones, Pixantrones, Plevitrexeds, Plomestanes, Porfiromycins, Prednimustines, Propamidines, Prospidiums, Pumitepas, Puromycins, Pyrazofurins, Ranimustines, Riboprines, Ritrosulfans, Rogletimides, Roquinimexs, Rufocromomycins, Sabarubicins, Safingols, Satraplatins, Sebriplatins, ines, Simtrazenes, Sizofirans, Sobuzoxanes, Sorafenibs, Sparfosates, Sparfosic Acids, Sparsomycins, ermaniums, Spiromustines, Spiroplatins, Squalamines, Streptonigrins, Streptovarycins, Sufosfamides, Sulofenurs, Tacedinalines, Talisomycins, Tallimustines, Tariquidars, Tauromustines, Tecogalans, Tegafurs, Teloxantrones, Temoporfins, Teroxirones, Thiamiprines, Tiamiprines, Tiazofurins, Tilomisoles, Tilorones, Timcodars, Timonacics, Tirapazamines, Topixantrones, Trabectedins, ascidin 743, Trestolones, Triciribines, Trilostanes, Trimetrexates, tin Tetranitrates, Triptorelins, famides, Tubulozoles, Ubenimexs, Uredepas, dars, Vapreotides, Verteporfins, Vinblastines, Vindesines, dines, Vinflunines, Vinformides, Vinglycinates, Vinleucinols, Vinleurosines, Vinrosidines, Vintriptols, Vinzolidines, Vorozoles, Xanthomycin A's, Guamecyclines, Zeniplatins, orbs [2-H], Zinostatins, cins, Zosuquidars, olamides, Acyclovirs, Adipiodones, Alatrofloxacins, Alfentanils, Allergenic ts, Alpha 1-proteinase inhibitors, Alprostadils, Amikacins, Amino acids, Aminocaproic acids, Aminophyllines, Amitriptylines, Amobarbitals, Amrinones, Analgesics, Anti-poliomyelitic vaccines, Anti-rabic serums, Antitetanus immunoglobulins, tetanus vaccines, Antithrombin IIIs, Antivenom serums, Argatrobans, Arginines, Ascorbic acids, ols, riums, Atropines, Aurothioglucoses, Azathioprines, Aztreonams, Bacitracins, Baclofens, Basiliximabs, Benzoic acids, Benztropines, Betamethasones, Biotins, rudins, Botulism antitoxins, Bretyliums, Bumetanides, Bupivacaines, Buprenorphines, Butorphanols, Calcitonins, Calcitriols, Calciums, Capreomycins, Carboprosts, Carnitines, Cefamandoles, Cefoperazones, Cefotaximes, Cefoxitins, Ceftizoximes, Cefuroximes, Chloramphenicols, Chloroprocaines, 353 Chloroquines, Chlorothiazides, Chlorpromazines, Chondroitinsulfuric acids, Choriogonadotropin alfas, Chromiums, Cidofovirs, Cimetidines, Ciprofloxacins, Cisatracuriums, Clonidines, Codeines, Colchicines, Colistins, Collagens, Corticorelin ovine triflutates, Corticotrophins, Cosyntropins, Cyanocobalamins, Cyclosporines, nes, Dacliximabs, Dalfopristins, Dalteparins, Danaparoids, Dantrolenes, Deferoxamines, Desmopressins, Dexamethasones, Dexmedetomidines, Dexpanthenols, Dextrans, Iron dextrans, Diatrizoic acids, Diazepams, ides, Dicyclomines, Digibinds, ns, oergotamines, Diltiazems, Diphenhydramines, Dipyridamoles, mines, Dopamines, Doxacuriums, Doxaprams, Doxercalciferols, Doxycyclines, Droperidols, Dyphyllines, Edetic acids, Edrophoniums, Enalaprilats, Ephedrines, Epoprostenols, Ergocalciferols, Ergonovines, Ertapenems, Erythromycins, Esmolols, Estradiols, Estrogenics, Ethacrynic acids, Ethanolamines, Ethanols, Ethiodized oils, Etidronic acids, Etomidates, Famotidines, Fenoldopams, Fentanyls, Flumazenils, Fluoresceins, Fluphenazines, Folic acids, Fomepizoles, rsens, Fondaparinuxs, Foscarnets, Fosphenytoins, Furosemides, Gadoteridols, Gadoversetamides, Ganciclovirs, Gentamicins, Glucagons, Glucoses, Glycines, Glycopyrrolates, Gonadorelins, Gonadotropin chorionics, Haemophilus B polysaccharides, Hemins, Herbals, Histamines, Hydralazines, Hydrocortisones, Hydromorphones, Hydroxocobalamins, Hydroxyzines, amines, Ibutilides, Imiglucerases, Indigo carmines, thacins, Iodides, Iopromides, Iothalamic acids, Ioxaglic acids, Ioxilans, Isoniazids, Isoproterenols, se encephalitis vaccines, Kanamycins, Ketamines, lols, Lepirudins, Levobupivacaines, Levothyroxines, Lincomycins, Liothyronines, Luteinizing es, Lyme disease vaccines, Mangafodipirs, Manthtols, ococcal polysaccharide vaccines, Meperidines, Mepivacaines, Mesoridazines, Metaraminols, Methadones, Methocarbamols, exitals, Methyldopates, ergonovines, Metoclopramides, Metoprolols, Metronidazoles, Minocyclines, Mivacuriums, Morrhuic acids, Moxifloxacins, Muromonab-CD3s, Mycophenolate mofetils, Nafcillins, Nalbuphines, Nalmefenes, Naloxones, Neostigmines, Niacinamides, Nicardipines, Nitroglycerins, Nitroprussides, Norepinephrines, Orphenadrines, Oxacillins, Oxymorphones, racyclines, Oxytocins, Pancuroniums, Panthenols, Pantothenic acids, Papaverines, Peginterferon alpha 2As, Penicillin Gs, Pentamidines, Pentazocines, Pentobarbitals, Perflutrens, Perphenazines, arbitals, lamines, Phenylephrines, Phenytoins, Physostigmines, Phytonadiones, Polymyxin, Pralidoximes, Prilocaines, Procainamides, Procaines, Prochlorperazines, terones, Propranolols, Pyridostigmine hydroxides, Pyridoxines, Quinidines, Quinupristins, Rabies immunoglobulins, Rabies vaccines, 354 Ranitidines, Remifentanils, Riboflavins, Rifampins, Ropivacaines, Samariums, Scopolamines, Seleniums, Sermorelins, Sincalides, Somatrems, Spectinomycins, Streptokinases, Streptomycins, Succinylcholines, Sufentanils, Sulfamethoxazoles, Tacrolimuses, Terbutalines, Teriparatides, Testosterones, Tetanus antitoxins, Tetracaines, Tetradecyl sulfates, Theophyllines, Thiamines, Thiethylperazines, Thiopentals, Thyroid stimulating hormones, Tinzaparins, Tirofibans, Tobramycins, lines, Tolbutamides, Torsemides, Tranexamic acids, Treprostinils, Trifluoperazines, Trimethobenzamides, Trimethoprims, Tromethamines, Tuberculins, Typhoid vaccines, Urofollitropins, Urokinases, Valproic acids, Vasopressins, Vecuroniums, Verapamils, Voriconazoles, Warfarins, Yellow fever es, Zidovudines, Zincs, Ziprasidone hydrochlorides, Aclacinomycins, Actinomycins, Adriamycins, Azaserines, 6-Azauridines, ophilins, Chromomycins, Denopterins, 6 Diazo 5 Oxo-L-Norleucines, abines, Floxuridines, Olivomycins, Pirarubicins, Piritrexims, Pteropterins, Tegafurs, Tubercidins, Alteplases, Arcitumomabs, bevacizumabs, Botulinum Toxin Type A's, Botulinum Toxin Type B's, Capromab Pendetides, Daclizumabs, Dornase alphas, Drotrecogin alphas, Imciromab Pentetates, - 131’s, an antibiotic agent; an angiogenesis inhibitor; ataract and anti-diabetic retinopathy substances; carbonic anhydrase inhibitors; tics; photodynamic therapy agents; prostaglandin analogs; growth factor; anti-neoplastics; anti-metabolites; anti-viral; amebicides and anti-protozoals; anti-tuberculosis and eprotic; antitoxins and antivenins; antihemophilic factor, anti-inhibitor coagulant complex, antithrombin III, coagulations Factor V, coagulation Factor IX, plasma protein fraction, von Willebrand factor; atelet agent a colony stimulating factor (CSF); an erythropoiesis stimulator; hemostatics and albumins; Immune Globulins; thrombin inhibitors; anticoagulants; a steroidal nflammatory drug ed from among alclometasones, algestones, beclomethasones, thasones, budesonides, asols, clobetasones, clocortolones, cloprednols, osterones, cortisones, cortivazols, deflazacorts, desonides, desoximetasones, dexamethasones, diflorasones, diflucortolones, difluprednates, enoxolones, fluazacorts, flucloronides, flumethasones, flunisolides, fluocinolones, fluocinonides, rtins, fluocortolones, fluorometholones, olones, fluprednidenes, fluprednisolones, flurandrenolides, fluticasones, formocortals, halcinonides, halobetasols, halometasones, halopredones, ortamates, hydrocortisones, loteprednol etabonate, mazipredones, medrysones, meprednisones, methylprednisolones, mometasone furoate, paramethasones, prednicarbates, solones, prednisones, prednivals, prednylidenes, rimexolones, tixocortols and 355 triamcinolones; Docosenoid, prostaglandins, prostaglandin analogs, antiprostaglandins and prostaglandin precursors; miotics, cholinergics and anti-cholinesterase; and anti-allergenics.

77. The pharmaceutical composition of any of claims 46-76 that is a liquid composition.

78. A co-formulation, comprising: a eutically effective amount of a modified PH20 polypeptide of any of claims 1- 31; and a therapeutically effective amount of a fast-acting insulin.

79. A co-formulation, comprising a therapeutically effective amount of a modified PH20 polypeptide of any of claims 1-15 or 17; and a therapeutically ive amount of a cting insulin

80. The co-formulation of claim 78 or claim 79, wherein the ed PH20 polypeptide in the formulation is stable at a ature from or from about 2 C to 8 C, inclusive, for at least 1 month or is stable at a temperature from or from about 30 C to 42 C, inclusive, for at least 3 days.

81. The co-formulation of any of claims 78-80, wherein the amount of modified PH20 polypeptide is from or from about 100 U/mL to 1000 U/mL, 200 U/mL to 800 U/mL, or 400 U/mL to 800 U/mL.

82. The mulation of any of claims 78-81, wherein the fast-acting insulin is regular insulin or is an insulin analog.

83. The co-formulation of any of claims 78-82, wherein the fast-acting insulin is a regular insulin that is a human insulin or a pig insulin.

84. The co-formulation of any of claims 78-83, wherein: the fast-acting insulin comprises an A chain having the sequence of amino acids set forth in SEQ ID NO:862 and a B chain having the sequence of amino acids set forth in SEQ ID NO:863; or the fast-acting insulin comprises an A chain with the sequence of amino acids set forth as amino acid e positions 88-108 of SEQ ID NO:864 and a B chain with the sequence of amino acids set forth as amino acid residue positions 25-54 of SEQ ID NO:864.

85. The co-formulation of any of claims 78-82, wherein the fast-acting insulin is an insulin analog selected from among insulin , insulin aspart and n glulisine. 356

86. The co-formulation of claim 85, wherein the insulin analog is selected from among an insulin having an A chain with the ce of amino acids set forth in SEQ ID NO:862 and a B chain having the sequence of amino acids set forth in any of SEQ NOS:865- 867.

87. The co-formulation of any of claims 78-86, wherein the amount of fast-acting insulin is from or from about 10 U/mL to 1000 U/mL, 50 U/mL to 500 U/mL, 100 U/mL to 1000 U/mL or 500 U/mL to 1000 U/mL, inclusive.

88. The co-formulation of any of claims 78-87 that has a pH of from or from about 7.0 to 7.6.

89. The co-formulation of any of claims 78-88, comprising NaCl at a concentration from or from about 0.1 mM to 200 mM, 0.1mM to 100 mM, 120 mM to 200 mM, 10 mM to 50 mM, 10 mM to 90 mM, 80 mM to 200 mM, 80 mM to 140 mM, 50 mM to 100 mM, 80 mM to 100 mM, 50 mM to 80 mM, 100 mM to 140 mM or 120 mM to 140 mM.

90. The co-formulation of any of claims 78-89, comprising an icrobial effective amount of at least one preservative.

91. The co-formulation of claim 90, wherein the anti-microbial effective amount is a total amount of one or more preservative agents as a percentage (%) of mass concentration (w/v) that is or is between 0.05% to 0.6%, 0.1% to 0.4%, 0.1% to 0.3%, 0.15% to 0.325%, 0.15% to 0.25%, 0.1% to 0.2%, 0.2% to 0.3% or 0.3% to 0.4% inclusive.

92. The co-formulation of claim 90 or claim 91, wherein the preservative(s) is a phenolic preservative(s), a non-phenolic preservative(s) or a phenolic preservative(s) and a enolic preservative(s).

93. The co-formulation of any of claims 90-92, wherein the vative(s) is(are) selected from among , m-cresol, methylparaben, benzyl l, thimerosal, benzalkonium de, 4-chlorobutanol, chlorhexidine dihydrochloride, chlorhexidine digluconate, L-phenylalanine, EDTA, bronopol, phenylmercuric acetate, glycerol, ea, chlorhexidine, sodium dehydroacetate, o-cresol, p-cresol, chlorocresol, cetrimide, benzethonium chloride, ethyl paraben, propylparaben, butylparaben and any combinations thereof.

94. The co-formulation of any of claims 90-93, wherein the composition contains a single preservative. 357

95. The co-formulation of any of claims 90-93, wherein the composition contains a mixture of preservatives that contains 2, 3 or 4 different preservatives.

96. The mulation of any of claims 78-95, comprising at least one phenolic preservative.

97. The co-formulation of claim 96, wherein the preservative(s) is(are) selected from among phenol, metacresol (m-cresol), benzyl alcohol, and a paraben.

98. The co-formulation of claim 97, wherein the preservative is a paraben that is methylparaben or propylparaben.

99. The co-formulation of any of claims 78-98, comprising a surfactant in an amount as a % of mass concentration (w/v) in the formulation that is at least or at least about 0.001%, 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.035%, 0.04%, 0.045%, 0.05%, , 0.06%, , 0.07%. 0.08% or 0.9%.

100. The co-formulation of claim 99, wherein the surfactant is ed from among a polypropylene , polyethylene glycol, glycerin, sorbitol, poloxamer and polysorbate.

101. The co-formulation of claim 100, wherein the surfactant is selected from among mer 188, polysorbate 20 and polysorbate 80.

102. The mulation of any of claims 78-101, comprising a buffering agent that is a non-metal binding agent or is a metal binding agent.

103. The co-formulation of claim 102, wherein the ing agent is selected from among Tris, histidine, phosphate and citrate.

104. The co-formulation of claim 102 or claim 103, wherein the concentration of the buffering agent is between or is between about 1 mM to 100 mM, 10 mM to 50 mM or 20 mM to 40 mM.

105. The co-formulation of any of claims 78-104, comprising glycerin in a concentration less than 60 mM, less than 55 mM, less than 50 mM, less than 45 mM, less than 40 mM, less than 35 mM, less than 30 mM, less than 25 mM, less than 20 mM, less than 15 mM, less than 10 mM.

106. The mulation of any of claims 78-105, comprising an antioxidant.

107. The co-formulation of claim 106, wherein the antioxidant is selected from among cysteine, tryptophan and methionine. 358

108. The co-formulation of claim 106 or claim 107, n the antioxidant is at a concentration from between or from about between 2 mM to 50 mM, 5 mM to 40 mM, 5 mM to 20 mM or 10 mM to 20 mM, inclusive.

109. The co-formulation of any of claims 78-108, comprising zinc.

110. The co-formulation of claim 109, wherein the concentration of zinc is between or about between 0.001 to 0.1 mg per 100 units of insulin (mg/100U), 0.001 to 0.05 mg/100U or 0.01 to 0.05 mg/100U.

111. A closed loop system, comprising the co-formulation of any of claims 79-110.

112. An insulin pump, comprising the co-formulation of any of claims 79-110.

113. An n pen, comprising the co-formulation of any of claims 80-110.

114. Use of a modified PH20 polypeptide of any of claims 1-31 or a ceutical composition of any of claims 46-77 for the manufacture of a medicament for treating a hyaluronan associated disease or condition.

115. The use of claim 114, n the hyaluronan-associated disease or condition is an inflammatory disease or a tumor or cancer.

116. The use of claim 115, wherein the tumor is a solid tumor.

117. The use of any of claims 114-116, wherein the hyaluronan-associated disease or condition is selected from among a late-stage cancer, metastatic cancers and undifferentiated cancers.

118. The use of any of claims 114-117, wherein the hyaluronan-associated disease or condition is selected from among ovarian , in situ carcinoma (ISC), squamous cell carcinoma (SCC), prostate , pancreatic cancer, non-small cell lung cancer, breast cancer and colon cancer.

119. Use of a pharmaceutical composition of any of claims 69-75 or mulation of any of claims 78-110 for the manufacture of a ment for treating diabetes.

120. The use of claim 119, wherein the diabetes is selected from among type 1 diabetes mellitus, type 2 diabetes mellitus or gestational es.

121. Use of the modified PH20 polypeptide of any of claims 1-31 or a pharmaceutical composition of any of claims 43-74 for formulation of a medicament for ng an excess of glycosaminoglycans; for treating a tumor; for treating 359 glycosaminoglycan accumulation in the brain; for ng a cardiovascular disorder; for treating an lmic disorder; for treating pulmonary disease; for increasing penetration of chemotherapeutic agents into solid tumors; for treating cellulite or for treating a proliferative disorder.

122. A pharmaceutical composition of any of claims 46-77 for use in treating a hyaluronan-associated disease or disorder.

123. A pharmaceutical composition of any of claims 69-75 or co-formulation of any of claims 78-110 for use in treating es.

124. A pharmaceutical composition of any of claims 46-77 for use in delivering a therapeutic agent to a subject.

125. A pharmaceutical ition of any of claims 46-77 for treating an excess of glycosaminoglycans; for treating a tumor; for treating glycosaminoglycan accumulation in the brain; for treating a vascular disorder; for treating an ophthalmic disorder; for ng pulmonary disease; for increasing penetration of chemotherapeutic agents into solid tumors; for treating cellulite; for treating a proliferative disorder; or for increasing bioavailability of drugs and other therapeutic agents.